UA111137C2 - CARBOXAMIDE IMIDASOL DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF - Google Patents

Abstract

The invention relates to a compound of compositions for inhibiting the fatty acid amide hydrolase enzyme (HAZ), the use of the compounds in the treatment and, in particular, for the treatment or prevention of conditions, development or symptoms of which are related to the substrates of the HAZ enzyme, and methods of treatment or prevention using the compounds and compositions.

Description

nb M

U-vv

M

In d-k we ag s. with. . with. and compositions for inhibiting the enzyme fatty acid amide hydrolase (FAH), the use of the compounds in the treatment and, in particular, for the treatment or prevention of conditions, the development or symptoms of which are associated with the substrates of the FAH enzyme, and methods of treatment or prevention using the compounds and compositions.

The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic uses in the treatment or prevention of conditions involving substrates, such as the neurotransmitter anandamide, that are degraded by the enzyme fatty acid amide hydrolase (FAH).

The enzyme GAJK cleaves fatty acid amides such as anandamide /(M-arachidonoylethanolamine), M-oleoylethanolamine, M-palmitoylethanolamine and oleamide. Anandamide, also known as M-arachidonoylethanolamine or ABEA, is an endogenous cannabinoid neurotransmitter found in animal and human organs, especially the brain. Anandamide has also been found to bind to the vanilloid receptor. Anandamide is cleaved by the enzyme fatty acid amide hydrolase (FAH) to ethanolamine and arachidonic acid. Accordingly, ACE inhibitors lead to increased levels of anandamide.

Anandamide is a neurotransmitter in the endocannabinoid system and stimulates cannabinoid receptors. Cannabinoid receptors, such as SVI and CB2, are protein-coupled receptors. SVI is found mainly in the central nervous system, while CB2 is found mainly in peripheral tissue. The endocannabinoid system is involved in a growing number of physiological functions, both in the central and peripheral nervous systems, as well as in peripheral organs. It is shown that the modulation of the activity of the endocannabinoid system has the potential of a therapeutic effect on a wide range of disabling diseases and pathological conditions. Thus, the endocannabinoid system, and the GABA enzyme in particular, has become a therapeutic target for the development of potential treatments for numerous diseases.

The endocannabinoid system is involved in the regulation of appetite, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Guillain de la Tourette syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, vomiting, alcohol disorders, abuse of narcotic substances such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, reperfusion myocardial damage, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease,

From acute and chronic liver disease, such as hepatitis and liver cirrhosis, arthritis and osteoporosis. The endocannabinoid system and the conditions with which it is associated are discussed in detail in Rasneg et al. (2006) Rpaptosai. Nem. 58:389-462.

In order to modulate the level of endogenous substrates of GABA, such as, for example, which in turn modulate the endocannabinoid system, inhibitors of the enzyme GABA have been developed. This allows, at least in part, to treat or prevent conditions and diseases associated with the endocannabinoid system.

Because PHA substrates bind to other receptors, such as the vanilloid receptor, and/or are involved in other signal transduction pathways, PHA inhibitors may also allow, at least in part, treatment or prevention of conditions and diseases associated with other pathways or systems , for example, the vanilloid system.

EK 2915198 and RK 2915199 disclose compounds that are inhibitors of GAZK.

05 7,208,504 and EC2915197 also disclose a number of compounds that are not similar to those disclosed in EC 2915198 and EC 2915199. These compounds are claimed to be suitable for inhibiting hormone-sensitive lipase (HSL) and monoacylglycerol lipase (MAHL), respectively. However, these compounds are not claimed to be suitable for inhibiting HACCP.

UMO 2009/117444 disclosed compounds that are inhibitors of both GAZK and MAGHL.

In accordance with the first aspect of the invention, a compound of Formula | or

Formulas II: y (A) x is what ra

M. V. M

KE, in another 7 heaven M Uzh o u b M dya V 2

Formula I Formula II where: each of K! and K2 may be independently selected from H, C1-6 alkyl, C1-6 alkoxy, aryl, heteroaryl, partially or fully saturated heterocyclyl, C3-0 cycloalkyl, C1-6 alkyl aryl, C1-6 alkyl heteroaryl, heterocyclyl C:i-e alkyl, C3-lo cycloalkyl C:-e alkyl, Ka, halogen, OH, ONTa, OSONtTa, 5H, 5Ata, 5SOVTa, MH, MNATa, МНБЗО»МН», МНЗО»НТа,

MATasovt, MNSOV and, MATant, SOVta, SZATa, SM, SOON, SOOVtTa, SOMN:, SOMNON,

SOMNATa, SOMNOV and, 502Ata, 5OzH, 502MN:, SOMATantr, 5O2MAlTakt, where КТа and КТФ are independently selected from C1-6 alkyl, substituted C3-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl and heterocyclyl, or Kia and KIB , together with the heteroatom to which they are attached, can form a heterocyclyl, where, if К1 or К2 is C0 alkyl, alkoxy, aryl, heteroaryl, heterocyclyl, C3-10 cycloalkyl, aryl C1-6 alkyl, heteroaryl C1-6 alkyl , heterocyclyl C 1-6 alkyl, C 3-10 cycloalkyl C 1-6 alkyl, C 1-6 alkyl, C 3-1 cycloalkyl or represents a group containing one or more of these fragments, each of the specified fragments may optionally be substituted by one or more groups selected from C1c, halogen, aryl, heteroaryl, heterocyclyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, aryl C1-6 alkyl, heteroaryl C1-6 alkyl, heterocyclyl C1-6 alkyl, aryl C1-6 alkoxy, heteroaryl C':-is alkoxy, heterocyclyl C:i-is alkoxy,

C:.-is alkylamino, C:-is dialkylamino, Сch1-1io alkyl, OH, OK1s, OSOMK1s, 5H, 5К1s, ЗСОК1s, МН», MO»

MNAtTs, MNbZO»MN:, MNbOO»Ats, MATsSOVtTa, Mne(MN)MN:, MNOSOVts, MAisATa, SoOV's,

SAS, SM, SOON, SOOVIS, SOMN:, SOMNON, SOMNAiTs, SOMNOVts, S(MON)MN",

SOMATETTA, 5O2NAis, 5OZN, 502MH»o, 5O2MATSKTA, where C1is and CtTa are independently selected from C1-6 alkyl, substituted C1-6 alkyl, aryl, heteroaryl, C3-C cycloalkyl and heterocyclyl, or C1c and a, together with a heteroatom , to which they are attached, can form heterocyclyl, where, if the substituent in K1 or K2 is C3-10 alkyl, aryl, heteroaryl, heterocyclyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, aryl C1-6 alkyl, heteroaryl C--alkyl, heterocyclyl C-alkyl, aryl C-alkyl, aryl C-alkyl, heteroaryl C-alkyl, heterocyclyl C-alkyl,

C 1 - is alkylamino, C 1 - is dialkylamino, C 1 - is alkyl, C 3 - is cycloalkyl or represents a group containing one or more of these fragments, each of the indicated fragments may optionally be

Co) substituted by one or more groups selected from C1e, halogen, C1-10 alkyl, OH, OKT1e, OSOKTe,

ZN, ZATE, ZSOVTe, MN", MO", MNATE, MNBZO2MN:, MNZO»2Ate, MATTesSonvii, MN!eSsmMn)MN",

MNSOAtTe, MATenvti, SOVte, С5АTe, SM, СООН, СООВтТе, SOMN?, SOMNON, SOMNae,

SOMNOate, C(MON)MH:, SOMATentie, 5O2AtTe, 5OzH, 5O»2MH:, 5O2MATecy, where KTe and KI are independently selected from C1-6 alkyl, substituted C6-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl and heterocyclyl, or KTe and K1i, together with the heteroatom to which they are attached, may form a heterocyclyl, except that K1 and K2 are not both H or both unsubstituted methyl, or

Q1 and Q2, together with M to which they are attached, may form a heteroaryl or heterocyclic group, each of which may optionally be substituted by one or more oxygen atoms or one or more groups selected from aryl, heteroaryl, partially or fully saturated heterocyclyl, C3-C cycloalkyl, C1-C alkyl, aryl C1-C alkyl, heteroaryl

C alkyl, heterocyclyl C alkyl, Czv cycloalkyl C-e alkyl, C ethoxy, aryloxy, heteroaryloxy, heterocyclyloxy, Kga, halogen, OH, OK2a, OSOKZa, 5H, 5K2a, 5СОоК2a, МН",

МО», МНАга, МНЗО2МН»г, МНЗО»2Ага, МА2гасонг, МНе(mMnuMn»г, МНнСОВга, МАганг, Совга, б5А2га, СМ, СООН, СбООВга, SOMN:., SOMNON, SOMNага, СОМНОВга, С(MON)МН ",

СсОоМАганг, 5О2Нга, 5ОзЗН, 502МН»г, 502МК2акг, where Kg2a and K256 are independently selected from C-6 alkyl, substituted C-6 alkyl, aryl, heteroaryl, C3-v cycloalkyl and heterocyclyl, or K2a and K2B, together with a heteroatom , to which they are attached, can form a heterocyclyl, where if the substituent in the heteroaryl or heterocyclyl formed by C1 and C2 together is aryl, heteroaryl, heterocyclyl, C3-1 cycloalkyl, C1-1 alkyl, C1-1 aryl alkyl, heteroaryl C 1 -C alkyl, heterocyclyl C 1 -C alkyl, C 3 -C cycloalkyl C 1 -C alkyl, C 1 -Alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, or a group containing one or more of the indicated fragments, each of the indicated fragments may optionally be substituted by one or more groups selected from halogen, hydroxyl, C1-6 alkyl, aryl, heteroaryl, heterocyclyl, C3-1 cycloalkyl, C1-4 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C3-1 cycloalkyloxy, aryl C-4 Alkoxy, C-4 Alkoxy heteroaryl, C-4 C-4 Alkoxy heterocyclyl, C-4 C-4 Cycloalkyl C-4 Alkoxy , K2s, OK2s,

OSOV2s, 5H, 5НА2s, 5СОНОs, МН, MO», МНА2s, МНЗО»МН:, МНБЗО»Н2s, МА2геСОвага,

МНСе(МНИМНг, МНСОВ2с, MA2сАга, СОвос, С5Н2с, СМ, СООН, СООВ2s, СОМН:г, SOMNON, 60 0 СОМНА2s, СОМНОВ2s, С(ИМОН)ИМН:, СОМА2геВга, 5О2В2s, 5ОзЗН, 502МН», 502МК2сК2a, where K2s and y2C2a are independently selected from C1-6 alkyl, substituted C1-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl, and heterocyclyl, or C2c and C24, together with the heteroatom to which they are attached, may form heterocyclyl, where, if the substituent in the substituent in heteroaryl or heterocyclyl, formed by K1 and K2 together, is C1-C alkyl, aryl, heteroaryl, heterocyclyl, C3-C cycloalkyl, C:-e alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C3-1 cycloalkyloxy, aryl Sil alkoxy, heteroarylCi. alkoxy, heterocyclylCi-4Alkoxy, C3-I cycloalkylCi-4Alkoxy, or represents a group containing one or more of these fragments, each of the specified fragments can optionally be substituted by one or more groups , selected from C:-4 alkoxy, K2e, halogen, OH, OK2e,

ОСОоВ2е, 5Н, 5НА2е, 5СОН2ге, МН, МО», МНАге, МН5ОЗО»МН:, МНЗО»Н2ге, MAgesorai,

МНе(МнИМН»г, MAгенги, МНСОВге, СОН2ге, С5А2е, СМ, СООН, СООНге, SOMN:г, SOMNON,

SOMNAge, SOMNOMvge, C(MON)MH», SOMAgenai, 5O2Hge, 5OzZN, 5O2MH»g, 502MK2enyi, where K2e and K2Y are independently selected from Si-alkyl, substituted Si-alkyl, aryl, heteroaryl, C3-8 cycloalkyl and heterocyclyl , or K2e and KO, together with the heteroatom to which they are attached, can form a heterocyclyl; ring A is selected from aryl, heteroaryl and heterocyclyl moieties, each of which may optionally be substituted with one or more groups selected from halogen, C 1-6 alkyl, aryl, heteroaryl, heterocyclyl, C 1-6 alkoxy, aryloxy, heteroaryloxy , heterocyclyloxy,

Ba, Si-io alkyl, OH, OKa, OSOKa, 5ZN, ZKa, ZSOKa, MNo, MO», МНВа, МНБЗО2МН», МНЗО»Ра,

MmAason, MmnSOVa, MNes(Mmn)Mmn», MAan, SOVa, С5Va, SM, СООН, СООВa, SOMN»:, SOMNVa,

SOMNON, SOMNOVa, C(MON)MH:g, SOMAan, 5O2Ba, 5OzH, 502MH»g, 5O2MKak, where Ka and Kb are independently selected from C-6 alkyl, substituted C-6 alkyl, aryl, heteroaryl, C3-c cycloalkyl and heterocyclyl, or Ca and CO, together with the heteroatom to which they are attached, can form a heterocyclyl, where, if ring A is substituted with Ci-alkyl, aryl, heteroaryl, heterocyclyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C :1-0 alkyl, C3-1 cycloalkyl or substituted by a group containing one or more of the indicated moieties, each of the indicated moieties may optionally be substituted by one or more groups selected from halogen,

Ac, Ci-o alkyl, aryl Ci-e alkyl, heteroaryl Ci-e alkyl, heterocyclyl Ci-e alkyl, OH, OKs,

Koo) OSOVs, ZN, 5As, 5SOVs, MN, MO», MNAs, MNBZO»MN:, MNbOO»As, MAsSOvVa, MNnooVs,

МНОС(МН)МН:, МАсАа, СОВс, С5Ас, СМ, СООН, СООВс, СОМН?, SOMNON, СОМНРс,

СОМНОо с, С(МОН)МН:, СОМАсНа, 5О2гНас, ЗОзН, 5О2МН»г, 502МКska, where Ks and Ka are independently selected from Ci alkyl, substituted Ci alkyl, aryl, heteroaryl, Czv cycloalkyl and heterocyclyl, or Ks and Ka, together with the heteroatom to which they are attached, can form a heterocyclyl;

M can be M, CH or C-KZ, where KZ is halogen, C1-6 alkyl, aryl, heteroaryl, heterocyclyl, C1-C6 cycloalkyl, C1-alkyloxy, aryloxy, heteroaryloxy, heterocyclyloxy, KZa, OH, OKZa, ZN, ZKZa , OSOMZa, 5SOZa, MN», MO», MNAZa, MNOZO»MN 5»,

MNBZO»AZa, MAZasovVzZz, MnSOAZa, MNOS(MN)MN:, MAZanz, SbOVZa, S5AZa, SM, SOON,

СооВЗа, СОМНг, SOMNON, СОМНаза, СОМНОВЗа, С(MON)IMНг, СОМАЗанвз, 5О2AZа, 5ОзН, 5О2МНг, 502МАЗакз, where КЗа and КЗб are independently selected from C:-e alkyl, C-substituted alkyl, aryl, heteroaryl, C3 -in cycloalkyl and heterocyclyl, or KZa and KZB, together with the heteroatom to which they are attached, can form a heterocyclyl, where, if KZ is C1-10 alkyl, aryl, heteroaryl, heterocyclyl, C:-is alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C1-6 alkyl, C3-6 cycloalkyl, or represents a group containing one or more of these fragments, each of the specified fragments can optionally be substituted by one or more groups selected from halogen, aryl, heteroaryl, heterocyclyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, KZs, Si-io alkyl, OH, OKZs, OSOKZS, 5H,

ZNAZs, 5SOVZs, MN, MO», MNAZs, MNBO»2MN:, MNBO»AZs, MAZsSSONZA, MNoSOVZs,

MNS(Mn)MN:, MAZsAZa, SOAZs, S5AZs, SM, SOON, SOOVZs, SOMN:, SOMNON, SOMNVAZs,

SOMNOVZs, C(MON)MH:, SOMAZSAZa, 5O2AZs, ZOzZN, 5O2MN:, 5O2MAZSKZa, where KZc and KZa are independently selected from C1-6 alkyl, substituted C6-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl and heterocyclyl, or KZc and KZa, with the heteroatom to which they are attached, can form a heterocyclyl, where, if the substituent in KZ is C1-10 alkyl, aryl, heteroaryl, heterocyclyl, C:-is alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C1 -is alkyl, C3-C cycloalkyl, or represents a group containing one or more of these fragments, each of the indicated fragments may optionally be substituted by one or more groups selected from halogen, C3-C6 alkyl, ON, OKZE,

OSOVZe, 5H, 5AZe, 5SONZe, MN, MO», MNAZe, MN5OZO»MN:, MN5ZO»AZe, MAZesopvZi, (510) MNOSOAze, МНОС(МН)МН:, MAZenzi, SOVAZe, С5AZe, SM, COON, SOOVAZe, SOMN":, SOMNON,

SOMNAZe, SOMNOVZe, C(IMON)IMN:, SOMAZeZe, 5O2AZe, 5OzH, 5O2MNeg, 502MEZeZe, where KZe and KZ are independently selected from Si-alkyl, substituted Si-alkyl, aryl, heteroaryl, C3-C8 cycloalkyl and heterocyclyl, or KZe and KZ, together with the heteroatom to which they are attached, can form a heterocyclyl;

MM can be M, CH, or C-C4, where C4 is halogen, C1-0 alkyl, aryl, heteroaryl, heterocyclyl, C1-alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C3-C cycloalkyl, C4a, OH, OK4a, ZN, ZK4a, OSOM4a, 5СОm4a, МН, MO», MNAd4a, МНЗО2МН»,

MNBZO»NYA4a, MA4asSsovVar, MNnSORl4a, МНОС(МН)МН:, MA4anair, СбОВ4a, С5А4a, СМ, СООН,

SOOovVl4a, SOMNg:, SOMNON, SOMNAl4a, SOMNOV.la, S(IMON)IMNg, SOMA4anvaiaj, 502Naa, 5OzN,

ZO2MNeg, 502ME4akya4r, where K4a and K4B are independently selected from C:-e alkyl, substituted C-C alkyl, aryl, heteroaryl, C3-C cycloalkyl and heterocyclyl, or C4A and KAB, together with the heteroatom to which they are attached, can form heterocyclyl, where, if K4 is C3-10 alkyl, aryl, heteroaryl, heterocyclyl, C1-10 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C1-10 alkyl, C3-10 cycloalkyl, or represents a group containing one or more of these moieties, each of said moieties may optionally be substituted by one or more groups selected from halogen, aryl, heteroaryl, heterocyclyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C4c, C1-10 alkyl, OH , OM4s, OSOKAs, 5H,

ZN4s, 5SOVAs, MN, MO», MNA4s, MNBO»MN:, MNBO»NAs, MA4sSONYA4a, MNooVas,

МНС(МНИМНг, МА4сАл4а, СОвас, С5А4с, СМ, СООН, СООВ4с, SOMN:, SOMNON, SOMNA4s,

SOMNO as, C(MON)MH, SOMA4cVAYAa, 502H4as, 5OzZN, 5O»2MH», 502МК4сК4а, where К4с and мк4а are independently selected from C-6 alkyl, substituted C-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl and heterocyclyl, or K4c and K4a, together with the heteroatom to which they are attached, can form a heterocyclyl, where, if the substituent in KA is C1-10 alkyl, aryl, heteroaryl, heterocyclyl, C:-is alkoxy, aryloxy, heteroaryloxy , heterocyclyloxy, C1-e alkyl, C3-3 cycloalkyl, or represents a group containing one or more of these fragments, each of the specified fragments can optionally be substituted by one or more groups selected from halogen, C4e, C- io alkyl, OH, OK4e,

OSOV4e, 5H, 5AN4e, 5SOVYA4e, MN, MO», МНА4e, МН5ОЗО»МН:, МНбЗО»ВН4е, MAdesopvai,

MNSOVl4e, MNOS(MN)IMN»:, MA4evai SOV4e, С5А4e, SM, СООН, СООВ4e, SOMNg, SOMNON,

SOMNA4e, SOMNOV ale, C("MON)MH":, SOMAl4enaAi, 502B4e, 5OzZN, 5O2MH»g, 502ME4ekai, where K4e and K4i are independently selected from Ci-alkyl, substituted Ci-alkyl, aryl, heteroaryl, C3-C8 cycloalkyl and heterocyclyl, or K4e and KAl, together with the heteroatom to which they are attached, can form a heterocyclyl;

CO, together with the ring carbon atom to which it is attached, may form a carbonyl group, where the double bond in the ring of Formula I to which it is attached may be rearranged and/or saturated, respectively, or K5 is selected from H, C- is alkyl, aryl, heteroaryl, heterocyclyl, Czv cycloalkyl, Civ alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, K5a, halogen, OH, OK5a, 5H, 5K5a, OSOK5a, ZСОm5a, МН», МО», МНА5a,

МНБЗО»МН:, МНЗО»Вба, МА5асон5р, МНнСО5а, МНОС(МН)ИМН:, МАБань, СОВ5ба, С5А5Ба, СМ,

СООНн, СбовВ5а, СОМНг, СОМНОН, СОМНАБа, СОМНОВ»a, С(МОН)МН:, СОМАБанср, 5О»2НВ5а,

ZOZN, 502MNeg, 502MA5akz5r, where K5a and K5B6 are independently selected from C:-6 alkyl, substituted C:-6 alkyl, aryl, heteroaryl, C3-1 cycloalkyl and heterocyclyl, or K5ba and K5B, together with the heteroatom to which they are attached , can form heterocyclyl, where, if K5 is C1-C alkyl, aryl, heteroaryl, heterocyclyl, C1-C1-C1-C1-C1-C1-C1-C6 alkyl, C1-C1-C1-C1 cycloalkyl, or C1-C1-C1 cycloalkyl, or is a group , containing one or more of these fragments, each of the specified fragments can be optionally substituted by one or more groups selected from halogen, aryl, heteroaryl, heterocyclyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C5c, C: - is alkyl, OH, OM5c, OSONM5c, 5H,

ZN5s, 5SOVBs, MN, MO", MNABs, MNBO»2MN:, MNBO»ABs, MABsSONBa, MNoONV5s,

МНС(Мн)МН:, МАБбеАБа, СОАБс, С5А5с, СМ, СООН, СООВБс, СОМН:, СОМНОН, СОМНА5с,

SOMNO»c, С(MON)МН:, СОМАБеВАБа, 5О2А5с, ЗОзЗН, 5О2МН:, 5О2МК5сК5а, where K5c and Ba are independently selected from C1-6 alkyl, substituted C6-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl and heterocyclyl, or K5bs and K5Ba, together with the heteroatom to which they are attached, can form a heterocyclyl, where, if the substituent in K5 is a C-C alkyl, aryl, heteroaryl, heterocyclyl, C:-is alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C3-C cycloalkyl, or represents a group containing one or more of these moieties, each of said moieties may optionally be substituted by one or more groups selected from halogen, C5e, C:-C alkyl, OH, OK5e, OSOK5e,

ZN, Abe, 5SONBbe, MN, MO», MNABbe, MNBZO»MN:, MNOO»Abe, MABesovoi, MnNoSOV5e, (510) МНС(МН)МН:, MAbevnoi, SOVA5bBe, С5ZABbe, SM, СООН, СООАБe, SOMN: , SOMNON, SOMNA5e,

SOMNOA»Be, C(MON)MH:, SOMABenyi, 5O2AbBe, 5OzH, 5O»2MH:, 5O2MA5ekoii, where K5be and KB are independently selected from C-6 alkyl, substituted C-6 alkyl, aryl, heteroaryl, C3-c cycloalkyl and heterocyclyl, or K5be and K5i, together with the heteroatom to which they are attached, can form heterocyclyl;

X can be O (where the double bond of the ring attached to X in Formula III is replaced by a single bond, respectively), M, CH or C-Cb, where Cb is selected from C1-6 alkyl, aryl , heteroaryl, heterocyclyl, C:1-e alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy,

Kba, halogen, OH, OKba, ZN, ZKba, OSOKba, 5SOmMba, MN, MO», MNAba, MNZO»MN»,

MNBZO»Aba, MAbasovnb, MnSOАba, МНОС(МН)МН:, MAbanb, СОАба, С5Аба, СМ, СООН, 11 СбООВАба, SOMN:, SOMNON, SOMNаba, SOMNOV ba, С(ИМОН)ИМН:, SOMAbanvb, 5О2Нbva, 5ОзН . form a heterocyclyl, wherein, if Kb is heteroaryl or heterocyclyl, each of said moieties may optionally be substituted with one or more oxygen atoms, and if Kb is

C 1-6 alkyl, aryl, heteroaryl, heterocyclyl, C 1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C 3-1 cycloalkyl, or represents a group containing one or more of these moieties, each of said moieties may optionally be substituted by one or more groups selected from halogen, Kbs, C1-6 alkyl, C1-alkynyl, aryl, heteroaryl, heterocyclyl, C1-alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C1-6 alkyl aryl, C1-6 alkyl heteroaryl, C1-6 alkyl heterocyclyl, arylCi-e alkoxy, heteroarylCi-e alkoxy, heterocyclylCi-e alkoxy, OH, ONbs, OSONVbs, 5Н, 5Абс, 5СОНбs, МН», МО», МНЕбs,

MNSe(MNIMN»g, MNBZO»MN»:, MNZO»Abs, MAbsSOVba, MNSOVbs, MAbsnba, SOVbs, C5Abs, SM,

СООН, СООАбс, СОМН:, СОМНАбс, СОМНОНбс, СОМНОН, С(МОН)МН», СОМАбсенНва, 5О2НАбс,

ZOZN, 502MNeg, 502MEbseba, wherein Rbs and Kba are independently selected from C:-e alkyl, substituted C:-6 alkyl, aryl, heteroaryl, C3a cycloalkyl and heterocyclyl, or Kbs and Kba, together with the heteroatom to which they are attached, may form a heterocyclyl, where, if the substituent in Kb is heteroaryl or heterocyclyl, each of said moieties may optionally be substituted with one or more oxygen atoms, or if

Ko) the substituent in Kb is C-C alkyl, C-E alkynyl, aryl, heteroaryl, heterocyclyl, C-E-alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, aryl C-E alkyl, heteroaryl C-E alkyl, C-E heterocyclyl alkyl, aryl C.i.e. alkoxy, heteroaryl C.i.e. alkoxy, heterocyclyl C.i.e. alkoxy,

C3-C cycloalkyl, or represents a group containing one or more of these moieties, each of said moieties may optionally be substituted by one or more groups selected from halogen, C6, C1-6 alkyl, C4-Alkoxy, OH, OKbe, OSOKbe, 5H, 5Kbe, 5SOKbe, MN", MO",

MNAbe, MNS(MN)IMNg, MNZO»MN:, MNbZO»2Abe, MAbesonby, MNSONbe, MAbenby, SONbe,

C5Abe, SM, SOON, SOONbe, SOMN:, SOMNON, SOMNAbe, SOMNOVbe, S(MONMN",

SOMAbenbi, 5O2Abe, 5OzH, 5O2MH", 502MKBekbii, where Kbe and Kbi are independently selected from C1-6 alkyl, substituted C-is alkyl, aryl, heteroaryl, C3-C cycloalkyl and heterocyclyl, or Kbe and

Kb, together with the heteroatom to which they are attached, can form a heterocyclyl;

M can be M, CH or C-K7, where K7 is selected from C:-is alkyl, aryl, heteroaryl, heterocyclyl, C-is alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, K7a, halogen, OH,

OvV?7a, 5H, 5A7a, OSON7Ta, 5SON7a, МН, MO», МНА7a, МНЗО2гМН»г, МНЗО»А7а, МА7асонт7н,

МНОСОА?a, МНОС(МН)ИМН:, МА7ант, СОВ7а, СЗА7а, СМ, СОН, СООН7а, СОМН»:, SOMNON, СОМНА7а, СОМНОВ?7a, С(ИМОН)МН:, СОМА7ант, 502Н7а, 5ОзН, 502МНг, 5О2МК7акт, where

K7a and K7b5 are independently selected from C1-6 alkyl, substituted C1-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl, and heterocyclyl, or K7a and K7b, together with the heteroatom to which they are attached, may form a heterocyclyl, where, if K7 represents heteroaryl or heterocyclyl, each of the specified fragments may optionally be substituted by one or more oxygen atoms, and if K7 represents

C 1 -alkyl, aryl, heteroaryl, heterocyclyl, C 1 -alkyl, aryloxy, heteroaryloxy, heterocyclyloxy, C 3 -C cycloalkyl or represents a group containing one or more of these moieties, each of said moieties may optionally be substituted by one or more groups , selected from halogen, C7c, C1 alkyl, C1-alkynyl, aryl, heteroaryl, heterocyclyl, C1-alkyloxy, aryloxy, heteroaryloxy, heterocyclyloxy, C1-6 alkyl aryl, C1-6 alkyl heteroaryl, C1-6 alkyl heterocyclyl, C1-6 alkyl, aryl Ci-E Alkoxy, heteroaryl Ci-E Alkoxy, heterocyclyl CiE Alkoxy, OH, O7c, OSOK7c, ZN, 5К7c, 5СОМ7c, МН», MO», МНА?7с,

МНе(МнуМНн»г, МНЗО»МН», МНЗО»А7с, МА7сССОВ?a, МНСОВ7s, МА7сА?7a, СОВ7s, С5А7s, СМ,

СооОНн, СООН7с, СОМН:, СОМНА7с, СОМНОНВ7с, СОМНОН, С(МОН)МН», СОМА7сНА?Та, 50287с, бо ЗОЗН, 502МНег, 502МЕ7св7а, where Б7с and К7а are independently selected from C:- is alkyl substituted by C:- 6 alkyl, aryl, heteroaryl, C1-C cycloalkyl and heterocyclyl, or K7/c and K7a, together with the heteroatom to which they are attached, can form a heterocyclyl, where, if the substituent in K7 is heteroaryl or heterocyclyl, each of the specified fragments is not required may necessarily be substituted by one or more oxygen atoms, or if the substituent in K7 is C-6 alkyl, C-6 alkynyl, aryl, heteroaryl, heterocyclyl, C6-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, aryl C6 alkyl, heteroarylCi-e alkyl, heterocyclylCi-e alkyl, arylCi-e lkoxy, heteroarylCi-e lkoxy, heterocyclylCi-e lkoxy,

C3-C cycloalkyl, or represents a group containing one or more of these moieties, each of said moieties may optionally be substituted by one or more groups selected from halogen, aryl, heteroaryl, heterocyclyl, arylCi alkyl, heteroaryl C !-C alkyl, heterocyclyl C-C alkyl, C:C-4 Alkoxy, C7e, C:C-C alkyl, OH, OK7e, OSOK?e, 5H, 5K7e, BSOK?7e,

MN, MO», MNA7e, MNZO»gMN:, MNZO»VA7e, MNOS(MN)MN:, MA7eSOv, MNSOV?e, MA7enli,

СОВ7e, С5А7e, СМ, СООН, СООВ7e, СОМН:, SOMNON, СОМНА7е, СОМНОНВ?еЕ, С(MON)МН»

SOMA7envli, 502A7e, 5OzH, 5O2MH», 502MK7ecli, where K7e and K7/i are independently selected from C1-6 alkyl, substituted C1-6 alkyl, aryl, heteroaryl, C3-C cycloalkyl and heterocyclyl, or K7e and KLI, together with the heteroatom to which they are attached, can form a heterocyclyl; 7 can be M, CH or C-K8, where K8 is selected from C-6 alkyl, aryl, heteroaryl, heterocyclyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, Kva, halogen, OH,

OVva, 5H, 5Ava, OSORVa, 5SOVVa, МНg, MO», МНАВа, МНЗО2МНг, МNBЗО»Ava, MAbVasopvv,

MNSO Va, MNOS(MN)IMNg, MAVanvr, SOVVva, S5ZAVa, SM, SOON, SOOAVa, SOMN», SOMNON,

SOMNAvVa, SOMNO Va, C(MON)MN:, SOMAVvVanvh, 502Ava, 5ОзН, 502МН»:, 5О2МКваквь, where

Kwa and K8b are independently selected from C1-6 alkyl, substituted C1-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl, and heterocyclyl, or Mwa and K8, together with the heteroatom to which they are attached, may form a heterocyclyl, where, if K8 represents C3-alkyl, C1-10 alkyl, aryl, heteroaryl, heterocyclyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C3-6 cycloalkyl, or represents a group containing one or more of these fragments, each of the indicated fragments may optionally be substituted by one or more groups selected from halogen, C8c, C1-6 alkyl, aryl, heteroaryl, heterocyclyl, C1-6 oxy, aryloxy, heteroaryloxy, heterocyclyloxy, arylC1-6 alkyl,

Z heteroaryl Ci-e alkyl, heterocyclyl C.:-e alkyl, aryl Ci-e alkoxy, heteroaryl Ci-e alkoxy, heterocyclyl Ci-e alkoxy, OH, OKvs, OSOM8s, 5H, 5К8s, 5СОКВвs, МН, MO», МНАВСс,

MNBZO»MN»g, MNBZO»2AVs, MAVSSOVVa, MNSOA vs, MNS(MN)IMN:, MAvsAVa, SOVVs, SAVsS, SM,

СООНн, СООВвВвс, СОМН:, SOMNON, SOMNAV8s, SOMNOVvs, С(MON)МН», СОМАВ8сНВа, 502А8с, 5ОЗН, 502МНег, 502МЕ8св8а, where P8c and K8a are independently selected from C:-e alkyl, substituted C:-6 alkyl , aryl, heteroaryl, C3-C6 cycloalkyl and heterocyclyl, or K8vs and K8a, together with the heteroatom to which they are attached, can form heterocyclyl, where, if the substituent in K8 is C-C alkyl, aryl, heteroaryl, heterocyclyl, C:- is alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, arylCi-e alkyl, heteroarylCi-e alkyl, heterocyclylCi-e alkyl, arylCi-e lkoxy, heteroarylCi-e alkoxy, heterocyclylCi-e lkoxy,

C3-C cycloalkyl, or represents a group containing one or more of these fragments, each of the specified fragments can optionally be substituted by one or more groups selected from halogen, C8e, C1-C alkyl OH, OKe, OSOCe, ZN, 5Kve, 5ZSOKve, MN, MO", MNAVe,

MNBZO»MN:, MNBZO»Ave, MAvbVesSoOvVI, MNSOVVe, MNOS(MN)IMN:, MAVenavai, SOVve, SZAVe, SM,

СООНн, СООвВве, СОМНг, СОМНОН, СОМНАВе, СОМНОВВе, С(МОН)МН»:, SOMAVenvi, 50286,

ZOZN, 5O2MH:, 502ME8evvy, where Kve and B8y are independently selected from C-6 alkyl, substituted C-6 alkyl, aryl, heteroaryl, C3a cycloalkyl and heterocyclyl, or Kwe and Kv, together with the heteroatom to which they are attached, can form heterocyclyl; where, no more than two atoms or groups marked X, Y and 7 can represent M; where, if UM is M, the SOMK1TK2 group may instead be attached to MU, rearranging the double bonds in Formula I, respectively; or a pharmaceutically acceptable salt or ester thereof; provided that if K! and K2 together form piperidinyl in compounds of Formula |, piperidinyl is not substituted by methyl, dimethyl, ethyl, isopropyl, tert-butyl, methoxycarbonyl, trifluoromethyl, chlorine, bromine or benzyl, provided that K1 and K2 together in compounds of Formula I do not form 6 ,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl, b-methoxy-3,4-dihydro-1H-isoquinolin-2-yl, 7-methoxy-3,4-dihydro-1H -isoquinolin-2-yl, 7-amino-3,4-dihydro-1H-isoquinolin-2-yl, 7-nitro-3,4-dihydro-1H-isoquinolin-2-yl, 3,4-dihydro -1 H-isoquinolin-2-yl, 3,4-dihydro-1 H-isoquinolin-1-yl, C,4-dihydro-2H-quinolin-1-yl, pyrrolidin-1-yl, 3,6-dihydro -2H-pyridin-1-yl, 8-aza-spiro|(4,5I|dec-v-yl, 1,3-dihydroisoindol-g-yl, oxahydroisoindol-g-yl, 60 1,2,6-triaza -spiro|2, B|oct-1-en-6-yl or azepan-1-yl,

provided that if C1 or C2 is unsubstituted methyl, the other of C1 or C2 is not 4-chlorobutyl, 4-azidobutyl, or 4-isothiocyanatobutyl, provided that ring A in compounds of Formula | does not form pyridine, pyrimidine, substituted pyridine or substituted pyrimidine if K! and K2, together with M to which they are attached, form piperidinyl, piperazinyl, substituted piperidinyl, or substituted piperazinyl, and provided that the compound is not (4-phenyl-1H-imidazol-1-yl)(4-(quinoline) -2-ylmethyl)piperazine-1-ylumethanone.

It was found that the compounds according to the invention modulate the activity of the enzyme fatty acid amide hydrolase (FAH). In particular, the compounds possess inhibitory properties in relation to this enzyme and demonstrate inhibition of GAZK ip miigo at a concentration of 10

MKM or less. In addition, many of these compounds exhibit potent inhibition of ip migo GABA at concentrations of 100 nM or less, and also exhibit inhibition of ip mimo in central nervous system tissue and peripheral tissue. It has also been found that the compounds of the invention are relatively specific in relation to GAC, such that they show a relatively low degree of inhibition of other serine hydrolases, for example, monoacylglycerol hydrolase. They are also relatively metabolically stable and exhibit a relatively high affinity for HACCP. This means. What can be expected to achieve a relatively long-term inhibition of GAZK with their help.

In addition, some compounds of the invention have been found to be selective, such that they inhibit GABA to a greater extent in central nervous system tissue compared to peripheral tissue. Other compounds have also shown selectivity, such that they inhibit GABA to a greater extent in peripheral tissue than in central nervous system tissue.

Certain compounds of the invention have been found to be particularly suitable for administration to the lungs of a subject. It has been found that the compounds can effectively inhibit GAP in the lungs without entering the subject's bloodstream. Thus, they have a localized inhibitory effect on GAZK, rather than a systemic effect.

The term "C1 alkyl" in this description denotes a linear or branched saturated hydrocarbon group containing from x to y carbon atoms. For example, C:1-alkyl denotes a linear or

From a branched, saturated hydrocarbon group containing from 1 to 6 carbon atoms. Examples of C1-6 alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl and hexyl. Preferably, the hydrocarbon group is linear.

The C-io alkyl group is preferably C alkyl. The term "C1 alkyl" is also used to denote a linear or branched saturated hydrocarbon group containing from x to y carbon atoms and in which the terminal methyl group is additionally substituted, i.e. in such a way as to represent a C1 alkylene group.

The term "Chu alkynyl" as used herein refers to a linear or branched hydrocarbon group containing from x to y carbon atoms and at least one carbon-carbon triple bond. For example, C:i-e alkynyl denotes a linear or branched hydrocarbon group containing from 1 to b carbon atoms. Examples of C1-E alkynyl groups include ethynyl, methylbutynyl (eg, 3-methyl-1-butynyl), 1,3-butadiinyl, and 1,3,5-hexatriynyl.

The term "aryl" as used herein refers to a C-2 monocyclic or bicyclic hydrocarbon ring where at least one ring is aromatic. Examples of such groups include phenyl, naphthalenyl, and tetrahydronaphthalenyl.

The term "teteroaryl" as used herein refers to a 5-6 membered monocyclic aromatic or fused 8-10 membered bicyclic aromatic ring, wherein the monocyclic or bicyclic ring contains from 1 to 4 heteroatoms selected from oxygen, nitrogen, and sulfur. Examples of such monocyclic aromatic rings include thienyl, furyl, furanyl, pyrrolyl, triazolyl, tetrazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyranyl, pyrazolyl, pyrimidyl, pyridazinyl, pyrazinyl, pyridyl, triazinyl, tetrazinyl, etc...

Examples of such bicyclic aromatic rings include quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, pteridinyl, cinolinyl, phthalazinyl, naphthyridinyl, indolyl, isoindolyl, azaindolyl, indolizinyl, indazolyl, purinyl, pyrrolepyridyl, furopyridyl, benzofuranyl, isobenzofuranyl, benzothienyl, benzoyl, benzoyl, benzoimidazole benzothiazolyl, benzoisothiazolyl, benzoxadiazolyl, benzothiadiazolyl and imidazopyridyl.

The term "heteroaryl substituted with one or more oxygen atoms" refers to a heteroaryl ring that contains one or more oxygen atoms attached to the ring. This does not mean that the heteroaryl ring contains one or more oxygen atoms as ring atoms, although in some embodiments this may be the case. Preferably, one or more oxygen atoms are attached to the nitrogen heteroatom in the heteroaryl ring. A heteroaryl substituted by an oxygen atom may contain an M-oxide. An example of a heteroaryl substituted by one or more oxygen atoms is 1-oxidopyridyl, in which the pyridyl nitrogen atom is oxidized.

The term "tetracyclyl" refers to a 3-8 (preferably 4-8- and more preferably 4-7-) membered monocyclic ring or a fused 8-12 membered bicyclic ring, which may be saturated or partially unsaturated, where the monocyclic or bicyclic the ring contains from 1 to 4 heteroatoms selected from oxygen, nitrogen, silicon or sulfur Examples of such monocyclic rings include oxaziridinyl, oxyranyl, dioxyranyl, aziridinyl, pyrrolidinyl, azetidinyl, pyrazolidinyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, hydantoinyl , валеролактаміл, оксираніл, оксетаніл, діоксоланіл, діоксаніл, оксатіоланіл, оксатіаніл, дитіаніл, дигідрофураніл, тетрагідрофураніл, дигідропіраніл, тетрагідропіраніл, тетрагідропіридил, тетрагідропіримідиніл, тетрагідротіофеніл, тетрагідротіопіраніл, діазепаніл та азепаніл. Приклади таких біциклічних кілець включають індолініл, ізоіїндолініл, бензопіраніл, хінуклідиніл, 2,3,4,5-tetrahydro-1H-3-benzazepine, 4-(benzoi|941(/1,3|dioxol-5-ylmethyl)pi perazin-1-yl and tetrahydroisoquinolinyl.

The term "heterocyclyl substituted with one or more oxygen atoms" refers to a heterocyclyl ring containing one or more oxygen atoms attached to the ring. This does not mean that the heterocyclyl ring contains one or more oxygen atoms as ring atoms, although in some embodiments this may be the case. Preferably, one or more oxygen atoms are attached to a heteroatom, such as nitrogen or sulfur, in the heterocyclyl ring. An example of a heterocyclyl substituted with one or more oxygen atoms is 1,1-dioxido-1,3-thiazolidinyl.

The terms "bicyclic ring" and "fused" in the context of a bicyclic ring refer to two rings that are joined together along a bond between two atoms (e.g., naphthalene), across a sequence of atoms, to form a bridge (e.g., quinuclidine), or together at to the same atom, with the formation of a spiro compound (for example, 1,4-dioxa-8-aza-spiro(4,5|decane and M,3,3-dimethyl-1,5-dioxaspirole5,5)|undecane-9 -il).

The term "C3-10 cycloalkyl" as used herein means a saturated hydrocarbon ring containing from x to y carbon atoms, which may be mono-, bi-, or tricyclic. For example, C3-10 cycloalkyl refers to a saturated mono-, bi-, or tricyclic hydrocarbon ring , containing from 3 to 10 carbon atoms. Examples of C3-O cycloalkyl groups include cyclopropyl, cyclobutyl,

Zo cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and adamantyl.

The term "aryl Chu alkyl" as used herein means an aryl group, as defined above, attached to a Chu alkyl, as defined above. For example, aryl C:-e alkyl denotes an aryl group attached to a linear or branched saturated hydrocarbon group containing from 1 to b carbon atoms. Examples of arylCi-alkyl groups include benzyl, phenylethyl, phenylpropyl, phenylbutyl, phenylpentyl and phenylhexyl.

The terms "heteroaryl Xu alkyl", "heterocyclyl Xu alkyl" and "Xu cycloalkyl Xu alkyl" herein refer to a heteroaryl, heterocyclyl or Xu cycloalkyl group, as defined above, attached to a Xu alkyl, as defined above.

The term "Chu alkyl" as used herein refers to an -O-Chu alkyl group, where Chu alkyl is as defined above. Examples of such groups include methoxy, ethoxy, propoxy, butoxy, pentoxy and hexoxy.

The term "aryloxy" herein refers to an -O-aryl group. Examples of such groups include phenoxy. The terms "heteroaryloxy" and "heterocyclyloxy" herein refer to the groups -O-heteroaryl and -O-heterocyclyl, respectively.

The term thalogen' in this specification denotes a fluorine, chlorine, bromine or iodine atom, unless otherwise specified.

The term "Chu alkylamino" in this description denotes a secondary amino group (-MH(K)), in which the group

E is selected from linear or branched saturated hydrocarbon groups containing from x to y carbon atoms. Examples of Xu alkylamino groups include methylamino, ethylamino, and propylamino.

The term "Schu dialkylamino" in this description denotes a tertiary amino group (-MAK(KU)) in which each of the groups K and K" is independently selected from linear or branched saturated hydrocarbon groups containing from x to y carbon atoms. Examples of Schu groups dialkylamino includes dimethylamino, methylethylamino, and diethylamino.

The term "substituted C 1-6 alkyl" is used herein with reference to the identity of the various groups identified as K (eg, in the expression "where K 1 and K 8 are independently selected from C 1-6 alkyl, substituted C 1-6 alkyl, aryl, heteroaryl, C 3 -in cycloalkyl and heterocyclyl"), and indicates that a specific group K (for example, Kta, K2c, 44, K5be, etc.) can be replaced by one or more groups selected from K", halogen, OH, OK, 5H, ZK .

SOOV SOMNo, SOMNON, SOMNA SOMA'V" SOMNOV', С(МОН)МН», ОВ", 5OzZN, 5О2МН»5,

ZOM", where K and K" are independently selected from C1-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl and heterocyclyl, or EC" and K", together with the heteroatom to which they are attached, can form heterocyclyl. "Pharmaceutically acceptable salts of the compounds of the present invention include salts with inorganic bases, salts with organic bases, salts with inorganic acids, salts with organic acids, and salts with basic or acidic amino acids. Salts with acids may, in particular, be used in some cases. Examples salts include the hydrochloride salt, the acetate salt, the trifluoroacetate salt, the methanesulfonate salt, the 2-hydroxypropane-1,2,3-tricarboxylate salt, the (2K, 3K)-2,3-dihydroxysuccinate salt, the phosphate salt, and the oxalate salt. may exist in a solvate form (eg, a hydrate) or a non-solvated form (eg, not a hydrate). In the case of a solvate form, additional solvents may be alcohols such as propan-2-ol. "Pharmaceutically acceptable esters of the compounds of the invention" - - these are derivatives in which one or more carboxyl groups (i.e. -С(О)ОН) in the indicated compounds are modified by reaction with an alcohol fragment of Ш-ОН with the formation of the group -С(О)ОЙ, where О can be С. in al ring (for example, C:-6 alkyl), aryl, heteroaryl, C3-6 cycloalkyl, or combinations thereof.

General methods of obtaining salts and esters are well known to a person skilled in the art.

The pharmaceutical acceptability of the salts and esters will depend on a variety of factors, including the processing characteristics of the drug and the behavior of the ip mimo, and one of ordinary skill in the art can readily evaluate such factors in light of this disclosure.

If the compounds of the invention exist in various enantiomeric and/or diastereomeric forms (including geometric double bond isomerism), said compounds may be obtained as isomeric mixtures or racemates, although the invention relates to all such enantiomers or isomers present in optically pure form or in the form of a mixture with other isomers.

Individual enantiomers or isomers can be obtained by methods known in the art, such as optical separation of products or intermediates (eg, chiral chromatographic separation (eg, chiral HPLC)), or an enantiomeric synthesis approach.

Likewise, while the compounds of the invention may exist as alternative tautomeric forms (eg, keto/enol, amide/imidic acid), the invention relates to the individual tautomers alone, as well as to mixtures of tautomers in all proportions.

In the compounds of Formula II, 0, 1 or 2 atoms or groups marked X, Y and 7 can be

M.

In a specific variant, the formula of the compound according to the invention is selected from Formula I or Formula II: dyan, -i

Co xx

And | m | 7

M Ve M also g t o u b M

Formula I Formula II where: each with CI! and K2 may be independently selected from H, C1-0 alkyl, alkoxy, aryl, heteroaryl, heterocyclyl, C3-0 cycloalkyl, aryl C1-6 alkyl, heteroaryl C1-6 alkyl, heterocyclyl C1-6 alkyl, and C3-0 cycloalkyl C1-6 -is alkyl, each of which, with the exception of H, may optionally be substituted by one or more groups selected from halogen, C1-6 alkyl, aryl, heteroaryl, heterocyclyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy , C'-alkyl aryl, C-alkyl heteroaryl, C-alkyl heterocyclyl, C-alkyl aryl, heteroaryl

C:-is alkoxy, C:-is alkoxy heterocyclyl, amino, C:-is alkylamino and C:-is dialkylamino, except that Q1 and Q2 are not both H, or

C1 and C2, together with M to which they are attached, may form a heteroaryl or heterocyclyl group, each of which may optionally be substituted with one or more groups selected from hydroxy, aryl, heteroaryl, heterocyclyl, C3-C cycloalkyl, C -is alkyl, aryl C1-6 alkyl, heteroaryl C1-6 alkyl, heterocyclyl C1-6 alkyl, C3-6 cycloalkyl C1-6 alkyl, C1-6 alkoxy,

aryloxy, heteroaryloxy and heterocyclyloxy, each of which may be optionally substituted with a group selected from halogen, hydroxyl, C1-4 alkyl, aryl, heteroaryl, C1-4 alkoxy, aryloxy, heteroaryloxy, arylC1-4 alkoxy and heteroaryl C:.4 alkoxy, each of which, with the exception of halogen and hydroxyl, may optionally be substituted by C.-4 alkoxy; ring A is selected from aryl, heteroaryl, and heterocyclyl moieties, each of which may be optionally substituted with one or more groups selected from halogen, hydroxyl, aryl, heteroaryl, heterocyclyl, C1-6 alkoxy, aryloxy, heteroaryloxy, and heterocyclyloxy, each of which, with the exception of halogen and hydroxyl, may optionally be substituted with halogen, cyano, amide and carboxylic acid;

M can be M, CH or C-C3, where C3 is halogen, aryl, heteroaryl, heterocyclyl or C3-C cycloalkyl, each of which, with the exception of halogen, may optionally be substituted with halogen;

MM can be M, CH or C-C4, where C4 is C3-0 alkyl, aryl, heteroaryl, heterocyclyl or C3-C cycloalkyl, each of which may optionally be substituted with halogen;

E5 is selected from H, C1-6 alkyl, aryl, heteroaryl, heterocyclyl and C3-6 cycloalkyl, each of which, with the exception of H, may optionally be substituted with halogen;

X may be M, CH, or C-Cb, where Cb is selected from C3-6 alkyl, aryl, heteroaryl, and heterocyclyl, each of which, with the exception of H, may optionally be substituted with one or more groups selected from halogen , hydroxyl, amine, amide, cyano, aryl, heteroaryl, heterocyclyl, C 1-6 alkyl, aryloxy, heteroaryloxy, heterocyclyloxy, C 1-6 alkyl aryl, C 1-6 alkyl heteroaryl, C 1-6 alkyl heterocyclyl, C 1-6 alkyl aryl , heteroaryl C 1-6 alkoxy and heterocyclyl C 1-6 alkoxy;

Y may be M, CH, or C-K7, where K7 is selected from C:-alkyl, aryl, heteroaryl, and heterocyclyl, each of which, with the exception of H, may optionally be substituted with one or more groups selected from halogen . C1-6 alkyl, aryl C1-6 alkoxy, heteroaryl C1-6 alkoxy and heterocyclyl C1-6 alkoxy, each of which may optionally be substituted with C1-4 alkyl, cyano, amine, amide, halogen, aryl , heteroaryl, heterocyclyl, aryl C1-6 alkyl, heteroaryl C1-6 alkyl, and heterocyclyl C1-6 alkyl; 27 may be M, CH or C-K8, where K8 is selected from C-C alkyl, aryl, heteroaryl, heterocyclyl or C-C cycloalkyl, each of which may optionally be substituted with halogen; or a pharmaceutically acceptable salt or ester thereof; provided that if K! and K2 together form piperidinyl in compounds of Formula I, the piperidinyl being unsubstituted by methyl, dimethyl, ethyl, isopropyl, tert-butyl, trifluoromethyl, chlorine, bromine or benzyl.

In accordance with another variant of the invention, a compound of Formula I or Formula is proposed

I: lk -x

And DYA

M Ve M shcha i ra; Her t 0 y b M

Formula I Formula II where: each with CI! and K2 may be independently selected from H, C1-0 alkyl, alkoxy, aryl, heteroaryl, partially or fully saturated heterocyclyl, C3-10 cycloalkyl, aryl C1-6 alkyl, C1-6 alkyl heteroaryl, C1-6 heterocyclyl alkyl, C3-lo cycloalkyl C:-e alkyl, Ka, halogen, OH, OKTa, 5H, ZKTa, OSOKTa, ZSOKTa, MN», MNEATa, MATant, Sova, С5Ata, SM,

СооОНн, СООвАта, СОМН», 502Ata, 5OzH, 502МНг, СОМАтТант, 502МАКтакт, where КТа and КТХ are independently selected from C1-6 alkyl, substituted C1-6 alkyl, C3-6 cycloalkyl and heterocyclyl, and КТа and КЙ, together with an adjacent heteroatom, can form a heterocyclyl,

where, if K1 or K2 is Co alkyl, alkoxy, aryl, heteroaryl, heterocyclyl, C3-10 cycloalkyl, aryl C1-6 alkyl, heteroaryl C1-6 alkyl, heterocyclyl C1-6 alkyl, C3-10 cycloalkyl C1-6 alkyl, C1-6 alkyl, C3-1 cycloalkyl or represents a group containing one or more of these fragments, each of the indicated fragments may optionally be substituted by K1c, halogen,

Siv alkyl, aryl, heteroaryl, heterocyclyl, C:-is alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, aryl C.-is alkyl, heteroaryl C.-is alkyl, heterocyclyl C.-is alkyl, aryl C-is alkyl, heteroaryl C, C-alkoxy, heterocyclyl, C-alkoxy, C-alkylamino, C-alkylamino,

Si-o alkyl, OH, OKITs, OSOKI1s, ZN, ZKI1s, ZSOMK1s, Mng, MNA Ts, MATeVtTa, SOVts, SA s,

СМ, СООН, СООВс, СОМН", 5О2НВИ1с, 5ОзЗН, 5О2МНхг?, SOMATeВta, 5О2МАста, where КИ1с and La are independently selected from C1-6 alkyl, substituted C1-6 alkyl, C3-1 cycloalkyl and heterocyclyl, and K1с and K14, together with an adjacent heteroatom, can form heterocyclyl, where, if the substituent in K1 or K2 is C3-10 alkyl, aryl, heteroaryl, heterocyclyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, aryl C1-6 alkyl , heteroaryl C--alkyl, heterocyclyl C-alkyl, aryl C-alkyl, aryl C-alkyl, heteroaryl C-alkyl, heterocyclyl C-alkyl,

C1 is alkylamino, C1 is dialkylamino, C1 is alkyl, C3 is cycloalkyl or represents a group containing one or more of these fragments, each of the specified fragments can optionally be substituted with KTe, Si-o alkyl, OH, OKTe, OSOMTe, 5H, ZKt1e, ZSOKTe, MNg, MNATe, MAtTevitt,

SOVATie, S5ATie, SM, SOON, SOOVtTe, SOMN"?, 5O»ATie, 5OZN, 502MN:, SOMAtenii,

ZO2MALTs, wherein C1e and C11 are independently selected from C1-6 alkyl, substituted C1-6 alkyl, C3-6 cycloalkyl, and heterocyclyl, and C1e and C1, together with an adjacent heteroatom, may form a heterocyclyl, except that C1 and K2 are not both H, or

Q1 and Q2, together with M to which they are attached, may form a heteroaryl or heterocyclyl group, each of which may be optionally substituted with one or more groups selected from hydroxy, aryl, heteroaryl, partially or fully saturated heterocyclyl, C3- in cycloalkyl, C1-6 alkyl, aryl C1-6 alkyl, heteroaryl C1-6 alkyl, heterocyclyl C6-6 alkyl, C3-8 cycloalkyl C6-6 alkyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, K2a, halogen,

ОН, ОвРга, 5Н, 5Рга, OSORга, 5СОРга, МН, МНАга, МАгангБ, СОВга, С5ЗАга, СМ, СОН,

СОовВга, СОМН», 502Вга, 5ОзН, 502МНг, СОМАганг, 5О2МК2акаг, where K2a and E25 are independently selected from C1-e alkyl, substituted C1-e alkyl, C3-jav cycloalkyl and heterocyclyl, and K2a and K2b,

Zo, together with an adjacent heteroatom, can form a heterocyclyl, where, if the substituent in heteroaryl or heterocyclyl, formed by K1 and K2 together, is aryl, heteroaryl, heterocyclyl, C3-1 cycloalkyl, C1-1 alkyl, C1-1 aryl alkyl, heteroaryl C 1 -C alkyl, heterocyclyl C 1 -C alkyl, C 3 -C cycloalkyl C 1 -C alkyl, C 1 -C alkyl, aryloxy, heteroaryloxy, heterocyclyloxy, or groups containing one or more of the indicated fragments, each of the indicated fragments is optional may optionally be substituted by a group selected from halogen, hydroxyl, C1-6 alkyl, aryl, heteroaryl, heterocyclyl, C3-1 cycloalkyl, C1-4 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C3-1 cycloalkyloxy, aryl C:- 4 Alkoxy, heteroaryl

C 6 lkoxy, heterocyclyl C-4 lkoxy, C3-1 cycloalkyl C-4 lkoxy, K2c, OK2c, 5H, 52,

ОоСОВ2с, 5СОНос, МН, МНА2с, MA2сНга, СОВ2с, С5Н2с, СМ, СООН, СООВ2с, СОМН»

ЗО2Н2с, 5ОзН, 502МНг, СОМА2еВга, 502МК2сК2а, where К2с and К2а are independently selected from C-6 alkyl, substituted C-C alkyl, C3-C cycloalkyl, and heterocyclyl, and K2C and K2A, together with an adjacent heteroatom, can form a heterocyclyl, where , if the substituent in the substituent in heteroaryl or heterocyclyl consisting of C1 and C2 together is C1-4 alkyl, aryl, heteroaryl, heterocyclyl, C3-1 cycloalkyl, C1-4 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C3- in cycloalkyloxy, C.-4 aryl, heteroaryl

Ci.« alkoxy, heterocyclyl Ci-4 alkoxy, C3-C cycloalkyl Ci-4 alkoxy, or represents a group containing one or more of these fragments, each of the specified fragments may optionally be substituted by C:-4 alkoxy, K2e, halogen, OH, OK2e, 5Н, 5К26, ОСОНге, 5СОН2ге, МН»

МНаге, MAгенгі, СОнге, С5Наге, СМ, СООН, СООН2ге, СОМН», 5О2Нге, ЗозЗН, 5О»МН»,

SOMAgenoi, 502MK2ev2i, where B2e and B2i are independently selected from C:-e alkyl, substituted C-6 alkyl, C3-b cycloalkyl and heterocyclyl, and K2e and KI, together with an adjacent heteroatom, can form heterocyclyl; ring A is selected from aryl, heteroaryl and heterocyclyl moieties, each of which may optionally be substituted with one or more groups selected from halogen, C3-C6 alkyl, hydroxyl, aryl, heteroaryl, heterocyclyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy , Ka, Si-o alkyl, OH, OKa, OSOKKa, 5H, 5Ka, ZSOKa, MNg, MNAa, MVanb,

СОБа, С5Ra, СМ, СООН, СООБа, СОМН", 50»2Ba, 5OzH, 502МНг, СОМАРанв, 50МКакр, where Ka and Kb are independently selected from C₁₀ alkyl, substituted C₁₀ alkyl, C₃₀ cycloalkyl and heterocyclyl, and Ka and KB, together with an adjacent heteroatom, can form a heterocyclyl, because where, if ring A is substituted by C-is alkyl, aryl, heteroaryl, heterocyclyl, C-is alkoxy,

aryloxy, heteroaryloxy, heterocyclyloxy, C1-0 alkyl, C3-1 cycloalkyl, or substituted by a group containing one or more of the indicated fragments, each of the indicated fragments may optionally be substituted by Ks, C1-0 alkyl, OH, OKs, OSOKs , 5H, 5Ks, SOS, MN",

МНАс, МАсВНа, СОАс, С5Ас, СМ, СООН, СООАс, СОМН», 5О2Ас, ЗозЗН, 5О»2МНг, СОМНАsna,

ZO2MKOKa, where Ks and Ka are independently selected from C..e. alkyl, substituted C.sub.3-e alkyl, C.sub.3-c cycloalkyl, and heterocyclyl, and Ks and Ka, together with an adjacent heteroatom, can form heterocyclyl;

M can be M, CH or C-CZ, where CZ is halogen, C1-C6 alkyl, aryl, heteroaryl, heterocyclyl, C1-C6 cycloalkyl, C1-C6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, CZa, OH, OKZa, 5H, 5KZa , OSOokZa, 5SOKZa, MNg, MNAZA, MAZanz, SoVzZa,

С5АЗа, СМ, СООН, СООАЗа, СОМН», 502АЗа, ЗОзН, 5О2МНо, СОМAZanz, 5ОгМКЗакз, where

KZa and KZp are independently selected from C 1-6 alkyl, substituted C 1-6 alkyl, C 3-1 cycloalkyl, and heterocyclyl, and KZa and KZB, together with an adjacent heteroatom, can form heterocyclyl, where if KZ is C 1-10 alkyl, aryl, heteroaryl, heterocyclyl, C:-1 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C1-1 alkyl, C3-6 cycloalkyl, or represents a group containing one or more of these fragments, each of the indicated fragments may optionally be substituted by aryl, heteroaryl, heterocyclyl, C-1-alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, KZs, C-o alkyl, OH, OKZs, OSOKZs, ZN, 5KZs, 5SOKZs, MH, MNAZs,

MAZsAZa, SOVZs, S5AZs, SM, SOON, SOOVAZs, SOMN", 5O2AZs, ZOzN, 502MN»g, SOMAZsevvZa,

ZO2MAZSKZa, where KZc and KZa are independently selected from C:i-e alkyl, substituted C:-e alkyl, C3-b cycloalkyl, and heterocyclyl, and KZc and KZa, together with an adjacent heteroatom, can form heterocyclyl, where, if the substituent in KZ represents C1-10 alkyl, aryl, heteroaryl, heterocyclyl, C1-10 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C1-10 alkyl, C3-3 cycloalkyl, or represents a group containing one or more of these fragments, each of the specified fragments can optionally be replaced by KZe, Si-o alkyl, OH, OKZe, OSOoKZe, ZN, 5KZe, ZSOKZe, MN», MNAZe,

MAZevzi, SOAZe, SZAZe, SM, SOON, SOOAZe, SOMN", 5O2AZe, ZOzN, 5O2MN:, SOMAZenvzi,

ZO2MAZexZi, where KZe and KZi are independently selected from C1-6 alkyl, substituted C1-6 alkyl, C3-C cycloalkyl, and heterocyclyl, and KZe and EZ1, together with an adjacent heteroatom, can form heterocyclyl,

Co) MM can be M, CH or C-K4, where K4 is a halogen, C1-0 alkyl, aryl, heteroaryl, heterocyclyl, C1-alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C3-8 cycloalkyl, Ka, OH, OK4a, ZN, ZK4a, OSOMK4a, 5СО4a, МН, МНА4a, MA4anir, SOvla,

С5А4а, СМ, СООН, СООНла, СОМН", 502Н4а, 5ОзЗН, 5О2МНо, СОМА4анар, 5О2МК4акав, where

C4a and C4p are independently selected from C1-6 alkyl, substituted C3-10 alkyl, C3-1 cycloalkyl, and heterocyclyl, and C4a and C4b, together with an adjacent heteroatom, can form a heterocyclyl, where if C4 is C3-10 alkyl, aryl, heteroaryl , heterocyclyl, C:-1 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C1-1 alkyl, C3-6 cycloalkyl, or represents a group containing one or more of these fragments, each of the specified fragments can be optionally substituted aryl, heteroaryl, heterocyclyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C4c, C1-0 alkyl, OH, OK4c, OSOK4c, 5H, 5H4c, 5СОВ4c, МН», МНС,

MA4sevYala, СОВа4с, С5А4с, СМ, СООН, СООвВ4с, СОМН», 502Н4с, 5ОзН, 5О2МН:, SOMAasvaa,

ZO2M4c4y, where K4c and K4a are independently selected from C1-6 alkyl, substituted C1-6 alkyl, C3-6 cycloalkyl, and heterocyclyl. and K4c and K4a, together with an adjacent heteroatom, can form a heterocyclyl, where, if the substituent in KA is C1-10 alkyl, aryl, heteroaryl, heterocyclyl, C:-alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C1-alkyl , C3-C cycloalkyl, or represents a group containing one or more of these fragments, each of the specified fragments can optionally be substituted by K4e, C1-io alkyl, OH, OK4e, OSOK4e, ZN, 5K4e, ZSOK4e, MH ", MNA 46,

MA4enai, СОВ4e, С5А4e, SM, СООН, СООВl4e, СОМН», 502Б4е, 5ОзН, 502МНг, SOMAlenai,

ZO2MA4enB4iY, where K4e and K4i are independently selected from C1-e alkyl, substituted C1-e alkyl, C3-b cycloalkyl, and heterocyclyl, and C4e and K4i, together with an adjacent heteroatom, can form a heterocyclyl,

K5 is selected from H, C':-is alkyl, aryl, heteroaryl, heterocyclyl, C3-1 cycloalkyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, K5ba, halogen, OH, OK5ba, 5H, 5K5a,

OoSOVBa, 5SOABa, MN, MNABba, MABanoh, SONBba, С5АБбBa, SM, СООН, СООРБа, SOMN»,

ZO2ABa, 5OzH, 502МНо, СОМАБанр, 502МК5Бакз, where Kba and K5b are independently selected from C-6 alkyl, substituted C'-v alkyl, C3-v cycloalkyl and heterocyclyl, and Kba and K5BB, together with an adjacent heteroatom, can form heterocyclyl, where, if K5 is C1-6 alkyl, aryl, heteroaryl, heterocyclyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C1-6 alkyl, C3-6 cycloalkyl, or represents a group containing one or more of these moieties, each of said moieties may optionally be substituted with aryl, heteroaryl, heterocyclyl, C 1-6 lkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, Cos, C 1-6 alkyl, OH, OK5s, OSOK5s, ZN, 5К5s, 5СОК5s, МН», МНА5Бс,

MABeAba, SOV5s, C5ABs, SM, COOH, SOOA5s, SOMN", 5O2ABs, 5OzH, 502МН»g, SOMA5Benv5a,

ZO2MABSKBa, where K5c and K5a are independently selected from C:i-e alkyl, substituted C:-e alkyl, C3-b cycloalkyl, and heterocyclyl, and Cos and Kba, together with an adjacent heteroatom, can form a heterocyclyl, where, if the substituent in K5 represents C1-6 alkyl, aryl, heteroaryl, heterocyclyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C3-6 cycloalkyl, or represents a group containing one or more of these fragments, each of the specified fragments being can necessarily be replaced by K5e, Si-e alkyl, OH, OK5e, OSOK5e, 5H, ZK5e, ZSOK5e, MNg, MNABe, MAB5Benoi,

SOABbe, S5NAbe, SM, SOON, SOOVABe, SOMN»?, 5O»Nbe, 5OzZN, 502MN:, SOMA5Benyi,

ZO2MABecoi, where KBbBe and C5i are independently selected from C1-e alkyl, substituted C1-e alkyl, C3-b cycloalkyl, and heterocyclyl, and C5e and C5i, together with an adjacent heteroatom, can form heterocyclyl,

X can be M, CH or C-Kb, where Kb is selected from C.-e alkyl, aryl, heteroaryl, heterocyclyl, C-e alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, Kba, halogen, OH,

ОВба, 5Н, 5Аба, ОСОНба, 5СОНба, МН, МНАба, МАбанб, СОВба, С5Аба, СМ, СООН,

СОВба, СОМН», 502НВва, 5ОзН, 502МНг, СОМАбанвб, 5О2МКваквбр, where Kba and Ebb are independently selected from C-e alkyl, substituted C-e alkyl, C 3-1 cycloalkyl, and heterocyclyl, and Kba and Kb, together with an adjacent heteroatom, can form heterocyclyl, where, if Kb is C 1-6 alkyl, aryl, heteroaryl, heterocyclyl, C 1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C 3-6 cycloalkyl, or is a group containing one or more of of these fragments, each of the indicated fragments may optionally be substituted

ABbs, C 1 alkyl, aryl, heteroaryl, heterocyclyl, C 1 alkyl, aryloxy, heteroaryloxy, heterocyclyloxy, aryl C 1 alkyl, heteroaryl C 1-6 alkyl, heterocyclyl C 1-6 alkyl, aryl C 1-6 oxy, heteroaryl C 1-6 Alkoxy, heterocyclyl Si Alkoxy, OH, OKbs,

OSOVbs, ZN, 5Abs, 5SOVbs, MN, MNAbs, MAbsnba, SOVbs, C5Abs, SM, SOON, SOONVbs,

SOMN", 5O2NAbs, ZOzN, 502МНг, SOMAbeNva, 502Mbsokva, where Kbs and Kba are independently selected from

From Civ alkyl, substituted C 1-6 alkyl, C 3-1 cycloalkyl and heterocyclyl, and Kbs and Kbva, together with an adjacent heteroatom, can form heterocyclyl, where, if the substituent in Kb is C 1-6 alkyl, aryl, heteroaryl, heterocyclyl, C:-alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, aryl C-alkyl, heteroaryl C-alkyl, heterocyclyl C-alkyl, aryl C-alkoxy, heteroaryl C-alkoxy, heterocyclyl C-alkoxy,

C3-C cycloalkyl, or represents a group containing one or more of these fragments, each of the specified fragments can optionally be replaced by Be, C1 alkyl, OH, OKbe,

OSOVbe, 5H, 5Abe, 5SOVbe, MN, MNAbe, MAbenby, SOVbe, С5Abe, SM, SOON, SOOVbe,

SOMN", 5O2Abe, ZOzN, 5O2MN:, SOMAbenbi, 502Mbekvi, where Kbe and Kb are independently selected from

Civ alkyl, substituted C1-6 alkyl, C3-1 cycloalkyl, and heterocyclyl, and Kbe and Kb, together with an adjacent heteroatom, can form heterocyclyl,

M can be M, CH or C-K7, where K7 is selected from C:-is alkyl, aryl, heteroaryl, heterocyclyl, C-is alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, K7a, halogen, OH,

ОВ7а, 5Н, 5А7а, ОСОН7а, 5СОН7а, МН, МНА7а, MA7an?t, СОВА7а, С5А7а, СМ, СООН,

СООВ?7а, СОМН», 502НА7а, 5ОзН, 502МНг, СОМА7ант, 5О2МК7акт, where K7a and E76 are independently selected from C1-6 alkyl, substituted C1-6 alkyl, C3-10 cycloalkyl and heterocyclyl, and K7a and K7B, together with the adjacent heteroatom, can form heterocyclyl, where, if K7 is C1-C alkyl, aryl, heteroaryl, heterocyclyl, C:-is alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C3-C cycloalkyl or represents a group containing one or more of these fragments, each of said fragments may optionally be substituted

BO B?7c, Сv alkyl, aryl, heteroaryl, heterocyclyl, C:-is alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, aryl C.-is alkyl, heteroaryl C.-is alkyl, heterocyclyl C.-is alkyl, aryl C- - is alkoxy, heteroaryl C.i.e. alkoxy, heterocyclyl C.i.e. alkoxy, OH, O7c, OSOK7c, ЗН, 5К7c,

ЗСОНВ7с, МН, МНА7с, МА7сА?Та, СОВ7с, С5А7с, СМ, СООН, СООВ7с, СОМН», 502Н7с, 5ОзН,

ZO2MNHg, SOMA7cBA7Ta, 502MK7cATa, where K7c and K7a are independently selected from C3-e alkyl substituted

Alkyl, C3-1 cycloalkyl, and heterocyclyl, and K7c and K74a, together with an adjacent heteroatom, can form a heterocyclyl, where, if the substituent in K7 is C1-6 alkyl, aryl, heteroaryl, heterocyclyl, C1-alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, aryl C 1-6 alkyl, heteroaryl C 1-6 alkyl, heterocyclyl C 1-6 alkyl, aryl C 1-6 alkoxy, heteroaryl C 1-6 alkoxy, heterocyclyl C 1-6 alkyl, 60 C 3-in cycloalkyl, or represents a group containing one or more of these fragments, each of the indicated fragments may optionally be substituted by K7e, C1 alkyl, OH, OK?7e,

OSOV?7e, 5H, 5А7e, 5СОН7e, МН, МНА7e, MA7en7, СОВ7e, С5НА7e, SM, СООН, СООНВ?e,

SOMN", 502A7e, 5OzZN, 5O2MN:, SOMA7en, 5O2MATekl Ya, where K7e and K7/i are independently selected from

Siv alkyl, substituted C1-6 alkyl, C3-1 cycloalkyl and heterocyclyl, and K7e and K7/y, together with an adjacent heteroatom, can form heterocyclyl, 7 can be M, CH or C-K8, where K8 is selected from Si. -is alkyl, aryl, heteroaryl, heterocyclyl, Si-is alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, Kva, halogen, OH,

ОВва, 5Н, 5АВа, OSORВа, 5СОРва, МН, МНАВа, MAВанвь, СбОВАва, С5Ава, СМ, СООН,

СооВВа, СОМН», 502В8va, 5ОзН, 502МНг, СОМАВанв, 5О2МКваквр, where Eva and Е8Б5 are independently selected from C-e alkyl, substituted C-e alkyl, C 3-jav cycloalkyl and heterocyclyl, and Kva and K8B, together with an adjacent heteroatom, can form heterocyclyl, where, if K8 is C1-C alkyl, aryl, heteroaryl, heterocyclyl, C1-C1-C1-C1-C1-C1-C1-C1-C1-C6 alkyl, C1-C1-C1-C6 alkyl, aryl, heteroaryl, heterocyclyl, C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C6 alkyl, C1-C1-C1-C6 cycloalkyl, or represents a group containing one or more of of these fragments, each of the indicated fragments may optionally be substituted

АВВвс, C1-6 alkyl, aryl, heteroaryl, heterocyclyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, aryl C1-6 alkyl, heteroaryl C1-6 alkyl, heterocyclyl C1-6 alkyl, aryl C1-6 oxy, heteroaryl C1-6 alkyl , heterocyclyl C alkoxy, OH, OKVvs,

OSOVVs, ЗН, 5Авс, 5СОНВ8с, МН, МНАВ8с, МА8сАВа, СОВВвс, С5Авс, СМ, СООН, СООВвВс,

СОМН», 5О2АВс, 5ОзЗН, 502МНх, СОМАВ8СНВа, 502М8сКва, where Квс and ква are independently selected from

Cv alkyl, substituted C1-6 alkyl, C3-1 cycloalkyl, and heterocyclyl, and Kvs and Kv, together with an adjacent heteroatom, can form heterocyclyl, where, if the substituent in K8 is C1-6 alkyl, aryl, heteroaryl, heterocyclyl, C :-alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, arylCi-alkyl, heteroarylCi-alkyl, heterocyclylCi-alkyl, arylCi-alkoxy, heteroarylCi-alkoxy, heterocyclylCi-alkoxy,

C3-C is cycloalkyl, or represents a group containing one or more of these fragments, each of these fragments may optionally be replaced by K8e, C:-e alkyl, OH, OKe, OSOKe,

ЗН, ЗАВе, 5СОНВе, МН, МНАВе, MAvenvy, SOVVe, С5Аве, SM, СООН, SOOVVe, SOMN",

ZO2Ave, 5OzH, 502MNh, SOMAVenvi, 502MAvekvi, where Kve and K8i are independently selected from C-6 alkyl, substituted C-6 alkyl, C3-C cycloalkyl, and heterocyclyl, and Kve and Kv, together with an adjacent heteroatom, can form heterocyclyl; or a pharmaceutically acceptable salt or ester thereof; provided that when K1 and K2 together form piperidinyl in compounds of Formula |, the piperidinyl is not substituted by methyl, dimethyl, ethyl, isopropyl, tert-butyl, trifluoromethyl, chlorine, bromine or benzyl, provided that K1 and K2 together in compounds of Formula I do not form 6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl, b-methoxy-3,4-dihydro-1H-isoquinolin-2-yl, 7-methoxy-3, 4-dihydro-1H-isoquinolin-2-yl, 7-amino-3,4-dihydro-1H-isoquinolin-2-yl, 7-nitro-3,4-dihydro-1H-isoquinolin-2-yl , 3,4-dihydro-1H-isoquinolin-2-yl, 3,4-dihydro-1H-isoquinolin-1-yl, 3,4-dihydro-2H-quinolin-1-yl, pyrrolidin-1-yl , 3,6-dihydro-2H-pyridin-1-yl, 8-aza-spiro|(4,5I|dec-v-yl, 1,3-dihydroisoindol-g-yl, oxahydroisoindol-g-yl, 1, 2,6-triaza-spiro|2, B|oct-1-en-6-yl or azepan-1-yl, and provided that ring A in the compounds of Formula I does not form pyridine, pyrazine, substituted pyridine or substituted pyrazine , if K1 and K2, together with the M to which they are attached, form piperidinyl, piperazinyl, substituted piperidinyl, or substituted pipe razinil

In accordance with an additional variant according to the invention, the proposed compound of Formula I or Formula I: sl u

I ht same "M Ve "4 t V. in another 7

IY M i o u b M

Formula I Formula II where: each of K! and K2 may be independently selected from H, C: alkyl, C1-6 alkoxy, aryl,

heteroaryl, partially or fully saturated heterocyclyl, C3-6 cycloalkyl, C3-6 alkyl aryl, C6-6 alkyl heteroaryl, C3-6 alkyl heterocyclyl, C3-6 cycloalkyl C6-6 alkyl, Ca, halogen, OH, OKTa , 5N, ZKTa, OSOKTa, ZSOKTa, MN", MNEATa, MATant, Sova, S5Ata, SM,

СооОНн, СООвАта, СОМН», 502Ата, 5ОзН, 502МНг, СОМАтТант, 502МАКтакт, where КТа and КТХ are independently selected from C1-6 alkyl, substituted C6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl and heterocyclyl, or Kia and K16, together with the heteroatom to which they are attached, can form a heterocyclyl, where, if K1 or K2 is C-20 alkyl, alkoxy, aryl, heteroaryl, heterocyclyl, C3-10 cycloalkyl, aryl C-10 alkyl, heteroaryl C. is alkyl, heterocyclyl, C1-6 alkyl, C3-10 cycloalkyl, C1-6 alkyl, C1-6 alkyl, C3-1 cycloalkyl, or represents a group containing one or more of these fragments, each of the specified fragments may optionally be substituted by one or more groups selected from C1c, halogen, aryl, heteroaryl, heterocyclyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C1-6 alkyl aryl, C1-6 alkyl heteroaryl, C1-6 alkyl heterocyclyl, C1-6 alkyl, aryl C :-is alkoxy, heteroaryl C:-is alkoxy, heterocyclyl C:i-is alkoxy,

C:.-is alkylamino, C:-is dialkylamino, Сch1-1io alkyl, OH, OK1s, OSOMK1s, 5H, 5К1s, ЗСОК1s, МН», MO»

MNAis, MAtTeAta, SOvVis, C5Ais, SM, SOON, SOOVIS, SOMN»:, 5O»Nis, 5OZN, ZO2MN»,

SOMAtTevaAtTa, 5O2MetsetTa, where Ks and KT1a are independently selected from C.:-e alkyl, substituted C-6 alkyl, aryl, heteroaryl, C3a cycloalkyl and heterocyclyl, or Kis and Ka, together with the heteroatom to which they are attached, can form heterocyclyl , where, if the substituent in K1 or K2 is C3-10 alkyl, aryl, heteroaryl, heterocyclyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, aryl C1-6 alkyl, heteroaryl C1-6 alkyl, heterocyclyl C1- is alkyl, aryl is C 1-4 alkoxy, heteroaryl is C 1-4 alkoxy, heterocyclyl is C 1-4 alkoxy,

C1-6 alkylamino, C6-6 dialkylamino, C6-6 alkyl, C3-6 cycloalkyl or represents a group containing one or more of these fragments, each of these fragments may optionally be substituted by one or more groups selected from K1e, halogen, C:-io alkyl, OH, OKT1e, OSOKTe,

ЗН, ЗАТе, 5СОАТе, МНг, МО», МНАТе, MATevti, SOVte, С5АТе, SM, СООН, СООВте, SOMN»

ZO2B1e, 5OZN, 502MNo, SOMAthenium, 502MK1ects, where Kie and Kie are independently selected from C1-6 alkyl, substituted C-is alkyl, aryl, heteroaryl, C3-C cycloalkyl and heterocyclyl, or K1e and

AK, together with the heteroatom to which they are attached, can form a heterocyclyl,

Ko) except that КИ and К2 are not both Н, or

Q1 and Q2, together with M to which they are attached, may form a heteroaryl or heterocyclic group, each of which may be optionally substituted with one or more oxygen atoms or one or more groups selected from hydroxy, aryl, heteroaryl, partially or fully saturated heterocyclyl, C3 cycloalkyl, C6 alkyl, aryl C6 alkyl, heteroaryl C6 alkyl, heterocyclyl C6 alkyl, C3 cycloalkyl C6 alkyl, C6 oxy, aryloxy, heteroaryloxy, heterocyclyloxy, K2a, halogen, OH, OKha, 5H, 5K2a, OoSOoKZa,

ЗСбОВга, МНг, МО», МНАга, MAgangr, СОВга, С5ЗАга, СМ, СООН, СООВга, СОМН», 50О»2НВга,

ЗОзЗН, 5О2МН, СОМАгангр, 5О2МК2акг, where K2a and K2p6 are independently selected from C1-6 alkyl, substituted C1-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl and heterocyclyl, or Ka and K2B, together with the heteroatom to which they are attached attached, may form a heterocyclyl, where when the substituent in the heteroaryl or heterocyclyl formed by K1 and K2 together is aryl, heteroaryl, heterocyclyl, C3-1 cycloalkyl, C1-1 alkyl, aryl C1-1 alkyl, heteroaryl C1 alkyl, heterocyclyl C 1 -C alkyl, C 3 -C cycloalkyl C 1 -C alkyl, C 1 -C Alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, or a group containing one or more of the indicated fragments, each of the indicated fragments may optionally be substituted by one or more groups selected from halogen, hydroxyl, C1-6 alkyl, aryl, heteroaryl, heterocyclyl, C3-1 cycloalkyl, C1-4 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C3-1 cycloalkyloxy, arylC1-4 alkoxy, heteroaryl C:-4 alkoxy, heterocyclyl C:-4 alkoxy, C3-C cycloalkyl C:-4 alkoxy, K2c, OK2c, 5Н, 5НА2с, ОСОВ2с, 5СОВ2с, МН, МО», МНА2с, МА2еВга, СОвВ2с, С5Н2с, СМ, СООН, СООВгс,

СОМН", 5О2Нгс, ОзЗН, 502МНг, СОМАгеНга, 502МК2skaa, where К2с and К2а are independently selected from

Si. alkyl, substituted C3-C alkyl, aryl, heteroaryl, C3-C cycloalkyl and heterocyclyl, or

K2c and K24, together with the heteroatom to which they are attached, can form a heterocyclyl, where, if the substituent in the substituent in heteroaryl or heterocyclyl, formed by K1 and K2 together, is C1-6 alkyl, aryl, heteroaryl, heterocyclyl, C3-6 cycloalkyl, C:-is alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C3-I cycloalkyloxy, aryl Sil alkoxy, heteroaryl Si. alkoxy, heterocyclyl C-4 alkoxy, C3-1 cycloalkyl C-4 alkoxy, or represents a group containing one or more of these moieties, each of said moieties may optionally be substituted by one or more groups selected from C- "Alkoxy, K2e, halogen, OH, OK2e, 5H, 60 5Аг2е, OSOV2ge, 5СОН2ge, МН", MO", МНАге, MAгенгой, МНСОВге, СОВге, С5А2ге, SM, COOH,

СооБ2е, СОМН», 502Н2е, 5ОзЗН, 5О2МНг, СОМАгенаой, 502Ме2екой, where K2e and К1 are independently selected from Ci alkyl, substituted Ci alkyl, aryl, heteroaryl, Czv cycloalkyl and heterocyclyl, or K2e and K2i, together with the heteroatom to which they are attached. attached, can form a heterocyclyl; ring A is selected from aryl, heteroaryl and heterocyclyl moieties, each of which may optionally be substituted with one or more groups selected from halogen, C3-C6 alkyl, hydroxyl, aryl, heteroaryl, heterocyclyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy ... 5ОзН, 5О0»МН»е,

СооМАан, 502МКак, where Ka and KB are independently selected from C1-6 alkyl, substituted C1-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl and heterocyclyl, or Ka and KB, together with the heteroatom to which they are attached, may form heterocyclyl, where, when ring A is substituted with C1-alkyl, aryl, heteroaryl, heterocyclyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C1-0 alkyl, C3-1 cycloalkyl, or substituted with a group containing one or more of said moieties, each of said moieties may optionally be substituted with one or more groups selected from halogen,

Bs, Si-io alkyl, aryl C:-v alkyl, OH, OBs, OSOKs, 5H, 5Ks, 5SOKs, MNg, MO», MNAs, MAsva,

СОВс, С5Ас, СМ, СООН, СООВс, СОМН», 5O2As, 5ОзН, 502МНг, СОМАсВа, 5О2МКсКа, where Ks and Ka are independently selected from C:i-e alkyl, substituted C:i- alkyl, aryl, heteroaryl, C3- in cycloalkyl and heterocyclyl, or Ks and Ka, together with the heteroatom to which they are attached, can form heterocyclyl;

M can be M, CH or C-CZ, where CZ is halogen, C1-C6 alkyl, aryl, heteroaryl, heterocyclyl, C1-C6 cycloalkyl, C1-C6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, CZa, OH, OKZa, 5H, 5KZa .

ZO2MeZakz, where KZa and KZp are independently selected from C:-6 alkyl, substituted C:-e alkyl, aryl, heteroaryl, C3-C cycloalkyl and heterocyclyl, or KZa and KZB, together with the heteroatom to which they are attached, can form heterocyclyl , where, if KZ is C1-10 alkyl, aryl, heteroaryl, heterocyclyl, C:-is alkoxy, aryloxy,

Z is heteroaryloxy, heterocyclyloxy, C1-6 alkyl, C3-6 cycloalkyl, or represents a group containing one or more of these moieties, each of said moieties may optionally be substituted by one or more groups selected from halogen, aryl .

ZAZs, 5SONZs, MN, MO", MNAZs, MAZSAZa, SOAZs, S5AZs, SM, SOON, SOOVZs, SOMN",

ЗО2АЗс, 5ОзН, 502МНг, СОМАЗсаЗа, 5О2МАЗсКЗа, where КЗц and КЗа are independently selected from C-6 alkyl, substituted C-6 alkyl, aryl, heteroaryl, C 3-C cycloalkyl and heterocyclyl, or КЗ and

Za, together with the heteroatom to which they are attached, can form a heterocyclyl, where, if the substituent in KZ is a C.-1o alkyl, aryl, heteroaryl, heterocyclyl, C:-is alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C1-is alkyl, C3-C cycloalkyl, or represents a group containing one or more of these moieties, each of said moieties may optionally be substituted by one or more groups selected from halogen, CZe, C1-10 alkyl, OH, OKZe ,

OSOoVze, 5H, 5AZe, 5SOVze, MNeg, MO», MNAze, MAZevze, SOVze, C5AZe, SM, SOON, SOOVze,

СОМНн», 5О2AZe, ЗОзН, ЗО2МНг, СОМAZevzi, 5О2MeZekzi, where KZe and KZ are independently selected from

Si. alkyl, substituted C3-C alkyl, aryl, heteroaryl, C3-C cycloalkyl and heterocyclyl, or

KZe and KZ, together with the heteroatom to which they are attached, can form a heterocyclyl;

MM can be M, CH, or C-C4, where C4 is halogen, C1-0 alkyl, aryl, heteroaryl, heterocyclyl, C1-alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C3-C cycloalkyl, C4a, OH, OKaa, 5H, 5K4a, OSOKla, 5SOKla, MN», MO», MNAl4a, MA4analir, SOVaa,

С5А4а, СМ, СООН, СООНла, СОМН", 502Н4а, 5ОзЗН, 5О2МНо, СОМА4анар, 5О2МК4акав, where

C4a and C45 are independently selected from C1-6 alkyl, substituted C1-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl, and heterocyclyl, or C4a and C46, together with the heteroatom to which they are attached, may form heterocyclyl, where, if KA is C1-10 alkyl, aryl, heteroaryl, heterocyclyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C1-6 alkyl, C3-6 cycloalkyl, or represents a group containing one or more of these fragments, each of the indicated fragments may optionally be substituted by one or more groups selected from halogen, aryl, heteroaryl, heterocyclyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C4c, C1-10 alkyl, OH, OM4c, OSOKAs , 5H,

ЗНа4ас, 5СОН4с, МН, МО», МНА4с, MA4сАЯa, СОвас, С5А4Ас, СМ, СООН, СООв4с, СОМН»,

ЗО2Нас, 5ОзН, 502МНг, СОМА4еВЯ4а, 502МК4сК4я, where K4c and K4y are independently selected from C6-6 alkyl, substituted C1-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl and heterocyclyl, or K4c and

44, with the heteroatom to which they are attached, can form heterocyclyl, where, if the substituent in KA is C1-10 alkyl, aryl, heteroaryl, heterocyclyl, C1-alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C1-alkyl , C3-C cycloalkyl, or represents a group containing one or more of these fragments, each of the specified fragments may optionally be substituted by one or more groups selected from halogen, C4e, C1-10 alkyl, OH, OK4e,

Oso Va4e, 5H, 5В4e, 5СОВ4e, МН», MO», МНА4e, MA4enaii, СОВ4e, С5А4e, SM, СООН, СООВаe,

СОМН», 502В4е, 5ОзЗН, 5О2МН:, СОМА4енай, 50О2МЕ4екаяй, where К4е and КАй are independently selected from

Si. alkyl, substituted C3-C alkyl, aryl, heteroaryl, C3-C cycloalkyl and heterocyclyl, or

K4e and KAI, together with the heteroatom to which they are attached, can form a heterocyclyl;

K5 is selected from H, C':-is alkyl, aryl, heteroaryl, heterocyclyl, C3-1 cycloalkyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, K5ba, halogen, OH, OK5ba, 5H, 5K5a,

Oso Н5а, 5СОВ5а, МНг, МО», МНАба, МАБань, СОН5Ба, С5А5ба, СМ, СООН, СОО5Ба, СОМН»;,

ZO2ABa, 5OzH, 502MNo, SOMABanr, 502MK5Bakz, where Kba and K5B are independently selected from C1-6 alkyl, substituted C1-6 alkyl, aryl, heteroaryl, C3-C cycloalkyl and heterocyclyl, or E5Ba and K5B, with a heteroatom to which they are attached, can form heterocyclyl, where, if K5 is C1-C alkyl, aryl, heteroaryl, heterocyclyl, C1-C1-C6 oxy, aryloxy, heteroaryloxy, heterocyclyloxy, C1-C6 alkyl, C1-C6 cycloalkyl, or represents is a group containing one or more of these fragments, each of said fragments may optionally be substituted by one or more groups selected from halogen, aryl, heteroaryl, heterocyclyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C5c, C:-is alkyl, OH, OM5c, OSONM5c, 5H,

ЗН5с, 5СОН5с, МН, МО», MNABs, MABsAbBa, СОАБs, С5АБs, СМ, СООН, СООВ5s, СОМН»,

ЗО2АБс, 5ОзН, 502МНг, СОМАБеВА5ба, 5О2МА5сК5а, where К5с and К5а are independently selected from C-6 alkyl, substituted C-6 alkyl, aryl, heteroaryl, C3-в cycloalkyl and heterocyclyl, or К5с and а, together with a heteroatom, to to which they are attached, can form a heterocyclyl, where, if the substituent in K5 is a C 1-6 alkyl, aryl, heteroaryl, heterocyclyl, C 1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C 3-6 cycloalkyl, or is a group, containing one or more of these moieties, each of said moieties may optionally be substituted by one or more groups selected from halogen, C5e, C:-e alkyl, OH, OK5e, OSOK5e,

ZN, Z5ABe, 5SOA5Be, MN, MO», MNA5e, MABbBenyi, SOV5e, SZABbe, SM, SOON, SOOA5e, SOMN»;,

Co) ZO2ABbe, 5OzH, 502MN:, SOMABen5ii, 502MK5eco5i, where Kbe and K5i are independently selected from C1-6 alkyl, substituted C-e alkyl, aryl, heteroaryl, C3-C cycloalkyl and heterocyclyl, or K5be and

ОЙ, together with the heteroatom to which they are attached, can form a heterocyclyl;

X can be M, CH or C-Kb, where Kb is selected from C. alkyl, aryl, heteroaryl, heterocyclyl, C-alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, Kba, halogen, OH, OBba, 5H, 5Aba , OSOVba, 5SOVba, MN, MO", MNAba, MAbanb, SOVba, S5ZAba, SM, SOON,

СООВba, СОМН», 502НВва, 5ОзН, 502МНг, СОМАбанвб, 5О2МКваквбр, where Kba and Ebb are independently selected from Ci alkyl, substituted Ci alkyl, aryl, heteroaryl, Czv cycloalkyl and heterocyclyl, or Kba and Kbr, together with the heteroatom to which they are attached attached, may form a heterocyclyl, wherein, if Kb is heteroaryl or heterocyclyl, each of said moieties may optionally be substituted with one or more oxygen atoms, and if Kb is

C 1-6 alkyl, aryl, heteroaryl, heterocyclyl, C 1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C 3-1 cycloalkyl, or represents a group containing one or more of these moieties, each of said moieties may optionally be substituted by one or more groups selected from halogen, Kbs, C1-6 alkyl, C1-alkynyl, aryl, heteroaryl, heterocyclyl, C1-alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C1-6 alkyl aryl, C1-6 alkyl heteroaryl, C1-6 alkyl heterocyclyl, aryl C-e alkoxy, heteroaryl C-e alkoxy, heterocyclyl C:-e alkoxy, OH, OKbs, OSOKbs, 5H, 5Kbs, 5СОНbs, МНг, МО», MNEAbs, MAbsenva,

SOVbs, SOAbs, SM, COON, SOOVbs, SOMN:, SOMNON, С(MON)МН», 5О2Абс, 5ОзЗН, 5О»МН»,

BO SOMAbsNba, 5O2MEbseba, where Kbs and ba are independently selected from C:-e alkyl, substituted C-6 alkyl, aryl, heteroaryl, C3-C cycloalkyl and heterocyclyl, or Kbs and Kba, with the heteroatom to which they are attached, can form heterocyclyl, where, if the substituent in Kb is heteroaryl or heterocyclyl, each of said moieties may optionally be substituted with one or more oxygen atoms, or if the substituent in Kb is C 1-6 alkyl, C 1-6 alkynyl, aryl, heteroaryl, heterocyclyl, C.i.e. alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, aryl C.i.e. alkyl, heteroaryl C.i.e. alkyl, heterocyclyl C.i.e. alkyl, aryl C.i.e. alkoxy, heteroaryl C.i.e. alkoxy, heterocyclyl C.i. is alkoxy,

C3-C cycloalkyl, or represents a group containing one or more of these moieties, each of said moieties may optionally be substituted by one or more groups selected from halogen, C6, C1-6 alkyl, C1-4 alkoxy , ОН, ОНбе, OSONВбе, 5Н, 5Абе, 5СОНбе, МН», MO»,

MNAbe, MAbenebi, SONBe, С5Абе, СМ, СООН, СООАбе, СОМН», С(МОН)МН», 5О»2Нбе, ЗозЗН,

ZO2Mng, SOMAbenbi, 502Mkbekbi, where Mbe and Kbi are independently selected from C.:-e alkyl substituted

Alkyl, aryl, heteroaryl, C3-1 cycloalkyl and heterocyclyl, or Kbe and Kb, together with the heteroatom to which they are attached, can form heterocyclyl;

M can be M, CH or C-K7, where K7 is selected from C:-is alkyl, aryl, heteroaryl, heterocyclyl, C-is alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, K7a, halogen, OH,

ОвВ7а, ZН, 5А7а, OSON?Ta, 5СОН7а, МН», MO», МНА7а, MA7ant, СОНВ7а, СЗНА7а, СМ, СООН,

СООВ?7а, СОМН", 502НА7а, 5ОзН, 502МНг, СОМА7ант, 5О2МК7акт, where K7a and E76 are independently selected from C alkyl, substituted C alkyl, aryl, heteroaryl, Czv cycloalkyl and heterocyclyl, or C7a and C7B, together with a heteroatom, to to which they are attached may form a heterocyclyl, where, if K7 is heteroaryl or heterocyclyl, each of said moieties may optionally be substituted by one or more oxygen atoms, and if K7 is

C 1 -alkyl, aryl, heteroaryl, heterocyclyl, C 1 -alkyl, aryloxy, heteroaryloxy, heterocyclyloxy, C 3 -C cycloalkyl or represents a group containing one or more of these moieties, each of said moieties may optionally be substituted by one or more groups , selected from halogen, C7c, C1 alkyl, C1-alkynyl, aryl, heteroaryl, heterocyclyl, C1-alkyloxy, aryloxy, heteroaryloxy, heterocyclyloxy, C1-6 alkyl aryl, C1-6 alkyl heteroaryl, C1-6 alkyl heterocyclyl, C1-6 alkyl, aryl Ci-e alkoxy, heteroaryl Ci-e alkoxy, heterocyclyl Ci-e alkoxy, OH, O7c, OSOK7c, ZN, 5K7c, ZSOK7c, МН», MO», МНА7с, MA7сНта,

СовВ7с, С5А7с, СМ, СОН, СООН7с, SOMN»:, SOMNON, С(MON)МН», 5О2гА7с, ЗозЗН, 5О»МН»

СОМА7сА?а, 502МЕ7св7а, where K7c and K7a are independently selected from C.:-e alkyl, substituted C-6 alkyl, aryl, heteroaryl, C3-b cycloalkyl and heterocyclyl, or K7c and K7y, with the heteroatom to which they are attached, may form heterocyclyl, where, if the substituent at C7 is heteroaryl or heterocyclyl, each of said moieties may optionally be substituted by one or more oxygen atoms, or if the substituent at C7 is C 1-6 alkyl, C 1-6 alkynyl, aryl . .and-are alkoxy,

C 3 -C cycloalkyl, or represents a group containing one or more of these moieties, each of said moieties may optionally be substituted by one or more groups selected from halogen, aryl, heteroaryl, heterocyclyl, arylCiv alkyl, heteroaryl C-C alkyl, heterocyclyl C-C alkyl, C:i-4 alkoxy, C7e, C1-e alkyl, OH, OMK7e, OSOK?7e, 5H, 5B7e, BSONB7e,

МН», MO», МНА7еее, MA7еВl, СОВ7е, С5А7е, SM, СООН, СООН7е, СОМН», СИ(ИМОН)МН», 5О2НА7е,

BOZN, 5O2MH:, SOMA7evli, 502MK7ekli, where K7e and K/i are independently selected from C1-e alkyl, substituted C1-c alkyl, aryl, heteroaryl, C3-c cycloalkyl and heterocyclyl, or K7e and K1, together with a heteroatom, to to which they are attached, can form a heterocyclyl; 7 can be M, CH or C-K8, where K8 is selected from C-6 alkyl, aryl, heteroaryl, heterocyclyl, C1-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, Kva, halogen, OH,

ОВвВа, 5Н, 5АВа, OSOVВа, 5СОВва, МН, МО», МНАва, MAvVanвъ, SOVVa, С5ЗАВа, СМ, СООН,

СооВВВа, СОМН», 502Б8ва, 5ОзН, 502МНг, СОМАВанв, 5О2МКваквр, where Eva and Е8Б5 are independently selected from Ci alkyl, substituted Ci alkyl, aryl, heteroaryl, Czv cycloalkyl and heterocyclyl, or Kva and K8B, with the heteroatom to which they are attached , can form heterocyclyl, where, if K8 is C3-alkyl, C1-10 alkyl, aryl, heteroaryl, heterocyclyl, C1-10 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C3-10 cycloalkyl, or represents a group that contains one or more of these moieties, each of said moieties may optionally be substituted by one or more groups selected from halogen, C8c, C1-6 alkyl, aryl, heteroaryl, heterocyclyl, C1 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, aryl C-6 alkyl, heteroaryl C-6 alkyl, heterocyclyl C:-6 alkyl, aryl C6-6 alkoxy, heteroaryl C6-6 alkoxy, heterocyclyl C6-6 alkoxy, OH, ОК8вс, ОСОКВвсС, 5Н, 5Квс, 5СОМвс, MN, MO", MNEAVs, MAVsNvVa,

СОвАВс, С5АВсС, СМ, СООН, СООАВс, СОМН», 5О»АВс, 5ОзЗН, 502МН:?, СОМАВсНвВа,

ZO2MA8cKva, where Kvs and K8a are independently selected from C1-6 alkyl, substituted C1-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl, and heterocyclyl, or Kvs and K8y, with the heteroatom to which they are attached, can form heterocyclyl, where, if the substituent in K8 is C-C alkyl, aryl, heteroaryl, heterocyclyl, C:-C alkyl, aryloxy, heteroaryloxy, heterocyclyloxy, aryl C-C alkyl, heteroaryl C-C alkyl, heterocyclyl C-C alkyl, aryl C-C is alkoxy, heteroaryl is C 1-6 alkoxy, heterocyclyl is C 1-6 alkoxy,

C3-C cycloalkyl, or represents a group containing one or more of these moieties, each of the 60 indicated moieties may optionally be substituted by one or more groups selected from halogen, C8e, C1-C alkyl, OH, OKe, OSOKve, 5H, ZKv8e, ZSOKve, MN», MO», MNEAVe, MAv8envI,

SOVAve, C5AVe, SM, COON, SOOVvVe, SOMN?, 502Ave, 5OzZN, 502МНг, SOMEAVenviI,

ZO2Me8equy, where Kwe and K8y are independently selected from C-6 alkyl, substituted C-e alkyl, aryl, heteroaryl, C3-C cycloalkyl and heterocyclyl, or Kwe and K8y, together with the heteroatom to which they are attached, can form heterocyclyl; where no more than two atoms or groups marked X, Y and 7 can be M; where, if UM is M, the SOMK1TK2 group can instead be attached to MU, with rearrangement of the double bonds in Formula I, respectively; or a pharmaceutically acceptable salt or ester thereof; provided that if K! and K2 together form piperidinyl in compounds of Formula |, piperidinyl is not substituted by methyl, dimethyl, ethyl, isopropyl, tert-butyl, methoxycarbonyl, trifluoromethyl, chlorine, bromine or benzyl, provided that K1 and K2 together in compounds of Formula I do not form 6 ,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl, b-methoxy-3,4-dihydro-1H-isoquinolin-2-yl, 7-methoxy-3,4-dihydro-1H -isoquinolin-2-yl, 7-amino-3,4-dihydro-1H-isoquinolin-2-yl, 7-nitro-3,4-dihydro-1H-isoquinolin-2-yl, 3,4-dihydro -1 H-isoquinolin-2-yl, 3,4-dihydro-1 H-isoquinolin-1-yl, C,4-dihydro-2H-quinolin-1-yl, pyrrolidin-1-yl, 3,6-dihydro -2H-pyridin-1-yl, 8-aza-spiro|(4,5I|dec-v-yl, 1,3-dihydroisoindol-g-yl, oxahydroisoindol-g-yl, 1,2,6-triaza- spiro|2, B|oct-1-en-6-yl or azepan-1-yl, and provided that ring A in the compounds of Formula I does not form pyridine, pyrimidine, substituted pyridine or substituted pyrimidine, if K! and K2 , together with the M to which they are attached, form piperidinyl, piperazinyl, substituted piperidinyl, or substituted pip erazinil

Preferably, the formula of the compound according to the invention is selected from Formula I, Formula Ia, Formula PIB,

Formulas Is and Formulas Pa.

IN;

Ve M Ve already; /

Not M Not M

B, B, / /

M M in; M o M

Not Ve

Formula Pa Formula Ir 8;

Av M x -

В, В, / / рлиши М в; M o u

Ve Ve

Coo)

Formula IIs Formula Pa

More preferably, the formula of the compound is selected from Formula Ia, Formula Pa, Formula PIB,

Formula IIb and Formula Pa.

K u;

M

Ky

H uz M i u o

Formula Ia

In one of the variants of the invention, K1 is preferably selected from H and C-alkyl. More preferably,

K1 is selected from H and C-C alkyl, even more preferably, K1 is selected from H, methyl and ethyl, and most preferably, K1 is selected from H and methyl.

K2 is preferably selected from Si. alkyl, aryl, heteroaryl, heterocyclyl, C3-0 cycloalkyl, aryl C1-6 alkyl, heteroaryl C1-6 alkyl, heterocyclyl C1-6 alkyl, and C3-10 cycloalkyl C1-6 alkyl, each of which may be substituted or unsubstituted. Preferably, aryl, heteroaryl, heterocyclyl and C3-0 cycloalkyl (including aryl C1-6 alkyl, heteroaryl C1-6 alkyl, heterocyclyl C1-6 alkyl and C3-0 cycloalkyl C1-6 alkyl) has the structure b -membered monocyclic ring. More preferably, aryl, heteroaryl, heterocyclyl, and C3-0 cycloalkyl (including arylC1-6 alkyl, heteroarylC1-6 alkyl, heterocyclyl C1-6 alkyl, and C3-0 cycloalkyl C6-6 alkyl) are selected from phenyl, cyclohexyl, phenyl C 1-6 alkyl and cyclohexyl C 1-6 alkyl, each of which may be substituted or unsubstituted. Preferably, C1-6 alkyl in each of aryl C1-6 alkyl, heteroaryl C1-6 alkyl, heterocyclyl C1-6 alkyl and C3-10 cycloalkyl C1-6 alkyl is a linear alkyl.

Alternatively, K2 may be selected from aryl, heteroaryl, heterocyclyl, arylCi-6alkyl, heteroarylCi-6alkyl, and heterocyclylCi-6alkyl, each of which may be substituted or unsubstituted, and wherein aryl, heteroaryl, and heterocyclyl (including aryl C-C alkyl, heteroaryl C-C alkyl and heterocyclyl C-C alkyl) have a bicyclic ring structure, preferably a 10-membered bicyclic ring structure. More preferably, K2 is selected from naphthalenyl and naphthalenyl C-C alkyl.

Each of the aryl, heteroaryl, heterocyclyl and C3-o cycloalkyl groups in KZ (including aryl C-6 alkyl, heteroaryl C-6 alkyl, heterocyclyl C-6 alkyl and C3-0 cycloalkyl

C.i.v alkyl) can be replaced by one or more halogen atoms.

Alternatively, each of the aryl, heteroaryl, heterocyclyl and C3-10 cycloalkyl groups (including aryl C1-6 alkyl, heteroaryl C1-6 alkyl, heterocyclyl C1-6 alkyl and C3-0 cycloalkyl C1-6 alkyl ) can be substituted by C.:-4 alkoxy or aryloxy. Preferably,

From Si. alkoxy is methoxy or ethoxy. Preferably, aryloxy is monocyclic aryloxy and, more preferably, phenoxy.

In a preferred embodiment, K1 is selected from H and C1-6 alkyl, and K2 is selected from aryl, heteroaryl, heterocyclyl, C3-0 cycloalkyl, aryl C1-6 alkyl, heteroaryl C1-6 alkyl, heterocyclyl C1-6 alkyl, and C3-10 cycloalkyl C1-1 is alkyl, each of which may be substituted or unsubstituted.

More preferably, CI! is selected from H, methyl and ethyl, and K2 is selected from aryl, heteroaryl, heterocyclyl and C3-0 cycloalkyl, each of which may be substituted or unsubstituted. More preferably, CI is methyl. More preferably, R 2 is selected from aryl, heteroaryl, heterocyclyl and C 1 -C 6 cycloalkyl, each of which is monocyclic and may be substituted or unsubstituted. Even more preferably, K 2 is selected from saturated heterocyclyl and C 1-6 cycloalkyl, each of which is monocyclic and may be substituted or unsubstituted. If K2 is a monocyclic C15-cycloalkyl, it is preferably unsubstituted. Preferably, K2 is cyclohexyl, such as unsubstituted cyclohexyl. If K2 is a monocyclic saturated heterocyclyl, the heterocyclyl ring preferably contains one heteroatom. Preferably, the heteroatom is a nitrogen or oxygen atom. More preferably, the heterocyclyl is b-h-ene, such as a piperidinyl or tetrahydropyranyl group. If the heteroatom is an oxygen atom, the heterocyclyl is preferably unsubstituted. If the heteroatom is a nitrogen atom, the nitrogen heteroatom may be substituted or unsubstituted. If the nitrogen heteroatom is substituted, it is preferably substituted with a group selected from C1-6 alkyl, aryl, heteroaryl, heterocyclyl, C3-6 cycloalkyl, C1-6 aryl, C1-6 alkyl heteroaryl, C1-6 alkyl heterocyclyl, and C3- o cycloalkyl C:-e alkyl, each of which may be substituted or unsubstituted. More preferably, the nitrogen heteroatom is replaced by a group selected from C.-4 alkyl,

aryl C. alkyl, heteroaryl C. alkyl, heterocyclyl C:-4 alkyl and C5-cycloalkyl C:-4 alkyl.

More preferably, the nitrogen heteroatom is substituted by a group selected from aryl C-4 alkyl and heteroaryl C-4 alkyl, where the aryl and heteroaryl are monocyclic and preferably b-membered.

Preferably, the nitrogen heteroatom is substituted with a group selected from phenyl C:alkyl and pyridyl C1-2 alkyl. Preferably, the heteroatom in the specified heterocyclyl group is in position 4 relative to the position of the attachment of the heterocyclyl group K2 to the urea nitrogen. If K1 and K2 are as defined in this paragraph, the compound preferably has the formula Pa. Mostly if

K1 and K2 are as defined in this paragraph, Kb is a substituted or unsubstituted aryl or heteroaryl and preferably a substituted or unsubstituted monocyclic aryl or heteroaryl. Monocyclic aryl or heteroaryl is preferably b-h-ene. In one of the options

Kb is a substituted or unsubstituted aryl (such as phenyl) and is preferably unsubstituted. In another embodiment, Kb is substituted or unsubstituted heteroaryl and, preferably, substituted or unsubstituted pyridyl. In one variant, the heteroaryl is substituted by an oxygen atom. For example, the nitrogen heteroatom in pyridyl can be replaced by an oxygen atom, so that it is oxidized, that is, an M-oxide is formed.

It was found that compounds with a choice of KI! and K2 in the previous paragraph demonstrate a relatively high specificity in relation to HACCP. Additionally, compounds in which K2 is a heterocyclyl, such as piperidinyl or tetrahydropyranyl, have been found to be relatively metabolically stable.

In an alternative version, K2 is preferably a C12-th alkyl. More preferably, K2 is a C3-alkyl and, even more preferably, K2 is a C1-12 alkyl. Preferably, the alkyl is a linear alkyl.

In a preferred embodiment, K1 is selected from H and C alkyl, and K2 is C-C alkyl.

In various variants, if K1 represents: H or C. alkyl; H or C-z alkyl; H, methyl or ethyl; H or methyl; or methyl, K2 may be selected from C1-6 alkoxy, aryl, heteroaryl, partially or fully saturated heterocyclyl, C3-16 cycloalkyl, aryl C1-6 alkyl, heteroaryl

C.i.e. alkyl, heterocyclyl C.i.e. alkyl, C.sub.3-o cycloalkyl C.i.e. alkyl, halogen, OH, OKTA, OSOKTA,

ZN, 5Ata, 5SOVTa, MN, MNATa, MNZO2gMN:, MNZO»ATa, MATasovtr, MnooOgta, MAtTaknt,

Owl, SZATa, SM, СООН, СООНtTa, SOMN:, SOMNON, SOMNAtTa, SOMNONta, 50»2Ната, 5ОзН,

Co) ЗО2гМНг, СОМАТант, 5О2МАТакт, where K1a and K1p are independently selected from C. -e alkyl, substituted

Alkyl, aryl, heteroaryl, C1-C1 cycloalkyl and heterocyclyl, or C1a and Kb, with the heteroatom to which they are attached can form heterocyclyl, where K2 may be substituted or unsubstituted.

Alternatively, in other variants, if K1 represents: H and C. alkyl; H and S.-z alkyl; H, methyl and ethyl; H and methyl; or methyl, K2 may be selected from aryl, heteroaryl, partially or fully saturated heterocyclyl, C3-0 cycloalkyl, aryl C1-6 alkyl, heteroaryl C1-6 alkyl, heterocyclyl C1-6 alkyl, C3-0 cycloalkyl C1-6 -is alkyl, where 2 may be substituted or unsubstituted.

In the preferred version of CI! and K 2 , together with M to which they are attached, form a heterocyclic group which may be substituted or unsubstituted. Preferably, the heterocyclyl is a 5- or b-membered monocyclic ring and, more preferably, a 5-membered monocyclic ring. In some embodiments, said heterocyclyl contains 1 or 2, preferably 1 additional heteroatom (ie, in addition to M). These additional heteroatoms can be, for example, M, O and/or 5. Preferably, heterocyclyl is oxazolidinyl. Preferably, the oxygen atom in the oxazolidinyl is in the C position relative to the urea nitrogen. Preferably, the oxazolidinyl is substituted 1, 2 or C with methyl or ethyl groups. More preferably, oxazolidinyl is substituted with 2 methyl or ethyl groups. Even more preferably, oxazolidinyl is substituted with 2 methyl groups at the same carbon atom. More preferably, oxazolidinyl is 4,4-dimethyloxazolidin-3-yl. If K1 and K2 are as defined in this paragraph, the compound is preferably of formula Ia or Pa. Preferably, if КИ1 and

K2 is as defined in this paragraph, and the compound has the formula Pa, Kb is substituted or unsubstituted aryl and, more preferably, phenyl. If KI! and K2 are as defined in this paragraph, and the compound is of formula Ia, ring A is preferably an unsubstituted or substituted benzo moiety.

Compounds containing such K1 and K2, as defined in the previous paragraph, have been found to be relatively potent inhibitors of GAC. It was also found that they have a relatively high specificity in relation to HACCP.

Alternatively, K1 and K2, together with the M to which they are attached, form a heterocyclic group which may be substituted or unsubstituted. Preferably, heterocyclyl bo is a 5- or b-membered monocyclic ring and, more preferably, a b6-membered monocyclic ring. Mostly, K! and K2 together form morpholino, piperazinyl, oxazolidinyl, pyrrolidinyl or piperidinyl. More preferably, CI! and K2 together form morpholino or piperazinyl.

Preferably, a heterocyclyl formed by KI! and K2 together, substituted with C 1-4 alkyl, aryl, heteroaryl, C 3-6 cycloalkyl aryl C 1-6 alkyl, heteroaryl C 1-6 alkyl, aryloxy, heteroaryloxy, aryl C 1-6 alkoxy, and heteroaryl C 1-6 alkoxy, each of which may optionally be substituted by one or more halogen atoms or C 1 alkyl groups. Preferably, the aryl, heteroaryl or C-C cycloalkyl substituent is a 5- or b-membered monocyclic ring. More preferably, the heterocyclyl formed by K1 and K2 together is substituted with aryl, aryl C 1-6 alkyl, and aryloxy, each of which may optionally be substituted with one or more halogen atoms. Even more preferably, the heterocyclyl formed by C 1 and C 2 together is substituted with phenyl, phenyl C 1 -alkyl or phenoxy, each of which may optionally be substituted with one or more halogen atoms.

Alternatively, the heterocyclyl formed by KK! and K 2 together, may be substituted with heteroaryl or heteroaryl with C 1-6 alkyl. In one variant, the heteroaryl has a bicyclic ring structure, for example, benzodioxolylmethyl. Alternatively, the heteroaryl may be monocyclic, for example, pyridyl.

As another alternative, the heterocyclyl formed by K1 and K2 together may be substituted with C3-C cycloalkyl. Preferably, C3-I cycloalkyl is a monocyclic cycloalkyl, such as cyclohexyl.

In one of the options, the heterocyclyl formed by KI! and K2 together, can be 1,4-dioxa-8-azaspiro|4,5|dec-8b-yl, dimethyloxazolidinyl, methylpiperazinyl, benzyloxyphenylpiperazinyl, tolyloxypiperidinyl, pyrrolidinyl C 1 alkyl piperidinyl, pyridylpiperidinyl, pyridyloxadiazol-5-ylpiperidinyl, or benzyloxypiperidinyl.

In one of the options, the heterocyclyl formed by KI! and K2 together, represents piperidinyl substituted phenoxy or phenyl C-4 alkoxy, phenyl may optionally be substituted with a halogen atom.

In one of the variants of the invention, if M is C-KZ, KZ is H or halogen.

In another embodiment of the invention, if M/ is C-K4, K4 is selected from H and aryl.

Preferably, K4 is selected from H and phenyl. More preferably, K4 is H.

In the compound according to the invention, ring A preferably represents a substituted or unsubstituted monocyclic aryl or heteroaryl fragment and, more preferably, a monocyclic aryl fragment. Preferably, ring A is a substituted or unsubstituted benzo moiety. If the monocyclic aryl in ring A is substituted, the substituent is one or more halogen atoms, C1-e alkyl or aryl, which may optionally be substituted by one or more halogen atoms, cyano, carboxyl or amide groups. Preferably, the aryl substituent is monocyclic aryl and, more preferably, phenyl. In a preferred embodiment, the compound containing ring A, as defined in this paragraph, has the formula Ia.

In one of the options, ring A is replaced by a fragment selected from C:-is alkoxy, C-is alkoxy

C-C alkyl and C-C alkyl-CO-C-C alkyl, where C:-is alkoxy, C-C-alkoxy is C-C alkyl, or C-C is alkyl-CO-

C1-6 alkyl is substituted by a fragment selected from aryl, heteroaryl, heterocyclyl, and C3-10 cycloalkyl, where each of the specified fragments can optionally be substituted with aryl, heteroaryl, heterocyclyl, C3-0 cycloalkyl, aryl C:-1 alkyl, heteroaryl C: is alkyl, heterocyclyl is C 1-6 alkyl, and C 3-0 cycloalkyl is C 1-6 alkyl. Preferably, ring A is substituted with C 1 -C alkyl-CO-C 1 alkyl, where C 1 alkyl-CO-C 1 alkyl is substituted with a fragment selected from aryl, heteroaryl, heterocyclyl, and C 3-0 cycloalkyl, where each of the indicated fragments may optionally be substituted aryl, heteroaryl, heterocyclyl, C3-0 cycloalkyl, aryl C1-6 alkyl, heteroaryl C1-6 alkyl, heterocyclyl C1-6 alkyl and C3-0 cycloalkyl C1-6 alkyl.

Preferably, ring A is substituted with a carbonyl moiety (ie, C 0 alkyl-C 0 -C 0 alkyl).

Preferably, C1 alkyl-CO-C1 alkyl is substituted with heterocyclyl, more preferably, monocyclic heterocyclyl, even more preferably, heterocyclyl containing 1 or 2 nitrogen heteroatoms, even more preferably, β-membered heterocyclyl and, most preferably, piperazine. Preferably, C 1 - is alkoxy, C 1 - is alkoxy C 1 - is alkyl, or C 1 -alkyl-CO-Co-6 alkyl is linear. Preferably, the compounds described in this paragraph have the formula Ia.

In another variant, ring A is substituted by one or more groups selected from halogen, C1-6 alkyl, C1-6 alkoxy, OH, OKa, OSOKa, ZN, ZKa, ZSOKa, MH, MO», MNBa, MNZO»MH»5,

МНБЗО»Ва, MAКасонр, МНнСОВа, МНеС(МН)МН:, MAан, СбОВа, С5На, SM, СООН, СООВа,

SOMN;, SOMNaa, SOMNON, SOMNORA, С(MON)МН:, СОМАан, 50О2На, 5ОзН, 5О2МН»,

ЗО2гМКакнт, where Ка and КБ are C1-e alkyl. Preferably, ring A is substituted by one or more groups selected from halogen, OH, 5Н, МН», MO», МНО(МНИМН:, СМ, СОН, СОМН»,

SOMNON, С(MON)МН», 5ОзН and 502МН». More preferably, ring A is substituted by one or more groups selected from halogen, OH, MHg, MO», МНО(МН)МН:, СМ, СОН, СОМН», СОМНОН,

С(МОН)МН», 5ОзН and 5О2МН». Preferably, the compounds described in this paragraph have the formula Ia.

Preferably, in the compound according to the invention, K5 is H or halogen, and, more preferably,

K5 is H.

In one variant, K5 together with the ring carbon atom to which it is attached does not form a carbonyl group. The compound has Formula II as above.

In another embodiment, X is not 0. The compound has Formula I as above.

In compounds of Formula III, if X is C-Cb, Cb is preferably a substituted or unsubstituted aryl. Preferably, aryl Kb is phenyl or naphthalenyl. More preferably, aryl Kb is phenyl. Preferably, the aryl Kb is substituted by one or more groups selected from halogen, C1-4 alkoxy, hydroxyl, amide, aryl, heterocyclyl, heteroaryl, heterocyclyl, aryloxy, each of which may be substituted or unsubstituted. Preferably, the aryl substituent in Kb is phenyl, which may be substituted or unsubstituted. If

Eb is as defined in this paragraph, the compound of Formula II is preferably an imidazole (ie, X is CH or C-Kb, Y is M, and 7 is CH or C-K8) or 1,2,3 - triazole (that is, X represents CH or C-Kb, Y represents M, and 7 represents M). More preferably, the compound has the formula Pa.

Alternatively, Kb is preferably H, halogen or aryl and, more preferably, H.

As defined in this paragraph, a compound of Formula II is preferably a pyrazole (ie, X is CH or C-Kb, Y is CH or C-K7, and 7 is M).

In one embodiment of the invention, if M is C-K7, K7 is selected from aryl or heteroaryl, each of which may be substituted or unsubstituted. Preferably, aryl and heteroaryl are monocyclic. Preferably, the aryl or heteroaryl is substituted with one or more halogen atoms. In a preferred embodiment of the invention, K7/7 is a substituted or unsubstituted aryl. If K7/ is as defined in this paragraph, the compound of Formula III is preferably pyrazole (ie, X is CH or C-Kb, Y is CH or C-

K7, and 7 is M) or 1,2,4-triazole (ie, X is M, M is CH or C-

K7, and 7 represents M).

Ko) In one of the variants, if U represents C-K7, K7 represents H.

In another embodiment of the invention, if 7 is C-K8, K8 is selected from H and aryl.

Preferably, K8 is selected from H and phenyl. More preferably, K8 is H.

In one of the variants of the invention, Kb is a group selected from aryl, heteroaryl, heterocyclyl, C3-0 cycloalkyl, where Kb of the group is substituted by a group selected from C1-6 alkoxy, C1-6 alkoxy C1-6 alkyl, and C1-6 alkyl -"CO-Co-is alkyl, where Si-is alkoxy, Si-is alkoxy C:-ve alkyl or Co.- in alkyl-CO-Co-is the alkyl group is substituted by a group selected from aryl, heteroaryl, heterocyclyl and C3 cycloalkyl. Preferably, Kb is a group selected from aryl, heteroaryl, heterocyclyl, C3-10 cycloalkyl, where the group Kb is substituted by a group selected from C1-6 alkoxy and C1-6 alkoxy C1-6 alkyl, where C1-6 alkoxy or C1-6 alkyl is C1-6 alkyl the group is substituted with a group selected from aryl, heteroaryl, heterocyclyl and C3-0 cycloalkyl. Preferably, Kb is a group selected from aryl, heteroaryl, heterocyclyl, C3-10 cycloalkyl, where the KbE group is replaced by a group selected from C1-6 alkoxy and C1-6 alkoxy C1-6 alkyl, where C1-6 is alkoxy or C1-6 alkoxy C1-6 alkyl group substituted with heterocyclyl. More preferably, Kb is an aryl substituted by a group selected from C1-6 alkoxy and C1-6 alkoxy C1-6 alkyl, where C1-6 alkoxy or C1-6 alkoxy is a C1-6 alkyl group substituted with heterocyclyl. Even more preferably, Kb is an aryl substituted with C- is alkoxy, where C- is alkoxy with a substituted heterocyclyl.

Preferably, Kb is aryl. Preferably, Kb has a monocyclic ring structure, such as a monocyclic aryl. In one embodiment, Kb has a b-membered ring structure, such as phenyl.

BO Preferably, C1-e alkoxy, C1-e alkoxy C1-e alkyl or C0-e alkyl-CO-C0-e alkyl is linear.

Preferably, the substituent in the C 1 -C 10 alkoxy or C 1 -C 1 -C 1 -C 1 -C 6 -C 6 -C 6 alkyl alkyl is monocyclic. Preferably, a substitute and si alcoxis or C: I-is alcox C: I-is alkyli would be. Preferably, the substituent of C1-6 alkoxy or C1-6 alkoxy of C1-6 alkyl is a heterocyclyl. Preferably, the heterocyclyl is fully saturated. Preferably, the heterocyclyl contains 1 or 2 heteroatoms, such as nitrogen or oxygen. Preferably, the heterocyclyl contains at least 1 nitrogen heteroatom. In one variant, heterocyclyl is piperidinyl, piperazinyl, or tetrahydropyranyl. In this variant, the compound preferably has the formula Pa.

In one of the options, if UM is M, and the group SOMCIK2 may not be attached to

E. In this embodiment, the compound is of Formula Y as shown above. because Formula I and Ia

In compounds of Formula I and, in particular, compounds of Formula Ia, ring A is preferably a substituted or unsubstituted aryl or heteroaryl moiety. More preferably, a ring

A is a substituted or unsubstituted monocyclic aryl or heteroaryl fragment. Even more preferably, ring A is a substituted or unsubstituted 5-membered aryl or heteroaryl fragment. Most preferably, ring A is a substituted or unsubstituted monocyclic aryl, such as a benzo moiety.

If ring A is substituted, the substituent may be one or more groups selected from halogen, OH, C 1 alkyl, C 4 alkoxy, ZH, MH, MO», CM, COOH, SOMN:, SOMNON, benzoxyaminocarbonyl, 5OZN, 502MN», aryl , heteroaryl, heterocyclyl and C3-C cycloalkyl.

If the substituent is C-4 alkyl, aryl, heteroaryl, heterocyclyl, or C3-C cycloalkyl, each of the indicated moieties may optionally be substituted by one or more groups selected from halogen, OH, 5H, MH, MO, CM, СООН, СОМН», 5ОзН, 502МН», C3-from alkyl, C-from alkoxy and benzyl.

Preferably, the substituent and rings A is one or more groups selected from halogen, OH,

C-C alkyl, C-C Alkoxy, MH, MO», CM, COOH, СОМН», monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl and Svv cycloalkyl. If the substituent is C1-C alkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl, or C1-C cycloalkyl, each of the indicated moieties may optionally be substituted by one or more groups selected from halogen, CM, COOH, COMH, and C :-from alkoxy.

More preferably, the substituent in ring A is one or more groups selected from halogen, OH, C 1-2 alkyl, C 1-2 alkoxy and phenyl. If the substituent is C1-6 alkyl or phenyl, each of the indicated fragments may optionally be substituted by one or more groups selected from halogen, CM, COOH, COMNH" and C-1-alkyloxy.

In the preferred version of Formula I compounds! and, in particular, in compounds of Formula Ia, Q1 and K2, together with M to which they are attached, form a heterocyclyl group which may be substituted or unsubstituted. Preferably, heterocyclyl is a 5- or b-membered monocyclic ring, more preferably, a b-membered monocyclic ring. In some embodiments, said heterocyclyl contains 1 or 2, preferably 1 additional heteroatom (ie, in addition to M). These additional heteroatoms can be, for example, M, O and/or 5. In one

Two of the heterocyclyl variants are morpholino. Alternatively, heterocyclyl is piperazinyl. In other embodiments, said heterocyclyl does not contain additional heteroatoms (ie, it contains 1 M atom). In one variant, heterocyclyl is piperidinyl. If the heterocyclyl is substituted, it is preferably a substituted aryl or aryl C-4 alkyl, where the aryl is preferably monocyclic and, more preferably, is phenyl. Alkyl is preferably linear. More preferably, heterocyclyl is substituted with aryl or aryl

C1-C6 alkyl, where aryl is preferably monocyclic and, more preferably, is phenyl.

In the preferred version of the compounds of Formula I and, in particular, in the compounds of Formula Ia, K1 is selected from

H and C alkyl, and K2 is selected from aryl, heteroaryl, heterocyclyl, C3-0 cycloalkyl, aryl C1-6 alkyl, heteroaryl C1-6 alkyl, heterocyclyl C1-6 alkyl, and C3-0 cycloalkyl C1-6 alkyl, each of which may be substituted or unsubstituted. In one embodiment, K1 is selected from H, methyl, and ethyl, and K2 is selected from aryl, heteroaryl, heterocyclyl, and C 1-6 cycloalkyl, each of which is monocyclic and may be substituted or unsubstituted. More preferably, K1 is selected from H and methyl. In one of the CT options! is methyl. Alternatively, K1 is H. More preferably, K2 is selected from saturated heterocyclyl and C0 cycloalkyl, each of which is monocyclic and may be substituted or unsubstituted. If K2 is a monocyclic C1-1 cycloalkyl, it is preferably unsubstituted. Preferably, K2 is cyclopentyl or cyclohexyl. More preferably, K2 is cyclohexyl, such as unsubstituted cyclohexyl. If K2 is a monocyclic saturated heterocyclyl, the heterocyclyl ring preferably contains 1 heteroatom. More preferably, the heterocyclyl is 6-membered, such as a piperidinyl or tetrahydropyranyl group. The nitrogen heteroatom can be substituted or unsubstituted.

Alternatively, K1 is selected from H, methyl, and ethyl, and K2 is selected from C1-6 aryl, C1-6 alkyl heteroaryl, C1-6 alkyl heterocyclyl, and C1-6 alkyl cycloalkyl, each of which is monocyclic and may be substituted or unsubstituted. More preferably, K2 is an arylCi alkyl wherein the aryl is monocyclic and may be substituted or unsubstituted. Even more preferably, K 2 is aryl C 1 -6 alkyl, wherein the aryl is monocyclic and may be substituted or unsubstituted, and the C 1 -6 alkyl is linear. Even more preferably, K 2 is phenyl C 1-6 alkyl, which may be substituted or unsubstituted, and

C.i.v alkyl is linear. In one embodiment, the phenyl is unsubstituted. 60 Alternatively, K1 is selected from H, methyl, and ethyl, and K2 is C-- alkyl,

substituted by a group selected from arylCi-4 alkoxy, heteroarylCi-4 alkoxy, heterocyclylCi-4 alkoxy and C 1-4 cycloalkylCi-4 alkoxy, each of which is monocyclic and may be substituted or unsubstituted. Preferably, K2 is a substituted C':-z alkyl. In one of the options, K2 is a substituted C.sub.6 alkyl. Preferably, the substituent in K2 is an aryl C-4 alkoxy wherein the aryl is monocyclic and may be substituted or unsubstituted. Even more preferably, the substituent in C 2 is an aryl C 1 -C 6 alkoxy, wherein the aryl is monocyclic and may be substituted or unsubstituted, and the C:-4 alkoxy is linear. Even more preferably, the substituent in K2 is a phenyl C-4 alkoxy, which may be substituted or unsubstituted, and the C-4 alkoxy is linear. In one embodiment, the substituent in K2 is an aryl C:-C 6 oxy, in which the aryl is monocyclic (eg, phenyl) and may be substituted or unsubstituted, and the C:-C 6-C oxy is linear. In some embodiments, phenyl is unsubstituted.

In another version of the compounds of Formula I and, in particular, in the compounds of Formula Ia, K1 is selected from H and

Alkyl salt, and K2 is selected from heterocyclyl, which may be substituted or unsubstituted.

Preferably, K1 is H, methyl or ethyl, and K2 is bicyclic heterocyclyl, which may be substituted or unsubstituted. More preferably, K1 is H or methyl, and K2 is a bicyclic heterocyclyl, which may be substituted or unsubstituted, where one of the heterocyclyl rings contains 2 oxygen atoms. In one of the options, K2 is 3,3-dimethyl-1,5-dioxaspiroi5,5)undec-9-yl.

In an alternative preferred version of compounds of Formula ! and, in particular, in compounds

In formulas Ia, K1 is selected from H and C... alkyl, and K2 is C1-th alkyl. More preferably, R1 is H, methyl or ethyl, and even more preferably, R1 is H or methyl.

Preferably, K2 is a C3 alkyl, where the alkyl is a linear alkyl. More preferably, K2 is a C-14 alkyl, where the alkyl is a linear alkyl.

Formula Pa

In a preferred embodiment of the compounds of Formula Ia, K1 is selected from H and C1 alkyl, and K2 is selected from aryl, heteroaryl, heterocyclyl, C3-0 cycloalkyl, aryl C1-6 alkyl, heteroaryl C1-6 alkyl, heterocyclyl C1-6 alkyl and C3- o cycloalkyl C:-e alkyl, each of which may be substituted or unsubstituted. More preferably, CI! is selected from H, methyl and ethyl, and K2 is selected from aryl, heteroaryl, heterocyclyl and C3-10 cycloalkyl, each of which may be substituted or

With unreplaced. More preferably, CI is methyl. More preferably, R 2 is selected from aryl, heteroaryl, heterocyclyl and C 1 -C 6 cycloalkyl, each of which is monocyclic and may be substituted or unsubstituted. Even more preferably, K 2 is selected from aryl, such as phenyl, saturated heterocyclyl, and C 1-6 cycloalkyl, each of which is monocyclic and may be substituted or unsubstituted. If K2 is monocyclic C1-C4 cycloalkyl (ie, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl) or aryl, it is preferably unsubstituted. Preferably, K2 is cyclohexyl, such as unsubstituted cyclohexyl.

If K2 is a monocyclic saturated heterocyclyl, the heterocyclyl ring preferably contains 1 heteroatom, such as nitrogen or oxygen. More preferably, the heterocyclyl is 6-membered, such as a piperidinyl or tetrahydropyranyl group. In one variant, the heteroatom is a nitrogen heteroatom, which may be substituted or unsubstituted.

Preferably, the heteroatom in the specified heterocyclyl group is in position 4 relative to the position of the attachment of the heterocyclyl group K2 to the urea nitrogen. In one of the options, the nitrogen atom is replaced by a monocyclic aryl (preferably, phenyl) C-z alkyl; preferably, the nitrogen atom is replaced by benzyl or phenylethyl; and, more preferably, the nitrogen atom is substituted by benzyl.

In an alternative preferred embodiment of the compounds of Formula Ia, K1 and K2, together with M to which they are attached, form a heterocyclyl group which may be substituted or unsubstituted.

Preferably, the heterocyclyl is a 5- or b-membered monocyclic ring and, more preferably, a 5-membered monocyclic ring. In some embodiments, said heterocyclyl contains 1 or 2, preferably 1 additional heteroatom (ie, in addition to M). These additional heteroatoms can be, for example, M, O and/or 5. Preferably, heterocyclyl is oxazolidinyl. Preferably, the oxygen atom in the oxazolidinyl is in the C position relative to the urea nitrogen. Preferably, the oxazolidinyl is substituted 1, 2 or C with methyl or ethyl groups. More preferably, oxazolidinyl is substituted with 2 methyl or ethyl groups. Even more preferably, the oxazolidinyl is substituted with 2 methyl groups at the same carbon atom. More preferably, oxazolidinyl is 4,4-dimethyloxazolidin-3-yl.

In another preferred version of compounds of Formula Pa, KI! and K 2 , together with M to which they are attached, form a heterocyclic group which may be substituted or unsubstituted.

Preferably, the heterocyclyl is a 5- or b-membered monocyclic ring, more preferably, because the b-membered monocyclic ring In some variants, this heterocyclyl contains 1 or 2,

preferably 1 additional heteroatom (ie, in addition to M). These additional heteroatoms can be, for example, M, O and/or 5. In one of the options, heterocyclyl is morpholino. Alternatively, heterocyclyl is piperazinyl. In other embodiments, said heterocyclyl contains no additional heteroatoms (ie, it contains 1 atom

M). In one variant, heterocyclyl is piperadinyl. If the heterocyclyl is substituted, it is preferably substituted with aryl, arylC. alkyl, C 1 -C 4 cycloalkyl or C 1-4 cycloalkyl C 1-4 alkyl, where aryl is preferably monocyclic and, more preferably, is phenyl, and cycloalkyl is preferably cyclohexyl. Alkyl is preferably linear. In one of the options, heterocyclyl is substituted by aryl or aryl C-4 alkyl (preferably C-2 alkyl), where aryl is preferably monocyclic, and, more preferably, is phenyl. Aryl may optionally be substituted by one or more halogen atoms.

In the compounds of Formula Ma, K5 is preferably selected from H, C:-is alkyl, aryl, heteroaryl, heterocyclyl, C3-z cycloalkyl, C1-is alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, Kza, halogen, OH, OK5a, ЗН, 5K5a , OSOK5a, 5СО5a, МН», MO», МНА5Ba, MABano, СОН5a, С5Р5a,

CM, СООН, СООНБ5а, СОМН»e, 5О2Н5ба, 5ОзН, 5О2МН:, СОМАБань, 5О2гМК5акзр, where К5ба and

C5r is independently selected from C1-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl, and heterocyclyl, and

K5ba and KB, together with the heteroatom to which they are attached, can form a heterocyclyl.

More preferably, K5 is selected from H, C1-6 alkyl, aryl, heteroaryl, heterocyclyl, C3-8 cycloalkyl, C6-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, halogen, OH, 3H, MH.

MO», SM, COOH, SOMN»g, 5ОзН, 5О2МН»:. Even more preferably, K5 is selected from H, C, alkyl, aryl, heteroaryl, heterocyclyl, C-4 cycloalkyl, C-4 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, halogen, OH, ЗН, МН», MO», СМ, СОН, СОМН », 5ОЗН, 5О2МН», where the aryl, heteroaryl, heterocyclyl and Сов cycloalkyl group are monocyclic. Even more preferably, K5 is selected from H, C-C alkyl, aryl, heteroaryl, heterocyclyl, C-C cycloalkyl, halogen, OH, MHe 2 , COOH, and COM, wherein the aryl, heteroaryl, heterocyclyl, and C-C cycloalkyl groups are monocyclic. Even more preferably, 5 is selected from H, C, alkyl and halogen. Even more preferably, K5 is selected from H and halogen such as E, C, and Hg. In one of the options, KE5 is H.

In the compounds of Formula Ia, Kb is preferably selected from aryl, heteroaryl, heterocyclyl and C3-c

From cycloalkyl, each of which may be substituted or unsubstituted. More preferably, Kb is selected from aryl and heteroaryl, each of which may be substituted or unsubstituted. In one variant, the heteroaryl contains 1 heteroatom, such as an oxygen or a nitrogen atom.

Preferably, the aryl or heteroaryl is monocyclic. More preferably, aryl or heteroaryl is a 6b-membered monocyclic ring, for example, phenyl or pyridyl. In one variant, the heteroaryl contains a nitrogen atom replaced by an oxygen atom, such as oxidopyridyl. In another embodiment, Kb is an unsubstituted monocyclic aryl, such as phenyl, or a monocyclic aryl, such as phenyl, substituted with one or more groups selected from halogen, C:1-2 alkoxy (optionally substituted with one or more halogen atoms), or ON.

In one of the variants, Kb is unsubstituted or substituted 2-oxo-2,3-dihydro-1H-benzoi|Ch|imidazolyl.

If Kb is substituted, the substituent is preferably one or more groups selected from halogen, C-4 alkoxy, aryl, heteroaryl, heterocyclyl, OH, CM, СОМН», МН», heterocyclyl

C-4 Alkoxy, Aryl C-4 Alkoxy, Heteroaryl C-4 Alkoxy, MO», 502МН»g, 5Oz, С(МОН)МН»,

SOMNONE, 2H-tetrazol-5-yl, dimethylamino, benzylamino, methylsulfonyl, morpholinosulfonyl, and piperidinylsulfonyl. Piperidinylsulfonyl may optionally be substituted with arylmethoxy (preferably benzoxy) or OH. Preferably, aryl, heteroaryl and heterocyclyl are monocyclic. In one embodiment, aryl, heteroaryl and heterocyclyl are b-membered monocyclic rings. In a specific embodiment in which Kb is a monocyclic aryl, it may optionally be substituted with one or more groups selected from halogen, OH, C1-C 6 alkoxy (preferably C:-2 alkoxy), aryl (for example, a monocyclic aryl such such as phenyl), heteroaryl (e.g., monocyclic heteroaryl containing 1 or 2 nitrogen atoms or 1 oxygen atom), heterocyclyl (e.g., piperazinyl, piperadinyl, or morpholino) C1-6 alkoxy (preferably C1-2 alkoxy), aryl ( e.g., monocyclic aryl such as phenyl) C1-C 6 alkoxy (preferably C 1 -C 6 oxy), SOMN", MNH, MO", OSNE", 502MH", morpholinosulfonyl and

C(MON)MN".

In another embodiment, wherein Kb is a monocyclic aryl, it may optionally be substituted with one or more groups selected from halogen, OH, methoxy, phenyl, pyridyl, pyrazinyl, pyranyl, piperazinylmethoxy, piperadinylmethoxy, morpholinomethoxy, benzyloxy,

SOMN», Mng, MO», OSNE», 5О2МН», morpholinosulfonyl and СИ(ИМОН)МН». because In one of the options, if Kb is a monocyclic aryl, such as phenyl, the substituent c

Kb is an aryl, preferably a monocyclic aryl, such as phenyl, which may be substituted or unsubstituted. If it is replaced, it is mostly replaced by SOMN."

If the substituent in Kb is C. alkoxy, aryl, heteroaryl, heterocyclyl, heterocyclyl

Si.4 alkoxy, aryl Si. Alkoxy, heteroaryl C.:-4 Alkoxy or 5Oz, each of the specified fragments may optionally be substituted by one or more groups selected from halogen, OH, Ci-C Alkoxy (which may be substituted by one or more halogen atoms), СОМН », SM, MSNzSNz,

МНОоОСН;», methylhydroxybutyl and methylhydroxybutynyl.

In the compounds of Formula Ma, K8 is preferably selected from H, C:-is alkyl, aryl, heteroaryl, heterocyclyl, C3-z cycloalkyl, C1-is alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, Kva, halogen, OH, OKva, 5H, 5Kva , OSOokva, 5SOva, MN», MO», MNAva, MAvanvy, Sova, Sova,

CM, SOON, SOOVVa, SOMN»g, 5О2НАвВа, 5ОзН, 5О2МН:, СОМАВанвъ, 5О2Мкваквр, de Kva and

C8p is independently selected from C1-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl, and heterocyclyl, and

Kwa and Ke8p, together with the heteroatom to which they are attached, can form a heterocyclyl.

More preferably, K8 is selected from H, C 1 alkyl, aryl, heteroaryl, heterocyclyl, C 3-8 cycloalkyl, C:-is alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, halogen, OH, ЗН, МН».

MO», SM, COOH, SOMN»g, 5ОзН, 5О2МН»:. Even more preferably, K8 is selected from H, C-alkyl, aryl, heteroaryl, heterocyclyl, C-4 cycloalkyl, C-4 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, halogen, OH, ZH, MH", MO", CM, СОН, СОМН », 5ОЗН, 5О2МН», where the aryl, heteroaryl, heterocyclyl and Сов cycloalkyl group are monocyclic. Even more preferably, K8 is selected from H, C-C alkyl, aryl, heteroaryl, heterocyclyl, C1-C cycloalkyl, halogen, OH, MHe 2 , COOH, and COMH", wherein the aryl, heteroaryl, heterocyclyl, and C1-C cycloalkyl group are monocyclic. Even more preferably, K8 is selected from H, C: alkyl, halogen, and monocyclic aryl such as phenyl. Even more preferably, K8 is selected from H,

C-C alkyl and halogen, such as E, SI and Hg. Even more preferably, K8 is selected from H and halogen such as E, C1 and Hg. In one of the options, K8 is H.

In one of the variants of compounds of Formula Ia, KI! selected from H and C-4 alkyl, K2 selected from aryl, heteroaryl, heterocyclyl, C3-0 cycloalkyl, aryl C1-6 alkyl, heteroaryl C1-6 alkyl, heterocyclyl C1-6 alkyl and C3-0 cycloalkyl C1-6 is alkyl, each of which may optionally be substituted by one or more groups selected from K2a, halogen, OH, OK2a, OSON2a, 5H, 5Ka2a,

Koo) ЗСбОВга, МНг, МНАга, МНЗО2МН»г, МНЗО»АНга, МА2гасСовгБ, МНе(Мн)МНн», МНСОВга, МАгарг,

СОВга, С5Ага, СМ, СООН, СООРга, СОМН:, SOMNON, СОМНАга, СОМНОВга, С(МОНИМН»,

ZO2Aga, 5OzH, 502МНо, СОМАганг, 502МКк2акгг, where Kg2a and K26 are independently selected from C1-6 alkyl substituted by C-:-e alkyl, aryl, heteroaryl, C3-b cycloalkyl and heterocyclyl, or K2a and K2p, together with a heteroatom, to which they are attached, may form a heterocyclyl, where, if the substituent in K2 is C1-6 alkyl, substituted C1-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl, heterocyclyl, or groups containing one or more of the indicated moieties, each of said moieties may optionally be substituted with one or more groups selected from

K2s, halogen, OH, OK2s, OSOMK2s, 5H, ZK2s, ZSOK2s, Mng, MNA2s, MNZO»MN», MNZO»Vgs,

MAheSOoVga, Mnes(MnuMnNeg, MNSOoVg2s, MA2geVga, СОовгс, С5В82с, СМ, СООН, СООВ2гс, СОМН»,

SOMNON, SOMNAGs, SOMNOROS, С(MON)МН:, 5О»Н2с, 5БОЗН, 5О2МН:, СОМНгсеснага,

ZO2MK2cK2a, where K2c and K24 are independently selected from C1-6 alkyl, substituted C1-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl, and heterocyclyl, or K2c and K2a, together with the heteroatom to which they are attached, may form a heterocyclyl,

K5 selected from H, Kzba, halogen, OH, OMK5a, OSOK5a, 5H, 5K5ba, 5СОК5a, МН», МНЕА5a,

МНБЗО»МН:, МНЗО»Вба, МАБ5асон5р, МнНе(МнН)ИМНнг, МНнСОВ»Ба, MAБбань, СОВ5ба, С5А5Ба, SM,

СОонН, бООВба, СОМН?, SOMNON, SOMNABA, SOMNOV»Ba, С(МОН)МНг, 502НА5Ba, 5ОзН,

ЗО2гМНг, СОМАБань, 502МА5акз5н, where Koba and K5r are independently selected from C. -e alkyl, substituted

Alkyl, aryl, heteroaryl, C3-1 cycloalkyl and heterocyclyl, or Kba and K5B, together with the heteroatom to which they are attached, can form heterocyclyl,

Kb is selected from aryl, heteroaryl, heterocyclyl, C3-C1 cycloalkyl, each of which may optionally be substituted by one or more groups selected from Kba, halogen, OH,

OVAba, OSOVba, 5Н, 5Аба, 5СОНба, МН, МНАба, МНбОО2МН:, МНБЗО»2Аба, MAbasonbr,

МНС(mMn)MnN:, МНnСОАРба, MAбанб, СОВНба, СЗАба, СМ, СООН, СООНба, СОМН»:, SOMNON,

SOMNAba, SOMNO ba, С(MON)МН»:, 5О2Аба, 5ОзН, 5О2МН:, СОМАбанвбь, 5О2Мкбвакврь, where

Kba and Kbb are independently selected from C1-6 alkyl, substituted C1-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl and heterocyclyl, or Kba and Mb, together with the heteroatom to which they are attached, may form heterocyclyl, and wherein, if Kb is heteroaryl or heterocyclyl, each of said moieties may optionally be substituted by one or more atoms

Gs10) of oxygen,

where, if the substituent in Kb is C 1-6 alkyl, substituted C 1-6 alkyl, aryl, heteroaryl, C 3-6 cycloalkyl, heterocyclyl, or a group containing one or more of the indicated moieties, each of the indicated moieties may optionally be substituted by one or more groups selected from

Ebs, halogen, OH, OKbs, OSORbs, 5H, ZKbs, ZSOKbs, MN, MNAbs, MNBZO»MN», MNZO»Vbs,

MAbeSONVva, MNesMn)MnN», MNSObs, MAbsNva, SoOVNbs, С5Abs, SM, СООН, СООНбs, СОМН»;,

SOMNON, SOMNabs, SOMNORbs, C(MON)MN:, 5O»Abs, 5BOzZN, 5О2МН:, SOMAbsnva,

ZO2MebsKba, wherein Kbs and ba are independently selected from C1-6 alkyl, substituted C1-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl, and heterocyclyl, or K2c and K2a, together with the heteroatom to which they are attached, may form heterocyclyl, and where, if the substituent in Kb is heteroaryl or heterocyclyl, each of said moieties may optionally be substituted with one or more oxygen atoms, and

K8 is selected from H, Kzba, halogen, OH, OMK5a, OSOK5a, 5H, 5K5ba, 5СОК5Ba, МН, МНЕА5a,

МНБЗО»МН:, МНЗО»Вба, МАБ5асон5р, МнНе(МнН)ИМНнг, МНнСОВ»Ба, MAБбань, СОВ5ба, С5А5Ба, SM,

СОонН, СООНаба, СОМН, SOMNON, СОМНАба, SOMNONBa, С(МОН)МН», 5О2АБа, 5ОзН,

ЗО2МНг, СОМАБань, 5О2МА5акз5н, where Koba and К5Бб are independently selected from C. alkyl, substituted

Civ alkyl, aryl, heteroaryl, C3-1 cycloalkyl and heterocyclyl, or Kba and 50, together with the heteroatom to which they are attached, can form heterocyclyl.

In the embodiment described above, preferably, R1 is selected from H, methyl and ethyl, and R2 is selected from aryl, heteroaryl, heterocyclyl and C3-0 cycloalkyl, each of which may be substituted or unsubstituted. More preferably, CT! is methyl. More preferably, R 2 is selected from aryl, heteroaryl, heterocyclyl and C 1 -C 6 cycloalkyl, each of which is monocyclic and may be substituted or unsubstituted. Even more preferably, K 2 is selected from heterocyclyl and C 1 -cycloalkyl, each of which is monocyclic and may be substituted or unsubstituted.

Preferably, the heterocyclyl is fully saturated. If K 2 is a monocyclic C 5-8 cycloalkyl (ie, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl), it is preferably unsubstituted. In one variant, K2 is cyclopentyl or cyclohexyl, such as unsubstituted cyclopentyl or unsubstituted cyclohexyl. If K2 is a monocyclic saturated heterocyclyl, the heterocyclyl ring preferably contains one heteroatom, such as nitrogen or oxygen. Preferably, the heterocyclyl is β-membered, such as piperidinyl or

Zo tetrahydropyranyl group. Preferably, the heteroatom in the specified heterocyclyl group is in position 4 relative to the position of the attachment of the heterocyclyl group K2 to the urea nitrogen. In one of the options, the heteroatom is a nitrogen heteroatom that can be substituted or unsubstituted.

In a specific variant, the nitrogen atom is replaced by a group selected from SM, СОМН»:, СИ(ИМОН)МН»5,

ЗО2-О1-4 alkyl, ЗО3-aryl (optionally substituted by C.-4 alkyl or C.i.-4 haloalkyl, such as trifluoromethyl), CO-heteroaryl (optionally substituted by heteroaryl or halogen), СО-

Ci.« alkyl, COO-C: 4 alkyl, Ci-4 alkyl (optionally substituted by OH, CM, COOH), aryl C with alkyl, heteroaryl Ci- with alkyl, such as piperidinyl Ci- with alkyl (optionally substituted COO-C1-C alkyl), heterocyclyl C-C alkyl, aryl, heteroaryl (optionally substituted with one or more halogen atoms, such as chlorine) and heterocyclyl. Preferably, the nitrogen atom is substituted by a group selected from CM, СОМН», СИМОН)МН», 502-Ch.4 alkyl, ZO»-monocyclic aryl (optionally substituted with C-4 haloalkyl, such as trifluoromethyl), CO-monocyclic heteroaryl (optionally substituted by monocyclic heteroaryl or halogen), CO-C..4 alkyl, COO-

Ci-4 alkyl, Sil alkyl (optionally substituted by OH, CM, COOH), monocyclic aryl Ci-C alkyl, monocyclic heteroaryl C:-C alkyl such as piperidinyl C:-C alkyl (optionally substituted COO-C .-with alkyl), monocyclic heterocyclyl C:-with alkyl, monocyclic aryl, monocyclic heteroaryl (optionally substituted with one or more halogen atoms, such as chlorine) and monocyclic heterocyclyl. More preferably, the nitrogen atom is substituted by a group selected from CM, C-4 alkyl (optionally substituted OH, CM, COOH), monocyclic aryl C.i-C alkyl and monocyclic heteroaryl C.-C alkyl (preferably, piperidinyl C- -from alkyl).

Even more preferably, the nitrogen atom is substituted by a group selected from C.i-4 alkyl (optionally substituted by OH, CM, COOH), monocyclic aryl C.-c alkyl and monocyclic heteroaryl C.1-c alkyl (preferably, piperidinyl C.- from alkyl).

In one of the variants, the nitrogen atom is replaced by a monocyclic aryl (mainly, phenyl) Сч1-z alkyl; preferably, the nitrogen atom is replaced by benzyl or phenylethyl; and, more preferably, the nitrogen atom is substituted by benzyl.

In one of the options, K5 is H, halogen, OH or C... alkyl. Preferably, K5 is H.

In another embodiment, Kb is selected from aryl, heteroaryl, and heterocyclyl, each of which may be substituted or unsubstituted. Preferably, Kb is selected from monocyclic aryl (such as phenyl), monocyclic heteroaryl (such as pyridyl) and heterocyclyl, each of which may be substituted or unsubstituted. In one variant, Kb is an unsubstituted aryl.

If Kb is a substituted aryl, it is preferably substituted with one or more groups selected from halogen, Kba, OH, OKba, MHg, MO», MHC(MH)IMH:, MNAba, MAbanbb, c(MoOHn)MH», SOBba, COOH, COOHBba, SOMN:, SOMNON, 502Aba, 502MEbacb, where Kba and Br are independently selected from C1-6 alkyl, substituted C1 alkyl, aryl, heteroaryl, C3-cycloalkyl and heterocyclyl, where Kba and Kbb are independently selected from C1-6 alkyl, substituted C3-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl and heterocyclyl, where, if the substituent in Kb is C6-6 alkyl, substituted C6-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl, heterocyclyl or is a group containing one or more of these moieties, each of said moieties may optionally be substituted by one or more groups selected from ОКбs, ОН and СОМН», where Кбс and Кба are independently selected from C-C alkyl substituted by СЧ -6 alkyl, aryl, heteroaryl, C3-C cycloalkyl and heterocyclyl, and where, if the substituent in Kb is heteroaryl or heterocyclyl, each of the indicated fragments v may optionally be replaced by one or more oxygen atoms.

Preferably, if Kb is a substituted aryl, it is substituted by one or more groups selected from halogen, OH, C 1 alkoxy, SOMN:, C(MON)MH:, SOMNON, 5052-CO1-4 alkyl, heterocyclyl (optionally substituted oxygen atom) and aryl (optionally substituted with

SOMN"). In one of the options, Kb can be substituted by one or more groups selected from 5-oxo-4,5-dihydro-1,2,4-oxadiazol-Z-yl, Z-carbamoylphenyl, 2H-tetrazol-b-yl, Sil Alkoxy, halogen, OH, SOMNON.

If Kb is a heterocyclyl, it is preferably substituted by an oxygen atom. The substituent in Kb can be 2-oxo-2,3-dihydro-1H-benzo|H|imidazol-5-yl or 2-oxo-2,3-dihydrobenzo|Foxazol-5-yl.

If Kb is heteroaryl, it is preferably unsubstituted or substituted with an oxygen atom. For example, a heterocyclyl may contain an M-oxide. In one variant, Kb is pyridyl or pyridyl oxide.

In another version, K8 is H, halogen, OH or C-C alkyl. Mostly, K8 represents

N.

From Formula IB

In a preferred embodiment of the compounds of Formula NAME, K1 is selected from H and C1 alkyl, and K2 is selected from aryl, heteroaryl, heterocyclyl, C3-0 cycloalkyl, aryl C1-6 alkyl, heteroaryl C1-6 alkyl, heterocyclyl C1-6 alkyl and C3- o cycloalkyl C:-e alkyl, each of which may be substituted or unsubstituted. More preferably, CI! is selected from H, methyl and ethyl, and K2 is selected from aryl, heteroaryl, heterocyclyl and C3-10 cycloalkyl, each of which may be substituted or unsubstituted. More preferably, CT! is methyl. More preferably, R 2 is selected from aryl, heteroaryl, heterocyclyl and C 1 -C 6 cycloalkyl, each of which is monocyclic and may be substituted or unsubstituted. Even more preferably, K2 is a monocyclic aryl, such as phenyl, and may be substituted or unsubstituted. If K2 is substituted, the substituent may be aryl, C1-4 alkoxy, aryl C1-4 alkoxy, or aryloxy. Preferably, the substituent in K2 is aryl, C:-C , aryl, C:-C, or aryloxy, where the aryl is monocyclic and, more preferably, is phenyl.

If K 2 is monocyclic C 1 cycloalkyl or aryl, it is preferably unsubstituted. Preferably, K2 is cyclohexyl, such as unsubstituted cyclohexyl.

If K2 is a monocyclic saturated heterocyclyl, the heterocyclyl ring preferably contains one heteroatom, such as nitrogen or oxygen. More preferably, the heterocyclyl is β-membered, such as a piperidinyl or tetrahydropyranyl group. In one of the options, the heteroatom is a nitrogen heteroatom that can be substituted or unsubstituted.

Preferably, the heteroatom in the specified heterocyclyl group is in position 4 relative to the position of the attachment of the heterocyclyl group K2 to the urea nitrogen. In one of the options, the nitrogen atom is replaced by a monocyclic aryl (preferably phenyl) C.i.-z alkyl.

In an alternative preferred embodiment of the compounds of Formula IB, K1 and K2, together with M to which they are attached, form a heterocyclyl group which may be substituted or unsubstituted.

Preferably, the heterocyclyl is a 5- or b-membered monocyclic ring and, more preferably, a 5-membered monocyclic ring. In some embodiments, said heterocyclyl contains 1 or 2, preferably 1 additional heteroatom (ie, in addition to M). These additional heteroatoms can be, for example, M, O and/or 5. Preferably, heterocyclyl is oxazolidinyl. Preferably, the oxygen atom in the oxazolidinyl is in the C position relative to the urea nitrogen. Preferably, the oxazolidinyl is substituted with 1, 2, or C methyl or ethyl groups. More preferably, oxazolidinyl is substituted with 2 methyl or ethyl groups. Even more preferably, the oxazolidinyl is substituted with 2 methyl groups at the same carbon atom. More preferably, oxazolidinyl is 4,4-dimethyloxazolidin-3-yl.

In another preferred embodiment of the compounds of Formula II, K1 and K2, together with M to which they are attached, form a heterocyclyl group, which may be substituted or unsubstituted.

Preferably, the heterocyclyl is a 5- or b-membered monocyclic ring, more preferably, a b-membered monocyclic ring. In some variants, this heterocyclyl contains 1 or 2, preferably 1 additional heteroatom (ie, in addition to M). These additional heteroatoms can be, for example, M, O and/or 5. In one of the options, heterocyclyl is morpholino. Alternatively, heterocyclyl is piperazinyl. In other embodiments, said heterocyclyl contains no additional heteroatoms (ie, it contains 1 atom

M). In one variant, heterocyclyl is piperadinyl. If the heterocyclyl is substituted, it is preferably substituted with aryl, aryl C 1-4 alkyl, C 1-4 cycloalkyl, or C 1-4 cycloalkyl C 1-4 alkyl, where the aryl is preferably monocyclic, and more preferably is phenyl, and the cycloalkyl is preferably cyclohexyl. Alkyl is preferably linear. In one of the options, heterocyclyl is substituted by aryl or aryl C-4 alkyl (preferably C-2 alkyl), where aryl is preferably monocyclic and, more preferably, is phenyl. Aryl may optionally be substituted by one or more halogen atoms.

In the compounds of Formula IB, K5 is preferably selected from H, C:-is alkyl, aryl, heteroaryl, heterocyclyl, C3-z cycloalkyl, C1-is alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, Kza, halogen, OH, ОК5а, ЗН, 5К5а , OSOK5a, 5СО5a, МН», MO», МНА5Ba, MABanvoy, СОН5Ba, С5В5а,

CM, СООН, СООНБ5а, СОМН»e, 5О2Н5ба, 5ОзН, 5О2МН:, СОМАБань, 5О2гМК5акзр, where К5ба and

C5r is independently selected from C1-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl, and heterocyclyl, and

K5ba and K5B, together with the heteroatom to which they are attached, can form a heterocyclyl.

More preferably, K5 is selected from H, C 1 alkyl, aryl, heteroaryl, heterocyclyl, C 3-8 cycloalkyl, C:-is alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, halogen, OH, ЗН, МН».

MO», SM, COOH, SOMN»g, 5ОзН, 5О2МН». Even more preferably, K5 is selected from H, C, alkyl, aryl, heteroaryl, heterocyclyl, C-4 cycloalkyl, C-4 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, halogen, OH, ЗН, МН», MO», СМ, СОН, СОМН », 5ОЗН, 5О2МН», where aryl,

Zo heteroaryl, heterocyclyl and Соv cycloalkyl group are monocyclic. Even more preferably, K5 is selected from H, C-C alkyl, aryl, heteroaryl, heterocyclyl, C-C cycloalkyl, halogen, OH, MHe 2 , COOH, and COM, wherein the aryl, heteroaryl, heterocyclyl, and C-C cycloalkyl groups are monocyclic. Even more preferably, K5 is selected from H, C6 alkyl and halogen. Even more preferably, K5 is selected from H and halogen such as E, C, and Hg. In one of the options, K5 is H.

In the compounds of Formula IB, Kb is preferably selected from H, C:-is alkyl, aryl, heteroaryl, heterocyclyl, C3-z cycloalkyl, C1-is alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, Kba, halogen, OH, OKbba, 5H, 5Kba , OSOKva, 5SOva, MN», MO», MNAba, MAbanb, SONba, Sova,

CM, СООН, СООНба, СОМН»e, 5О2Нба, 5ОзН, 5О2МН:, SOMAbanvb, 5О2МКбаквбр, where Kba and

Cbr is independently selected from C1-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl, and heterocyclyl, and

Kba and Kbr, together with the heteroatom to which they are attached, can form a heterocyclyl.

More preferably, Kb is selected from H, C 1 alkyl, aryl, heteroaryl, heterocyclyl, C 3-8 cycloalkyl, C:-is alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, halogen, OH, ЗН, МН».

MO», SM, COOH, SOMN»g, 5ОзН, 5О2МН»:. Even more preferably, Kb is selected from H, C, alkyl, aryl, heteroaryl, heterocyclyl, C-4 cycloalkyl, C-4 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, halogen, OH, ЗН, МН», MO», СМ, СОН, СОМН », 5ОЗН, 5О2МН», where the aryl, heteroaryl, heterocyclyl and Сов cycloalkyl group are monocyclic. Even more preferably, Kb is selected from H, C.:- from alkyl, aryl, heteroaryl, heterocyclyl, C-C cycloalkyl, halogen, OH, MH, COOH, and COM, wherein the aryl, heteroaryl, heterocyclyl, and C-C cycloalkyl group are monocyclic. Even more preferably, Mb is selected from H, C-6 alkyl and halogen. Even more preferably, Kb is selected from H and a halogen such as E, Si and Hg. In one of the options, Kb is H.

In compounds of Formula IB, C7 is preferably selected from aryl, heteroaryl, heterocyclyl and C3-C cycloalkyl, each of which may be substituted or unsubstituted. More preferably, K7 is selected from aryl and heteroaryl, each of which may be substituted or unsubstituted. In one embodiment, heteroaryl contains one heteroatom, such as an oxygen or nitrogen atom.

Preferably, the aryl or heteroaryl is monocyclic. More preferably, aryl or heteroaryl is a b-membered monocyclic ring. In one variant, the heteroaryl contains a nitrogen atom replaced by an oxygen atom, for example, in oxidopyridyl. In another embodiment, K7 is an unsubstituted monocyclic aryl, such as phenyl, or a monocyclic aryl, such as

Z is phenyl substituted by one or more groups selected from halogen, C: 1- alkoxy (optionally substituted by one or more halogen atoms), or OH. In a specific embodiment, 7 is an unsubstituted monocyclic aryl such as phenyl.

If K7 is substituted, the substituent is preferably one or more groups selected from halogen, C-4 alkoxy, aryl, heteroaryl, heterocyclyl, OH, СОМН", МН", heterocyclyl C-4 alkoxy, aryl C 1-4 alkoxy, heteroaryl C 1-4 alkoxy, МО», 5О02МН:, 5053, С(МОН)МН»: and morpholinosulfonyl. Preferably, aryl, heteroaryl and heterocyclyl are monocyclic. In one embodiment, aryl, heteroaryl and heterocyclyl represent a b-membered monocyclic ring. In a specific embodiment in which K7 is a monocyclic aryl, it may optionally be substituted with an aryl or heteroaryl, each of which is monocyclic.

Formula Is

In a preferred embodiment of the compounds of Formula Ic, K1 is selected from H and C1-4 alkyl, and K2 is selected from aryl, heteroaryl, heterocyclyl, C3-0 cycloalkyl, aryl C1-6 alkyl, heteroaryl C1-6 alkyl, heterocyclyl C1-6 alkyl and C3-0 cycloalkyl is C1-6 alkyl, each of which may be substituted or unsubstituted. More preferably, R1 is selected from H, methyl and ethyl, and R2 is selected from aryl, heteroaryl, heterocyclyl and C3-10 cycloalkyl, each of which may be substituted or unsubstituted. More preferably, CT! is methyl. More preferably, R 2 is selected from aryl, heteroaryl, heterocyclyl and C 1 -C 6 cycloalkyl, each of which is monocyclic and may be substituted or unsubstituted. Even more preferably, K 2 is selected from aryl, such as phenyl, saturated heterocyclyl, and C 1-6 cycloalkyl, each of which is monocyclic and may be substituted or unsubstituted. If K 2 is monocyclic C 1 -cycloalkyl or aryl, it is preferably unsubstituted. Preferably, K2 is cyclohexyl, such as unsubstituted cyclohexyl. If K2 is a monocyclic saturated heterocyclyl, the heterocyclyl ring preferably contains one heteroatom, such as nitrogen or oxygen. More preferably, the heterocyclyl is β-ene, such as a piperidinyl or tetrahydropyranyl group. In one of the options, the heteroatom is a heteroatom of nitrogen which can be substituted or unsubstituted. Preferably, the heteroatom in the specified heterocyclyl group is in position 4 relative to the position of the attachment of the heterocyclyl group K2 to the urea nitrogen. In one of the options, the nitrogen atom is replaced by a monocyclic aryl (preferably phenyl) C:-alkyl.

Zo In an alternative preferred embodiment of the compounds of Formula Ps, K1 and K2, together with M to which they are attached, form a heterocyclyl group which may be substituted or unsubstituted.

Preferably, the heterocyclyl is a 5- or b-membered monocyclic ring and, more preferably, a 5-membered monocyclic ring. In some embodiments, said heterocyclyl contains 1 or 2, preferably 1 additional heteroatom (ie, in addition to M). These additional heteroatoms can be, for example, M, O and/or 5. Preferably, heterocyclyl is oxazolidinyl. Preferably, the oxygen atom in the oxazolidinyl is in the C position relative to the urea nitrogen. Preferably, the oxazolidinyl is substituted 1, 2 or C with methyl or ethyl groups. More preferably, oxazolidinyl is substituted with 2 methyl or ethyl groups. Even more preferably, the oxazolidinyl is substituted with 2 methyl groups at the same carbon atom. More preferably, oxazolidinyl is 4,4-dimethyloxazolidin-3-yl.

In another preferred version of the compounds of Formula Is, KI! and K 2 , together with M to which they are attached, form a heterocyclic group which may be substituted or unsubstituted.

Preferably, the heterocyclyl is a 5- or b-membered monocyclic ring, more preferably, a b-membered monocyclic ring. In some variants, the indicated heterocyclyl contains 1 or 2, preferably 1 additional heteroatom (ie, in addition to M). These additional heteroatoms can be, for example, M, O and/or 5. In one of the options, heterocyclyl is morpholino. Alternatively, heterocyclyl is piperazinyl. In other embodiments, said heterocyclyl contains no additional heteroatoms (ie, it contains 1 atom

M). In one variant, heterocyclyl is piperadinyl. If the heterocyclyl is substituted, it is preferably substituted with aryl, aryl C 1-4 alkyl, C 1-4 cycloalkyl, or C 1-4 cycloalkyl C 1-4 alkyl, where the aryl is preferably monocyclic and, more preferably, is phenyl, and the cycloalkyl is preferably cyclohexyl. Alkyl is preferably linear. In one of the options, heterocyclyl is substituted by aryl or aryl C-4 alkyl (preferably C-2 alkyl), where aryl is preferably monocyclic and, more preferably, is phenyl. Aryl may optionally be substituted by one or more halogen atoms.

In the compounds of the Formula Ps, K5 is preferably selected from H, C:-is alkyl, aryl, heteroaryl, heterocyclyl, C3-z cycloalkyl, C1-is alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, Coba, halogen, OH, ОК5а, ЗН, 5К5а .

C5r is independently selected from C1-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl, and heterocyclyl, and

K5ba and KB, together with the heteroatom to which they are attached, can form a heterocyclyl.

More preferably, K5 is selected from H, C 1 alkyl, aryl, heteroaryl, heterocyclyl, C 3-8 cycloalkyl, C:-is alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, halogen, OH, ЗН, МН».

MO», SM, SOON, SOMN», 5OzN, 50О2МН»g. Even more preferably, K5 is selected from H, Si. alkyl, aryl, heteroaryl, heterocyclyl, C-4 cycloalkyl, C-4 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, halogen, OH, ЗН, МН», MO», СМ, СООН, СОМН», 5ОЗН, 5О2МН», where aryl, heteroaryl , heterocyclyl and Sov cycloalkyl group are monocyclic. Even more preferably, K5 is selected from H, C-C alkyl, aryl, heteroaryl, heterocyclyl, C-C cycloalkyl, halogen, OH, MHe 2 , COOH, and COM, wherein the aryl, heteroaryl, heterocyclyl, and C-C cycloalkyl groups are monocyclic. Even more preferably, 5 is selected from H, C, alkyl and halogen. Even more preferably, K5 is selected from H and halogen such as E, C1 and Hg. In one of the options, KE5 is H.

In compounds of Formula Ic, b is preferably selected from aryl, heteroaryl, heterocyclyl and C3-C cycloalkyl, each of which may be substituted or unsubstituted. More preferably, Kb is selected from aryl and heteroaryl, each of which may be substituted or unsubstituted. In one embodiment, heteroaryl contains one heteroatom, for example, an oxygen or nitrogen atom.

Preferably, the aryl or heteroaryl is monocyclic. More preferably, aryl or heteroaryl is a b-membered monocyclic ring. In one variant, the heteroaryl contains a nitrogen atom replaced by an oxygen atom, such as oxidopyridyl. In another embodiment, Kb is an unsubstituted monocyclic aryl, such as phenyl, or a monocyclic aryl, such as phenyl, substituted with one or more groups selected from halogen, Ci. alkoxy (optionally substituted by one or more halogen atoms) or OH. In a preferred embodiment, Kb is an unsubstituted aryl and, preferably, a monocyclic aryl such as phenyl.

If Kb is substituted, the substituent is preferably one or more groups selected from halogen, C-4 alkoxy, aryl, heteroaryl, heterocyclyl, OH, СОМН», МН», heterocyclyl C-4 alkoxy, aryl C 1-4 alkoxy, heteroaryl C 1-4 alkoxy, МО», 5О02МН:, 5053, С(МОН)МН»: and morpholinosulfonyl. Preferably, aryl, heteroaryl and heterocyclyl are monocyclic. In one variant, aryl, heteroaryl and heterocyclyl are b-membered monocyclic

From the ring. In a particular embodiment, in which Kb is a monocyclic aryl, it may optionally be substituted with one or more groups selected from halogen, OH, C1-6 alkoxy, aryl (e.g. monocyclic aryl such as phenyl), heteroaryl (e.g. , monocyclic heteroaryl containing 1 or 2 nitrogen atoms or 1 oxygen atom), heterocyclyl (e.g., piperazinyl, piperadinyl, or morpholino) C:i-z alkoxy, aryl (e.g., monocyclic aryl such as phenyl) C:i- from Alkoxy, СОМН», МНг, MO», ОСНЕ»:, 5О2МН», morpholinosulfonyl and

C(MON)MN".

In one of the options, if Kb is a monocyclic aryl, such as phenyl, the substituent in

Kb is an aryl, preferably a monocyclic aryl, such as phenyl, which may be substituted or unsubstituted. If it is replaced, it is mostly replaced by SOMN."

If the substituent in Kb is C.4 alkoxy, aryl, heteroaryl, heterocyclyl, heterocyclyl

Si.4 alkoxy, aryl Si. alkoxy, heteroaryl C.-4 alkoxy or 5Oz, each of the indicated fragments may optionally be substituted by one or more groups selected from halogen, OH, Ci-C alkoxy (which may be substituted by one or more halogen atoms), СОМН» :, SM, MSН3СН3,

МНОоОСН;», methylhydroxybutyl and methylhydroxybutynyl.

Formula Ia

In a preferred embodiment of the compounds of Formula Ia, K1 is selected from H and C1 alkyl, and K2 is selected from aryl, heteroaryl, heterocyclyl, C3-0 cycloalkyl, aryl C1-6 alkyl, heteroaryl C1-6 alkyl, heterocyclyl C1-6 alkyl and C3- o cycloalkyl C:-e alkyl, each of which may be substituted or unsubstituted. More preferably, CI! is selected from H, methyl and ethyl, and K2 is selected from aryl, heteroaryl, heterocyclyl and C3-10 cycloalkyl, each of which may be substituted or unsubstituted. More preferably, CT! is methyl. More preferably, R 2 is selected from aryl, heteroaryl, heterocyclyl and C 1 -C 6 cycloalkyl, each of which is monocyclic and may be substituted or unsubstituted. Even more preferably, K 2 is selected from aryl, such as phenyl, saturated heterocyclyl, and C 1-6 cycloalkyl, each of which is monocyclic and may be substituted or unsubstituted. Even more preferably, R 2 is an aryl such as phenyl, which is monocyclic and may be substituted or unsubstituted. If K2 is substituted, the substituent is preferably one or more halogen atoms.

In one variant, K2 is cyclohexyl, such as unsubstituted cyclohexyl. If

K2 is a monocyclic saturated heterocyclyl, the heterocyclyl ring preferably 60 contains one heteroatom, such as nitrogen or oxygen. More preferably, the heterocyclyl is b--lene,

such as a piperidinyl or tetrahydropyranyl group. In one variant, the heteroatom is a nitrogen heteroatom, which may be substituted or unsubstituted. Preferably, the heteroatom in the specified heterocyclyl group is in position 4 relative to the position of the attachment of the heterocyclyl group K2 to the urea nitrogen. In one of the options, the nitrogen atom is replaced by a monocyclic aryl (mainly phenyl) C. with alkyl.

In an alternative preferred embodiment of the compounds of Formula Pa, K1 and K2, together with M to which they are attached, form a heterocyclyl group which may be substituted or unsubstituted.

Preferably, the heterocyclyl is a 5- or b-membered monocyclic ring and, more preferably, a 5-membered monocyclic ring. In some embodiments, said heterocyclyl contains 1 or 2, preferably 1 additional heteroatom (ie, in addition to M). These additional heteroatoms can be, for example, M, O and/or 5. Preferably, heterocyclyl is oxazolidinyl. Preferably, the oxygen atom in the oxazolidinyl is in the C position relative to the urea nitrogen. Preferably, the oxazolidinyl is substituted 1, 2 or C with methyl or ethyl groups. More preferably, oxazolidinyl is substituted with 2 methyl or ethyl groups. Even more preferably, the oxazolidinyl is substituted with 2 methyl groups at the same carbon atom. More preferably, oxazolidinyl is 4,4-dimethyloxazolidin-3-yl.

In another preferred version of compounds of Formula I, KI! and K 2 , together with M to which they are attached, form a heterocyclic group which may be substituted or unsubstituted.

Preferably, the heterocyclyl is a 5- or b-membered monocyclic ring, more preferably, a b-membered monocyclic ring. In some embodiments, said heterocyclyl contains 1 or 2, preferably 1 additional heteroatom (ie, in addition to M). These additional heteroatoms can be, for example, M, O and/or 5. In one of the options, heterocyclyl is morpholino. Alternatively, heterocyclyl is piperazinyl. In other embodiments, said heterocyclyl contains no additional heteroatoms (ie, it contains 1 atom

M). In one variant, heterocyclyl is piperadinyl. If the heterocyclyl is substituted, it is preferably substituted with aryl, aryl C-4 alkyl, C 1-4 cycloalkyl, or C 1-4 cycloalkyl C 1-4 alkyl, wherein the aryl is preferably monocyclic and, more preferably, is phenyl, and the cycloalkyl is preferably cyclohexyl. Alkyl is preferably linear. In one of

Of the options, heterocyclyl is substituted by aryl or aryl C-alkyl (preferably C-alkyl), where aryl is preferably monocyclic and, more preferably, is phenyl. Aryl may optionally be substituted by one or more halogen atoms.

In the compounds of Formula I, K5 is preferably selected from H, C:-is alkyl, aryl, heteroaryl, heterocyclyl, C3-z cycloalkyl, C1-is alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, Kza, halogen, OH, OK5a, ЗН, 5K5a , OSOK5a, 5СО5a, МН», MO», МНА5Ba, MABano, СОН5a, С5Р5a,

CM, СООН, СООНБ5а, СОМН»e, 5О2Н5ба, 5ОзН, 5О2МН:, СОМАБань, 5О2гМК5акзр, where К5ба and

C5r is independently selected from C1-6 alkyl, aryl, heteroaryl, C3-6 cycloalkyl, and heterocyclyl, and

K5ba and KB, together with the heteroatom to which they are attached, can form a heterocyclyl.

More preferably, K5 is selected from H, C1-6 alkyl, aryl, heteroaryl, heterocyclyl, C3-8 cycloalkyl, C6-6 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, halogen, OH, 3H, MH.

MO», SM, COOH, SOMN»g, 5ОзН, 5О2МН»:. Even more preferably, K5 is selected from H, C, alkyl, aryl, heteroaryl, heterocyclyl, C-4 cycloalkyl, C-4 alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, halogen, OH, ЗН, МН», MO», СМ, СОН, СОМН », 5ОЗН, 5О2МН», where the aryl, heteroaryl, heterocyclyl and Сов cycloalkyl group are monocyclic. Even more preferably, K5 is selected from H, C-C alkyl, aryl, heteroaryl, heterocyclyl, C-C cycloalkyl, halogen, OH, MHe 2 , COOH, and COM, wherein the aryl, heteroaryl, heterocyclyl, and C-C cycloalkyl groups are monocyclic. Even more preferably, K5 is selected from H, C6 alkyl and halogen. Even more preferably, K5 is selected from H and halogen such as E, C, and Hg. In one of the options, KE5 is H.

In compounds of Formula Ia, K7 is preferably selected from aryl, heteroaryl, heterocyclyl and C3-C cycloalkyl, each of which may be substituted or unsubstituted. More preferably, K7 is selected from aryl and heteroaryl, each of which may be substituted or unsubstituted. In one embodiment, heteroaryl contains one heteroatom, for example, an oxygen or nitrogen atom.

Preferably, the aryl or heteroaryl is monocyclic. More preferably, aryl or heteroaryl is a b-membered monocyclic ring. In one variant, the heteroaryl contains a nitrogen atom replaced by an oxygen atom, such as oxidopyridyl. In another embodiment, K7 is an unsubstituted monocyclic aryl, such as phenyl, or a monocyclic aryl, such as phenyl, substituted with one or more groups selected from halogen, C-2 alkoxy (optionally substituted with one or more halogen atoms), or OH. 60 If K7 is substituted, the substituent is preferably one or more groups selected from halogen, C-4 alkoxy, aryl, heteroaryl, heterocyclyl, OH, СОМН», МН», heterocyclyl C-4 alkoxy, aryl C 1-4 alkoxy, heteroaryl C 1-4 alkoxy , MO», 5О02МН:, 5053, С(МОН)МН» and morpholinosulfonyl. Preferably, aryl, heteroaryl and heterocyclyl are monocyclic. In one embodiment, aryl, heteroaryl and heterocyclyl are b-membered monocyclic rings. In a specific embodiment in which R7 is a monocyclic aryl, it may optionally be substituted with one or more groups selected from halogen, OH, C1-C6 alkoxy, aryl (e.g. monocyclic aryl such as phenyl), heteroaryl (e.g. , a monocyclic heteroaryl containing one or two nitrogen atoms, or one oxygen atom), heterocyclyl (eg, piperazinyl, piperadinyl, or morpholino) C:1-C alkoxy, aryl (eg, a monocyclic aryl such as phenyl) C 1 -C 6 alkyl »:, МН, МО», OSNE», 5О2МН», morpholinosulfonyl and С(ИМОН)МН». In one embodiment, if K7 is a monocyclic aryl, such as phenyl, the substituent in K7 is an aryl (eg, a monocyclic aryl, such as phenyl) C:-C alkoxy.

If the substituent in K7 is C. alkoxy, aryl, heteroaryl, heterocyclyl, heterocyclyl

Si.4 alkoxy, aryl Si. alkoxy, heteroaryl C.-4 alkoxy or 5Oz, each of the indicated fragments may optionally be substituted by one or more groups selected from halogen, OH, Ci-C alkoxy (which may be substituted by one or more halogen atoms), СОМН» , SM, MSН3СН3,

МНОоОСН;», methylhydroxybutyl and methylhydroxybutynyl.

In an alternative version of the invention, a compound of Formula I or Formula II is proposed: (A) K x shi scho / /

M Ve M also ra; M o u, o M

Formula I Formula II where K1, K2, KU", ring A, U, MU, X, U and 2 are as defined above; or a pharmaceutically acceptable salt or ester thereof; provided that ring A in compounds of Formula I does not form pyridine, pyrimidine, substituted pyridine or substituted pyrimidine, if K! and K2, together with M to which they are attached, form piperidinyl, piperazinyl, substituted piperidinyl, or substituted piperazinyl, provided that ring A is not unsubstituted benzo, hydroxybenzo, phenoxybenzo,

Co) fluorochlorobenzo, chlorobenzo, bromobenzo, nitrobenzo, aminobenzo, cyanobenzo, methylbenzo, trifluoromethylbenzo, trifluoromethylchlorobenzo, phenylketobenzo, phenylhydroxymethylbenzo, cyclohexylthiobenzo, methoxycarbonylbenzo or methoxybenzo, provided that if K1 or K2 is methyl, the other of K1 or K2 is not is 4-chlorobutyl, 4-azidobutyl or 4-isothiocyanatobutyl, and provided that the compound is not (4-phenyl-1H-imidazol-1-yl)(4-(quinolin-2-ylmethyl)piperazin-1- Ilumethanon.

According to the second aspect of the invention, there is provided a pharmaceutical composition containing a compound according to the first aspect of the invention together with one or more pharmaceutically acceptable excipients.

The pharmaceutical compositions of the present invention contain any of the compounds according to the first aspect of the present invention with any pharmaceutically acceptable carrier, excipient or solvent. Pharmaceutically acceptable carriers, excipients and solvents that can be used in the pharmaceutical compositions of the present invention are those widely used in the field of pharmaceuticals and include, but are not limited to, sugar, sugar alcohols, starches, ion exchange agents, silicon dioxide, aluminum stearate, lecithin, whey proteins such as human serum albumin, buffer substances such as phosphates, glycerin, sorbic acid, potassium sorbate, mixtures of partial glycerides of saturated fatty acids of vegetable origin, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silicon dioxide, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, wax, block polymers polyethylene-polyoxypropylene, polyethylene glycol, and wool fat.

The pharmaceutical compositions of the present invention can be administered orally, parenterally, by inhalation of a spray, rectally, nasally, buccally, vaginally, or via an implanted reservoir. Oral administration is preferred. The pharmaceutical compositions of the present invention may contain any conventional non-toxic pharmaceutically acceptable carriers, excipients or solvents. The term "parenteral" as used herein includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intralesional, and intracranial methods of injection or infusion.

Pharmaceutical compositions can take the form of a sterile injectable preparation, for example, a sterile aqueous or oily suspension for injection. Such a suspension can be formed by methods known to a person skilled in the art, using suitable dispersing or wetting agents (eg, Tween 80) and suspending agents.

A sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic diluent or solvent acceptable for parenteral administration, for example, in the form of a solution in 1,3-butanediol. Among the acceptable carriers and solvents that may be used are mannitol, water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, non-volatile oils are widely used as a solvent or suspending medium. For this purpose, any light non-volatile oil can be used, including synthetic mono- or diglycerides. Fatty acids such as oleic acid and its glyceride derivatives are suitable for the manufacture of injectable forms, as are natural pharmaceutically acceptable oils such as olive oil or castor oil, especially in polyoxyethylated forms. Said oily solutions or suspensions may also contain a diluent in the form of a long-chain alcohol or a dispersing agent, for example, as described in the Swiss Pharmacopoeia, or a similar alcohol.

Pharmaceutical compositions according to the present invention for oral use can be administered in any dosage form acceptable for oral administration, including, but not limited to, capsules, tablets, powders, granules, as well as aqueous suspensions and solutions.

The indicated dosage forms are obtained by methods known to the 3rd level of technology in the field

From pharmaceutical preparations. In the case of tablets for oral administration, carriers commonly used include lactose and corn starch. Lubricants such as magnesium stearate are also commonly added. For oral administration in capsule form, suitable diluents include lactose and dry corn starch. If aqueous suspensions are administered orally, the active ingredient is combined with emulsifiers and suspending agents. If desired, some sweeteners and/or flavors and/or colors may be added.

Pharmaceutical compositions according to the present invention can also be administered in the form of a suppository for rectal administration. Said compositions may be prepared by mixing a compound of the present invention with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and thus melts in the rectum to release the active ingredients. Such materials include, but are not limited to, cocoa butter, wax, and polyethylene glycols.

Pharmaceutical compositions according to the present invention can be administered in the form of a nasal spray or inhalation. Such compositions are prepared by methods known in the pharmaceutical art and may be prepared as solutions in salt solutions, using benzyl alcohol or other suitable preservatives, absorption enhancers to increase bioavailability, fluorocarbon derivatives and/or other solubilizers or dispersants known in the art.

The compounds of the present invention can be administered at a dose of from about 1 to about 20,000 μg/kg per dose, depending on the condition to be treated or prevented and the characteristics of the subject to whom the compound is administered. In many cases, the dose may be from about 1 to about 1500 mg/kg/dose. A treatment regimen for a particular compound can be readily determined by one skilled in the art having access to this specification.

In one specific embodiment, the pharmaceutical composition according to the invention additionally contains one or more additional active pharmaceutical ingredients. A compound of the invention may be administered with one or more additional active pharmaceutical ingredients. This can be done in the form of a single composition containing a compound of the invention and one or more additional active pharmaceutical ingredients.

Alternatively, this may be carried out in the form of two or more separate compositions, where the compound of the invention is contained in one composition, and one or more additional active pharmaceutical ingredients are contained in one or more separate compositions.

In a third aspect of the present invention, there is provided a compound according to the first aspect of the invention or a composition according to the second aspect for use in therapy.

In a fourth aspect of the invention there is provided a compound according to the first aspect of the invention or a composition according to the second aspect for use in the treatment or prevention of a condition the development or symptoms of which are associated with a substrate of the enzyme GASK, wherein the only conditions of the first aspect that apply are -- it i) that ring A in the compounds of Formula I does not form pyridine, pyrimidine, substituted pyridine or substituted pyrimidine, if KI and К2, together with

M, to which they are attached, form piperidinyl, piperazinyl, substituted piperidinyl or substituted piperazinyl, and) if K1 or K2 is methyl, the other K1! or K2 is not 4-chlorobutyl, 4-azidobutyl or 4-isothiocyanatobutyl, and ii) the compound is not (4-phenyl-1H-imidazol-1-yl)(4-(quinolin-2-ylmethyl) piperazin-1- Ilumethanon.

The invention also provides the use of a compound according to the first aspect of the invention or a composition according to the second aspect in the manufacture of a medicinal product for the treatment or prevention of a condition, the development or symptoms of which are associated with the substrate of the enzyme GAJK, where the only conditions of the first aspect that apply are -- this i) that ring A in the compounds of Formula | does not form pyridine, pyrimidine, substituted pyridine, or substituted pyrimidine if K1! and K2, together with the M to which they are attached, form piperidinyl, piperazinyl, substituted piperidinyl, or substituted piperazinyl, and (iii) if K1 or K2 is methyl, the other K1 or K2 is not 4-chlorobutyl, 4-azidobutyl, or 4-isothiocyanatobutyl , and iii) the compound is not (4-phenyl-1H-imidazol-1-yl)(4-(quinolin-2-ylmethyl)piperazin-1-yl)umethanone.

A number of conditions, the development or symptoms of which are associated with the substrate of the GAZK enzyme, are known to the expert. Some of them are discussed above.

A fifth aspect of the invention also provides a method of treating or preventing a condition, the development or symptoms of which are associated with a substrate of the enzyme GASK, wherein the method comprises administering to a subject in need of such treatment or prevention a therapeutically effective amount of a compound according to the first aspect of the invention or composition according to the second aspect, where the only conditions of the first aspect that apply are i) that ring A in the compounds of the Formula | does not form pyridine, pyrimidine, substituted pyridine, or substituted pyrimidine if K1! and K2, together with the M to which they are attached, form piperidinyl, piperazinyl, substituted piperidinyl, or substituted piperazinyl, and (iii) if K1 or K2 is methyl, the other K1 or K2 is not 4-chlorobutyl, 4-azidobutyl, or 4-isothiocyanatobutyl , and iii) the compound is not (4-phenyl-1H-imidazol-1-yl)(4-(quinolin-2-ylmethyl)piperazin-1-yl)methanone.

The compound according to the fourth aspect or the method according to the fifth aspect, wherein the condition is a disorder related to the endocannabinoid system.

In some embodiments, the type of condition to be treated may be selected from: () pain, particularly acute or chronic neurogenic pain such as migraine and neuropathic pain (eg, diabetic neuropathic pain, postherpetic neuralgia, trigeminal neuralgia); acute or chronic pain associated with inflammatory diseases such as arthritis, rheumatoid arthritis, osteoarthritis, spondylitis, gout, vasculitis, Crohn's disease and irritable bowel syndrome; acute or chronic peripheral pain; (iii) dizziness, vomiting and nausea, in particular, as a result of chemotherapy; (ii) eating disorders, in particular anorexia and cachexia of various nature; (im) neurological and psychiatric pathologies, such as tremors, dyskinesias, dystonias, spasticity, obsessive-compulsive behavior, Tourette's syndrome, all forms of depression and anxiety of any nature and origin, mood disorders and psychosis; (m) acute and chronic neurodegenerative diseases, such as Parkinson's disease, disease

Alzheimer's, senile dementia, Huntington's chorea, damage associated with brain ischemia and traumatic brain injury; (mi) epilepsy; (my) sleep disorders, including sleep apnea; (my) cardiovascular diseases, such as heart failure, hypertension, cardiac arrhythmias, arteriosclerosis, heart attack, ischemia of the heart and ischemia of the kidneys; (their) various types of cancer, for example, benign skin tumors, brain tumors and papillomas, prostate tumors and brain tumors (glioblastomas, medulloepitheliomas, medulloblastomas, neuroblastomas, tumors of embryonic origin, astrocytomas, astroblastomas, ependymomas, oligodendrogliomas, plexus tumors, neuroepitheliomas, tumor of the pineal gland, ependymoblastomas, malignant meningiomas, sarcomatosis, malignant melanomas and schwannomas); because (x) disorders of the immune system, in particular, autoimmune diseases such as psoriasis, lupus erythematosus, connective tissue disease or collagen disease, Sjorgen's syndrome, ankylosing spondylitis, ankylosing spondylitis, Behcet's disease, autoimmune hemolytic anemia, multiple sclerosis, amyotrophic lateral sclerosis, amyloidosis, transplant rejection, diseases affecting the plasmacytic line, allergic diseases; immediate or delayed hypersensitivity, allergic rhinitis or conjunctivitis, contact dermatitis; (xi) parasitic, viral or bacterial infectious diseases such as AIDS and meningitis; (xi) inflammatory diseases, in particular, joint diseases, such as arthritis, rheumatoid arthritis, osteoarthritis, spondylitis, gout, vasculitis, Crohn's disease, irritable bowel syndrome; (khii) osteoporosis; (chem) ophthalmic conditions such as high eye pressure and glaucoma; (hu) pulmonary conditions, including diseases of the respiratory tract, bronchospasm, cough, asthma, chronic bronchitis, chronic obstruction of the respiratory tract and emphysema; (chmi) gastrointestinal diseases such as irritable bowel syndrome, inflammatory bowel disorders, ulcers, diarrhea, urinary incontinence and inflammation of the bladder.

In a sixth aspect of the present invention, there is provided the use of a compound according to the first aspect of the invention in the manufacture of a medicament for the treatment or prevention of a condition, the development or symptoms of which are associated with a substrate of the enzyme GASK, wherein the only condition of the first aspect that applies is that that ring A in compounds of Formula I does not form pyridine, pyrimidine, substituted pyridine, or substituted pyrimidine, if C1 and C2, together with M to which they are attached, form piperidinyl, piperazinyl, substituted piperidinyl, or substituted piperazinyl.

The above are examples of states corresponding to the sixth aspect.

In some embodiments of the fourth, fifth, or sixth aspects, one or both of the other conditions of the first aspect also apply.

Further, the invention will be described in more detail only with the help of examples. 1. Synthesis methodology

The methods used to synthesize the compounds of the invention are illustrated in general terms

With the diagrams below and the following preparative examples. All compounds and intermediates were characterized by nuclear magnetic resonance (NMR) data. The starting materials and reagents used to prepare the indicated compounds are available from commercial suppliers or can be prepared by methods obvious to those skilled in the art. The general schemes shown are only illustrative of the ways in which the compounds of the present invention can be synthesized, and various modifications of the schemes shown can be made and will occur to one of ordinary skill in the art based on this description.

Room temperature in the following diagrams indicates a temperature in the range from 202C to 2526.

BENZOTRIAZOLE

5B-Bromo-1H-benzoi41(1,2,3)griazole (formation of a derivative of 1H-benzoi9411I1,2,3)|griazole). re) he them A u

Mne O-Ma-- and, M

JSC ZBZSHZBZBZ--- ay

Vg MN" Vg M

A solution of sodium nitrite (4.06 g, 58.8 mmol) in water (10 ml). After stirring in an ice bath for 1 hour, add an additional amount of acetic acid (20 ml, 349 mmol), heat with stirring to 80--852C, hold at this temperature for 1 hour, filter the solution while hot to remove insoluble material black in color, cooled to 0-52, kept for 30 min, the precipitate was collected, washed with water, dried under vacuum at a temperature of 4526.

Yield: 9.48 g (90 b).

M-Cyclohexyl-M-methyl-1H-benzoyl9a1(1,2,3|)griazole-1-carboxamide (formation of disubstituted triazole-1-carboxamide)

N

OT and M

M SOS" M, Rugpaipe m

That's because - because oh

M

N fa ki

Rugidipe - Pyridine

A solution of 1H-benzoi|411,2,3|griazole (0.5 g, 4.20 mmol) in tetrahydrofuran (25 ml) is added dropwise with stirring to 20 95 phosgene solution (5.30 ml, 10.1 mmol) in toluene at 0-5960.

The reaction mixture is stirred at a temperature of 20-252C for 2 hours. (according to the data

TLC reaction is completed). Argon is passed through the solution for 15 minutes. Next, the solvent was evaporated under vacuum to give 1H-benzo|41(/1,2,3)griazole-1-carbonyl chloride (0.763 g, 4.20 mmol) as a clear oil. The product is used without further purification.

Pyridine (0.357 mL, 4.41 mmol) was added dropwise with stirring to a solution of oil in tetrahydrofuran (25 mL) at 0-52C. Then M-methylcyclohexanamine (0.499 g, 4.41 mmol) was added dropwise at 0-52C. The reaction mixture is stirred overnight at 20-252C. Water and EAs are added, and the organic fraction is separated, washed with 1 M HCl, water, and salt solution.

The organic fraction is dried (Md5O»x) and evaporated under vacuum to obtain a clear oil.

The oil is recrystallized from a mixture of 2-propanol/DHM, the solid is collected, dried under vacuum at 40-4520. Yield: 230 mg (21 b). (8)-M-(Quinuclidin-3-yl)-1H-benzoyl|941(1,2,3Igriazole-1-carboxamide hydrochloride (formation of monosubstituted triazole-1-carboxamide)

NOAH

(c) in -k

Ha OA 3 1 sh

Ch ss Mn NS Sfli: -e sl o 0-5

M

To a solution of 1H-benzoin|41(1,2,3|griazole (0.238 g, 2 mmol) in dry DCM (5 ml) is added at 0-50 20 to a solution of phosgene (1.052 ml, 2.000 mmol) in toluene. The mixture is stirred for 30 min at 20-252 C, cooled to 0-52 C, and triethylamine (0.279 mL, 2.000 mmol) was added with stirring. The suspension was diluted with dry DCM (5 mL), solid (K)-quinuclidin-3-amine dihydrochloride (0.398 g, 2.000 mmol) and triethylamine (0.836 mL, 6.00 mmol) at 0-596.

Mixtures are allowed to heat up to 20-252C for 30 minutes, diluted with 2-propanol, evaporated to dryness. The residue is partitioned between water (15 ml) and DCM (15 ml), the organic fraction is dried (M9505), evaporated, separated on a column (DCM/Meon, 9:1), the fractions are collected from

With the production of oil. The oil is dissolved in ether with a minimum amount of dichloromethane, the solution is acidified with 2 M HCl in ether to pH 1-2, the precipitate is collected, washed with ether, dried under vacuum at 4520. Yield: 0.12 g (19.5 95).

M-(4-Phenylbutyl)-1H-benzoyl|41(11,2,3)griazole-1-carboxamide (formation of monosubstituted triazole-1-carboxamide)

M,

M, Mer, M

Mo. 7 -Z526V2B- M

(4-Isocyanatobutyl)benzene (463 mg, 2.64 mmol) is added dropwise with stirring to a solution of 1H-benzoin|941(11,2,3)Hygriazole (300 mg, 2.52 mmol) in DCM (18 ml) at 0-52С. The transparent reaction mixture is stirred at 20-252C, keeping at this temperature overnight.

The solvent is removed under vacuum to give a clear oil. The oil hardens on standing to form a colorless solid. The product is recrystallized from 2-propanol, the solid is collected, and dried under vacuum at 452C. Yield: 477 mg (64 Ob).

IMIDAZOLES: 4-(4-Fluorophenyl)-1H-imidazole (synthesis of imidazole) o M o

Vg L - -- | in; and M. M

IS

IS

2-Bromo-1-(4-fluorophenyl)ethanone (5.93 g, 27.31 mmol), formamide (13.45 mL, 339 mmol) and water (1 mL) were added to a 50 mL pear-shaped flask. The reaction mixture is heated to 140 "C, kept at this temperature for 4 hours. Then it is cooled to room temperature and poured into 150 ml of water. The residue is filtered, washed with water. The pH of the filtrate is brought to 12 by adding 1095 of a solution of MaonN. The precipitate obtained is filtered, washed with water and dried under vacuum.(Yield: 2.02 g, 45 Vol.) (4-Phenyl-1H-imidazol-1-yl)(4-phenylpiperazin-1-yl)umethanone (acylation)

Sha (oh "ah,

U Me he M M be - U 8, ; and

Pyridine (0.489 mL, 6.00 mmol) and DMAP (48.9 mg, 0.400 mmol) were added to a solution of 4-phenyl-1H-imidazole (577 mg, 4 mmol) in tetrahydrofuran (20 mL) with stirring. The pale yellow solution is treated with 4-phenylpiperazine-1-carbonyl chloride (944 mg, 4.20 mmol) and heated to 90 °C, keeping at this temperature for 20 h. Then THF is removed under vacuum, the residue is distributed between a mixture of DCM and IPS (70:30) and water. The organic fraction was dried over magnesium sulfate and filtered. After evaporation, the crude product was recrystallized from hot IPS, filtered, and dried under vacuum. (Yield: 777 mg, 58 95).

M-(4-Fluorophenyl)-4-(4-hydroxyphenyl)-M-methyl-1H-imidazole-1-carboxamide (deprotection)

IS

(c) ud o

M I VV - the same M

WHAT; M

M | p;

That's it

Coo) schi F)

To a solution of M-(4-fluorophenyl)-4-(4-methoxyphenyl)-M-methyl-1H-imidazole-1-carboxamide (0.283 g, 0.870 mmol) in dichloromethane cooled in a bath containing methanol and dry ice (8 mL) add boron tribromide (0.164 mL, 1.740 mmol). The dark-colored reaction mixture is allowed to warm to room temperature and stirred for 2 hours. TLC data show completion of the reaction, after which the reaction mixture is poured into a mixture of water and ice and stirred for 30 min. No sediment is formed. The mixture is extracted with DCM LPS (70:30), the organic fraction is dried over magnesium sulfate and filtered. DCM is removed under vacuum and the product is precipitated from IPS, filtered and dried under vacuum. (Yield: 210 mg, 78 95). 1,2,A-TRIAZOLES: 3-(4-Chlorophenyl)-1 H-1,2,4-triazole (ring synthesis) and X. - units of (FI CI 4-Chlorobenzamide (7.371 g, 47.4 mmol) is suspended in 1,1-dimethoxy-M,M-dimethylmethanamine (15.73 ml, 118 mmol). The reaction mixture is heated to 80 "С, kept at this temperature for 1 h. Then it is cooled to room temperature, and the excess of 1 ,1-dimethoxy-M,M-dimethylmethanamine was removed under vacuum.The resulting solid was triturated with petroleum ether, filtered and dried under vacuum.(Yield: 9.44 g, 95 9Urv).

M

) M" -

Sus I NIM MN" and

BUT si 7 p

With stirring, hydrazine hydrate (1.524 ml, 49.1 mmol). The reaction mixture is immediately solidified, and it is heated to 120 "С, kept at this temperature for 2 hours. Then it is cooled to room temperature and azeotropic distillation with toluene is carried out. The crystalline residue is stirred with water for some time.

The residue is filtered, washed with water and dried under vacuum. (Yield: 7.27 g, 91 Urv). (3--4-Methoxyphenyl)-1H-1,2,4-triazol-1-yluomorpholino)methanone (acylation)

About TV

M" M: with M su o - A

M o. M M M ke; then

With stirring, pyridine (0.489 mL, 6.00 mmol) and DMAP (48, 9 mg, 0.400 mmol)

The solution was treated with morpholine-4-carbonyl chloride (0.490 mL, 4.20 mmol). and heated to

From 90 C, keeping at this temperature for 20 hours. TLC data show that the reaction is almost complete. THF is removed under vacuum, the residue is partitioned between DCM and water. The organic fraction is dried over magnesium sulfate, filtered and evaporated.

Recrystallization from hot IPS gave 749 mg of white crystals (Yield: 65 9). 1,2,3-TRIAZOLES: 4-Phenyl-1H-1,2,3-triazole (ring synthesis)

MN s ras s no ra M. MSh- - 222 2 2 2

Azidotrimethylsilane (2.65 mL, 20.00 mmol) was added in one portion to a stirred solution of phenylacetylene (1.098 mL, 10 mmol) in absolute toluene (10 mL). The reaction mixture is heated to 100 °C, held at this temperature for 3 days, then cooled to room temperature, and the toluene is removed under vacuum. The residue is partitioned between DCM and water. The organic fraction is dried over magnesium sulfate and filtered. After evaporation, the crude product is chromatographed. in petroleum ether:

EUAcS-21. (Yield: 355 mg, 24 95).

Morpholino(4-phenyl-1H-1,2,3-triazol-1-yl)umethanone (acylation)

N Her M mi M-i x ZH x

School building (303 --- Sh

M o. M M M

With stirring, pyridine (0.286 ml, 3.51 mmol), DMAP (0.029 g, 0.234 mmol) was added to a solution of 4-phenyl-1H-1,2,3-triazole (0.340 g, 2.342 mmol) in tetrahydrofuran (12 ml). .

The solution was treated with morpholine-4-carbonyl chloride (0.287 mL, 2.459 mmol). The reaction mixture is heated to 90 "C, kept at this temperature for 20 h. Then THF is removed under vacuum, the residue is partitioned between DCM and water. The organic fraction is dried over magnesium sulfate and filtered. After evaporation, the crude product is recrystallized from hot IPS, filtered and dried under vacuum (Yield: 193 mg, 29 95).

PYRAZOLES:

Z-phenyl-1H-pyrazole (RING SYNTHESIS) o and (c) -d-

SY su--- Sh

Acetophenone (5.89 mL, 50 mmol) was dissolved in 1,1-dimethoxy-M,M-dimethylmethanamine (13.39 mL, 100 mmol). The reaction mixture is heated to 120 "C, kept at this temperature for 24 h. The dark red solution is cooled to room temperature, and the excess of 1,1-dimethoxy-M,M-dimethylmethanamine is removed under vacuum. The resulting solid is triturated with petroleum ether, filtered and dried under vacuum. (Yield: 6.78 g, 77 o.).

My

Zo During stirring, hydrazine hydrate (1.459 ml, 30.0 mmol). The reaction mixture is heated to 100 "C, held at this temperature for 2 h. Then it is cooled to room temperature, and the ethanol is removed under vacuum. The residue is partitioned between DCM and water. The organic fraction is dried over magnesium sulfate and filtered. After evaporation, the crude product is purified by trituration. with a mixture of petroleum ether and ethyl acetate (Yield: 1.59 g, 73 v).

Morpholino(3-(pyridin-3-yl)-1H-pyrazol-1-yl)umethanone (acylation)

Sha 0005

M. X. M. UM and 7 in the village of Su Phi, M

She: Oh. M Y /

She in

M | p

M

With stirring, pyridine (0.367 ml, 4.50 mmol), DMAP (18.33 mg, 0.150 mmol) was added to a solution of 3-(1H-pyrazol-3-yl)pyridine (0.435 g, 3 mmol) in tetrahydrofuran (15 ml) ). The solution was treated with 4-morpholinecarbonyl chloride (0.368 mL, 3.15 mmol). The reaction mixture is heated to 80 "C, kept at this temperature for 20 h. THF is removed under vacuum, and the residue is partitioned between DCM and water. The organic fraction is dried over magnesium sulfate and filtered. After evaporation, the crude product is chromatographed in petroleum ether: EtOAc-2 : 1. (Yield: 174 mg, 21 b).

BENZIMIDAZOLES:

M-Methyl-M-phenyl-1H-benzo|d|imidazole-1-carboxamide (acylation) х од з о оо зур 0 -- m

M o M M in;

M

With stirring, pyridine (0.367 mL, 4.50 mmol) was added to a solution of 1H-benzo|dCh|imidazole (354 mg, 3 mmol) in tetrahydrofuran (15 mL), followed by the addition of methyl(phenyl)carbamoyl chloride (534 mg, 3.15 mmol). The reaction mixture is heated to 80 °C, kept at this temperature for 20 h. THF is removed under vacuum, the residue is partitioned between DCM and water. The organic fraction is dried over magnesium sulfate and filtered. After evaporation, the crude product is chromatographed in a mixture of petroleum ether/IproOdAs-2 :1.(Yield: 365 mg, 46 9).

The following section provides additional synthesis examples for specific compounds.

Preparation of compound 362 a) M-Cyclohexyl-M-methyl-4-(pyridin-3-yl)-1H-imidazole-1-carboxamide

Her tm OO

H (6) ; ос 9. Ом 3. y: M - re щ Kk я - фи 1 | p;

I M SI F - with M

M | Ge; M! about r

NOI M

When stirring to a suspension of 3-(1H-imidazol-4-yl)upyridin dihydrochloride (1.745 g, 8 mmol)"acioiechi Keu-"09E20188" pate-"(Keasiapibv)" ipdekh-"1"Peid-"Keasiapie" yure- "Peia"

So Iepdiip-"62"/" in a mixture of tetrahydrofuran (29 ml)"aceoiehi Keu-"09E20189" pate-"|Boimepiv|" ipaeh-"1" Peid-"Zoimepiv" ture-Ped" Iepdiip-"23"/" and DMF (2.90 ml)"ashoiehi Keu-"09E20O18A" pate-"Izoimepiv)|" ipdeh-"2" Peid- Potassium 2-methylpropan-2-olate (1.795 g, 16.0 mmol) is added to "Boimepiv" ure-"Peiy" Iepdiy-"13"7/" and "ashioiehi Keu-"09E20188" pate-"|Neasiapiv|" ipdeh -"3" Peid-"Keasiapie" iure-"Pei" Iepdium-"54"/» and the mixture is boiled under reflux for 30 min. The resulting brown suspension is cooled to room temperature and treated with pyridine (0.979 ml, 12 mmol )"ashoiehi Keu-"09E20O18C" pate-"(Keasiapiv)|" ipaeh-"4" Pped-"Keasiapiv" ture-Ped" Iepoip-"317"/" and M,M-dimethylpyridin-4-amine (0.098 g . ipdeh-"5"

Teiy-"Neasiapiv" ture- Chivid" Iepdiy:-"49"/» With the subsequent addition of cyclohexyl(methylucarbamoyl chloride (1.476 g, 8.4 mmol)"sashioiehi Keu-"09E2018E" pate-"I(Keasiap|" ipaeh-" 2" Peid-"Keasiapie" iure-"Pei" Piepdiy-"56"/". The reaction mixture is heated to 90 "C, kept at this temperature overnight, after which the mixture is diluted with water and extracted with ethyl acetate. The organic fraction is dried (Mo5O4) and filtered. After evaporation, the crude product was chromatographed on silica gel using dichloromethane/methanol (9:1). The homogenous fractions were combined and evaporated to give a white powder (160 mg, 7 U).

b) 3-(1-"Cyclohexyl(methyl)carbamoyl)-1H-imidazol-4-yl) pyridine 1-oxide o | o o

It's yours

M and (c) -- and M

WHAT; |» r SI

M M o

When stirring to a solution of M-cyclohexyl-M-methyl-4-(pyridin-3-yl)-1H-imidazol-1-carboxamide (90 mg, 0.317 mmol) in chloroform (5 ml) "ashioiehi Keu-"09E82106" pate-"I(Keasiapibv|" ipdeh-"1" Ped-"Keasiapie" iure-"Piei" Iepdiy-"85"7/» add 3- chlorobenzoperoxonic acid (149 mg, 0.475 mmol) c«acyoiehi Keu-"09E82107 " pate-"|Neasiapivi|" ipdeh-:"2" Pezd-"Keasiapiv" иure-Peii" Iepdiy-"47"/» in the form of one portion.

The reaction mixture is stirred at room temperature for 20 hours. The TLC data indicated completion of the reaction and the mixture was evaporated to dryness. The residue is triturated with ether, the resulting white crystals are filtered off and dried in air. Recrystallization from hot isopropanol gave a white powder (46 mg, 46 9).

Preparation of compound 408

M-Cyclohexyl-M-methyl-4-(3-(2-morpholinoethoxy)phenyl)-1H-imidazole-1-carboxamide hydrochloride b o / M and "AB, a" TO

OO sr, Kolo Vyos-ya o o i o SHI i TNE mo on g

TNE - TgF

M-Cyclohexyl-4-(3-hydroxyphenyl)-M-methyl-1H-imidazole-i-carboxamide (170 mg, 0.568 mmol)"acioiechy Keu-"OATE8484" pate-(Keasiapiv)"ipdeh-"1"Peid - "Keasiapiv" Toure-"Peia"

Epoxy-"89"/" is transferred into anhydrous tetrahydrofuran (10 ml)" satioiechy Keu-"OATE8485" pate-"ISOI MEMT51)" ipaech-"1" Peide-"Boimepiv" ure-"ei" Iepide-"33"/ » in a nitrogen atmosphere with the formation of a colorless solution "IooKir" Iepdip-"8"/». Add M-beta-hydroxyethylmorpholine (0.068 ML, 0.568 mmol), "ashoiehi Keu-"OAT1E8488" pate-"IKeasiapiv|" ipadeh-"2" Peid-"Keasiapib" yture-ey" Iepdipy-"52"/» and the solution is cooled to 0 C. Add triphenylphosphine (179 mg, 0.681 mmol), "aceioiechi Keu-"OAtTE8489"

From pate-"(Keasiapiv|" ipdeh-:"3" Peid-"Keasiapiv" ture- Ped" Iepdip-"39"/" with the following addition

DEAD (0.108 ml, 0.58 mmol)"aceoiehi Keu-"OATE848A" pate-"|Keasiapiv|" ipdeh-"4"

Teid-"Neasiapiv" iure-"Pei" Iepdiy-"27"7/» dropwise, allowing the yellow color produced after each drop to disappear before each drop is added.

The resulting pale yellow solution is allowed to warm to room temperature and stirred for 18 hours. The reaction mixture is further cooled to 0 °C, and another portion of triphenylphosphine (179 mg, 0.681 mmol) is added. -"39"/" and DEAD (0.108 ml, 0.68 mmol)"ashoyehi

Keu-"OA2060О8А" pate:-"|(Keasiapiv)" ipaeh-"4" Peid-"Keasiapiv" ture- "Ped" Iepoaip-"27"/». The solution is stirred for another hour. The solvent was evaporated and the yellow oil was purified by chromatography (silica gel H; 9/1, 8/2, 6/4, 5/5, 4/6 toluene/acetone). The fraction containing the pure product is evaporated, and the pale yellow oil is dissolved in ethyl acetate, which is then precipitated. The suspension is heated until the solid dissolves, and then the solution is cooled to 0 "C. An excess of 2 N HCl solution in ether is added dropwise. The resulting mixture is stirred at 0 "C, kept at this temperature for 10 min, and then allowed to warm to room temperature and stir for another 15 minutes. The residue was filtered, washed with ether and dried. Recrystallization from ethyl acetate gave a light cream solid, (39 mg, 14 Ob).

Preparation of compound 397 a) tert-Butyl-4-(2-(4-(1-(cyclohexyl(methyl)carbamoyl)-1H-imidazol-4-ylphenoxy)ethyl)piperazine-1-carboxylate about 7 b u-m ra about u-m

M M M su g. chu i oyi por - re su g. no Sol

TNE - TGgF

M-cyclohexyl-4-(4-hydroxyphenyl)-M-methyl-1 H- imidazole-1-carboxamide (200 mg, 0.668 mmol)"sacioiehi Keu-"0AOovbE5Or" pate-"(Keasiapiv|" ipaeh-"1"

Teide-"Neasiapiv" iure-ei" Iepdip-"89"/» in tetrahydrofuran (10 ml)" acsioiehi Keu-"OdDOvbe5E" pate-"ISOI MEMT51)" ipaeh-"1" Peid-"Boimepiv" iure-ei" Iepdip-"23"/» in a nitrogen atmosphere with the formation of a pale pink solution "atsioieehi Keu-"OAOVbEbO" 0/0 pate-"I|IZOI M/5O5RI" ture-"IooKir" Iepdip-"8"/». Add tert-butyl-4-(2-hydroxyethyl)piperazine-1-carboxylate (184 mg, 0.8 mmol), "azioiechi Keu-"0АОВбЕб1" pate-"(Keasiap|" ipdeh-"2" Peid-"Keasiap " iure-"Pey" Iepdip-"74"/» and the solution is cooled to 0 "C. "Neasiapiv" iure-"Peia"

Iepdip-"39"/" is added, followed by the dropwise addition of DEAD (0.127 ml, 0.8 mmol)"ashoyehi

Keu-"0АОВбЕб63" pate-"Neasiapiv|" ipdeh-"4" Peid-"Neasiapiv" yure-Chiveiy" Iepdip-"27"/", allowing the yellow color that forms after the addition of each drop to disappear before adding the next drop. The resulting pale yellow solution is allowed to warm to room temperature and stirred for 24 h. The solvent was evaporated, and the pale yellow oil was purified by chromatography (silica gel H; 10 95, 20 95, 30 o, 40 95, 50 Fo, 60 95 acetone/toluene). The fractions containing the pure product were evaporated , and the beige solid (167 mg) was used in the next step without further purification. imidazole-1-carboxamide

Zo dihydrochloride

Uk nya Uk: UAE - A R A o

OK su" R dk no su"

One Hundred Glass

Tert-butyl-4-(2-(4-(1-(cyclohexyl(methyl )carbamoyl)-1H-imidazol-4-ylphenoxy)ethyl)piperazine-1-carboxylate (167 mg, 0.326 mmol)"azioiechi

Keu-"0AOORgE5O" pate-"|(Neasiapiv|)" ipdeh-"1" Tey-"Neasiapiv" iure-"Pei" Iepdip-"128"/».

Trifluoroacetic acid (3 mL, 38.9 mmol) was added to give pale-yellow "ashoyehi" Keu-"OAOOGE5E" pate-"ISOG OK" iure-"IooKir" Iepdip-"6"/" solution of"ashoyehi

Keu-"OOOREbO" pate-"IZOI M/5IZRI" iure-"ooKir" Iepdiip-"8"/", which is stirred at room temperature for 1 hour. The solvent is evaporated, the remaining yellow oil is dissolved in ethyl acetate and cooled to 0 "С. Then an excess of 2 N HCl solution in ether is added. The mixture is stirred at 0 "С, kept at this temperature for 10 min, and then allowed to warm to room temperature and stir for 15 min. The mixture is evaporated and the residue is recrystallized from hot isopropanol. The crystals were filtered off, washed with isopropanol and dried to give the product as a white solid (115 mg, 69 g).

Preparation of compound 389 a) 1-(4,4-Dimethyloxazolidine-3-carbonyl)-1H-benzoi|4111,2,3)triazole-5-carboxylic acid o 6) o «pp

M man sfe Mo an --- cha sho as;

A solution of 1H-benzoi9411,2,3|Hygriazole-5-carboxylic acid (3 g, 18.39 mmol)"ashzoiechi

Keu-"0A02960E" pate-"|Keasiapiv)" ipdeh-"1" Ppezd-"Keasiapiv" ture-Ped" Iepdr(p-"62"/» in a mixture of tetrahydrofuran (90 ml) and dimethylformamide (50 ml)" Asioiehi Keu-"OA5BAbbO" pate-"ISOiYimepiv)" ipaeh-"2" Ped-"BoiYimepiv" yure-"Peiy" Iepoip-"117/" are added dropwise with stirring to a suspension of sodium hydride (1.839 g, 46 mmol)" khatsioiehi Keu-"09gAAVVO" pate-"(Neasiapiv|" ipdeh-"Z3" Peid-"Neasiapiv" yure-Ped" Iepaijp-"35"/» in tetrahydrofuran (30 ml) at 0 "C. The suspension is stirred at room temperature for 30 min, after which a solution of 4,4-dimethyloxazolidine-3-carbonyl chloride (3.16 g, 19.31 mmol) was added dropwise at 0 °C. -"2" Peiy-"Neasiapiv" yure- "ey"

Ipain-"64"/" in tetrahydrofuran (10 ml). The reaction mixture is stirred at room temperature for 4 hours. Water is added at 0 C, and the solvent is evaporated. A mixture of dichloromethane/isopropanol (7:3) is added, and the organic fraction is separated. The aqueous fraction is again extracted with dichloromethane, the combined organic fractions are dried (Mo95O4), filtered and evaporated. The orange residue was recrystallized from isopropanol to give a beige solid (840 mg), which was used in the next step without further purification. b) 1-(4,4-Dimethyloxazolidine-3-carbonyl)-1H-benzo|41(11,2,3)Hygriazole-5-carboxamide (c) m o

So uv "boru d-mto a-8 i (fi i MNz-- ts (c) M i- (c) -- i

Thionyl chloride (0.633 ml, 8.67 mmol)"ashioiehi Keu-"0AO051453" pate-"(Keasiapiv|" ipdeh-"2"

Ted-"Keasiapiv" ture-Peia" Iepoaip-"38"/" is added dropwise with stirring to a solution of 1-(4,4-dimethyloxazolidine-3-carbonyl)-1H-benzoi411,2,3)Igriazol-b6- of carboxylic acid (0.763 g, 2.63 mmol) "Acioiech!i Keu-"0AO51454" pate:-"|Keasiapiv|" ipdeh-"1" Peid-"Neasiapiv" iure- TCeia"

Iepipe-"104"/" and pyridine (0.702 ml, 8.67 mmol)"ashoiehi Keu-"0A051455" pate-"|(Keasiapivi" ipdeh-"3" Ped-"Keasiapib" ure-"Pe" Iepdiy-" 30"7/" in dichloromethane (17 ml) x"ashoyehi

Keu-"0А051456" pate-"|boimepiv|" ipdeh-"1" Peid-"Zoimepiv" iure-"Pei" Iepdiy-"117/" at

From room temperature. The yellow solution is stirred at room temperature for 15 minutes. Next, the resulting solution is added dropwise to 1.75 N ammonia solution (15.02 ml, 26.3 mmol) of azioiehi Keu-"0AO51457" pate-|(Neasiapiv|" ipadeh-"4" Peid-"Neasiapiv" yure- "pad"

Iepoyl-"29"/» in ethanol at 0 oC, after which a white suspension is formed. The reaction mixture is stirred at room temperature for another 30 min. Water is added, and the ethanol is evaporated. Next, the residue is diluted with dichloromethane, the organic fraction is separated and washed with a 1 N solution of HCl. The organic fraction is dried (Md5O»54), filtered and evaporated to give a yellow solid. The solid was recrystallized from dichloromethane/ethanol to give the product as a beige solid (151 mg, 20 mol).

Preparation of compound 438

M-Cyclohexyl-4-(4-methoxy-3-(2H-tetrazole-5-iluphenyl)-M-methyl-1H-imidazole-1-carboxamide) / M

M t - What: ? and TV and M o, then

SM M M

NM-M

4-(3-Cyano-4-methoxyphenyl)-M-cyclohexyl-M-methyl-1H-imidazole-1-carboxamide (305 mg, 0.901 mmol) mixture " ipdeh-"1" Peid-"Keasiapiv" ure- "ey" Iepdii-"97"/", dibutylstannanone (28.0 mg, 0.113 mmol)" acioiechi Keu-"0A728619" pate-"(Keasiapiv)|" ipaeh-"2" Ped-"Keasiapiv" ture-Ped" Iepoip-"39"/" and azidotrimethylsilane (0.239 ml, 1.803 mmol)"ashtioiehi Keu-"0A72861A" pate-"|Keasiap|" ipaeh-"3" Pied -"Keasiapiv" yure-Ped" Iepdip-"43"/» heat in toluene (8 ml)"ashioiehi Keu-"0A728618" pate-"|Boimepiv|" ipaeh-"1" Pezd-"Boimepiv" Turey" Iepoip-"14"/» at 115 "C, keeping at this temperature for 20 hours. The mixture is then cooled to room temperature and evaporated to dryness. The crude product is chromatographed on silica using a mixture of dichloromethane/methanol (95:5). After evaporation of the homogeneous fractions, the residual product was triturated with diethyl ether, filtered and dried to give the product as almost white crystals (196 mg, 54 Vol).

Preparation of compound 576 4-(3-(-2H-Tetrazol-5-yl/uphenyl)-M-cyclohexyl-M-methyl-1H-imidazole-1-carboxamide (c) y, x UM and M

M - va in S - I ?

M mm

M-M MU M

NM-M

With stirring, a mixture of 4-(3-(2-benzyl-2H-tetrazole-5-iluphenyl)-M-cyclohexyl-M-methyl-1H-imidazole-1-carboxamide (256 mg, 0.58 mmol)"acioiechi Keu- "OV2EVSAE8" pate-"(Keasiapiv|" ipdeh-"1" Peid-"Neasiapiv" ture-iv" Iepaip-"109"/", 10 96 palladium on charcoal (30.9 mg, 0.029 mmol)"aceoiehi Keu- "0В2EBСАЕ9У" pate-"(Keasiapiv|" ipdeh-"2" Ped-"Keasiapiv" iure- "ep"

Iepipe-"31"7/: and cyclohexene (1.175 mL, 116 mmol)"ashioiehi Keu-"OV2EVAEA" pate-"(Keasiap|" ipaeh-"3" Peid-"Keasiap" andure-ey" Iepdip-"34" /" is heated to 80 C in a stoppered test tube. Then the reaction mixture is cooled to room temperature, filtered through a layer of brownmillerite and evaporated to dryness. The remaining oil is purified by chromatography on silicon dioxide using a mixture of dichloromethane/methanol (90:10).

The homogeneous fractions were combined and evaporated, and the residual oil was crystallized from diethyl ether with

Obtaining the product in the form of an almost white powder (45 mg, 21 95).

Preparation of compound 423

M-(1-Benzylpiperidin-4-yl)-4-(3-(hydroxycarbamoyl)phenyl)-M-methyl-1H-imidazole-1-carboxamide o, (c) and o

What 9

M vd in Vekhvyvy! AND

Vg M o Mn o o TMNn on

When stirring to a suspension of 4-(3-(benzyloxycarbamoyl)phenyl)-M-(1-benzylpiperidin-4-yl)y-M-methyl-1H-imidazole-1-carboxamide (120 mg, 0.229 mmol)"acioiechi Keu- "0А4С5АСИ1" 5 pate-"(Keasiapiv|" ipaeh-"1" Ped-"Keasiapiv" iure-"Peij" Iepdium-"116"/» in dichloromethane (5 ml)"acioiechi Keu-"0А4С5АС2" 0 pate-" |Zoimepiv|" ipdeh-"1" bPei-"Zoimepiv" iure- "from"

Tribromoborane (0.022 ml, 0.229 mmol) was added to 107/- at -78°C.

Keu-"0А4СБАСЗ" pate-"|(Neasiapiv|" ipdeh-"2" Peiy-"Neasiapiv" іure-Chieiy" Tepdiy-"37"/".

The reaction mixture is stirred in the cold state for 5 min, and then allowed to warm to room temperature for 1 h. The mixture is cooled to -20 C and carefully quenched with methanol. Next, the solvent is evaporated, and the residue is transferred to a mixture of dichloromethane/isopropanol (7:3), washed with a saturated solution of ManHsSoOz, and then dried (M9505). After filtration, dichloromethane is evaporated to a small volume, the resulting precipitate is filtered off, washed with isopropanol and dried to give the product as an almost white powder (58 mg, 55 Vol).

Preparation of compound 551 a) (2)-M-Cyclohexyl-4-(4-(M'-hydroxycarbamimidoyl) phenyl)-M-methyl-1H-imidazole-1-carboxamide o um a x M

M o NaM-OH o 0 ----2 What;

WHAT; EUN M

M s but to MN

In a round-bottom flask with a capacity of 25 ml "ashioiehi Keu-"OAEEOOYUO37" pate-"IME5ZETSI"

4-(4-cyanophenyl)-M-cyclohexyl-M-methyl-1H-imidazole-1-carboxamide (600 mg, 1.946 mmol) satioiechi Keu-"OAEEEOYUOZ38" pate-"(Keasiapiv|" ipdeh-"1"

Ted-"Keasiapibe" Toure-"Pei" Iepdiip-"87"7/» in ethanol (9 ml)"acshioiehi Keu-"OAEEO039" pate-"|(ZOI MEMTO1)" ipdeh-"1" Yaed-"ZoYimepie" iure-"Pei" Iepdiy-"14"7/» at room temperature with obtaining a suspension of white color "atsshioiyekhi Keu-"OAEEOYuzZV" pate-"|ZOI M/ZIOBRI" iure-"IooKir" Iepdiy-"10"/». 50 95 Hydroxylamine solution in water (0.298 ml, 4.86 mmol) "Azioiehi Keu-"OAEEOOZZS" pate-"(Neasiapiv|" ipdeh-"2" Peid-"Neasiapiv" iure-Chivid"

Zo Iepdip-"46"/" is added dropwise, and the resulting mixture is heated to 90 "C, kept at this temperature for 90 min. Then the mixture is cooled to room temperature with the formation of a certain amount of precipitate, which is filtered off and washed with ethanol. The resulting solid recrystallized from a hot mixture of ethyl acetate (70 mL) and petroleum ether (4150 mL). The crystals were filtered off, washed with petroleum ether, and dried to give a white solid (230 mg, 29 b). 6). (2)-M-Cyclohexyl- 4-(4-(M'(Methoxycarbonyloxy)carbamimidoyl)phenyl)-M-methyl-1H-imidazole-1-carboxamide still still id id 500 aiHu t -k ho zhd sieve 0 сНХСи» bod (in) no» "oh"

MN MN

To a pear-shaped flask with a capacity of 25 ml.

Iepdaip-"10"7/" contain /(2)-M-cyclohexyl-4-(4-(M'-hydroxycarbamimidoylphenyl)-M-methyl-1H-imidazole-1-carboxamide (228 mg, 0.668 mmol)" acioiechi Keu-"OAEEZE5B" pate-"|Neasiapiv|" ipadeh-"1" Peid-"Keasiapiv" ture-"Peia" Iepdip-"111"/" in anhydrous dichloromethane (3 ml)"achioiehi

Keu-"OAEEZE5S" pate-"IZOI MEMT51)" ipadeh-"1" YaPed-"Zoimepib" yure-"Peij" Iepdium-"34"/» in a nitrogen atmosphere with obtaining a suspension of white color "cacioiehi Keu-"OAEEZE5O" pate -"|SOGOVI|" iure-"ChooKir" Iepdiy-"5"/» "ashyuoiehi KeUU-"OAEEZEBE" pate-"|5ОЙ M/5О5РИ" iIure-"yuoKir" Iepdip-"10"/». Add triethylamine (0.102 ml, 0.735 mmol),

The suspension is cooled to 0 C and stirred for 30 min. acid (0.065 ml, 0.835 mmol) "ashoiehi Keu-"OAEEZEb60" pate-"|Keasiapiv|" ipdeh-"2" Peid-"Neasiapiv" and urea" Iepdiy-"54"/" are added dropwise, and the mixture is stirred at 0 "C, holding at this temperature for 30 min, after which it is allowed to warm to room temperature and stirred for another 30 min. The residue is filtered and dissolved in a mixture of isopropanol and dichloromethane (3:7). The resulting solution is combined with the filtrate obtained above and washed with 1 N HCl, water, and brine, then dried (M9505), filtered, and evaporated to give a white solid (228 mg, 82 vol).

B) M-Cyclohexyl-M-methyl-4-(4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)uphenyl)-1H-imidazole-1-carboxamide o uk Uk x M " --- same I" » KhM M

M uepe 6)

MN" her 9)

HuYiepe - Xylene

To a pear-shaped flask with a capacity of 50 ml "ashoiehi Keu-"OAB2033E" pate-"MOG OMEI" ture-"IooKir" Iepdiip-"5"/" atioiehi Keu-"0Ag20340" pate-"MEZZETS" yure-"IooKir" Iepdiy- "1 0"/»

(2)-M-cyclohexyl-4-(4-(M'-(methoxycarbonyloxy)carbamimidoyl)phenyl)-M-methyl-1H-imidazole-1-carboxamide (200 mg, 0.501 mmol) was added to "OAg20341" pate-"(KEASTAMTO51" ipdeh-"1" Peid-"Neasiapiv" iure-Ped" Iepdip-"124"/» in xylene (10 ml)" ashoiehi Keu-"OAE20342" pate-"ISOI MEMT51)" ipdeh-"1" Peid-"Boimepiv" yure-"Peid" Iepdip-"14"7/" in a nitrogen atmosphere, with obtaining a suspension of white color"atsioiehi Keu-"UAE20343" pate-"|ISOG OK" yure-"IooKir "

Ieepipe-"5"/» "ashoyehi Keu-"UAE20344" pate-"IZOI M/505RI" iure-"IooKir" Iepdip-"10"/». The mixture is heated to 140 "C, held at this temperature for 4 hours, and then cooled to room temperature. The residue formed is filtered off, and the residue on the filter is washed with xylene. After drying, the resulting solid is dissolved in a mixture of dichloromethane and isopropanol. After evaporation to a small volume, the solution is cooled to room temperature, the precipitate formed is filtered off and dried to give the product as a pale pink solid (134 mg, 69 Vol).

Preparation of compound 553 a) 4-(3-Aminophenyl)-M-cyclohexyl-M-methyl-1H-imidazole-1-carboxamide o o -. ra u-m

M "she: still I RY (Z- 6 6 - -k I "

MeOH/EUAs M

МО» МН 10 95 Palladium on charcoal (0.122 g, 0.115 mmol)"atsoiehi Keu-"О0Аг4С184" pate-"|Neasiapiv|" ipaeh-"2" Peid-"Keasiapiv" ture-"Peia" Iepdip-"24"/» is added with stirring to a solution of M-cyclohexyl-M-methyl-4-(3-nitrophenyl)-1H-imidazole-1-carboxamide (0.755 G, 2.299 mmol)"acioiehi Keu-"0Ag4С183" pate-"|(Keasiapiv|" ipaeh-"1" Pei-"Neasiapiv" iure-"Ped"

Iepdip-"88"/" in a mixture of ethyl acetate (46 ml)"ashoiehi Keu-"O0Ag4C186" pate-"|ZoiYimepiv|" ipdeh:"1"

Tei-"Boimepie" iure-"ei" Iepdip-"15"7/" and methanol (46 ml)"ashioiehi Keu-"O0Ag4C187" pate-"|Zoimepiv|" ipdeh-"2" Pei-"Boimepiv" iure-"Peid" Iepdium-"14"/» in an argon atmosphere at room temperature. Next, the mixture is stirred at room temperature in a hydrogen atmosphere for 50 min. The mixture is filtered through brownmillerite, and the brownmillerite layer is washed with methanol. The combined filtrates were evaporated to give a clear oil/foam (691 mg, 100 95), which was used in the next step without further purification. b) M-Cyclohexyl-4-(3-guanidinophenyl)-M-methyl-1H-imidazole-1-carboxamide hydrochloride o) and (6)

UM Ya

M. I. M

AND; and | NSKU o-- WHAT

M MN» EOn M

MN" mani

NOAH

MN

Anhydrous hydrogen chloride gas (0.096 mL, 1.156 mmol) was added with stirring to suspension of 4-(3-aminophenyl)-M-cyclohexyl-M-methyl-1H-imidazole-1-carboxamide (0.345 g, 1.156 mmol)"aceoiehi Keu-"OAE4C130" pate-"|Keasiap|" ipaeh-"1 "Piezd-"Keasiapiv" iure-"eiy" Iepdip-"88"/" and cyanamide (0.135 ml, 1.734 mmol)"azioiechi Keu-"0AB4cS131" pate-"(Neasiapiv|" ipdeh-"2" Pei-"Neasiapiv" "iure-ei" Iepdium-"Z2"/" in ethanol (1.2 ml)"ashioiehi Keu-"OAB4C132" pate:-"|Zoimepiv|)" ipaeh-"1" Pei-"Zoimepiv" iure- "Ped "

Pipe-"16"7/" at room temperature. The clear solution is stirred under reflux for 1 hour. with the formation of a colorless solid.

The reaction mixture is stirred at reflux for another 7 hours, after which the mixture is allowed to cool. the solid substance is separated by filtration and

C was washed with ethanol to give the product as a colorless solid (298 mg, 68 vol).

Preparation of compound VIA 533 a) M-Methyl-M-(piperidin-4-yl)-4-(pyridin-3-yl)-1H-imidazole-1-carboxamide bis(2,2,2-trifluoroacetate)

E he sho y -- o M still zacheche 7 "Vos - 6yuzhЖ Ж M МН

ХУ and Хр; live M

KK on

M 2 --

M -o; and he --

E 0

To tert-butyl-4-(N-methyl-4-(pyridin-3-yl)-1H-imidazol-1-sagrohamido)piperidine-1-carboxylate (500 mg, 1.297 mmol)"acioiechy Keu-"OAE240EV" pate -"|Keasiapiv|" ipaeh-"1" 5 Ted-"Keasiapiv" yture-"ey" Iepdipy-"112"7/» add trifluoroacetic acid (4 ml, 51.9 mmol)"acioiehi Keu-"OAE24104" pate-"|(Keasiapiv| " ipdeh-"2" Ped-"Neasiapiv" iure- Che"

Pipe-"24"/» with obtaining a cloudy solution. The mixture is stirred at room temperature for 1 hour, after which the solvent is removed by evaporation. The oily residue was triturated with ether, and the resulting white solid was filtered off to give a white solid (653.2 mg, yield 88 95). ipdeh-"1" Pey-"Rhodysiv" yure-ey" Iepatp-"134"/". p) M-Methyl-M-(1-(methylsulfonyl)piperidin-4-yl)-4-(pyridin-3- yl)-1H-imidazole-1-carboxamide

OO //

M s (o) / iy ih ku uh

That 60-X in SU and M MN i -5-6-ШШ and t» ho d M

M v on B o | There is ov -- in

E O

To a suspension of M-methyl-M-(piperidin-4-yl)-4-(pyridin-3-yl)-1H-imidazole-1-carboxamide bis(2,2,2-trifluoroacetate) (300 mg, 0.584 mmol)"ashoiehi

Keu-"О0АЕ4СА9С" pate-"|Neasiapiv|" ipadeh-"1" Yaed-"Keasiapiv" yure-"Peij" Iepd(p-"12077" in dichloromethane (10 ml)"ashioiehi Keu-"O0AE4SAZO" pate-"|Zoimepiv|" ipdeh-"1" Yaeid-" DMAP (35.7 mg, 0.292 mmol) is added to Zoimepiv" iure-"Peij" Iepdiip-"23"/" ashoyehi Keu-"OAE4СА9E" pate-"|(Neasiapiv|" ipaeh-"4" Peid-"Keasiapiv" ture-"ey" Iepdip-"26"/", followed by the dropwise addition of triethylamine (0.326 ml, 2.337 mmol)"ashoiehi Keu-"OAEgE4СА9E" pate-(Keasiapivi" ipaeh-"3" Ted-"Keasiapiv" iure - Theia" Iepat-"26"/", With the subsequent addition of methanesulfonyl chloride (0.072 ml, 0.934 mmol)"ashoyehi Keu-"OAE4SAAO" pate-"(Keasiapivi" ipadeh-"2" Peid-"Keasiapiv" iure-"Pei" Iepdip-"47"/". The solution is stirred at room temperature overnight, after which the reaction is quenched by the addition of methanol and allowed to stir at room temperature. The white precipitate is separated by filtration, washed with methanol and ether, and further dried to give the product as a white solid substance, (158 mg, 74 b).

From Preparation of compound 550

M-(1-Benzylpiperidin-4-yl)-4-(3'-carbamoylbiphenyl-3-yl)-M-methyl-1H-imidazole-1-carboxamide -

M o, 9 o o on OchU o mali la» id ne -ess o Sr. Ra 5 i o7ta. NNth su 9 rights;

Ve with Ff Mne o

Tetrakis(triphenylphosphine) palladium complex (0.076 g, 0.066 mmol) "ashoiehi Keu-"OAE9ZOV1" pate-"Neasiapiv|" ipdeh-"Z" Pei4-"Neasiapiv" ture-Ped" Iepdip-"32"/" are added with stirring to the dispersion of M-(1-benzylpiperidin-4-yl)-4-(3-bromophenyl)-M-methyl- 1 H-imidazole-1-carboxamide (0.600 g, 1.323 mmol)"aceoiechy Keu-"OAE93082" pate-"|(Keasiapiv|" ipdehai"1"

Teide-"Neasiapiv" ure- "Ped" Iepdatp-"1027/", 3-carbamoylphenylboronic acid (0.229 g, 1.390 mmol) "hacyoiechy Keu-"sOAEgE93OV3" pate-"|(Keasiapiv)" ipdeh-"2" PeId- "Keasiapiv" Tture-Peia"

Iepoyl-"51"/" and 2 M sodium carbonate solution (0.794 ml, 1.588 mmol)" of Keu-"OAE930OV4" pate-"|Neasiapiv|" ipadeh-"4" Pezd-"Keasiapiv" ture-Che" Iepoip-"39"/" in a mixture of 1-propanol (5 ml)"atsshioiehi Keu-"OAE9U3OV5" pate-"ISOimepiv)|" ipaeh-"1" Ppeid - "BoiYimepiv" ture- Pe"

Iepdium-"17"7/" and water (1 ml)"ashoiehi Keu-"UAE930O86" pate-"|ZoiYimepiv|" ipdeh:"2"

Thea-"boimepiv" iure- "Ped" Iepdip-"16"/» at room temperature. The reaction mixture is stirred at 90 "C, kept at this temperature for 1 h. Water is added, and the organic fraction is diluted with a mixture of dichloromethane/isopropanol (7:3). The organic fraction is separated, dried (Ma5O5), filtered and evaporated to give an orange oil Column chromatography (silica, dichloromethane/methanol 5 9s) gave the product as an orange oil.The oil was triturated with petroleum ether/ethyl acetate/ether to give the product as a beige solid (123 mg, 17 Vol).

Preparation of compound 485 a) 4-(3-Amino-4-methoxyphenyl)-M-cyclohexyl-M-methyl-1H-imidazole-1-carboxamide also, about

M (o) o x U UM 2 ka EHUOAs/mMeon M od I

M

Me

Me

МО МН» 10 95 Palladium on charcoal (0.16 g, 0.15 mmol) is added with stirring to a solution of M-cyclohexyl-4-(4-methoxy-3-nitrophenyl)-M-methyl-1H-imidazole-1- carboxamide (1.075 g, 3 mmol) in a mixture of ethyl acetate (50 mL) and methanol (50 mL) at room temperature under an argon atmosphere.

Hydrogen is passed through the solution for 1 hour. Next, the solution is filtered through brownmillerite, and the layer of brownmillerite is washed with ethyl acetate. The combined filtrates were evaporated to give an oily brown solid, which was used in the next step without further purification.

Zo b) M-Cyclohexyl-4-(4-methoxy-3-c"methylsulfonamido)phenyl)-M-methyl-1H-imidazole-1-carboxamide:

M her id x ! M y Od MTM ---- i I; yes TNE M

Me What nm

MN" and (c)

TNE - TgF

Mesyl chloride (0.247 ml, 3.17 mmol) "ashoiehi Keu-"OAA446E6" pate-"|Keasiapiv)" ipaeh-"2"

Teid-"Neasiapiv" ure-Che" Iepdip-"30"/" is added with stirring to a solution of 4-(3-amino-4-methoxyphenyl)-M-cyclohexyl-M-methyl-1H-imidazole-1-carboxamide ( 1.04 g, 3.17 mmol)"ashioiehi

Keu-"O0dA446E7" pate-"|Keasiabib)" ipdeh-"1" Ped-"Keasiabibe" iure-"Peiy" Iepdiip-"96"/» and triethylamine (0.441 ml, 3.17 mmol) "ashoiehi Keu-" OAA446E8" pate-"|(Keasiapiv|" ipdeh-"Z3"

Ted-"Keasiapiv" iure-"Peiy" Iepdip-"35"7/" in tetrahydrofuran (6 ml)"ashoiehi Keu-"OdDA446E9"

pate-"|Zoimepivi|" ipdeh-"1" Peiy-"Boimepiv" iureva" Iepdiip-"10"/" at room temperature.

The brown mixture is stirred at room temperature over the weekend. Water is added and the solvent is evaporated. Next, the aqueous fraction is acidified, and the residue is extracted with ethyl acetate. The aqueous fraction is extracted twice with a mixture of dichloromethane/isopropanol (7:3).

The organic fraction was separated, dried (Ma5O54), filtered and evaporated to give an off-white solid. The solid was recrystallized from ethanol/dichloromethane to give the product as an off-white solid (434 mg, 34 vol).

Preparation of compound 564

M-Cyclopentyl-M-methyl-4-(2-oxo-2,3-dihydrobenzo|H|oxazol-5-yl)-1H-imidazole-1-carboxamide (6) / (9) /

M M

ОО ее 5

M bovbcho boem M sh/F) o

MNH )-MH (in) rum - dhmM 2095 Solution of phosgene in toluene (0.590 ml, 1.121 mmol) «ashoiehi Keu-"OVOOg8bA" pate-"IKeasiapiv!|" ipaeh-"2" Pezd-"Keasiapiv" ture-"Peia" Iepoip-"317/" is added dropwise at room temperature and with stirring to a solution of 4-(3-amino-4-hydroxyphenyl)-M-cyclopentyl-

M-methyl-1H-imidazole-i-carboxamide (0.259 g, 0.862 mmol) "ashioiehi Keu-"ovoOOg86Bv" pate-"(Keasiapiv|" ipaeh:"1" Pez-"Keasiapiv" ture- "Ped" Iepdiy:- "99"/" in dichloromethane (5 ml), and almost white"ashioiehi Keu-"ОВОО0г86Сс" pate-"|bZoimepiv)|" ipdeh:"1" yed-"Boimepiv" yure- "Ped"

Iepaip-"10"/ ap suspension is stirred for 5 hours. Water is added, and the organic fraction is diluted with a mixture of dichloromethane/isopropanol (7:3). The organic fraction was separated, dried (M9505), filtered and evaporated to give an off-white solid which was triturated with hot methanol. Filtration and drying gave the product as an off-white solid (90 mg, 30 95).

Preparation of compound 580

M-Cyclohexyl-M-methyl-4-(4-(sulfamoylamino)phenyl)-1H-imidazole-1-carboxamide and ; (F) (6) u-m - x o M

M SHI I »

I r I NM Z MN (-- :--- M

M o) nom.

In about M

NoM N

Sulfamide (0.089 g, 0.922 mmol) "ashoiehi Keu-"0АО28С003" pate-"(Keasiapiv)" ipdeh-"2"

Ted-"Keasiap" and ure-"Pey" Iepdipy-"317/" are added with stirring to a suspension of 4-(4-aminophenyl)-M-cyclohexyl-M-methyl-1H-imidazole-1-carboxamide (0.250 g, 0.838 mmol)«ashcshioiehi

Keu-"OA028004" pate-"|(Keasiapiv|" ipadeh-"1" Ped-"Keasiapiv" iure-"Pei" Iepdium-"88"7/» in dioxane (2 ml)"ashoyehi Keu-"0OA028C005" pate -"|ZoiYimepiv)" ipdeh-"1" Ped-"Boimepiv" ture-ep"

Iepaip-"14"/» at room temperature. The suspension is refluxed for 4 hours. with obtaining a clear solution, after which an additional amount of sulfamide (0.089 g, 0.922 mmol) is added, "ashoiehi Keu-"082984ВЕ" pate-"(Keasiapiv|)|" ipdeh-"2"

Ted-"Keasiapiv" yture-"Peiy" Iepdiy-"31"7/» and the mixture is boiled under reflux for another 2.5 hours. The solvent is removed and the brown residue is purified by chromatography (silica, dichloromethane/methanol, 1 95, 2 Us, 5 90). Homogeneous fractions are combined and evaporated. The residue is triturated with ethyl acetate, and a colorless solid,

which is formed, is removed by filtration. The filtrate is evaporated and purified again by preparative TLC (silicon dioxide, dichloromethane/10 95 methanol). The product is eluted from silicon dioxide with a mixture of 10 95 methanol/ethyl acetate. Evaporation of the solvent gave a clear oil, which was triturated with a mixture of ethyl acetate and methanol to give the product as an off-white solid (19 mg, 6 95).

Preparation of compound 541

M-(1-(2-Cyanoethyl)piperidin-4-yl)-4-(3-fluoro-4-methoxyphenyl)-M-methyl-1H-imidazole-1-carboxamide

S her o S (o; (in; id shk dk

M

What, OM u dyna - (SRNA du"

M EUN

Me Me Yi

IS

Triethylamine (0.159 ml, 1.139 mmol) "ashoiehi Keu-"OAESO7SO" pate-"|(Keasiapiv|" ipaeh-"2"

Ted-"Keasiapiv" ure-"Ped" Iepo(n-"36"/» is added with stirring to a suspension of 4-(3-fluoro-4-methoxyphenyl)-M-methyl-M-(piperidin-4-yl)- 1H-imidazole-1-carboxamide hydrochloride (0.200 g, 0.542 mmol) "ashioiehi Keu-"OAESO7C1" pate-"|(Keasiapiv)" ipdeh-"1" YaPed-"Keasiapiv" andIure-"Pe" Iepodoi-"1197/ » and 3-chloropropanenitrile (0.058 g, 0.51 mmol)« azioiechi

Keu-OAESO7C2" pate-(Keasiapiv)" ipdeh-"3" Ped-"Keasiapiv" yure-"Peiy" Iepdip-"44"/» at room temperature. The clear solution is stirred at reflux for 2 hours ., giving a white suspension. The mixtures were allowed to cool to room temperature, diluted with dichloromethane/isopropanol (7:3), and then washed with water. The organic fraction was dried (Md95Oz), filtered, and evaporated to give a colorless solid which triturate with ethanol to obtain the product (142 mg, 64 9b).

Preparation of compound 505 a) (IN-Benzoi|d|1(11,2,3)griazol-5-yl)(4-cyclohexylpiperazin-1-yl)umethanone c) o - o M «So i o, KU t shcha And TNE M i

TNE - TGgF

1H-benzo|41(11,2,3)griazole-5- -carboxylic acid (510 mg, 3.126 mmol) "Hacyoiehi Keu-"OAAZO47E" pate-"(Keasiapib)Y" ipdeh-"1" Yaed-"Keasiapiv" yure-"Peid" Iepoiy-"63"/" in anhydrous tetrahydrofuran (10 ml) "ashoiehi Keu-"OAAZO47E" pate-"ISOI MEMT51)" ipdeh-"1" Peid-"Boimepiv" iure-"Peij" Iepdip-"33"7/" in a nitrogen atmosphere, with the receipt of "ashoiehi Keu -"0AAZUO480" pate-"ISOGOKI" yure-"IyuoKir" Iepdiy-"5"/" suspension of brown color"ashoiehi Keu-"OAAZOi81" pate-"ISOI M/5I5RI" ture-"IooKir" Iepain-"1 077" .

KDI (558 mg, 3.439 mmol) "asioiehi Keu-"0AAZOi482" pate-"|Keasiapibv)|" ipaeh-"3"

TPed-"Keasiapiv" ture-Che" Iepdip-"22"/" are added in portions, and the mixture is stirred at room temperature for 1.5 h. Next, 1-cyclohexylpiperazine (658 mg, 3.908 mmol) is added.

Keu-"OAAZO483" pate-"|Keasiapiv|" ipaeh-"2" Ped-"Keasiapiv" ture-"Ped" Iepdip-"41"/" are added in portions, and the resulting brown solution is stirred at room temperature for another 30 minutes. The solvent is evaporated and the brown oil is partitioned in a mixture of 30 95 isopropanol/dichloromethane/water. The fractions are separated, the organic fraction is washed with water and salt solution, then dried (M9505), filtered and evaporated. The resulting beige foam is purified by chromatography (silica gel H; dichloromethane, 295, C95, 595 methanol/dichloromethane). The fractions containing the pure product were evaporated, and the pale orange foam was triturated with heptane. The solid was filtered and dried to give a beige solid (605 mg, 54 Vol). b) (4-Cyclohexylpiperazin-1-yl)(2-(4,4-dimethyloxazolidine-3-carbonyl)-2H-benzo|4|11,2,3|griazol-5-yl)umethanone oxalate (o); ! Who are they?

Mo i M t Man - - -n M zm o m M uko OM FI

FI and p

TNE - THF, OME - DMF

(1H-benzo|41(11,2,3)griazole-5- yl)(4-cyclohexylpiperazin-1-yl)umethanone (612 mg, 1.953 mmol)"ashoiehi Keu-"OAVISSE4" pate-"|(Keasiapiv)" ipaeh-:"1"

Ted-"Keasiapib" iure-"Pei" Iepdiy-"90"/" in a mixture of tetrahydrofuran (15 ml)"ashoyehi

Keu-"OAVISSE5" pate-"|Zoimepiv|" ipdeh-"1" Pyezd-"BZoimepiv" ture-ei" Iepdiy-"23"/" and M, M- dimethylformamide (C ml)"ashoyehi Keu-"OAVISSE8" pate-"|ZoiYimepiv)" ipaeh-"Z3" Ped-"Zoimepiv" yure-"Pei" Iepdiy-"28"7/" with obtaining "acyoieehi Keu-"0AVISSEb" pate-"SOG OV" yure-"yuoKir" Iepdiy-"b"/" solution of pale yellow color "Casioiehi Keu-"OAVISSE7" pate-"ISOI M/5IO5RI|" iture-"IooKir" Iepoip-"8"/". The resulting solution is cooled to 0 C, and 60 95 dispersion of sodium hydride in mineral oil (70.3 mg, 2.93 mmol)"acyoigehi

Keu-"0AVISSE9" pate-"Neasiapiv|" ipdeh-"3" Peid-"Veasiapibv" iure-"Cheii" Iepdiy-"ZB"/».

Allow the resulting pale pink solution to warm to room temperature and stir for 45 minutes. Then the mixture is cooled again to 0 °C, and a solution of 4,4-dimethyloxazolidine-3-carbonyl chloride (351 mg, 2.148 mmol) is added dropwise.

Keu--OAV1О0С02" pate-"|(Keasiapib5)" ipdeh-"2" Peid-"Keasiabije" iure-"Pei" Iepdiip-"b4"/» in tetrahydrofuran (2.5 ml)"acioiechi Keu-"ОАВ10ОСО03" pate-"|boimepiv)" ipaeh-"2" Peza-"Zoimepiv" yure- ey" Iepdiip-"24"/». The resulting pale yellow solution is allowed to warm to room temperature and stirred for 4 hours. The solvent is evaporated and water is added to the residue, which is extracted with toluene. The organic fraction is washed with water

Keu-"OAVISSEA" pate-"YIMUKOR OY MI" ture-"IyuoKir" Iepdip-"3"/" and salt solution, "ashoyehi

Keu-"OAVISSES" pate-"MUKOR OYI M5) yure-"yuoKir" Iepdiy-"8"/» then dried

Koo) (M95054) "ashoyehi Keu-"0AVISSRE" pate-CHOvMmIMsa ASEMT) iure-"ooKir" Iepdiy-"5"/", filter and evaporate. The resulting yellow oil was purified by chromatography (silica gel H; dichloromethane, 2 96 methanol/dichloromethane. Fractions containing pure product were combined and evaporated to give a pale yellow foam (690 mg, 80 Vol).

To a pear-shaped flask with a capacity of 50 ml «atsioiehi Keu-"ОАВ5BA5бОВ" pate-"MOH OMEI"

З5 июре-ХооКир" Iepaii-"b"/» "ациоехи Кеу-"0АВБАбБОС" pate-"|MEZBZETS /июре-"ооКир"

Iepatp-"10"/"contain (4-cyclohexylpiperazin-1-yl)(2-(4,4-dimethyloxazolidine-3-carbonyl)-2H-benzo|4|1,2,3|Hygriazol-bo-yl) umethanone (300 mg, 0.81 mmol) c«acyoiehi Keu-"OAV5BA5BOYU" pate-"I(Keasiapiv|" ipaeh-"1" Peid-"Keasiapie" iure-"Pei" Iepdiy-"129"/» in methanol (5 ml) "ashioiehi Keu-"OAV5BA5bBOE" pate-"ISOI MEMT51|" ipaeh-"1" Ped-"Zoimepiv" Toure- Chivia"

Iepdium-"15"/" at room temperature, with the production of yellow "acyoigehi Keu-"ОАВ5А5БОЕ" pate-"ISOG OK." ІІure-"IooKir" Iepdiip-"b"/» solution"ashoiehi Keu-"ОАВ5BA5БАО" pate-"|ZOI M/ZIOBRI" іure-"yuooKir" Iepdiy-"8"/». Oxalic acid dihydrate (86 mg, 0.681 mmol)"aceoiehi Keu-"OAV5BABAT" pate-"|Keasiapiv)|" ipdeh-"2" Peid-"Keasiapie" iure-"Peiy"

Iepdaip-"41"/» is added in the form of one portion, and the solution is stirred at room temperature for 2 hours. The solvent is evaporated, and the resulting pale yellow foam is crystallized from isopropanol. After filtration and drying, the product is obtained as a white solid (150 mg, 39 vol).

Preparation of compound 595 a) M-(1-Cyanopiperidin-4-yl)-4-(4-methoxyphenyl)-M-methyl-1H-imidazole-1-carboxamide o o

Uk Um still shah o su" mno VYM (-ШШШШШШШЩЙk su" M

CM o o

NOI Y

To a solution of /4-(4-methoxyphenyl)-M-methyl-M-(piperidin-4-yl)-1H-imidazole-1-carboxamide hydrochloride (287 mg, 0.818 mmol) of thiocyanate Keu-"0818864A" pate-"| (Keasiapiv)" ipaeh-"1" Peid-"Neasiapiv" yure-ei" Iepd(-"109"7/» in DMF (5 ml)"ashoiehi Keu-"08188648" pate-"ISOimepiv|" ipdeh-"1 "Peia-"Boimepiv" iure-"Peii" Iepoa (n-"10"7/" add potassium tert-butoxide (184 mg, 1.636 mmol), "ashioiehi Keu-"0818864C" pate-"(Keasiap|" ipdeh- "2"

Teide-"Neasiapiv" iure-"Peiy" Iepdium-"44"7/" and the mixture is stirred at room temperature for 30 min, after which it is cooled in a bath containing ice water and cyanogen bromide (0.818 ml, 2.454 mmol, From a solution in dichloromethane) cationic Keu-"08188640" pate-"(Neasiapivi|" ipdeh-:"3" Peid-"Keasiapiv" ture-Ped" Iepdip-"52"/" are added dropwise for 10 minutes. The reaction mixture is allowed to slowly warm to room temperature for 1 hour, then partitioned between water and a mixture of dichloromethane/isopropanol (7:3). the solvent was removed under reduced pressure. The residue was dissolved in a minimal volume of chloroform, and the insoluble material was removed by filtration. The filtrate was evaporated to give an off-white solid, (345 mg, 67 95). b) M-(1-(2H-Tetrazole) -5-yl)piperidin-4-yl)-4-(4-methoxyphenyl)-M-methyl-1H-imidazole-1-carboxamide 9/7 O / u- ex. uU- m o i same d M, y ky VI t В-8--ШО-2Ш22 | d M cm y c) (c) M.M

Yi M

N

To a suspension of M-(1-cyanopiperidin-4-yl)-4-(4-methoxyphenyl)-M-methyl-1H-imidazole-1-carboxamide (151 mg, 0.445 mmol)"acioiechi Keu-"083438C02" pate- "(Keasiapiv|)" ipaeh-"1"

Ted-"Keasiapib" andTure-"ey" Iepdiy-"102"/» in toluene (10 ml)"ashoiehi Keu-"083438С3" pate-"|Zoimepiv|" ipdeh-"1" Peid-"Boimepiv" ture-Ped" Iepdiy-"15"7/" add dibutylstananone (13.84 mg, 0.056 mmol), "ashoiehi Keu-"083438С4" pate-"(Keasiapiv|" ipaeh- "2" Pez-"Keasiapiv" yure-"Pei" Iepdip-"40"7/" followed by the addition of azidotrimethylsilane (0.207 ml, 1.557 mmol)"atsioiehi Keu-"08343805" pate-"Neasiapiv|" ipadeh-"Z3" Ped-"Veasiapiv" iure-eia"

Pipe-"43"/». The reaction mixture is refluxed for 5 hours, after which

It is filtered hot, and the resulting pink solid is washed successively with toluene, dichloromethane, and finally with ether. The solid was recrystallized from methanol to give the product as a light pink solid (100 mg, 56 95). 2. Examples of compounds

/ x x ! ohms 2 RU 0) M o - x-/

Z Y r;

M

4 What's more,

See also M about at

BV te, - M M i u

What are we in?

Oh,

WITH

(0) them and her /

M uk i g o

MAG S

11 X g SI

JACQUES

12 a: c o; at

UK

AND

0) and 14 Ko »

WITH

(dk o o--sn" (0) 16 ud

M. Z

СО - о-с5 о, и зе

M 3

She

M

BV

(0) 18 u-k

CH,

M

M

In o and I or)

M

Su

M dk

Residential complex

(0) M Go! 3- :) m GI / day more

M

22 g

M

SHE

And contact with Fr. sn, 8 (0) i

SN

24th day of the week

WHAT

IN:

Not at 26 MM su with 7 o'clock, and at 27 M SN sg

M sa vo

(c) and 28 M Sn p

M

Su (c) (9) and 293 M sn su

M

IS

(about) and

From M NE, in;

M

Oh, m

M sn 31 | »

M r o /v

HK

/ 32 si Kk I;

D-х 0) H

CH,

SI M x / 33 M ud o u

CH,

WITH

Mokh / for M SA i o M sn, o kIshkesya 35 ov

IS

36 ik p

M su " uh yi 37 M

She 2

M

(9) from 38 Mov p

M

(9)

and in /

M

39 | p;

M

In that (0) m 40 g, Sh

SHE

ON

M

Fe; /

M

4 ry o) moe

M

/ 42 M

Y-h o)

IS

(9) 43 lux with ! and " in 44 M s i

M

IS

45 nak

AND

46 M

Oh,

E u o 47 M x- "DL x o 9 given 48 t. 4- Ki On

M in;

M

49 X- ak ts

M o

Sh U

M

/

M

FOR

GO wa and che

BI M

AND;

M

ON

U. o

M or, 2 o'clock M

BUT

M in; / x CH. / 3 53rd

Uh oh

BA Za,

Goy

M but in

hmm /

We are; In, (0;

Mem sf Ge)

SC with IF: Fr

Meme 07 and "about Art

WITH

Hmm / what about M

Sta

MM

F x 9)

M

Hm

/

M them (F)

M in; / 61 M (0; vv xx si yoe / 62 M shcha (0)

M si

Moss / 63 M -h o M

SN, about, from 64 KK kht

IN

M

S. (0) (o; (o;

UK

My village

M

9 M te

With o. and 67 Language

Mt. Shi

M

In o

M-7 p

M s - "sv s I aa

ME

Moss / 70 M i o) in E

CH,

M in; /

M

7 Y-h U-o

What?

IN

72 M

M

What

C v8 o (o)

Uk x-th 73 | p; 7 counts

Oh, | TE 74 ud m-

AND WHAT

M what

M u

Hm 75 M i 0) M

SN

WITH

: about d

M. I

Go; M

SN, m s o v; / 77 M o--CH,

M o u

CH,

about (6;

UK

Ms. So

M

E E

6)

M

79 Oy m

WHAT;

M

E E

E o E with mon- mon,

ШЕ 7 ho

M

E E

What what

M M--sn,

Hmm / 81 M

D-х (0) H

SN, h

She has SS

M

82

D-x 6) M

M

Phi; / 83 M NS of Rmy

ОХ tov x 84 M -

M

D-ya o u

SNa about her

unit

85 M d-ye 0) sy, in dya

S s khm / 87 M d-y o shk s sd /

M d-« (0); oh oh

M. H. and

M

M fi; NS /

M

D-x (6; Si o)

M va;

M

91 councils of the university 5-7

M

(Doc /

M

92

D-x and IV

M fi; /

M

93

KI

NSI

M in; /

M

94

M o)

M

DI x Ah 75

D-x

Go) M sn,

IS

8 of

What /

M

Lk

Art

Vg M

HK

/ 97 M

D-x o M sn,

M ho /

M. I

F) you

M o (o)

M in; / 100 others

Oo-o o -esnyuo 101 Kk

She 2

M o M

IN

102 (SHU

M

(0)

U-k 103 Language

She »

M

M

hmm /

M

104

M

Sho

M fe; on 105 M and I p;

M

Phi; / 106 FI and g

D-x

E M

Svv 0) ON 107 . h

Y-h

M

St

05 MV, oi, 108 FI xx 7 arr

M

D-th same century

M

Fi XM /

M

109 FI zu Y same sun, 07 mn,

M

/ 110 M

Mr

IF)

S" ryh 111 M

WHAT,

M

(0) M M

Uh-hmm, bye

M

112?

NM. (0) (9) and 113 KO, no. (0)

M

/

M

114

M what o)

M. Zh

M

Hm 115 in i

Ho) M

CH,

M

Hm

116 x a

Oh-M

M s -x / 117 M -x 6) Ge)

M

118 in; /

M

And yes

SN

M

Hm

/ 119 M KO

X- CH,

M

Ho) M

CH,

M

Hm

/ 120 M

D-x (6) Go)

in; 121 M on;

GI

M in xx Na

M

122 it

Mov h dya o M sn,

On o ( M oo 124 M-

What

M

9) Гх ид х- pa 125 s 0;

M

Hu M 126 MN | shhhhhh--

M fi; / 127 x ran i (i

M

/ 128 K i 0 t) 129 7 M

HIGHER

M

Mr

Go) and" sleep,

M

Fe /

M E o M sn,

M

J

/ 181 M a

D-ya

Ho) M

SV,

Ho) 16) unit

M- sb J 132 i

OZ that NS about (9)

UK

M-th so and 133 M

WITH

WITH

Go) 6) h

M

134 Ii y; dream

E E

M

F; / 135 I dl o o

M

WITH

M

136 year I x

F; 137 uk Iv) "st 6) x Go) o iy tv

M

AND

M

138 Goi su 9) K Go) o so and 139 M

WITH

And that

Sn o /

M

IN

M- 140 I - F M (0)

In o

M- - 144 | p; and M 6)

NSIM about ts (in Hu y

YOU

142 oh! and

NS sn, Fr

M dya

Go) M sn,

M fi; en 144 M with o

I) Fr. poh C)

Uh at 145 s on "oh,

Sn 9 / in m sn, 146 o I;

M

"o. 6) 8o ul o k- - 147 o What;

M

IF)

UOO

M

148 and Her?

M

6) o i sn 149 k-i o | p;

Maybe 0) n) sun,

IN

150 " p

M

E about

In - 151 what about | p;

M

6) o) another 152 4 X 9 m-M o p

You

M

/

M

153 KU

IF) o»

M fi » / 154 x uz 0 i -s

What, sh-- M i: /

SHSH

Y-x 0 XM

St so schi

SHI

M

Y-x (0) I

St

NOSE

Ka -x

M

M

Hm / 159 M i o OH o 160 U-k sn, x-

SU

M is sleep, oh food

Huh? 161 M

WHAT,

M

M hm / 162 Ve x r ya r) that

M

FI; /

M

163 Fi Y-to lei om, then

164 B!

M y-h o (o)

M

Residential complex

So 165 Oh

H o--sn,

M

/ 166 M Iv); d-x o.

Hm

/ 167 M. Ii

Yo oh / sun, 168 xx /

M i z, o

H

Khm / 169 L -0 and Location

M hm / 170 M l o (0; u. 171 M hm

Co

M

(0) uh 172 M "M

WITH

M that (0) and 173 x that phi i

M

(6) and 174

M

"M

Co

M

SN, and in uh 175 ke NE /

M

Go o)

Ole 176 CH,

M

M co

M o sn o eh / 3 o 177 3- х-

M

M

CO

M

0) oh that

SN

178 U-x-/ !

M

M

WITH

M

(0) (0) u-ya MN, 179

M

M

WITH

M

(0) and 180 sm m- "

AND

- M

M 8

. t

IN

181 k-t with se -e

M

0) that 182 ik

Mt

Ol

M

Not St. m-kM 183 | X vi "M

E E chen 184 I

She

M

So 185 -M with i

M

(at St. B

M,

In-cl

M

186

WHAT,

M si sho s o ik o m- 187 yakh u

M o. 6) all sleep, about food

Huh?

M

188 M- that

M

Od not sleep, b

M

Huh?

M

189 M-

AND

M s (0) cha

St

190 m

WHAT,

WITH

Hh

I SN, 191; . p on foot 192 KY

SN, about Gah 9) se U

M "St.

M

/

M

CH, o -k (0)

M

194 U-A

M SNU

M

/

M o CH 195 in XX

M sleep hmm /

M

(o) TU,

OO

196 2 0) from 197 s GU

SI about (0) us

M (0) 198 | p;

M to s shcha

M

199 Yi- "st., to

M on the bark 200 s we "o

WITH; F, hi 201 | »

M

IS

202 fa; with

Food

Cheek

NSI o) o 203 What - well,

More,

NU M los o o

Oh oh

M-x 204 s r,

M s 0) u-k

М-Х 205 с г 0) (v, o already

Gdynia 5 206 Kh

U o g 207 V o. ro o, KDD S a

Eat? 208 o.

And c) | u/t9 what

Her that stv

M o. at

MN, oh, M Go) - M k-

AND

M

210 (9)

HA

MH,

IN"

M sh-M 211 s r;

M o sn,

He

M x-7

M- 212 p; on

M si

00/79

Kk

M SN. 213 IT in; what

AND

- M

M 8 o /-8

CA

Her. 214 r; su" si at 5 p.m

M

215 | ?

IS

IS

IF) is corrosive

M

And what is 216 ?d

From St. that in-x

M "sn, 217! du y

Ve 0) b st o

BUT

M

218 | ? si si phi;

M

219 Y-x to kA to

With SN Fr

M

220 kg su

M that o u-x 221 M

And p; what

M

M in; 222 M

D-x o u

CH,

(o) I-0)-

M

- mch 223 s in;

M

(FI!

NVH Fr

M

224 Yi- "st., p. i

M

C, 6) tue dk

M in 225?

FD ro; that 0) Tue Sun

M

226 | p; nose xx I NSI

Her

Bl

M what o Z y-x 227 M

LE

M

0); that's it

M ve Ov 228 ?d 15(0) s y

0) and shk

NS 6) in, in- 230 MS,

What, 97 M post 6) tu o sha

M

231 ShF (0) tue zho

M

F, that SN, 232 F

СХ same (6) what what about about

M

233 - m s u;

Oh my

M

234 And who from what about eater 235 x sn

And then With c and c 0) in/that what

Mr. - S

HER

(9) (0)

Hu

MN panna 237 St., uh

M IF,

WHAT

M

- (A 5

MN; 05 u-k » x »

M

239 FI o u shk u-kh o, iy

M

240 FI

It is the same (0) (0) and 241 Uk

M s r;

M

M

Hmm / 242 no M i o M

CH,

NM F M

Phi; 243 i) M

X-kto bns-u- that 16) u-k x 244 M SN, c and

M. with u. and

ZU vm7Oho u ts » a 246 FI

Fe u i" » o a 247 FI you u i" »

WHAT;

M

248 FI 955 ok che b, u-x 249 M u-shchv;

Year and

M a che u-x 250 M u-sv s I

M or u-x SNU 251 M ust

Her and what

M z /A y-x SN, 252 M us

SOMETHING

M s her o) ts-o what --M 253 M s i

M a o. и 254 и: kedy

WHAT,

M che oh

And a

M. Z

255 I century

M r, no

And in 256 | ns

M ro; that 900 u-k ho a 257 (F

X, m o y

M me o

Z u tsa ho

IN

259 FI

IS

And o) o) what

M sn 260 What With where

M

BUT

0; From the

M

261 And A

AND

M no (0) still in-x

M. IZ

262 L?

M

ON

00/79

Kk to U, these dreams, 263 | With su- 9) in, eat 264 s M CH

WHAT;

M che id

M. Z

265 | with

Y f"

ON

M

Fe / I V,

D-ya o u

SNU

TS sn io k sn 267 M su"

M

7 what in o o si what 268

Go

M

0 HH 9

Ma - bo 269 su" Ma SN

M si

WHAT SN

M uU- SV 270 M

L

M

0 Sn u-x

M

271 | And also

M ost» 0 s u-k

M

272 | p;

M

IS

E o Sn u-x

M

273 p

M

IS

(0) Rv y-x

M

274 | p;

M s s ov u-ya ho 275 s oho o TT u-kh

M

276 pp.

E M ba

SN. 0) / 3 in-x

M

277 I A and

M

(FI 10) o. o and 278 X SV,

What,

Mo;

IN

279 M SNU

Y-St

M

0) Tue

In M

SN. 280 | what is p; gu" with u i

M

281 2

Od c y

That 282 9 iv, in "art

WHAT;

M

(0)

IN

SN. 283 k-th and

What;

M o.

IN

284 m - SN.

St. John

M

00/79

Kk

A-M dream

M that 285 | with in; t) t) a

A-M (i

M. Z

286 | 2-66, su r NM

Do that

M yan 287 Yan, ho ns, 0)

Yes 288 OZ schi (6;

Hu x -sh- 289 others, / them (0);

YES

M -- 290 in, V Phi 0)

YES with"

M ---- 291 in, shk

M

So SN,

In the village of 292 M s;

M si

M

Me / o M 293 | etc

SN, mo ko to

CH o with y-

M

294 | p;

M no (0) /ly y (FI M

SN. 295 I I: see r, su- o

DKS x y 296 Jan,

ON

ON DI 297 Kh

PI

MEM CH,

So SN, o Zh o os 298 of them / 2

M

So SN, what

M

299 x s y;

M si ch uh 300 am oossv

IF;

M

(0) Tue

Vg M 301 su NS SN,

M

SI

7) about ido 302

00/70 u-x " iy 303 2 sn,

IS

IS

0) Tue u-h d, (C 304 o St that 9 (0)

DS

M i- 305 in, -KM x y 0)

Yes su

M Jan 306 Jan, -M o 0/5 u-k

M

307 L?

M

ON

0) Tue U-h

M

308 d

IS

IS

0000/-9 in-x

M

- and their

M

(6) tu u-x goes 310 I r; what

FI b "su sht u-x 811 What o

IS

- s g ay

M, 312: and 313; And m

(0) y-ya "sn 314 A ? y

M

VO.

IS

(0) y-x xx

M SN, 315

WHAT;

M

Unit

IS

IF) / idkya

M no sn 316 ? With that

IS

(0) lavzhkh

M nik SV 317 yen, M ge (0)

YES g xO- oh well 318 to her -- oh fuck with 005 u-x

M

She

319 d

IS

(0) then (0)

Dos»

M r 320 in, in h

(0); From the

M

For ?d

So what about

Enough!

Zg2 other, 5-5 C) (o;

Addendum 323 o - o

M / "St., Fr

Dos gAguh o o

DA s" x -- 325

СН, / (в ра 0 у-х ); 326 su" Ka i

SNU

(0); more

M

327 s what and o ,/-o dk

M dream

What's with it?

Snu 0) tuo edkoya

M

What SV 329 s what 9 (0) o

M 3 330

Y r; )8(F)

And what's more

M "sn, 331 Y r; ) 58)

Oh, 9 children

M

SNU that 332 | ? With no

IS

000079 id

M dream

What with 333 Sh!

IS

He (9)

IN

334 she » p M

Mo (0)

IN

335 Language

Wow

Y » 6) lova 336 ish a x 000.79 dk

M SN, 337 | D-56,

M

00/79 idea

Minutes in 338 | in; and n M

M o

(6) that's right

M

339

IS

M o) ;-o u-x

M

340 s that 9 o'clock Gwei uk

M for su"

She

St (o) with y-x

M what and (6) she y-x

M

343 | ?

M

E he o SN, / у-х

M in 344 | ?

M

And he still "well, in 345 Kk with U

E M in what 9 / in-

M

346 She?

M

IS

E at 7-9 p.m

M dream

And that 7 he o, tuesday - x SN. then

IN; 348

DI

(0) not St.

what "uh

IN

349 I »

M

WITH

SI that ", u-x 35O M GU su"

M

6) Tue

M

SN.

I ns 73

ZB d

And (0) it's corrosive

M

WITH

ZB?

ON

What sn, t)

X uduitzhm x vk

Z35Z kn, / ChZm-o 10)

DZ Sack; 5 354 what -k x what "sh, y-k

Also, 355 | »

M o sn, o) tu edkoya

M dream

And that 7 356 2 then.

MN, (9); Az uh-h

IN

357 to ? but

NS

MH,

Go) /-o eater

M se

And what with no

NS

MH,

SI M

/

M

359 -what c3- what

IS

M

HK

/ 360 E M

What am I doing?

Fe; /

M

361 heh, chi

WHAT St. (0)

IN

Like 362

What, in M

She 2

M

I. (6) what

She

363 ot o. (0) Tue

M

And that's it

WITH

364 o.

Go o Av y-x ho 365 | ? eat

Sleep MN,

M M

And to them dne-f( z66 D-«kTo 0) ka what

M

Khm / ts M 367 Х-х о бе ж в; -

M M ra 368

And (0) that

M

Me / 369 M

X- m/o o ich

SN, M o h

M

Fe

M and Mo ki

IS

IS

M

Eh heh that 371 M 3 CH,

Y-I would H o

BUT so 372 M is not

Ve. MO of the United Nations,

D-ya o X o

M yo 373 M ra o HM /

IS

IS

Eh hee

M

374 dream, y

NS M yo / 375 that M -ya o) M

SNU

WHAT, zd 376 su? With

M o h

J. U

VS about

Note that / 377 Sto M st

X-x (0); and p. 378 of U shk

What /

Co. M o

IN

379 and about

IN,

E M

In "St

C80 baud

M.

M r-ny

N with M

my /

ZV not x

H-sah what

Y" i) M

M ns 382 / N o MO sn

St. Lya

OH oh he oh. 383 In,

AND"

M and:

From o so 384 Mne

NS MO ost --y o No "ud edkoya

M dream

And what about Z 385? nk (in) that sv o ish zho. z86 NS M ov

M co

From SN, about Zh

NS U

387 x

Olya

Co

With sleep 0)

NS pd

Just like that one

NM M ky o

M

/ 389 M

H-who is what (0; seh u-k

M

390 | p;

M nm (in)

M

391 sa M

And whoever

MM va ikh d-Zhy 392

X-k7to (o; "3 that ts SN, che

M

M

393 yo s u,

M

6)

NM.

0/5

M

NS - 394 odes

Duty on Dn; on day 395 I » IF, 6) M obo ch sv ch

NS M o 396 and the same sodu no o iz

M ns Y- IF zi "7 gu" ku

IF) (5 398 X "sv, s I no tu (0)

At the UA

She

399 s ay (in) still in-

NS M IF, 400 s ? 6)

WE.

o on M 401 on s i o

K sia o na to 402 s February

AND

(o) ше у-х о 403 о" 07 Mn,

WHAT, 404 | 2 in

IN

SU

With St

NS 5 eat what 405 What

M

NM

0)

more

IN

M av 406 | »

Mr. No

MN, 6) still in school at Ims o 407 at y aa i 05 u-n

NSI Y in IF, o and 408 ka b 0 in u-x

Go M 409 ro that O o

Gu

M NSI

ZO

410 su o/z o id i

M toast tone

What about 411 M u. From 412 t o,

Sn but about him

Gweya uh ho 413 o (9) on

HELL

He (9) in. tsa ho same 414 0) no---on

ON

415 Ve

St. Water

M. M. 416 t 7 hu M 2 y o Zh r,

M. 417 " D xx -

M o Iz u-kh » In 418 p. M ef, o. dream

SN uh » C 419 gu" M fi ko (6) gi

From Z 420 K M s

SN zy that, 421 M 7 va

M

I. (0)

which goes 422 k z

WHAT;

M v s me ke 423 ho o" te o, u

MF

424 : And 2

M

(0; МН -5 9) 425 o 2 v o o what does 426 s go?

oh uh-

M

427? Mm,

IS

IS

"Dn u-k ho 428

WITH

900 u-x 2O 429 vch 005 u-x

ZO

430

That's it

IS

Her" Her" raFf 0)

M. M. 431 98 what and what -

M what! 432 p. 9)

AND

Go ke

ON

Go) iz y-x 2 te 0) r; What what

M

434 | 7

M o, in h

M SN, 435 | »

Many (6)

M

NO x / 436 M

D-t 3 that 00/79 id

M sm 437 mayor: at 7 am

FN

9) I

M St. 438 7

Ve. 9)

Ku

Mmmm

NN (0) o

CC et 439 2

BUT

M-M

N

00/79 goes 440 x. not

M 3

MN and no M o

U. c

M

41 2 M

From ozh

M

442? M what about sleep

Kk o U

I

443 M. M

O.O

E about; CH;

IN

M i po ! in o sleep,

Well, what's up

M sleep 445 s r;

M

And soch (0)

THESE

M more, 446 dk

In, from what in

M CH, 447 g »

M

Co

M i, MN, (6) ti otoh zi 448 7 su: ! t

I. (9) sleep, injections

M

449 M Y;

B

M and 6) o) she u-x

IN

450 | ? MN

BUT.

MN;

6) A u-k o 451 su M no vyt

M

452 p

M oh

M

I. (in; 75 ay that 453 oh -

M

СО two Ж, /й -щО Сн, НВ

E o g h o s te

M SNU

455 su

M xx

M

I. (o; sn; a

M. Y. A

456 X 7 skh or ik

SN. wow 3

ZO

457 d MO NVg 59) obo (0); uh

M

458 in, dry --

St. M, a

M. So 459 p

M

B

IR to her

M

Hm

Ol I-y 460 IYI ud m/o bve-3-

SN, o u-k u; 461 su Ka

M

IE

M

HK

VM M

462 o D-t o le

SN, i" raFf

M o 463 xx -

M ii i 464 Kk IF

J

-

M

IN

M

465 d M 5/6)

ON NVI

00 p.m

Ukh 7 466 and Fr

S. o

E ke: u- not u, 467 sus M 05 u- 468 | 2 a

But about

МН, 0 сн к

M

469 WHAT IS SV,

M M MF,

X-9 5) 0)

Then (0) M is another 470 M Y; xx

M

I. (9) ii o. M. dt at 7

IN

Mk

AND

(9) dream of y-kh 472

IS

9) from y-x

M

473? Go!

IS

E o En uh 474

E M kA o sn; in-x

In the village of 475

Kk o

S. у (0) ше у-х

M

476 2 Fr

NS about what and about Gn; in

M

477 And in, p. o

SI XX century My

She and M 478 s o D-t o that

M

St. h

Still r

M. 479 all h o i o m (0)

M

NM Kh

2 Hu 480 M

D-x

Go) in

IED

M

Me

MN M

481 ope, (0) "3 (0)

IN

M Sn 482

Pho te. (6) (in; MN,

M

/

M

SN, / 483 J-ya (0) o r u-x

M

She

484 d o

So what?

(0,

IN

M SV

485 WHAT,

M o. in (07 Sep

What's up,

Fe Y

M

We are xx

M

486 sa y-chto kg what s o ra

M

С МН хх м 487 M de o ko what o) still uh u

She and she

M

1

Мхххос их 489 M

What the hell?

M

M

/

MN M

490

Go) Mr. I what

(0);

M

NM

2 Me 491 M i (0) u

SNU

M va; /

University of St.

M

(6) 492 (Z

M by -3

Go) y-x xx 493 M Snu

M in A

M

M

494 2 o no oo o) SN. / in the city

M.Sc. 495 year o) )5 (0)

E o su so" / 496 M

What the hell

(at)

IN

497 Mob about, ; -x p (in) 6) shk u-k

M

498 c and; dream that 9 and more

M

In "St., 499 | X shchi no (9; MN, (0) Az u-kh

M

500? (9)

IS

ON

(6; from u-x ) F 501 I

OO

6) With y-x

M

502? in that that and ov in-

M

503 in; M

M ns "

E sn shcha

M IF

504 M 7

M on the neck

M tk

S S Sh

505 Fi o r on (v; o o o. M y sn,

Mtk soooloniya 506 oh but oh what not

K sn, 507 o

S. o vk ZK on z oyi o 508 U

M s ak i

0) still in

M

509 2 у что оо 0) Az у-х

M

AND

510? in about that

From o in u-k

IN

511 | ? M "i

MN; 0) what is it?

M

512 du" M ! sn sv b sn z : oh what

In "St

M

513 | p;

M no (8; МН, о) СН, у-х о / st Е Сн»

then raFf

M M 0 515

M 7 "Y st.,

Chu kre - SN,

M on 516 id "St., p

With

Go)

M M xx

S yo i 517 i ve-3--

GI not but in 6) o

IN! 518 M SN,

ЧО, r. sn; ra

M M. and 519 s sn, ex, zchI

I. c) o) more y-x

Bho s? M 0 / (in sn,

(9) Az u-kh ho 521 su" u o ch st 0) v u-k ho ni SN. o7 Kho i 0) zhk u- o 523 d M

IS

ОН о у-х: ФО 524 | ? )

MN, Sn

SN, t more, food

M SN, 525 I" o "A m (c)

then about M, aF

M Mo osn 526 -m

In

M

4 o M 527 and I x c

L M o / 0-X (0)

M-th IC 528 schi 3 SV in (0) 75 raFf

M, M. -Ik 529 sn i

The same

M

(0)

IN

5ZO Languages »

SU M ri

That and

M FI

5ZI ex NS 4 NSI

9) ud u-x »

AND

532 su" U rysvrya o oto sn, o) u u

M

5ZZ I And her M

Thu M th Sun - 07 H

M (0) n

NS M

IN

5ZA is going

M 3

WHAT;

M

(6) (in, E "xx ts / 535 Me M what

M

X-x o) I sn, 0; in u-kh

M

536? But what?

IS

6) what is it?

M

She

537? IN

So that's 9

M

Hm

/ 538 М сн удо

M o) u

CH,

SNU o / u-x "sn 5Z9 3 dk M

M xx | /

M M

5AO ch

BA m 1 6) still in- 52 M Se

M

0) o o u 5AZ Language

WHAT, in M 1 mya (0)

SN. in. SHI, 3

M

BA d M oo M- hy y-

M

545? M

SN. what and

In and"

H

She

5Ab Kk M 5 s not o in M | xx

St 4 o'clock 5 u-x a 547 su" 2 M 10) ! Sun Sun, then o M a

M Mo SV 548

M (0)

Western

M

Ho) And uh-h

M s 5AZ M ho ikh i -U

SNU E

This is it

BBO; | RI c)

IN

Ms

M. b u (c) sv t what, mi 552 Mo sv 7 oy mn dn o

E

M SV

AND

553 p

NM MN,

Vii NS

MN

BBA id a v" " sn u-k 759 su" MN no

NVI o dk uh

In o (v, ME, 0) is already y-x

M

557 su" U-

M o M u-a and u a

To her about M o

GSK

558 ОН xx y

M sn; more

M, M. 5BO sh to

X KA o o no o what y-x 5bO Moossv, y

More o u u-k o

BV 2nd

So what?

ON NVg u. USD

M in 562 | ? 5(6);

MN, NS about u

Article 563 p

M

NM. MN, y

МН у-х

M. IZ

WHAT; 564 Mo; district (in; still at 565 dk and ?

MN b that 566 Their yin that, 567 dk u

ST U

0/5 in-x

M

WHAT m 568 M x,7o

XX

29; Oh oh oh

IS

10) she y-x

M

569 SU M -

M M-

With o / y-

IN

570 | ? M on NVg Svv that,

BT

V, but tn (9) that, 572 I- and but and oh I uh-x

WITH

573 su" M o (0) -- p

0 sn y-x ) Fo 574 And y-to no that o) y-k xx

M SV

575 d

IN.

She NS

MN; o) y-x x

And and and

M-A-M n o sn ide

M

577 su" M

Go) Az u-ya

M

578? M (about i

M u (0) she u-k ho 579 I su"

Igy o u- x 580 M SNU in, vh - and ME

M still in 581 M NE du u;

M

Ve. at

She ay

MN; o sv uh ho and h o x st

(o) already in-x

IN

583 su M o / her u

Her" (0) M

SS" -

M M 5th 5BA in; Ki and eh -

M

(9) Az y-x

IN

585? M u /

On NVg SN, (0) A u-x: yus 586 | y ) on NVg SN, 0) Av y-x

M

587 su M 20) M-

NVg M. Y

M

In u-k x 588 M St u

M

She

MH,

Ge) seh u-h

M

589 d KM ok s You (0) y-x x

M SN

590 o"

SM

In

M-M

N

SN o Z u-x

M

WHAT,

M

5 OII

Quarter 4

Me

In Jan

M

» 5BO2 | ? M mini xx o nya ON vn,

M

In u-x x 5OZ M SV,

L

M

(6) seh

Comrade KI

SN b y )

What Yi A

M

594

MY sMN x shk (6;

SN. (0) / 3 y-x ) GU 595 ? M as o M x

ZM

Sleep n

SN. (0) / 3 y-x ; (In 596 2 M u o o o

CH,

SN. 0) / With y-x ) (In t

The compounds of the invention described above are characterized by melting point data and

NMR spectroscopy, as detailed below. NMR spectra were recorded on a spectrometer

VgyKeg Amapse OKH400 using a solvent as an internal standard. The spectra of 736 were recorded at 100 MHz, and the spectra of "H were recorded at 400 MHz. The data were recorded in the following order: chemical shift (ppm), number of protons, multiplicity (w, broadened; 4, doublet; t, multiplet; 5, singlet; Her , triplet) and coupling constant (Hz).

Compound number 1 (MR: 89-91). NMR solvent: OM5O 130: 150.4, 137.1, 128.9, 118.6, 65.7, 46.1 1H: 8.04 (1H, 5), 7.48 (1H, 5), 7.03 (1H, 5), 3.65 (4H, t, y - 5.0 Nzg ), 3.50 (4Н, т, У - 5.0 Н2)

Compound number 2 (MR: 58). NMR solvent: SOSIZ 130: 150.2, 142.9, 137.7, 130.3, 129, 128, 125.9, 118.4, 40.1

1H: 7.57 (1H, 5), 7.39 (2H, her, y - 7.7 Ng), 7.32 (1H, her, y) - 7.3 Ni), 7.13 (2H, a, y - 7.7 No), 6.85 (IN, 5), 6.81 (TN, 5), 3.50 (ZN, 5)

Compound number C (MR: 97-99). NMR solvent: SOSIZ 130: 150.8, 142.7, 136.9, 132.7, 128.7, 127.7, 125.2, 112.8, 66.5, 46.8 1Н: 7.92 (1Н, 5), 7.79 (2Н, а, 9 - 7.8 Но), 7.47 (1Н, 5).

Compound number 4 (MR: 104-105). NMR solvent: SOSIZ 130: 150.1, 142.9, 141.4, 137.7, 132.8, 130.4, 128.5, 128.2, 127.4, 126, 125, 113.5, 40.2 1Н: 7.60 (2Н, а, у - 7.7 Nl (1Н, 7.53) ), 7.40 (2H, her, y) - 7.7 Nl), 7.34 (1H, t), 7.32 (2H, 1.9 - 7.6 H2g), 7.25 (1H, t), 7.19 (2H, t), 7.18 ( 1Н, 5), 3.52 (ЗН, 5)

Compound number 5 (MR: 117). NMR solvent: SOSIZ 130:154.2, 146.9, 136.6, 131.7, 129.9, 129.2, 129.1, 128.8, 126.3, 124.7, 119.8, 106.7 1H: 9.19 (H, 5), 8.36 (1H, a, y - 2). 7.91 (2H, y, U - 68.0 Nl), 7.67 (2H, y, y - 7.8 H2), 7.49 (2H, t, y - 7.2. Nz), 7.43 (ZH, t), 719 (1H, y, y - 7.4 N?), 6.79 (1H, a, U - 2.7 N?g)

Compound number 6 (MR: 98-99). NMR solvent: SOSIZ 130: 156.7, 154.1, 147.2, 131.8, 129.9, 129.5, 129.1, 128.8, 126.2, 121.7, 114.4, 106.5, 55.5 1Н: 9.05 (1Н, 5), 8.2, Н2, 34 (1Н2, 8) ), 7.89 (2H, t, y - 8.4 Nzg), 7.55 (2H, t, y - 8.8 H2g), 7.47 (2H, y - 7.7 NI), 7.A1 (1H, her, y - 7.3 Но), 6.94 (2H, t, y - 8.8 Ng), 6.76 (1H, y, y - 2.8 H2), 3.83 (ZH, 5)

Compound number 7 (MR: 62). NMR solvent: SOSIZ 130: 151.7, 149.1, 145.7, 143.1, 129.6, 127.7, 125.8, 40.5 1H: 8.64 (1H, 5), 7.73 (1H, 5), 7.37 (2H, her, y) - 7.7 No), 7.ZO(1H, 1, U - 7.3 No), 713 (2H, a, - 7.68

H2), 3.56 (ZN, 5)

Compound number 8 (MR: 64-65). Solvent NMR: SOSIZ 130: 151.7, 144.6, 141.8, 131.1, 129.3, 126.6, 125.4, 107.3, 40.4 1H: 8.01 (1H, a ri, U - 2.7 Nl), 7.40 (1H, ryu), 7.33 (2H, t , U - 8.1 Ng), 7.23 (1Н, т, у - 7.6 Н2), 7.11 (2Н, т, У - 8.3 Н?), 6.25 (11Н, и а, У - 1.7, 2.7 Но), 3.55 (ЗН , 5)

Compound number 9 (MR: 71-72). NMR solvent: SOSIZ 130: 146.8, 142.3, 136.6, 129.2, 128.7, 124.7, 119.6,109

Koo) 1H: 9.13 (IN, 5), 8.33 (IN, y a, Y - 0.6, 2.7 No), 7.69 (IN, y a, Y - 0.6, 1.6 H2g), 7.63 (2H, t, y - 8.7 Nz), 7.40 (2H, t, y - 68.0 Ng), 7.18 (IN, t, U - 7.5 N?), 6.47 (IN, a a, U - 1.6, 2.7 Ng)

Compound number 10 (MR: 125-126). NMR solvent: SOSIZ 130: 157.4, 154.3, 154, 147.1, 132, 131.7, 130, 129.8, 129.2, 128.8, 126.3, 123.2, 121.6, 119.7, 118.6, 106.6 (H. 14, 9.1, 1H, 9.1). y, U - 2.8 Nz), 7.91 (2H, y, U - 68.0 Nl), 7.62 (2H, y, y - 9.0 H2), 7.49 (2H, 1, y - 7.6 Ng), 7.43 (IN, 1, U - 7.2 No), 7.36 (2H, I, U - 8.0 No), 7.12 (1H, y - 7.5 Nzg), 7.08 (2H, 9.9 - 9.0 H2g), 7.04 (2H, a, U - 68.2 No ), 6.80 (1Н, ай, У - 2.8 N?g)

Compound number 11 (MR: 110). NMR Solvent: SOSIZ 130: 155.9, 154.1, 147.1, 136.8, 131.8, 129.9, 129.8, 129.1, 128.8, 128.6, 128, 127.5, 126.2, 121.7, 115.4, 106, 70.5, 1H, y, y - 2.7 IN), 7.90 (2H, y, Y - 8.3 Nl), 7.56 (2H, t, y - 9.0 Н2), 7.47 (2H, t), 7.45 (2H, t), 7.43 ( 1H, t), 7.40 (2H, t), 7.34 (1H, t), 7.03 (2H, t, y - 9.0 Н?), 6.78 (IN, a,

U - 2.7 IN), 5.09 (2H, 5)

Compound number 12 (MR: 79). NMR solvent: SOSIZ 130:153, 151.3, 144.9, 132.3 (2 parts), 129.2, 128.5 (2 parts), 126.7, 125.9, 125.9, 104.7, 40.5 1H: 811 (IN, a, y - 2.5 Ng) . , 3.59 (ZN, 5)

Compound number 13 (MR: 79-80). Solvent NMR: SOSIZ 130:153.7, 151, 133.3, 132.1, 128.8, 128.7, 126, 104.9, 66.8, 47 1H: 8.19 (IN, y, U - 2.8 Nzg), 7.83 (2H, 9, U - 8.4 No) , 7.44 (2H, U - 7.7 No), 7.39 (1H, t, y - 7.2

Ng), 6.70 (1H, y, U - 2.8 H2), 4.0 (AN, 5 Bi), 3.84 (4H, t)

Compound number 14 (MR: 132). NMR solvent: SOSIZ 130: 150, 142.9, 141.4, 137.9, 133.5, 132.8, 130.4, 130.1, 128.2, 128.2, 128.1, 127.6, 126.2, 126, 125.7, 123.6, 123.3 ), 7.85-7.77 (ZN, t), 7.64 (IN, a y, ,1.8, 8.7 N2g), 7.56 (IN, y, U - 1.3 Nzg), 7.44 (AN, t), 7.36 (1Н, t, U - 7.4 Ng), 7.34 (1H, y, U - 1.3 Ng), 7.21 (2H, t, U - 8.1 Ng), 3.54 (ZN, 5)

Compound number 15 (MR: 134). NMR solvent: Acefope 130: 154.8, 148.1, 141.2, 138, 137.9, 133, 131.1, 129.9, 129.8, 129.7, 128.2, 128.1, 127.6, 1271, 121.5, 107.4

1H: 10.05 (1H, 5), 8.45 (IN, a, U - 3.0 No), 8.03 (2H, t, y - 8.7 Nzg), 7.94 (2H, t, y - 68.6 Н2), 7.72 (2H, t , y - 68.6 Nl), 7.69 (2H, t, y - 8.3 H2), 7.49 (2H, t), 7.47 (2H, t), 7.43 (1H, t), 7.36 (1H, t, y - 7.4 NO ), 7.06 (IN, а, У - 3.0 Н2)

Compound number 16 (MR: 119-120). IMR solvent: SOSIZ 130: 159.2, 150.1, 141.2, 137.9, 135.5, 133.6, 132.8, 130.2, 128.2, 128.1, 127.6, 127.3, 126.2, 125.7, 123.2, 123.3, 115.5, . )

Compound number 17 (MR: 138). NMR solvent: SOSIZ 130:159.1, 150.1, 141.2, 137.7, 135.5, 132.8, 128.6, 127.4, 127.3, 125, 115.5, 113.7, 55.5, 40.5 1H: 7.64 (2H, a, 17-17, 17-8). . 2Н, и, У - 8.6 Н2), 3.81 (ЗН, 5), 3.49 (ЗН, 5)

Compound number 18 (MR: 123-124). Solvent NMR: SOSIZ 130: 150.9, 143.4, 142.7, 141.5, 132.4, 130.3, 127.6, 125.4, 124.8, 123.9, 120.2, 114, 39.7 1Н: 7.9511Н, a, y - 7.68 No, 7. U - 8.0 Nl), 7.54 (1H, 5), 7.38 (1H, t), 7.33 (2H, t), 7.32 (1H, t), 7.25 (IN, t), 7.12 (2H, y, U - 7.8 Ng), 3.58 (ZN, 5)

Compound number 19 (MR: 104). Solvent NMR: SOSIZ 130: 149.4, 145.3, 133.1, 129.5, 125.4, 119.9, 113.6, 66.7, 48.2, 45.6 1Н:8lО(1Н, а, У - 8.3 Н2g), 8.01 (IN, и, У - 8.4 Но) , 7.62 (1H, 1, U - 7.9 No), 7.A7 (1H, I, yu - 7.6

H2), 3.96 (AN, 5 Bi), 3.89 (4H, 5 Bi)

Compound number 20 (MR: 181-183). NMR solvent: ОМ5О 130: 153, 147.4, 140.6, 139.5, 137.4, 130.8, 130.7, 129, 128.8, 127.8, 127, 126.8, 126.7, 124.4, 121, 106.8 1Н: 18, 10.36 9, U - 2.6 No), 8.18 (2H, a, U - 8.1 No), 7.82 (2H, a, U - 6.2 NO), 7.78 (2H, t), 7.76 (2H, y, U - 8.7 Nl) .

Compound number 21 (MR: 208-211). NMR solvent: ОМ5О 130:150, 147.8, 143.2, 140.7, 140, 134.5, 130.5, 126.8, 106.1, 66, 46.6 1Н: 9.35 (1Н, 5), 8.86 (2Н, t), 8.40 (IN, y, U - 2.5 No), 8.02 (1H, gri, y - 6.3 Ng), 7.31 (1H, y, - 02.5 Ng), 3.77 (4H, ri), 3.71 (4H, Bi)

Compound number 22 (MR: 168-170). NMR solvent: OM5O 130: 159.6, 153, 147.3, 140.6, 139.5, 138.6, 130.8, 130.7, 129.6, 129, 127.8, 127, 126.9, 126.7, 113, 109.9, 106.9, 10 ), 8.50 (1Н, а, У - 3.0 Но), 8.18 (2Н, а, У - 8.5 Nl), 7.81 (2Н, а, у - 8.5 Н2), 7.76 (2Н, а, У - 8.6 Нзг), 7.75(1H, 1, U - 2.3 No), 7.50 (2H, 1, U - 7.8 No), 7.42 (1H, t), 7.39 (1H, t, y - 7.2

Hg), 7.31 (1Н, У - 68.5 Но), 7.19 (IN, а, У - 3.0 Но), 6.76 (1Н, т, У - 1.0, 2.4, 8.3 Н2), 3.76 (ЗН, 5)

Compound number 23 (MR: 163). NMR solvent: OMB5O 130: 156.2, 152.9, 147.5, 140.5, 139.5, 130.8, 130.7, 130.2, 129, 129, 127.8, 127, 126.8, 126.7, 122.9, 113.9, 106.6, 5 1H, io, U - 2.6 No), 8.18 (2H, a, U - 8.1 No), 7.82 (2H, a, 9 - 8.1 NO), 7.77 (2H, a, 9 - 7.4 Nl), 7.66 (2H, y, U - 9.0 No), 7.50 (2H, her, 9 - 7.8 No), 7.40 (1H, I, y - 7.3 No), 7.16 1H, 9.9 - 2.6 H2g), 6.98 (2H, y, U - 9.0 H2), 3.77 (ZN, 5)

Compound number 24 (MR: 99). NMR solvent: SOSIZ 130: 150.9, 150.1, 149.4, 147.4, 144.7, 133, 132.6, 129.3, 128.1, 126.9, 125.9, 123.4, 104.6, 40.5 1Н: 8.61 (ТН, Н, 05, 18, 18). 4.9 No), 8.16 (IN, y, U - 2.6 No), 7.65 (IN, y, y - 7.9 Nz), 7.36 (2H, U - 7.6 Ng), 7.29 (1H, I, U - 7.5 NN), 722 1Н, аа, у - 4.9, 7.9 Но), 7.17 (2Н, а, 9 - 7.8 Н2), 6.59 (1Н, а, У - 2.6 Н2), 3.58 (ЗН, 5)

Compound number 25 (MR: 137). NMR solvent: OMBO 130: 151.6, 150.7, 144.5, 140.1, 139.5, 133, 131, 1291, 129, 127.7, 126.8, 126.6, 126.5, 126.1, 125.8, 105.1, 40.2, 1Н2, 85 H?), 7.69 (2H, 9, 9 - 7.8 No), 7.64 (2H, y, U - 8.4 Ng), 7.59 (2H, a, y - 68.4

Nzg), 7.46 (2Н, 1 У - 7.6 Нз), 7.37 (ЗН, т), 7.26 (ЗН, т), 6.92 (1Н, и, У - 2.5 Н2), 3.48 (ЗН, 5)

Compound number 26 (MR: 123-125). NMR solvent: SOSIZ 130: 151.9, 146.5, 141.4, 130.3, 129.3, 129, 128.9, 128.3, 127.3, 126.9, 124.1, 120, 38.9 1Н: 7.43-7.24 (6Н, т), 7.3 (Н, т.6) , 6.33 (2H, Bi), 3.37 (ZH, in Bi)

Compound number 27 (MR: 121). Solvent NMR: SOSIZ 130: 149.9, 142.8, 140.3, 137.8, 133, 131.3, 130.4, 128.7, 128.2, 126.2, 126, 113.7, 40.2 , U - 1.3 Nz), 7.42 (2H, t, y - 7.7 Ng), 7.35 (1H, t, y - 7.4 NO), 7.29 (2H, t, U - 68.6 No), 7.19 (1H, a, U - 1.3 Nl), 7.18 (2H, t), 3.52 (ZH, 5) because Compound number 28 (MR: 127). NMR solvent: SOSIZ

130: 159, 150.1, 142.9, 141.2, 137.6, 130.3, 128.1, 126.3, 125.9, 125.5, 113.9, 112.4, 55.2, 40.2. - 1.4 No), 7.41 (2H, t, y - 7.9 Ng), 7.34 (IN, t, y - 7.5 Ng), 7.19 (2H, t, y - 8.3 Ng), 7.09 (IN, y, U - 1.4 Н?), 6.87 (2Н, т, У - 8.9 Н2), 3.80 (ЗН, 5), 3.52 (ЗН, 5)

Compound number 29 (MR: 127-129). NMR solvent: SOSIZ 130: 162.2 (y, 9 - 246.0 N?), 150.0, 142.9, 140.5, 137.8, 130.4, 129.0 (0, 9 - 3.3 N?), 128.2, 126.7 (9, U - 8.0 N), 126.0. ) - 7.7 Ng), 7.35 (IN, t, U -7.3 NI), 7.18 (2Н, t), 7.15 (1Н, а, У - 1.3 Но), 7.01 (2Н, 1, У - 8.7 Н2г), 3.52 (ZN, 5)

Compound number 30 (MR: 126). NMR solvent: SOSIZ 130: 159.5 (a, U - 249.0 NO), 150.0, 142.8, 137.3, 135.1 (a, U - 2.6 No), 130.3, 128.3 (y, U - 8.6

Ng), 128.2, 127.7 (90.9 - 4.0 No), 125.9, 124.2 (a, 94 - 3.2 No), 120.7 (0.9 - 12.8 No), 117.7 (9.9 - 16.0 Nz), 115.4 (a0.9 - 22.0 No), 40.2 1Н:8.02 (IN, а, У - 2.0, 7.6 Но), 7.65 (IN, y, У - 1.3 Ng), 7.41 (2Н, т), 7.34 (1Н, т ), 731 NN, and 15. a, - 1.3, 3.6 No), 7.19 (2H, t), 7.16 (IN, t), 7.15 (1H, t, U - 1.6, 7.4), 7.03 (IN, t, U - 1.5, 7.6, 11.4 H2), 3.53 (ZN, 5)

Compound number 31 (MR: 128-129). NMR solvent: SOSIZ 130: 159.8, 150, 142.9, 141.2, 137.7, 134.2, 130.4, 129.6, 128.2, 126, 117.4, 113.8, 113.6, 109.9, 55.2, 40.2 1НЖ - 1Н17.5 , 7.41 (2H, t, y - 7.8 Ng), 7.34 (1H, t, y - 7.4 Ng), 7.23 (IN, 1, y - 7.68

Nzg), 7.21 (1H, t), 7.19 (ZN, t), 7.16-7.13 (IN, t), 6.79 1H, y and a, 1.0, 2.5, 8.0 No), 3.81 (ZN, 5), 3.52 ( ZN, 5)

Compound number 32 (MR: 144-146). NMR solvent: SOSIZ 130: 149.7, 143.5, 143.4, 136, 133.4, 129.6, 127.6, 126.4, 126, 120.7, 113.3, 40.4 1H: 8.10 (1H, a, U - 1.6 Nzg), 7.91 (1H, a, U - 8.8 No), 7.40 (IN, a a, 9 - 1.6, 8.8 Nz), 7.34 (2H, t,

U - 7.9 H2g), 7.27 (1H, t), 7.17 (2H, a, U - 7.6 Nzg), 3.67 (ZH, 5)

Compound number 33 (MR: 112). NMR solvent: SOSIZ 130: 149.7, 145.6, 143.4, 131.5, 131, 130.1, 129.6, 127.6, 125.9, 119.3, 114.2, 40.4 1H:8.0 (1 H, a, U - 68.9 Nzg), 7.98 (1H, y U - 1.6 Ng), 7.57 (IN, a a, U - 1.6, 8.9 No), 7.34 (2Н, U -

Zo 8.1 NO), 7.27 (1H, t), 7.17 (2H, y, U - 7.8 Ng), 3.67 (ZH, 5)

Compound number 34 (MR: 89-90). NMR solvent: SOSIZ 130: 150.2, 145, 143.6, 132.8, 129.5, 129.3, 127.4, 125.9, 125.1, 119.9, 113.2, 40.3 U - 8.4 Nz), 7.61 (1H, t, y - 7.7 Ng), 7.43 (1H, t, y - 7.7

Nzg), 7.32 (2H, U - 7.8 No), 7.25 (1H, 1, y - 7.5 No), 7.18 (2H, a, U - 7.5 Н?), 3.68 (ЗН, 5)

Compound number 35 (MR: 166-169). NMR solvent: OMBO 130: 149.8, 142.9, 139.7, 139.7, 138.7, 137.9, 132.1, 129.9, 129, 129, 127.7, 127.4, 126.9, 126.5, 126.2, 125.2, 114.5, 39.6 1. H2), 7.69-7.61 (6H, t), 7.48-7.39 (4H, t), 7.39-7.30 (4H, t), 3.44 (ЗН, 5)

Compound number 36 (MR: ой). NMR solvent: OMBO 130: 160.8 (9, U - 245 No), 158.6, 149.9, 140.2, 139.3 (y, U - Z No), 137.6, 128.6 (y, U - 9 H2), 126.0, 125.6, 116.7 ( y, U - 23.5 No), 114.1, 113.0, 55.1, 39.5 1H: 7.69 (1H, 5), 7.57 (2H, y, U - 8.7 Nz), 7.45 (1H, 5), 7.41 (2H, t), 7.25 (2H, 1, U - 8.7 Nl), 6.90 (2H, a, U - 8.7 Ng), 3.73 (ZN, 5), 3.40 (ZN, 5)

Compound number 37 (MR: 162-164). NMR solvent: SOSIZ 130: 149.7, 142, 137.6, 137.4, 132.8, 131.7, 128.9, 128.6, 127.5, 127.1, 125.8, 125.1, 123, 113.1, 45.8, 26.6, 23.9, 8 (H, 1.8, 23.9, 1) 2H, y, U - 7.7 Nl), 7.36 (2H, 1, U - 7.7 Nz), 7.28 (1H, 5), 7.26 (1H, t), 7.23 (IN, a, - 7.5 Ne), 7.11 (IN , U - 7.6 Но), 7.03 (1Н, У - 7.7 НО), 6.75 (1Н, а, У - 68.0 Н2), 3.92 (2Н,

I, U - 6.6 Ng), 2.87 (2H, 1, U) - 6.6 Nz), 2.11 (2H, ai, U - 6.6 N?g)

Compound number 38 (MR: 232-233). NMR solvent: OMBO 130: 158.3, 147.9, 141.9, 137.2, 135.4, 129.9, 128.2, 126.9, 126.3, 118.8, 115.8, 114, 39.9 1Н: 8.79 (1Н, 5), 8.78 (1Н7, 5), 1Н7, 5 .

Compound number 39 (MR: 97-98). Solvent: SOSIZ 130: 159.9, 149.6, 141.8, 137.6, 137.4, 134.2, 131.8, 129.6, 128.9, 127.1, 125.8, 123, 117.5, 113.7, 113.4, 110.1, 55.3. , I, U - 1.3 Nzg), 7.29 (1H, t), 7.28 (1H, y, U - 1.3 Ng), 7.24 (2H, t), 7.23 (1H, t), 72 (Nau - 1.2, 7.5 H2 ), 7.04 (IN, a, y - 1.5, 8.0 H2), 6.83 (1H, a a a a, 1.5, 2.5, 7.5 H?), 6.75 (On reg, - 8.0 No), 3.93 (2H, 1, U - 6.7 Н2), 3.84 (ЗН, 5), 2.88 (2Н, 1, У - 6.6 Н2), 2.12 (2Н, а, 9 - бо 6.6 Н2g)

Compound number 40 (MR: 139-141). NMR solvent: OM5O 130: 157.6, 149.7, 142.8, 139.9, 137.7, 133.9, 129.9, 129.7, 127.7, 126.2, 115.5, 114.3, 114.2, 111.5, 39.6 1H: 1, 1, 9.45, H. 7, 85 . (1Н, и, У - 8.0 Н2g), 3.42 (ЗН, 5)

Compound number 41 (MR: 152). NMR solvent: OMBO 130: 150.6, 148.8, 144.7, 132.5, 129.6, 129.1, 125.5, 119.6, 119.5, 115.9, 113.4, 48.3, 47.1, 44.8 1H: 8.21 (IN, a, U - 7.5 Ng7) , a, U - 8.3 Nl), 7.71 (1H, t, y - 7.8 N?), 7.55 IN, t, y - 7.6 Ng), 7.25(2H, 1, 9 - 7.5 No), 7.0 (2H, a , o) - 8.2 No), 6.83 (1H, her, y - 7.3 No), 3.92 (4H, t), 3.33 (4H, t)

Compound number 42 (MR: 79-80). NMR solvent: OMBO 130: 148.6, 144.7, 140, 132.5, 129.4, 129.1, 128.3, 125.9, 125.4, 119.6, 113.1, 47.6, 45, 41.9, 37.1, 31.6 o), 7.90 (1H, y, U - 8.4 Nl), 7.68 (1H, t, y - 8.0 Ng), 7.53 (IN, t, y - 7.6 Ng), 7.29 (2H, I, y - 7.3 Nz) . 1.88 (IN, t), 1.70 (2Н, ры), 1.34 (2Н, т, У - 4.0, 12.5 Н2)

Compound number 43 (MR: 105). NMR solvent: SOSIZ 130: 161.7 (0, 9U - 250.0 N?), 149.8, 140.5, 138.8 (a, 9 - 3.6 N?), 137.7, 133.1, 131.2, 128.8, 127.8 (9, U - 8.4 N) . - 68.8 Ng), 7.23 (IN, 9, - 1.4 Н2), 7.17 (2Н, t), 7.12 (2Н, t), 3.50 (ЗН, 5)

Compound number 44 (MR: 145). NMR solvent: SOSIZ 130: 162.3 (a, U - 246.5 Nl), 149.6, 141.1, 137.6, 137.5, 131.8, 129.0 (y, 9 - 3.0 Nzg), 129, 1271, 126.8 (9, U - 8.0 Nzg), 125.9. 7.24 (1H, t), 7.23 (IN, a, U - 1.3 Ng), 7.12 (1H, t), 7.05 (2H, t, U - 68.9 No), 7.05 (IN, t, y - 1.2, 7.5 No ), 6.75 (1H, t, y - 8.1 No), 3.92 (2H, 1.9 - 6.6

Ng), 2.88 (2H, Her, U - 6.6 No), 2.12 (2H, a, U - 6.6 H2)

Compound number 45 (MR: 93-96). NMR solvent: SOSIZ 130: 161.7 (0.9 - 249.5 No), 159.6 (a, U - 249.0 No), 150.0, 138.9 (y, U - 3.5 No), 137.2, 135.3

Koo) (9.9 - 2.0 No), 128.4 (y, 9 - 8.3 Ng), 127.8 (y, 9 - 68.3 No), 127.7 (0, U - 4.0 H2), 124.3 (90.94 - 3.2 H2) . , а, - 2.0, 7.8 Но), 7.68 (IN, а, У - 1.4 Н?), 7.30 (1Н, и а, у - 1.4, 3.5 Н?), 7.19 (2Н, т), 7.16 (TN, t), 7.15 (IN, t), 7.10 (2Н, t), 7.04 (1Н, ай а, у - 1.4, 7.9, 11.3 Но), 3.50 (ЗН, 5)

Compound number 46 (MR: 90-91). NMR solvent: SOSIZ 130: 158.9 (0.9 - 238.0 No), 154, 131.7, 130.2 (a, 10.0 N?), 127.5, 114.2 (a, 9 - 9.5 Nl), 111.9 (94.9 - 26.0 N2) . . (4H, t, y - 5.0, 6.0 H2)

Compound number 47 (MR: 112-113). NMR solvent: SOSIZ 130:155.5, 154.4, 130.3, 130, 126.7, 114, 113.2, 106.1, 103.1, 66.7, 55.7, 471 1H: 7.60 (1H, a, U - 8.9 No), 7.30 (1H, a, U - 3.5 Но), 7.06 (1Н, а рт, У - 2.5 Н?), 6.9511Н, а и, У - 2.5, 8.9 Но2), 6.55(1Н, и а, У - 0.7, 3.5 Н2), 3.86 (ZN, 5), 3.79 (4H, t, y - 5.0 H2), 3.61 (AN, t, y - 5.0

Nz)

Compound number 48 (MR: 184). NMR solvent: OMBO 130: 162.4, 148.7, 147.4, 147, 144.7, 132.5, 129.6, 128.6, 125.5, 123.3, 119.7, 113.4, 109.9, 108.1, 101.1, 60.5, 4 , U - 8.4 No), 7.93 (1H, y, U - 8.4 No), 7.71 (1H, 1, - 68.0 No), 7.54 1H, 1, U - 7.5

Nzg), 6.97 (1H, 5 bi), 6.91 (IN, a, U - 8.0 H2), 6.85 (1H, and a, 9 - 1.5, 8.0 Nl), 6.02 (2H, 5), 3.84 (4H, t ), 3.75 (2H, 5), 2.80 (AN, t)

Compound number 49 (MR: 89). NMR solvent: OMBO 130: 158.6, 148.9, 147.6, 144.7, 137.8, 132.5, 129.6, 125.5, 119.6, 113.5, 113.4, 107.3, 46.9, 44.А 1Н: 8.21 (IN, 9, Н11 - 8.17), 8.5 , а а, У - 1.5, 4.8 Н2), 7.97 (IN, y, У - 8.3 Н2), 7.71 (1Н, t), 7.58 (IN, t), 7.55 (IN, t), 6.88 (1Н, т , U - 8.7 No), 6.69 (IN, a a, 9 - 4.8, 7.1 H2g), 3.88 (4H, t), 3.71 (AN, t)

Compound number 50 (MR: 113-114). NMR solvent: ОМ5О 130: 149.2, 144.7, 134.4, 132.6, 129.5, 128.6, 128.6, 126.8, 126.5, 126.3, 125.5, 119.6, 113.5, 48.6, 46.7, 45.8, 27.8, 42.2

1H: 8.21 (IN, at, y - 0.8, 8.3 Ng), 7.95 (1H, a, Y - 8.3 Ng), 7.70 (1H, y - 7.8 N?), 7.54 TN, a a 9.9 - 1.0, 7.1, 8.3 Nz), 7.24 (AN, Bri), 4.94 (2H, Big), 3.96 (2H, 1, U - 6.0 Nz), 3.04 (2H, 1, U - 6.0 Nz)

Compound number 51 (MR: 188). NMR solvent: SOSIZ 130: 158.6, 150.8, 142.6, 138.8, 138.6, 134.8, 133.7, 130.8, 130, 127.8, 127, 124.1, 117.6, 115.8, 114.9, 113, 47. , U - 1.4 Но), 7.36 (IN, y, У - 1.4 Н2), 7.28 1Н, and р, У - 7.7 НН), 71511Н, У - 7.8 Нг), 7.13 (1Н, У, 7.09 (1Н, т ), 7.07 (1H, t), 7.04 (IN, y, y - 1.5, 8.0 H2), 6.79 (1H, a b, y - 8.2

Hg), 6.69 IN, aa a, o - 1.1, 2.5, 8.0 No), 3.91 (2H, 1, U) - 6.5 N?g), 2.90 (2H, 1, 9 - 6.5 No), 2.10 (2H,

Teas, U - 6.5 Ng)

Compound number 52 (MR: 174). NMR solvent: OMBO 130:153.5, 152.6, 130.2, 129.1, 127.3, 113.8, 112.9, 105.1, 105, 65.9, 46.5 1Н: 9.09 (Н, 5), 7.47 (IN, а, У - 9.0 Nz), 7.44 ( 1H, a, U - 3.5 No), 6.91 (1H, y, U - 2.0 Nz), 6.74 (PN. aa, y - 2.0, 9.0 No), 6.50 (1H, y, U - 3.5 H2g), 3.67 ( 4H, t), 3.47 (4H, t)

Compound number 53 (MR: ой). NMR solvent: SOSIZ 130: 150.9, 145.3, 135.7, 133.2, 129.4, 128.8, 128.1 (Big), 128.0, 125.2, 119.8, 113.7, 55.3, 53.8, 37.7 1Н:8lI (1.Н, 06Но, -8) (IN, y, U - 8.2 НО), 7.63 (1Н, her, У - 7.4 НО), 7.AB (1Н, 1, У - 7.8

Nz), 7.40 (BN, Big), 4.94 (2H, Bi), 3.31 (ZN, Bi)

Compound number 54 (MR: 218-220). NMR solvent: SOSIZ 130: 161.8 (0.94 - 251.0 Nz), 159, 146.3, 136.7 (a, 9 - 4.0 Nzo), 136, 134.3, 127.9 (a, 9 - 9.0 H2), 127, 117.2 (9, 94 - 23.0 No), 115.9, 115.6, 113.6, 40.1 1H: 8.89 (1H, t), 7.18 (2H, t), 7.09 (2H, t, y - 8.7 Nl), 7.05 (IN, t), 6.95 ( 2H, t, y - 8.6 H2), 6.65 (2H, t, y - 8.7 Nz), 3.35 (ZH, 5)

Compound number 55 (MR: 116). NMR solvent: SOSIZ 130: 149.3, 145.3, 133.2, 129.3, 125.2, 119.8, 113.5, 106.6, 64.6, 46.1, 43.6, 35.3 1H: 8.09 (IN, y, U - 8.5 No), 7.99 (1H, y, U - 8.3 No), 7.61 (1H, 1, - 8.1 No), 7.46 (1H, 0 - 7.4

Nz), 4.03 (4H, 5), 3.98 (4H, bi), 1.93 (4H, 1, U) - 6.0 Nz)

Compound number 56 (MR: 134). NMR solvent: SOSIZ 130: 157.1, 154.5, 146.6, 146.5, 131.6, 131.3, 130.3, 129.8, 125.7, 123.4, 121.9, 120.2, 119.7,

Koo) 118.7, 114 1H: 9.15 (1H, 5), 8.35 (IN, a, U - 8.4 N?), 8.15 (1H, y, 9 - 8.3 Ng), 7.69 (IN, her, U - 7.6 Nz) . (2H, t, y - 9.2 Ng), 7.05 (2H, t, y - 8.5 N2g)

Compound number 57 (MR: 156-157). NMR solvent: SOSIZ 130:157.2, 146.6, 146.4, 131.6, 130.2, 128.9, 125.6, 122, 120.2, 114.5, 114, 55.5 1Н: 9.06 (1Н, 5), 8.34 (IN, y, U - 8.5 Н?) . (2Н, т, у - 9.1 Н2), 3.85 (ЗН, 5)

Compound number 58 (MR: 101-102). Solvent NMR: SOSIZ 130: 150.4, 145.2, 133.2, 129.1, 125, 119.7, 113.5, 57.1, 32.4, 30.4, 29.7, 25.5, 25.3 , U - 8.5 Nl), 7.60 (1H, t, y - 7.8 No), 7.45 IN, t, y - 7.6 Ng), 4.26 (1H, BI), 3.18 (ZN, 5), 2.0 (2H, a ri , U - 11.0 NzI), 1.87 (2H, Bi), 1.67 (1H, Bi), 1.63 (2H, t, y - 3.0, 12.3 Ni), 1.43 (2H, t), 1.16 (IN, t)

Compound number 59 (MR: 148-150). NMR solvent: SOSIZ 130: 160.6 (a a, U - 11.5, 248.0 NO), 153.4 (a a, U - 12.0, 249.0 NO), 146.5, 146.4, 131.5, 130.5, 125.9, 122.7 (yes, - 2.0, 9.3 H2), 121.0 (Yes, 9 - 3.7, 11.0 No), 120.4, 113.8, 111.6 (а а, У - 4.0, 22.5

Ng), 104.2 (da, U - 22.5, 27.0 Ng) 1H: 9.28 (1H, 5), 8.32 (1H, t, y - 8.3 No), 8.27 (1H, t, U - 6.0, 8.9 No), 8.17 (1Н, т, У - 68.3 Н2), 7.70 (1Н, т, У - 68.2 Н2з), 7.53 (IN, т, у - 8.1 Н2), 7.0 (2Н, т)

Compound number 60 (MR: 142-143). Solvent NMR: SOSIZ 130: 146.5, 146.4, 136.1, 131.6, 130.3, 129.4, 125.7, 125.3, 120.2, 120, 114 1H: 9.19 (TN, 5), 8.95 (IN, 9, U - 8.3 Ng(), 8.15 1H, y, U - 68.4 Nl), 7.70 (2H, a, y - 8.0 N?2), 7.69 (IN, t), 7.52 (1H, 1, y - 7.8 Nz), 7.45 (2H, 1, U - 68.0 No), 7.25 (1H, 1, y - 7.4 Nz)

Compound number 61 (MR: 109). Solvent NMR: SOSIZ 130: 149.2, 146.3, 136.9, 131.6, 130, 128.9, 128, 127.8, 125.5, 120, 113.9, 44.4 1H: 8.32 (IN, 9, U - 8.4 N?), 8.11 (IN, a, U - 8.4 Nz), 7.67 (1Н, т), 7.65 (1Н, и, У - 7.8 Н2г), 7.49 (IN, У - 8.0 Н2г), 7.43 (2Н, т), 7.40 (2Н, 1, У - 7.7 No), 7.34 (IN, t), 4.75 (2Н, а, У - 6.0 N?g)

Compound number 62 (MR: 195-197). Solvent NMR: SOSIZ 130: 146.5, 146.3, 134.7, 131.5, 130.4 (2 parts), 129.4, 125.9, 121.2, 120.3, 113.9 1Н: 9.19 (1Н, 5), 8.34 (IN, а, У - 8.3 Но) . ), 7.42 (2Н, а, У - 8.8 N?g)

Compound number 63 (MR: 62). Solvent NMR: SOSIS 130: 150, 145, 142.2, 133.1, 132.8, 129.7, 129.5, 127.3, 125.3, 119.9, 113.3, 40.3 1nH: 8.06 (IN, y, U - 8.5 H2), 8.02 (IN, y, U - 8.3 No), 7.62 (1H, 1, y - 7.9 No), 7.45 (1H, ОЙ - 7.7

Nzg), 7.30 (2Н, а, У - 68.6 Н2g), 7.13 (2Н, а, У - 8.6 Н2), 3.65 (ЗН, 5)

Compound number 64 (MR: 84-85). NMR solvent: SOSIZ 130: 161.9, 160.9, 149.1, 146.3, 143.5, 129.5, 128, 127.5, 126.1, 122.4, 113.8, 55.2, 40.4 1H: 8.66 (1H, 5), 7.71 (H2 - U, 8.5 ), 7.39 (2H, 1, y - 7.9 No), 7.32 (IN, her, y - 7.2 Nz), 7.19 (2H, a, 9 - 7.9 No), 6.87 (2H, a, U - 8.5 Н2), 3.82 (ZN, 5), 3.58 (ZN, 5)

Compound number 65 (MR: 105-106). NMR solvent: SOSIZ 130: 162.6, 161.2, 148.8, 147.3, 128.3, 122.3, 114.1, 66.6, 55.3, 46.9 1H: 8.81 (1H, 5), 8.06 (2H, a, U - 68.9 Ng), 6.98 (2H, a, U - 8.9 Nz), 3.98 (4H, Bi), 3.87 (ZN, 5), 3.83 (AN, t Bi)

Compound number 66 (MR: 116). NMR solvent: SOSIZ 130: 162.1, 161.5 (a, 9 - 248.0 Nl), 161, 149.1, 146.5, 139.5 (a, U - 3.5 Ni), 128.1 (a, 9) - 9.0

Nzg), 128, 122.3, 116.3 (9, U - 22.5 Ng), 113.9, 55.3, 40.7 1H: 8.74 (1H, 5), 7.72 (2H, y, U - 8.4 Nz), 7.20 (2H, t, y - 5.0, 9.0 Nl), 7.09 (2H, her, U - 8.68 H2), 6.89 (2H, a, U - 8.9 Ng), 3.83 (ZN, 5), 3.56 (ZN, 5)

Compound number 67 (MR: 91). NMR solvent: SOSIZ 130: 161.2, 148.8, 146.5, 143.3, 135.8, 129.5, 128.7, 128.3, 127.8, 127.7, 126.1, 40.5 1Н: 8.69 (1Н, 5), 7.69 (2Н, т.3, ул), 8 7.39 (2H, 1, y - 7.8 H2), 7.32 (1H, t), 7.31 (2H, t, y -, 8.3 Nzg), 7.19 (2H, a, У - 8.0 Н2), 3.58 (ЗН, 5)

Compound number 68 (MR: 120-121). NMR solvent: SOSIZ 130: 161.9, 148.5, 147.6, 136.2, 129, 128.2, 128.1, 66.6, 47.5, 46 1Н: 8.84 (1Н, 5), 8.06 (2Н, 9.9 - 8.7 Nl), 7.44 (2Н, y, U - 8.7 No), 3.98 (AN, ri), 3.84 (4H, 5 Bi)

Compound number 69 (MR: 127-128). Solvent NMR: SOSIZ 130: 161.6 (a, U - 248.5 N?), 161.4, 148.8, 146.7, 139.3 (0, U - 3.3 Ni), 135.9, 128.8, 128.2, 128.1 (9.9 - 8.5 Ng), 127.8 . 2Н, т), 7.09 (2Н, 1, ю - 8.5 Н2), 3.56 (ЗН, 5)

From compound number 70 (MR: 91-92). Solvent NMR: SOSIZ 130:161.8 (ai a, U - 11.5, 251.0 Nl), 157.7 (y a, U - 12.5, 252.0 INz), 150.1, 144.9, 132.7, 129.6, 129.3 (da, 0 - 1.5, 10.0 No ), 127.7 (da, U - 5.0, 12.0 N?), 125.4, 119.9, 113.5, 1121 (da, 9 - 4.0, 23.0 Nzg), 105.1 (a a, 9 - 24.0, 26.5 N2g), 39.7 1Н:8.10 (1 H, y, U - 8.4 No), 8.01 (1H, 9, U - 8.1 Nl), 7.63 (1H, t, y - 7.8 Ng), 7.45 (1H, 1, - 7.7

Nzg), 7.30 (1H, t), 6.88 (IN, t), 6.84 (1H, t), 3.60 (ZH, 5)

Compound number 71 (MR: 65-66). NMR solvent: SOSIZ 130: 146.1, 145.3, 132.8, 129.4, 125.5, 119.8, 114.4, 82.5, 79.6, 62.2, 23 1nН:8.23(1Н, а, У - 8.4 Н7), 8ЛО(1Н, а, У - 8.3 No), 7.62 (1H, 1, U - 7.8 No), 7.48 (1H, I Yu - 7.7

Nzg), 5.54 (2H, 5), 3.90 (2H, 5), 1.69 (6H, 5)

Compound number 72 (MR: 85). NMR solvent: SOSIZ 130: 152, 142.2, 138.9, 130.1, 124.2, 122.8, 119.8, 115.2, 67.1, 47.2 1H: 8.09 (IN, y, U - 8.6 No), 7.69 (IN, y, U - 8.2 H2g) , 7.58 (1H, 1, U - 7.5 No), 7.36 (1H, 1, - 7.5

Nzg), 3.87 (4H, Big), 3.80 (4H, Bri)

Compound number 73 (MR: 80). NMR solvent: SOSIZ 130: 162.8, 148.7, 147.4, 130.2, 129.6, 128.7, 126.7, 66.6, 47.3, 46.2 1Н: 8.85 (1Н, 5), 8.12 (2Н, т), 7.47 (ЗН, т), 4.02 ( AN, ri), 3.84 (4H, t)

Compound number 74 (MR: 114). Solvent NMR: SOSIZ 130: 162.4, 162.0 (а а, 9 - 15.0, 251.0 Но), 158.0 (а а, 9 - 13.0, 252.0 Н?), 148.9, 146.7, 130.0, 129.6, 129.2 (4 а, У - 2.0, 10.0 Nl), 128.6, 127.6 (t, U - 13.0 No), 126.5, 111.8 (9 a, U - 4.0, 22.5

Н2g), 104.8 (, У - 25.0 Н2), 39.9 1Н: 8.86 (1Н, 5), 7.74 (2Н, Biг), 7.38 (ЗН, t Bi), 7.28 (1Н, t), 6.95 (1Н, t) , 6.92 (1H, t), 3.52 (ZH, 5)

Compound number 75 (MR: ой). NMR solvent: SOSIZ 130:150.5, 145.2, 133.2, 129.2, 125.1, 119.7, 113.6, 51.7, 50.4, 38.0, 35.7, 30.1, 29.0, 19.8, 13.8 1Н:8.LO (1Н, а4, Н? - 8 ), 8.0 (1H, a, 9 - 8.3 Ng), 7.59 (IN, her, U - 7.8 No), 7.45 (1H, 1, U - 7.6

Nzg), 3.67 (2H, Big), 3.91 (ZN, t bi), 1.78 (2H, t), 1.45-1.30 (2H, t bBg), 1.0-0.9 (ZN, t Bi)

Compound number 76 (MR: 130). NMR solvent: SOSIZ 130:150.3, 150.1, 144.9, 135.3, 132.8, 129.2, 126.8, 125, 119.8, 115.8, 113.2, 66.7, 48.7, 40.5 1H: 8.04 (IN, Y, U2 - 8.4 H1) , 9, U - 6.2 H2), 7.60 (IN, her, y - 7.9 No), 7.42 (1H, 1, - 7.6 60 Nzg), 7.08 (2H, y, U - 7.7 No), 6.80 (2H, a , U - 8.7 Н2), 3.83 (4Н, т), 3.63 (ЗН, 5), 3.13 (4Н, т)

Compound number 77 (MR: 163-138). NMR solvent: SOSIZ 130:161.2, 150.1, 145.2, 145, 132.8, 129.3, 125.1, 119.8, 113.2, 104.4, 99.1, 55.4, 40.3 , U - 8.9 Nz), 7.61 (1H, 1, y - 7.7 No), 7.44 (1H, ОЙ - 7.7

Hg), 6.34 (1H, U - 2.0 No), 6.31 (2H, a, U - 2.0 No), 3.70 (6H, 5), 3.65 (ZH, 5)

Compound number 78 (MR: 155-157). NMR solvent: SOSIZ 130: 163.8 (a a, 9 - 12.0, 253.0 IN2?), 160.8 (a a, 9 - 12.0, 258.0 N?i), 158.4 (a, 9) - 6.0 Nz), 148.4, 146.9, 131.54 a, 9 - 4.0, 10.0 No), 114.3 (9 a, U) - 4.0, 11.5 Ng), 111.8 (9 a, U - 4.0, 21.5 No), 105.0 (U - 25.0 H2), 66.6, 47.9, 45.9 1H: 8.87 (1H, 5), 8.12 (1H, t, y - 6.7, 8.5 Nzg), 7.0 (1H, t), 6.95 (1H, t), 4.10 (AN, Bi), 3.83 (4H, 5

For

Compound number 79 (MR: 86). NMR solvent: SOSIZ 13C: 163.8 (a a, U - 12.0, 253.0 No), 160.8 (a a, 9 - 12.5, 259.0 No), 158.2 (y, 9 - 5.5 H2g), 148.5, 146.7, 139.7, 131.5 ( a a, U - 4.0, 10.0 N?), 129, 128.3, 126.1, 114.6 (9 9, U - 4.0, 11.0 N2g), 111.7 (d.a,

U -4.5, 21.0 Но), 105.0 (i, У - 26.0 Н2), 47.7, 46.2, 42.8, 38, 31.9 1Н: 8.83 (Н, 5), 8.13 (1Н, т, У - 6.8, 8.3 Nl), 7.31 (2H, her, y) - 7.5 H), 7.23 (1H, t, y - 7.3 H2), 7.17 (2H, a, Y) - 7.8 Nz), 7.0 (1H, t), 6.96 (1H, t ), 4.62 (2H, t By), 3.02 (2H, ri), 2.61 (2H, a, y - 6.9

Nzg), 1.87 (1Н, т), 1.81 (2Н, а ре, у - 14.0 Н2), 1.43 (2Н, т, У - 4.0, 13.0 Нз)

Compound number 80 (MR: 91). NMR solvent: SOSIZ 130:163.7 (da a, 94 - 12, 253.5 No), 162.1 (da, 94 - 11.0, 250.5 N?), 160.7 (a a, U - 12.0, 260.0

Ng), 158.2, 157.9 (a a, U - 12.5, 251.5 N?), 148.8, 146.2, 131.2 (d.a, U - 4.0, 10.0 No), 129.0 (a ru, y - 10.5 N?), 126.4 (d a, 7 - 4.5, 13.0 No), 114.2 (da, 9 - 4.0, 12.0 No), 111.68 (4 a, 9 - 3.0, 22.5 H2), 111.6 (9 a, 9 - 4.0, 21.5 Ng ), 104.9 J, U - 25.3 H7, 2 Saibopv), 40.0 1H: 8.89 (1H, 5), 7.84 (1H, Bi), 7.26 (1H, t), 6.98-6.77 (AN, t), 3.51 (ZN , 5)

Compound number 81 (MR: 99-100). NMR solvent: SOSIZ 130: 150.4, 149.4, 144.9, 132.9, 132.2, 129, 126.7, 124.9, 119.7, 113.1, 112.5, 40.5, 40.4 1H: 8.03 (1H, 9, U - 8.04 (1H, 8) , U - 8.4 Nzg), 7.59 (1Н, т, у - 7.8 Но), 7.41 (1Н, и, 7.6 Н2), 7.03 (2Н, рі), 6.59 (2Н, a horn, У - 8.0 Н2г), 3.62 (ZH, 5), 2.92 (6H, 5)

Compound number 82 (MR: 179-182 (des)). NMR solvent: OMBO 130: 148.6, 144.7, 132.5, 129.6, 125.5, 119.7, 113.4, 61.7, 49, 46, 43.5, 25.8, 22.5, 21.6

Coo) 1H: 10.52 (IN, 5 bi), 8.20 (IN, a, U - 8.3 No), 7.93 (IN, y, U - 68.4 No), 7.71 (IN, her, y - 7.7 NO), 7.55( 1H,, y - 7.7 No), 4.43 (2H, and ri, y - 13.5 No), 3.52 (IN, t), 3.41 (2H, a g, y - 11.5 N?g), 3.23 (2H, b) , 2.94 (2H, t, y - 12.0 Ng), 2.25 (2H, Bi), 1.88 (2H, bi), 1.86 (4H, t), 1.71 (IN, t, U - 14.0

Ng), 1.40 (1H, t)

Compound number 83 (MR: 259-261 (des)). NMR solvent: OMBO 130: 148.8, 144.8, 132.5, 129.8, 125.7, 119.7, 113.6, 51.9, 43.3, 42 1Н: 11.59 (IN, 5 Bi), 8.22 (IN, I, U - 8.3 No), 7.96 (1Н , а, У - 68.3 Но), 7.73 (IN, her, у - 7.8 Н2), 7.56 (IN, her, У - 7.6 Но), 4.47 (2Н, т), 3.71 (2Н, т), 3.52 (2Н , t), 3.29 (2Н, t), 2.81 (ЗН, 5)

Compound number 84 (MR: 92). NMR solvent: SOSIZ 130:155.9, 150.4, 148.7, 145.2, 138.4, 132.6, 129.5, 125.3, 121.8, 119.9, 119.5, 113.5, 37.8 1n:8.32 tn, aa, o - 1.6, H1, 5.0 a, U - 8.3 Н?2), 8.02 (1Н, и, У - 8.3 Но), 7.69 (1Н, и,

U - 1.9, 7.9 Ng), 7.63 (IN, 1, U - 7.8 N?), 7.AB (1N, U - 7.7 No), 718 (1N, a, o - 8.1 NN), 715 Na a, 9 - 5.0, 7.5 Nzg), 3.74 (ZN, 5)

Compound number 85 (MR: 66). NMR solvent: SOSIZ 130: 149.2, 146.2, 141.8, 131.6, 129.9, 128.4 (2 5 id.), 125.9, 125.4, 120, 113.9, 40.3, 35.4, 29.1, 28.5 1H: 8.29 (1H2, 8.3, t ), 8.10 (1H, t, y - 8.4 Nz), 7.63 (IN, t, y - 1.0, 7.1 Nz), 7.47 (1H, t,

U - 1.0, 7.1 Nl), 7.33 (1H, Bi), 7.30 (2H, t), 7.20 (2H, t), 7.19 (1H, t), 3.58 (2H, t), 2.71 (2H, t, y - 7.0 H2g), 1.77 (4H, t)

Compound number 86 (MR: 60). NMR solvent: SOSIZ 130: 149.2, 146.3, 131.6, 129.9, 125.3, 119.9, 114, 40.5, 31.9, 29.6, 29.6, 29.5, 29.5, 29.3, 29.2, 26.8, 22.7, 1:9, Н1, 1441 - 8.3 N?), 8.10 (1H, a, U - 8.4 H2g), 7.63 (1H, t, y - 1.0, 7.1 Ng), 7.47 (1H, t, U - 1.0, 7.1 No), 7.33 (1H, гг, У - 5.0 Nzg), 3.55 (2Н, т), 1.71 (2Н, т), 1.50-1.15 (18Н, т), 0.88 (ЗН, 1,

At -7. N?d)

Compound number 87 (MR: 73). Solvent NMR: SOSIZ 130: 148.4, 146.3, 131.7, 129.8, 125.3, 119.9, 114, 49.8, 33, 25.3, 24.7 1H: 8.28 (IN, y, U - 8.4 No), 8.09 (1H, y, U - 8.4 No), 7.63 (1H, 1, U - 7.8 Ng), 7.A7 (1H, I, yu - 7.6

Ng), 7.21 (1H, a, U - 7.5 Ng), 3.95 (1H, t), 2.11 (2H, t), 1.83 (2H, t), 1.69 (1H, t), 1.43 (4H, t), 1.29 (1H, t) 60 Compound number 88 (MR: 186-188). NMR solvent: SOSIZ

130: 146.5, 146.4, 140.2, 138.2, 135.3, 131.6, 130.3, 128.8, 128, 127.4, 126.9, 125.8, 120.3, 120.2, 114. ), 8.16 (IN, y, U - 68.5 Nl), 7.78 (2Н, а, у - 8.6 Н2), 7.69 (IN, t), 7.68 (2Н, а, У - 68.6 Ng), 7.62 (2Н, а , U. - 7.7 No), 7.53 (1H, her, U - 7.8 No), 7.47 (2H,. 1.9 - 7.7

Ng), 7.37 (IN, Her U - 7.6 N?)

Compound number 89 (MR: 167 (aes)). NMR solvent: SOSIZ 130: 148.1, 146.8, 129.3, 129, 128.8, 125.9, 120.9, 66.6, 48.5, 45.8 1Н: 8.38 (1Н, 5), 7.88 (2Н, y, y - 8.2 Nz), 7.47 (2Н, 1, y -.7.7 INg), 7.39 (1H, t, y - 7.5 N?g), 4.04 (2H, t Bi), 3.84 (6H, t)

Compound number 90 (MR: 230-231 (des)). Solvent NMR: OMBO 130: 148.6, 144.7, 132.5, 129.6, 125.6, 119.7, 113.4, 63.3, 61.9, 48.3, 45.6, 43.6, 25.8 1H: 11.53 (IN, 5 bi), 8.20 (IN, 8.3, U - No), 7.93 (1H, a, U - 8.2 Nz), 7.71 (1H, t, y - 7.5 H2), 7.55 (1H, t, U - 7.6 Ng), 4.44 (2H, a ri, y - 12.5 No ), 3.98 (2H, a ry, y - 11.5 Ng), 3.90 (2H, 1, U - 12.0 H2), 3.54 (1H, t), 3.45 (2H, a ry, y - 12.0 Ng), 3.22 (2H , Bi), 3.11 (2H, t), 2.28 (2H, BI), 1.90 (2H, t, U - 4.0, 12.3 H2)

Compound number 91 (MR: 143). IMR solvent: OMBO 130: 152.5, 148.7, 145.1, 144.7, 137.5, 132.6, 129.6, 128.4, 127.8, 127.6, 125.5, 119.7, 118, 115.4, 113.4, 69.4, 49.8, 49.8 , U - 8.4 No), 7.96 (1H, y, U - 8.4 Nz), 7.71 (1H, y - 7.6 No), 7.55 (1H, 1, U - 7.5

Nz), 7.43 (2H, y, U - 8.0 No), 7.38 (2H, y) - 7.7 No), 7.91 (1H, t, U - 7.1 Nl), 6.94 (AN, t), 5.03 (2H, 5 ), 3.90 (4H, t), 3.19 (4H, Bi)

Compound number 92 (MR: 218-220 (des)). NMR solvent: OMBO 130: 148.7, 144.8, 132.5, 129.6, 125.5, 119.7, 113.4, 60.2, 50.5, 45.7, 43.2, 27.9, 22.7 1Н: 11.24 (1Н, 5), 8.20 (1Н - Н, 8.2 U ), 7.93 (1H, a, U - 8.3 No), 7.70 (1H, her, y - 7.7 Nz), 7.54 (IN, y - 7.4 No), 4.40 (2H, a re, U - 13.0 H2), 3.49 (2H, Bi), 3.45 (1H, t), 3.22 (2H, t Bi), 3.08 (2H, ro), 2.20 (2H, bi), 1.96 (4H, t), 1.89 (2H, t)

Compound number 93 (MR: 254-256 (des)). NMR solvent: OMBO 130: 148.8, 144.8, 132.5, 131.5, 129.8, 129.6, 129.4, 128.8, 125.7, 119.7, 113.6, 58.6, 50.1, 43.6, 4241

So 1H: 11.97 (1H, 5 Bi), 8.21 (IN, a, U - 8.4 No), 7.95 (1H, a, 9 - 6.3 Nl), 7.67 (2H, t), 7.56 (IN, 1, U - 7.7 NO), 7.47 (ZN, t), 7.33 (IN, her, y - 7.6 No), 4.47 (2H, and g, y - 15.0 Nl), 4.39 (2H, 5), 3.79 (2H, t), 3.43 (2H, t), 3.28 (2H, t)

Compound number 94 (MR: 109-111). NMR solvent: SOSIZ 130: 149.4, 145.4, 144.7, 133.2, 129.3, 128.6, 126.8, 126.6, 125.2, 119.8, 113.5, 48.8, 46.1, 42.6, 33.2 1Н: 8.12, Т. (1H, t, y - 8.4 Nz), 7.63 (IN, t, y - 1.0, 7.1 Nz), 7.47 (1H, t,

У - 1.0, 7.1 Nl), 7.35 (2Н, т, у - 7.7 Но), 7.27 (2Н, т), 7.25 (1Н, т), 4.70 (2Н, and g, у - 13.5 Н2), 3.29 (2Н , Bi), 2.89 (1H, t), 2.01 (4H, t)

Compound number 95 (MR: 157). NMR Solvent: SOSIZ 130: 150.2, 145.9, 141.5, 136.4, 133.2, 131.8, 131.1, 131, 129.9, 128.7, 118.6, 118, 114.4, 113.2, 58.6, 57.2, 32.6 (1H, Bi), 8.09 (1H, a, U - 68.6 N?), 7.90 (1H, a d, U - 7.9 N?), 7.80 1H, yes, 9 - 1.6, 8.7

Nzg), 7.70 (1H, a, y - 7.6 Ng), 7.62 (IN, Her, U - 7.7 No), 4.29 (1H, t bi), 3.21 (ZN, 5), 2.02 (2H, t bi), 1.90 (2H, t Bi), 1.73 (IN, ry), 1.64 (2H, t), 1.46 (2H, t), 1.17 (IN, t)

Compound number 96 (MR: 146-147). NMR solvent: SOSIZ 130: 162.6 (a, U - 247.0 Nl), 150.3, 146, 137.9, 136.3 (0, U - 3.0 Nl), 132.7, 129.1 (a, U - 8.4

Nzg), 129.0, 117.4, 115.9 (a, U - 22.0 No), 113.8, 58.6, 57.2, 32.7, 30.4, 29.6, 25.5, 25.3 1nH: 8.21 (IN, ro), 8.03 (1H, a, U - 8.5 Но), 7.80 (1Н, а а, у - 1.5, 8.5 N?g), 7.62 (2Н, та, у - 5.3, 8.7 Nг), 7.19 (2Н, her, У - 8.5 Н2g), 4.27 (1Н, t Big), 3.20 (ZH, 5 Big), 2.01 (2H, t), 1.89 (2H, t), 1.73 (IN, t), 1.64 (2H, t), 1.44 (2H, t), 1.17 (IN , t)

Compound number 97 (MR: 158). NMR solvent: SOSIZ 130: 149.9, 146.3, 132.4, 132.3, 122.4, 118.3, 114.9, 58.8, 57.1, 32.6, 30.9, 29.5, 25.5, 25.3 1H: 8.25 (1H, ri, Ug - 7.0 NIN) , y, U - 6.8 N?), 7.68. 1H, a a, y - 2.0, 8.8 H?), 4.27 (IN, t

Bo), 3.18 (ZH, 5), 1.98 (2H, t), 1.89 (2H, t), 1.70 (1H, t), 1.61 (2H, t), 1.45 (2H, t), 1.17 (IN, t )

Compound number 98 (MR: 93-94). NMR solvent: SOSIZ 130: 148.8, 145.1, 133, 129.2, 125.2, 119.7, 114.3, 50.3, 48.5, 26.6, 24 1Н: 8.18 (1Н, т, у - 8.4 Н2), 8.09 (1Н, т, У - 8.3 Nz), 7.60 (1H, t, y - 1.0, 7.0 Nz), 7.46 (1H, t,

U - 1.0, 7.0 H2g), 4.08 (2H, t), 3.81 (2H, t), 2.04 (AN, t)

Compound number 99 (MR: 139-141). NMR solvent: SOSIZ

130: 154.7, 149.4, 145.4, 133.2, 130.7, 130.1, 129.3, 125.2, 119.8, 116.2, 113.5, 70.9, 44.4, 41.9, 30.4, 20.5. , a, y - 8.4 Ng), 7.62 (IN, i, y - 7.8 No), 7.46 (IN, her, U - 7.6

Hg), 7.12 (2H, t, y - 8.5 No), 6.87 (2H, t, y - 8.5 No), 4.66 (1H, t), 4.0 (4H, t), 2.31 (ZH, 5), 2.10 ( AN, t)

Compound number 100 (MR: 80). NMR solvent: SOSIZ 130: 149.3, 145.3, 142.1, 133.2, 129.2, 128.4, 128.3, 125.8, 125.1, 119.8, 113.4, 48.4, 45.8, 38, 35.4, 32.8, 32.2, 18, НО, No), 7.98 (1H, y, U - 8.3 No), 7.61 (1H, 1, U - 68.0 Ng), 7.46 (1H, 1, yu - 7.8

Nzg), 7.31 (2H, U - 7.1 NO), 7.21 (1H, t), 7.20 (2H, y, y - 7.9 No), 4.53 (2H, a ry, U - 12.0 H2), 3.15 (2H, Bi ), 2.69 (2H, t, y - 7.5 H2g), 1.93 (2H, Bi), 1.49 (2H, BI), 1.67 (ZH, t)

Compound number 101 (MR: 134). NMR solvent: SOSIZ 130: 150.7, 150.5, 142.6, 137, 132.8, 129.3, 128.7, 127.7, 125.2, 121.1, 116.9, 112.9, 49.5, 46.5 1H: 7.91 (1H, 2 - 5), Х, 7.8. 7.9 Ng), 7.51 (1H, 5), 7.42 (2H, 1, y - 7.8 Nz), 7.32 (ZH, t), 6.96 (ZH, t), 3.83 (4H, t, y - 5.0 Nzg), 3.29 (4Н, т, У - 5.0 Н2)

Compound number 102 (MR: 122). NMR solvent: SOSIZ 130: 150.6, 142.4, 137.1, 137, 132.8, 129.1, 128.7, 128.4, 127.6, 127.4, 125.1, 113, 62.7, 52.5, 46.5 , 7.80 (2H, y, U - 8.0 H2), 7.47 (IN, 9, U - 1.3 No), 7.41 (2H, 1, - 7.8

Nz), 7.34 (4H, t), 7.32 (1H, t), 7.29 (1H, t), 3.67 (4H, t, y - 5.0 Ng), 3.58 (2H, 5), 2.55 (4H, t, y - 5.0 Ng)

Compound number 103 (MR: 154). NMR solvent: SOSIZ 130: 151.3, 142.1, 136.9, 133, 128.7, 127.5, 125.1, 113.2, 57.5, 31.3, 30, 25.4, 25.2 1H: 7.92 (1H, y, U - 1.0 Nz), 7.81 (2H , U - 8.2 Nz), 7.50 (IN, a, U - 1.0 Ng), 7.41 (2H, 1.0) - 8.0

Hg), 7.29 (1H, her, y - 7.5 No), 3.96 (1H, t), 2.99 (ZH, 5), 1.86 (4H, t), 1.70 (IN, and BI, y - 13.5 Н2), 1.58 (2H, t, y - 3.5, 13.1 No), 1.38 (2H, t), 1713 (1H, ha, y - 3.5, 13.0 Ng)

Compound number 104 (MR: 83). NMR solvent: SOSIZ 130: 150, 145.2, 133.3, 129, 125, 119.7, 113.5, 58.9, 40, 31.2, 25.7, 25.3, 15.1 1H: 8.10 (1H, a, U - 8.3 No), 7.97 (1H, 9 , U - 8.3 Ng), 7.59 (1H, t, y - 1.0, 7.1 Ng), 7.45 (1H, t, U

Zo -1.0,7.1 No), 4.17 (1H, t), 3.63 (2H, t, U - 6.6 No), 2.02 (2H, and horn, U - 12.0 No), 1.85 (2H, and Bi, - 12.0 Н2 ), 1.69 (ZH, bi), 1.31 (5H, Bi), 1.17 (1H, t)

Compound number 105 (MR: 204). NMR solvent: SOSIZ 130: 149.2, 145.3, 133, 129.3, 125.2, 119.7, 113.4, 53.5, 53.1, 48, 45.4, 33.5, 31.7 (2 5id.), 23.3 1Н: 12.38 (1Н, 507 Bi), 8. IN, а, У - 8.3 Ng), 7.94 (IN, а, У - 68.4 Но), 7.59 (1Н, 1, У - 7.7 Н2), 7.44 (1Н, У - 7.5 Но), 4.52 (2Н, а г , y - 12.0 Nl), 3.79 (2H, Bi), 3.15 (2H, Bi), 3.12 (2H, t), 2.79 (2H, t Bi), 2.24 (2H, t bi), 2.08 (2H, t bi ), 1.90 (BN, t bi), 1.50 (2H, t bi)

Compound number 106 (MR: ой). NMR solvent: SOSIZ 130: 162.9 (0, U - 248 N?), 150.5, 144.6, 141.7, 136.3 (y, U - Z No), 133.9, 129.4 (y, 9 - 8 H2), 125.1, 119.9, 115.8 (9, 9) - 21.5 Ni), 111.5, 58.9 (horn), 57.0 (ri), 32.6 (ri), 30.6 (Bri), 29.7 (ri), 25.5, 253 1H: 8.12 (2H, t), 7.66 -7.62 (ZH, t), 7.17 (2H, t, y - 8.7 Nzg), 4.28 (1H, bi), 3.19 (ZH, in Bi), 2.0 (2H, t Bi), 1.88 (2H, bg), 1.76-1.56 (ZN, Bi), 1.44 (2H, BI), 1.18 (IN, t Bi)

Compound number 107 (MR: 232-233). IMR solvent: OM5O 130: 167.2, 149.6, 145.5, 139.7, 136.9, 132.3, 131.8, 131.7, 129.5, 128.9, 128.6, 127.9, 117.3, 113.9, 56.9, 32.2 . bi), 3.08 (ZH, 5), 1.88 (2H, t), 1.80 (2H, t), 1.67 (2H, t), 1.60 (1H, t), 1.33 (2H, t), 1.16 (1H, Bi )

Compound number 108 (MR: 183). NMR solvent: SOSIZ 130: 169.2, 150.3, 145.9, 140.8, 137.7, 134.1, 132.9, 131, 129.3, 129, 126.7, 126.3, 117.7, 114, 58.8, 57.1, 25.6, 30.7 (1H, 5 Bi), 8.15 (1H, 5 bi), 8.04 (IN, a, U - 8.5 H2), 7.85 (1H, Bi), 7.83 (1H, t), 7.81 (IN, t), 7.56 ( IN, i, y - 7.8 Ng), 6.42 (1H, 5Bi), 6.12 (1H, 5B), 4.30 (1H, ry), 3.22 (ZH, 5), 2.03 (2H, t), 1.91 (2H , t), 1.76 (1H, t), 1.67 (2H, t), 1.47 (2H, t), 1.20 (1H, t)

Compound number 109 (MR: 209-210). Solution Solvent: OM5O 130: 167.7, 149.7, 144.2, 140.9, 139.3, 135.2, 133.4, 130.3, 129.3, 127.4, 126.5, 125.2, 120, 111, 58.3, 57.2, 32.2, 29.3 (1H, 9, U - 8.6 N?g), 8.26 (1H, with Bi), 8.22 (1H, 5 bi), 8.17 (1H, Bi), 7.94 (2H, t), 7.91 (1H, t), 7.61 (IN, her, U - 7.7 Nz), 7.53 (1H, 5 Bi), 4.03 (1H, Bi), 3.09 (ZH, 5), 1.89 (2H, t), 1.80 (2H, t), (510 ) 1.60 (1H, t), 1.36 (2H, t), 1.67 (2H, t), 1.16 (IN, t)

Compound number 110 (MR: 66-67). NMR solvent: SOSIZ 130: 149.3, 145.3, 142.3, 133.1, 129.2, 128.3, 128.3, 125.7, 125.1, 119.8, 113.4, 48.4, 45.8, 36, 35.9, 35.8, 32.2, 1, Н2, Н8, 1 - 8.4 No), 7.97 (1H, y, U - 8.3 No), 7.60 (1H, 1, U - 7.5 No), 7.45 (1H, U - 7.7

Nzg), 7.30 (2H, I, U - 7.8 No), 7.20 (1H, t), 7.19 (2H, y, U - 7.8 Nz), 4.51 (2H, t, ryu), 3.14 (2H, bi), 2.64 (2H, 1, y - 7.6 H2g), 1.86 (2H, t), 1.69 (2H, t), 1.64 (IN, t), 1.43 (2H, t), 1.38 (2H, t)

Compound number 111 (MR: 83). NMR solvent: OMBO 130: 161.4, 150.6, 148.4, 148.1, 130.2, 129.7, 129.1, 129, 126.4, 119.5, 115.9, 48.2, 45.7 1Н: 9.17 (1Н, 5), 8.09 (2Н, 1.5, т 7.2 Nl), 7.53 (ZN, t), 7.25 (2Н, 1, У - 7.6 Но), 6.99 (2Н, а, 1097-81 Н2), 6.83 (1Н, у) - 7.2 Но), 3.90 (4Н, Running), 3.30 (4H, t)

Compound number 112 (MR: 203). NMR solvent: ОМ5О 130: 167.6, 149.9, 140.1, 137.9, 137.7, 136, 132.6, 128.9, 128.3, 128, 127.1, 124.4, 115.6, 61.7, 52.1, 45.9 1Н1:Н2, а2, У.13 ), 8.09 (1H, 9, U - 1.2 H2), 7.98 (1H, 5 By), 7.91 (AN, t by), 7.36 (1H, 5

Bo), 7.33 (4H, t), 7.26 (1H, t), 3.56 (4H, t, U - 5.5 No), 3.53 (2H, 5), 2.47 (4H, t, U - 5.5 N?)

Compound number 113 (MR: 231-233 (des)). NMR solvent: OM5O 130: 167.6, 149.7, 142.8, 139.3, 138, 135.7, 132.6, 129.9, 128, 127.7, 126.2, 124.2, 115.6, 39.6 1H: 7.95 (1H, 54 U (2, 7. - 8.5 Ng), 7.74 (1Н, а, 9) - 1.0 Но), 7.72 (2Н, а, о - 8.5 Н2), 7.60 (IN, а, у - 1.0 Nl), 7.41 (2Н, У - 7.6 Ng), 7.35 (1H, 5 Big), 7.35 (2H, t), 7.91 (1H, her, U - 7.1 No), 3.43 (ZH, 5)

Compound number 114 (MR: 135-136). NMR solvent: ОМ5О 130: 153.8, 149.8, 148.7, 144.7, 132.6, 129.5, 125.4, 122.4, 119.6, 113.3, 47.7, 45.2, 40.5, 31.8 1Н: 8.50 (2Н, t.0, Н2 - 8.5, Н2). , y, U - 8.5 No), 7.95(1H, io, U - 6.3 Ng), 7.71 (1H, 1, U - 7.9

Ng), 7.54 (IN, y - 7.7 Ng), 7.34 (2H, t, U - 5.0 H2), 4.39 (2H, Big), 3.32 (2H, Bi), 2.96 (1H, t), 1.95 (2H, Bi), 1.82 (2H, t, y - 4.0, 12.3 H?)

Compound number 115 (MR: ой). Solvent NMR: SOSIZ 130: 150.5, 145.2, 138.1, 133.2, 129.1, 128.7, 128.6, 126.6, 125.1, 119.7, 113.8, 53.1 (Big), 38.2 (meg Bgoad), 34.3 (ri) 08 (H: 18) , U - 8.3 Nz), 7.91 (1H, royu), 7.57 (IN, her, y - 7.7 No), 7.44 (1H, her, y - 7.7 Nz), 7.23

Koo) (BN, Bi), 3.96 (2H, Big), 3.91 (ZH, 5), 3.10 (2H, t, y - 7.2 Nz)

Compound number 116 (MR: 147). NMR Solvent: SOSIZ 130: 181.1, 166.4, 152.1, 149.4, 148.6, 145.4, 134.7, 133.1, 129.5, 125.3, 123.7, 122.9, 119.9, 113.5, 46.9, 44.2, ) - 1.7 Н2), 8.76 (1Н, и и, У - 1.6, 4.9 Н2), 8.37 (IN, а, У - 2.0, 8.0 Но), 812 (IN, а, - 8.4 Н?), 8.0 (IN , a, U - 8.4 Nz), 7.63 (1H, her, U - 7.9 No), 7.A8 (IN, 1, U - 7.9 No), 7.45 1H, aa, y - 4.9, 8.0 N?), 4.56 (2H, and Bi), 3.57 (2H, Bri), 3.46 (1H, t), 2.37 (2H, t), 2.27 (2H, t)

Compound number 117 (MR: 138-139). Solvent NMR: SOSIZ 130: 155.4, 149.4, 145.4, 133.1, 129.6, 129.4, 126.2, 125.2, 119.9, 117.4, 113.5, 71.2, 44.4, 42, 30.4 (1H, y, U - 8.2 No), 7.62 (1H, 1, U - 7.8 No), 7.47 (1H, I, - 7.8

Nzg), 7.27 (2H, t, y - 9.0 No), 6.89 (2H, t, y - 9.0 H2z), 4.67 (1H, t), 4.01 (4H, 5 Bi), 2.15 (2H, t), 2.06 (2H, t)

Compound number 118 (MR: ой). NMR solvent: SOSIZ 130: 150.5, 142.5, 141.0, 133.2, 129.2, 128.5, 128.2, 126.1, 125.1, 119.8, 113.6, 51.4, 50.4, 38.1, 35.8, 32.9, Н, 1, 28.1, 29.6 -8.5 H2), 8.01 (IN, 9, U - 8.2 Nz), 7.61 (IN, i, U - 7.9 No), 7.46 (IN, 1, y - 7.7

Nzg), 7.24 (BN, Big), 3.71 (2H, t, y - 7.2 No), 3.31 (ZN, Bi), 2.71 (2H, Bi), 2.15 (2H, t, y - 7.5 N?)

Compound number 119 (MR: ой). NMR solvent: SOSIZ 130: 160.1, 151.0, 145.3, 137.4, 133.3, 129.9, 129.3, 125.2, 120.3, 119.9, 113.7 (2 via.), 113.4, 55.3, 54.2, 37.5, 1H, 1, 8, 8 No), 8.06 (IN, y, U - 8.3 No), 7.62 (1H, 1, y - 7.8 No), 7.47 (1H, U - 7.5

Nzg), 7.30 (1H, her, y - 7.7 No), 6.96 (2H, bi), 6.87 (1H, y, y - 8.2), 4.89 (2H, bi), 3.81 (ЗН, 5), 3.29 (ЗН , would)

Compound number 120 (MR: 70-71). NMR solvent: SOSIZ 130: 156.9, 149.4, 145.4, 133.2, 129.7, 129.3, 125.2, 121.3, 119.8, 116.1, 113.5, 70.6, 44.4, 42, 30.4 1Н:8.11 (IN, 8.3, Нг), Г (1H, a, 9 - 8.3 Ng), 7.62 (IN, her, U - 7.8 No), 7.47 (IN, 1, U - 7.6

Nz), 7.33 (2H, t, y - 8.0 Ng), 7.0 (IN, her, y - 7.4 No), 6.97 (2H, y, y - 8.3 H2), 4.72 (1H, t), 4.01 (4H, 5 Run), 2.16 (2H, t), 2.10 (2H, t) because Compound number 121 (MR: 115). NMR solvent: SOSIZ

130. 52.7. ) (2H, 5), 2.63 (4H, 5 Bi)

Compound number 122 (MR: 188 (AES)). NMR solvent: ОМ5О 130: 148.6, 144.7, 132.5, 129.5, 125.4, 119.6, 113.3, 59.7, 52.9, 46.5, 45.6, 44.1, 42.1, 27.9 1H: 10.72 (1H, ri -, 8.19 U (IN) 8.4 H2), 7.91 (1H, a, U - 8.3 No), 7.70 (1H, 1, y - 7.9 H2), 7.53 (IN, y - 7.8 No), 4.28 (2H, 5 Big), 3.21 (4H, t Bi), 2.96 (4H, t bi), 2.68 (6H, t), 1.90 (2H, t bi), 1.57 (2H, t Bi)

Compound number 123 (MR: ой). NMR solvent: SOSIZ 130: 151.0, 145.2, 137.9, 134.7, 133.2, 130.1, 129.5, 128.2, 127.9, 126.2, 125.3, 119.9, 113.7, 54.8, 53.4, 37.8, 1H1, 18, 15, Н18, Н2 . BI), 7.32 (ZN, Bi), 4.90 (2H, ry), 3.28 (ZN, Bi)

Compound number 124 (MR: 258-259 (des)). NMR solvent: OM5O 130: 161.6, 148.4, 148.3, 131.5, 130.3, 129.6, 129.5, 129.1, 129, 128.8, 126.5, 58.6, 50, 42.6 1H: 12.03 (1H, 5Bi (1H, 9.16), 8.07 (2H, t), 7.67 (2H, t), 7.51 (ЗН, t), 7.45 (ЗН, t), 4.55 (2Н, t), 4.38 (2Н, 5), 3.73 (2Н, t, 12.0 Ng), 3.41 (2H, ri, y - 11.7 N2g), 3.24 (2H, t)

Compound number 125 (MR: 232 (des)). IMR SOLUTHER: OMB5O 130: 161.4, 159.9, 148.4, 148.2, 136.8, 131.5, 129.6, 129.5, 128.8, 128.5, 128.1, 128, 128, 127.9, 122.2, 115.2, 69.4 ), 9.12 (IN, 5), 8.0 (2H, a, U - 8.6 Ng), 7.66 (2H, t), 7.45 (5H, t), 7.40 (2H, 1.9 - 7.5 Ng), 7.33 (1H , U - 7.2 NI), 7.15 (2H, y, U - 68.6 Nzg), 5.17 (2H, 5), 4.55 (2H, t), 4.37 (2H, 5), 3.70 (2H, t, y - 12.0 N2g ), 3.41 (2H, t), 3.24 (2H, t)

Compound number 126 (MR: 135). Solvent NMR: SOSIZ 130: 147.3, 146.3, 131.6, 129.7, 125.2, 119.9, 114.1, 52.8, 41.6, 36.1, 29.4 1H: 8.27 (1H, a, U - 8.4 No), 8.09 (1H, a, U - 68.4 No), 7.61 (1H, t, U - 1.0, 7.0, 8.0 H2g), 7.45 (IN, t, U - 1.0, 7.0, 8.0 H2g), 7.17 (1H, 5), 2.20 (9H, 5), 1.76 (6H, 5)

From Complex number 127 (MR: 101). NMR solvent: OMBO 130: 148.6, 144.7, 132.5, 129.5, 125.5, 119.7, 113.3, 62.6, 48.4, 45.2, 28.3, 25.9, 25.4 1H:8l18 (IN, a, y - 8.2 No), 7.91 (IN, y , U - 8.5 No), 7.69 (1H, 1, U - 7.8 No), 7.56 (IN, i, y - 7.6

Nzg), 3.71 (AN, t), 2.63 (4H, 5 Bi), 2.30 (IN, t), 1.76 (2H, t), 1.73 (2H, t), 1.56 (1H, y, U - 12.4 Н2) , 1.20 (4H, t), 1.07 (1H, t)

Compound number 128 (MR: ойЙ). NMR solvent: SOSIZ 130: 149.4, 145.3, 138.4, 133.1, 129.3, 128.5, 127.7, 127.4, 125.1, 119.8, 113.5, 72.5, 70.1, 44.9, 42.3, 30.9 1H6, 8 uLO (1H6, 8 uLO) . 4.62 (2H, 5), 4.06 (2H, t), 3.81 (ZH, t), 2.08 (2H, t), 1.94 (2H, Bi)

Compound number 129 (MR: ой). NMR solvent: SOSIZ 130: 150.5, 145.2, 142.3, 133.2, 129.2, 128.4, 128.3, 125.7, 125.1, 119.7, 113.6, 51.8, 50.6, 38.0, 35.68, 31.1, 28, 28.0 . y - 7.7 No), 7.17 (ZN, t), 3.66 (2H, t), 3.31 (ZN, bi), 2.64 (2H, Bi), 1.82 (2H, t, y - 7.7 Ni), 1.71 (2H, Bi), 1.47-1.31 (2H, meg rhoad)

Compound number 130 (MR: оийЙ). NMR solvent: SOSIZ 130: 162.4 (y, 9 - 247 N?), 150.9, 145.2, 133.2, 131.5 (y, Y - Z Hl), 129.9, 129.4, 125.3, 119.9, 115.8 (9, Y - 22 NI) . .

Compound number 131 (MR: ой). Solvent NMR: SOSIZ 130: 150.9, 145.2, 133.9, 133.2, 130.9, 129.4, 128.9, 126.8, 126.1, 125.3 (2 Nav), 123.1, 119.9, 113.6, 53.1, 51.7, 1:37.5, H-4, Н-37.5 t), 7.98-7.82 (2H, t), 7.65 (IN, aa a, y - 1.1, 7.0, 8.0 Nz), 7.60-7.45 (4H, t, ro), 7.48 1H, aa, y - 1.0, 7.0 , 8.0 H2g), 5.38 (2H, t run), 3.28 (ZN, in Bi)

Compound number 132 (MR: 129-130 (des)). NMR solvent: ОМ5О 130: 161.3, 154.6, 150.6, 148.5, 147.6, 130, 129.6, 127.4, 120.8, 115.9, 115.5, 71.1, 51.8, 44.7, 43, 41.9, 30.15, 20.

1H: 11.17 (1H, 5), 9.05 (1H, 5), 7.92 (2H, y, y - 7.8 Ng), 7.11 (2H, a, Y - 7.8 Ng), 7.08 (2H, a, - 7.6 H2) . 3.17 (4H, t), 2.79 (ZN, 5), 2.22 (ZN, 5), 2.05 (2H, 5 Bi), 1.74 (2H, Bi)

Compound number 133 (MR: 140). NMR solvent: ОМ5О 130:161.7, 152.1, 148.6, 147.7, 138, 129, 128.3, 127.4, 127.1, 119.5, 114.7, 65.9, 62, 52.4, 47.4, 46.2 1Н: 9.04 (2, 1Н, 8). y, 9 - 8.2 Nl), 7.33 (4H, bi), 7.27 (1H, Bi), 7.02 (2H, a, U - 8.2 H2), 3.75 (4H, t Bi), 3.70 (4H, t Bi), 3.52 (2H, Bi), 3.23 (4H, Bi), 2.50 (4H, Bi)

Compound number 134 (MR: ой). NMR solvent: OMBO 130: 163.1 (a a, 9 - 13.5, 251.5 Nl), 160.1 (a a, 9) - 13.0, 257.5 No), 157.1 (a, 9 - 6 Nzl), 154.6, 148.2, 147.4, 131.6 (yes, 9 - 4.5, 10.5 No), 130.0, 129.6, 116.0, 114.6 (a a, U - 4.0, 11.5 No), 112.3 (a 9, U - 4.0, 22.0 No), 105.3 (1, U - 25.5 No), 71.1, 43.1 (horn), 30.3, 20.1 1H: 9.17 (IN, 5), 8.12 (1H, 1, y - 6.7, 8.6 No), 7.43 (IN, ad a, o - 2.5, 9.4, 11.5 N?), 7 26. IN, a

Its U - 2.5, 8.5 Nl), 7.08 (2H, y, U - 8.4 No), 6.89 (2H, a, y - 8.4 Ng), 4.64 (1H, t, y - 3.7 N?), 3.93 (2H, t Bi), 3.61 (2H, t bi), 2.22 (ZN, with Bi), 2.05 (2H, t), 1.73 (2H, t)

Compound number 135 (MR: ой). NMR solvent: SOSIZ 130: 149.4, 145.3, 141.8, 133.1, 129.3, 128.4, 128.3, 125.8, 125.1, 119.8, 113.4, 73.0, 67.3, 45.0, 42.4, 32.3, 31.5 - 8.4 No), 7.98 (1H, y, U - 8.3 No), 7.61 (1H, 1, y - 7.7 No), 7.A6 (1H, y - 7.5

Nzg), 7.30 (2H, her, y - 7.9 H2), 7.21 (ZH, t), 4.04 (2H, t), 3.77 (2H, t), 3.66 (1H, t, y - 3.4 Ng), 3.50 ( 2H,, U - 6.3 Ng), 2.74 (2H, 1, U) - 7.9 Ng), 2.02 (2H, t), 1.94 (2H, t), 1.85 (2H, t)

Compound number 136 (MR: 197-198). NMR solvent: OMBO 130:151.5, 148.7, 144.7, 143.7, 132.6, 129.6, 125.5, 119.7, 118.6, 115.6, 113.4, 50.3, 47.4, 45.2 1Н: 8.95 (1Н, 5 (1Н - У, 8.2) 8.3 N?), 7.95 (1H, y, U - 8.4 Ng), 7.71 (1H, y - 7.7 Ng), 7.55 (IN, U - 7.7 Ng), 6.85 (2H, t, y - 9.0 Nzg), 6.68 (2H, t, U - 9.0 No), 3.89 (4H, t Bi), 3.12 (AN, t)

Compound number 137 (MR: 100-101). NMR solvent: SOSIZ 130: 154.4, 150.8, 149.4, 145.4, 133.1, 129.3, 125.2, 119.8, 117.8, 114.8, 113.5, 72, 55.7, 44.5, 41.9, 30.5 1Н1:Н2, а8, 11У , 8.0 (1H, a, U - 6.6 Ng), 7.62 (IN, a, U - 7.6 Ng), 7.47 (1H, t, y - 7.8

Zo H2g), 6.92 (2H, t, y - 9.2 Nl), 6.86 (2H, t, y - 9.2 Nz), 4.57 (1H, t), 3.99 (4H, t bi), 3.79 (ZH, 5), 2.09 (4H, t)

Compound number 138 (MR: 187-188). NMR solvent: ОМ5О 130:161.5, 151.9, 150.9, 149.8, 147.4, 129, 127.4, 120, 119.3, 115.7, 115, 48.2, 47.5, 37.8 1Н: 9.02 (1Н, 5), 7.92 (2Н, t 9.0 Н2), 7.25(2Н, аа, у - 7.3, 8.5 Но), 7.11 (2Н, т, У - 9.0 Н2), 7.0 (2Н, а, у - 8.5 Но), 6.81 (1Н, и, у - 7.3 No), 3.38 (4H, t), 3.29 (4H, t), 3.16 (6H, 5 Big)

Compound number 139 (MR: 161-162). NMR solvent: OM5O 130: 161.7, 152, 148.6, 147.7, 127.4, 119.5, 114.7, 65.9, 54.4, 47.2, 46.3, 45.7 1H: 9.04 (1H, 5), 7.89 (2H, t, y - 9.0 Nl), 7.03 (2H, t, y - 9.0 Ng), 3.75 (AN, Bi), 3.70 (4H, t), 3.23 (4H, t, y - 5.0 N?g), 2.47 (AN, t, U - 5.0 No ), 2.23 (ZN, 5)

Compound number 140 (MR: 167-168). Solvent NMR: SOSIZ 130: 161.8, 161, 156.4, 149.8, 147.2, 134.2, 128.8, 126.9, 120.3, 118.7, 118.4, 106.3, 39.3, 38.6 1Н: 8.84 (1Н, 2 - 5), Н, 18.1. 8.8 Ng), 7.64 (2H, y, U - 9.0 Nl), 7.15 (2H, y, U - 68.8 H2), 7.08 (2H, y, U - 9.0 Н2g), 3.41 (ЗН, 5), 3.23 (ЗН , 5)

Compound number 141 (MR: 144-145). NMR solvent: SOSIZ 130:162, 160.9, 156.6, 148.6, 147.6, 134.2, 128.9, 126.5, 120.3, 118.7, 118.4, 106.4, 66.6, 46.6 1Н: 8.85 (1Н, 5 (2Н - У, 8.1) 8.8 Nl), 7.64 (2H, y, U - 68.9 Ng), 7.15 (2H, y, U - 8.8 H2), 7.08 (2H, a, U - 8.9 H2g), 4.0 (8H, 5 Bi)

Compound number 142 (MR: 202-203). NMR solvent: ОМ5О 130: 149, 145.5, 131.4, 130.2, 125.8, 119.9, 113.6, 49.6, 45.7, 45.4, 45, 24.7, 21.4, 17.2 1Н: 10.72 (1Н, 5 ri), 9.55, У, 1Н - 6.8 Н2), 8.23 (1Н, y, У - 8.3 Н?), 8.18 (1Н, а, 9 - 8.2 Н2), 7.74 (1Н, т, У - 8.0 Нз), 7.57 (1Н, т, у - 7.6 Nzg), 4. AT (IN, t), 3.66 (1Н, и, у) - 11.5 Но), 3.40 (1Н, т), 3.20 (4Н, t), 2.30 (1Н, т), 2.12 (1Н , t), 1.94 (IN, t), 1.74 (1Н, t)

Compound number 143 (MR: 108-109). NMR solvent: SOSIZ 130: 150.6, 145.2, 133.2, 129.2, 125.1, 119.8, 113.5, 96.3, 70.3, 70, 57.9, 55.8, 32.6, 31, 30.2, 2611, 24.8, 2:2.6 1H, - 8.3 No), 7.98 (1H, y, U - 8.4 No), 7.61 (1H, 1, y - 7.5 No), 7.46 (1H, U - 7.6

Nzg), 4.37 (1H, Big), 3.53 (4H, 5), 3.18 (ZH, 5), 2.41 (2H, ri), 1.91 (4H, t), 1.53 (2H, Bi), 0.99 (6H, 5 )

Compound number 144 (MR: 67-68). NMR solvent: SOSIZ 130: 153.8, 152.9, 149.3, 145.3, 133.1, 129.2, 125.1, 119.8, 115.3, 114.6, 113.4, 65.6, 55.7, 48.4, 60 45.8, 25.16, 32

1Н: 8.11 (НН, т, У - 8.4 Н2), 7.98 (IN, y, У - 8.4 Нз), 7.61 (1Н, т, У - 1.0, 7.1, 8.1 Но), 7.46 (IN, т, У - 1.0, 7.1, 8.1 No), 6.85 (AN, 5), 4.55 (2H, and ri, U - 13.0 No), 4.01 (2H, 1, U - 6.2 H2), 3.78 (ZN, 5), 3.19 (2H , 5 Bi), 1.96 (ZN, t), 1.81 (2Н, ad, У - 6.2 Н2г), 1.52 (2Н, т)

Compound number 145 (MR: 179-180 (des)). NMR solvent: ОМ5О 130: 160.8, 160.4, 156.2, 148.3, 148.2, 147.9, 134.8, 129.4, 128.6, 126.3, 122.8, 120.4, 118.7, 117.7 (2 5 id.), 105.4, 19.1, H: 1.59, H. 5). 9, U - 8.6 N?g), 7.19 (2H, y, 9 - 8.4 Nz), 7.05 (1H, 1, y - 7.0 No), 4.05 (4H, ri), 3.46 (AN, t Bi)

Compound number 146 (MR: 192-193). NMR solvent: ОМ5О 130: 167.1, 160.8, 158.8, 157.4, 149.7, 147.7, 129.9, 129.6, 128.4, 125.6, 119.5, 118.1, 37.8 1Н: 9.10 (1Н, 5), 8.10 (2Н2 - 8, Н2 - 8, 8). ), 7.97 (1H, zv Bi), 7.93 (2H, a, U - 8.9 Nl), 7.35 (IN, v5 Bi), 7.20 (2H, a, y - 8.8 Nz), 7.11 (2H, a, U - 68.9 Nzo), 3.16 (6H, in Big)

Compound number 147 (MR: 220-221). NMR solvent: OMBO 130:167.1, 160.9, 158.7, 157.5, 148.5, 148.1, 129.9, 129.6, 128.5, 125.5, 119.5, 118, 65.9, 46.2 1Н: 9.13 (1Н, 52), Н, 8.10 8.8 HO), 7.98 (1H, with Bi), 7.93 (2H, a, U - 8.9 Nl), 7.36 (1IN, in Bi), 7.20 (2H, a, y - 8.8 Nz), 7.11 (2H, a, y - 68.9 Ng), 3.75-3.70 (8Н, t)

Compound number 148 (MR: 187-188). NMR solvent: OM5O 130: 167.1, 161, 158.7, 157.5, 150.6, 148.4, 148.1, 129.9, 129.6, 129.1, 128.5, 125.5, 119.5, 119.5, 118.1, 115.9, 48.9 8.12 (2H, y, U - 8.5 H2), 7.98 (1H, in Bi), 7.94 (2H, y, U - 68.6 Nz), 7.36 (1H, 5 Bi), 7.25 (2H, 1, U - 8.0 No ), 7.21 (2H, y, 7 - 8.5 No), 7.11 (2H, a, U - 8.5 H?), 6.98 (2H, a, 9 - 8.2 H2), 6.82 (1H, 1, U - 7.5 No) , 3.90 (4H, t), 3.29 (4H, t)

Compound number 149 (MR: 191-192). NMR solvent: OMBO 130: 167.1, 160.3, 158.6, 157.4, 148.7, 147.4, 143.2, 129.8, 129.6, 129.3, 128.1, 127.3, 126.1, 125.4, 119.2, 118.2), 1H, 5 Big), 7.92 (2H, a, 9 - 8.6 No), 7.75 (2H, a, y - 8.2 No), 7.37 (2H, 1 - 7.5 No), 7.35 (1H, with Bi), 7.32 ( 2Н, а, У - 68.0 Но), 7.28(1Н, 1, у - 7.0 Н2), 7.08 (2Н, а, У - 6.7 Н2), 7.07 (2Н, а, у - 8.7 Но), 3.49 (ЗН, in)

From Complex number 150 (MR: 91-92). NMR solvent: SOSIZ 130: 162.3 (a, U - 246.5 Nl), 151.8, 141.5, 137, 135.2, 129.1, 129.0 (0, U - 3.3 No), 128.2, 127.5, 126.8 (9, U - 8.0 Ng), 115.6 (d0, U - 21.5 No), 112.8, 54.1, 36.5 1H: 7.96 (1H, y, U - 1.3 No), 7.73 (2H, aa, 0 - 5.3, 8.9 Nzg), 7.49 (IN, y, U - 1.3 Nl), 7.43 (2H, t,

U - 7.5 Nz), 7.37 (1H, t, y - 7.2 Nz), 7.32 (2H, t, y - 8.1 Nz), 7.08 (2H, t i, U - 8.9 H2), 4.69 (2H, 5), 3.09 (ZN, 5)

Compound number 151 (MR: 143-144). NMR solvent: OM5O 130: 167, 160.9, 158.6, 157.3, 149.7, 147.7, 136.2, 129.6, 129.6, 128.5, 128.2, 127.5, 127.4, 125.4, 119.2, 117.9, 53.3. 8.05 (2H, a rg, U - 8.0 H2), 7.93 (2H, y, U - 68.5 H2), 7.87 (1H, 5 Bi), 7.40 (4H, t), 7.33 (IN, t), 7.21 (IN .

Compound number 152 (MR: 95-96). NMR solvent: SOSIZ 130: 150.5, 145.2, 138.7, 133.2, 129.2, 128.4, 127.5, 127.5, 125.1, 119.8, 113.5, 76.1, 70.1, 56.3, 32.6, 31, 27.0, 8:8, Н - АН, No), 7.98 (1H, y, U - 8.3 No), 7.60 (1H, her, U - 7.6 Ng), 7.46 (1H, 1, - 68.0

Nz), 7.40-7.33 (4H, t), 7.30 (1H, t), 4.58 (2H, 5), 4.30 (IN, t), 3.36 (1H, t), 3.16 (ЗН, 5), 2.24 (2H , a re, y - 10.0 No), 2.06 (2H, a re, 9 - 12.0 H2g), 1.72 (2H, t, y - 1.8, 13.0 Nz), 1.51 (2H, 5 Bi)

Compound number 153 (MR: 75). NMR solvent: SOSIZ 130: 160.8, 160, 149.4, 145.4, 133.2, 129.9, 129.3, 125.2, 119.8, 113.5, 106.5, 106.4, 100.9, 71.8, 55.3, 48.1, 45.1, 36.1. ) . )

Compound number 154 (MR: 129-130). NMR solvent: OM5O 130: 148.6, 144.7, 132.5, 129.6, 125.5, 119.7, 113.3, 66.4, 51.4, 47.7, 44.9, 29.8, 23.7 1H: 8.19 (IN, y, U - 8.4 Nl), 1 H, 7.91 (t , U - 8.4 Ng), 7.69 (1H, t, U - 1.0, 7.0, 8.0 H2), 7.53 (IN, t, y - 1.0, 7.0, 8.0 Ng), 3.73 (4H, t), 2.51 (1H, t), 2.50 (4H, t), 1.79 (2H, t), 1.61 (2H, t), 1.49 (2H, t), 1.34 (2H, t) because Compound number 155 (MR: 108). NMR solvent: SOSIZ

130: 158.9, 150.7, 148.4, 147.4, 132.4, 129.3, 127.9, 127.8, 127.7, 120.8, 116.7, 49.4, 46.4. 7.44 (1H, yes, - 1.2, 5.1 No), 7.33 (2H, yes, - 7.3, 8.8 H7), 7.15 (1H, and a, U - 3.7, 5.1 No), 6.98 (2H, t a, U - 68.8 No), 6.95 (1H, t, y - 7.3 Nzg), 4.11 (4H, Bi), 3.34 (4H, t, y - 5.2 N?)

Compound number 156 (MR: 66-67). NMR solvent: SOSIZ 130: 150.9, 145.2, 137.8, 133.2, 129.2, 128.4, 127.7, 127.5, 125.1, 119.7, 113.6, 73.2, 68.2, 51.5, 51, 39.7, 371, 83, 1Н - УLO No), 7.96 (1H, y, U - 8.0 No), 7.58 (1H, 1, U - 68.2 Ng), 7.A45 (1H, I, - 7.9

Nz), 7.30 (5H, t), 4.53 (2H, 5 Bi), 3.93 (2H, with Big), 3.85 (2H, 5 Bi), 3.41 (ZN, 5 Bi)

Compound number 157 (MR: ойЙ). NMR solvent: SOSIZ 130: 154.1, 152.3, 150.9, 150.8, 145.2, 133.2, 129.3, 125.2, 119.8, 115.3, 114.6, 113.7, 66.9, 55.7, 50.9, 40, 37.1, Х1, 37.1, У.1, У Hg), 8.03 (1H, y, U - 8.4 Ng), 7.61 (1H, t, y - 1.0, 7.1, 8.3 Но), 7.47 (IN, t, y - 1.0, 7.1, 8.3 H2g), 6.81 (4H )

Compound number 158 (MR: 257-259 (des)). NMR solvent: OMBO 130: 157.8, 148.2 (2 5 id.), 132, 131.5, 129.6, 129.4, 128.8 (2 5 id.), 128.3, 127.7, 58.6, 49.9, 42.6 1H: 11.94 (1H, 5 ri), 9.13 (1H, 5), 7.73 (2H, y, U - 4.0 H2g), 7.65 (2H, t), 7.46 (ZH, t), 7.20 (1H, y,

U - 4.2 Nl), 4.47 (2H, ri), 4.37 (2H, 5), 3.70 (2H, t, y - 12.5 Ng), 3.40 (2H, and p, y - 12.0 H2), 3.22 (2H, t )

Compound number 159 (MR: 143). NMR solvent: SOSIZ 130: 149.4, 145.3, 133.1, 129.3, 125.2, 119.8, 113.5, 66.4, 44.9, 42.4, 34 1H:8lLO (1H, a, U - 8.3 No), 7.98 (1H, y, U - 8.4 No), 7.61 (1H, 1, U - 8.0 No), 7.46 1H, 1, U - 7.7

Nzg), 4.16 (2H, t), 4.12 (1H, t), 3.69 (2H, t), 2.10 (2H, t), 1.80 (2H, t), 1.86 (1H, y, U - 3.8 Н2g)

Compound number 160 (MR: 78-80). NMR solvent: SOSIZ 130: 163.6, 149.2, 146.1, 143.3, 136.8, 129.5, 128.7, 128.3, 127.4, 126.5, 125.8, 40.3, 34.4 1Н: 8.52 (1Н, 5), 7.33 (Н2, 71), ЗН2 , t), 7.20 (1N, t), 7.11 (2Nn, and g, y - 8.0 Nl), 7.0 (gNn, and

B, U - 7.0 No), 3.86 (ОН, 5), 3.53 (ЗН, 5)

Compound number 161 (MR: 89). NMR solvent: SOSIZ

Zo 130: 146.5, 142.6, 136.2, 132.7, 128.7, 127.7, 125.2, 112, 81.1, 80.3, 61.8, 22.8 1H: 7.96 (1H, y, U - 1.3 Nz), 7.79 (2H, t, U - 68.3 No ), 7.52 (1H, y, U - 1.3 No), 7.41 (2H, t, y - 7.9 Nz), 7.30 (1H, t, y - 7.3 No), 5.13 (2H, 5), 3.88 (2H, 5 ), 1.62 (6Н, 5)

Compound number 162 (MR: 119-121). Solvent NMR: SOSIZ 130: 145.7, 144.1, 133.7, 129.3, 124.2, 120.8, 117.5, 82.4, 79.5, 62.4, 22.9 1Н: 8.48 (1Н, 5 Bi), 7.96 (1Н, y, U - 8.7 Но), 7.59 (1Н, и а, У - 1.5, 8.7 Nl), 5.53 (2Н, 5), 3.90 (2Н, 5), 1.68 (6Н, 5)

Compound number 163 (MR: 231-232). IMR solvent: OM5O 130: 167.6, 145.6, 144.3, 141.2, 139.3, 135.2, 133, 133, 130.3, 129.3, 127.5, 126.5, 125.6, 120.2, 111.7, 81.8, 78.7, 61.7. 8.30 (1H, a, U - 8.5 No), 8.26 (1H, Big), 8.22 (1H, 5 Bi), 7.94 (2H, t), 7.93 (IN, y,

U - 8.5 N2g), 7.62 (1H, 1, U - 7.6 Ng), 7.52 (1H, in ri), 5.46 (2H, 5), 3.91 (2H, 5), 1.60 (6H, 5)

Compound number 164 (MR: 102). NMR solvent: SOSIZ 130: 153.5, 150.9, 149.4, 145.3, 137.1, 133.1, 129.3, 128.6, 127.9, 127.5, 125.2, 119.8, 117.7, 115.8, 113.5, 71.5, 70.5, 70.5, . 8.2 Nz), 7.44 (2H, y, y - 7.0 Nl), 7.40 (2H, t, y - 7.4 No), 7.34 (1H, t, y - 7.1 Н2), 6.93 (AN, t), 5.04 (2Н , 5), 4.58 (IN, t), 3.99 (4H, Bi), 2.10 (4H, t Bi)

Compound number 165 (MR: 131). NMR solvent: SOSIZ 130: 153.8, 152.9, 149.4, 145.3, 133.1, 129.3, 125.1, 119.8, 115.3, 114.6, 113.4, 72.5, 55.7, 48.1, 45.5, 36.2, Н. 2941, 1:81, А3 No), 7.99 (1H, y, U - 8.4 No), 7.61 (1H, her, y - 7.8 No), 7.46 (IN, Her, U - 7.6

H2g), 6.85 (AN, 5), 4.61 (2H, and Big, y - 13.0 No), 3.85 (2H, y, U - 6.4 No), 3.78 (ZN, 5), 3.23 (2H, 5 Bi), 2.18 (IN, t), 2.03 (2Н, t), 1.62 (2Н, t)

Compound number 166 (MR: 87). NMR solvent: SOSIZ 130: 160.9, 158.1, 149.4, 145.4, 133.1, 130.1, 129.4, 125.2, 119.8, 113.5, 108, 106.6, 102.6, 70.6, 55.3, 44.5, 41.1, 30.1, UIN: - 8.4 N?), 8.0 (1H, a, U - 8.4 Nz), 7.62 (IN, t, U - 1.0, 7.1, 8.2 Nz), 7.47 (IN, t, y - 1.0, 7.1, 8.1 Ng), 7.22 (1H, 1, y - 8.2 N?o), 6.58-6.54 (2H, t), 6.52 (IN, her, y) - 2.2 Nz), 4.70 (1H, t), 4.01 (4H, t), 3.81 (ZH, 5), 2.12 (4H, t) because Compound number 167 (MR: 162 (des.)). NMR solvent: SOSIZ

130: MO SATA 1H: 8.15 (2H, t), 7.69 (1H, t, y - 1.0, 7.1, 8.2 Nzg), 7.55 (1H, t, y - 1.0, 7.1, 8.2 Nz), 5.09 (2H, 5

Bo), 4.46 (2H, 5 Bi), 3.45 (2H, 1, U) - 7.1 Nz)

Compound number 168 (MR: 72). NMR solvent: Socializer 130: 153.9, 150.6, 149.4, 145.3, 133.1, 129.3, 125.2, 119.8, 117.8, 115.4, 113.5, 71.9, 68.2, 44.5, 41.8, 31.4, 30.5 . ), 6.90 (2H, t, y - 9.3 No), 6.85 (2H, t, y - 9.3 Ng), 4.57 (1H, t), 3.99 (4H, ri), 3.93 (2H, 1, y - 6.5 Н2 ), 2.11 (2H, t), 2.05 (2H, t), 1.76 (2H, t), 1.49 (2H, t), 0.98 (ЗН, и, У - 7.4 N?g)

Compound number 169 (MR: 90). NMR solvent: SOSIZ 130:151, 145.1, 132.9, 129.6, 125.4, 119.9, 113.5, 62.2, 36.4 1Н: 8.11 (1Н, а, У - 8.4 Ng), 8.05 (1Н, и, У - 68.4 Но), 7.62 (IN, t, Y - 1.0, 7.1, 8.3 Nzg), 7.47 (IN, t, y - 1.0, 7.1, 8.2 H2), 3.99 (ZN, 5), 3.55 (ZN, 5)

Compound number 170 (MR: 51). Solvent NMR: SOSIZ 130: 148.4, 145.2, 132.9, 129.6, 125.6, 119.9, 114.1, 51.8, 51, 31.7, 29.2 1Н: 8.14 (1Н, а, У - 8.5 Н2), 8.11 (1Н, и, У - 8.4 No), 7.63 (1H, 1, U - 7.8 No), 7.49 1H, 1, U - 7.4

H2), 5.0 (2H, with Big), 4.28 (2H, 5 Bi), 3.19 (2H, 1, U - 6.3 Nz)

Compound number 171 (MR: 81). NMR solvent: SOSIZ 130: 150.1, 145.1, 133.1, 129.1, 125, 119.7, 113.4, 51.5, 49.8, 26.9, 26.7, 25.8, 25.2, 241 1H:8.10 (1 H, a, U - 8.3 Ng), 8 1H, a, U - 8.3 No), 7.59 (IN, t, U - 1.1, 7.1, 8.1 No), 7.45 (1H, t, y - 1.0, 7.1, 8.2 No), 3.86 (2H, t, U - 5.3 H2g), 3.79 (2H, t, U - 5.3 Nzg), 1.95 (2H, t), 1.79 (2H, t), 1.67 (6H, t)

Compound number 172 (MR: 37-38). NMR solvent: SOSIZ 130:150.5, 145.1, 133.2, 129.1, 125, 119.7, 113.5, 50.4, 49, 2941, 27.4, 27.3, 26.6 1H: 8.09 (IN, t a, U - 8.3 H2g), 8.01 (1H t s, U - 8.5 Nh), 7.59 (1H, t, U - 1.0, 7.0, 8.2 H2), 7.45 (IN, t, y - 1.0, 7.1, 8.2 Ng), 3.87 (2H, 1, 9 - 6.0 No), 3.79 (2H, her, U - 6.0 Nl), 1.94 (2H, t), 1.90 (2H, t), 1.71 (2H, t), 1.68 (2H, t)

Compound number 173 (MR: ой). NMR solvent: SOSIZ 130: 150.2, 145.1, 133.3, 129, 124.9, 119.7, 113.1, 49, 30.1, 21.4, 13.8

Zo 1H: 8.10 (1H, a, U - 8.5 No), 7.92 (IN, y, U - 8.3 Ng), 7.59 (IN, t, y - 7.9 No), 7.45 (1H, t, y - 7.6 Ng) . 7.1 N?g)

Compound number 174 (MR: 193). NMR solvent: SOZIZ 130: 148.9, 145.1, 136.6, 134.4, 133.1, 129.5, 127.9, 127.9, 125.5, 122.6, 122.6, 119.8, 114.5, 56, 54.8 1nH:8.28, 1H, 4.4, 1H? (1H, y, U - 8.3 No), 7.64 (1H, 1, U - 7.7 No), 7.50 (1H, y - 7.6

Nz), 7.36 (4H, t), 5.53 (2H, 5), 5.19 (2H, 5)

Compound number 175 (MR: ой). NMR solvent: SOSIZ 130: 150.1, 149.2, 145.4, 133.3, 129.1, 125, 125, 119.8, 113.5, 113.4, 54.4, 52.6, 42.3, 39.2, 31.6, 27.4, 18.8, 18, 1Н, - 8.3 No), 7.97 (1H, and y - 8.4 No), 7.59 (1H, 1, y - 7.6 No), 7.AA N.Yu - 7.6

H2g), 4.45 (1.4H, y, U - 12.0 Nl), 3.88 (0.6H, bi), 3.50 (0.6H, Big), 2.63 (1.4H, Bi), 2.15 (0.6H, t), 1.89 ( 1.4H, t), 1.0-0.96 (6H, t by), 1.93, 1.57, 0.9 (2H, t)

Compound number 176 (MR: 48). NMR solvent: SOSIZ 130: 173.9, 149.4, 145.3, 133.1, 129.4, 125.2, 119.8, 113.5, 60.8, 47.4, 44.9, 40.7, 28, 14.2 1Н: 8.10 (1Н, а, У - 68.3 Nz (IN), , a, U - 8.3 Nz), 7.61 (1H, t U - 7.8 Ng), 7.46 (1H, t, y - 7.8

Hg), 4.41 (2H, a, yu - 4.0, 13.5 No), 4.19 (2H, 4, U - 7.1 No), 3.39 (2H, 5 6), 2.11 (2H, a ry, U - 12.9

Nzg), 1.98 (2H, t), 1.29 (ZH, 1, U - 7.1 Ng)

Compound number 177 (MR: 75). NMR solvent: SOSIZ 130:155.3, 149.5, 145.3, 133.1, 129.6, 125.4, 119.9, 113.6, 61.9, 47.8, 45.1, 43.5, 14.6 1H: 8.11 (IN, y, U - 8.4 Н?), 8.0 ( y, U - 8.4 Nz), 7.63 (1H, t, y - 6.2 Nzg), 7.48 (1H, t, y - 7.6

Ng), 4.20 (2H, a, U - 7.2 Nz), 3.92 (AN, 5 Bi), 3.71 (4H, t), 1.30 (ZN, I, U - 7.2 Ng)

Compound number 178 (MR: 143). Solvent NMR: SOSIZ 130: 169.2, 149.5, 145.3, 133.1, 129.7, 125.5, 120, 113.6, 47.8, 46.3, 46, 41.2, 21.4 1H: 8.11 (IN, a, U - 8.3 N?g), 8.0 (IN , a, U - 8.3 Ng), 7.63 (1H, t, y - 1.0, 7.1, 8.2 H2g), 7.A8 (IN, t, y - 1.0, 7.1, 8.2 Ng), 3.94 (AN, 5 Bri) , 3.85 (2H, t), 3.71 (2H, t), 2.18 (ЗН, 5)

Compound number 179 (MR: 197 (aes.)). NMR solvent: OMBO 130:175.7, 148.7, 144.7, 132.5, 129.5, 125.4, 119.6, 113.2, 47.1, 44.5, A1, 28.4

1H: 8.19 (1H, y, U - 8.4 Nz), 7.91 (IN, y, U - 8.3 Nl), 7.70 (1H, t, y - 7.8 Ng), 7.53 (IN, t, y - 7.7 NI), 7.38 (1H, 5 Bi), 6.90 (1H, 5 Bi), 4.23 (2H, 5 Bi), 3.24 (2H, in Bi), 2.47 (1H, t), 1.85 (2H, 5 Bi), 1.69 (2H , t, y - 4.2, 12.0 N?g)

Compound number 180 (MR: ой). Solvent NMR: 158.2, 148.8, 146.4, 143.2, 132.5, 129.5, 127.7, 127.7, 127.5, 127.3, 126.1, 40.5 d), 7.39 (2H, t, U - 8.0 Nz), 7.33 (1H, t, y - 7.3 H2), 7 (NN, aa, - 1.2, 5.0 NI), 7.19 (2H, t, U - 8.3 N ?g), 7.02 (1Н, и а, У - 3.6, 5.0 Н2г), 3.58 (ЗН, 5)

Compound number 181 (MR: 79). NMR solvent: SOSIZ 130: 158.8, 149.9, 147.3, 135.8, 132.5, 128.8, 128, 127.8, 127.6, 127.6, 54.4, 36.9, 36.2 1H: 8.86 (1H, 5), 7.46-7.30, 7.30 (IN, BI), 7.11 (1H, her, U - 4.0 Ng), 4.93 (2H, ri), 3.24 (ZN, bi)

Compound number 182 (MR: 87). NMR solvent: SOSIZ 130: 164.3, 150.7, 148.6, 147.3, 137, 129.3, 128.8, 128.6, 126.8, 120.7, 116.7, 49.4, 46.5, 34.7 1H: 8.73 (1H, 5-75), 7.1 (t.27) , 7.32 (2H, t), 6.95 (2H, t), 6.93 (IN, t), 4.11 (2H, 5), 4.03 (4H, Bi), 3.27 (4H, t)

Compound number 183 (MR: 144). NMR solvent: SOSIZ 13C: 163.8 (a a, U - 12.0, 253.0 No), 160.8 (a a, U - 14.0, 261.0 H2g), 158.5 (a, U - 6.0 Ng), 145.6, 144.7, 131.4 (da, 9) -4.2,.10.0 No), 114.4 (da, U) - 4.0, 11.5 No), 111.8 (9 a, U - 4.0, 22.0 No), 105.0 (9 - 25.0 H2), 82.1, 79.2, 62.2, 22.8 1H: 8.96 (1H, 5), 8.12 (1H, t, y - 7.0, 8.4 Nl), 7.0 (IN, t), 6.95 (1H, t), 5.53 (2H, 5), 3.84 (2H, 5 ), 1.62 (6Н, 5)

Compound number 184 (MR: 126). NMR solvent: SOSIZ 130: 151, 142.5, 136.9, 133.7, 132.8, 131.7, 128.9, 128.7, 127.6, 127.3, 126.8, 126.3, 125.2, 112.9, 48.5, 44.6, 19, 19, 28.5 ,3 H2), 7.82 (2H, t, U - 8.2 Nzg), 7.55 (1H, y, U - 1.3 No), 7.42 (2H, 1, U - 7.8

Na), 7.91 (1H, t, y - 7.4 Nz), 7.27-7.19 (ZH, t), 7.12 (1H, t), 4.80 (2H, Bi), 3.88 (2H, 1, 9 - 5.6 H2), 3.05 (2H, 1, U - 5.8 H2g)

Compound number 185 (MR: 125). NMR solvent: ОМ5О 130: 160.4, 148.6, 147.8, 134.7, 134.2, 132.4, 129, 128.6, 128.4, 128, 126.7, 126.3, 126.2, 47.3, 442,28 1Н: 9.14 (Н2, 18.0), (1Н t, y - 8.6 Nzg), 7.59 (2H, t, y - 8.6 Nz), 7.23 (AN, Bi), 4.88 (2H, Bi), 3.93 (2H, 1, U - 5.8 No), 3.02 (2H, 1, U - 5.68 N?g)

Compound number 186 (MR: 136). NMR solvent: SOSIS 130: 146.3, 141.6, 136.2, 133.3, 131.3, 128.9, 126.4, 112.3, 81.1, 80.4, 61.9, 22.8 1H: 7.94 (1H, y, U - 1.3 Nz), 7.72 (2H, t - 68.7 No), 7.51 (1H, a, U - 1.3 No), 7.37 (2H, t, y - 8.7 Nzg), 5.13 (2H, 5), 3.89 (2H, 5), 1.62 (6H, 5)

Compound number 187 (MR: 176-177). NMR solvent: ОМ5О 130: 167.1, 161.1, 158.7, 157.5, 147.1, 144.6, 129.8, 129.6, 128.5, 125.5, 119.5, 118, 81.4, 78.4, 61.4, 22.4 1Н, 2, 1, 1, 1, 1, 1, 1, 1, 1. y, U - 8.8 HO), 7.98 (1H, zv Bi), 7.93 (2H, a, U - 6.4 Nl), 7.36 (IN, v5 Bi), 7.20 (2H, a, y - 8.8 Ng), 7.11 ( 2Н, а, У - 8.4 Н2), 5.44 (2Н, 5), 3.85 (2Н, 5), 1.52 (6Н, 5)

Compound number 188 (MR: 88). NMR solvent: SOSIZ 130: 162.8, 161.1, 146, 145, 128.2, 122.4, 114.1, 82, 79.3, 62.1, 55.3, 22.8 1Н: 8.90 (1Н, 5), 8.05 (2Н, т, У - 9.0 Н2g), 6.98 (2H, t, y - 9.0 Nl), 5.56 (2H, 5), 3.87 (ZH, 5), 3.84 (OH, 5), 1.62 (6H, 5)

Compound number 189 (MR: 132). NMR solvent: SOSIZ 130: 162.1, 146.3, 144.7, 136.1, 129, 128.3, 128, 81.9, 79.3, 62.3, 22.8 1H: 8.93 (1H, 5), 8.05 (2H, t, y - 8.6 Nzg), 7.44 ( 2H, t, y - 8.6 Nz), 5.55 (2H, 5), 3.85 (2H, 5), 1.62 (6H, 5)

Compound number 190 (MR: 82). NMR solvent: SOSIZ 130: 162.7, 150.1, 147.4, 136, 134.1, 133.1, 128.8, 128.7, 128.4, 128, 128, 127.8, 127.1, 126.9, 126.7, 126.5, 123.7, 5 8.64 (1H, Bri), 8.15 (1H, Bi), 7.90 (ZN, t), 7.53 (2H, t), 7.47-7.31 (BN, t), 5.0 (2H, Bi), 3.28 (ZN, Bi)

Compound number 191 (MR: 107). NMR solvent: OMBO 130: 161.7, 150, 147.3, 136.3, 133.6, 130.6, 128.7, 128.6, 128.5, 127.6, 127.1, 126.1, 125.8, 125.4, 53.6, 37.3, 18.5 (H, 1.8, 35.8), IN, b), 8.27 (IN, 9, U - 7.2 No), 8.06 (IN, a, U - 68.0 Н2), 8.0 (1Н, б), 7.63 (IN, U - 7.5 Ng), 7.55 (1Н, Bi), 7.46-7.26 (6H, t), 4.90 (2H, Big), 3.16 (ZH, 5) because Compound number 192 (MR: 121-123 (des.)). NMR solvent: OMBO

130: 161, 148.7, 146.9, 143.5, 133.4, 130.5, 129.6, 129.5, 128.4, 128.3, 127.2, 127. aa, -yu - 1.2, 7.2 No), 7.98 (1H, a, U - 6.2 H2g), 7.93 (2H, t), 7.60-7.30 (ВН, t), 3.52 (ЗН, 5)

Compound number 193 (MR: 142). Solvent NMR: SOSIZ 130: 149.2, 145.3, 133.1, 129.5, 125.3, 119.9, 113.5, 71.8, 53.3, 50.2, 18.6 1H: 8.11 (IN, io, U - 8.3 No), 8.0 (1H, a, U - 8.4 Nz), 7.62 (IN, t, U - 1.0, 7.1, 8.1 Nzg), 7.47 (IN, t, U - 1.0, 7.1, 8.1 No), 4.42 (2Н, а рт, У - 13.0 Н?), 3.83 (2H, t), 3.03-2.90 (2H, t bi), 1.26 (6H, 5 bi)

Compound number 194 (MR: 75). NMR solvent: SOSIZ 130:150, 145.3, 133.1, 129.5, 125.4, 119.9, 113.6, 66.1, 52.8, 49.7, 17.5 1Н:8lI1 (1Н, а, у - 8.3 Н2), 8.01 (IN, y, У - 8.3 No), 7.63 (1H, 1, U - 7.8 No), 7.48 (IN, 1, U - 7.8

Nzg), 4.22 (2H, 5 Big), 4.06-3.90 (2H, t bi), 3.66 (2H, 5 Big), 1.91 (6H, 5 Bi)

Compound number 195 (MR: ой). NMR solvent: SOSIZ 130: 150.9, 145.3, 139.1, 133.3, 129.3, 128.7, 127.9, 127.3, 125.2, 119.8, 113.6, 55, 32.2, 16 1Н: 8.12 (1Н, т, У2 - 8.3 Н) , t, y - 8.4 H2), 7.63 (1H, t, y - 1.0, 7.0, 8.0 Nz), 7.48 (IN, t, y - 1.0, 7.1, 8.3 Ng), 7.45 (2H, Bi), 7.41 ( 2Н, т, у - 7.4 Nz), 7.34 (IN, т У - 8.0 Н2), 5.95 (IN, d, У - 6.8 Н2г), 3.0 (ЗН, 5), 1.78 (ЗН, й, у - 7.1 Ng )

Compound number 196 (MR: 140). IMR Solvent: SOSIZ 130: 150.7, 150.5, 142.6, 141.7, 140.9, 137.1, 133.2, 129.3, 129.2, 128.7, 127, 127.4, 127.2, 126.5, 124.1, 124, 121.1, 116.2 . y, U - 1.2 H2), 7.56 (1H, and 1, U) - 1.5, 7.7 No), 7.49 (1H, Her, U - 7.5 H2), 7.47 (2H, t,

U - 7.7 Nz), 7.37 (1H, t, U - 7.2 Nz), 7.32 (2H, t, U - 8.2 Nz), 6.96 (ЗН, t), 3.85 (4Н, t, U - 5.0 Ne), 3.30 (4H, t, y - 5.0 N?g)

Compound number 197 (MR: 113). NMR solvent: SOSIZ 130: 150.5, 142.2, 141.3, 137, 133.1, 131.5, 128.8, 128.3 (2 part.), 126.4, 125.8, 113.3, 47, 35.9, 35.68, 35.7, 32.1, 1:28.8, Н: 28.4 y, U - 1.3 Ng), 7.73 (2H, t), 7.45 (1H, y, U - 1.3 Nz), 7.37 (2H, t), 7.30 (2H, t, y -

Zo 7.5 Ng), 7.20 (1H, t, y - 7.6 Nzg), 7.19 (2H, t, U - 8.0 H2), 4.14 (2H, aby, - 13.2 No), 3.04 (2H, a,

U - 2.3, 13.0 N?), 2.63 (2H, her, 9 - 7.7 No), 1.83 (2H, and b, y - 13.5 Nl), 1.67 (2H, t), 1.58 (1H, t), 1.36 ( 2H, t), 1.25 (2H, d 9, y - 4.2, 13.1 H?)

Compound number 198 (MR: 178). NMR solvent: SOSIZ 130: 150.3, 140.3, 137.2, 133, 132.8, 131.2, 130.6, 127, 124.3, 113.9, 106.1, 64.6, 44.8, 35 1Н: 7.90 (1Н, а, У - 2.0 Нзг1 (7.0Н9), , y, U - 1.4 Но), 7.61 (1Н, а а, У) - 2.1, 8.4 Н?), 7.А9 ИН, а, - 1.4 Н2), 7.46 (IN, й, У - 8.4 Н2), 4.01 (4H, 5), 3.73 (4H, t, y - 5.5 Ng), 1.82 (4H, t, y - 5.5 N?g)

Compound number 199 (MR: 174). NMR solvent: SOSIZ 130:150.2, 145.8, 143, 141.7, 137.5, 130.3, 128, 126.2, 125.9, 123.5, 115.1, 111.7, 40.1 1Н: 7.49 (IN, 9, U - 1.2 NI (2Н, 7.41) , y - 8.4 Nl), 7.40 (2H, t, y - 7.5 N?), 7.33 (IN, t, y - 7.4 NO), 7.17 (2H, t, y - 68.4 N?g), 7.04 (IN, a, 9 - 1.2 H2), 6.65 (2H, t, y - 8.4 H2), 3.69 (2H, 5), 3.51 (ZH, 5)

Compound number 200 (MR: Nudgozsoris). NMR solvent: OMBO 130: 157.8, 149, 142.4, 137.5, 130, 129.9, 127.9, 126.2, 118, 115.4, 114.4, 111, 62.3, 54.4, 48.4, 39.7. , 5), 8.04 (1H, 5), 7.82 (1H, 5), 7.42 (2H, 1, 7 - 8.0 Nl), 7.39 (1H, 5), 7.36 (2H, t), 7.32 (1H, t) , 7.30 (2H, t), 6.92 (IN, t), 4.46 (2H, t), 3.63 (6H, t), 3.48 (4H, t), 3.45 (ЗН, 5)

Compound number 201 (MR: 119). Solvent NMR: SOSIZ 130: 149.8 (a yo, U - 13.0, 244.5 IN?), 149.8, 148.5 (a a, 9 - 12.5, 245.0 N?o), 138.9, 137.9, 131.1 (a 9, y - 4.0, 7.0 Nz), 121.4 (Da, 9 - 3.0, 6.5 No), 117.8 (d, U - 17.3 No), 115.2, 113.5 (y, U - 18.7 Н2), 62.7, 48.1, 46.5, 28.5, 25.8, 25.3 1Н : 8.12 (1H, 5), 8.06 (IN, 5), 7.87 IN, a and a, Y - 2.0, 7.8, 12.0 H2), 7.70 (1H, t), 7.46 (1H, 1, y - 8.7, 10.7 Nz), 3.51 (4H, t), 2.57 (4H, t), 2.29 (1H, Bi), 1.74 (AN, t), 1.57 (IN, a ri, U - 12.0 Н2), 1.20 (4H, t) , 1.07 (IN, 1 Bg, U - 10.0 H2)

Compound number 202 (MR: ойЙ). NMR solvent: SOSIZ 130: 150.4, 145.1, 137.8, 133.2, 129.2, 128.4, 127.7, 127.6, 125.1, 119.7, 113.7, 73.3, 69.4, 68.3, 48.7, 45.1, 12, Н1, 13.6, Н, 19.0 - 68.4 N?o), 7.98 (IN, y, U - 8.3 N2g), 7.58 (1H, her, U - 7.9 No), 7.45 (1H, t, U - 1.0, 7.2, 8.2 Nl), 7.31 (BN . NMR solvent: OMBO

130: 157.4, 148.6, 142.2, 137.3, 136.6, 129.9, 128, 126.5, 126.3, 123.2, 115.2, 114.3, 62.4, 54.4, 48.4, 39.7. 2H, 5), 7.88 (1H, 5), 7.62 (2H, y, U - 8.8 H2g), 7.57 (1H, 5), 7.42 (2H,.1, U - 7.4 NI), 7.36 (2H, a, У - 8.8 Но), 7.32 (1Н, her, у - 7.4 NO), 7.0 (2Н, а, У - 8.8 Н2), 4.42 (2Н, т), 3.61 (6Н, т), 3.47 (4Н, т) , 3.43 (ZN, 5)

Compound number 204 (MR: 141). Solvent NMR: SOSIZ 130: 161.7, 148.5, 147.3, 136.1, 128.9, 128.4, 128, 106.5, 64.6, 44.7, 35.1 1Н: 8.80 (1Н, 5), 8.07 (2Н, а, У - 8.8 Ng), 7.43 ( 2H, y, U - 68.8 H2), 4.02 (4H, 5), 3.95 (4H, ri), 1.89 (AN, t)

Compound number 205 (MR: 74-75). NMR solvent: SOSIZ 130: 162.3, 161, 148.8, 147, 142.3, 128.3 (2 parts), 128.2, 125.7, 122.6, 114, 55.3, 47, 36, 35.8 (2 parts), 32.1, 28.5. 1H: 8 (1H, 5), 8.07 (2H, a, U - 7.7 No), 7.28 (2H, t), 7.19 (ЗН, t), 6.98 (2H, y, 9 - 7.7 Н2), 4.61 (2H, Bri) , 3.03 (2H, Bi), 3.86 (ZH, 5), 2.62 (2H, t), 1.84 (2H, t), 1.67 (2H, t), 1.59 (1H, t), 1.30 (4H, t)

Compound number 206 (MR: 131). NMR solvent: OM5O 130: 161.8, 150.6, 148.5, 147.3, 133.6, 130.7, 130, 129.1, 128.7, 128.4, 127.3, 126.4, 126.3, 125.8, 125.4, 119.5 ), 9.03 (1H, y, U - 8.4 H2), 8.28 11H, da, y - 1.0, 7.3 H2), 8LO(1H, a, 0 - 8.1 H2), 8.05 (1H, a, - 8.0 Nl), 7.72-7.57 (ZH, t), 7.25 (2H, 1, y - 7.8 Ng), 6.99 (2H, a, y - 8.3 H2), 6.82 (IN, Y - 7.3 Ng), 3.94 (AN, 5 ri) , 3.32 (4Н, т, у - 5.0 Н2)

Compound number 207 (MR: 181). IMR solvent: OM5O 130: 167.1, 160.7, 158.8, 156.6, 148.7, 148, 134.2, 132.6, 131.7, 131.1, 129.9, 129.7, 128.6, 126.8, 126.4, 126.2, 126.8 28.2 1H: 9.15 (1H, 5), 7.98 (1H, with Bi), 7.96 (2H, y, U - 8.8 H2), 7.90 (1H, y, U - 7.7 Nzg), 7.66 (1H, t bi), In 8.8 Ng), 4.83 (2H, t Big), 3.88 (2H, t Bi), 2.96 (2H, 1, U - 5.3 N?g)

Compound number 208 (MR: 217-218). NMR solvent: ОМ5О 130: 167.2, 160.7, 159, 156.4, 150.6, 148.3, 148.1, 131.7, 131.1, 129.8, 129.6, 129.1, 122, 121,

Zo 119.5, 117.9, 116.6, 115.9, 48.2, 45.68 1H: 9.15 (1H, 5), 7.98 (1H, 5 Big), 7.94 (2H, y, U - 8.8 Nl), 7.91 (IN, t), 7.69 ( IN, t By), 7.59 (1Н,

I, U - 8.0 H2), 7.36 (1H, 5 Bi), 7.24 (2H, 1.0) - 7.7 Ng), 7.23 (1H, t), 7.11 (2H, a, U - 8.8 No), 6.97 ( 2H, 9.9 - 8.0 H2), 6.82 (1H,i, U - 7.0 Nzg), 3.88 (4H, Bi), 3.27 (AN, Bi)

Compound number 209 (MR: 192-193). NMR solvent: ОМ5О 130:167.1, 160.8, 159, 156.3, 147.2, 144.5, 131.7, 131.1, 129.8, 129.5, 122.1, 121, 117.8, 116.8, 81.3, 78.3, 61.34, НН2, 9.0, 2.0 7.96 (1H, 5 Big), 7.93 (2H, t, y - 8.8 Ng), 7.90 (1H, t), 7.69 (IN, y a, Y - 1.6, 2.4

Ng), 7.57 (IN, 1, U - 8.0 H2), 7.35 (1H, 56), 7221, aa, o - 0.9, 2.5, 8.2 Nz), 7.09 (2H, t, U - 8.8

Н2г), 5.39 (2Н, 5), 3.82 (2Н, 5), 1.50 (6Н, 5)

Compound number 210 (MR: 185). NMR solvent: OMBO 130: 167.1, 160.7, 158.9, 156.5, 148.3, 148.1, 131.7, 131.1, 129.8, 129.6, 122, 120.9, 118, 116.5, 65.8, 46.2 (Н: 1.7, 9.13), zv Bi), 7.93 (2H, y, U - 8.7 Ng), 7.88 (IN, y, U - 7.7 Ng), 7.65 (1H, t Bi), 7.58 (IN, 1, U - 7.8 Ng), 7.35 ( IN, 5 bi), 7.22 1Н, и а, У - 1.9, 7.9 Nz), 7.10 (2Н, и, У - 8.7 Н2), 3.80- 3.63 (8Н, т)

Compound number 211 (MR: 116). NMR solvent: SOSIZ 130: 162.6, 161.2, 157.7 (0, U - 240.0 No), 148.7, 147.4 (0, 94 - 2.0 N?), 147.3, 128.3, 122.3, 118.7 (9, U - 7.8 No), 115.8 (0.9 - 22.0 Nz), 114.1, 55.3, 50.5, 46.4 1H: 8.83 (1H, 5), 8.08 (2H, t), 7.01 (2H, 1, U - 9.4 Н2), 7.0 (2H, t) , 6.93 (2H, t), 4.12 (4H, bi), 3.88 (ЗН, 5), 3.25 (4H, t)

Compound number 212 (MR: 281 (aes.)). NMR solvent: OMBO 130: 160.6, 148.5, 148.1, 135, 129.2, 128.4, 128.2, 64.3, 47.3, 42.9, 26.1, 24.7, 24.5 1Н: 11.29 (1Н, 5), 9.20 (1Н, 10 5), Н8 . 11.5 Но), 3.23 (ЗН, т), 2.13 (2Н, а рт, у - 10.5 Н2), 1.82 (2Н, а рг, У - 12.8 Но), 1.61 (1Н, а ре, У - 12.5 Н2з), 1.43 (2H, t, y - 11.5 Ng), 1.26 (2H, t, y - 12.8 H2), 1.10 (1H, t, y - 12.5 Н2)

Compound number 213 (MR: 99). NMR solvent: SOSIZ 130: 159, 146.2, 144.7, 132.4, 127.9, 127.7, 127.6, 82, 79.2, 62.2, 22.8 1Н: 8.89 (1Н, 5), 7.74 (1Н, y, У - 3.0 Н2), 7.41 ( 1H, y, U - 4.9 No), 7.13 (1H, t), 5.51 (2H, 5), 3.84 (510) (2H, 5), 1.61 (6H, 5)

Compound number 214 (MR: 121). NMR solvent: SOSIZ 130: 162.1, 147.0 (2 5 id.), 136.2, 129, 128.2, 128.1, 51.8, 51.1, 32, 28.9 1Н: 8.93 (1Н, 5), 8.07 (2Н, t, y - 8.8 Nz) , 7.44 (2H, t, U - 8.8 H2g), 4.97 (2H, t Bi), 4.23 (2H, t ro), 3.14 (2H, Bi)

Compound number 215 (MR: 129). Solvent NMR: SOSIZ 130: 150.6 (a a, U - 13.0, 248.0 N?o), 149.9 (a a, 9 - 13.0, 249.0 Nzo), 149.4, 140.9, 137, 129.9 (a 9,9 - 4.0, 7.0 Ng), 121.2 (da, 9 - 4.0, 6.5 No), 117.6 (o, U - 17.7 Ng), 114.3 (90, 9 - 19.0 H2), 113, 51.3, 50.9, 30.5 1nH:8.02 (1H, I, In - 1.4 H2), 7.61. IN, aa, - 2.0, 7.7, 11.5 No), 7.55 (1Н, а, У - 1.4 Н2), 7.50 (IN, t), 7.19(1Н, а, - 8.3, 10.0 Nz), 4.71 (2Н, 5 ), 3.98 (2H, 1, U - 6.3 Ng), 3.14 (2H, 1, U - 6.3 H2)

Compound number 216 (MR: 115). NMR solvent: SOSIZ 130: 149.3, 149, 144.2, 136.4, 135.8, 121, 118, 114, 112, 109.1, 80.7, 79.3, 61.4, 55.8, 55.6, 22.2 1H: 9.22 (1.3, 6 (1.5), Н8 5).

U - 8.4 Н2), 5.22 (2Н, 5), 3.87 (2Н, 5), 3.83 (ЗН, 5), 3.79 (ЗН, 5), 1.52 (6Н, 5)

Compound number 217 (MR: 154-155). NMR solvent: SOSIZ 130: 151.3, 149.1, 148.5, 141.9, 136.7, 126.1, 117.4, 112.4, 111.2, 108.4, 57.5, 55.9 (2 parts), 31.4, 30, 25.4, 25.2, 1H, 1.75 (1) . . ), 1.13 (1H, t)

Compound number 218 (MR: 140-141). NMR solvent: SOSIZ 130: 149.2, 139.9, 137, 133.1, 132.8, 131.1, 130.6, 126.9, 124.3, 113.6, 48.9, 25.3 1H: 8.05 (1 H, y, U - 1.3 Ng), 7.90 (1H, a U - 2.0 No), 7.65 (1H, a, U - 1.3 No), 7.61 (1H, aa, m - 2.0, 8.5 H2g), 7.46 (IN, y, U - 8.5 H2), 3.68 (4H, t) , 2.03 (AN, t)

Compound number 219 (MR: 106). NMR solvent: SOSIZ 130: 147, 143.1, 139.8, 131.8, 124.8, 124, 120.7, 113, 81, 80.6, 61.5, 23.1 1H: 8.11 (1H, 5), 7.82 (IN, 9, U - 7.8 NN), 7.70 (IN, y, y) - 7.7 No), 7.40 (1H, y, U - 1.5, 7.4 H2), 7.36 (1H, a, U - 1.5, 7.4 No), 5.04 (2H, 5), 3.92 ( 2H, 5), 1.67 (6H, 5)

Compound number 220 (MR: 114-115). NMR solvent: SOSIZ

Zo 130: 146.9, 142.2, 136.6, 132.8, 128.7, 127.6, 125.1, 112.5, 96.3, 63.5, 48.2, 241 1H: 8.06 (1H, y, U - 1.4 Nz), 7.80 (2H, t, U - 8.2 Nz ), 7.62 (IN, y, Y - 1.4 No), 7.41 (2Н, Y - 7.8

Nzg), 7.30 (1H, t, y - 7.4 Ng), 4.10 (2H, 1, y - 6.0 N?), 3.84 (2H, 1, y - 6.0 NI), 1.73 (6H, 5)

Compound number 221 (MR: 120). NMR solvent: SOSIZ 130: 151.4, 142.2, 136.7, 133, 128.7, 127.4, 125.1, 113.2, 49.1, 30, 21.2, 13.6 1H: 7.87 (IN, y, U - 1.5 Nz), 7.80 (2H, t, U - 8.0 Ng), 7.46 (IN, I, U - 1.5 No), 7.41 (2H, 1, - 8.0

Nzg), 7.29 (1H, t, y - 7.5 Ni), 4.41 (2H, t), 1.90 (1H, t), 1.77 (2H, t), 1.66 (2H, t), 1.62 (1H, t), 1.39 (6H, y, U - 7.2 H2g)

Compound number 222 (MR: 116). NMR solvent: SOSIZ 130: 151.7, 143.3, 141.4, 132.1, 124.5, 123.6, 120.6, 112.6, 57.4, 31.3, 30, 25.4, 25.3 1H: 8.16 (1H, 5), 7.82 (1H, t8, No - 7 ), 7.55 (IN, t), 7.38 (1Н, а, у - 1.5, 7.3 Но), 7.35 1Н, а

Her, U - 1.5, 7.3 No), 4.0 (1H, t, y - 3.4, 12.1 N?g), 2.96 (ZH, 5), 1.89 (4H, t), 1.70 (IN, and horn, U - 13.5

Hg), 1.61 (2H, d 9, U - 4.0, 12.5 H2?), 1.38 (2H, 14, 9 - 4.0, 13.5 No), 1.14 (1H, ta, y - 3.5, 13.5 N?g)

Compound number 223 (MR: 155). NMR solvent: SOSIZ 130: 157.9 (a, 9) - 241.0 Nl), 150.5, 147.1 (a, 9 - 2.5 Ni), 141.6, 137, 133.3, 131.3, 128.9, 126.4, 118.9 (90, U - 7.7 Ng) . - 1.2 Ni), 7.38 (2Н, т, у - 8.6 Н2), 7.01 (2Н, т), 6.91 (2Н, т), 3.82 (4Н, т, у - 5.0 Н2г), 3.19 (4Н, т, У - 5.0 Ng)

Compound number 224 (MR: 201-202). NMR solvent: ОМ5О 130: 156.8, 149.8, 143, 139.8, 137.7, 129.9, 127.7, 126.5, 126.3, 126, 114.9, 113.3, 62.2, 54.9, 52.8, 39.6, 22.5, 1:15 (Н2, Н1, Н2) . (2H, a, y - 7.3 No), 7.32 (1H, t, y - 7.2 No), 6.98 (2H, a, U - 8.9 Nz), 4.32 (2H, y - 5.0 Nl), 3.50 (2H, Bi ), 3.48 (2H, t), 3.42 (ZN, 5), 3.0 (2H, BI), 1.79 (2H, Bi), 1.69 (ZN, bi), 1.39 (IN, Bi)

Compound number 225 (MR: 109). NMR Solvent: SOSIZ 130: 149.8, 147.8, 146.5, 142.5, 137, 136, 128.5, 127.8, 127.2, 126.4, 117.4, 114.1, 111.3, 108.9, 81.1, 80.4, 71, 71.8 .

Nzg), 7.38 (2H, her, y) - 7.7 No), 7.31 (1H, t), 7.21 (1H, aa, y - 2.0, 8.3 No), 6.91 (IN, y, U - 8.3 Н2), 60 5.20 (2Н, 5), 5.12 (2Н, 5), 3.97 (ЗН, 5), 3.88 (2Н, 5), 1.61 (6Н, 5)

Compound number 226 (MR: 230-232 (des.)). NMR solvent: OMBO 130: 145.4, 140.5, 139.7, 138.3, 137.6, 134.8, 132.6, 127.5, 117.7, 80.7, 79.3, 61.1, 22.4 1H: 9.34 (IN, 9, U - 1.8 H97 (IN, 8. ha, U - 1.5, 8.2 No), 8.81 (1H, and Big, U - 5.2 No), 8.59 (IN, a,

У - 1.3 Н?), 8.41 (IN, а, - 1.3 Н2), 8.11 (IN, а а, у - 5.2, 8.2 Но), 5.20 (2Н, 5), 3.86 (2Н, 5), 1.50 (6Н , 5)

Compound number 227 (MR: 118-119). NMR solvent: SOSIZ 130: 148.7, 142.6, 136.7, 132.7, 128.7, 127.7, 125.2, 112.3, 88, 66.4, 48, 19.2 1H: 8.08 (1H, y, U - 1.2 Nz), 7.81 (2H, y, U - 8.4 No), 7.62 (1H, 9, U - 1.2 Nzg), 7.42 (2H, 1, - 7.9

Nzg), 7.91 (1H, t. y - 7.4 N?), 5.49 (1H, 4, U - 5.2 H2I), 4.27 (1H, t), 3.89 (1H, t), 3.80 (2H, t), 1.57 (ZN, 9, U - 5.2 N?g)

Compound number 228 (MR: 204-205). NMR solvent: OM5O 130: 147.7, 146.3, 145.9, 141.3, 136.6, 124.8, 117.5, 115.6, 111.9, 109, 80.6, 79.3, 60.8, 55.6, 22.4 1Н: 9.03 (Н, 8, 95), and U - 1.0 Ng), 7.87 (IN, y, U - 1.0 H2), 7.38 (IN, y, U - 1.7 Nz), 7.26 pn. aa, - 1.7, 8.1 НН), 6.77 (IN, а, У - 8.1 Но), 5.17 (2Н, 5), 3.84 (2Н, 5), 3.81 (ЗН, 5), 1.50 (6Н, 5)

Compound number 229 (MR: 152). NMR solvent: SOSIZ 130:151.2, 142.1,137.2, 133.1, 128.6, 127.4, 125.1, 113, 58.4, 38.6, 36.2, 34.1, 29.7 1H: 7.92 (1H, 9, U - 1.2 Nz), 7.80 ( , U - 8.6 Nzg), 7.48 (IN, 9, U - 1.2 No), 7.40 (2H, 1, - 7.68

Ng), 7.29 (1H, her, U - 7.3 Nz), 2.99 (ZH, 5), 2.20 (9H, 5), 1.73 (6H, 5)

Compound number 230 (MR: 67-68). NMR solvent: OMBO 130: 157.4, 148.7, 142.3, 137.4, 136.8, 129.9, 127.9, 126.5, 126.3, 123.4, 115.1, 114.2, 63.1, 62.3, 54.7, 51.6, 18.1, 18.5, Bi.H. (1H, 5), 7.70 (1H, 5), 7.66 (2H, y, 9 - 8.9 Nzg), 7.43 (2H, 1, y - 7.9 H2), 7.40 (2H, a, 9) - 7.7 No), 7.34 (1H, t, y - 6.9 Nl), 7.03 (2H, a. y - 11.70 Nl), 3.54 (2H, t), 3.48 (2H, t), 3.46 (ZH, 5), 3.19 (2H, t)

Compound number 231 (MR: 46-47). NMR solvent: SOSIZ 130: 146.5, 142.5, 141.7, 140.9, 136.3, 133.2, 129.1, 128.7, 127.4, 127.2, 126.5, 124.1, 124, 112.2, 81.1, 80.1, 80.4 1.6 No), 7.99 (1H, a, U - 1.3 No), 7.77 (1H, a, y - 1.3, 7.6 No), 7.66 (2H, a, y

Zo - 8.2 2), 7.58 (1H, a, y - 1.3 No), 7.54 (1H, ta, y - 1.5, 7.7 No), 7.AB (1H, I, y - 7.7 Nz), 7.46 (2H, 1,

U - 7.8 N2g), 7.37 (1H, t, U - 7.4 Nz), 5.15 (2H, 5), 3.89 (2H, 5), 1.63 (6H, 5)

Compound number 232 (MR: 191-192). NMR solvent: OM5O 130: 167.9, 146.2, 140.7, 140.1, 140, 137.1, 135, 134, 129.6, 129.4, 129, 126.7, 125.8, 125.7, 124.2, 123.2, 114, 80.2 -8.17 (4H, t), 8.15 (1H, 5 Big), 7.88 (ЗН, t), 7.63 (1H, t, у - 8.1 Но), 7.57 (IN, 1, У - 7.8

Ng), 7.52 (1H, U - 7.8 No), 7.49 (1H, 5 Bi), 5.20 (2H, 5), 3.86 (2H, 5), 1.51 (6H, 5)

Compound number 233 (MR: 130-131). NMR solvent: SOSIZ 130: 146.5, 141.2, 136.7, 133.3, 131.4, 128.9, 126.4, 112.8, 98.6, 63.6, 48.8, 29.2, 22.3, 7.6 1Н: 8.05 (1Н, y, У2 - 1.3 Нз) . (2H, t), 2.21 (IN, t), 2.06 (1H, t), 1.70 (ЗН, 5), 0.95 (ЗН, и,

In - 7.4 N?g)

Compound number 234 (MR: 135-136 (aes.)). IMR Solvent: SOSIZ 130: 150.1, 148.4, 143.6, 142.3, 142.2, 137.1, 137, 132.6, 132.3, 128.8, 128.7, 128, 127.7, 125.3, 125.2, 125.2 22.1 1H: 8.18 (IN, y, U - 1.4 No), 7.98 (1H, y, U - 1.4 Nl), 7.81 (2H, t, U - 8.5 H2g), 7.77 (2H, t, y - 8.5 Ng) .

Nzg), 7.33 (1H, t), 7.30 (IN, t), 5.61 (1H, t), 4.73 (2H, 1, y) - 5.3 No), 4.12 (2H, her, y) - 5.3 Nz), 2.34 (2H, t), 2.30 (2H, t), 1.91 (2H, a, U - 7.6 Nzg)

Compound number 235 (MR: 154-155). NMR solvent: SOSIZ 130: 147.3, 141.7, 136.1, 133.3, 131.3, 128.9, 126.4, 112.3, 88.8, 78.6, 62.5, 24.8, 22, 20.7 1H: 7.92 (1H, y, U - 1.2 Nz), , a, U - 68.6 Nzg), 7.50 (1H, y, U - 1.2 Nl), 7.38 (2H, a, U - 68.6

Ng), 5.48 (1H, 9, U - 5.2 No), 3.93 (1H, y, U - 8.6 Ng), 3.72 (1H, a, U - 68.6 Nz), 1.62 (ZN, 5), 1.47 ( ZN, 5), 1.20 (ZN, a, y) - 5.2 N?g)

Compound number 236 (MR: 114-115). NMR Solvent: SOSIZ 130: 159.9, 146.5, 142.5 (2 from.), 141.6, 136.3, 133.2, 129.7, 129.1, 126.6, 124.2, 124, 119.7, 112.8, 112.8, 112.9, 81.3 1H: 8.02 (1H, her, U - 1.8 No), 7.99 (1H, a, U - 1.5 No), 7.78 (IN, ta, y - 1.5, 7.6 No), 7.57 (IN, 9, U -1.5 2 ), 7.53 (1Н, та, у - 1.5, 7.7 Ng), 7.АВ (IN, и, У - 7.7 Но), 7.38 (1.1, У - 681 ng), 7 2511nН, aa 9.9 - 1.0. BN, 5), 1.63 (6Н, 5)

Compound number 237 (MR: 148-149). NMR solvent: SOSIZ 130: 146.8, 143.2, 135.9, 132.9, 128.7, 127.6, 125.2, 110.7, 53.2, 41.5, 36.1, 29.4 1Н: 8.10 (1Н, 5), 7.79 (2Н, и, Н2), 68.0. 7.52 (1H, 5), 7.40 (2H, 1, U - 8.0 No), 7.ZO(1H, U - 7.5

Nzg), 5.39 (1H, 5), 2.17 (ZH, 5), 2.11 (6H, 5), 1.74 (6H, 5)

Compound number 238 (MR: 175). NMR Solvent: SOSIZ 130: 169.3, 151.3, 141.8, 141.5, 140.6, 137, 133.8, 133.7, 130.7, 129.3, 129, 126.3, 126.3, 126.1, 124.5, 124, 253.6, 57. :8.11 (1H, her, U - 1.8 H2), 8.08 (IN, her, U - 1.6 H2), 7.94 (IN, y, U - 1.2 H2), 7.81 (2H, t), 7.78 (IN, t) . ), 5.93 (IN, 5 Bi), 3.97 (1Н, т), 3.0 (ЗН, 5), 1.88 (2Н, т), 1.85 (2Н, т), 1.70 IN, аб, - 13.5 Н2), 1.58 ( 2H, and 9, y - 3.5, 12.5 H2), 1.38 (2H, 149, y - 3.0, 13.0 H2), 1.13 (IN, 4, y - 3.3, 13.0

Nz)

Compound number 239 (MR: 129). NMR solvent: SOSIZ 130: 151.3, 142.1, 141.7, 141, 137, 133.5, 129.1, 128.7, 127.3, 127.2, 126.3, 124, 124, 113.4, 57.5, 31.3, 30, 25.2, 8.1, Ни: 25.4, 7 , U - 1.8 No), 7.95(1 Na, y - 1.3 No), 7.78 (1H, and, 9 - 1.7, 7.7 No), 7.67 (2H, a, - 8.0 Ng), 7.56 (IN, 9, U - 1.3 No), 7.54 (1H, and her, U) - 1.8, 7.9 Nz), 7.48 (1H, 1, U) - 7.7 Ng), 7.46 (OH. 1, U - 7.9 H2), 7.37 (1H, t), 3.97 (1H, t), 3.0 (ZH, 5), 1.89 (2H, t), 1.85 (2H, t), 1.71 (IN, and rt, y - 13.0

Ng), 1.59 (2H, da, y - 3.5, 12.5 Ng), 1.38 (2H, da, 9 - 3.0, 13.0 Nh), 1.13 (1 H, a, y - 3.5, 13.0 N?g)

Compound number 240 (MR: 129-130). NMR Solvent: SOSIZ 130: 159.9, 151.3, 142.6, 142, 141.5, 137, 133.5, 129.7, 129.1, 126.4, 124.2, 124, 119.8, 113.4, 112.8, 112.8, 57.5, 5 : 8.04 (1Н, и, У - 1.6 Ng), 7.94 (1Н, и, У - 1.3 Но), 7.79 (1Н, И, У - 1.5, 7.5 Но), 7.56 (1Н, а, - 1.3 Н2), 7.52 (1Н, ау - 2.0, 7.9 Но), 7.48 (1Н, ю, У - 7.8 Но), 7.38 (IN, и, у - 7.9 Н2), 72511, а а 25. а,9у-1.0,1.7, 7.7 H?), 7.19(1H, a a, U - 1.8, 2.5 H2), 6.92 1H, aa, o - 1.0, 2.6, 8.2), 3.97 (1H, t), 3.89 (ZH, 5), 3.0 ( ЗН, 5), 1.88 (2Н, т), 1.85 (2Н, т), 1.71 (IN, and Бг, У - 13.0 Н2?), 1.59(2Н, 444.9 - 3.5, 12.3 Н2), 1.39 (2Н , а, 9 - 3.0, 13.0 НН), 113 (IN, а, У - 3.3, 13.0 Нз)

Compound number 241 (MR: 173-174). NMR solvent: SOSIZ 130: 149.1, 141.7, 136.7 (2 viad.), 133.4, 131.2, 129.7, 128.9, 128.8, 126.9, 126.4, 112.5, 91, 66.2, 47.9 1Н: 8.01 (НН7.6 Big8), . 1H, Bri), 4.12 (1H, t), 4.04 (1H, t), 3.94 (IN, t)

Compound number 242 (MR: 173-174). Solvent NMR: SOSIZ 130: 158.9, 151.8, 140.2, 134.6, 120.8, 117, 97.4, 59.7, 57.3, 33.2, 30.9, 29.6, 25.4, 25.3 1H: 8.61 (1H, 5 Bi), 7.94 (IN, y - 9.0 Ng), 7.53 (IN, а, У - 2.0 Н?), 7.06 1Н, а а, о - 2.0, 9.0

Nz), 3.21 (ZH, 5), 2.0 (2H, t), 1.89 (2H, t), 1.70 (2H, t), 1.61 (ZH, t), 1.18 (IN, t)

Compound number 243 (MR: 165-166). NMR solvent: ОМ5О 130: 167.7, 145.6, 145.5, 139, 137.4, 135.1, 131.9, 130, 129.2, 129.1, 127.1, 126.1, 117.3, 114.5, 81.8, 78.7, 2.6, 17.6, 17.6 0 - 0.7, 1.6 H?), 8.31 (IN, 1, - 1.7 H2), 6.21 1H, aa, - 0.7, 8.8 H2g), 8.18 (H,5bB), vl 1H, aa, y - 1.6, 8.8 No ), 7.98 (1H, a, y - 1.5, 7.8 H2), 7.91 (1H, a, Y - 1.4, 7.68 H2), 7.60 (1H, Y - 7.7 Nz), 7.51 (1H, in Bi), 5.46 ( 2H, 5), 3.91 (2H, 5), 1.60 (6H, 5)

Compound number 244 (MR: 148). NMR solvent: SOSIZ 130:151.5, 141.1, 137, 133.1, 131.5, 128.8, 126.4, 113.5, 59.3, 31.2, 28.9, 24.4 1H: 7.91 (IN, y, U - 1.2 Nl), 7.73 (2H, a, U - 68.6 No), 7.50 (1H, a, U - 1.2 Ng), 7.37 (2H, a, y - 6.6

Hg), 4.44 (1H, ai, U - 8.2 H2l), 3.0 (ZH, 5), 1.95 (2H, t), 1.78 (2H, t), 1.68 (2H, t), 1.63 (2H, t)

Compound number 245 (MR: 213-215). NMR solvent: OM5O 130: 167.6, 150.9, 142.7, 140.4, 139.6, 137.7, 134.2, 133.2, 129.4, 128.2, 126.6, 125.6, 124.4, 123.1, 115, 56.2, , 1, U - 1.8 Н7), 8.18 (1Н, а, ЯА 1.1 Н?), 8.15 (1Н, а, У - 1.1 Но), 8.07 (1Н, with Bi), 8.0 (2Н, а, 9 - 8.4 No), 7.90 (1H, and, 9 - 1.4, 7.7 Nl), 7.83 (2H, and, U - 68.4 No), 7.62 (IN, and, U - 1.6, 8.0

Ng), 7.51 (IN, y - 7.7 Ni), 7.44 (1H, 5 Bri), 3.84 (1H, t), 2.95 (ZH, 5), 1.80 (4H, t), 1.60 (1H, t), 1.57 (2H, t), 1.30 (2H, t, y - 12.7 Ng), 1.11 (1H, t, y - 13 Н2)

Compound number 246 (MR: 118-119). NMR solvent: SOSIZ 130: 163.1 (0.9) - 245.0 Nl), 151.3, 143.3 (0.9 - 8.0 N?), 141.8, 140.4 (a, U - 2.0 H2I), 137, 133.7, 130.1 (a, U - 8.5 No), 129.2, 126.2, 124.5, 123.9, 122.8 (0.9 -), 114.1 (9.9) - 22.0 No), 114.1 (94.9 - 21.0 H2), 113.5, 57.6, 31.4, 30 . .

(ZH, 5), 1.89 (2H, t), 1.87 (2H, t), 1.71 (1H, and Bbg, U - 11.5 H?), 1.59 (2H, ad, y - 3.6, 12.5 H2), 1.39 ( 2H.ta, 9 - 3.2, 13.2 H2), 1.13 (1H, 19, U - 3.3, 13.0 H2)

Compound number 247 (MR: 208-209). NMR solvent: OM5O 130: 157.9, 150.9, 141.6, 140.7, 140.5, 137.7, 134, 130, 129.2, 125.3, 123.8, 122.9, 117.6, 114.8, 114.5, 113.6, 56.8, (1H, 5, ri), 8.14 (2H, 5), 8.08 (1H, 5), 7.83 (1H, a, y - 2.0, 6.6 H2), 7.47 (1H, t), 7.45 (N.U - 7.7 Н2), 7.27 (1Н, 1, У - 8.0 Н2), 713 (IN, aa, о - 1.0, 1.7, 7.6 Но), 7.08 (IN, 1, У - 1.9

Н2г), 6.78 (1Н, и а на, 1.0, 2.4, 8.0 Н?2), 3.84 (1Н, т), 2.94 (ЗН, 5), 1.79 (4Н, т), 1.60 (1Н, т), 1.57 (2Н, т), 1.30 (2Н, 9, У - 12.7 Н?2), 1.13 (1Н, т, у - 13.0 Н2)

Compound number 248 (MR: 131-132). NMR solvent: OM5O 130: 150.9, 149 (t, 0) - 2.0 Nl), 142.5, 140.3, 138.8, 137.7, 134.3, 130.9, 129.5, 126.0, 125.6, 124.6, 123.1, 120.2 (6, 0 H - 9.0 ), 119.9, 119.4, 115.1, 56.8, 31.4, 29, 25.2, 24.9 1Н:8.20(1Н, а, 0) - 1.2 Н2), 8.17 (IN, 1.9 - 1.6 Н2), 8.1511Н, Я, 7 - 1.2 H2), 7.91 (1H, ta, m - 1.4, 7.8 H2), 7.79 (1H, a, 9 - 7.9 Nz), 7.71 (1H, ro), 7.62 (1H, her, y - 8.1 Nl), 7.61 (1H, t), 7.51 (1H,

U - 7.7 NI), 7.39 (1H, y, U - 8.2 H2), 2.94 (ZH, 5), 3.84 (1H, t), 1.78 (4H, t), 1.60 (1H, t), 1.56 (2H, t), 1.30 (2H, t, U - 12.8 Ng), 1.11 (1H, t)

Compound number 249 (MR: 162-163). NMR solvent: SOSIZ 130: 151.5, 141.2, 136.9, 136.8, 133.1, 131.4, 128.9, 128.8, 127.7, 126.6, 126.3, 113.1, 51.7, 48.6, 20.4 1H: 7.3, 1.91, 1H - 1.7 (1H - 1.7). (IN, a, U - 1.3 No), 7.64 (2H, a, U - 68.6 No), 7.39 (2H, 1.9) - 7.5

Nz), 7.34 (2H, a, y - 8.6 H2), 7.32 (1H, t), 7.31 (2H, a, Y - 8.2 Nl), 4.61 (2H, 5), 4.20 (1H, t, y - 6.8

Nz), 1.37 (6Н, и, У - 6.8 Н2)

Compound number 250 (MR: 111). NMR solvent: SOSIZ 130: 151.7, 142.3, 137, 136.7, 132.9, 128.9, 128.6, 127.7, 127.5, 126.6, 125.1, 112.9, 51.7, 48.5, 20.4 1H: 7.93 (IN2 - 1.7, 3), (2Н, ю, У - 68.2 Н2g), 7.А8 (IN, ю, У - 1.3 Нг), 7.39 (2Н, т), 7.37 (2Н, т), 7.31 (ЗН, т), 7.27 (1Н, t), 4.62 (2H, 5), 4.21 (IN, t, U - 6.7 Ng), 1.37 (6H, y, U - 6.7 Nz)

Compound number 251 (MR: 132-133). NMR solvent: SOSIZ 130:152.2, 142, 138.4, 136.8, 133, 129, 128.6, 127.6, 127.3, 126.1, 125, 113, 59.4, 51.3, 28.1

So 1H: 7.91 (1H, 9, U - 1.4 No), 7.65 (2H, a, y - 8.5 Nz), 7.46 (IN, y, U - 1.4 No), 7.38 (2H, 1) - 7.1

Nzg), 7.35 (2H, her, y - 8.0 No), 7.31 (1H, t, y - 7.4 Nl), 7.26 (2H, t), 7.25 (IN, t), 4.69 (2H, 5), 1.52 ( 9H, 5)

Compound number 252 (MR: 129-130). NMR solvent: SOSIZ 130: 152.1, 141, 138.4, 136.9, 133, 131.5, 129, 128.8, 127.6, 126.2, 126.1, 113.2, 59.5, 51.3, 28.1 1Н: 7.89 (1Н, 1.7, Н7-5), (2H, a, U - 8.6 Nzg), 7.43 (IN, 9, U - 1.3 No), 7.38 (2H, 1, U - 7.6

Na), 7.31 (1H, t), 7.31 (2H, y, U - 8.6 Ng), 7.24 (2H, y, U - 68.0 H2g), 4.68 (2H, 5), 1.52 (9H, 5)

Compound number 253 (MR: 147-148). NMR solvent: SOSIZ 130: 162.9, 147.5, 147.3, 136.8, 129.1, 128.2, 127.5, 64.6, 47.3, 44.2 1Н: 8.95 (1Н, 5), 8.07 (2Н, y, U - 8.7 Н2), 7.47 (2Н, ad, U - 8.7 Nl), 5.15 (2H, Bi), 4.36 (2H, Bi), 3.40 (2H, 1, U - 6.8 Ng)

Compound number 254 (MR: 141-142). NMR solvent: SOSIZ 130:151.5, 138.3, 134.2, 133.9, 128.4, 127.1, 126.8, 122.9, 57.2, 30.8, 30.1, 25.4, 25.2, 10.5 1H: 7.68 (2H, 9, U - 8.1 NO), 7.6 NO . 1.86 (2H, t), 1.81 (2H, t), 1.70 (1H, and Bg, y - 13.0 Nz), 1.57 (2H, t), 1.36 (2H, t), 1.12 (1H, t)

Compound number 255 (MR: ой). NMR solvent: SOSIZ 130: 159.9, 151.6, 142.1, 137, 136.7, 134.3, 129.7, 128.9, 127.7, 126.6, 117.5, 113.7, 113.2, 110, 55.3, 51.7, 207.9, Н: 48.6, 207.9, - 1.0 Ng), 7.47 (IN, 9, U - 1.0 No), 7.39 (2H, her, y - 7.2 NO), 7.31 (4H, t), 7.28 (2H, t), 6.84 (1H, t), 4.61 (2H, 5), 4.21 (1H, t, U - 6.8 Ng), 3.85 (ZH, 5), 1.37 (6H, y, U - 6.8 Ng)

Compound number 256 (MR: ой). NMR Solvent: SOSIZ 130: 159.8, 152.2, 141.8, 138.5, 136.8, 134.4, 129.6, 129, 127.6, 126.1, 117.4, 113.8, 113.3, 109.7, 59.4, 55.2, 51.2. - 1.2 No), 7.A5(1H, 9, U - 1.2 Nl), 7.39 (2H, 1, U - 7.6 No), 7.30 (1H, t, y - 7.3

Na), 7.26 (2H, t), 7.24 (2H, t), 7.19 (IN, t), 6.81. 1Н, и а а, У - 1.2, 2.6, 8.0 N?g), 4.69 (2Н, 5), 3.82 (ЗН, 5), 1.53 (9Н, 5)

Compound number 257 (MR: 138-139). NMR solvent: SOSIZ 130: 151.3, 142.8, 141.8, 140.2, 137, 134.6, 133.7, 129.9, 129.2, 127.3, 127.3, 126.2, 125.4, 60 124.5, 123.9, 25,

1H: 8.04 (1H, t), 7.94 (IN, a, U - 1.3 Nl), 7.78 (IN, t), 7.66 (IN, her, U - 1.7 No), 7.57 (IN, y, - 1.3 H2) . 1.5,2.2, 8.1 Н2), 3.98 (1Н, т), 3.02 (ЗН, 5), 1.89 (2Н, т), 1.87 (2Н, т), 1.71 (IN, and re, у - 13.3 Н?), 1.60 (2H, t), 1.39 (2H, ta, y - 3.0, 12.7 N?), 1.14 (1H, ha, U - 3.3, 13.0 Ng)

Compound number 258 (MR: 115-118). NMR solvent: SOSIS 130: 159.2, 151.3, 142.5, 142, 141.6, 137, 133.5, 129.7, 129.1, 126.4, 124.1, 124, 119.6, 113.4 (2 5 units), 113.3, 63.5, 31.5, 3.4, 5.5 . -1.4 2), 7.52 (1H, au - 1.5, 7.9 Ng), 7.47 (IN, U - 7.6 No), 7.36 (1H, 1, U - 8.0 H2), 7. 2411H, aa 10a9u-1.0,1.7, 7.7 Н7), 71911, aa, -1.7, 2.5Н2), 6.91 (IN, ada, о - 1.0, 2.5, 8.2 Ni), 4.11 (2Н, а, У - 7.0 Но), 3.97 (1Н, т), 3.01 (ZN, 5), 1.89 (2H, t), 1.86 (2H, t), 1.71 (IN, a rg, U - 12.5 H2), 1.59 (2H, da, y - 3.5, 12.5 Ng), 1.46 ( ЗН, и, У) - 7.0 Ng), 1.39 (2Н, та, 9 - 3.0, 13.0 Н2), 113 (IN, 14, У - 3.5, 13.0 Н?)

Compound number 259 (MR: 137-139). NMR solvent: SOSIZ 130: 158.3 (a, U - 248.0 N?l), 151.3, 141.7, 137.0, 135.0 (a, U - 1.3 No), 133.5, 130.5 (a, U - 3.5

Ng), 130.4 (t. U - 14.0 N?), 129.3 (a, 9 - 3.3 Ng), 128.9, 128.7 (9, U - 8.5 Ng), 128.0, 125.6 (j, y - 2.5 Ng), 124.9, 117.4 (0.9 - 25.0 H2g), 113.6, 57.5, 31.4, 30, 25.4, 25.2 1H: 7.97 (1H, 5 Bi), 7.93 (1H, y, y - 1.1 No), 7.82 (1H, ta, y - 1.7, 7.2 N?), 7.56 1N, a,04-11

Nzg), 7.52-7.43 (ZH, t), 7.29 (1H, t), 7.11 (1H, her, U - 9.5 Н2), 3.96 (IN, t), 3.0 (ZH, 5), 1.88 (2H, t ), 1.85 (2H, t), 1.71 (1H, a g, y - 13.0 No), 1.59 (2H, a 9, y - 3.5, 12.5 No), 1.39 (2H, 14, y - 3.0, 13.0

Na), ТZ (1Н, Та, у - 3.5, 13.0 N?g)

Compound number 260 (MR: 190-191). NMR solvent: ОМ5О 130: 156.8, 146.3, 141.3, 136.7, 126.2, 124.4, 115.4, 111.6, 80.6, 79.3, 60.8, 22.5 1Н: 9.48 (1Н, 5), 8.09 (IN, Я, Ug - 1.3 Н) 7.80 (1H, and, U - 1.3 Nz), 7.64 (2H, t a, U - 8.5 N?), 6.76 (2H, and, U - 8.5 Nz), 5.14 (2H, 5), 3.84 (2H, 5 ), 1.49 (6Н, 5)

Compound number 261 (MR: 197-199). NMR solvent: ОМ5О 130: 156.7, 151, 140.9, 137.3, 126.1, 124.4, 115.4, 112.5, 56.8, 31.3, 2941, 25.2, 24.9 1Н: 9.48 (1Н, 5), 8.05 (1Н, 1.3, Н - уг ), 7.77 (1Н, а, У - 1.3 Nl), 7.64 (2Н, т, у - 8.3 Н2), 6.77 (2Н, т, У - 8.3 Но), 3.80 (1Н, т), 2.91 (ЗН, 5 ), 1.77 (4H, t), 1.59 (1H, t), 1.55 (2H, t), 1.28 (2H, t),

Koo) 110 (1H, t)

Compound number 262 (MR: 170 (aes.)). NMR solvent: OMBO 130: 157.9, 149, 137.3, 135.3, 130.2, 129.5, 116.3, 116, 115.9, 112.3, 58.7, 31.5, 28.2, 24 1Н: 9.70 (1Н, 5), 9.24 (1Н, 5), 18.3 (IN, 5), 7.29 (IN, her, y - 7.8 Nz), 7.27 (1H, t), 7.24 (1H, t), 6.83 (1H, t, y - 2.2, 6.7 Н2), 4.39 (1H, t), 2.97 (ZH, 5), 1.89 (2H, t), 1.70 (4H, t), 1.53 (2H, t)

Compound number 263 (MR: 89-91). NMR solvent: SOSIZ 130: 146.8, 138.7, 134, 133.1, 128.4, 127.2, 126.9, 122.8, 81.2, 80.7, 61, 23, 10.6 1H: 7.66 (2H, y, U - 8.4 NO), 7.53 (1H, ), 7.43 (2H, 1, U) - 7.8 No), 7.31 (IN, Her, y - 7.4 N?g), 4.93 (2H, 5), 3.90 (2H, 5), 2.49 (ZN, 5), 1.61 (6H, 5)

Compound number 264 (MR: 118-119). NMR solvent: SOSIZ 130:152.1, 138.7, 135.3, 134.2, 134.1, 129.1, 128.4, 128.2, 127.7, 127.2, 126.9, 123.2, 53.9, 36, 10.6 1Н: 7.69 (Н2, а7, 5), U - 8.3 No), 7.43 (2H, 1, U - 7.7 Ni), 7.31 (IN, i, U - 7.4 H2), 7.40-7.27 (BN, t), 4.66 (2H, 5), 3.01 (ZN, 5), 2.49 (ZN, 5)

Compound number 265 (MR: 178-180 (aes.)). Solution Solvent: OMBO 130: 157.9, 149.1, 137.3, 136.8, 135.8, 130.2, 129.5, 128.5, 127.2, 126.8, 116.3, 116.1, 115.4, 112.4, 51.4, 47, 47.1, 1H, 5), 8.29 (1H, 5), 7.36-7.28 (5H, t), 7.27 (IN, Her, U - 8.0 NzI), 7.21 (1H, t), 7.18 (IN, t), 6.82 (1H , t, y - 2.5, 8.1 Ng), 4.65 (2H, 5), 4.16 (1H, t), 1.28 (6H, a, U - 6.7 Ng)

Compound number 266 (MR: ой). NMR solvent: SOSIZ 130: 150.7, 145.2, 133.2, 129.1, 125.1, 119.7, 113.5, 59.3, 28.8, 24.3 1Н: 8.09 (1Н, t s, U - 68.3 N2g), 7.98 (IN, t a, U - 8.3 Nzg), 7.59 (IN, t, y - 7.7 Ng), 7.A5 (IN, t, Y - 7.7 NI), 4.78 (1Н, t), 3.17 (ЗН, 5), 2.07 (2Н, т), 1.75 (4H, t), 1.63 (2H, t)

Compound number 267 (MR: 142-143). Solvent NMR: SOSIZ 130: 146.6, 141.2, 136.7, 133.2, 131.4, 128.9, 126.4, 112.8, 96.5, 75.9, 53.4, 25.6, 25.4, 23.7, 9.8 1Н: 8.03 (1.Н7, а2, Н27), 9 - 8.5 No), 7.59 (IN, ri), 7.37 (2Н, а, У - 8.5 Н2), 4.10 (IN, t), 3.81 (IN, и а, у - 5.5, 9.0 Но), 3.43 (IN .

Compound number 268 (MR: 117-118). NMR solvent: SOSIZ 130: 144.9, 136.5, 133.6, 131.7, 128.5, 127.8, 126.4, 110.8, 95.7, 63.1, 47.7, 23.9

1H: 7.96 (2H, y, U - 8.8 NI), 7.78 (1H, 5), 7.45 (2H, 1, U) - 8.0 Nz), 7.35 (IN, Her, U - 7.5 N?g), 4.07 ( 2H,... U - 6.2 H2), 3.58 (2H, 1, 9 - 6.2. H2g), 1.74 (6H, 5)

Compound number 269 (MR: 92-93). NMR solvent: SOSIZ 130: 141.6, 135.3, 133.9, 129.4, 128.8, 128.1, 127.5, 111.0, 80.6, 61.3, 29.7, 22.7, 22.5 1H: 7.85 (2H, 9, U - 8.4 H0 (2, 7) , U - 8.8 Н2), 4.81 (2Н, 5), 3.84 (2Н, 5), 1.65 (6Н, 5)

Compound number 270 (MR: ой). NMR solvent: SOSIZ 130: 146.7, 142.2, 136.6, 132.9, 128.7, 127.6, 125.2, 112.5, 96.4, 75.9, 53.4, 25.6, 25.4, 23.7, 9.8 (2H, a, U - 8.5 No), 7.61 (IN, 9, U - 1.3 No), 7.41 (2H, 1.0) - 8.0

Ng), 7.30 (TN,, U - 7.4 NO), 4.11 (IN, t), 3.81. (1H, and a, 9 - 5.2, 9.0 No), 3.44 (1H, 1, U - 9.5 No), 1.75 (ЗН, 5), 1.73 (ЗН, 5), 1.72 (2Н, т), 1.0 (ЗН , Her, U - 7.7 Ng)

Compound number 271 (MR: 113-114). Solvent NMR: SOSIZ 130: 156, 151.7, 137.4, 136, 128, 127.6, 121.7, 120.9, 117.2, 110.6, 57.5, 55.2, 31.1, 30.1, 25.4, 25.2 1n:8.23 - 7.1, aa, o No), 7.94 (1H, a, U - 1.3 No), 7.82 (1H, y, U - 1.3 H2), 7.28 1H, a, 15.9 -2.0, 7.6 No), 7.07 (1H, U - 1.1, 7.6 No ), 6.97 (1H, a, U - 8.3 H?), 3.95 (ZH, 5), 3.95 (1H, t), 2.99 (ZH, 5), 1.87 (4H, t), 1.69 (IN, a horn, U - 12.3 Но), 1.59 (2Н, а 4, 9 - 3.5, 12.5 Н2), 1.37 (2Н, 14.9 - 3.0, 13.0 Н2), 113 (IN, а, 9 - 3.3, 13.1 Нз)

Compound number 272 (MR: 178-181). NMR solvent: SOSIZ 130:151.0, 150.5 (а а, 9 - 12.7, 247 Ni), 149.7 (а а, У - 13.0, 248.0 Но), 140.3, 137, 130.3 (а а, 20.9 -3.7, 6.6 Н? ), 121.0 (9 a, 9) - 3.5, 6.3 No), 117.5 (0, U - 17.5 No), 114.1 (0.9 - 18.5 H2), 113.5 (9, - 1.0 H2), 57.6, 31.3, 29.9 , 25.4, 25.2 1Н: 7.88 (1Н, а, У - 1.3 Н2), 7.61. NN, aa, - 2.2, 7.7, 11.6 Ni), 7.49 (IN, t), 7.45 1Н, y, У - 1.3 Н2), 7.17 (IN, й, у - 8.4, 10.5 Н?), 3.93 (1Н, t), 2.99 (ZH, 5), 1.86 (4H, t), 1.70 (1H, a ry), 1.58 (2H, aa, y - .3.5, 12.3 No), 1.37 (2H, 19, 3.0, 13.0 Н ?), 1.12 (1H, ha, U - 3.5, 13.0 Ng)

Compound number 273 (MR: 142-143). Solvent NMR: SOSIZ 130: 162.3 (y, 9 - 246 Nz), 151.3, 141.3, 136.9, 129.2 (0, Y - 3.2 Nz), 126.8 (a, 9 - 8.0 Nz), 115.6 (9.9 - 22.0 Nz ), 112.9, 57.5, 31.3, 30, 25.4, 25.2. Hg), 7.09 (2Н, т, у - 8.8 Н2), 3.95 (1Н, т), 2.99 (ЗН, 5), 1.87 (4Н, т), 1.70 (1Н, and Bi, У - 13.0 Н?), 1.58 (2H, 44.9 - 3.5,

Zo 12.2 NO), 1.37 (2H, and, 9. - 3.5, 13.0 No), 1.13 (1H, ha, y - 3.5, 13.0 N?g)

Compound number 274 (MR: 156-158). NMR solvent: SOSIZ 130:151, 140, 137.1, 133.2, 132.8, 131.1, 130.6, 126.9, 124.3, 114, 57.6, 31.4, 29.9, 25.4, 25.2 1Н: 7.91 (1Н, а, Но - 2.90) (1H, a, 9 - 1.4 N?), 7.61 1H, a a, 0 - 2.0, 8.4 H2), 7.1 pn, a, yu - 1.4 H2), 7.45 (IN, y, U - 8.4 N?g) . , 13.0 H2), 113 (1H, 9, U - 3.5, 13.0 Ng)

Compound number 275 (MR: 160-162). NMR solvent: SOSIZ 130: 150.9, 148.6, 140, 137.3, 134.9, 130.9, 129.7, 122, 119.9, 114.6, 57.6, 31.4, 29.9, 25.4, 25.2 1H: 8.61 (IN, her2, y) - 8.14 (2H, t), 7.94 (1H, y, U) - 1.3 No), 7.64 (IN, y, U - 1.3 Nz), 7.57 (IN, y - 68.0 No), 3.96 (1H, t, y - 12.0 H2g), 3.02 (ZH, 5), 1.88 (4H, t), 1.72 (IN, t), 1.60 (2H, ad, U - 3.5, 12.5 H2), 1.39 (2H, ha, U - 3.0, 13.0 H2g), 1.14 (IN, 149, U - 3.5, 13.0 Ng)

Compound number 276 (MR: 130-131). NMR solvent: SOSIZ 130: 151.2, 150.5 (1, 9 - 2.7 No), 141.1, 137, 130.5, 126.5, 119.7, 115.9 (, )U - 259.5 IN2I), 113.2, 57.6, 31.3, 30, 25.2, 1H 25 : 7.89 (IN, y, U - 1.3 Nz), 7.79 (2H, a, U - 68.8 No), 7.47 (1H, a, 9 - 1.3 No), 7.15 (2H, a, U - 68.8

Hg), 6.54 (IN, i, U - 74 No), 3.95 (1H, t, U - 11.0 H2), 3.0 (ZH, 5), 1.86 (4H, t), 1.70 (1H, ab, y - 14.0 H2), 1.58 (2H, a 9, U - 3.6, 12.2 NO), 1.37 (2H, U - 3.2, 13.0 H2), 1.13 (IN, U - 3.5, 13.0 N?g)

Compound number 277 (MR: 168-169). NMR solvent: SOSIZ 130:151.2, 141.1, 137, 133.1, 131.6, 128.8, 126.4, 113.4, 57.6, 31.3, 30, 25.4, 25.2 1Н: 7.90 (1Н, y, U - 1.3 Nl), 7.73 (а, 2Н . U - 8.7 No), 7.49 (1H, a, 9 - 1.3 Ng), 7.37 (2H, U - 8.7

H2g), 3.95 (1H, t, y - 11.68 Nz), 2.99 (ZH, 5), 1.86 (4H, t), 1.70 (1H, y, U - 13.5 No), 1.58 (2H, a 4, - 3.5 , 12.3 H?), 1.38 (2H, a, y - 3.0, 13.0 H2), 113 (IN, ta, y - 3.5, 13 H?)

Compound number 278 (MR: 160). NMR solvent: SOSIZ 130:151.5, 142.3, 136.9, 132.8, 128.7, 127.6, 125.1, 113.1, 67, 54.4, 31.68, 29.5 1H: 7.94 (1H, 5), 7.80 (2H, y, U - 7.6 Nz), 7.51 (1H, 5), 7.41 (2H, 1, y - 7.6 No), 7.ZO(1H, y - 7.3

Hg), 4.28 (1Н, т), 4.09 (2Н, а а, 9 - 4.0, 11.5 Но), 3.50 (2Н, 1, У - 11.5 Н?), 3.04 (ЗН, 5), 1.94 (2Н, а a, U - 4.5, 12.3 No), 1.77 (2H, a ri, U - 12.0 Nz)

Compound number 279 (MR: 157-159). NMR solvent: SOSIZ 130:152.2, 145.6, 140.7, 133.3, 128.6, 127.1, 125, 112.4, 57, 30.7, 30.1, 25.4, 25.2, 14

1H: 7.76 (2H, a, U - 8.2 NI), 7.38 (2H, her, y) - 7.9 Nz), 7.26 (1H, her, y) - 7.5 Ng), 7.21 (1H, 5), 3.90 (IN ) NO), 1.35 (2Н, г, У - 12.5 Н2), 1.11 (1Н, га, у - 3.0, 13.0 Ng)

Compound number 280 (MR: 137). NMR solvent: SOSIZ 130: 143.9, 135.7, 133.7, 133.7, 130.1, 128.7, 127.7, 111.2, 80.9, 80.6, 61.3, 22.9 1Н: 7.90 (2Н, а, У - 8.6 Ng), 7.53), (1Н, 7.41 (2H, 5, U - 68.6 Ng), 4.88 (2H, 5), 3.91 (2H, 5), 1.62 (6H, 5)

Compound number 281 (MR: 132-134). NMR solvent: SOSIZ 130: 151.7, 149.1, 148.5, 142, 136.7, 126.1, 117.4, 112.4, 111.2, 108.4, 59.3, 55.9, 55.9, 31.2, 28.8, 243 1Н: 7.93, У, 1.91 (Но) . 8.3 Ng), 4.44 (1H, t, y - 8.2 No), 3.96 (ZH, 5), 3.91 (ZH, 5), 2.99 (ZH, 5), 1.95 (2H, t), 1.73 (4H, t) , 1.62 (2H, t)

Compound number 282 (MR: 189-191). NMR solvent: SOSIZ 130: 151.5, 142.2, 138.1, 137, 132.9, 129.1, 128.7, 128.3, 127.6, 127.2, 125.1, 113.1, 62.8, 55.8, 52.5, 31.6, 28.9, 28.9, 1, 1, 1, 3 Nz), 7.80 (2H, t, U - 8.0 Nzg), 7.50 (1H, y, U - 1.3 Nz), 7.41 (2H, 1, - 7.6

Nzg), 7.37-7.25 (6Н, т), 4.03 (1Н, т), 3.53 (2Н, 5), 3.03 (ЗН, 5), 3.01 (2Н, т), 2.11 (2Н, 1, -11.2

Nzg), 1.90 (2H, i rg, U - 12.0 Ng), 1.79 (2H, a re, y - 12.0 Ng)

Compound number 283 (MR: 128). NMR solvent: SOSIZ 130: 162.3, 149.8, 147.2, 130.1, 129.9, 128.7, 126.7, 57.6, 30.2 (2 via.), 25.5, 25.3 1Н: 8.82 (1Н, 5), 8.15 (2Н, t), 7.48 ( ЗН, t), 4.32 (IN, t bi), 3.14 (ЗН, 5), 1.93 (4Н, т), 1.71 (IN, a re, у - 13.3 Н2), 1.59 (2Н, т), 1.40 (2Н , t), 1.15 (1Н, а, У - 3.5, 13.0 Nz)

Compound number 284 (MR: 151-153). NMR solvent: SOSIZ 130:160.3, 153.3, 151, 130.3, 129.6, 128.6, 126.5, 58.7, 30.8, 29.5, 25.5, 25.2, 13.8 1H: 8.10 (2H, t, y - 7.5 Ng), 7.45 (ЗН ), 4.21-3.80 (1H, t), 3.03-2.99 (ЗН, t), 2.69 (ЗН, 5), 1.88 (4Н, t), 1.72 (1Н, t), 1.58 (2Н, t), 1.54 ( 2H, t), 1.12 (1H, t)

Compound number 285 (MR: 135-138). NMR solvent: SOSIZ 130: 162.9, 146.2, 144.9, 130.1, 129.8, 128.7, 126.7, 82, 79.3, 62.2, 22.8

Zo 1H: 8.94 (1H, 5), 8.12 (2H, t), 7.47 (ZH, t), 5.57 (2H, 5), 3.86 (2H, 5), 1.63 (6H, 5)

Compound number 286 (MR: 125-127). NMR solvent: SOSIZ 130: 160, 157.7, 146.4, 129.9, 129.9, 128.6, 126.6, 82.2, 79.6, 61.7, 22.8, 15.1 1Н: 8.08 (2Н, т), 7.45 (ЗН, т), 5.40 (2Н, 5 ), 3.85 (2Н, 5), 2.80 (ЗН, 5), 1.62 (6Н, 5)

Compound number 287 (MR: 222-224). NMR solvent: OM5O 130: 167.8, 150.7, 140.5, 140.2, 140, 137.8, 135, 135, 134.2, 129.6, 129.3, 129, 126.7, 125.8, 125.6, 124.1, 123.1, 114.9, 11 : 8.21 (1H, t, U - 1.6 H2g), 8.17 (1H, t, y - 1.6 H?), 8.15(1H, 5 0), 8.14 (IN, a, U - 1.3 H2), 8lL2(1H, a, - 1.3 No), 7.88 (IN, a 9, U - 1.6, 7.8 No), 7.88 (2H, t), 7.62 (IN, t), 7.57 (IN, i, U - 7.8

Hg), 7.51 (1H, U - 7.8 No), 7.48 (1H, in Big), 2.94 (ЗН, 5), 2.16 (6Н, 5), 2.11 (ЗН, 5), 1.66 (6Н, 5)

Compound number 288 (MR: 138-139). NMR solvent: SOSIZ 130: 159.2, 151.2, 141.9, 137.2, 137, 134.6, 129.7, 128.5, 127.9, 127.5, 117.8, 114.3, 113.3, 111.2, 69.9, 58.4, 38.9 , 9, U - 1.3 Nl), 7.50 (1H, t), 7.47 (2H, t), 7.46 (IN, y, 9) - 1.3 Nz), 7.40 (2H, t), 7.38 (IN, t), 7.34 (IN, t), 7.31 (IN, 1, U - 7.9 Н2), 6.92 IN, ada, у - 1.0, 2.5, 8.2 Но), 5.14 (2Н, 5), 2.99 (ЗН, 5), 2.20 ( 9H, 5), 1.74 (6H, 5)

Compound number 289 (MR: 165-169 (des.)). NMR solvent: SOSIZ 130: 150.9, 148.4, 146.7, 139.1, 137.6, 132.4, 129.1, 123.6, 113.8, 58.5, 38.5, 36.2, 34.1, 29.6 1Н: 9.0(1Н, и, У2 - 1.85 Н? (1Н, и а, У - 1.3, 4.7 Н?), 811 (1Н, а, у - 1.8, 7.8 Но), 7.94 (IN, 5), 7.55(1Н, 5), 7.33 (IN, а а, y - 4.9, 7.7 Nl), 2.99 (ZH, 5), 2.19 (9H, 5), 1.73 (6H, 5)

Compound number 290 (MR: 149). NMR Solvent: SOSIZ 130: 151.2, 142, 141.6, 141, 137.3, 133.6, 129.1, 128.7, 127.3, 127.2, 126.3, 124, 123.9, 113.2, 58.4, 38.6, 36.2, 34.2. Bg, y - 1.8 Ng), 7.954 (1H, y, U -..13 No), 7.78. (1H, au - 1.5, 7.5 No), 7.67 (2H, t,

U - 8.5 Ng), 7.53 (IN, 0, U - 1.3 Nl), 7.53 (1H, t), 7.48 (IN, 1, U) - 7.6 N?g), 7.46 (2H, 1, 9 - 7.8 Ne ), 7.37 (1H, t, U - 7.5 Ng), 3.0 (ZH, 5), 2.21 (9H, 5), 1.74 (6H, 5)

Compound number 291 (MR: 208-210). NMR solvent: SOSIZ 130: 151.1, 150.2, 148.2, 141.5, 138.6, 137.4, 134.1, 129.4, 126, 125.7, 123.8, 121.7, 113.5, 58.5, 38.6, 36.2, 29.7, 34.1

1Н: 8.67 (2Н, т, у - 5.0 Н2), 8.11 (IN, т, У - 2.0 Но), 7.95 (1Н, а, У - 1.3 Н?), 7.84 (1Н, аю - 1.7, 7.5 Нз) . 5), 1.73 (6Н, 5)

Compound number 292 (MR: 75-77). NMR solvent: SOSIZ 130: 146.4, 141.3, 136.9, 136.3, 133.2, 131.3, 129, 128.9, 128.8, 126.4, 126.2, 112.5, 97, 76.3, 55.5, 25.4, 24, Н01Н1, Х. ), 7.70 (2Н, а, У - 8.5 Н2), 7.56 (IN, и, У - 1.0 Нз), 7.46-7.38 (5Н, т), 7.35 (2Н, а, 9У - 8.5 Н2), 5.21 (1Н , а а, у - 5.5, 9.8 Н2), ALLO (НН, а а, 9 - 5.5, 9.3 Но), 3.68 (1Н, 1, - 9.5 Н2), 1.88 (ЗН, 5), 1.87 (ЗН, 5 )

Compound number 293 (MR: 164-165). Solvent NMR: SOSIZ 130: 161.4, 146.5, 140.5, 134.4, 120.3, 117.9, 94.7, 82.6, 79.6, 62.1, 56, 23 1Н: 7.92 (1Н, aa, U - 0.5, 9.0 Nzo), 7.58 (IN, a )

Compound number 294 (MR: 190-193 (des.)). NMR solvent: OMBO 130: 156.9, 151, 140.3, 137.2, 126.2, 123.8, 115.4, 112.7, 58.4, 31.2, 28.2, 24 1Н: 9.53 (1Н, 5), 8.18 (1Н, 5), 7.81 (1Н, 5 ), 7.65 (2H, a, U - 68.7 Ng), 6.79 (2H, y, U - 68.7 Ng), 4.36 (IN, t), 2.92 (ZH, 5), 1.86 (2H, t), 1.67 (4H , t), 1.53 (2Н, t)

Compound number 295 (MR: 91-93). NMR solvent: SOSIS 130: 144.0, 136.6, 133.6, 131.6, 128.5, 127.9, 126.5, 110.9, 81.0, 80.6, 61.3, 22.9 1Н: 7.96 (2Н, а, у - 8.4 Nzg), 7.54), (1Н, 7.45 (2H, t, y - 7.8 Ng), 7.35 (1H, t, y - 7.6 Ng), 4.88 (2H, 5), 3.91 (2H, 5), 1.62 (6H, 5)

Compound number 296 (MR: 106-110). NMR solvent: SOSIZ 130: 156.9, 150.9, 141.6, 137.3, 134, 130, 117.1, 115.1, 113.5, 112.6, 58.5, 38.5, 36.2, 34.1, 29.7 1Н: 7.95 (1Н, 65), Н7 . )

Compound number 297 (MR: 119-121). NMR solvent: OM5O 130: 149.8, 144.6, 132.6, 129.3, 125.3, 119.6, 113.3, 67.9, 57.6, 56.1, 34.2, 27.2 1H: 8.18 (1H, a, U - 8.3 No), 7.90 (1H, y, U - 8.3 No), 7.68 (1H, 1, U - 7.8 Ng), 7.52 (1H, 1, - 7.6

Nzg), 4.64 (1H, 5 bi), 4.03 (1H, 5 Bi), 3.40 (1H, 5 Big), 3.03 (ZH, 5), 1.90 (2H, 5 bi), 1.82 (2H, 5 Bi), 1.75

Koo) (2H, 5 Bi), 1.26 (2H, 5 Bi)

Compound number 298 (MR: 94-95). NMR solvent: SOSIZ 130: 146.6, 142.4, 136.9, 136.3, 132.8, 129, 128.9, 128.7, 127.6, 126.2, 125.2, 112.3, 96.9, 76.3, 55.5, 25.4, 24, 1, 1, 1, 1H Nzg), 7.78 (2H, t, y - 8.3 Nzg), 7.58 (1H, y, y - 1.3 Nz), 7.44 (5H, t), 7.39 (2H, t, y - 7.8 N?), 7.29 (1H , t, y - 7.4 H2), 5.21 11H, aa, 0 - 5.5,9.8 H2), 411 1 NN, aa, 0 - 5.5, 9.3

Но), 3.69 (1Н, и, У - 9.5 Н2), 1.89 (ЗН, 5), 1.87 (ЗН, 5)

Compound number 299 (MR: 140-142). NMR solvent: SOSIZ 130: 146.7, 141.2, 136.7, 133.3, 131.4, 128.9, 126.4, 112.8, 96.4, 63.6, 48.3, 24.1 1Н: 8.06 (1Н, ры), 7.73 (2Н, t, Uz - ), 68.6 7.61 (1Н, Б), 7.38 (2Н, т, у - 8.6 Н?), 4.12 (2Н, 1.9 - 6.0 Н2г), 3.85 (2Н, 1, У - 6.0 Н2), 1.74 (6Н, 5)

Compound number 300 (MR: 149-150). NMR solvent: SOSIZ 130: 149.1, 136.3, 134.3, 131.9, 128.5, 127.7, 126.4, 111.6, 57, 30.6, 29.8, 25.3, 25.2 1Н: 7.98 (2Н, и, У - 8.2.2 Н2), 7.7 Bi), 7.45 (2H, t, y - 7.6 Nzg), 7.34 (1H, t, y - 7.5 H2g), 4.24 (IN, t Bi), 2.88 (ZH, run), 1.86 (4H, t), 1.70 (1H, t), 1.56 (2H, t), 1.40 (2H, t), 1.13 (IN, t)

Compound number 301 (MR: 136-137). NMR solvent: SOSIZ 130: 144.3, 138.8, 135.2, 133.8, 130.5, 128.6, 128.1, 96.1, 81.1, 80.7, 61.3, 22.9 1H: 7.91 (2H, y, U - 8.5 H2), 7.82), (1H, 5 7.41 (2H, y, U - 8.5 H2), 4.84 (2H, 5), 3.91 (2H, 5), 1.63 (6H, 5)

Compound number 302 (MR: 108). Solvent NMR: SOSIZ 130: 149.4, 143.0, 136.4, 132.6, 128.7, 127.8, 125.2, 112.2, 80.7, 71.4, 57.8, 24.9, 9.8 1H: 7.98 (1H, Bg), 7.81 (2H - 8. a2 No, y ), 7.54 (1H, Bri), 7.42 (2H, 1, U - 7.4 No), 7.31 (1H, 1, U - 7.3 NN), 5.13 (IN, a, y - 4.5 No), 5.0 (1H, and )

Compound number 303 (MR: 80-81). Solvent NMR: SOSIZ 130: 150.6 (a a, U - 13.0, 247.5 IN?), 149.9 (a and, U - 13.0, 249.0 Ng), 149.1, 141.1, 136.5, 129.9 (a a, y - 3.8, 7.0 H2 ), 121.2(d a, 9 - 3.5, 6.2 Nzi), 117.6 (0, U - 17.5 Ni), 114.3 (0, 9 - 18.6 Ng), 112.5, 80.7, 71.5, 57.8, 24.9, 9.8 1Н: 7.95( 1Н, 9, У - 1.3 Н?2), 7.62 1нН, aa, - 2.0, 7.5, 11.5 Но), 7.50 (1Н, ио, У - 1.3 Н2г), 7.49 (IN, t), 719 (1Н, а . 1Н, t), 1.64 (IN, t), 0.98 (ЗН, и, У - 7.4 Ng)

Compound number 304 (MR: 100-101). NMR solvent: SOSIZ 130: 159.9, 149.3, 142.8, 136.4, 134, 129.7, 117.6, 113.9, 112.4, 110.3, 80.7, 71.4, 57.8, 55.3, 24.9, 9.8 1Н: 7.92, Но1, У1.98 . aa, o - 1.4, 2.6, 8.0 НН), 513 (1Н, а, У - 4.5 Н2), 5.0 IN, а, м - 4.5 Но), 4.32 (2Н, т), 3.88 (ЗН, 5), 3.73 (1H, t), 1.90 (1H, t), 1.63 (1H, t), 0.98 (ЗН, и, У - 7.5 Н2)

Compound number 305 (MR: 131-132). NMR solvent: SOSIZ 130: 151.1, 148.5, 148.3, 141.6, 138.3, 137.3, 136.5, 134.5, 134, 129.4, 126.2, 124.8, 123.9, 123.5, 113.4, 58.4, 38.6 , а, У - 2.5 Н?), 8.61 (1Н, а и, У - 1.7, 4.8 Н?), 8.05 (1Н, т), 7.95(1Н, и, У - 1.3 Н), 7.95 (IN, т ), 7.82 (IN, t), 7.55 (IN, a, U - 1.3 Nl), 7.51 (1Н, t), 7.50 (IN, t), 7.36 (1Н, а да, шу - 0.8, 4.8, 7.9 Nzg ), 3.0 (ZN, 5), 2.10 (OH, 5), 1.73 (6Н, 5)

Compound number 306 (MR: 195-196). NMR solvent: SOSIZ 130: 157.5, 155, 151, 141.2, 137.4, 134.7, 134.4, 134.2, 129.7, 125.9, 125.6, 123.7, 113.6, 58.5, 38.5, 36.2, 3.61, 25, H92, 1:92 9.01 (2H, 5), 8.05 (1H, 5), 7.95 (1H, c), 7.85 (IN, a, y - 7.5 Nz), 7.56 (1H, 5), 7.54 (1H, U - 7.5 No), 7.48 (1Н, а, У - 7.5 Но), 3.0 (ЗН, 5), 2.19 (9Н, 5), 1.73 (6Н, 5)

Compound number 307 (MR: 150-151). NMR solvent: ОМ5О 130: 157.6, 150.8, 140.7, 137.5, 134.6, 129.6, 115.7, 114.3, 114.1, 111.7, 56.8, 31.3, 29.1, 25.2, 24.8 1Н: 9.53 (1, 1Н, 9), 1Н, 0 U - 1.0 Ng), 7.90 (1Н, а, У - 1.0 Nz), 7.26 (2Н, т), 7.16 (IN, У - 8.0 Н2), 6.6511Н, ай а, 0 - 1.0, 2.2, 8.0 Но) . 1H, 4, y - 13.0 H2)

Compound number 308 (MR: 139-140). NMR solvent: SOSIZ 130: 150.6 (a a, U - 13.0, 248.0 N?), 149.9 (a a, U - 13.0, 249.0 No), 148.1, 141.1, 136.7, 136.1, 129.8 (yes, 9 - 3.9, 6.5 Но), 129.1, 128.9, 126.1, 121.2 (d a, 9 - 3.5, 6.2 Но), 117.6 (y, - 17.8 Н2), 114.3 (9, У - 18.5 Н2), 112.4, 80.4, 80.1, 53.0 1Н: 8.0511Н, а, У - 1.3 Н?2), 7.62 1nН, аа, о - 2.0, 7.6, 11.5 Ng), 7.56 (IN, о, У - 1.3 Н2g), 7.45 (IN, t), 7.42-7.37 (5Н, т), 718 (IN, а, 7 - 8.3, 10.0 Н2g), 5.44 (IN, О, У - 4.5 Н2), 5.26 (1Н, и, У - 4.5Н7), 518 (1Н, aa, -6.1,8.8 H2), 4lb(1H, a a, 0 - 6.1, 10.0 H?), 3.68 (IN, yes, U - 9.0,10.0

Nz)

Compound number 309 (MR: 155-157). NMR solvent: SOSIZ 130: 148.4, 142.9, 136.6, 136.2, 132.5, 129.0, 128.9, 128.7, 127.8, 126.1, 125.2, 112.1, 80.4, 80.0, 53.0 1Н: 8.08, Н2, 7 (1.08, Н2, 7) U - 8.0 Nl), 7.60 (1H, Bi), 7.42 (7H, t), 7.31 (IN, 1, y - 7.5 H2), 5.44 (1H, a, U - 4.8 H2), 5.27 (1H, a, У) - 4.8 Н2), 5.16 1Н, и а, У - 6.3, 8.8 Н2), 416 (1Н, ас, - 6.3, 10.1 Н2), 3.68 (1Н, и, У - 9.6 Н2g)

Compound number 310 (MR: 126-127). NMR solvent: SOSIZ 130: 148.9, 142.9, 136.4, 132.6, 128.7, 127.8, 125.2, 112.1, 80.4, 73.4, 52.9,17 1H: 7.99 (1H, a, U - 1.3 H2), 7.80 (2H, t a, U - 8.4 No), 7.54 (IN, y, U - 1.3 N?), 7.42 (2H, those, y - 7.8 H2), 7.31 (IN, those, y - 7.5 Ng), 5.14 (1H, 9, U - 4.5 No), 5.04 (1H, y, U - 4.5 No), 4.39 (1H, t), 4.36 (IN, t), 3.63 (IN, and y, U - 6.9, 8.4 N?g), 1.37 ( ZN, 9, U - 6.0 N?g)

Compound number 311 (MR: 127). Solvent NMR: SOSIZ 130: 150.6 (a a, U - 12.5, 247.5 IN?), 149.9 (a a, U - 13.0, 248.5 No), 148.6, 141.1, 136.4, 129.9 (a au -3.5, 7.0 N?) . У - 1.3 Н?2), 7.62 1Н, аа, - 2.1, 7.7, 11.5 Но), 7.51 (1Н, о, У - 1.3 Н2g), 7.49 (IN, t), 7.19 (1Н, а, У - 8.3 , 10.1 No), 5.13 (1H, a, U - 4.5 No), 5.04 (1H, a, U - 4.5 No), 4.39 (1H, t), 4.36 (1H, t), 3.65 (1H, t), 1.37 (ZN, a, U - 6.0 H2)

Compound number 312 (MR: 118). NMR solvent: SOSIZ 130: 150.9, 142.2, 136.5, 133, 128.7, 127.4, 125.1, 113, 58.9, 39.4, 31.4, 25.6, 25.1, 14.9 1Н: 7.89 (1Н, а, У - 1.3 Нз (2 7), Н . . U - 7.1 No), 1.13 (1H, t)

Compound number 313 (MR: 121-122). NMR solvent: SOSIZ 130: 150.9, 149.1, 148.5, 142, 136.2, 126.2, 117.3, 112.3, 111.2, 108.4, 58.9, 55.9, 55.9, 39.4, 31.4, 25.6, 25.1, 14 (UIN: 7, 8, 14 - 1.3 No), 7.41 (1H, 5), 7.41 (1H, a, U - 1.3 No), 6.91 (1H, a, U - 8.4 H2), 7.30

Mon. aa, U - 2.0, 8.4 H2), 3.96 (ZN, 5), 3.91 (ZN, 5), 3.77 (IN, 11, y - 3.5, 12.0 No), 3.43 (2H, 49.9 - 60 7.1 Nl) .

Compound number 314 (MR: 208). NMR solvent: OM5O 130: 151.6 (a, 9 - 243.0 Nl), 150.6, 146.1 (a, 9 - 11.0 No), 139.5 (j, U - 2.5 No), 137.2, 126.8 (a,

U - 7.0 H2), 120.8 (y, 9 - 3.4 No), 114.1 (a, 9) - 2.0 No), 113.7, 112.1 (a, 9 - 19.5 No), 56.8, 56, 31, 28.9, 25, 24.6 1H: 8.04 (1H, 9, U - 1.3 No), 7.90 (1H, a, U - 1.3 No), 7.64 1H, yes, U) - 2.0, 8.3 NO ), 7.61 (1H, t), 78 (IN , U - 9.3 Но), 3.86 (ЗН, 5), 3.80 (1Н, т), 2.92 (ЗН, 5), 1.79 (4Н, т), 1.62 (1Н, т), 1.59 (2Н, т), 1.30 (2H, t), 1.12 (1H, t)

Compound number 315 (MR: 162-163). NMR solvent: OM5O 130: 151.6 (y, U - 242.5 No), 150.7, 146.4 (a, 92 - 10.5 N?), 138.5, 137.5, 125.7 (0, U - 7.6 N2), 121.2 (0.9 - 3.0 Ng), 114.3, 114.1 (a, 9) - 2.0 No), 112.4 (a, 9 - 19.5 No), 58.5, 56.1, 31.3, 28.2, 24 1H: 8.31 (IN, 56), 8.03 (1H, a, y - 1.2 No), 7.69 (1H, and a, U - 2.0, 12.5 No), 7.65 (1H, t), 7.21 (IN, U - 8.8 Ng), 4.37 (1H, t), 3.86 (ZN, 5 ), 2.93 (ZH, 5), 1.88 (2H, t), 1.68 (4H, t), 1.53 (2H, t)

Compound number 316 (MR: 205). NMR solvent: OM5O 130: 151.6 (0, U - 243.5 Nzo), 147.2 (y, U - 10.5 No), 144.6, 136.8, 136, 122.9, 121.8 (a, 9 - 3.3

Nzg), 114.5, 114.3, 112.9 (a, U - 20.0 No), 80.7, 79.3, 61.3, 56.1, 22.3 1H: 9.05 (1H, 5 Big), 8.31 (IN, y, U - 1.3 N?), 7.82 1Н, а а, У) - 2.2, 12.7 Но), 7.74 1Н, а, у - 8.5

NO), 7.28 (1H, U - 6.7 No), 5.21 (2H, 5), 3.87 (ZH, 5), 3.86 (2H, 5), 1.51 (6H, 5)

Compound number 317 (MR: 173-174). NMR solvent: SOSIZ 130: 151.3, 150, 142.3, 141.5, 137.2, 133.4, 129 (2 5 id.), 127.7, 125.4, 123, 122.8, 113.1, 112.7, 58.3, 40.6, 38.2, 1.1, 34.7, Н: 36. 8.01 (1H, 5), 7.95 (1H, 5), 7.69 (IN, y, U - 7.5 Nl), 7.59 (2H, t, y - 8.8 Nz), 7.51 (1H, 5), 7.50 (IN, a . ), 1.74 (6Н, 5)

Compound number 318 (MR: 181-182). NMR solvent: SOSIZ 130: 168.1, 164.5, 157.6, 151.1, 141.7, 137.2, 1333.7, 133.4, 128.7, 128, 128, 125.5, 124.4, 116.1, 113.3, 58.4, 54.2 (1H, 5), 7.93 (1H, 5), 7.91 (1H, 5), 7.78 (1H, a, U - 7.6 Ng), 7.50 (1H, 5), 7.A6 (IN, 1, U - 7.5 Hg), 7.40 (1Н, а, 9 - 7.5 Н?), 4.04 (ЗН, 5), 4.03 (ЗН, 5), 2.99 (ЗН, 5), 2.19 (9Н, 5), 1.73 (6Н, 5)

Compound number 319 (MR: 109-111). NMR solvent: SOSIZ

Zo 130: 151.9 (a, U - 246.0 Nl), 151.2, 147.8 (a, 9) - 11.0 H2), 141.3, 136.8, 129.6 (a, 9 - 3.5 H2), 117.3 (a, 9) - 7.0 No) . . 8.3. , and 9, y - 4.5, 13.5 Н2), 1.37 (2Н, 14, У - 3.0, 13.0 Н2),

TK (1N,ta, U - 3.4, 13.0 N?)

Compound number 320 (MR: 170-171). Solvent NMR: SOSIZ 130: 163.1 (a, U - 240.0 NI), 151.1, 145.9 (a, 9 - 15.0 Nl), 141.5, 139.9 (a, 9 - 8.0 Nz), 137.4, 137.2, 134.7 (9, U - 4.5 H), 134.1, 129.5, 126.1, 124.8, 123.8, 113.5, 109.4 (0.9 - 37.5 Nzg), 8.05 (1H, t, y - 2.5, 7.5 No), 8.02 (1H, t, y - 1.6 Ng), 7.95 (11H, y, Y - 1.3 H2), 7.81 (1H, a, Y) - 1.5, 7.5 No), 7.55(1H, a, 9 - 1.3 No), 7.51 (IN, y - 7.5 No), 7. A NN, a

And U -1.5, 7.8 No), 7.03 (IN, t, y - 3.0, 8.5 Nzg), 3.0 (ZN, 5), 2.20 (OH, 5), 1.74 (6Н, 5)

Compound number 321 (MR: 100-103). NMR solvent: SOSIZ 130: 151.9 (a, U - 246.0 NI), 151.5, 147.8 (a, 9 - 11.0 Nl), 141.3, 136.8, 129.5 (y, U - 3.5 N?g), 117.3 (9, U - 7.0 No), 116.2 (0, U - 19.0 Nz), 113.2, 110.3, 59.3, 56.2, 31.2, 28.9, 24.3 1Н: 7.94 (1Н, и, У - 1.0 Н?), 7.50 (1Н, а а, у - 2.0, 7.50 No), 7.47 (IN, a, 9) - 1.0 n2), 7 24 tN, and yes» - 2.0, 4.3, 8.3 НН), 7.09 (1Н, аа, 0 - 8.3, 11.0 Н? ), 4.44 (1Н, di, У - 6.0 Н2), 3.97 (ЗН, 5), 3.0 (ЗН, 5), 1.96 (2Н, т), 1.75 (4Н, т), 1.63 (2Н, т)

Compound number 322 (MR: 216-217). NMR Solvent: SOSIZ 130: 156.9, 151, 142.4, 141.9, 141.4, 137.3, 132.9, 129.7, 129, 126.3, 124.2, 124.1, 118.8, 114.7, 114.5, 113.4, 38.7 (1H, Big), 8.03 (1H, a, U - 1.3 Ng), 7.90 (1H, 5 bg), 7.70 (1H, y, U - 1.7, 7.4 Nz), 7.52 (1H, 9.9 - 1.3 No ), 7.44 (1H, a y, U) - 1.6, 7.8 H2?), 7.40 (1H, U - 7.6 No), 7.24 (1H, her, U - 7.9 No), 717 (IN, 56Bi), 713 ( IN, t), 6.85(1Н, а а а, 9 - 0.9, 2.5, 8.0 Н2), 3.0 (ЗН, 5), 2.20 (9Н, 5), 1.74 (6Н, 5)

Compound number 323 (MR: 184-185). NMR solvent: SOSIZ 130: 163.6, 151.2, 145, 141.8, 138.3, 137.6, 137.3, 133.8, 130, 129.3, 125.7, 124, 123.5, 113.3, 110.7, 58.4, 53.6, 39.2, 39.6, 3.4, 3.4, 3.4

1nH: 8.44 (1H, aa, 9 - 0.6, 2.5 No), 7.98 (IN, t), 7.95 (1H, y, Y - 1.3 H?), 7.87 (IN, 4 a, y - 2.5, 8.6 H2) . а а, У - 0.6, 8.6 Н2о), 3.99 (ЗН, 5), 3.0 (ЗН, 5), 2.20 (9Н, 5), 1.73 (6Н, 5)

Compound number 324 (MR: 138-140). Solvent Names: SOSIZ 130: 168.4, 151.2, 142, 140.9, 137.3, 137.3, 136.8, 133.5, 129.1, 127.6, 126, 123.8, 123.6, 120, 113.3, 58.4, 38.6, 36.2 (IN, 1, У - 1.7 Но), 7.95(11Н, а, 9 - 1.2 Н2), 7.74 (1Н, and у - 1.7, 7.3 Нл), 7.60 (АН, б), 7.52 (1Н, а,» - 1.2 No), 7.49 (1H, a, y - 1.9, 7.8 No), 7.44 (1H, her, U - 7.6 Nz), 3.0 (ZN, 5), 2.20 (9H, 5), 2.19 (ZN, 5 ), 1.73 (6Н, 5)

Compound number 325 (MR: 150-152). Solvent NAMR: SOSIZ 130: 151.1, 143.6, 141.8, 138.7, 137.2, 133.6, 132.8, 129.1, 126.3, 124.9, 123.7, 122.5, 113.2, 108.9, 58.4, 38.5 ), 7.94 (1H, 5), 7.81 (1H, 5), 7.66 (IN, t), 7.51 (1H, 5), 7.49 (1H, t), 7.40 (2H, t), 6.78 (1H, t) , 2.99 (ZH, 5), 2.20 (9H, 5), 1.73 (6H, 5)

Compound number 326 (MR: 105-107). NMR solvent: SOSIZ 130: 159.1, 151.8, 142, 136.8, 126.4, 125.8, 114, 112.1, 59.3, 55.3, 31.1, 28.8, 24.3 1Н: 7.91 (IN, y, U - 1.2 Nz), 7.73 (2Н , У - 6.8 Н2), 7.41 (1Н, а, у - 1.2 Но), 6.95 (2Н, а, 9 - 8.8

Н2г), 4.45 (1Н, аи, У - 8.0 Н2г), 3.85 (ЗН, 5), 3.0 (ЗН, 5), 1.95 (2Н, т), 1.76 (2Н, т), 1.67 (2Н, т), 1.63 (2H, t)

Compound number 327 (MR: 92-94). NMR solvent: SOSIZ 130: 159.9, 151.6, 142, 136.9, 134.4, 129.7, 117.5, 113.6, 113.5, 110.1, 59.3, 55.3, 31.2, 28.9, 24.3 1H: 7.93 (1H - 1.3, 1, 1, 1), (1H, a, Y) - 1.3 No), 7.40 (1H, a a, 9 - 1.4, 2.4 No), 7.36 (1H, y,

У -1.2, 7.6 Н2g), 7.32 (1Н, 1, У - 7.7 Н?), 6.86 НН, аа, 0 - 1.5, 2.7, 8.0 Но), 4.45 (1Н, т), 3.88 (ЗН, 58), 3.0 (ZH, 5), 1.96 (2H, t), 1.78 (2H, t), 1.68 (2H, t), 1.60 (2H, t)

Compound number 328 (MR: 153-154). NMR solvent: SOSIZ 130: 159.2, 146.6, 142.5, 136.1, 126.4, 125.5, 114.1, 110.9, 81.1, 80.3, 61.8, 55.3, 22.9 1Н: 7.93 (IN, y, U - 1.5 Ng (2Н, 7.71) , У - 68.9 Н?), 7.А1 (1Н, а, у - 1.5 Но), 6.94 (2Н, а, о - 68.9

NO), 5.13 (2Н, 5), 3.88 (2Н, 5), 3.84 (ЗН, 5), 1.61 (6Н, 5)

From Compound number 329 (MR: 100-101). Solvent NMR: SOSIZ 130: 159.9, 146.4, 142.4, 136.1, 134.1, 129.7, 117.5, 113.8, 112.3, 110.2, 81, 80.3, 61.8, 55.3, 22.8 7.51 (1Н, а, 9 - 1.3 Но), 7.40 (1Н, а а, 9 - 1.5, 2.5 Н2), 7.34 (IN, and,

U - 1.5, 7.6 H2g), 7.30 (IN, her, U - 7.8 H2), 6.8511Н, а а а, у - 1.5, 2.7, 7.9 Но), 5.12 (2Н, 5), 3.67 (2Н, 5) , 3.86 (ZH, 5), 1.61 (B6H, 5)

Compound number 330 (MR: 164-166). NMR solvent: ОМ5О 130:151.2 (а, 9 - 240.0 Но), 150.8, 144.0 (а, 9 - 12.3 Н2?), 139.9 (y, 9 - 2.0 Н?g), 137.4, 125.4 (а,

U - 7.0 NO), 121.0 (9, 9 - 3.0 No), 117.9 (y, U - 3.2 No), 113.5, 112.5 (y, U - 19.5 No), 56.8, 31.3, 29, 25.1, 24.8 1Н: 9.89 (1H, 5), 8.06 (IN, I, U - 1.3 No), 7.88 (IN, y, U - 1.3 No), 7.58 1H, aa, o - 2.0, 12.7 H2), 7.48 (IN, t, y - 2.0, 8.4 Н?), 6.95(1Н, y y, У - 8.4, 9.0 Но), 3.80 (1Н, т), 2.91 (ЗН, 5), 1.76 (4Н, т), 1.60 (1Н, т) , 1.55 (2H, t), 1.29 (2H, t), 1.10 (1H, t)

Compound number 331 (MR: 170-171). NMR solvent: OM5O 130:151.2 (a, 9 - 240.0 Nl), 151.2, 144.0 (a, 9 - 12.5 N?), 139.9 (y, 9 - 2.6 No), 137.4, 125.4 (a, y - 6.9 Ng) . (IN, I, U - 1.3 No), 7.88 (IN, y, U - 1.3 No), 7.58 1Н, аа, о - 2.0, 12.7 Н2), t4v(In, aaa, - 1.0, 2.0, 8.4 Н? 2), 6.95 (1Н, а а, У - 8.4, 9.1 Но), 4.35 (1Н, т), 2.92 (ЗН, 5), 1.87 (2Н, т), 1.67 (4Н, т), 1.53 (2Н, t)

Compound number 332 (MR: 194-196). NMR solvent: OM5O 130:151.2 (a, 9) - 240.0 Ng), 146.2, 144.1 (a, 2 - 12.0 No), 140.2 (y, 9 - 2.3 No), 136.9, 125.3 (a,

U - 6.8 Ng), 121.1 (9.94 - 3.0 Ng), 117.9 (y, 9 - 3.7 Nz), 112.5 (a, U - 20.0 Nz), 112.5, 80.6, 79.3, 60.8, 22.4 1Н: 9.91 (1Н . - 2.1, 8.6 H?), 6.95 (1H, and 9, U - 8.6, 9.1 H2o), 5.16 (2H, 5), 3.84 (2H, 5), 1.49 (6H, 5)

Compound number 333 (MR: 173-176). NMR solvent: OM5O 130: 150.4 (a, U - 240.0 No), 146.1, 145.0 (a, 9 - 12.5 Nl), 140.2, 136.9, 130.1 (a, U - 3.0 N2), 116.2 (9, U - 18.5 Nl ), 115.9 (a, 9 - 6.3 No), 114.3 (0, U - 2.7 Nl), 113.1, 80.6, 79.3, 60.8, 22.4

1H: 9.93 (1H, 5), 8.13 (1H, 9, Y - 1.3 H2g), 7.92 (1H, y, Y) - 1.3 No), 7.46 (1H, yes, Y - 2.1, 8.8 H2), 724p1n, adcha,-2.1, 44, 8.5 H2), 73 (IN, and a, U - 8.5, 11.2 NO), 5.16 (2H, 5), 3.84 (2H, 5), 1.49 (6H, 5)

Compound number 334 (MR: 154-155). NMR solvent: SOSIZ 130: 154.6, 150.9, 150.7, 137.8, 134.3, 128.9, 124.2, 122.9, 121, 114.6, 110.9, 101.9, 57.6, 31.4, 29.9, 25.4, 25.2, 1.7, 25.2 U.N. H2g), 7.61 (IN, y, U - 1.3 No), 7.60 (1H, t), 7.49 (IN, y, U - 68.0 Nz), 7.28 (N.Ya y - 15, 7.5 N?), 7.24 ( 1Н, Y У - 1.1, 7.3 No), 7.10 (1Н, 5), 3.97 (IN, т), 3.01 (ЗН, 5), 1.87 (4Н, т), 1.71 (1Н, а рт, у - 13.0 Но ), 1.59 (2H, and 9, U - 3.5, 12.5 No), 1.39 (2H, 49, U - 13.0 H2z), 1.14 (IN.ta, y - 3.5, 13.0 N?)

Compound number 335 (MR: 161-163). NMR solvent: SOSIZ 130:151, 148.5, 146.7, 139.2, 137.3, 132.4, 129, 123.6, 114, 57.6, 31.4, 30, 25.4, 25.2 1Н: 9.01 1Н, аа, о - 0.8, 2.3 Н?2), 8.53 (1Н, и а, У - 1.7, 4.8 Н7), 8.12 1нН, аа, - 1.8, 2.2, 8.0

Hg), 7.94 (1H, 9, U - 1.3 No), 7.58 1H, a, y - 1.3 No), 7.34 (IN, a a a, - 0.8, 4.9, 8.0 H2o), 3.95 1H, t), 3.01 (ZH, 5), 1.87 (4H, t), 1.71 (1H, a bg, U - 13.5 N?), 1.59 (2H, and 4, y - 3.5, 12.5 Ng), 1.38 (2H, 1 a, U - 3.5, 13.0 НН), 1.13 (IN, 19, У - 3.5, 13.5 Н?)

Compound number 336 (MR: 211-213). NMR solvent: SOSIZ 130: 151, 150.4, 148, 141.4, 137.4, 137.3, 137, 135.5, 134.2, 129.5, 126, 125.1, 124.2, 123.8, 113.6, 58.5, 38.6, 36.2 .

U - 7.3 Nz), 7.55 (1H, 5), 7.51 (1H, her, y - 7.51 Nl), 7.46 (IN, 9, U - 8.0 No), 7.41 (IN, a, 9 - 8.3 H2), 3.0 (ЗН, 5), 2.20 (9Н, 5), 1.73 (6Н, 5)

Compound number 337 (MR: ой). Solvent NMR: SOSIZ 130: 147.5, 145.8, 140.9, 133, 128.6, 127.3, 125, 111.1, 81, 80.6, 61, 22.9, 14.3 1H: 7.74 (2H, y, U - 8.3 Nl), 7.38 (2H, her , y) - 7.9 Nz), 7.27 (1H, her, y - 7.6 Nl), 7.20 (1H, 5), 4.90 (CH, 5), 3.88 (2H, 5), 2.56 (ZH, 5), 1.61 ( 6H, 5)

Compound number 338 (MR: 129-130). NMR solvent: SOSIZ 130: 154.6, 150.4, 146.1, 137.3, 134.9, 128.8, 124.3, 123, 121.1, 113.2, 110.9, 102.3, 81.1, 80.3, 62, 22.8

Zo 1H: 8.04 (1H, a, U - 1.3 Nl), 7.61 (1H, a, 1.3 No), 7.60 (1H, t), 7.48 (1H, t, y - 7.8 Ng), 7.30 (1H, 91, 9 - 1.5, 7.3 H?), 7.2A (1H, 1, Y - 1.2, 7.4 NO), 7.10 (1H, 5), 5.16 (2H, 5), 3.89 (2H, 5), 1.62 (6H, 5 )

Compound number 339 (MR: 154-155). NMR solvent: SOSIZ 130: 148.6, 142.8, 136.5, 132.6, 128.7, 127.8, 125.2, 112.2, 80.3, 67.1, 46.0 1H: 8.05 (1H, a, U - 1.3 Nzg), 7.80 (2H, t a, U - 68.4 No), 7.60 (1H, y, 9 - 1.3 No), 7.41 (2H, those» - 7.5 Nz), 7.31 (IN, those, U - 7.3 No), 5.12 (2H, 5), 4.15(2Н ,1, 9 - 6.5 Но), 3.80 (2Н, 1, У - 6.5 Н?)

Compound number 340 (MR: 122-123). NMR solvent: SOSIZ 130: 159.9, 148.4, 142.8, 136.6, 136.2, 133.9, 129.7, 129, 128.9, 126.1, 117.6, 113.9, 112.3, 110.3, 80.4, 80, 535.17, Н. - 1.3 Ng), 7.59 (1H, a, U - 1.3 Nz), 7.47-7.37 (BN, t), 7.40 (IN, t), 7.36 (1H, t), 7.31 (IN, her, y - 7.7 Н2 ), 6.87 (1H, a a a, y - 1.5, 2.6, 7.9 No), 5.43 (IN, a, U - 4.5 No), 5.26 (IN, a,

U -4.5Н2),516(1Н, аа, у - 6.1, 8.8 Н?), 4.16 (IN, а а, У - 6.2, 10.0 Н2), 3.87 (ЗН, 5), 3.68 (IN, 1, У - 9.5 H2g)

Compound number 341 (MR: 164-165). Solvent NMR: SOSIZ 130: 159.1, 151.4, 142, 136.8, 126.4, 125.8, 114, 112.1, 57.5, 55.3, 31.3, 30, 25.4, 25.2 1Н: 7.89 (1Н, а, У - 1.3 Но), 7.40 , 9, У - 1.3 Но), 7.33 (2Н, т и, У - 9.0 Н2), 6.95 (2Н, та, у - 9.0 Нг), 3.95 (1Н, т), 3.84 (ЗН, 5), 2.99 ( ЗН, 5), 1.86 (4Н, т), 1.70 (1Н, a re, У - 13.0 Н2g), 1.58 (2Н, aa, - 3.5, 12.5 Н2г), 1.37 (2Н, 14, У - 3.2, 13.0 Н2 ), 112 (IN, a, U - 3.5, 13.0 N?g)

Compound number 342 (MR: 122-123). NMR solvent: SOSIZ 130: 159.9, 151.3, 141.9, 136.8, 134.4, 129.7, 117.5, 113.6, 113.5, 110.1, 57.5, 55.3, 31.3, 30, 254, 25.2 1nH: 7.3, 1) , 7.49 1H, a, U - 1.3 No), 7.40 (1H, a a, 9 - 1.4, 2.5 No), 7.36 (IN, and,

У - 1.4, 7.7 Ni), 7.31 (IN, 1Н, у - 8.0 Н2), 6.8511Н, а а а, о - 1.2, 2.5, 7.9 Ng), 3.95 (1Н, т), 3.88 (ЗН, 5) . , 1.38 (2H, 14.94 - 3.2, 13.0 No), 1.13 (1 N, ha, U - 3.5, 13.0 N?h)

Compound number 343 (MR: 150-152). NMR solvent: OM5O 130: 150.3 (y, U - 240.0 N?o), 150.8, 144.9 (a, 9 - 12.5 Nl), 139.9, 137.5, 130.2 (y, U - 3.5 N?g), 116.2 (9, U - 18.7 Nl), 115.9 (a, 9) - 6.3 Ng), 114.2 (a, 9) - 3.0 No), 114.1, 56.8, 31.3, 29, 25.1, 24.8 1H: 9.89 (1H, with Bi), 8.08 (1H, 5), 7.89 (IN, 5), 7.45 (IN, y, U - 8.3 Nz), 7.24 (1H, 5 bi), 7.13 (IN, t, y - 9.0, 11.0 Nzg), 3.79 (1H , 5 Big), 2.91 (ZH, 5), 1.76 (4H, t), 1.58 (ZH, t), 1.29 (2H, t), 1.10 (IN, bo t)

Compound number 344 (MR: 144-145). NMR solvent: OM5O 130: 151.1, 150.3 (a, U - 241.0 Nl), 144.9 (a, 9 - 12.5 No), 140.0, 137.5, 130.2 (y, 9U - 3.2 H2g), 116.3 (9, U - 18.5 Nl), 115.9 (a, 9 - 6.5 No), 114.2 (0.9 - 3.0 No), 114.1, 58.4, 31.2, 28.2, 24.0 1Н: 9.91 (1Н, 5), 8.08 (1Н, 5), 7.88 ( IN, y, U - 1.3 No), 7АА5 (1Н, аа, у - 2.0, 8.7 Nl), 7.24 (IN, t), 7.13 (IN, а а, 9 - 8.6, 11.2 Н2g), 4.35 (1Н, t), 2.92 (ZH, 5), 1.87 (2H, t), 1.68 (4H, t), 1.53 (2H, t)

Compound number 345 (MR: 113-114). Solvent NMR: SOSIZ 130:150.8, 150.5 (I, U - 3.0 No), 141.2, 136.6, 130.5, 126.5, 119.7, 115.9 (, U - 259.5 No), 113.1, 58.9, 39.4, 31.4, 25.16, 25. , 14.9 1Н: 7.87 (1Н, а, У - 1.3 Н2г), 7.80 (2Н, т и, У - 68.8 Но), 7.45 (1Н, 9, У - 1.3 Но), 716 (2Н, та, у - 8.8 Н2?), 6.54 (IN, 1, y - 74 No), 3.7541Н, Her, У - 3.5, 12.0 Но), 3.43 (2Н, а, у - 7.1 Nl), 1.85 (АН, т), 1.68 ( 2H, t), 1.64 (1H, t), 1.29 (2H, t), 1.25 (ЗН, 1, У - 7.1 Но), 1.12 (1Н, t)

Compound number 346 (MR: 129-131). NMR solvent: SOSIZ 130: 150.6 (a a, 9 - 13.0, 247.5 IN?), 150.6, 149.7 (a a, 9 - 12.5, 248.0 H?o), 140.4 (a, 9 - 2.0 H2), 136.6, 130.3 (а а, 9 - 3.5, 7.0 Но), 121.0 (4 а, У - 3.6, 6.1 Но), 117.5 (9,9. - 17.5 Но), 114.1 (y, - 18.5 Н2), 113.4, 59, 39.5 , 31.4, 25.6, 25.1, 14.9 1Н: 7.85 (1Н, а, 9 - 1.3 Н2), 7.61. Naida, - 2.2, 7.6, 11.6 Ni), 7.49 (IN, t), 7.44 IN, y, У - 1.3 Н2), 718 (1Н, and у - 8.4, 10.2 НО), 3.74 (1Н, 1, У - 3.5, 12.0 No), 3.43 (2H, 9, U - 7.1 No), 1.85 (4H, t), 1.67 (2H, t), 1.64 (1H, t), 1.30 (2H, t), 1.25 (ЗН, 1, U - 7.1 No), 1.13 (1H, t)

Compound number 347 (MR: 144-145). NMR solvent: ОМ5О 130: 157.6, 146.2, 141, 136.9, 134.6, 129.6, 115.7, 114.2, 113.4, 111.7, 80.6, 79.3, 60.8, 22.4 1Н: 9.43 (1Н, 1-Н, 813) 1.3 No), 7.93 (1H, a, U - 1.3 No), 7.26 (2H, t), 7.16 (IN, U - 7.8 H2), 6.66 1H, aa a, U - 1.5, 2.0, 8.0 No), 5.17 (2H, 5), 3.83 (2H, 5), 1.50 (6H, 5)

Compound number 348 (MR: 129-130). Solvent NMR: SOZIZ 130: 146.4, 141.8, 136.4, 132.9, 130.6, 128.7, 128.5, 125, 123.1, 112.4, 94, 81.9, 81.1, 80.3, 65.5, 61.9, 31.5, Я, Н: 227, 17, 227 - 1.3 Nl), 7.85 (1H, B), 7.74 (1H, t), 7.51 (1H, a, U - 1.3 Ng), 7.34 (2H, t), 5.12 (2H, 5), 3.88 (2H, 5 ), 1.63 (6Н, 5), 1.61 (6Н, 5)

Compound number 349 (MR: 129-131). NMR solvent: OMBO

Зо 130: 150.3, 138.4, 137.5, 134.2, 131.5, 130.9, 129.1, 126.3, 124.8, 115.7, 58.3, 39.1, 30.2, 25.3, 24.7, 14.7 1H, I, U - 1.3 H2g), 8.09 (1H, y, U - 2.0 No), 7.84 (1H, and a, - 2.0, 8.4 No), 7.65 (1H, a, U - 8.4 N?), 3.57 (IN, gg, y - 10.5 N?g), 3.38 (2H, a, y -. 7.1 Nl), 1.79 (2H, t), 1.75 (2H, t), 1.64 (2H, t), 1.55 (1IN , t), 1.17 (2Н, t), 1.1 (ЗН, 1, У - 7.1 Н2g), 1.10 (1Н, t)

Compound number 350 (MR: 92-93). NMR solvent: SOSIZ 130: 159.1, 151, 142, 136.4, 126.4, 125.8, 114.1, 111.9, 58.9, 55.3, 39.3, 31.4, 25.6, 25.1, 14.9 1Н: 7.87 (1Н, а.3, Н72 - 1), (2Н, т и, У - 68.8 Ng), 7.38 (IN, 9, У - 1.3 Но), 6.85 (2Н, та, у - 8.8 Н2г), 3.84 (ЗН, 5), 3.77 (IN, 1, У ) - 3.5, 12.0 No), 3.43 (2H, 1, U) - 7.1 No), 1.85 (4H, t), 1.68 (2H, t), 1.64 (1H, t), 1.30 (2H, t), 1.25 (ZN, Her, U - 7.1 N?), 1112 (1N, t)

Compound number 351 (MR: 100-101). Solvent NMR: SOSIZ 130: 152.0 (a, U - 246.5 Ni), 147.8 (a, 9 - 11.0 No), 146.4, 141.8, 136.1, 129.4 (a, U - 3.5 N?g), 117.4 (9, U - 7.0 No), 116.2 (0, U - 18.5 Nz), 112, 110.4 (9, U - 1.5 No), 81.1, 80.3, 61.9, 56.2, 22.8 1Н: 7.94 1Н, and, U - 1.3 N?), 74 PN, aa, o - 2.0, 8.2 Ng), 7.47 (IN, a, U - 1.3 N?), 723 "IN, aa 9, y - 2.0, 4.3, 8.3 N?), 7.09 (IN, and a, y - 8.5, 11.0 Но), 5.13 (2Н, 5), 3.96 (ЗН, 5), 3.89 (2Н, 5), 1.61 (6Н, 5)

Compound number 352 (MR: 113-114). Solvent NMR: SOSIZ 130: 146.5, 143.1, 142.6, 136.2, 132.8, 128.8, 127.8, 125.2, 122.6, 112, 81.1, 80.4, 70.9, 61.8, 45.7, 30.7, 29.3, 29.7, Н. -, 1.3 Но), 7.68 (1Н, б, у - 2.0 Н2), 7.58 (IN, т а, У - 7.7 Но), 7.50 (1Н, й, У - 1.3 Н2), 7.32 (1Н, у - 7.6 No), 7.15 (1H, t y, U - 7.7 No), 5.13 (2H, 5), 3.89 (2H, 5), 2.75 (2H, t), 1.84 (2H, t), 1.62 (6H, 5) , 1.30 (6H, 5)

Compound number 353 (MR: 192 (aes.)). NMR solvent: SOSIZ 130: 150.4, 137.9, 137.5, 136.7, 136, 132.9, 125.9, 122.7, 115.2, 58.7, 38.5, 36.1, 34.1, 29.6 1H: 8.68 (TN, 5), 8.13 6.3 Ng), 7.92 (1H, y, U - 0.9 No), 7.70 (1H, a, U - 8.1 Nz), 7.56 (1H, a, y - 0.9 N?), 7.30 (1H, a a, 9 - 6.5, 8.1 Н2), 2.98 (ЗН, 5), 2.18 (9Н, т), 1.72 (6Н, т)

Compound number 354 (MR: 217 (aes.)). NMR solvent: SOSIZ 130: 151, 141.1, 140.2, 137.6, 137.6, 137.5, 135.5, 134.4, 129.7, 125.9, 125.8, 125.7, 124.8, 123.7, 113.6, 58.5, 38.6 , 19 - 1.5 2), 8.21 NN, ada, o - 1.0, 1.6, 6.4 N?), 8.0 (IN, her, U - 1.8 No), 7.95 (1H, 60 a, -1.3 No), 7.86 (IN , 4, y - 1.5, 7.8 N?), 7.56 (1H, aa, y - 1.0, 1.5, 8.0 No), 7.55(1H, a, Y) - 1.3

Hg), 7.52 (1H, y - 7.8 H2), 7.44 1H, aa, - 1.5, 1.68, 7.8 H?), 7.36 (1H, a a, 9 - 6.5, 8.0 H2), 3.0 (ZH, 5), 2.20 (9H, 5), 1.73 (6H, 5)

Compound number 355 (MR: 144-147). NMR solvent: SOSIZ 130: 160, 149.9, 140.6, 135.9, 132.5, 129.9, 117.6, 114.5, 113.5, 110.3, 59.2, 55.5, 39.7, 31.3, 25.5, 25, 14.9 1H, (1.7, 13, 8, 1H). 1Н, т), 7.50 (IN, 9, У - 1.3 Ng), 7.38 (IN, т, у - 7.7 Но), 7.34 (1Н, 1, У - 7.8 Н2), 6.90 1Н, а а а, У - 1.3, 2.6, 8.0 N2g), 3.90 (ZN, 5), 3.72 (IN, Her, U - 3.5, 12 N?g), 3.44 (2H, 49, U -7.1 NI), 1.86 (AN, t), 1.69 (2H, t), 1.65 (IN, t), 1.30 (2H, t), 1.27 (ZN, 1, U. - 7.1 Ne), 113 (1H, t)

Compound number 356 (MR: 120-121). NMR solvent: ОМ5О 130: 146.3, 145.9, 141.7, 137.5, 136.5, 126.1, 113.2, 111.7, 110.7, 110.6, 80.6, 79.3, 60.8, 55.3, 22.5 1Н: 8.07 (1.7, Н, 1.7), 1H, a, - 1.3 H7), 714 chn, a, - 2.0 n2), 70 1Hn, aa, - 2.0, 8.5 H2g), 6.79 (IN, a, U - 8.5 H2g), 5.16 (2H, 5), 4.72 (2Н, 5), 3.83 (2Н, 5), 3.77 (ЗН, 5), 1.49 (6Н, 5)

Compound number 357 (MR: 176 (des.)). NMR solvent: OMB5O 130: 150.8, 149.5, 137.3, 136.7, 126.1, 122, 121, 119.7, 116.6, 114.3, 57, 31.4, 28.9, 25, 24.8 1Н: 11.13 (1Н, 5), Н, 10. . (1H, t), 2.93 (ЗН, 5), 1.78 (4Н, t), 1.55 (ЗН, t), 1.30 (2Н, t), 1.16 (1Н, t)

Compound number 358 (MR: 209 (des.)). NMR solvent: OMB5O 130: 150.7, 145.2, 137.8, 136.9, 126.1, 122.8, 121, 119.6, 116.6, 113.3, 80.6, 79.3, 61.1, 22.4 1H: 11.08 (TN, 5 (З), 9.98 Bi), 8.62 (1H, with Big), 8.04 (1H, 5 Bi), 7.81 (IN, y, U - 2.0 H2), 7.70 pn. aa, - 2.0, 8.5 Н?), 711 (1Н, а, У - 8.5 Н2g), 5.18 (2Н, 5), 3.85 (2Н, 5), 1.50 (6Н, 5)

Compound number 359 (MR: 97-98). Solvent NMR: SOSIZ 130: 145.9, 145.6, 131.5, 131.3, 130.3, 119.2, 115.4, 82.4, 79.5, 62.4, 22.9 1Н: 8.18 (1Н, а, У - 8.8 Н2), 8.08 (1Н, и, У - 1.4 Но), 7.58 (1Н, а на, 9 - 1.4, 8.8 Но), 5.53 (2Н, 5), 3.90 (2Н, 5), 1.68 (6Н, 5)

Compound number 360 (MR: 138-140). Solvent NMR: SOSIZ 130:163.3 (9 a, U - 10.0, 252.0 No), 152.9 (a a, 9 - 15.0, 262.5 No), 145.3, 1351 (da, - 7.2,

Zo 16.8 N2g), 132.7 (y, 9 - 19.0 No), 101.7 (da, 9 - 20.0, 30.0 N?), 97.2 (a a, 9 - 5.5, 29.5 N?z), 82.4, 79.5, 62.5, 22.9 1Н: 7.7511Н, аа, - 0.9, 2.1, 8.0 Ng2), 6.97 (IN, а, У - 2.1, 9.4 Nl), 5.52 (2Н, 5), 3.90 (2Н, 5), 1.67 (6Н, 5)

Compound number 361 (MR: 146-147). NMR solvent: SOSIZ 130: 146.2, 144.7, 143.1, 140.2, 133.5, 128.9, 128.1, 127.9, 125.7, 119.9, 112.4, 82.5, 79.6, 62.2, 23 1n: 8.44 1H, 1.7, 1.7, 1.7, yes 8.14 (1H, y a, U - 0.7, 8.7 No), 7.74 (1H, d a, 0 - 1.6, 8.7 H2), 7.11 (2H, t, y - 6.2 Nz), 7.50 (2H, t, y - 7.9 Nzg), 7.42 (1H, t, y - 7.5 No), 5.57 (2H, 5), 3.92 (2H, 5), 1.70 (6H, 5)

Compound number 362 (MR: 225 (des.)). NMR solvent: OMB5O 130: 150.4, 138.3, 137.1, 135.7, 134.7, 132.8, 126.7, 121.2, 117, 56.8, 31.4, 29, 25.1, 24.8 1Н: 8.70 (1Н,, У - 1.2 Н8,18 5), 8.20 (1H, 5), 8.11 (1H, a, U - 6.5 No), 7.78 (1H, a, 0 - 61

Нg), 7.45 (1Н, и а, 9 - 6.5, 8.1 Но), 3.80 (1Н, т), 2.92 (ЗН, 5), 1.77 (4Н, т), 1.56 (ЗН, т), 1.30 (2Н, t), 1.11 (1H, t)

Compound number 363 (MR: 171). NMR Solvent: SOSIZ 130: 161.6, 155.2, 151.1, 141, 137, 135.5, 134.1, 130.5, 121.8, 119.3, 118.9, 117.9, 117, 113.9, 105.7, 57.6, 31.3, 29.9 , 9, U - 1.3 No), 7.64 (1H, and, y - 1.2, 7.9 Nz), 7.60 (2H, t 4, U - 8.9 N2g), 7.53 (IN, 1 re, U - 2.0 Ng), 7.51 (IN, y, У - 1.3 Но), 7.43 (1Н, 1, у - 7.9 Но), 7.05 (2Н, та, у - 6.9 Н7), 7.0 НН, and 5о аа, - 1.0, 2.5, 7.9 Но) . , 12.3 Но), 1.37 (2Н, та, у - 3.0, 12.7 Н2), 112 (1Н, та, у - 3.2, 13.2

Nz)

Compound number 364 (MR: 173). NMR solvent: SOSIZ 130: 161.6, 155.3, 146.2, 141.5, 136.2, 135.2, 134.1, 130.5, 121.8, 119.5, 118.9, 118, 117.1, 112.8, 105.8, 81, 81, 81, 81, 81, 81, 8 , 9 - 1.3 Nl), 7.64 (1Н, т), 7.61 (2Н, та, у - 9.0 Но), 7.53 (IN, ю, У - 1.3 Н2), 7.52 (IN, Б, У - 2.0 Ng), 7.44 (IN, 1, У - 8.0 Н?g), 7.05 (2Н, та, у - 9.0 Н2), 7.0 НН, ааа,у - 1.0, 2.5, 8.0 NI), 5.11 (2Н, 5), 3.88 ( 2H, 5), 1.61 (6H, 5)

Compound number 365 (MR: 154 (aes.)). NMR solvent: OMBO

130: 150.6, 148.4, 139.9, 137.4, 130, 125.9, 118.8, 114.9, 113.4, 111.6, 56.8, 55.8, 31.3, 29, 25.2, 24.8 1H: 8.19 (1H, 54 Bi (1H), 7. . B), 2.92 (ZH, 5), 1.77 (4H, t), 1.57 (ZH, t Bi), 1.29 (2H, 4

Bi, - 13.0 Ng), 1.11 (IN, d org, U - 13.0 N?)

Compound number 366 (MR: 135-136). Solvent NMR: SOSIZ 130: 156.8, 149.5, 145.4, 125.7, 124, 123.6, 82.4, 79.4, 62.5, 22.9 1n:8.82 1Н, а а, - 1.6, 4.5 Н?7), 8.60 (1Н, и а, У - 1.6, 8.4 H?), 7.57 (IN, yes, y - 4.5, 8.4 H2), 5.58 (2H, 5), 3.90 (2H, 5), 1.68 (6H, 5)

Compound number 367 (MR: 67-68). NMR solvent: SOSIZ 130: 146.1, 144, 140.4, 133.3, 127.6, 119.1, 113.7, 82.5, 79.6, 62.1, 23, 22 1Н: 8.02 (1Н, Bi), 7.95 (1Н, y, U - 8.5 Н?) .

Compound number 368 (MR: 111-112). NMR solvent: SOSIZ 130:152.2, 145.9, 144.3, 136.8, 129, 121, 81.9, 80, 62.1, 22.9 1nН:8.88 (1Н, а а, у - 1.0, 4.4 Н?7), 8.46 1Н, и а, У - 1.0, 8.3 Но), 7.AB (1Н, и а, У - 4.4, 8.3 Н2), 5.37 (2Н, 5), 3.93 (2Н, 5), 1.72 (6Н, 5)

Compound number 369 (MR: 84-85). NMR solvent: SOSIZ 130: 147.4, 145.4, 132.6, 129.7, 125.6, 119.8, 114.3, 81.3, 80.5, 68.5, 65.8, 47.7, 45.7 1H: 8.24 (1H, 9, U - 8.3 No), 8.1 ) , 4.20-3.91 (4H, 2 5)

Compound number 370 (MR: 121-123). NMR solvent: SOSIZ 130: 156.4, 146.2, 144.4, 140.7, 133, 131.2, 129.6, 129.5, 128.1, 120.9, 118.7, 114.6, 111.1, 82.5, 79.6, 62.1, 53.1, TN: 2.8, 35.6 85.09 (1H, 4 a, U - 0.7, 8.5 Ng), 7.67 (IN, and a, U - 1.5, 8.5 N?), 7.39. Na, m - 7.6 H2), 7.38 (IN, t), 7.06 (1Н, а, У - 1.0, 7.5 Nz), 7.02 (IN, а, У - 8.4 Nl), 5.54 (2Н, 5), 3.90 ( 2H, 5), 3.83 (ZH, 5), 1.68 (B6H, 5)

Compound number 371 (MR: 134-136). NMR solvent: SOSIZ 130: 145.5, 144.6, 134.4, 128.2 (d, U - 33.0 Ni), 126.0 (d, U - 3.3 No), 123.7 (4.9 - 273.0 Nz),

Koo) 117.9 (d, U - 5.0 Ng), 115.5, 82.5, 79.6, 62.5, 22.9 1H: 8.42 (1H, t), 8.38 (IN, y, U - 68.8 Ng), 7.8511H, a a, 9 - 1.5, 8.8 No), 5.55 (2Н, 5), 3.92 (2Н, 5), 1.69 (6Н, 5)

Compound number 372 (MR: 157-159). NMR solvent: SOSIZ 130: 162.9, 151.6, 146.5, 135.7, 133, 97.8, 87.1, 82.6, 79.6, 62.1, 56.2, 56.1, 23 1Н: 7.14 (1Н, 5), 6.42 (1Н, 52), 5.50 (Н , 5), 4.05 (ZH, 5), 3.91 (ZH, 5), 3.88 (2H, 5), 1.67 (6H, 5)

Compound number 373 (MR: 118-119). Solvent NMR: SOSIZ 130: 146.5, 145.1, 133.1, 129.4, 125.4, 119.8, 114.3, 96.5, 64, 49, 24.2 1H: 8.18 (IN, t. U - 8.3 No), 8.11 (1H, t, y - 8.3 Ng), 7.62 (1H, t, y - 7.7 N?), 7.A.AV (IN, t, y - 7.7 NI), 4.29 (2H, t, y - 6.2 Ni), 4.15 (2H, t, U - 6.2 H2), 1.81 (6H, 5)

Compound number 374 (MR: 143-144). Solvent NMR: SOSIZ 130: 149.8, 144.5, 134.9, 127.8 (d, U - 33.0 No), 125.7 (d, U - 3.3 No), 123.8 (9, y - 272.5 N2g), 117.9 (d, U - 4.5 Ng ), 114.7, 58.9, 57.2, 32.5, 30.7, 30.2, 29.5, 25.5, 25.3. . (2H, BI), 1.18 (1H, Bi)

Compound number 375 (MR: 102-104). NMR solvent: SOSIZ 130: 150.7, 144.4, 139.6, 134.8, 132.2, 118.8, 113, 57.6, 32.4, 29.9, 25.5, 25.3, 20.9, 20.4 1Н: 7.81 (1Н, 5), 7.75 (1Н, 4.4). (IN, t), 3.15 (ZN, 5), 2.43 (ZN, 5), 2.41 (ZN, 5), 1.98 (2H, a ri,

U - 11.5 H2), 1.87 (2H, Bi), 1.70 (IN, t), 1.61 (2H, y d, y - 3.7, 12.5 Ng), 1.40 (2H, Bi), 1.16 (1H, t)

Compound number 376 (MR: 220-221 (des)). NMR solvent: ОМ5О 130: 150.6, 142.3, 139.3, 138.1, 136.7, 126.2, 124.9, 116.2, 56.9, 31.4, 29, 25.2, 24.9 1Н: 8.19 (2Н, 5), 8.04 (2Н, 85, Н - У ?), 7.83 (2Н, а, У - 8.5 Н2), 7.37 (2Н, 5), 3.83 (1Н, т Bi), 2.95 (ЗН, 5), 1.80 (4Н, т), 1.60 (ЗН, т) , 1.31 (2H, t), 1.14 (IN, t)

Compound number 377 (MR: 93-95). NMR solvent: SOSIZ 130: 162.6, 151.6, 150.9, 136.1, 132.9, 97.3, 86.2, 58.9, 56.8, 56.2, 56, 32.7, 30.8, 29.5, 25.5,

DC 25.3 1Н: 6.89 (IN, а, У - 2.0 Н2), 6.39 (1Н, и, У - 2.0 Но), 4.25 (1Н, т), 4.05 (ЗН, 5), 3.88 (ЗН, 5), 3.15 (ZH, 5), 1.98 (2H, and Bi, U - 12.0 Nz), 1.87 (2H, Bi), 1.69 (1H, Bi), 1.60 (2H, and d9, U - 3.4, 12.2 H2), 1.43 ( 2H, Bi), 1.15 (IN, t)

Compound number 378 (MR: 118-119). NMR solvent: SOSIZ (510) 130: 145.4, 143.8, 139.8, 117.1, 82.4, 79.6, 62.3, 22.6, 21.1

1H: 7.61 (2H, 5), 5.41 (2H, 5), 3.88 (2H, 5), 2.40 (6H, 5), 1.67 (6H, 5)

Compound number 379 (MR: 175). NMR solvent: ОМ5О 130: 150.9, 140.6, 139.2, 137.7, 133.4, 128.6, 128.3, 127.4, 127.3, 127.1, 124.7, 114.4, 75.6, 69.1, 56.1, 31.5, Н2, 1.2, 38.6 - 1.3 No), 8.0 (1 H, y, U - 1.3 Nz), 7.85 (2H, y, U - 68.5 Nzg), 7.39 (2H, 1, - 7.6

Na), 7.35-7.29 (AN, t), 7.27 (1H, t), 7.25 (1H, t her, y - 7.3 Nl), 4.51 (2H, 5), 3.86 (1H, t), 3.33 (1H, t), 2.91 (ZN, 5), 2.13 (2H, and rt, y - 11.5 No), 1.81 (2H, and rt, y - 12.5 No), 1.68 (2H, and 9, y - 2.5, 12.5

Nzg), 1.30 (2H, ad Bg, U - 12.5 N?g)

Compound number 380 (MR: 207). NMR solvent: ОМ5О 130:155.1, 150.7, 139.6, 138, 136.2, 127.4, 125.5, 122.4, 115.9, 56.9, 31.4, 29, 25.2, 24.8 1H: 16.76 (1H, Bi), 8.18 (2H, t) (4H, t), 3.83 (1H, t), 2.94 (ZH, 5), 1.78 (4H, t), 1.60 (1H, t), 1.58 (2H, t), 1.30 (2H, ad bg, U - 13.0 Nzg), 1.11 (1H, t, y - 12.9 H2)

Compound number 381 (MR: 102-103). NMR solvent: SOSIZ 130: 146.4, 144.5, 140.1, 135.3, 131.7, 118.9, 113.8, 82.5, 79.6, 62.1, 23, 20.9, 20.4 1Н: 7.99 (1Н, 5), 7.82 (1Н, 355), 2Н5 , 5), 3.89 (2Н, 5), 2.44 (ЗН, 5), 2.42 (ЗН, 5), 1.68 (6Н, 5)

Compound number 382 (MR: 112-114). NMR solvent: SOSIZ 130:152.5, 149.2, 146.4, 139.7, 128.4, 98.6, 94.7, 82.6, 79.5, 62.1, 56.6, 56.2, 23 1Н: 7.63 (1Н, 5), 7.39 (1Н, 5, (), 5.5 2Н, 5), 4.04 (ЗН, 5), 4.0 (ЗН, 5), 3.89 (2Н, 5), 1.68 (6Н, 5)

Compound number 383 (MR: 139). NMR solvent: SOSIZ 130: 151.4, 142.2, 137, 132.8, 128.7, 127.6, 125.1, 113.1, 69.6, 56.4, 34.1, 31.7, 274 1Н: 7.92 (1Н, 9, У - 1.3 Н?), Н7,80 t a, U - 68.0 Nz), 7.49 (IN, y, U - 1.3 N?), 7.41 (2H, ti, y - 7.9 Nzg), 7.30 (1H, t ii, U - 7.5 No), 4.01 (1H , t), 3.62 (1H, t), 2.99 (ZH, 5), 2.11 (2H, ag, y - 12.5

Nzg), 1.90 (2H, arg, U - 12.5 No), 1.71 (2H, and 9, U - 3.0, 12.5 No), 1.46 (2H, ad, 9 - 3.5, 13.0 N?g)

Compound number 384 (MR: 158-160). NMR solvent: SOSIS 130: 163.3, 151.7, 149.2, 134.4, 133.9, 97.6, 86.7, 69.5, 56.3, 56.2, 56.1, 24.3 1H: 7.43 (1H, 5), 7.13 (1H, io, U - 2.0 No), 6.40 (IN, y, U - 2.0 N?2), 4.05 (ZN, 5), 3.90 (ZN, 5), 3.82 (2H, a, 9 - 5.5 No), 3.34 (IN, 1, U) - 5.5 No), 1.51 (6H, 5)

Compound number 385 (MR: 224-226). NMR solvent: ОМ5О 130: 167.6, 146.1, 140.1, 137.3, 136, 132.6, 128, 124.4, 114.7, 80.6, 79.3, 60.9, 22.4

Zo 1H: 8.20 (1H, a, U - 1.3 No), 8.15 (1H, a, U - 1.3 No), 7.98 (1H, in Bi), 7.91 (4H, t), 7.36 (1H, 5 Bi), 5.19 (2H, 5), 3.85 (2H, 5), 1.50 (6H, 5)

Compound number 386 (MR: 183-185). NMR solvent: ОМ5О 130: 157.8, 144.5, 136.6, 136.3, 126.9, 122.5, 115.2, 113.8, 80.7, 79.3, 62.5, 61.3, 54.6, 52.6, 22.3, 22.3, 21.3 1Н85, (1.9, 10.85) 1H, with Bi), 8.27 (1H, 5), 7.89 (2H, y, U - 68.6 No), 710 (2H, a, 9 - 6.6 H2), 5.21 (2H, 5), 4.48 (2H, 1, U - 5.0 H2g), 3.87 (2H, 5), 3.49 (2H, t), 3.45 (2H, t), 2.99 (2H, t), 1.80 (4H, t), 1.69 (IN, 9, U - 15.0 Nz), 1.51 (6Н, 5), 1.38 (1Н, т)

Compound number 387 (MR: 172-175). NMR solvent: ОМ5О 130: 157.9, 144.2, 136.6, 135.7, 127, 122, 115.2, 114, 80.7, 79.3, 63.2, 62.4, 61.3, 54.7, 51.7, 223 1Н: 11.69 (1Н, 1Н, 18), 5), 8.31 (1H, 5), 7.91 (2H, a, U - 8.6 Ng), 712 (2H, y, 9 - 8.6 H2), 5.22 (2H, 5), 4.51 (2H, 1, U - 5.0 H2g), 3.96 (2H, a horn, U - 12.6 H2), 3.87 (2H, t), 3.87 (2H, 5), 3.56 (2H, t), 3.49 (2H, a B, U - 12.4 H2I), 3.20 (2H, t), 1.51 (6H, 5)

Compound number 388 (MR: 218-220). NMR solvent: ОМ5О 130: 157.6, 144.6, 136.6, 136.6, 126.8, 122.9, 115.3, 113.7, 80.7, 79.3, 62.4, 61.3, 54.5, 48.5, 39.5, 22.3 1Н: Н2, 12.18 (1.9, 12.18), 5), 8.98 (1H, 5), 8.24 (1H, 5), 7.88 (2H, y, 9 - 6.9 Ng), 7.11 (2H, a, - 8.9 Ng), 5.20 (2H, 5), 4.48 (2H , 1, 9 - 5.0 H2), 3.86 (2H, 5), 3.64 (2H, 1, y - 5.0 H2), 3.75 (4H, t), 2.50 (4H, Bi), 1.50 (6H, 5)

Compound number 389 (MR: 216-218). NMR solvent: ОМ5О 130: 166.9, 145.4, 144.6, 133.7, 131.9, 129.1, 119, 113.9, 81.7, 78.7, 61.7, 22.5 1Н: 8.71 1Н, ata, y - 0.8, 1.3 Н2), 8.26 (1Н) , 8.21 (1H, a, y - 1.3, 8.6 H?2), 8.16. 1H, and a, U - 0.8, 8.6 H2), 7.63 (1H, 5Bi), 5.43 (2H, 5), 3.90 (2H, 5), 1.58 (6H, 5)

Compound number 390 (MR: 245-247). NMR solvent: OMBO 130: 167.6, 150.7, 139.8, 137.9, 136.1, 132.5, 128, 124.3, 115.6, 56.8, 31.3, 29, 25.1, 24.8 1H:8.15:1H, a, y - 1.1 H3 (?), 8 IN, a, U - 1.3 No), 7.97 (1H, 5), 7.92 (2H, t), 7.89 (2H, t), 7.35 (IN, 5), 3.82 (1H, t), 2.93 (ЗН, 5 ), 1.78 (4H, t), 1.59 (ZH, t), 1.30 (2H, a rg, U - 12.7 Ng), 1.11 (IN, a re, U - 13.0 Ng)

Compound number 391 (MR: 165 (aes)). NMR solvent: SOSIZ 60 130:155.9, 154.1, 144.5, 137.7, 137.1, 136.9, 129.4, 128.9, 127.7, 124.7, 82.5, 79.6, 62.8, 22.6

1H:9.21(1H, o, U - 2.2 H?), 8.40 1H, a, U - 2.2 No), 7.68 (2, a, 9 - 8.2 NO), 7.56 (2H, 1, U - 7.68

Hg), 7.50 (IN, U - 7.3 No), 5.50 (2H, 5), 3.93 (2H, 5), 1.71 (6H, 5)

Compound number 392 (MR: 120). Solvent NMR: SOSIZ 130: 156.2, 149.4, 145.6, 137.8, 136.8, 129.3, 128.9, 127.9, 126.1, 121, 82.5, 79.4, 62.6, 22.9 1Н: 9.07 (IN, 9, U), Н - 8.2 Но(1 - 2.2 2.5) , а, 9) - 2.2 Nz), 7.71 (2Н, а, У - 68.2 Но), 7.54 (2Н, 1, У) - 7.6

Ng), 7.49 (1H, Her, U - 7.4 No), 5.61 (2H, 5), 3.92 (2H, 5), 1.70 (6H, 5)

Compound number 393 (MR: 179-180). NMR solvent: OMBO 130: 158.9, 144.2, 136.5, 135.9, 127, 121.3, 115, 113.7, 80.7, 79.3, 71.4, 61.3, 42.6, 33.1, 25.1, 22.2 1Н:9.2511Н, 1, 0. 9.17 (1Н, 5), 8.93 (IN, а, У - 9.5 Ng), 8.29 (1Н, 5), 7.88 (2Н, 9.9 - 8.6 Н2), 7.06 (2Н, а, 9 - 8.6 Н2), 5.22 (2H, 5), 3.91 (2H, a, U - 6.2 H2), 3.88 (2H, 5), 3.28 (2H, 9, m - 12.0 H2), 2.89 (2H, 9, U - 11.5 H2), 2.08 (1H, t), 1.92 (2H, y, U - 13.0 Nz), 1.54 (2H, 9, U - 12.5 H2), 1.52 (6H, 5)

Compound number 394 (MR: 189-190). NMR solvent: ОМ5О 130:157.9, 148.9, 137, 135.5, 127, 122, 115.2, 114.7, 62.5, 57.2, 54.6, 52.6, 31.5, 28.8, 25, 24.8, 22.3, 21.2 1Н86: 10, bi. 9.14 (1H, 5), 8.28 (1H, 5), 7.91 (2H, a, U - 9.0 Ng), 7.11 (2H, y, U - 9.0 H2), 4.49 (2H, 1, y) - 5.2 H2) . 1.58 (ZH, t), 1.39 (1H, t), 1.30 (2H, t), 1.12 (1H, t)

Compound number 395 (MR: 74-76). NMR solvent: OMBO 130: 158, 148.7, 136.9, 134.8, 127.1, 121.3, 115.3, 115, 63.2, 62.5, 57.2, 54.7, 51.7, 31.5, 28.8, 25, 24.8 1H: 12 (IN, 11.72), 11.72 1H, 5), 8.35 (1H, 5), 7.94 (2H, a, U - 8.6 No), 7.15 (2H, y, 9 - 8.6 H2), 4.53 (2H, her, y - 5.0 No), 3.97 ( 2H, a ri, U - 13.0 N?), 3.90 (1H, t), 3.88 (2H, 1 rt, y - 11.8 H2g), 3.57 (2H, t), 3.50 (2H, a ri, y - 12.4 N ?), 3.21 (2H, t), 2.98 (ЗН, 5), 1.80 (4Н, t), 1.61 (ЗН, t), 1.33 (2Н, t, U - 12.5 Ng), 1.14 (1Н, t)

Compound number 396 (MR: 180-181). NMR solvent: ОМ5О 130: 159, 144.3, 136.5, 136, 127, 121.3, 115, 113.6, 80.7, 79.4, 65.3, 61.4, 43, 34.7, 30.4, 28.3, 22.3

So 1H: 9.13 (1H, a, U - 1.3 No), 9.04 (1H, t), 8.82 (IN, t), 8.25 (1H, y, U - 1.3 No), 7.85 (2H, a, m - 9.0 Nz), 7.03 (2H, a, U - 9.0 Nz), 5.21 (2H, 5), 4.06 (2H, 1, U - 6.1 H2g), 3.87 (2H, 5), 3.22 (2H, a ri, U - 12.5 H2?), 2.83 (2H, 4 BI, y - 11.5 N?), 1.85 (2H, and Big, U - 14.0 Nl), 1.76 (1H, t), 1.68 (2H, t), 1.51 (6H, 5), 1.41 (2H, and 9, U - 4.0, 13.8 N?g)

Compound number 397 (MR: 205-207). NMR solvent: ОМ5О 130: 157.8, 148.8, 137, 135.3, 127, 121.9, 115.3, 114.8, 62.4, 57.2, 54.4, 48.4, 39.7, 31.5, 28.8, 25, 24.8 1H: 12, 12.50, 1H. (2H, 5), 9.21 (1H, 5), 8.91 (1H, 5), 7.92 (2H, a, U - 8.6 Ng), 7.14 (2H, a,

U - 8.6 N2g), 4.50 (2H, 1, U - 4.8 Ng), 3.81 (1H, t), 3.65 (2H, 1, y - 4.8 Nz), 3.50 (8H, in Big), 2.96 (ZN, 5 ), 1.79 (4Н, т), 1.59 (ЗН, т), 1.31 (2Н, 9, У - 12.5 Н2), 112 (1Н, 9, У - 13.0 Н?g)

Compound number 398 (MR: 201 (des.)). NMR solvent: OMB5O 130: 156.7, 151.2, 141, 137.3, 126.1, 124.5, 115.3, 112.5, 66.3, 54.1, 31.5, 29.1 1H: 9.46 (1H, 5), 8.06 (IN, Y, U - 1.3 Nzg), 7.79 (IN, y, U - 1.3 Nz), 7.64 (2Н, т а, У - 8.8 Н2), 6.77 (2Н, т 4, У - 8.8 Н2), 4.09 (1Н, т), 3.93 (2Н, ю y, U - 4.5, 11.1 No), 3.73 (2H, ri, U - 12.0 H2), 2.94 (ZH, 5), 1.85 (2H, and 4, U - 4.5, 12.2 Ng), 1.69 (2H, and, y - 12.3 H2)

Compound number 399 (MR: 176-178). IMR solvent: OM5O 130: 157.9, 144.9, 137.4, 136.9, 131.9, 130.2, 118.2, 114.9, 114.8, 111.1, 80.7, 79.3, 62.5, 61.2, 54.6, 52.6, 22.3 ), 8.83 (1H, 5), 8.35 (1H, 5), 7.59 (1H, ri), 7.54 (IN, and rt, y - 7.5 Ng), 7.39 (IN, i,

U - 7.9 H2), 6.96 (1H, and a, y - 2.0, 8.2 NI), 5.21 (2H, 5), 4.50 (2H, her, y) - 5.2 H2g), 3.67 (2H, 5), 3.46 ( 4H, t), 3.0 (2H, t), 1.80 (4H, t), 1.69 (1H, t), 1.51 (6H, 5), 1.38 (1H, t)

Compound number 400 (MR: 200-202). NMR solvent: ОМ5О 130: 159, 148.8, 136.9, 135.3, 127, 121, 115, 114.6, 71.4, 57.2, 42.6, 33.1, 31.5, 28.68, 25.1, 25, 24.8 1Н: 9.24 (9.24), 1Н2 1H, 5), 8.93 (1H, t), 8.29 (1H, 5), 7.88 (2H, y, U - 8.9 H2g), 7.06 (2H, a, - 8.9 H2), 3.91 (2H, a, 9 - 6.3 Но), 3.85 (IN, t), 3.27 (2Н, and ры, У - 12.4 Н2), 2.96 (ЗН, 5), 2.88 (2Н, 9,

U - 11.0 H2), 2.07 (1H, t), 1.91 (2H, and rg, U - 13.0 Nl), 1.79 (4H, t), 1.58 (ЗН, t), 1.55 (2H, t), 1.31 (2Н , t, U - 13.0 No), 1.12 (IN, t, y - 13.0 N?)

Compound number 401 (MR: 160-162). NMR solvent: ОМ5О 130: 157.8, 145.1, 138.1, 136.9, 132.5, 130.1, 118.2, 114.7, 114.6, 111.1, 80.6, 79.3, 62.4, 61.1, (510) 54.4, 48.5, 2

1H: 12.23 (1H, 5 Big), 9.84 (2H, 5), 8.69 (1H, Bi), 8.29 (1H, 5), 7.58 (1H, Bi), 7.53 (IN, y, y - 7.6

Hg), 7.38 (1Н, и, у - 7.9 Н2), 6.97 (IN, и а, У - 1.6, 8.0 Но), 5.20 (OH, 5), 4.50 (2Н, т), 3.86 (OH, 5) , 3.66 (2H, t), 3.50 (8H, BI), 1.51 (6H, 5)

Compound number 402 (MR: 137-140). NMR solvent: ОМ5О 130: 157.9, 144.6, 136.8, 136.6, 131.1, 130.2, 118.3, 115.2, 115.1, 111.2, 80.7, 79.3, 63.2, 62.5, 61.3, 54.7, 51.7, 1.1, H: 2.1, 1.7, Н. 9.0 (1H, 5), 8.41 (1H, 5), 7.62 (IN, Big), 7.56 (IN, y, U - 7.8 Ng), 7.40 (IN, 1, U - 8.0 H2), 7.0 (1H, aa , y - 2.0, 8.2 НО), 5.22 (2Н, 5), 4.54 (2Н, 1, У - 4.7 НО), 3.96 (2Н, ab, У - 13.0

Nzg), 3.87 (2H, 5), 3.87 (2H, t), 3.57 (2H, t), 3.51 (2H, rt, U - 13.0 Н2), 3.22 (2H, t), 1.51 (6H, 5)

Compound number 403 (MR: 204-206). NMR solvent: ОМ5О 130: 167.9, 150.8, 140.1, 137.7, 134.7, 133.5, 128.6, 127.3, 126.1, 123.9, 114.9, 56.8, 31.4, 29, 25.2, 24.8 1Н2 (Н2, НН1, 8.15) . , U - 1.5, 7.9 No), 7.47 (1H, i, U) - 7.7 No), 7.42 (1H, in bi), 3.83 (IN, t), 2.94 (ZN, 5), 1.78 (4H, t) , 1.58 (ZH, t), 1.29 (2Н, t), 1.11 (1Н, t)

Compound number 404 (MR: 198-200). NMR solvent: SOSIZ 130: 150.9, 140.3, 137.9, 137.3, 133.3, 128.4, 125.5, 115.2, 66.1, 57.7, 46, 31.4, 30, 25.4, 25.2 1H: 7.97 (2H, y.93, U - 7.8), 6 (1H, 9, U - 1.3 No), 7.78 (2H, a, U - 68.5 No), 7.64 (1H, a, - 1.3

H2g), 3.95 (1H, t, U - 11.5 Ng), 3.75 (4H, t, y - 5.0 H2), 3.02 (4H, t, y) - 5.0 Nz), 3.01 (ZH, 5), 1.87 (4H . 13.2 H2)

Compound number 405 (MR: 152-154). NMR solvent: ОМ5О 130: 159, 144.7, 137.2, 136.8, 131.5, 130.1, 117.6, 114.9, 114.9, 110.9, 80.7, 79.3, 71.4, 61.2, 42.6, 33.2, 25.2, Н1: 2, t.1, H9.1 8.89 (1H, 5), 8.85 (1H, t), 8.34 (1H, 5), 7.52 (1H, Bi), 7.49 (1H, t), 7.35 (IN, i,

U - 7.8 H2), 6.91 (IN, y y, U - 2.0, 8.3 Ng), 5.20 (2H, 5), 3.92 (2H, y, U - 6.5 H2), 3.86 (2H, 5), 3.28 (hn , ab, - 12.2 H2), 2.89 (2H, and ri, U - 11.5 H?), 2.08 (1H, t), 1.93 (2H, and rt, y - 13.0 H2I), 1.52 (2H, t), 1.51 (6H, 5)

Compound number 406 (MR: 190-191). NMR solvent: OM5O

Koo) 130: 150.8, 150.6, 140.2, 137.7, 133.9, 131.8, 125.6, 124.4, 114.8, 56.8, 31.3, 29, 25.2, 24.8 1Н: 9.64 (1Н, 5), 8.12 (1Н 1, Я3, У ), 8.04 (1Н, y, У - 1.3 N?g), 7.84 (2Н, та, У - 8.5 Н2), 7.69 (2Н, та, у - 8.5 Н2з), 5.82 (2Н, 5), 3.81 ( IN, t), 2.93 (ZH, 5), 1.78 (4H, t), 1.59 (2H, t), 1.57 (1H, t), 1.29 (2H, d B, U - 12.8 Н2), 1.11 (1H, d re, u - 12.9 Ng)

Compound number 407 (MR: Pudgossoris). NMR solvent: OMBO 130: 157.9, 149.3, 137.4, 136.4, 131.1, 130.3, 118.4, 116, 115.2, 111.4, 62.6, 57.2, 54.5, 48.5, 39.7, 31.6, 28.9. ), 9.87 (2H, 5), 8.97 (1H, 5), 8.37 (1H, 5), 7.62 (1H, Bi), 7.55 (1H, y, U - 6.0 H2),

TA (IN, - 8.0 H2), 7.01 (IN, a a, 9 - 2.0, 8.2 Ng), 4.50 (2H, t), 3.90 (IN, t), 3.70 (4H, Bri), 3.67 (2H, t ), 3.50 (4H, t), 2.96 (ЗН, 5), 1.79 (4Н, t), 1.58 (ЗН, t), 1.31 (2Н, t), 1.14 (IN, t)

Compound number 408 (MR: 124-127). NMR solvent: OM5O 130: 158, 148.8, 137.3, 135.4, 130.3, 130.2, 118.4, 116.3, 115.5, 111.4, 63.2, 62.6, 57.2, 54.7, 51.7, 31.8 ), 9.21 (1H, 5 Bi), 8.48 (1H, 5), 7.67 (1H, ri), 7.58 (1H, 9, y - 7.5 Ng), 7.42 (IN, i,

У - 8.0 Н2), 7.02 (1Н, а а, у - 1.5, 8.1 Ng), 4.55 (2Н, т), 3.96 (2Н, а рт, у - 12.5 Но), 3.90 (1Н, т), 3.87 ( 2H, BI, 9 - 12.0 H2), 3.58 (2H, t), 3.51 (2H, and ri, U - 12.1 No), 3.22 (2H, t), 2.97 (ZH, 5), 1.79 (4H, t) , 1.59 (ZH, t), 1.32 (2Н, t), 1.12 (1Н, t)

Compound number 409 (MR: 183). NMR solvent: OM5O 130: 164, 151.1, 140.7, 137.8, 133.3, 132.4, 130.6, 128.8, 128.7, 128.7, 127.1, 124.8, 114.4, 59.5, 53.1, 50.8, 31.6 - 1.3 Но), 8.0 (1Н, и, У - 1.3 Но), 7.85 (2Н, т и, У - 68.5 Н2), 7.49-7.40 (ВН, т), 7.39 (2Н, 1, 9 - 7.7 Но) , 7.26 (1H, those, y - 7.5 No), 4.05 (2H, 5), 4.05 (1H, t), 3.26 (2H, and Bug, y - 12.0

Nzg), 2.94 (ZH, 5), 2.81 (2H, Grg, y - 12.0 N?), 2.08 (2H, and 9, y - 3.3, 12.7 No), 1.90 (2H, a rg, Y - 12.0

Nz)

Compound number 410 (MR: 177-178). NMR solvent: ОМ5О 130: 149.6, 137.6, 136.6, 131.4, 129.9, 129.6, 129.5, 129, 128.8, 128.5, 125.3, 115.6, 58.7, 52.3, 50.2, 31.6, 24.6, 1, 1, 1, 2, H, 19, 24.6, with (1H, 5), 8.91 (1H, 5), 7.92 (2H, t y, U - 8.5 H2), 7.64 (2H, t), 7.50-7.43 (BN, t), 7.37 (IN, those, y - 7.7 No), 4.26 (2H, y, U - 5.0 H2), 4.20 (1H, t), 3.39 (2H, and Bi, U - 12.0 H2), 3.09 (2H, and Bi, y - 12.0 Nzg), 2.97 (ZH, 5), 2.43 (2H, and 9, 9. - 3.3, 13.0 No), 1.95 (2H, and horn, U - 13.0 N?g) because Compound number 411 (MR: 191-192). NMR solvent: OM5O

130: 151.2, 140.7, 137.8, 133.3, 131.3, 129.7, 129, 128.7, 127.2, 124.8, 114.4, 59.2, 52.2, 50.7, 39.8, 31.8, 25.2. ) . 2.93 (ZN, 5), 2.35 (ZN, 5), 2.12 (2H, 4 ri, U - 13.5 N2g), 2.0 (2H, a re, U - 12.5 N?)

Compound number 412 (MR: 178). NMR solvent: OM5O 130: 175.7, 171.4, 151.1, 140.7, 137.7, 135.7, 133.4, 129.7, 128.7, 128.5, 127.9, 127.2, 124.8, 114.4, 23 (1H, 5 Bi), 8.00 (1H, 5, Bi), 7.84 (2H, a, U - 7.9 Nz), 7.43-7.30 (7H, t), 7.26 (IN, 1, U - 7.5 NI), 3.93 (1H, t), 3.73 (2H, 5), 3.07 (2H, and Big, U - 11.0 H2), 2.93 (ZH, 5), 2.68 (2H, and p, y - 15.3

Ng), 2.58 (2H, y, U - 15.3 No), 2.37 (2H, ri, y - 12.5 Ni), 1.92 (2H, ad ri, U - 12.5 No), 1.80 (2H, a ri,

In - 12.0 Ng)

Compound number 413 (MR: 195). NMR solvent: OM5O 130: 173.4, 151, 140.6, 137.7, 137.3, 133.4, 129.2, 128.6, 128.3, 127.3, 127.1, 124.7, 114.4, 72.1, 61.4, 55, 52. ), 8.0 (IN, 5), 7.84 (2H, and By, 9 - 7.7 No), 7.38 (2H, 1, y - 7.6 Nl), 7.35-7.28 (BN, t), 7.25 (1H, thii, U - 7.5 Ni), 4.24 (2Н, 5), 3.87 (1Н, т), 3.58 (2Н, 5), 2.96 (2Н, т), 2.94 (ЗН, в), 2.15 (2Н, ры, у - 11.0 Н2 ), 1.87 (2H, and Big, y - 12.3 Ni), 1.76 (2H, and g, Y - 11.0 Ng)

Compound number 414 (MR: 192). NMR solvent: OMBO 130: 151, 140.6, 137.7, 136.8, 133.4, 129.3, 128.6, 128.4, 127.5, 127.1, 124.8, 114.4, 61.2, 54.9, 51.8, 31.5, 27.1, Н1, 27.1, 1, 2, H1 N?), 8.0 (1 H, y, U - 1.3 No), 7.85 (2H, y, U - 8.3 N?g), 7.39 (2H, 1, U - 7.5

Nzg), 7.36-7.27 (5H, t), 7.23 (1H, t ii, U - 7.4 Hlo), 3.89 (1H, t), 3.62 (2H, 5), 2.99 (2H, a ri, y - 12.0

Nzg), 2.94 (ZH, 5), 2.21 (2H, 1 rg, y - 12.0 N?), 1.91 (2H, and 9, y - 3.3, 12.2 NN), 1.77 (2H, a rt, y - 11.68

Nz)

Compound number 415 (MR: 175). NMR solvent: SOSIZ 130: 151, 140.5, 138.3, 137.4, 137.3, 134.5, 128.4, 128.2, 127.6, 127.4, 125.4, 115, 71.9, 69.8, 57.7, 43.3, 31.2, 5, 30.2, 4.5.

For 1H: 7.95 (2H, t, y - 8.0 H2g), 7.93 (IN, y, Y - 1.3 H?), 7.78 (2H, t, y - 68.0 H2), 7.62 (IN, a,» - 1.3 H2 ), 7.34-7.21 (BN, t), 4.46 (2Н, 5), 3.95 (1Н, t), 3.46 (1Н, t), 3.29 (2Н, t), 3.0 (ЗН, 5), 2.96 (2Н, t), 1.90 (2H, t), 1.67 (4H, t), 1.80 (2H, t), 1.71 (1H, and rt, y) - 13.3 Н?), 1.60 (2H, and 4, 9. - 3.5 , 13.5 N2), 1.38 (2Н, 149, у - 3.5, 13.3 N?), 1.14 (1Н, ha, У) - 3.5, 13.2 N?g)

Compound number 416 (MR: 176-177). NMR solvent: SOSIZ 130: 151.2, 148.6, 146.7, 139.3, 138, 137.3, 132.4, 129.1, 129, 128.3, 127.2, 123.6, 113.9, 62.8, 55.9, 52.5, 31.9, Н2, Н2(1, 80, 1, 9, 9) 07.22 No), 8.53 (1Н, и а, У) - 1.7, 4.9 Н2), 8.12 (1Н, Я, У - 1.7, 7.9 Н2), 7.94 (1Н, а, У - 1.3 Но), 7.58 ( 1H, y, U - 1.3 Nl), 7.35 (1H, t), 7.34-7.24 (BN, t), 4.02 (1H, t), 3.52 (2H, 5), 3.03 (ZH, 5), 3.0 (2H .

Compound number 417 (MR: 112-113). NMR solvent: SOSIZ 130: 151.4, 148.5, 146.6, 139.2, 137.3, 132.4, 129, 123.6, 114, 59.4, 31.2, 28.9, 24.3 1Н: 9.01 (1Н, а, у) - 1.7 Н2), 8.53 (1 and a, U - 1.5, 4.8 H7), 8.12 (1H, and, y - 2.0, 7.9 H2g), 7.96 (IN, a, y - 1.3 No), 7.59 (1H, y, U - 1.3 No), 7.34 (1H, y 9, U - 4.8, 7.9 N?), 4.44 (IN, di, y - 8.2 NI), 3.0 (ZH, 5), 1.96 (2H, t), 1.77 (2H, t), 1.70 ( 2H, t), 1.63 (2H, t)

Compound number 418 (MR: 138-140). IMR Solvent: SOSIZ 130: 159.9, 151.5, 142.1, 138, 136.9, 134.3, 129.7, 129.1, 128.3, 127.2, 117.5, 113.7, 113.4, 110.1, 62.8, 55.8, 55.3 , 9, U - 1.3 No), 7.49 (1H, y, y - 1.3 No), 7.40 (1H, a a, 9 - 1.4, 2.4 No), 7.38-7.24 (6H, t), 7.31 (IN, her , y - 7.6 Н?2), 6.86 (1Н, а and а, Ю - 1.2, 2.5, 7.9 Но), 4.02 (1Н, т), 3.88 (ЗН, 5), 3.52 (2Н, 5), 3.02 ( ЗН, 5), 3.0 (2Н, т), 2.10 (2Н, 1 Б, У - 11.5 Н?), 1.94 (2Н, и 49, У - 3.3, 12.0 Н2), 1.79 (gn, ar, у - 12.0 Ng)

Compound number 419 (MR: 190-191). NMR solvent: SOSIZ 130: 159.2, 151.6, 142.1, 138, 136.8, 129.1, 128.3, 127.2, 126.4, 125.8, 114.1, 112, 62.8, 55.8, 55.3, 52.5, 31.6, 28: Х. - 1.3 Nl), 7.73 (2H, ta, y - 9.0 Nl), 7.39 (IN, y, U - 1.3 Ni), 7.37-7.23 (BN, t), 6.85 (2H, t y, U - 9.0 N2g) . (2H, and 9, y - 3.6, 12.0 No), 1.78 (2H, and ri, y - 13.0 N?g)

Compound number 420 (MR: 190-191). NMR solvent: SOSIZ

130: 158.4, 151.6, 142.1, 138, 136.9, 136.8, 129.1, 128.6, 128.3, 128, 127.5, 127.2, 126.4, 126, 115, 112.1, 70, 62.8, 55.8 . ), 7.02 (2H, t y, U - 8.6 Ng), 5.10 (2H, 5), 4.01 (1H, t), 3.52 (2H, 5), 3.01 (ZH, 5), 2.99 (2H, t), 2.09 (2H, Tbg, U - 10.7 Ng), 1.93 (2H, d big, y - 12.5 No), 1.78 (2H, a ry, y - 12.5 Ng)

Compound number 421 (MR: 165-166). NMR solvent: SOSIZ 130: 150.9, 137.6, 137.6, 136.9, 136, 132.8, 125.9, 122.6, 115.3, 59.4, 31.2, 28.9, 24.3 1H: 8.67 (IN, TB, y - 1.5 H1), aa, 813 y - 1.7, 6.5 Но), 7.98 (1Н, а, У - 1.3 Н2), 7.71 (1Н, та, 9 - 1.2, 8.0 Н?), 7.59 (1Н, а, У - 1.3 Но), 7.31 (1Н ) , 1.63 (2H, t)

Compound number 422 (MR: 197). NMR solvent: ОМ5О 130: 150.6, 139.0, 138.8, 138.4, 138.2, 127.5, 125.2, 116.8, 56.8, 43.6, 31.3, 29.0, 2541, 24.8 1Н: 8.26 (1Н, 5), 1Н, 8.15), (8.1, 8.25) (2Н, ю, У - 8.5 Nz), 7.93 (2Н, ю, У - 8.5 Н2), 3.81 (1Н, т), 3.22 (ЗН, 5), 2.93 (ЗН, 5), 1.78 (4Н, т) , 1.58 (ZH, t), 1.30 (2H, and Bi, y - 12.7 Ni), 1.12 (1H, t)

Compound number 423 (MR: 179). NMR solvent: OMBO 130: 164.1, 150.9, 140.1, 138.5, 137.8, 133.6, 133.5, 128.8, 128.7, 128.2, 127, 127, 125.4, 123.2, 114.9, 61.9, 55.5, 5 , Bri), 9.15 (1H, run), 8.23 (IN, bi), 8.15(1H, a, U - 1.3 H?), 8.05 (1H, y, U - 1.3 H2), 7.95 (1H, t a, U - 7.8 No), 7.62 (1H, y, U - 7.8 Ng), 7.45 (1H, 1, U - 7.7 No), 7.36-7.21 (5H, t), 3.83 (IN, t), 3.47 (2H, 5), 2.95 (ZH, c), 2.90 (2H, a rt, U - 11.2 No), 2.0 (2H, b, y - 11.0 H2g), 1.83 (2H, a a, U - 3.3, 11.9 N?) , 1.73 (2H, and the corner, y - 12.3 H?)

Compound number 424 (MR: 176). NMR solvent: OMBO 130: 163.8, 149.2, 137.8, 136.1, 133.6, 130, 129.2, 127.8, 126.6, 124, 116.1, 57.1, 31.5, 28.8, 25.1, 24.8 1Н: 11.1, Н1, Н1 (1.31), 5), 8.37 (IN, 5), 8.27 (1H, is rg, y - 1.5 H?2), 8.0 (1H, ta, y - 1.5, 7.7

Hg), 7.73 (1H, Ta, 9 - 1.4, 7.8 NO), 7.56 (1H, y - 7.7 No), 3.86 (1H, t), 2.98 (ZH, 5), 1.81 (4H, t), 1.60 ( ЗН, т), 1.32 (2Н, 9 Ббг, У - 12.8 Н2), 1713 (1Н, 94 Бе, у - 13.0 Нг)

Compound number 425 (MR: 140-142). NMR solvent: SOSIZ 130: 151.1, 144.6, 140.2, 137.2, 137, 133.6, 132.1, 129, 127.8, 127.1, 122.9, 121.2, 114.7, 112.5,

Koo) 57.6, 47.2, 31.5, 30, 25.4, 25.2. . 2H, a, 0). - 5.7

H2g), 3.96 (1H, t), 3.0 (ZN, 5), 1.87 (4H, t), 1.71 (IN, and rt, U - 13.0 Nz), 1.60 (2H, t), 1.39 (2H, 9 Bi ,

U - 13.0 N?2), 1.13 (1N, t, u - 3.5, 13.2 Ng)

Compound number 426 (MR: 261). NMR solvent: SOSIZ 130: 155.4, 151.1, 141.6, 137.1, 136.2, 130, 128.8, 128.4, 127.7, 127.3, 126.8, 118.5, 112.6, 108.6, 106.4, 25.6, 44.5, 44.5. (1H, 5), 8.17 (IN, 9, U - 1.3 Ng), 7.74 (1H, y, U - 1.4 No), 7.A5 (IN, y, U - 1.3 Nz), 7.39 (Na, y - 1.4. 4H, t), 1.70 (1H, t), 1.58 (2H, a Big, U - 13.0 No), 1.38 (2H, 4 bi, y - 13.0 Н2), 113 (1H, a g, y - 12.8 Н2g)

Compound number 427 (MR: 204-205). Solvent NMR: SOSIZ 130: 150.6 (α, 0 - 13.0, 247.5 Но), 151.2, 149.8 (а, 9 - 12.0, 248.0 Н?), 140.4, 138, 137, 130.2 (а, 9 - 4.0, 6.5 No), 129.1, 128.3, 127.2, 121.0 (d a, 9 - 3.5, 6.2 No), 117.5 (0.9 - 17.5 H2), 114.2 (9, U - 19.0 No), 113.5, 62.8, 55.9, 52.5, 31.7, 28.9 1Н: 7.89 (1Н, а, У - 1.3 Н2), 7.61. PN, aa, - 2.2, 7.2, 11.5 No), 7.50 (IN, t), 7.46 (IN, y, U - 1.3 NO), 7.37-7.25(5Н, т), 718 (1Н, а, у - 8.4 . 44, U - 3.5, 12.0 Ng), 1.78 (2H, a g, U - 12.0 Ng)

Compound number 428 (MR: 222-223). NMR solvent: SOSIZ 130: 151.3, 141.2, 138, 137, 133.1, 131.5, 129.1, 128.8, 128.3, 127.2, 126.4, 113.4, 62.8, 55.8, 52.5, 31.6, 28.9, 1.91, Н. Но), 7.49 (IN, 9, У - 1.3 Н2), 7.73 (2Н, т и, У - 8.5 Нзг), 7.37 (ОН, та, у - 8.5 Н2), 7.35-7.25 (5Н, т), 4.02 (1Н, т), 3.52 (2Н, 5), 3.02 (ЗН, 5), 3.0 (2Н, т), 210 (2Н, 1, У - 11.5 Н2), 1.93 (2Н, У - 3.5, 12.0 Но) , 1.78 (2H, a re, y - 12.0 Ng)

Compound number 429 (MR: 203-204). NMR solvent: SOSIZ 130: 151.4, 150.5, 141.2, 138, 137, 130.4, 129.1, 128.3, 127.2, 126.6, 119.7, 115.9, 113.2, 62.8, 55.9, 52.5, 31.9, 17.1, - 1.3 Nl), 7.79 (2H, t y, U - 8.8 No), 7.47 (IN, y, U - 1.3 Nl), 7.37-7.25 (BN, t), 7.16 (2H, t y, U - 8.8 No ), 6.54 (1H, 1, U - 74.0 Nzo), 4.03 (1H, t), 3.53 (2H, 5), 3.03 (ZH, 5), 3.01 60 (2H, t), 2.11 (2H, 1 bg, y - 12.0 No), 1.93 (2H, and d, y - 3.5, 12.0 No), 1.79 (2H, a horn, y - 12.5 Н2)

Compound number 430 (MR: 211-212). NMR solvent: SOSIZ 130: 162.3 (a, 9 - 247.0 Nl), 151.4, 141.4, 138, 136.9, 129.2 (a, 9 - 3.5 No), 1291, 128.3, 127.2, 126.8 (9, U - 8.0 Ng), 115.6 (ad, U - 21.5 No), 112.9, 62.8, 55.8, 52.5, 31.6, 28.9 1H: 7.90 (1H, y, U - 1.3 H2), 7.76 (2H, t, y - 5.3, 8.8 No), 7.45 (1Н, а, У - 1.3 Но), 7.37-7.25 (БН, т), 7.10 (2Н, т и, У - 68.9 Но), 4.03 (IN, т), 3.52 (2Н, 5), 3.02 (ЗН . d)

Compound number 431 (MR: 190-191). NMR solvent: SOZIZ 130: 159.3, 151.2, 148.5, 146.7, 139.2, 137.2, 132.4, 129, 128.7, 123.6, 114, 113.7, 103.8, 56.2, 55.8, 52.1, 18.1, 19.1, 19.1, H: , U - 1.8 N?), 8.53 (1H, and a, U - 1.5, 4.8 H2), 811 (IN, a, U - 1.8, 7.9 No), 7.92 (1H, 9.9 - 1.0 Ng), 7.57 (IN, y, U - 1.0 Ng), 7.3А (1Н, а а, У - 4.8, 7.9 Но), 7.22 (1Н, 1, У - 8.3 Н2), 6.57 (2Н, а, у - 8.3 Н2о) . 11.6 H?), 1.94 (2H, and 4, y - 3.2, 12.0 H), 1.72 2H, and g, - 12.0 N?h)

Compound number 432 (MR: 190 (aes)). NMR solvent: OM5O 130: 150.4, 139.1, 137.9, 137.7, 133.4, 127.8, 125, 116.3, 63.8, 56.7, 43.1, 32.8, 31.2, 29, 2541, 24.8 1Н: 8.294, Н - 1Н, 1? ), 8.19 (IN, y, U - 1.3 No), 8.09 (2H, y, U - 6.5 Ng), 7.73 (OH, ta, y - 8.5 N2g), 4.68 (IN, y, U - 4.0 No) . .

Compound number 433 (MR: 161-162). IMR solvent: SOSIZ 130: 151.6, 149.1, 148.6, 142.1, 138, 136.7, 129.1, 128.3, 127.2, 126.1, 117.4, 112.3, 111.3, 108.4, 62.8, 55.9, 55.9, 55.9, 55.9 (1H, y, U - 1.3 No), 7.42 (1H, y, U - 1.3 No), 7.40 (1H, a, U - 1.9 Ng), 7.37-7.24 (BN, t), 7ZO0 (NN, aa, - 1.9, 8.3 Но), 6.91 (IN, а, У - 68.3 Н2о), 4.03 (1Н, т), 3.97 (ЗН, 5), 3.92 (ЗН, 5), 3.53 (2Н, 5), 3.03 (ЗН . d)

Compound number 434 (MR: 126-128). NMR solvent: SOSIZ 130: 150.7, 142.2, 136.8, 133, 128.7, 127.5, 125.1, 113.1, 56.2, 42.2, 35.3, 31, 25.9, 25.4, 24.4, 23.7, 19.9 (1H: 7.8, 18.7, 8). 2H, y, U - 7.8 Nzg), 7.46 (1H, 5), 7.41 (2H, 1. U - 7.7 No), 7.30 (1H, 1, U - 7.4

Ng), 4.19 (1H, 5 run), 3.91 (1H, 5 Bi), 3.14 (IN, i, U - 12.7 No), 2.10-1.20 (IZN, t)

Compound number 435 (MR: 127-128). NMR solvent: SOSIZ 130: 151.2, 145.3, 140.4, 139.1, 137, 130, 123.4, 123.2, 118.3, 112.6, 57.5, 42.5, 31.4, 29.9, 254,25.2 1H:8.18 (1H, 2, a2) . 3.95 (1H, t), 3.0 (ZH, 5), 2.93 (6H, 5), 1.88 (2H, t), 1.85 (2H, t), 1.70 (1H, a rt, U - 13.0 No), 1.58 ( 2H, and 9, U - 3.4, 12.2 NO), 1.38 (2H, 14, 9 - 3.0, 13.0 No), 1.13 (1H, and, 9 - 3.5, 13.2 Nzg)

Compound number 436 (MR: 215-217). NMR solvent: ОМ5О 130: 166.6, 145.3, 144.6, 134.6, 130, 128.6, 121.5, 114.3, 81.7, 78.7, 61.7, 22.5 1Н: 13.38 (IN, BI), 8.70 (1Н, 5), 8.24 (IN, а , У - 9.0 Н2), 8.19 (IN, а, У - 9.0 Н2), 5.43 (2Н, 5), 3.90 (2Н, 5), 1.58 (6Н, 5)

Compound number 437 (MR: 181). NMR solvent: OM5O 130: 163.6, 144.4, 144.3, 142.8, 135.9, 132.7, 129.1, 128.4, 128.4, 127.3, 119.5, 118.7, 81.6, 78.7, 77.1, 61, 61.2, 22.2. 1H, 5), 8.11 (IN, y, Y - 9.0 Ng), 7.87 (IN, I, Y - 9.0 H2g), 7.49 (2H, a, - 7.0 NI), 7.41 (ZH, t), 5.29 (2H , 5), 4.98 (2H, 5), 3.92 (2H, 5), 1.57 (6H, 5)

Compound number 438 (MR: 194). NMR solvent: OMBO 130:155.6, 151.2, 150.8, 139.6, 137.7, 129.3, 126.7, 125.6, 114, 112.5, 112.4, 56.8, 56, 31.4, 29, 25.2, 24.9 1Н: 18, 16.0 Bi (1.8, 16.0). 1Н, Я, У - 2.2 НН), 8.13 (1Н, а, У - 1.3 Но), 8.0511Н, и, 9 - 1.3 Но), 8.04 (IN, aa, - 2.2, 8.9 Но), 7.31 (1Н, y, U - 8.9 Nz), 3.99 (ZH, 5), 3.82 (1H, t), 2.94 (ZH, 5), 1.78 (4H, t), 1.58 (ZH, t), 1.30 (2H, ad, U - 12.5 No), 1.11 (IN, 4, U - 13.0 Ng)

Compound number 439 (MR: 226-228 (OES.)). NMR solvent: ОМ5О 130: 154.5, 151.9, 150.9, 139.9, 137.6, 129.1, 125.4, 125.2, 116.7, 113.4, 110.8, 56.8, 31.3, 29, 25.2, 24.9 1Н: 1.1, 16.0 (Н: 1.1, 1.0). bi), 8.48 (1H, y, 2 - 2.2. H2), 8112 (1H, a, y - 1.3 No), 7.95 (1H, 5 bi), 787 1H, aa, - 2.2, 8.5 No), 7.09 ( IN, а, У - 6.5 Н?), 3.82 (1Н, т), 2.94 (ЗН, 5), 1.78 (4Н, т), 1.57 (510) (ЗН, т), 1.30 (2Н, d, У - 12.5 H2), 1711 (IN, ad, U - 13.0 N?g)

Compound number 440 (MR: 104-105). NMR solvent: OM5O 130: 163.3, 144.4, 144.2, 142.9, 133.2, 127.4, 119.3, 118.1, 81.6, 78.7, 61.8, 22.2 1H: 11.56 (1H, Bi), 9.27 (1H, 5 Bi (IN), 8.39 5), 8.10 (1Н, а, 9 - 9.1 Но), 7.89 (IN, и, У - 9.1 Н2), 5.29 (2Н, 5), 3.92 (2Н, 5), 1.57 (6Н, 5)

Compound number 441 (MR: 169-170). IMR Solvent: SOSIZ 130: 152.2, 151.2, 139.9, 139.6, 138, 137.2, 130.7, 129.1, 128.3, 127.2, 126, 122.3, 113.8, 113.3, 62.8, 56.6, 55.8 , а,юу-2.2 Н2), 8.0 1Н, и а, У - 2.2, 8.8 Но), 7.91 (1Н, 9, У - 1.3 Но), 7.49 Т1Н, а, У - 1.3 Н2), 7.37-7.25 ( 5H, t), 7.13 (1H, y, U - 8.8 Ng), 4.03 (1H, t), 4.0 (ЗН, 5), 3.53 (2Н, 5), 3.03 (ЗН, 10.5), 3.01 (2Н, t ), 2.11 (2H, 1 ri, y - 11.5 H2), 1.93 (2H, y 9, 9 - 3.5, 12.0 Но), 1.79 (2H, and ri, y - 12.0

Nz)

Compound number 442 (MR: 162). NMR solvent: SOSIZ 130: 151.9 (0, 9 - 246.0 Nl), 151.4, 147.8 (a, 9 - 11.2 H2o), 141.5, 138, 136.8, 129.6 (a, U - 4.0

Ng), 129.1, 128.3, 127.2, 117.3 (8, 9) - 7.0 Nl), 116.2 (a, 9) - 18.5 No), 113.1, 110.4 (0.9) - 1.7 N2g), 62.8, 56.2, 55.9, 52.5. 7.27 (BN, t), 7.24 (IN, t), 7.09 (1Н, и а, У - 8.5, 11.0 Но), 4.03 (1Н, т), 3.97 (ЗН, 5), 3.53 (2Н, 5), 3.03 (ZN, 5), 3.01 (2H, t), 2.10 (2H, TB, U - 11.8 H?2), 1.94 (2H, and 4, U - 3.0, 12.0 H2?), 1.79 (2H, a, - 11.5 N?g)

Compound number 443 (MR: 188-189). NMR solvent: SOSIZ 130: 152.5 (a, 9) - 245.0 Nz), 151.4, 147.1 (a, U - 11.0 No), 141.1 (a, 9 - 2.5 No), 138, 136.9, 129.1, 128.5, 127.2, 126.5 (8, 9 - 7.2 No), 120.9 (y, 9 - 3.5 No), 113.5 (a, 9 - 2.5 Ng), 113.1 (a, - 19.7 Nzg), 112.6, 62.8, 56.3, 55.8, 52.5, 31.6, 28.9 1H: 7.89 (IN, y, U - 1.3 No), 7.53 (1H, t), 7.50 (1H, a a, U - 2.5, 8.5 No), 7.40 (1H, a, 9 - 1.3 Н2), 7.37 -7.23 (5H, t), 6.99 (IN, i, U - 68.4 N?g), 4.02 (1H, t), 3.92 (ZH, 5), 3.52 (2H, 5), 3.02 (ZH, 5), 3.0 (2H,.t), 210 (2H, 1 Bg, U - 11.8 N?), 1.93 (2H, and 4, U - 3.5, 12.0 No), 1.78 (2H, t)

Compound number 444 (MR: 168). NMR solvent: OM5O 130: 157.6, 153.8, 151.1, 140.6, 137.5, 137.1, 128.5, 127.9, 127.8, 126.3, 126.1, 114.9, 113.2, 78.8, 69.2, 55.1, 43, 43.1

From 1H: 8.09 (IN, y, U - 1.3 Ng), 7.88 (IN, y, U - 1.3 H2), 7.77 (2H, y, U - 8.7 N?g), 7.46 (2H, a, - 8.4 Ng), 7.40 (2H, 1, y - 7.4 No), 7.33 (1H, her, U - 7.3 Ng), 7.03 (2H, and, y - 8.7 N?), 5.12 (2H, 5), 4.03 (ZN . 5)

Compound number 445 (MR: 170-171). NMR solvent: SOSIZ 130: 160.4, 151.1, 140, 137.1, 131.1, 130.3, 126.5, 116.3, 113, 111.6, 102, 57.6, 56.2, 31.4, 30, 25.4, 25.2 1n1H, 7.8, 7.8 - aa Но), 7.97 (1Н, и, У - 2.2 Но), 7.89 (IN, 9, У - 1.3 Н?), 7.44 (1Н, а, - 1.3 Н2), 7.02 (IN, а, У - 8.5 Н2g) . , 1.38 (2Н, га, у - 3.0, 13.0 Н2), 113 (IN, та, У - 3.5, 13 Н?)

Compound number 446 (MR: 176-177). Solvent Name: SOSIZ 130: 160.5, 151.2, 140.1, 138, 137.1, 131.1, 130.3, 129.1, 128.3, 127.2, 126.4, 116.3, 112.9, 111.6, 102, 62.9, 52.9, 55.2. H, aa, - 2.2, 8.5 No), 7.97 (1H, y, U - 2.2 No), 7.90 (1H, a, U - 1.3 No), 7.AA (1H, a, U - 1.3 NO), 7.37 -7.23 (5Н, т), 7.01 (1Н, а, У - 8.5 Н?), 4.01 (1Н, т), 3.96 (ЗН, 5), 3.53 (2Н, 5), 3.03 (ЗН, 5), 3.01 (2H, t), 2.10 (2H, TB, U - 12.0 H2), 1.94 (2H, and 4, U - 3.5, 12.0 H?), 1.79 (2H, ab, - 12.0 H2)

Compound number 447 (MR: 103-105). NMR solvent: SOSIZ 130: 151.5, 142.3, 141.4, 140.3, 136.8, 128.9, 119.4, 115.4, 112.4, 112, 57.5, 43.6, 31.3, Z0, 25.4, 25.2 1H: 7.89, U - 1 . , Big), 3.94 (1H, t), 2.99 (ZH, 5), 2.69 (6H, 5), 1.85 (4H, t), 1.70 (1H, and p, U - 14.0 H?), 1.58 (2H, and 9, 9 - 3.5, 12.5 H2), 1.37 (2H, ta, y - 13.0 No), 1.13 (IN, ta, y - 13.0 Nz)

Compound number 448 (MR: 180-182). NMR solvent: SOSIZ 130:155.1, 150.2, 137.9, 137.6, 137.5, 136.2, 132.5, 126, 122.7, 115, 62.1, 46.4, 43.3, 14.6 1H: 8.68 (1H, 5 bi), 8.15 (1H - 6.3 Ng), 7.94 (1H, y, U) - 1.3 No), 7.71 (1H, a, U - 68.0 H2), 7.57 (Na, - 1.3 No), 7.33 (1H, a a, 9 - 6.3, 8.0 Но), 4.20 (2Н, а. у - 7.2 НО), 3.64 (ВН, т), 1.30 (ЗН, и, У - 7.2 НИ)

Compound number 449 (MR: 110-112). NMR solvent: SOSIS (510) 130: 150.8, 137.6, 137.6, 136.9, 136, 132.7, 125.9, 122.7, 115.3, 50.6, 36.4, 29.3, 19.8, 13.7

1H: 8.67 (IN, 1, 9) - 1.5 H2), 8.14 (Nay a, y - 1.0, 1.6, 6.4 No), 7.94 (IN, y, U - 1.3 Nz), 7.71 (1H.ta, - 1.3 , 8.1 No), 7.58 (1H, a, - 1.3 No), 7.32 (1H, a a, y - 6.4, 8.1 No), 3.46 (2H, 1, U - 7.6

Nzg), 3.13 (ZH, 5), 1.68 (2H, t), 1.37 (2H, t), 0.97 (ZH, i, U - 7.4 Ng)

Compound number 450 (MR: 122-123). NMR solvent: ОМ5О 130: 151.1, 145.9, 141.4, 137.6, 137.2, 126.2, 113.2, 112.6, 110.7, 110.6, 55.7, 55.4, 45.4, 31.4, 29.5 1Н: 8.53 (1, 8, 1Н, 1Н, 6). , 7.14 (1Н, и, У - 1.8 Н2), 7.0. (1H, y y, Y - 1.8, 8.2 H2?), 6.79 T1H, a, y - 8.2. H2), 4.73 (2H, with Bi), 3.88 (IN, t), 3.76 (ZH, 5), 3.01 (2H, and Big, y - 12.0 No), 2.93 (ZH, 5), 2.47 (2H, t ), 1.67 (4H, t)

Compound number 451 (MR: 170-172). NMR solvent: ОМ5О 130: 157.6, 150.2, 138.3, 137.3, 131.4, 129.7, 129.7, 129, 126.7, 121.6, 115.7, 113.3, 59.1, 52.3, 50.6, 31.9, 25.62, Т. (1H, 5), 8.0 (1H, 5), 7.65 (2H, y, U - 8.2 Hl), 7.55 (2H, t), 7.49 (ЗН, t), 6.82 (2H, y, U - 8.2 Н2) . (2H, a re, 9 - 12.0 Ng)

Compound number 452 (MR: 74-76). Solvent NMR: SOSIZ 130:150.3, 137.6, 137.3, 136.9, 136, 132.7, 125.9, 122.8, 115.1, 42.8, 13.2 1H: 8.67 (IN, TBg, U - 1.3 N?), 8.14 (IN, a, U - 6.4 No), 7.93 (1H, a, U - 1.3 N?), 7.72 (1H, 9, - 8.0 Ng), 7.57 (1H, y, U - 1.3 No), 7.32 (1H, y a, U - 6.4 , 8.0 N2g), 3.49 (4H, 9, U - 7.2 Ng), 1.31 (6H,. 1, y - 7.2 NO)

Compound number 453 (MR: 130-132). NMR solvent: ОМ5О 130: 149.6, 147.8, 145.7, 142.8, 138.2, 137.1, 132.2, 129.9, 129, 127.7, 126.3, 124, 115.6, 39.6 1nH: 8.87 (IN, yes, 98, 2.2 - 0.6 Н). (1Н, а а, У - 1.7, 4.9 Н?2), 8.04 (IN, ha, У - 1.9, 8.0 Н2), 7.81 (1Н, а, У - 1.3 Но), 7.61 (1Н, и, У - 1.3 Nl), 7.45-7.28 (6H, t), 3.43 (ZH, 5)

Compound number 454 (MR: 170-172). NMR solvent: OM5O 130: 151.2 (y,.9U - 240.0 NI), 151.1, 144.0 (а,.9Й - 12.2 Н?), 140.0 (а, У - 2.5 Но), 137.6, 131.4, 129.7 (2 parts. ), 128.9, 125.2 (0, 9 - 7.0 No), 121.1 (9,9 - 2.5 No), 117.9 (y, 9 - 3.0 No), 113.5, 112.5 (94,9 - 20.0 No), 59.0, 52.1, 50.6, 31.7, 25.1 1H: 9.91 (1H, 5), 9.57 (IN, t), 8.10 (1H, 5), 7.90 (1H, 5), 7.58 (1H, t), 7.55 (2H, t), 7.48 (4H, t),

Koo) 6.96 (1H, her, U - 8.8 Nl), 4.31 (2H, 5 Big), 4.16 (1H, t), 3.45 (2H, t), 3.15 (2H, t), 2.92 (ЗН, 5), 2.17 (2Н, а, У - 12.5 Но), 1.98 (2Н, а бг, У - 12.5 Н?)

Compound number 455 (MR: 171-173). NMR solvent: SOSIZ 130:145.8, 137.7, 137.2, 136.8, 136.1, 132.6, 126, 122.7, 114.3, 81, 80.3, 62.1, 22.8 1H: 8.69 (1H, TB, U - 1.5 H2), 8.14 (NN, aa , y - 1.0, 1.5, 6.4 Но), 7.96 (1Н, а, У - 1.3 Н2), 7.70 (На, - 1.2, 8.2 NO), 7.63 (1Н, 9, 9 - 1.3 Н?), 7.31 (1Н , aa, o - 6.4, 8.2 No), 5.12 (2H, 5), 3.90 (2H, a), 1.62 (6H, c)

Compound number 456 (MR: 181-182). NMR solvent: ОМ5О 130: 149.4, 142.6, 138.3, 137.1, 135.2, 134.6, 132.4, 129.9, 127.7, 126.6, 126.2, 121.1, 117.1, 39.6 1Н: 8.50 (1Н, Б18, Н85, Н85), . ), 7.50-7.29 (BN, t), 3.43 (ZN, 5)

Compound number 457 (MR: 179 (des.)). NMR solvent: OMBO 130: 151.4, 150.6, 137.9, 137.7, 137, 131.7, 131.4, 129.7, 129.1, 128.9, 123.9, 121, 119.6, 114.7, 59, 52.2, 50.5, 1.1, 1.35, H: 1.1, 35 Running), 9.59 (IN, 5), 8.39 (1H, 5), 8.33 (IN, y, U - 2.0 No), 8.14 (IN, 5), 8.02 IN, a a, 9 - 2.0, 8.6 H2), 7.55 (2H, t), 7.49 (ZH, t), 7.19 (1H, y, U - 8.6 N?g), 4.32 (2H, y, y - 4.9 Ng), 4.18 (IN, t), 3.46 (2H )

Compound number 458 (MR: 163-164). NMR solvent: ОМ5О 130: 148.1, 147.7, 146.1, 138.3, 136.8, 131.9, 129.1, 123.9, 113.6, 50, 32.2, 25.1, 24.8 1nH: 9.02(1Н, aa, У - 0.8, 2.4Н, 1Но), a a, U - 1.7, 4.7 No), 8.38 (1H, y, 9 - 1.3 No), 8.33 (NN, ab» - 7.3 Ng), 8.30 (IN, a, U - 1.3 N?2), 8.15 (1H, a, U - 1.9, 7.9 H7), 7.42 1nH, aa, - 0.8, 4.7, 7.9 Nz), 3.63 (1H, t), 1.90 (2H, t), 1.75 (2H, t), 1.61 ( 1H, and re, U - 12.7 Nz), 1.32 (AN, t), 1.14 (IN, t)

Compound number 459 (MR: 199-201). NMR solvent: SOSIZ 130: 150.8, 137.9, 137.6, 137.6, 136.9, 136, 132.7, 129.1, 128.3, 127.2, 125.9, 122.6, 115.3, 62.8, 56, 52.4, 31.9, 18.6, Н1.6, H1.6 . 1Н, т), 3.52 (2Н, 5), 3.02 (ЗН, 5), 3.01 (2Н, т), 2.10 (2Н, 1 ог, У - 10.9 Н2), 60 1.93 (2Н, т), 1.78 (2Н , and Bg, U - 10.9 N?g)

Compound number 460 (MR: 148). NMR solvent: SOSIZ 130: 165.8, 147.2, 145.6, 132.6, 131.5, 126.5, 119.6, 116.6, 82.4, 79.6, 62.4, 61.7, 23, 14.3 1nH: 8.91 (1H, aa, - 0.67, 1.17, 18 ИН, а и, У - 1.4, 8.7 Н7), 812 (1Н, аа, у - 0.8, 8.7 Н?g), 5.53 (2Н, 5), 4.45 (2Н, 4, У - 7.2 Но), 3.91 ( 2Н, 5), 1.70 (6Н, 5), 1.44 (ЗН, И, У - 7.2 Ng)

Compound number 461 (MR: 186). NMR solvent: MEOY 130: 149.5, 138.8, 138.8, 137.7, 136.9, 135, 128.4, 127.1, 116.7, 52.2, 33.8, 26.7, 26.5 1H: 8.75 (1H, Big), 8.36 (IN, 1.2, N - Ug ), 8.25 (1H, t), 8.24 (1H, t), 7.98 (1H, y, 9 - 8.2. H2), 7.58 (1H, aa, - 6.6, 8.2 Ng), 3.73 (1H, t), 2.02 (2H, t), 1.87 (2H, t), 1.70 (1H, a rt, U - 13.5 He), 1.45 (2H, t), 1.38 (2H, t), 1.24 (1H, t)

Compound number 462 (MR: 125 (des.)). NMR solvent: OMB5O 130: 167.1, 145.8, 145.4, 135.3, 132.2, 124.9, 119.4, 113.9, 81.7, 78.7, 61.6, 22.5 1H: 8.63 (1H, 5), 8.34 (1H, 5bi(1H), 8.25 a, U - 8.5 N?2), 8.01 (IN, and a, U - 1.5, 8.7 N?), 7.65 (IN, 5 Bg), 5.43 (2H, 5), 3.91 (2H, 5), 1.60 ( 6H, 5)

Compound number 463 (MR: 181-183). NMR solvent: SOSIZ 130:151.2, 148.6, 146.7, 139.4, 137.3, 132.5, 128.9, 123.6, 113.9, 66.9, 54.5, 31.8, 29.5 1nH:9.00(1Н, aa, - 1.0, 2.2Н, 1.2Н, 53Н2), , y - 1.7, 4.8 H2), 81 IN, aa, o - 1.6, 2.3, 7.9

Nzg), 7.96 (1H, y, U - 1.3 Ng), 7.59 (1H, a, U - 1.3 H7), 7.34 IN, aa, o - 1.0, 4.6, 7.9 N?), 4.29 (1H, t), 4.09 (2H, and a, 9 - 4.6, 11.5 No), 3.50 (2H, a, y - 2.2, 12.0 Nz), 3.04 (ZH, 5), 1.95 (2H, t), 1.78 (2H, t)

Compound number 464 (MR: 143-144). NMR solvent: SOSIZ 130: 150.6, 148.5, 146.7, 139.3, 136.9, 132.4, 129.1, 123.6, 113.8, 59, 39.5, 31.4, 25.6, 25.1, 14.9 1nH:9.01 (1Н, 2.3, О7), (IN, and a, 9 - 1.7, 4.8 H7), 8.12 (IN, ta, y - 2.0, 8.0 H2), 7.91 (IN, a, y - 1.3 No), 7.56 (1H, y, y - 1.3 No ), 7.3A (IN, a da, 9 - 0.8, 4.8, 8.0 NI), 3.75 (1Н, t), 3.44 (2Н, а, у - 7.0 Нl), 1.84 (4Н, т), 1.66 (ЗН, t), 1.30 (2Н, т, у - 13.0 Но), 1.26 (ЗН, и, у - 7.0 Н2), 1.13 (IN, t, У - 13.0 Н?g)

Compound number 465 (MR: 184-185). NMR solvent: MeEOU 130: 151.9, 147.7, 147.1, 140.6, 138.4, 132.6, 131.6, 130.6, 130.4, 123, 118.8, 116.9, 114.7, 114.1, 61.8, 54.7, 36.8, 36.8, 52.5

So 1H: 8.64 (1H, 5 Bi), 7.82 (1H, 5 Big), 7.58 (2H, t), 7.52 (ZH, t), 7.18 (IN, a, U - 2.0 Ng), 7.11 (IN, da , - 2.0, 8.3 No), 6.83 (1H, a, U - 68.3 Ng), 4.36 (2H, 5), 4.28 (IN, t), 3.63 (2H, a Big, y - 12.5 H2), 3.24 (2H )

Compound number 466 (MR: 221-222). NMR solvent: OM5O 130: 151.7 (a, U - 242.5 INl), 151.0, 146.2 (a, 9 - 10.8 No), 139.6 (a, 9 - 2.5 No), 137.7, 126.7 (a, 09 -7.5 No), 120.9 (0, 9) - 3.5 Ng), 114.1 (2 5id.), 112.3 (0, U - 19.7 No), 66.3, 56.0, 54.2, 31.6, 29.1 1H:vlLI (Na, y - 1.3 No), 7.98 (1H, y, U - 1.3 No), 7.66 (1H, t), 7.63 (IN, t), 7.19 (1H, U - 8.7 Nzg), 4.09 (IN, t), 3.93 (2H, a y, U - 4.5, 12.3 No), 3.85 (ZH, 5), 3.38 (2H, t), 2.94 (ZH, 5), 1.85 (2H, aa, y - 4.5, 12.3 No), 1.69 (2H, a horn, U - 12.3 H2)

Compound number 467 (MR: 177). NMR solvent: SOSIZ 130: 151.5, 142.3, 140, 137, 132.9, 128.7, 128.6, 128.4, 127.6, 126.1, 125.1, 113.1, 60.2, 55.7, 52.6, 33.8, 31.6, 28 (UIN: 9, 9, 19, 28 - 1.3 Но), 7.81 (2Н, та, у - 8.2 Ng), 7.51 (IN, и, У - 1.3 Н2g), 7.41 (2Н, 1, У - 7.9 Нзг), 7.30 (ЗН, и, У - 7.4 Hl), 7.22 (1H, t), 7.21 (2H, a, 9 - 7.4 No), 4.06 (1H, t), 3.13 (2H, a Big, U - 11.8 H2g), 3.04 (ZH, 5), 2.82 (2H, t), 2.63 (2H, t), 2.17 (2H, y, y - 2.4, 12.0 No), 1.96 (2H, a 4.9 - 3.6, 12.1 Н?), 1.85 (2H, a re, y - 12.0 N?)

Compound number 468 (MR: 186-187). NMR solvent: ОМ5О 130: 151.2, 145.9, 141.4, 137.5, 137.2, 126.2, 113.2, 112.6, 110.7, 110.6, 66.3, 55.3, 54.1, 31.6, 29.1 1Н: 8.05, Н3 - 7.1, 1Н. (1H, y, U - 1.3 N?), 71511H, a, - 2.2 NI), 7.0 NN, aa, - 2.2, 8.4 N?), 6.79 (IN, y, U - 8.4 Nzg), 4.73 (2H, 5), 4.09 (1H, t), 3.93 (2H, and, Y - 4.5, 11.3 H2), 3.77 (ZH, 5), 3.38 (2H, and 1, Y - 1.5, 12.0 N?g), 2.94 (ZH, 5), 1.84 (2H, and 9, Y - 4.5, 12.3 No), 1.69 (2H, da, o - 2.8, 12.3 H?)

Compound number 469 (MR: 111 (des.)). NMR solvent: OMBO 130: 156.7, 153.8, 151.1, 141, 137.3, 126.1, 124.4, 115.3, 112.5, 78.8, 55, 43, 42.2, 31.7, 28.1,

CD 281 1H: 9.46 (1H, 5), 8.06 (1H, 5), 7.78 (1H, 5), 7.64 (2H, a, U - 68.7 Ng), 6.77 (2H, a, U - 68.7 Ng), 4.03 (ZH, t), 2.91 (ZH, 5), 2.79 (2H, 5b), 1.75 (2H, and ri, y - 12.0 H?), 1.66 (2H, and 9, y) - 4.1, 12.2 H2I) , 1.41 (9H, 5)

Compound number 470 (MR: 217 (aes.)). NMR solvent: SOSIZ 60 130: 150.8, 137.7, 137.6, 137, 136.1, 132.7, 126, 122.8, 115.3, 66.9, 54.6, 31.9, 29.5

1Н: 8.68 (IN, 1, У - 1.3 Н2), 815 1Н, а да, ою - 1.0, 1.6, 6.4 Но), 7.95(1Н, а, у - 1.3 Нз), 7.73 (1Н.ta,у - 1.2. Но), 3.51 (2Н, and her, У - 1.8, 12.0 Н2), 3.04 (ЗН, 5), 1.96(2Н,а4,9-44,122

Nzg), 1.79 (2H, t)

Compound number 471 (MR: 205-207). NMR solvent: SOSIZ 130:150.1, 137.6, 137.2, 136.9, 136, 132.8, 125.9, 122.8, 115.1, 59.1, 39.6, 31.3, 25.5, 25, 14.9 1Н: 8.67 (IN, 16, Н2 - 8.14), 14.1 (IN, aa, yu - 1.0, 1.6, 6.4 N?), 7.89 (IN, a, U - 1.3 Nl), 7.72 (1N.ta, y - 1.3, 8.1 No), 7.55 (1N, a, 9 - 1.3 No), 7.31 (1H, 4a, U - 6.4, 8.1 Nl), 3.69 (IN, t), 3.42 (2H, a, y - 7.0 Nl), 1.84 (4H, t), 1.68 (ЗН, t ), 1.27 (2H, t, U - 13.0 N?), 1.25 (3H, 1.9 - 7.0 H2), 1.12 (IN, t, y - 12.8 Ng)

Compound number 472 (MR: 153-154). Solvent NMR: SOSIZ 130: 162.3 (0, 9 - 246.7 INl), 151.4, 141.5, 136.9, 129.1 (a, 9 - 3.6 Hlo), 126.8 (y, 9 - 8.5 H2), 115.6 (9, U - 21.7 Ng ), 112.8, 67, 54.4, 31.8, 29.5 1H: 7.91 (1H, y, U - 1.3 No), 7.76 (2H, t, y - 5.5, 8.9 Ng), 7.46 (IN, y, U - 1.3 Ng) . (ZH, 5), 1.95 (2H, and 4, y - 4.6, 12.3 No), 1.77 (2H, abrg, - 11.0 N?g)

Compound number 473 (MR: 146-147). Solvent NMR: SOSIZ 130:151.2, 150.6 (a a, 9 - 13.1, 247.3 No), 149.8 (a a, y - 12.8, 248.2 N?), 140.5, 137.0, 130.1 (a a, 9 - 4.0, 6.5 Ng ), 121.1 (9 a, 9 - 3.8, 6.3 No), 117.5 (9, U - 17.6 No), 114.2 (0, 9) - 18.8 Nzg), 113.4, 67.0, 54.5, 31.8, 29.5 1Н: 7.91 NN, a, y - 1.1 H2), 7.61 1H, aya, - 21, 7.68, 11.6 Hl), 7.50 (1H, t), 7.46 (1H, 5), 7 (IN, 1, U - 8.5, 10.0 H2), - 4.4, 12.2 NO), 1.77 (2H, and g, y - 13.5 No)

Compound number 474 (MR: 148-149). NMR solvent: SOSIZ 130: 151.4, 150.6 (1, 9) - 2.7 N?), 141.3, 137, 130.3, 126.6, 119.7, 115.9 (her, U - 260.0 H2I), 113.1, 67, 54.4, 31.8, 29.5 1Н : 7.92 (1H, y, U - 1.3 Ng), 7.79 (2H, y, U - 68.8 N?g), 7.48 (IN, 9, U - 1.3 N?), 7.16 (OH, and, y - 8.8 Hg), 6.54 (1H, her, U) - 74.0 No), 4.29 (1H, t), 4.09 (2H, and also, U - 4.5, 11.5 No), 3.50 (2H, a, - 2.0, 12.0 Н2) , 3.04 (ZH, 5), 1.95 (2H, and 9, U - 4.5, 12.3 No), 1.78 (2H, t)

From Compound number 475 (MR: 183-184). Solvent NMR: SOSIZ 130: 159.2, 151.6, 142.2, 136.8, 126.4, 125.6, 114.1, 112, 67, 55.3, 54.3, 31.8, 29.5 1H: 7.91 (1H, a, U - 1.3 H2g2), 7.72 (H, t y, U - 68.9 Ng), 7.40 (IN, 9, U - 1.3 N?), 6.94 (OH, and, y - 8.9 H2), 4.28 (IN, t), 4.08 (2Н, and y, 9 - 4.4 . 2N, and, in - 12.3 N?)

Compound number 476 (MR: 130). NMR solvent: SOSIZ 130: 151.5, 149.1, 148.6, 142.2, 136.7, 125.9, 117.4, 112.3, 111.2, 108.4, 67, 55.9, 55.9, 54.4, 31.8, 29.5 1H, IN - 1.91, U (1.91) . . , 3.04 (ZH, 5), 1.95 (2H, and 4, 9 - 4.5, 12.4 H2), 1.77 (2H, argo - 12.3 Nzg)

Compound number 477 (MR: 174-176). NMR solvent: SOSIZ 130: 151.3, 141.3, 137, 133.2, 131.4, 128.9, 126.4, 113.3, 67, 54.4, 31.8, 29.5 1Н: 7.92 (1Н, 5), 7.73 (2Н, и, У - 8.5 Н2), 7.50 (1H, 5), 7.37 (2H, y, y - 8.5 Ng), 4.28 (IN, t), 4.09 (2H, aa, y - 4.5, 11.5 No), 3.50 (2H, 1. U - 11.5 No ), 3.03 (ZH, 5), 1.95 (2H, and 9, y - 4.5, 12.2 H2), 1.77 (2H, and g, y - 12.5 H?)

Compound number 478 (MR: 222-225). NMR solvent: SOSIZ 130: 166.1, 146.3, 145.9, 137.5, 132.5, 125.2, 120, 112.4, 82.5, 79.5, 62.4, 52.1, 28.8, 23 1n: 8.46 (IN, yes, - 0.68, 1.5 (2), 1.5 1H, a a, y - 0.8, 8.7 No), 7.91, 1H, yes, 0 - 1.5, 8.7 H2), 6.12 (1H, 5), 5.53 (2H, 5), 3.91 (2H, 5), 1.69 ( 6Н, 5), 1.51 (9Н, 5)

Compound number 479 (MR: 193-195). NMR solvent: SOSIZ 130:170.3, 145.7, 145.3, 137.7, 132.4, 124.7, 120.2, 113.2, 82.4, 79.6, 62.3, 39.6, 35.4, 22.9 1H: 8.30 (1H, 5 61, 1H, 18.1). - 8.6 No), 7.53 (IN, and a, U - 1.4, 8.6 No), 5.53 (2Н, 5), 3.91 (2Н, 5), 3.16 (ЗН, 5), 3.0 (ЗН, 5), 1.68 ( 6H, 5)

Compound number 480 (MR: 233-234). NMR solvent: ОМ5О 130: 167, 149.8, 144.5, 134, 131.6, 128.8, 119, 113.1, 59, 31.9, 28.4, 24 1Н: 8.71 (1Н, 5), 8.25(1Н, 5Б61), 8.18 1Н, and , U - 1.4, 8.3 Ng), 7.94 (1H, y, U - 68.3 Nz), 7.61 (1H, 5 Bi), 4.57 (IN, Bi), 3.07 (ZN, 5), 1.93 (2H, t), 1.78 (2H, t), 1.72 (2H, t), 1.54 (2H, t)

Compound number 481 (MR: 171-172). NMR solvent: SOSIZ

130: 165, 145, 144.6, 143.5, 137.6, 135.9, 129.1, 127.5, 124.9, 120.4, 119.9, 118.7, 82.4, 79.6, 62.7, 22.6. 7.95 (2H, t), 7.69 (2H, y, U - 7.9 No), 7.39 (2H, 1, - 7.9 H2), 7.19 (1H, 1, U - 7.3 No), 5.40 (2H, 5), 3.92 (2Н, 5), 1.69 (6Н, 5)

Compound number 482 (MR: 185-186). NMR solvent: OM5O 130: 166.4, 156.3, 150.9, 140, 137.6, 128.6, 127.1, 126, 123, 113.6, 112.3, 56.7, 56, 31.3, 29, 25.2, 24.9 1Н: 8, 1, 2, 2, 1 No), 8.09 (1H, in Big), 7.95 (IN, 5 60), 7.92 1H, and a, U - 2.3, 8.7 N?l), 7.67 (IN, 5 Bi), 7.56 (1H, 5 Big) . 2H, t), 1.30 (2H, t, U - 13.0 No), 1.11 (1H, t)

Compound number 483 (MR: 117). NMR solvent: SOSIZ 130: 150.6, 145.3, 133.2, 129.3, 125.2, 119.8, 113.6, 67.1, 54.6, 29.9 (2 part.) 1Н: 8.10 (1Н, t s, U - 8.4 Н2), 7.99 (IN, t y, U - 8.4 Nz), 7.61 (1H, t, U - 1.0, 7.0, 8.2 H2), 7.47 (IN, t, y - 1.0, 7.1, 8.2 Но), 4.54 (IN, t), 4.10 (2Н , and Big, U - 11.5 H2), 3.51 (2H, 5 Bi), 3.21 (ZH, 5), 2.03 (2H, aa, - 4.6, 12.3 No), 1.91 (2H, and ri, y - 11.5 N? )

Compound number 484 (MR: 119-120). NMR solvent: SOSIZ 130: 151.9 (a, U - 246.5 NI), 151.4, 147.8 (a, 9 - 11.2 Nl), 141.5, 136.8, 129.5 (a, U - 3.8 N?g), 117.3 (9, U - 6.9 Nzg), 116.2 (0, U - 18.7 Nz), 113, 110.3 (9, U - 2.0 Nz), 67, 56.2, 54.4, 31.8, 29.5 1nH: 7.92 (1H, a, 9) - 1.3 No), 7.50 1H, a a, U - 2.0, 8.3 Nz), 7.47 (AN, y, U - 1.3 Nz), 7.24 (1H, t), 7.09 (1H, y a, y - 8.5, 11.0 N?), 4.29 (IN, t), 4lLO (2Н, а а, У - 4.5, 11.5 Но), 3.96 (ЗН, 5), 3.50 (2Н, 9, У - 1.8, 12.0 Н2), 3.04 (ЗН, 5), 1.95 (2H, y 9, Y - 4.6, 12.4 H?), 1.78 (2H, and ry, y - 12.5 H2)

Compound number 485 (MR: 181). NMR solvent: ОМ5О 130: 153.2, 148.8, 137.1, 135, 126.4, 124.2, 123.2, 121.1, 115, 112.4, 57.2, 56.1, 40.7, 31.5, 28.8, 25, 24.8 1H: 1.250, 9. (1H, 5), 8.31 (IN, 5), 7.77 (IN, and a, Y - 2.3, 8.2 H2g), 7.76 (1H, 5), 7.20 (IN, a, y - 8.2 H2), 3.87 (ZN , 5), 3.84 (1H, bi), 3.03 (ZH, 5), 2.96 (ZH, 5), 1.79 (4H, t), 1.61 (IN, t), 1.57 (2H, t), 1.32 (2H, t), 1.12 (1H, t)

Compound number 486 (MR: 200-203 (dec.)). NMR solvent: SOSIZ 130: 164.7, 145.6, 145, 137.7, 134.5, 132.8, 129.2, 128.6, 124.9, 120.4, 118.8, 115, 82.4, 79.5,

Koo) 62.5, 23 1H: 8.61 (1H, 5), 8.30 (1H, y, U - 8.6 H?7), 8.19 (IN, 561), 8.15 (1H, a a, U - 1.3, 8.6 H2), 7.70 (2H, 9.9 - 8.0 Nl), 7.41 (2H, 1, U - 8.3 No), 7.20 (1.1, y - 7.5 No), 5.53 (2H, 5), 3.92 (2H, 5), 1.70 (6H, 5)

Compound number 487 (MR: 175-177). NMR solvent: SOSIZ 130: 165.7, 145.7, 145.1, 134.2, 133.8, 128.4, 118.3, 114.6, 82.5, 79.5, 62.4, 52, 28.8, 23 1n:8.42 1Н, yes, - 0.5, Н1.25, Н1.6 . 1.69 (B6H, 5), 1.53 (9H, 5)

Compound number 488 (MR: 175). NMR Solvent: SOSIZ 130: 151.2, 148.6, 146.7, 140, 139.3, 137.3, 132.4, 128.9, 128.6, 128.4, 126.1, 123.6, 113.9, 60.2, 55.8, 52.6, 33.8, 33.8 - 0.7, 2.2 H2), 8.53 (1Н, и а, У - 1.6, 4.8 Н2), 812 1нН, авда, у - 1.7, 2.6, 8.0

Nzg), 7.96 (1H, y, U - 1.3 No), 7.59 (1H, y, U - 1.3 N?), 734 (TN, aa, y - 1.0, 4.6, 8.0 Nl), 7.30 (2H, t, y - 7.5 Ng), 7.21 (1H, t), 7.20 (2H, t, y - 7.1 No), 4.05 (IN, t), 3.14 (2H, a horn, y) - 12.0 Н2), 3.05 (ZN, 5), 2.81 (2H, t), 2.63 (2H, t), 217 (2H, a, - 2.0, 11.6 H?), 1.97 (2H, and 49, 9. - 3.7, 12.0 H2), 1.85 (2H , and Bi, y - 12.0 Nz)

Compound number 489 (MR: 197). NMR solvent: OMBO 130: 164.3, 145.4, 144.5, 133.6, 132.4, 129, 118.7, 113.9, 81.7, 78.7, 61.7, 48.7, 32.5, 25.3, 25, 22.5 1Н: 8.68 (IN, 8.4, 5) I, U - 8.0 Н2), 8.18 (1Н, и 9, У - 1.4, 8.7 Н?7), 8.15 (1Н, а, У - 8.7 Н2), 5.44 (2Н, 5), 3.90 (2Н, 5) , 3.80 (IN, t), 1.86 (2H, t), 1.75 (2H, t), 1.61 (1H, t), 1.58 (6H, 5), 1.35 (2H, t), 1.30 (2H, t), 1.15 (1H, t)

Compound number 490 (MR: 194-196). NMR solvent: OMBO 130: 164.6, 144.4, 144.2, 143, 135.2, 128, 118.9, 118.4, 81.7, 78.7, 61.8, 48.7, 32.4, 25.3, 25, 22.2 1Н: 8.52 (1Н, 505), (IN t), 8.07 (IN, a, U - 8.0 Ng), 7.97 (IN, a a, U - 1.4, 9.0 Nl), 5.31 (2H, 5), 3.92 (2H, 5), 3.79 (1H, t) , 1.85 (2H, t), 1.75 (2H, t), 1.62 (1H, t), 1.58 (6H, 5), 1.34 (2H, t), 1.31 (2H, t), 1.15 (1H, t)

Compound number 491 (MR: 254-256). NMR solvent: ОМ5О 130: 167, 149.5, 144.5, 134.1, 131.6, 128.8, 119, 113.1, 58.4, 56.8, 32.3, 30.1, 28.9, 25.1, 24.8 1Н: 8.71 (Н, 5 (IN), 8.24) . 1.97-1.00 (TON, t)

Compound number 492 (MR: 223-224). NMR solvent: ОМ5О 130: 150, 144.7, 132.6, 131.4, 129.9, 129.5, 129.5, 128.8, 125.5, 119.6, 113.5, 58.7, 52.8, 50.3, 32.5, 25.4 1H(1H:11.21, 11.21 Bi), , t, U - 8.3 H2), 7.91 (IN, t a, U - 8.3 Nzg), 7.70 (1H, t, y - 1.0, 7.0

Nzg), 7.63 (2H, t), 7.54 (1H, t, y - 1.0, 7.0 Nl), 7.45 (ZH, t), 4.39 (1H, t bi), 4.26 (2H, t bi), 3.40 (2H , t), 3.06 (ZN, 5), 3.05 (2H, t Bi), 2.47 (2H, t), 2.05 (2H, a rt, U - 12.0 N?g)

Compound number 493 (MR: 140). NMR solvent: SOSIZ 130: 150.8, 150.2, 140.4, 139.6, 137.3, 119.4, 115.7, 57.7, 31.4, 30, 25.4, 25.2 1Н: 8.62 (2Н, t), 7.93 (IN, y, U - 1.3 Но), 7.68 (IN, a, U - 1.3 Ng), 7.67 (2H, t), 3.94 (1H, t), 3.0 (ZH, 5), 1.86 (4H, t), 1.71 (1H, a rg, U - 13.0 Но), 1.59 (2Н, а 9, У - 3.4, 12.3 Но), 1.38 (2Н, та» - 13.0 Н2), 1.13 (1 Н, Та, у - 3.4, 13.0 Н?g)

Compound number 494 (MR: 193-194). NMR solvent: SOSIS 130: 154.4, 151.2, 139.9, 137.2, 134.5, 133.7, 126, 121, 120.3, 113.4, 67, 54.5, 31.9, 29.5 1Н: 10.61 (1Н, 5), 8.5 -, 91 (1Н 2.2 Н2), 8.02 1Н, и а, у - 2.2, 8.7 Но), 7.93 1Н, а, 9 - 1.3 Н2), 7.52 1Н, а,» - 1.3 Но), 7.21 (1Н, Я, У - 8.7 Н ?), 4.29 (1H, t), 410 (2H, a a, y - 4.5, 11.5 No), 3.51 (2H, a, y - 1.6, 12.0 H2), 3.05 (ZH, 5), 1.95 (2H, and 9, U - 4.6, 12.4 H?), 1.78 (2H, and Bri, y - 12.5 H2)

Compound number 495 (MR: 185-187). NMR solvent: OM5O 130: 151.1 (a,9U - 241.0 No), 149.2, 145.5 (a, 9 - 12.2 Ng), 137.2, 135.3, 122.0 (0, 9 - 3.0 Nz), 120.5, 118.2 (9, 9 - 3.5 No), 114.8, 113.4 (a,.9U - 20.5 Ng), 66.2, 54.5, 31.7, 28.9 1Н: 10.36 (1Н, 5 Big), 9.08 (1Н, 5), 8.23 (1Н, 5), 7.7А 1H, d a, U - 2.0, 12.4 N?), 7.56 (IN, da, U - 1.5, 8.3 No), 7.07 (IN, Her, y - 8.7 Ng), 4.11 (IN, t), 3.94 (2H , а а, у - 4.0, 11.5 Но), 3.39 (2Н, 1, У) - 11.5 Н2), 2.97 (ЗН, 5), 1.86 (2Н, и 9, У - 4.2, 12.2 НО), 1.70 ( 2N, and rt, y - 12.0 N?)

Compound number 496 (MR: 116-118). NMR solvent: SOSIZ 130: 166.2, 145.6, 145.1, 137.8, 134.4, 132.2, 128.9, 128.4, 128, 127.8, 118.8, 114.8, 82.5, 79.5, 62.4, 44.5, 23.52 (Н.82, 18.55). IN, y, U - 8.8 Ng), 8.09 (IN, a a, U - 1.5, 8.7 Ng), 7.40-7.30 (5H, t), 6.56 (IN, U - 5.3 Ng), 5.54 (2H, 5) , 4.72 (2H, a, 9 - 5.3 No), 3.91 (2H, 5), 1.69 (6H, 5)

Compound number 497 (MR: 173 (aes.)). NMR solvent: SOSIZ 130: 150.6, 139.3, 138.2, 137.5, 131.5, 121.8, 115.4, 57.7, 31.4, 29.9, 25.4, 25.1

Zo 1H: 8.22 (2H, 9, U - 7.0 H2g), 7.90 (1H, 5), 7.68 (2H, a, 9 - 7.0 Nz), 7.61 (1H, 5), 3.93 (1H, t), 3.0 ( ЗН, 5), 1.86 (4Н, т), 1.71 (1Н, 9, У - 13.0 Н2?), 1.59(2Н, 44, У - 2.68, 12.2. Н2), 1.38 (2Н, 4, У - 13.0

Na), 113 (1Н, 4, У - 13.0 Н2)

Compound number 498 (MR: 109-110). NMR solvent: SOSIZ 130: 159.6, 151.1, 141.7, 136.5, 133.9, 129.4, 117.2, 113.3, 113, 109.8, 60, 55.4, 54.9, 52.3, 31.2, 28.4, 19.8, 11.6 - 1.3 H?), 7.491H, a, U - 1.3 No), 7.39 (1H, aa, y - 1.4, 2.6 No), 7.35 (IN, a,

U - 1.4, 7.7 N?), 7.31 (1H, her, U - 7.7 No), 6.85411N, Ya a a, U - 1.4, 2.6, 8.0 No), 4.02 (1N, t), 3.87 (ZN, 5 ), 3.06 (2H, a ri, y - 11.7 Но), 3.02 (ЗН, 5), 2.32 (2Н, т), 2.06 (2Н, ГТ бг, У - 11.5 Н?), 1.95(2Н, 4 4, - 3.4, 12.2 HO), 1.80 (2Н, and Bi, у - 12.0 Н2), 1.52 (2Н, т), 0.91 (ЗН, и, У - 7.4 N?g)

Compound number 499 (MR: 170-171). NMR solvent: ОМ5О 130:171.2, 160.9, 149, 137.2, 135.4, 130.8, 125.9, 119.6, 118, 115.2, 114.7, 57.2, 31.6, 28.8, 25, 24.8 1Н: 12.99 (1Н, 19), . 7.02 (1Н, а, У - 8.5 Но), 3.86 (1Н, т), 2.98 (ЗН, 5), 1.79 (4Н, т), 1.60 (ЗН, т), 1.39 (2Н, 9, У - 12.8 Н2 ), 112 (1H, a, 9 - 13.0 N?g)

Compound number 500 (MR: 191-193 (des.)). NMR solvent: OMBO 130:151.0, 150.3 (9, U - 240.0 Nz), 144.9 (a, U - 12.5 No), 140.0, 137.6, 130.1, 116.2 (a, 9 - 18.0

Nzg), 115.9 (a, U - 6.3 No), 114.2 (0, U - 1.5 No), 114.1, 66.3, 54.2, 31.6, 29.1 1Н: 9.89 (1Н, 5), 8.10 (1Н, 5), 7.90 ( 1H, 5), 7.46 (IN, y, U - 8.5 No), 7.24 (IN, t), 713 (IN, t, y) - 9.2 H2), 4.08 (1H, t), 3.93 (2H, a rt , y - 10.0 H2), 3.36 (2H, t), 2.94 (ZH, 5), 1.84 (2H, d 9, y - 12.0

Ng), 1.69 (2Н, а бг, У - 11.0 N?g)

Compound number 501 (MR: 138-140). NMR solvent: ОМ5О 130:158.5, 151, 140.6, 137.4, 126.1, 126, 114, 113.1, 55.1, 55.1, 44.9, 31.5, 28.7 1Н: 8.08 (1Н, 5), 7.87 (1Н, 52), 7.77 (Н . , 5), 2.56 (2H, t), 1.73 (4H, t)

Compound number 502 (MR: 120-121). NMR solvent: SOSIZ 130: 159.9, 151.5, 142.1, 136.9, 134.3, 129.7, 117.5, 113.7, 113.4, 110.2, 55.7, 55.3, 52.2, 5241, 31.6, 28.8, 12.7.1 (Н.7, 12.15), 1H, 5), 7.39 (1H, i run), 7.36 (IN, y, y - 7.6 No), 7.30 (IN, her, y - 7.9 H2), (510) 6.85(1H, and Bg, U - 8.1 No), 4.03 (1H, t), 3.87 (ZH, 5), 3.08 (2H, and Bg, y - 11.0 H2g), 3.02 (ZH, 5), 2.45

(2Н, а, У - 7.3 Но), 2.05(2Н, 1 Би, у - 11.4 Н?), 1.96(2Н, и 9, У - 2.5, 11.8 Н?), 1.85(2Н, ar, - 11.0 Н2 ), 1.11 (ZN, i, U - 7.3 Nz)

Compound number 503 (MR: 158-159). NMR solvent: SOSIZ 130: 152.5 (a, 9 - 245.0 INl), 151.4, 147.1 (a, 90 - 11.0 No), 141.1 (0, U - 2.5 Ni), 136.9, 126.4 (y, 009 - 7.0 Ng), 120.9 (a, U - 3.6 H2), 113.5 (9, U - 2.5 No), 113.0 (y, U - 20.0 No), 112.6, 56.3, 55.7, 52.2, 52.1, 31.6, 28.7, 12.1 1Н: 7.88 (IN . . 2H, ad, U - 3.5, 12.0 Nz), 1.83 (2H, and Bg, U - 12.0 Nz), 1.11 (ZN, i, U - 7.3 Nz)

Compound number 504 (MR: 183-184). NMR solvent: OM5O 130: 149.3, 137.5, 136.1, 129.1, 129, 128.7, 125.4, 115.8, 52.6, 42.3, 31.8, 24.6 1Н: 9.33 (IN, d g, y - 10.0 Н2), 9-20 (1Н, and Bg, y - 10.0 No), 9.13 (1H, 5), 8.37 (1H, 5), 7.94 (2H, 9.9 - 8.2 Nl), 7.48 (2H, 1, U - 7.8 No), 7.39 (IN , i, y - 7.3 No), 4.23 (1H, t), 3.34 (2H, and horn, y - 12.0

Nz), 3.0 (2H, t), 2.98 (ZH, 5), 2.19 (2H, and 9, y - 3.5, 12.8 No), 1.92 (2H, a ri, y - 12.4 N?)

Compound number 505 (MR: 143-144). Solvent NMR: ОМ5О 130: 167.9, 163.8, 144.4, 143.5, 142.8, 135.5, 128, 119.7, 118, 81.6, 78.7, 63.9, 61.8, 47.7, 45.2, 26.8, 25.1, 2.2, 1:2.1, 24.8, НН 61), 8.11 (1H, y, U - 9.0 No), 7.59 (1H, aa, U - 1.2, 8.9 H?), 5.29 (2H, 5), 3.92 (2H, t), 3.84 (2H, Big) . , t), 1.57 (6H, 5), 1.29 (4H, t), 1.09 (1H, t)

Compound number 506 (MR: 133-135). NMR solvent: OM5O 130: 168, 162.4, 147.4, 147, 144.4, 143.4, 142.8, 135.9, 128.5, 127.9, 123.3, 119.7, 117.7, 109.8, 108.1, 101.1, 81.6, 78.6 40.7, 22.2 1H: 8.10 (1H, a, U - 9.3 No), 8.09 (1H, 5), 7.54 (IN, a, U - 9.3 No), 6.94 (1H, 5), 6.90 1H, a, U - 8.0 H2), 6.83 (1H, a, U - 8.0 H2g), 6.01 (2H, 5), 5.29 (2H, 5), 3.92 (2H, 5), 3.75 (2H, t), 3.72 (2H, 5) , 3.47 (2H, t), 2.69 (4H, t), 1.57 (6H, 5)

Compound number 507 (MR: 213-214). NMR solvent: ОМ5О 130: 156.3, 150.9, 150.7, 140.2, 137.5, 126.5, 126.3, 125.7, 122.9, 113.3, 111.9, 56.7, 55.7, 31.3, 29, 25.2, 24.8

Koo) 1H: 9.38 (Н, 5), 8.07 (IN, y, U - 1.3 Nl), 7.91 (IN, y, U - 1.3 Но), 7.84 (IN, а, У - 2.2 Н2), 7.82

PN, aa, - 2.2, 8.6 No), 7.08 (1H, a, U - 68.6 No), 5.63 (2H, 5), 3.81 (IN, t), 3.81 (ZN, 5), 2.92 (ZN, 5) .

Compound number 508 (MR: 172-173). NMR solvent: ОМ5О 130: 150.7, 147.4, 145.5, 138.1, 137.5, 132.5, 129.4, 124.1, 115.7, 67.9, 56.3, 34.2, 31.4, 26.8 1Н: 9.08 (1Н, 5 (ИН, 5), 8.4 У 4.8 N?), 8.24 (IN, and, U - 1.7, 8.0 Ng), 8.19 (1N, 5), 8.18 (1N, 5), 727 (1nN, aa, - 5.0, 8.0 Ng), 4.62 (1N, ri), 3.79 (IN, t), 3.38 (1Н, t), 2.92 (ЗН, 5), 1.89 (2Н, аб, - 12.0 Нз), 1.80-1.60 (4Н, т), 1.23 (2Н, 4, U - 11.3 N?)

Compound number 509 (MR: 137-139 (des.)). NMR solvent: OMBO 130: 150.7, 148.4, 138.5, 138.2, 135.2, 131, 130.3, 121.6, 118.9, 116.3, 55.6, 51.9, 51.4, 31.5, 28y1,122 1H: 8.66 (IN - 1.8) . 7.69 (1H, i, U - 68.0 H2g), 3.83 (1H, t), 2.96 (2H, t), 2.95 (ZH, 5), 2.32 (2H, a, - 7.1 Ni), 1.93 (2H, B, y - 10.5 N?), 1.82 (2H, a 9, 9 - 3.0, 12.0 Ng), 1.73 (2H, a g, y - 12.0

H2g), 0.99 (ZN, i, U - 10.5 N?)

Compound number 510 (MR: 133-134). Solvent NMR: SOSIZ 130: 151.5, 149.1, 148.6, 142.1, 136.7, 126, 117.4, 112.3, 111.2, 108.4, 55.9, 55.9, 55.6, 52.2, 52.1, 31.6, 28.17, 19 (IN: 7.9, 18.17, 1 - 1.3 Ng), 7.42 (1H, 9, U - 1.3 No), 7.39 (1H, a, U - 2.0 N?), 7. ZO (1H aa, yuyu - 2.0, 8.4 IN), 6.90 (1H, a , y - 8.4 Nl), 4.04 (1H, t), 3.96 (ZH, 5), 3.91 (ZH, 5), 3.08 (2H, and Big, y - 11.5

Nzg), 3.02 (ZH, 5), 2.44 (2H, 9, 9 - 7.4 No), 2.05 (2H, 1 Big, 9 - 11.5 Ng), 1.96 (2H, 49, U - 3.0, 11.8 H2), 1.82 (2H, a ri, y - 11.8 N?), 1.10 (ZN, i, U - 7.4 Ng)

Compound number 511 (MR: 142-144). NMR solvent: OM5O 130: 151.6, 146.7, 142.3, 136.8, 133.9, 129.6, 115.5, 114.4, 113.1, 111.9, 55.7, 52.2, 52.1, 31.6, 28.7, 1241 1H: 1.7, 5 (1.7, 9.5), 7.5 5). t), 3.73 (2H, 5 run), 3.08 (2H, and bg, U - 11.0 H2), 3.01 (ZH, 5), 2.45 (2H, her,

U - 7.1 No), 2.05 (2H, 1 BI, U - 11.5 N?), 1.96 (2H, 9, y - 12.0 No), 1.82 (2H, and ri, y - 12.0 Н2), 1.11 (ZN. her , U - 7.1 N?g)

Compound number 512 (MR: 153-154). NMR solvent: SOSIZ

130: 151.5, 149.1, 148.6, 142.1, 136.7, 126.1, 117.4, 112.3, 111.3, 108.4, 60.4, 55.9, 55.9, 55.8, 52.6, 31.6, 28.9, 28.9, Ng), 7.42 (1H, y, U - 1.3 No), 7.40 (1H, a, U - 2.0 N?), 7. ZO (1H aa, yuyu - 2.0, 8.3 No), 6.90 (1H, a, U - 8.3 No), 4.02 (1Н, t), 3.96 (ЗН, 5), 3.91 (ЗН, 5), 3.04 (2Н, а, У - 11.0

Nzg), 3.02 (ЗН, 5), 2.31 (2Н, т), 2.05 (2Н, 1, У - 1.8, 11.8 Н7), 1.93 (2Н, а 9, 9 - 3.7, 12.0 Н2), 1.80 (2Н, and ry, y - 12.0 Но), 1.51 (2Н, т), 0.9 (ЗН, и, У - 7.3 N?g)

Compound number 513 (MR: 215-216 (aes.)). NMR solvent: OMBO 130: 172.1, 160.3, 151, 140.2, 137.5, 130.5, 124.4, 124.2, 117.7, 114.4, 113.3, 66.3, 54.2, 31.7, 29.1 1H: 13.02 (1H, 8, 5) . , a, U - 68.5 Ng), 4.11 (IN, t), 3.94 (2H, aa, y. - 3.5, 11.0 Ne), 3.38 (2H, t), 2.96 (ZH, 5), 1.96 (2H, a d, y - 4.6, 12.4 No), 1.70 (2H, and d, U - 12.3 Ng)

Compound number 514 (MR: 185-186). NMR solvent: SOSIZ 130: 152.5 (a, 9 - 245.0 Nzg), 151.4, 147.0 (a, ) -.11.0 No), 141.1 (a, 9) - 2.6 No), 136.9, 126.4 (y, 15.9 - 7.3 No ), 120.9 (y, U - 3.5 Ng), 113.4 (a, 9 - 2.0 No), 113.0 (9, U - 20.0 No), 112.6, 60.4, 56.2, 55.8, 52.6, 31.6, 28.9, 20.3, 11.9 1Н : 7.88 (IN, y, U - 1.3 Nl), 7.50 (2Н, т), 7.40 (IN, а, У - 1.3 Н?), 6.99 (IN, 1, У - 8.4 Н2), 4.0 (IN, t ), 3.91 (ZN, 5), 3.04 (2H, a ri, U - 11.7 No), 3.01 (ZN, 5), 2.31 (2H, t), 2.05 (2H, au - 2.0, 12.0 H2), 1.93 ( 2Н, и 9, У - 3.5, 12.0 Но), 1.80 (2Н, а ре, у - 12.0 Н2), 1.51 (2Н, т), 0.9 (ЗН, и, У - 7.5

Not)

Compound number 515 (MR: 171-172). NMR solvent: SOSIZ 130: 154.5, 151.2, 148.6, 146.7, 139.4, 137.4, 132.5, 128.9, 123.6, 113.9, 80, 55.7, 42.9, 31.9, 28.7, 28.4 1H:9.92, 1H2 - 1H2, 07? 2). . , t), 1.48 (9Н, 5)

Compound number 516 (MR: Pudgossoris). NMR solvent: OMBO 130:150.1, 138.7, 137.4, 135.1, 134.4, 133, 127.6, 127.4, 118.1, 67.9, 56.4, 34.2, 31.5, 26.8 , t a, U - 6.3 Н2g), 8.42 (1Н, 5), 8.40 (IN, 5), 8.19 (IN, та, у -

Zo 8.1 Ng), 7.74 1H, aa, o - 6.3, 8.1 Nz), 3.79 (1H, t bi), 3.40 (1H, t), 2.91 (ZH, 5), 1.88 (2H, a ri,» - 12.0 H2), 1.70 (4H, t), 1.23 (2H, and Bi, U - 12.0 H?)

Compound number 517 (MR: 130-132). NMR solvent: OM5O 130: 168, 162.4, 145.4, 144.2, 135.1, 133, 132.7, 129.7, 128.8, 128.5, 128, 118.4, 114.5, 81.7, 78.7, 61.6, 61, 61, 51.8, 51.8, 61.8, 61, 61, 7 (IN, 5), 8.16 (1H, y, U - 8.5 No), 7.71 (IN, y a, U - 1.5, 8.5 Ng), 7.40-7.25 (5H, t), 5.42 (2H, 5), 3.91 (2H, 5), 3.65 (2H, 5Bi), 3.43 (4H, t), 2.55 (AN, t), 1.60 (6H, 5)

Compound number 518 (MR: 122). NMR solvent: SOSIZ 130:152.2, 151.2, 149.3, 142.3, 137.5, 136.8, 122.2, 119.7, 115.9, 57.4, 31.4, 29.8, 25.4, 25.2 1H:8.56 (Naida, - 1.8, 8.0, 8.0, 1.0). 1Н, and, 9 - 1.1, 8.0 Но), 7.97 (IN, и, У - 1.5 Н2), 7.88 (1Н, о, У - 1.5 Н2), 7.7511Н, а, У - 1.9, 7.7 Н?), 719 1Н, аа, - 1.2, 4.8, 7.6 Но), 3.98 (1Н, т), 3.0 (ЗН, 5), 1.88 (2Н, т), 1.85 (2Н, т), 1.69 (1Н, а, 9 - 13.0 H2), 1.56 (2Н, а 4, у - 3.7, 12.2 Н2), 1.38 (2Н, 14, у - 3.0, 13.0 НН), 1.12 (1Н, 49, У - 3.5, 13.0 Ng)

Compound number 519 (MR: 158-159). NMR solvent: SOSIZ 130: 150.8, 137.6, 137.6, 136.9, 136, 132.7, 125.9, 122.8, 115.3, 60.4, 56, 52.6, 31.7, 28.8, 20.2, 11.9 1Н: 8.66, У7 - 1. , 813 1Н, аа, у - 1.0, 1.7, 6.4 Но), 7.93 (1Н, а, У - 1.3 Н2), 7.71 (На, у - 1.2, 7.9 Но), 7.59 (1Н, а, 9 - 1.3 Но ), 7.31 (IN, 4 a, U - 6.4, 7.9 No), 3.98 (IN, t), 3.04 (2Н, та, у - 12.0 Nz), 3.01 (ЗН, 5), 2.30 (2Н, т), 2.04 (2H, y, y - 2.0, 12.0 N?), 1.93 (2H, a 49.9 - 3.5, 12.0 H2g), 1.80 (2H, a g, Y - 11.5 H2g), 1.50 (2H, t), 0.9 (ZN, i, U - 7.4 Ng)

Compound number 520 (MR: 170). NMR solvent: SOSIZ 130:159.2, 151.6, 142.1, 136.8, 126.4, 125.7, 114.1, 112, 60.4, 55.8, 55.3, 52.6, 31.5, 28.9, 20.2, 11.9 1Н: 7.90, Н2 - 1Н. . 5), 3.04 (2Н, т), 3.01 (ЗН, 5), 2.30 (2Н, т), 2.04 (2Н, at - 2.0, 12.0 Н2), 1.94 (2Н, and 9, 9 - 3.7, 12.0 Но) , 1.80 (2Н, a re, у - 12.0 Н2), 1.50 (2Н, t), 0.9 (ЗН, 1, У - 7.4

Nz)

Compound number 521 (MR: 163-164). NMR solvent: SOSIZ 130: 159.1, 151.6, 142.1, 136.8, 126.4, 125.7, 114.1, 112, 55.7, 55.3, 52.2, 52.1, 31.5, 28.8, 12.2 1H: 7.89 (1H, 1. 7, 2, 7, 2, 2, 1, 2, 7, 7, 7, 7, 7, 7 (2Н, т и, У - 68.9 Ng), 7.39 (IN, 9, У - 1.3 Н?), 6.94 (ОН, та, у 60 - 8.9 Но), 4.02 (1Н, т), 3.84 (ЗН, 5 ), 3.07 (2H, and, y - 11.7 Nl), 3.01 (ZH, 5), 2.43 (2H, 49.9 - 7.3

Hg), 2.03 (2H, and 1, U - 2.0, 12.0 No), 1.93 (2H, 4 4, U - 3.5, 12.0 No), 1.82 (2H, and Bg, U - 12.0 H2), 1.09 (ZN, . her, in - 7.2 H2g)

Compound number 522 (MR: 127). NMR solvent: ОМ5О 130: 150.7, 148.4, 138.5, 138.2, 135.2, 131, 130.3, 121.6, 118.9, 116.4, 59.6, 55.6, 52.4, 31.6, 28.2, 19.8, 11.9, 6, 1. No), 8.32 (1H, 5), 8.30 (IN, a horn, y - 7.9 N?), 8.20 (1H, 5), 811 (NN, aa, -2.2, 8.1 H2g), 7.69 (IN, Her, Y - 8.1 H2), 3.82 (1H, t), 2.95 (ZH, 5), 2.93 (2H, t), 2.21 (2H, BI, y - 7.5

Ng), 1.91 (2H, TB, U - 11.2 NI), 1.81 (2H, y 9, 9 - 3.0, 11.7 No), 1.72 (2H, a ri, y - 12.0 Nz), 1.41 (2H, t), 0.84 (ZN, i, U - 7.5 Nzg)

Compound number 523 (MR: 163-164 (aes.)). NMR solvent: OMBO 130:151, 150.4 (a, 9 - 240.5 Nz), 144.9 (a, 9 - 12.5 No), 140, 138.5, 137.6, 130.2 (9, U - 3.2 H2), 128.9, 128.3, 127, 116.3 (y, U - 19.0 No), 115.9 (9, 9) - 6.5 No), 114.2 (y, 9. - 2.5 N?), 114.1, 61.8, 55.4, 52.2, 31.5, 28.2 1Н: 9.20 (NN, 5), 8.08 (1H, 5), 7.89 (1H, 5), 7.A5 (IN, a a, U - 1.7, 8.7 Nz), 7.39-7.19 (6H, t), 7.13 (Us, - 8.7, 11.2 H2g), 3.82 (1H, t bi), 3.47 (2H, 5), 2.93 (ZH, 5), 2.90 (2H, t bi), 2.0 (2H, t bi), 1.83 (2H, t Bi), 1.72 (2H, t Bi)

Compound number 524 (MR: 124-125). NMR solvent: ОМ5О 130: 151.1, 148.8, 141.4, 137.3, 133.8, 129.1, 113.7, 113, 112.8, 110.4, 59.6, 55.6, 52.4, 31.4, 28.2, 19.8, 11.9, 1Н (Х. No), 7.79 (1H, a, y - 1.3 No), 7.08 (IN, U - 2.0 H2), 7.0 (1H, her Yu - 7.6

Нg), 6.9541Н, та, у - 1.2, 7.5 Н7), 6.А5(1Н, ай а, У - 1.4, 2.4, 7.8 Но), 5.08 (2Н, 5), 3.79 (1Н, т), 2.95 (2H, t), 2.92 (ZH, 5), 2.23 (2H, 1, ri, U - 7.5 No), 1.92 (2H, 1 Bg, y - 11.0 No), 1.81 (2H, y 4.9 - 3.0 )

Compound number 525 (MR: 167-168). NMR solvent: SOSIZ 130: 151.2, 148.6, 146.7, 139.3, 137.3, 132.4, 128.9, 123.6, 113.9, 55.9, 52.2, 52.1, 31.6, 28.8, 12.2 1Н: 9.0(1Н, 1.0, Н2, Н2) , 8.52 (1Н, yes, У - 1.7, 4.9 Н7), 81. IN, ada, -1.7, 2.2, 7.9

Ng), 7.94 (1H, 9, U - 1.3 No), 7.58 (1H, a, U - 1.3 H7), 7.34 IN, aa, - 1.0, 4.9, 8.0 N?), 4.03 (1H, t), 3.07 (2Н, та, У - 11.5 Н2g), 3.03 (ЗН, 5), 2.43 (2Н, 9, У - 7.3 Но), 2.03 (2Н, 1, У) - 2.0, 11.7 Н2),

Зо 1.44 (2Н, и 49, У - 3.5, 12.0 Nzg), 1.83 (2Н, а ри, у - 12.0 Н2), 1.09 (ЗН, и, У - 7.3 Н2)

Compound number 526 (MR: 117). NMR solvent: OM5O 130: 167.9, 151, 140.5, 140.2, 140, 137.7, 135, 134.1, 129.6, 129.4, 129, 126.8, 125.8, 125.7, 124.2, 123.1, 115, 29.2 19.5, 11.8 1H: 8.21 (IN, her, U - 1.7 No), 8.19 (IN, i, U - 1.7 No), 8.16 (ZN, t), 7.88 (ZN, t), 7.63 (1H, a aa, - 1.2, 2.0, 7.8 No), 7.57 (IN, Her, U - 7.7 No), 7.52 (1H, Her, y - 7.8 H2g), 7.49 (1H, in Bi), 3.87 (IN, t Bi), 3.0 (2H, t bi), 2.96 (ZN, 5), 2.31 (2H, t Bi), 2.05 (2H, t bi), 1.86 (2H, 49 Big, U - 12.0 Ng), 1.46 (2H, a re , U - 10.5 Н2), 1.45 (2Н, т), 0.85 (ЗН, и, У - 7.4 Нз)

Compound number 527 (MR: 85-87). Solvent NMR: SOSIZ 130: 154.4, 150.3, 148.9, 132.3, 129, 126.2, 123, 58.8, 56.6, 31.1, 30.6, 29.4, 25.4, 25.3 1Н: 7.90 (2Н, т а, У - 8.56 Но), 7.7 1Н, ти, У - 7.3 INg), 7.49 (2Н, ти, У - 7.8 Нг), 4.13, 3.70 (ИН, 2 5 BI), 3.0 (ЗН, 5), 1.87 (4Н, т), 1.68 ( IN, а, У - 12.0 Ng), 1.52 (2Н, а, У - 12.0 Н2), 1.40 (2Н, 5

BO, 12 1Nta, in -, 3.2, 13.0 N?)

Compound number 528 (MR: 138-140). Solvent NMR: SOZIZ 130: 153.3, 149.8, 144.2, 132.5, 129.1, 126.2, 122.7, 81, 79.8, 61.8, 22.8 - 7.3 Ni), 7.50 (2Н, тии, у) - 7.2 Nz), 5.23 (2Н, 5), 3.83 (2Н, 5), 1.59 (6Н, 5)

Compound number 529 (MR: 154-155). NMR solvent: SOSIZ 130: 151.2, 148.6, 146.7, 139.3, 137.3, 132.4, 128.9, 123.6, 113.9, 60.4, 55.9, 52.6, 31.6, 28.9, 20.3, 11.9 1Н2 - Н2:9.0(7.0) . - 1.3 No), 7.33 (IN, aa, o - 4.6, 8.1 No), 4.01 (1H, t), 3.05 (2H, t), 3.02 (ZH, 5), 2.30 (2H, t), 2.04 (2H , t Bi, U - 11.5 N?), 1.93(2H, ad, 9 - 3.1, 12.0 N?), 1.81 (2H, a ri,

U - 11.2 Н2), 1.50 (2Н, t), 0.9 (ЗН, и, У - 7.4 Нз)

Compound number 530 (MR: 185-186 (aes.)). NMR solvent: OMBO 130:151, 143.1, 140, 137.5, 132.9, 125.7, 124.2, 122.8, 121.8, 57.4, 31.4, 29.9, 25.4, 25.2 1H: 8.87 (IN, a, U - 1.37 (?), 3.3 1Н, а а, У - 2.0, 8.3 Но), 8.31 (1 Н, и, У - 6.0 Но), 8.06 (IN, 9, У -1.3 Н2), 7.37 (IN, а1,9У -1.2,8.4 Н2 ), 717 (IN, а, У - 2.2, 7.1 Но), 4.0 (1Н, т), 3.0 (ЗН, 5), 1.87 (4Н, т), 1.69 (IN, 9, У - 13.0 Н2), 1.57 (2H, and 4, U - 3.5, 13.0 No), 1.39 (2H, ta, y - 13.0 Ni), 1.12 (IN, ta, y - 13.0 Nz) because Compound number 531 (MR: 5iom/dec. 2160) . NMR solvent: OM5O

130: 150.4, 140.2, 139.9, 139, 137.9, 134.8, 132.6, 127.4, 118.6, 52.4, 42.4, 31.8, 24.7. 1Н, а, У - 10.0 Ng), 8.94 (IN, 9, У - 8.2 Н2), 8.80 (IN, а, у - 5.3 Но), 8.55 (1Н, 5), 8.38 (IN, 5), 85.08( 1H, a a, U - 5.3, 8.2 H2g), 4.22 (1H, t), 3.34 (2H, 9.9 - 12.0 Ng), 3.01 (2H, 9, U - 13.0 Ng), 2.96 (ZH, 5) , 2.17 (2H, a, Y - 13.2 No), 1.92 (2H, a, y - 12.0

Nz)

Compound number 532 (MR: 245-246 (des.)). NMR solvent: OMBO 130:158.5, 151.2, 140.6, 137.5, 126.1, 126, 114, 113.1, 55.1, 54.5, 44.9, 34.3, 31.6, 27.7 1Н: 8.10 (1Н, а, У - 1.3 Но), 7.88 (IN , 9, U - 1.3 Ng), 7.77 (2H, and, U - 8.9 H2g), 6.96 (2H, and, y - 8.9 H2), 3.98 (1H, t), 3.77 (ZH, 5), 3.66 (2H , and rg, U - 12.0 H2g), 2.95 (ZH, 5), 2.88 (ZH, 5), 2.84 (2H, t), 1.87 (4H, t)

Compound number 533 (MR: 259-260). NMR solvent: OM5O 130: 150.9, 148.1, 146.2, 138.2, 137.8, 131.9, 129.1, 123.8, 115.5, 54.5, 44.9, 34.4, 31.7, 27.7 1H: 9.07 (1H, 5), 1.8, 8.45 (ZH, t), 7.42 (1H, 5 Bi), 3.98 (1H, t bi), 3.66 (2H, and, y - 10.0 H2), 2.96 (ZH, 5), 2.88 (ZH, 5), 2.85 ( 2H, t bi), 1.88 (4H, t Bi)

Compound number 534 (MR: 162). NMR solvent: OMBO 130: 151.5 (90, U - 243.0 No), 149.4, 147.3 (y, 9 - 10.6 No), 137.4, 135.4, 122.4 (t), 121.9 (a, - 2.8 H2g), 115.2, 114.3 ( 90, U -1.5 No), 113.0 (0, U - 20.2 No), 56.2, 52.5, 42.3, 31.7, 24.6 1H: 8.91 (2H, t), 8.49 (1H, 5), 8.11 (1H, 5), 7.71 NN, aa, y - 2.0, 12.7 H2), 7.67 (IN, ta, y - 8.8

Ng), 7.23 (1H, her, y - 6.8 Ng), 4.21 (1H, t), 3.86 (ZH, 5), 3.36 (2H, and Big, y - 12.5 Ng), 3.02 (2H, t bi), 2.95(Z3H, 5), 211 (2H, and 9, Y - 4.0, 12.8 H?), 1.92 (2H, and horn, y - 12.8 H2)

Compound number 535 (MR: 141-142). NMR Solvent: SOSIZ 130: 149.6, 144.4, 137.9, 135.2, 131.4, 129.1, 128.3, 127.2, 125.6, 118.1, 115.3, 109.1, 62.8, 57.6, 55.6, 52.8 , - 1.0, 1.4 n7), 8.12 1Н, и а, у - 1.0, 8.7 Ng), 7.82 1Н, и а, У - 1.4, 8.7 Н2), 7.43-7.20 (5Н, т), 4.32 -4.20 (1Н , 25 Bi), 3.54 (2H, 5), 3.21 (ZH, 5), 3.03 (2H, 5 Bi), 2.18 (2H, 5 Bi), 2.01 (2H, t Bi), 1.94 (2H, t Bi)

Compound number 536 (MR: 173-174). NMR solvent: OM5O 130:151.2 (a, 9 - 240.0 No), 151, 144 (0,9 - 12.5 No), 139.9 (0, U - 2.4 Nz?), 137.5, 125.4 (0,9 - 7.0 NO) . . 2.0. Bi), 1.98 (2H, t bi), 1.85 (2H, t Big), 1.77 (2H, t Bi), 1.02 (ZH, t bi)

Compound number 537 (MR: 144-146). Solvent NMR: SOSIZ 130: 151.9 (a, U - 246.2 NI), 151.4, 147.8 (a, 9 - 11.0 H2), 141.5, 136.8, 129.6 (a, 9 - 3.8 H2), 117.3 (a, U - 6.8 N ?), 116.1 (a, U - 19.0 No), 113.1, 110.3 (9, 9) - 1.5 No), 56.2, 55.8, 52.2, 52.1, 31.6, 28.68, 12.2 1Н: 7.90 (1Н, 5), 7.49 ( 1Н, и а, У - 1.7, 8.5 Но), 7.45 (1Н, 5), 7.24 (IN, t), 7.08 НН, а а, У - 8.6, 11.1 Н2), 4.03 (1Н, т), 3.96 ( ЗН, 5), 3.08 (2Н, and Big, y - 11.2 Н2), 3.02 (ЗН, 5), 2.44 (2Н, 49.9 - 7.4

Hg), 2.05 (2H, Tr, U - 11.0 N?), 1.95 (2H, 4 9, U - 2.6, 11.9 No), 1.83 (2H, a ri, y - 10.5 H2), 1.10 (ZN, i, In - 7.4 Ng)

Compound number 538 (MR: 44-46). NMR solvent: SOSIZ 130: 150.7, 145.2, 133.1, 129.3, 125.2, 119.8, 113.6, 40, 38 1H:811 (IN, a, U - 8.4 N?2), 8.0 (IN, y, U - 8.4 Nl) .

Compound number 539 (MR: 90-91). NMR solvent: SOSIZ 130: 156.8, 149.9, 149.2, 126, 123.9, 123, 40, 38.3 1n: 8.82 1Н, yes, у - 1.6, 4.4 Н7), 8.42 1Н, и а, У - 1.6, 8.5 Н2g), 7.57 (IN, and a, U - 4.4, 8.5 H2), 3.49, 3.31 (6H, 25)

Compound number 540 (MR: 164). NMR solvent: OMBO 130: 151.7 (a, U - 242.5 INl), 151, 146.2 (0, U - 10.5 No), 139.5 (0, 9 - 2.5 Nzg), 137.6, 126.7 (ad, U - 7.3 IN), 120.9 (y, U - 3.0 Nl), 114 (2 C), 112.2 (y, U - 9.4 No), 60, 58.8, 56, 55.5, 52.8, 31.5, 28.2 1Н: 8.09 (IN, y, U - 1.3 No), 7.96 (1H, y, U - 1.3 No), 7.66 (1H, 4 a, U - 2.0, 13.5 N?), 7.63 (IN, t), 7.19 (IN, her, U - 8.7 No), 4.41 (1H, her, U - 5.3 H2), 3.85 (ZH, 5), 3.80 (1H, t), 3.48 (2H, t), 2.95 (2H, art, - 11.5 H2g), 2.93 (ZH, 5) . ?2)

Compound number 541 (MR: 220-221). NMR solvent: SOSIZ 130: 152.5 (a, 9 - 245.0 Nl), 151.5, 147.1 (a, 9 - 10.0 Nl), 141.2 (a, 9 - 3.0 N?o), 136.9, 126.4 (a,

U - 7.0 Nzg), 120.9 (a, 9 - 3.5 No), 118.7, 113.5 (0, U - 2.0 Nz), 113.1 (j, 9) - 19.0 No), 112.6, 56.3, (510) 55.3, 53, 52.2, 31.7, 28.7, 16.3

1Н: 7.90 (1Н, и, У - 1.3 Nl), 7.50 (2Н, t), 7.40 (IN, а, У - 1.3 Но), 7.0 (IN, и, У - 8.5 Н2), 4.04 (IN, т ), 3.93 (ZN, 5), 3.03 (ZN, 5), 3.02 (2H, t), 2.71 (2H, 1, U) - 7.0 No), 2.52 (2H, 1, U - 7.0 Ng), 2.22 ( 2H, a, - 2.0, 11.5 H7), 1.94 (2H, a 9, U - 3.5, 12.2 No), 1.83 (2H, and Bi, y - 12.2 НН?)

Compound number 542 (MR: 175). Solvent NMR: SOSIZ 130:151, 150.3, 140.2, 139.8, 137.3, 119.4, 115.6, 66.9, 54.5, 31.9, 29.5 1Н: 8.63 (2Н, тса, У - 4.6 Но), 7.9511Н, и, У - 1.3 Hg), 7.69 (1Н, а, У - 1.3 Н2г), 7.67 (ОН, та, у - 4.6 Н2), 4.28 (IN, т), 4.09 (2Н, а а, 9 - 4.7, 11.5 Но), 3.50 (2H, au - 2.1, 12.0 No), 3.04 (ZH, 5), 1.95 ((2H, and 9, U - 4.9, 12.5 No), 1.78 (2H, ta, y - 12.3 N?g)

Compound number 543 (MR: 173-174 (des.)). Solvent NMR: SOSIZ 130: 150.8, 139.3, 138.5, 137.5, 131.3, 121.8, 115.3, 66.9, 54.6, 31.9, 29.5 1H: 8.22 (2H, a, U - 6.8 H2g), 7.93 (1H, 8 (5), 7.6 2H, y, U - 6.8 H2g), 7.62 (1H, 5), 4.28 (1H, t), 4.10 (2H, aa, y - 4.0, 11.7 No), 3.51 (2H, her, U - 11.7 No), 3.04 (ЗН, 5), 1.95 (2Н, и 9, у - 4.5, 12.2 Н2), 1.78 (2Н, а рі, у - 12.0 Нз)

Compound number 544 (MR: 163-164). NMR solvent: SOSIZ 130: 159.1, 158.2, 151.6, 149.4, 142.1, 136.8, 136.4, 126.4, 125.7, 123.2, 122.1, 114.1, 112, 64.3, 55.6, 55.8, 52.8, c, U - 4.9 Nzg), 7.89 (1H, y, U - 1.3 Nzg), 7.72 (2H, and, y - 68.9 No), 7.66 (1H, y1, U - 1.8, 7.7 No), 7.39 (1H, a, y - 1.3 Но), 7.36 (1Н, а, У - 8.0 Н2), 7.18 1Н, ааа, у - 1.0, 4.9, 7.4 Н2), 6.94 (2Н, т а, У - 8.9 Но), 4.04 ( 1H, t), 3.84 (ZH, 5), 3.66 (2H, 5), 3.02 (2H, t), 3.01 (ZH, 5), 2.20 (2H, a, y - 1.6, 12.0 H2), 1.97 (2H , and 9, U - 3.8, 12.2 No), 1.78 (2H, and Bi, y - 12.0 Nz)

Compound number 545 (MR: 127-128). NMR solvent: SOSIZ 130: 151.9 (a, U - 246.5 NI), 151.4, 147.8 (a, 9 - 11.0 Nl), 141.4, 136.8, 129.6 (y, U - 4.0 H2), 117.3 (9, 9) - 7.0 No), 116.1 (y, U - 18.8 N?), 113.1, 110.3 (9, 9 - 2.0 N?), 60.4, 56.2, 55.8, 52.6, 31.6, 28.8, 20.2, 11.9 1Н: 7.89 1Н, а, о - 1.3 H?), 7.49.1H, aa, o - 2.0, 8.2 No), 7.45(1H, y, U - 1.3 NI), 7.24 (1H, t), 7.09 (IN, a a, U - 8.3, and , y - 2.0, 12.0 N?), 1.94 (2H, and 9, Y - 3.5, 12.0 No), 1.80 (2H, and ru, y - 12.0

NO), 1.51 (2Н, т), 0.91 (ЗН, и, У - 7.5 N?g)

Compound number 546 (MR: 240-241). NMR solvent: OM5O

COO) 130: 163.6, 161.9, 158.5, 151.3, 151.1, 151, 147.1, 140.6, 137.5, 133.9, 128.6, 126.1, 126, 125, 125, 124.4, 114, 114, 113.1, 55.1 28.1 1H:918 (НН, а, у - 2.0 Н2), 8.71 (IN, а а, У - 1.6, 4.9 Н7), 8.35(1Н, а, 9 - 1.6, 7.9 Но), 8.27 (IN, 5) ... 7.9 No), 6.96 (2H, t a, U - 8.8 N?g), 4.64 (IN, a rt, U - 12.0 No), 4.37 (IN, a horn, U - 12.0 H2), 4.22 (IN, t ), 3.77 (ZH, 5), 3.25 (1H, t), 2.97 (ZH, 5), 2.92 (1H, t), 1.88 (4H, t)

Compound number 547 (MR: 204-205). NMR solvent: SOSIZ 130: 168.8, 159.2, 151.6, 142.3, 136.9, 126.4, 125.6, 114.1, 111.9, 55.3 (2 parts), 45.5, 40.7, 31.9, 29.1, 28.4, 21.74, 1Н, 1Н, (1Н U - 1.3 N2g), 7.72 (2H, t y, U - 68.8 N?g), 7.40 (IN, 9, U - 1.3 N?), 6.94 (OH, and, y - 8.8 H2?), 4.82 (IN , ta, u - 13.5 Ng), 4.27 (1H, t), 3.95 (IN, t a, U - 14.0 N?), 3.84 (ZN, 5), 3.18 (Nau - 2.5, 13.5 No), 3.0 (ZN .

Compound number 548 (MR: 196-197). NMR solvent: SOSIZ 130: 168.8, 151.2, 148.6, 146.7, 139.4, 137.4, 132.5, 128.8, 123.6, 113.8, 55.4, 45.4, 40.6, 32, 2971, 28.3, 21.4, 1Н, 0, 1Н2 ?2), 8.53 (1Н, а а, 9 - 1.6, 4.9 2), 811 НН, ай а, у - 1.8, 2.2, 7.9 Н2), 7.96 (IN, и, У - 1.3 Но), 7.59(1Н , а, у - 1.3 Но), 7.34 (1Н, ай а, 0 - 0.9, 4.9, 8.0 Н2?), 4.83 (IN, та,

U - 13.5 H2), 4.28 (IN, t), 3.96 (1H, t y, U - 14.0 N?), 3.19 (IN, tii, y) - 2.7, 13.5 No), 3.01 (ZN, 5), 2.61 (IN, a, y - 2.6, 13.2 NI), 2.13 (ZH, 5), 1.94 (1H, t), 1.89 (IN, t), 1.75 (2H, t)

Compound number 549 (MR: 206-207). NMR solvent: SOSIZ 130:159.2, 151.6, 142.3, 137.3, 136.8, 132.0 (d, U - 34.0 Nl), 130.7, 130.1, 129.7 (d, U - 3.8 H2), 126.4, 125.5, 124.5 (d, U - 3.8 No), 123.1 (d, 94 - 273.0 NzI), 114.1, 111.9, 55.3, 54.2, 45.6, 31.9, 28.0 1H: 8.03 (IN, i Bo), 7.97 (IN, a, U - 7.9 No), 7.90 (1Н, а, У - 68.0 Nzg), 7.87 (1Н, а, У - 1.3 Н2), 7.73 (IN, У - 7.9 Но), 7.70 (2Н, т и, У - 8.9 Нг), 7.36 (1Н, а, У - 1.3 Но), 6.93 (2Н, та, у - 8.9 Н2), 4.01 (ЗН, т), 3.84 (ЗН, 5), 3.02 (ЗН, 5), 2.42 (2Н, а, у - 2.8 , 11.8 H7), 2.0 (2H, and 9, Y - 4.0, 12.3 NO), 1.93 (2H, and Bi)

Compound number 550 (MR: 89-101 (AES)). NMR solvent: OMBO 130: 167.9, 151, 140.5, 140.1, 140, 138.5, 137.7, 135, 134.1, 129.6, 129.4, 129, 128.8, 128.2, 127, 126, 126.7, 125.8, 125.9 55.5, 52.2, 31.6, 28.2

1H: 8.20 (IN, her, U - 1.6 N?), 8.18 (IN, her, U) - 1.7 Ng), 8.15 (2H, 5), 8.14 (1H, 5 Bi), 7.88 (ZN, t), 762 1H, aa, - 1.2, 1.8, 7.8 Ng), 7.57 (1H, her, y - 7.8 Ng), 7.51 (IN, her, y - 7.8 No), 7.47 (IN, 5 Bi), 7.37-7.20 ( 5H, t), 3.85 (1H, t), 3.47 (2H, 5), 2.96 (ZH, 5), 2.90 (2H, and BG, y - 12.0 Но), 2.01 (2H, 1 BG,

U - 12.0 Н?), 1.84 (2Н, и 49, У - 3.5, 12.0 Но), 1.73 (2Н, а ры, ю - 12.0 Н2)

Compound number 551 (MR: 258-260 (des)). NMR solvent: OMBO 130: 160.1, 157.3, 150.6, 139.4, 138.1, 137.1, 126.5, 125.3, 121.5, 116.2, 56.9, 31.4, 29, 25.2, 24.8 1H: 12.94 (1H, 1.19, in Bi), ), 8.18 (1Н, 5), 8.04 (2Н, т 4, У - 68.4 Н?), 7.83 (ОН, та, у - 8.4

Н2г), 3.82 (1Н, t bi), 2.93 (ЗН, 5), 1.78 (4Н, т), 1.58 (ЗН, т), 1.30 (2Н, 9, У - 13.0 Но), 1.11 (IN, d, In - 13.0 Nzg)

Compound number 552 (MR: 126 (aes.)). NMR solvent: OMBO 130: 164.2, 150.9, 140, 137.8, 133.6, 133.3, 128.7, 127.3, 125.4, 123.3, 115, 59.6, 55.6, 52.4, 31.5, 28.2, 19.8, H: 15 (1.1, 1.15) . y, y - 7.9 Ng), 7.62 (IN, t y, U - 7.8 No), 7.46 (IN, Her, U - 7.7 No), 3.81 (IN, t), 2.94 (ZN, 5), 2.93 (2Н , t), 2.22 (2H, t), 1.91 (2H, 1 ri, U - 11.0 H2?), 1.81 (2H, y 4, y - 3.2, 11.7

NO), 1.72 (2Н, арг, У - 11.7 Н2з), 1.42 (2Н, т), 0.84 (ЗН, И, У - 7.5 Н?г)

Compound number 553 (MR: 271-272). NMR solvent: OM5O 130: 156.2, 150.7, 139.7, 137.8, 135.7, 134.9, 130, 123.1, 122.8, 120.7, 115.2, 56.8, 31.4, 29, 25.2, 24.8 1H: 1.1, 10.15 5). ), 711 (1H, a a, U - 1.3, 7.9 No), 3.81 (1H, t bi), 2.93 (ЗН, 5), 1.78 (4Н, т), 1.58 (ЗН, т), 1.29 (2Н, 9, U - 12.5 N2), 1.11 (IN, 4, U - 13.0 N?)

Compound number 554 (MR: 187-188). NMR solvent: ОМ5О 130: 172.1, 160.3, 151, 140.2, 137.4, 130.5, 124.4, 124.2, 117.7, 114.4, 113.3, 59.5, 55.4, 52.3, 31.6, 28, 19.7, 1.0, Н3, 1.15, Н3 8.50 (1H, 5 Bi), 8.32 (IN, y, U - 2.0 H2), 8.12 (1H, a, y - 1.3 H2), 7.97 (1H, 5 ro), 7.88 1H, aa, o - 2.0, 8.5 No), 7.86 (IN, a, 9 - 1.3 No), 6.91 (1H, 9, U - 8.5 No), 3.84 (1H, t), 2.98 (2H, t), 2.95 (ZN, 5), 2.26 ( 2H, t), 1.97 (2H, Bi), 1.84 (2H, d, U - 12.5 N?), 1.73 (2H, a, y - 11.5

Zo Hz), 1.44 (2H, t), 0.84 (ZH, I, U - 7.3 Ng)

Compound number 555 (MR: 219-222). NMR solvent: ОМ5О 130: 158.4, 149, 137, 135.4, 127.2, 118.7, 115.9, 114.2, 52.7, 42.5, 32, 24.8 1Н: 9.89 (1Н, Big), 9.3 (IN, 5), 8.7 (IN, and . Но), 4.22 (1Н, т), 3.40 (2Н, а ры, у - 12.0 Н2), 3.06 (2Н, аб, -11.5 Н2г), 2.97 (ЗН, 5), 2.09 (2Н, а д, у - 3.5, 12.5 Ng), 1.96 (2H, and Bg, U - 12.5 Ng)

Compound number 556 (MR: 141). IMR Solvent: SOSIZ 130: 151.7, 142.4, 141.4, 140.3, 138.1, 136.8, 129.1, 128.8, 128.3, 127.1, 119.4, 115.4, 112.3, 111.9, 62.8, 55.8 . 2.0, 8.2 No), 7.03 (1H, a, U - 8.2 No), 4.01 (ZH, t), 3.52 (2H, 5), 3.0 (ZH, 5), 2.99 (2H, t), 2.69 (6H, 5), 2.09 (2H, Big, U - 12.0 H2), 1.92 (2H, a 4, U - 3.5, 12.0 H2), 1.77 (2H, ab, - 12.0 H2g)

Compound number 557 (MR: 183-184). NMR solvent: SOSIZ 130: 170.5, 163.9, 159.3, 151.7, 142.4, 136.9, 126.5, 125.5, 114.1, 111.9, 55.3, 54.9, 43.4, 32.1, 283 1H: 7.93 (1H2, 7.7, 1H2, a3). (2Н, т и, У - 68.9 Ng), 7.41 (IN, 9, У - 1.3 Но), 6.95 (2Н, та, у - 8.9 Н2г), 4.97 (2Н, та, У - 13.5 Н2), 4.38 ( 1Н, т), 3.84 (ЗН, 5), 3.05 (2Н, а, у - 2.7, 13.5 Но), 3.02 (ЗН, 5), 2.02 (2Н, а рі, у - 13.0 Н2), 1.82 (2Н, and 9, 9 - 4.5, 12.5 N?)

Compound number 558 (MR: 179 (aes.)). NMR solvent: OMBO 130: 169.4, 150.9, 148.1, 146.2, 138.2, 137.8, 131.9, 129.1, 123.8, 115.5, 58.1, 54.1, 51.5, 31.5, 26.9 1H: 9.07 (H1, 4, 5) . 2.0 (2H, and Big, U - 12.0 N2g), 1.81 (2H, and g, 9 - 11.0 N?g)

Compound number 559 (MR: 194-195). NMR solvent: SOSIZ 130: 159.1, 156.1, 151.2, 148.6, 146.7, 144, 139.3, 137.3, 132.4, 128.9, 123.6, 118.8, 113.9, 110.9, 55.4, 54.9, 52.5, 5 . Ng), 7.57 (IN, y, U) - 1.3 No), 7.33 (IN, a and, U - 4.9, 7.9 No), 7.14 (1H, a, y - 3.5 No), 6.35 (1H, a, y - 3.5 Н2g), 4.0 (1Н, т), 3.88 (ЗН, 5), 3.64 (2Н, 5), 3.04 (2Н, т), 3.02 (ЗН, 5), 2.21 (2Н, 1 Bi, U 60 - 12.0 H2), 1.96 (2H, a d, U - 3.6, 12.0 Nl), 1.81 (2H, a b, 9 - 12.0 Ng)

Compound number 560 (MR: 165). NMR solvent: SOSIZ 130:152.1, 151.5, 149.3, 142.6, 137.6, 136.9, 122.4, 119.8, 115.8, 67, 54.4, 31.8, 29.5 1n:8.57 (IN, aa, - 1.0, 2.0, 4.8 Н10) IN, and, y) - 1.1, 8.1 Н2), 8.0 (1Н, и, У - 1.5 Н2), 7.89 (1Н, о, У - 1.5 Но), 7.76 (IN, та, У - 1.8, 7.7 Н2) . H2), 3.05 (ZH, 5), 1.94 (2H, and 4.9 - 4.5, 12.0 H2), 1.78 (2H, and, U - 12.3 N?g)

Compound number 561 (MR: 201-202). Solvent NMR: ОМ5О 130: 151.1, 150.4 (а, 9) - 240.5 НХ), 144.9 (а, 9) - 12.5 НХ), 140, 137.7, 130.1 (а, 9) - 3.5 Н?2), 116.3 (9 , 9 - 18.5 No), 116.0 (a, 9 - 6.5 No), 114.3 (y, U - 2.5 No), 114.1, 52.1, 50.9, 50.2, 31.6, 25.3, 9.2 1Н: 9.90 (1Н, 5), 9.36 (1H, 5 Run), 8.13 (IN, 5), 7.92 (1H, 5), 7.46. 1Н, а а, 2 - 2.0, 8.7 Н2), 7.25 (IN, т), 7.14 1Н, и а, У - 8.5, 11.3 Но), 4.19 (1Н, т), 3.58 (2Н, т и, У - 11.5 No), 3.10 (4H, t), 2.94 (ZN, 5), 2.18 (2H, t a, y - 12.5 No), 2.0 (2H, a rt, U - 12.5 Ng), 1.24 (ZN, 1, U - 7.2 Nz)

Compound number 562 (MR: 190-192 (des.)). NMR solvent: OMBO 130: 151.3, 149.5, 137.2, 135.8, 126.5, 121.4, 121, 119.7, 116.7, 114.6, 58.7, 31.4, 28.2, 24.1 1H: 11.26 (1H, 5Bi), (Z, 10). 8.96 (1H, 5), 8.10 (IN, 5), 7.84 (IN, y, 9 -2.2 H2g), 7.74 IN and 9.9 - 2.2, 8.5 No), 7.19 (1H, y, 9 - 8.6 Nl) , 4.36 (1H, t), 2.95 (ZH, 5), 1.88 (2H, t), 1.69 (4H, t), 1.53 (2H, t)

Compound number 563 (MR: 250-252). NMR solvent: OM5O 130: 155.3, 150.8, 140.1, 138.9, 137.7, 134.8, 129.8, 122.9, 121.7, 120.5, 114.9, 56.8, 31.3, 29, 25.2, 24.8 1H (1.8, 8.15), 5). 8.2 Н2), 3.8 (1Н, т), 2.93 (ЗН, 5), 1.78 (4Н, т), 1.58 (ЗН, т), 1.29 (ОН, та,

У -12.5 Н2), 1.11 (IN, t 9, у - 12.5 Н2)

Compound number 564 (MR: 250). NMR solvent: OMBO 130: 154.7, 151.1, 142.6, 140.3, 137.6, 130.8, 129.6, 118.6, 114.2, 109.6, 106, 58.4, 31.3, 28.2, 24 1H: 11.71 (1H, a, lo). - 1.2 H2), 8.0(1Н, а, 9 - 1.2 Н2), 7.59 НН, а а, У - 1.7, 8.3 Н2), 7.53 (IN, и, У - 1.7 Нг), 7.29 (1Н, и, У - 8.3 No), 4.36 (1H, t), 2.93 (ZH, 5), 1.87 (2H, t), 1.68 (4H,

Koo) t), 1.53 (2H, t)

Compound number 565 (MR: 188-189). NMR Solvent: SOSIZ 130: 151.5, 146.7, 142.2, 138, 136.8, 133.9, 129.6, 129.1, 128.3, 127.2, 115.5, 114.4, 113.1, 111.9, 62.8, 55.8, 52.8, ), 7.45 (1H, 5), 7.38-7.24 (5H, t), 7.21 (1H, GB), 7.17 (IN, t), 7.16 (1H, t), 6.63 (IN, ta, y - 7.5 No) , 4.02 (1H, t), 3.74 (2H, 5), 3.52 (2H, 5), 3.01 (ZH, 5), 3.0 (2H, t), 2.10 (2H, 1 Bri,

У - 11.5 Н2), 1.93 (2Н, а 4, у - 3.3, 12.0 Но), 1.78 (2Н, а ры, у - 11.0 Ng)

Compound number 566 (MR: 196). NMR solvent: ОМ5О 130: 163.9, 149.6, 137.8, 136.9, 133.5, 130.7, 129.1, 127.7, 126.4, 123.9, 115.9, 67.9, 56.5, 34.1, 31.5, 26.7 1H, 1, 1, 18, 1H1, 18 5). her, U - 7.8 Н2), 3.85 (1Н, т), 3.41 (1Н, т), 2.94 (ЗН, 5), 1.90 (2Н, and Ри, У - 12.0 Нз), 7.71 (4Н, т), 1.25 (2H, and Bi, U - 12.3 H?)

Compound number 567 (MR: 219-220). NMR solvent: ОМ5О 130: 150.7, 139, 138.8, 138.5, 138.4, 138.3, 128.8, 128.2, 127.6, 127, 125.2, 116.8, 61.9, 55.6, 52.2, 43.7, 31.2, 28, Н1.2 - 1.1 N?), 8.20 (1H, 9, U - 1.1 N?), 8.10 (2H, t a, U - 8.7 H2), 7.93 (2H, ta, y - 8.7 Nz), 7.36-7.20 (BN, t), 3.83 (1Н, t), 3.46 (2Н, 5), 3.22 (ЗН, 5), 2.95 (ЗН, 5), 2.90 (2Н, та» - 11.0 Н2), 2.0 (2Н, rt, u - 11.0 N?), 1.83 (2H, a 49, U - 3.5, 12.0 No), 1.72 (2H, a g, y - 12.0 N?g)

Compound number 568 (MR: 193-194). NMR solvent: OM5O 13C: 158.3, 148.9, 137.0, 136.9, 135.3, 131.6, 131.3, 130.1 (d, U - 33.0 No), 130.0 (d, U - 3.5 H2g), 127.1, 123.8 (d, U - 4.2 NO ), 123.4 (d, U - 273.0 Ng), 118.8, 115.9, 114.2, 54.3, 45.2, 31.9, 27.3 1H: 9.88 (1H, Big), 9.21 (1H, 5), 8.17 (TN, 5), 8.14 ( IN, a ri, y - 7.8 H7), 8LO(1H, a g, 9 - 8.0 H2), 7.99 (1H, 1 ro), 7.92 (1H, y - 7.9 Nz), 7.64 (2H, ta, y - and )

Compound number 569 (MR: 157-158). NMR solvent: SOSIZ 130: 157.9, 151.2, 149.5, 148.5, 146.7, 139.3, 137.3, 136.4, 132.4, 128.9, 123.6, 123.3, 122.2, 113.9, 64.2, 55.7, 52.7 , - 2.2 H2?2), 8.59 1H, ai a, o - 1.0, 1.8, 4.9 H?), 8.53 (IN, y y, U - 1.6, 4.8 H2), lin, aa, - 1.8, 2.2, 7.9 No), 7.94 (1H, 9, U - 1.3 No), 7.67 (IN, and her, U) - 1.9, 7.7 Nzg), 7.57 (1H, 60 a, 9uU-1.3NI), 7Z7 Na, - 7.7 H7 ), 7.34 tn, ada, y - 0.8, 4.68, 7.9 H2), 719 1Н, aa, - 1.0,

4.9, 7.7 Nl), 4.05 (1Н, т), 3.68 (2Н, 5), 3.04 (2Н, та, у - 12.0 Нз), 3.03 (ЗН, 5), 2.23 (2Н, 10, У - 11.5 Н2) , 2.01 (2H, and 9, U - 3.5, 12.0 No), 1.79 (2H, and B, U - 12.0 N?g)

Compound number 570 (MR: 206-207). NMR solvent: MeEOU 130: 153.2, 152.8 (a, U - 241.0 Nl), 146.6 (y, 9 - 13.5 N?), 142.5, 139.2, 131.0 (a, U - 3.5 N?g), 118.0 (a, U - 6.5 H2), 117.3 (0, U - 19.3 No), 116.0 (a, U - 3.0 No), 115.1, 60.0, 55.2, 53.3, 33.3, 27.4, 19.5, 11.6 1Н:8.12 1Н, а, U - 1.4 Н?), 7.7511Н, 9, У) - 1.4 No), 7.36 (1Н, и и, У - 2.3, 8.5 NO), 7.22 (1Н, т), 7.06 (1Н, и а, У - 8.4, 11.0 No), 4.22 (1H, t), 3.60 (2H, and Bi, U - 12.0 Н2g), 3.07 (ЗН, 5), 2.98 (4Н, t), 2.25(2Н, я4,9 - 3.0, 13.0 Н2) , 212 (2H, a horn, U - 13.0 Nz), 1.76 (2H, t), 1.02 (ZH, i, U - 7.5 Ng)

Compound number 571 (MR: 182). NMR solvent: OMBO 130: 163.7, 150.3, 138.1, 138, 134.1, 131.7, 131.4, 129.7, 129.7, 129, 127.5, 124.8, 116.1, 59, 52.3, 50.5, 31.9, Н1, 19 (Н1, 11, 15). 9.65 (1H, in Bi), 8.59 (1H, 5), 8.27 (1H, 5), 7.93 (2H, i.e., U - 68.5 Nz), 7.81 (2H, i.e., U - 8.6 Nzg), 7.56 ( 2H, t), 7.48 (ZH, t), 4.32 (2H, y, U - 5.0 No), 4.19 (IN, t), 3.46 (2H, ag, - 12.0 Н2), 3.17 (2H, t), 3.95 (ZH, 5), 2.21 (2H, and Big, U - 13.0 No), 2.0 (2H, and Bi, y - 12.5 H2)

Compound number 572 (MR: 223). NMR solvent: OM5O 130: 171.3, 160.9, 149.5, 137.4, 136, 131.5, 130.8, 129.7, 129.7, 128.9, 125.9, 120, 118, 115.1, 114.7, 59, 59, 52.4. , running), 9.77 (1H, 5), 9.06 (1H, 5), 8.47 (1H, 5), 8.44 (1H, 5), 8.23 (1H, 5), 8.08 (1H, 5), 7.89 (IN, a, U - 8.5 Н2l), 7.59 (2Н, т), 7.49 (ЗН, т), 7.02 (1Н, и, У - 68.5 Н?g), 4.35 (2Н, а, 9 - 4.0 Н2), 4.26 ( 1H, t), 3.48 (2H, a rt, U - 11.0 H2), 3.18 (2H, t), 3.0 (ZH, 5), 2.26 (2H, ad bg, U - 12.0 H2), 2.02 (hn, a rg, y - 12.5 N?)

Compound number 573 (MR: 173-174). NMR Solvent: SOSIZ 130: 165.1, 164.9, 159.2, 151.7, 151.6, 150.4, 150.2, 147.1, 146.8, 142.3, 142.3, 136.9, 136.9, 136.8, 132, 131.8, 126.4 111.9, 111.8, 55.3, 55.2, 54.9, 46.4, 45.6, 41, 40.9, 32.3, 32, 28.9, 28.9, 28.3, 28.2. t), 7.71 (2H, t 4, U - 8.8 Nz), 7.71 apa 7.64 IN, 2 t), 7.40 (IN, t), 7.35(1H, y a, U - 4.9, 7.5 No), 6.94 (2H . (ZH, 2 5), 2.89 (1H, t), 2.11-

Koo) 1.58 (4H, t)

Compound number 574 (MR: 242-243). NMR solvent: ОМ5О 130: 168.1, 156.7, 151.2, 141, 137.4, 126.1, 124.5, 115.4, 112.5, 55.1, 44.9, 40, 31.6, 28.6, 28, 21.4 1Н: 9.46 (Н1, 07), Н18, 05 5), 7.79 (1H, 5), 7.64 (2H, a, U - 8.0 Ng), 6.77 (2H, y, U - 68.0 H2g), 4.50 (IN, a, y - 12.5 N?), 4.09 (IN . ), 1.61 (1H, t)

Compound number 575 (MR: 233-234). NMR solvent: ОМ5О 130:156.2, 153.3, 150.9, 139.8, 137.6, 126.6, 125.2, 124.2, 123.1, 113.8, 112.8, 56.8, 55.9, 31.3, 29, 25.2, 24.8, 18 (1.0, 1H), 1.13H 1H, y, U - 1.3 No), 7.97 (1H, y, U - 1.3 No), 7.83 1H, and a, y - 2.3, 8.6 Н2g), 7.69 (IN, y, У - 2.3 Н2g), 7.21 ( ZN, 5 Bi), 7.19 (1H, y, U - 8.6 No), 3.85 (ZN, 5), 3.80 (1H, t), 2.92 (ZN, 5), 1.77 (AN, t), 1.59 (ZN, t), 1.29 (2H, ad rt, U - 12.5 Ni), 1.11 (IN, d Big, U - 12.5 N?)

Compound number 576 (MR: 137-138). NMR solvent: ОМ5О 130: 155.8, 150.7, 139.7, 137.9, 134.5, 129.7, 127.1, 125.4, 125.2, 123.1, 115.3, 56.8, 31.4, 29, 25.2, 24.9 1Н: Н8, 19 (1, 8.56) , 5), 8.13 (IN, 5), 8.02 (1H, t and, y - 7.9 H2g), 7.91 (IN, and, y - 7.8

Nzg), 7.61 (1 H, 1, y - 7.9 No), 3.83 (1H, t), 2.95 (ZH, 5), 1.79 (4H, t), 1.58 (ZH, t), 1.30 (2H, dB, y - 13.0 N2), 1.12 (1H, d bg, U - 13.0 Ng)

Compound number 577 (MR: 146-147). NMR solvent: OMBO 130: 151.3, 148, 141.7, 138.5, 137.1, 128.8, 128.2, 127, 125.8, 121.2, 113.9, 111.4, 61.9, 55.5, 52.3, 31.4, 28.3 (5, 6, 1H): 1H, 5), 7.49 (2H, t y, U - 8.5 Nzg), 7.36-7.21 (5H, t), 6.56 (2H, t y, U - 8.5

Nzg), 5.13 (2H, 5), 3.80 (1H, t), 3.46 (2H, 5), 2.92 (ZH, 5), 2.88 (2H, and Big, U - 13.0 H2g), 1.99 (2H, 1 Bg , U - 11.0 H2), 1.81 (2H, ad, U - 3.0, 12.0 No), 1.70 (2H, a g, 9 - 11.5 Ng)

Compound number 578 (MR: 167-168). NMR solvent: ОМ5О 130: 150.8, 142.3, 139.3, 138.1, 136.6, 129, 128.7, 128.3, 127.1, 126.2, 124.9, 116.2, 61.8, 55.4, 52.1, 31.6, 28.18, 28.3, Н, 185 (2H, t y, U - 8.6 H2), 7.83 (2H, t s, U - 68.6 Ng), 7.40-7.20 (5H, t), 7.28 (2H, 5Bi), 3.86 (IN, t Big), 3.49 (2H, BI), 2.95 (BN, t), 2.02 (2H, Big), 1.87 (2H, Bi), 1.76 (2H, Bi) because Compound number 579 (MR: 168). NMR solvent: OMBO

130: 151.1, 148, 141.7, 137, 125.8, 121.3, 113.9, 111.4, 56.8, 31.3, 29.1, 25.2, 24.9. Н2з), 7.48 (2Н, т и, У - 8.5 Н2), 6.56 (2Н, та, У - 8.5 Н2), 5.13 (2Н, 5), 3.80 (1Н, т), 2.91 (ЗН, 5), 1.77 (4H, t), 1.58 (ЗН, t), 1.29 (2Н, t, у - 12.6 Н2), 1.11 (IN, t, у - 12.6 N?g)

Compound number 580 (MR: 183-184). NMR solvent: ОМ5О 130: 150.9, 140.6, 138.5, 137.4, 127.3, 125.3, 118, 113.4, 56.8, 31.3, 29, 25.2, 24.9 1Н: 9.55 (IN, 5 BI), 8.07 (IN, a3, U - 1 Но), 7.88 (IN, y, У - 1.3 Но), 7.73 (2Н, та, у - 8.7 Н2), 7.16 (2Н, т и, У - 8.7 Нзг), 7.13 (2Н, in Bi), 3.81 ( 1Н, т), 2.92 (ЗН, 5), 1.78 (4Н, т), 1.57 (ЗН, т), 1.29 (2Н, а рт, у - 12.7 No), 1.11 (IN, та, у - 12.5 Н? d)

Compound number 581 (MR: 182 (des.)). NMR solvent: ОМБ5О 130: 155.7, 153, 151, 140.1, 138.5, 137.5, 128.8, 128.2, 127, 126.5, 123.6 (2 5 id.), 113.5, 112.6, 61.9, 55.7, 55.5, 1: 31.2, Н: 52.2 8.09 (IN, y, U - 1.3 N?g), 7.93 (1H, a, U - 1.3 H2), 7.72 (1H, y a, y - 1.7, 8.6 Nz), 7.59 (1H, 5 ro), 7.36 -7.21 (5H, t), 7.12 (1H, a, U - 8.6 Nl), 7.01 (4H, Big), 3.81 (1H, t), 3.81 (ZH, 5), 3.47 (2H, 5), 2.93 ( ЗН, 5), 2.90 (2Н, а рт, У - 11.5 Н?), 1.99 (2Н, рт, 9 - 11.2 Н2), 1.83 (2Н, а 9, У - 3.5, 12.1 Н2), 1.71 (2гН, and rt, y - 12.5 N?)

Compound number 582 (MR: 199-200). NMR solvent: SOSIZ 130: 159.3, 151.7, 142.4, 136.9, 126.5, 125.5, 117.4, 114.1, 111.8, 55.3, 53.8, 49, 32.2, 27.7 1Н: 7.91 (1Н, а, 2 (Н2) - 1.77Н). . 2H, and, U - 13.5 No), 3.19 (2H, and 1, U - 2.9, 12.9 No), 3.06 (ZH, 5), 2.0 (2H, and 9, U - 4.4, 12.3 No), 1.91 (2H , and ry, y - 12.0 H2)

Compound number 583 (MR: 166-167). NMR solvent: SOSIZ 130:159.2, 151.6, 142.2, 136.8, 126.5, 125.6, 114.5, 114.1, 112, 55.3, 54.5, 51.5, 46, 31.9, 28.3 1H: 7.90 (1H, a.3, Ug - 1) (2H, ta, y - 9.0 Ng), 7.40 (IN, y, U - 1.3 H?), 6.94 (OH, ta, y - 9.0 H2), 4.07 (1H, t), 3.84 (ZH, 5), 3.54 (2H, 5), 3.03 (ZH, 5), 2.94 (2H, t a, U) - 11.5 No), 2.51 (2H, 91.9 - 3.0, 11.5 H2), 1.97 (2H, and 9, U - 4.0, 12.0 H2), 1.90 (2H, t)

Compound number 584 (MR: 189-191). NMR solvent: SOSIZ 130: 151.2, 148.6, 146.7, 139.4, 137.3, 132.5, 128.9, 123.6, 114.5, 113.8, 54.7, 51.4, 45.9, 32, 28.3

From 1nH: 9.02 (1Н, а, У - 2.0 Н2), 8.55 (1Н, и а, У - 1.7, 4.9 НН), 813 (1Н, та, у - 1.9, 8.0 Н2), 7.96 (1Н, а, y - 1.3 No), 7.59(1Н, y, У - 1.3 Н?), 7.35 (1Н, and ю, У - 4.9, 8.0 Но), 4.08 (1Н, t), 3.55 (2Н, 5), 3.05 ( ЗН, 5), 2.96 (2Н, а ри, У - 11.4 Н?), 2.53 (2Н, at, - 3.0, 11.5 Н?), 1.98 (2Н, d 9, ю - 3.9, 12.0

Nzg), 1.92 (2H, t)

Compound number 585 (MR: 197-198 (des)). NMR solvent: ОМ5О 130: 157.8, 149.8, 137.6, 137.1, 131.1, 130, 116.1, 115.4, 115.3, 112.1, 57.3, 52.3, 50.7, 31.9, 25.1,17,11 1H: 1, 9.35, (8.9, 9.35). 1H, 5), 8.21 (1H, 5), 7.26 (ZH, t), 6.78 (IN, t), 4.22 (1H, t), 3.59 (2H, and re, U - 11.5 Н2), 3.12 (2H, a Big, U - 11.5 Ng), 3.0 (2H, t), 2.97 (ZH, 5), 2-23 (2H, and 9, y - 3.0, 13.0

Ng), 2.0 2H, ag, - 12.5 Ng), 1.70 (2H, t), 0.91 (ЗН, и, У - 7.5 N?)

Compound number 586 (MR: 183 (des.)). NMR solvent: MEOY 130: 150.1, 149.1, 147.6, 137.9, 136.6, 119.3, 118.8, 117.1, 116, 114.4, 59.8, 55.1, 53, 33.7, 26.9, 18.9, 11.4 1H, 1.9, 1.9, 1.9 H?), 85.09 (1H, I, U - 1.3 H2), 717 (1H, a, - 2.2 NI), 7Lo NN aa,yu - 2.2, 8.2 No), 6.90 (IN, y, U - 8.2 H2I) . 2.36 (2H, and 4, U - 3.2, 12.8 No), 2.23 (2H, and ri, U - 13.5 No), 1.82 (2H, t), 1.04 (ZN, i, U - 7.5 Nzg)

Compound number 587 (MR: 153-156 (des.)). Solvent NMR: MeEOU 130: 158.7, 153.4, 152.4, 151.1, 143.5, 139.3, 139, 127.9, 125.6, 125.6, 125.5, 116.6, 113.8, 61.5, 54.8, 53.6, 2.8, 9.6, 33.6 - 5.0 Н2), 8.11 (1Н, 9, У - 1.3 Но), 7.92 (1Н, а, у - 1.7, 7.6 Но), 7.67 (IN, о, У - 1.3 Нз), 7.61 (2Н, та, у - 8.7 No), 7.52 (1H, a, y - 7.9 N?), 747 (NN, aa, y - 5.0, 7.6 H2), 6.81 (2H, t y, U - 8.7 Ng), 4.45 (2H, 5 ), 4.28 (IN, t), 3.65 (2H, and Bg, U - 11.5 No), 3.25 (2H, t), 3.09 (ZN, 5), 2.91 (2H, and ri, y - 13.0 No), 2.14 (2H, and ri, y - 12.5 H2),

Compound number 588 (MR: 184). NMR solvent: ОМ5О 130: 151.1, 140.6, 138.5, 138.5, 137.4, 128.8, 128.2, 127.3, 127, 125.3, 118, 113.3, 61.9, 55.5, 52.2, 31.5, 28.2, 55 (8. Н. 1Н, 8. 51). (IN, о, У - 1.3 N?g), 7.88 (IN, y, У - 1.3 Но), 7.73 (2Н, та, у - 8.7 Н2), 7.36-7.20 (5Н, т), 7.16 (2Н, t y, U - 8.7 No), 7.13 (2Н, 5 Bi), 3.81 (IN, т), 3.46 (2Н, 5), 2.94 (ЗН, 5), 2.89 (2Н, та, у - 11.0 Н2), 2.0 (2H, B, U - 11.0 H2), 1.83 (2H, and 9, U - 3.0, 12.0 Ng), 1.71 (2H, a ri, 60 0 U -12.0 N2g)

Compound number 589 (MR: 126-129 (address)). NMR solvent: OMBO 130: 152.8, 151.1, 148.9, 141.1, 138.5, 137.5, 134, 129.1, 128.8, 128.2, 127, 122, 119.6, 117.8, 114.1, 61.9, 55.5, 55.2 , a, U - 1.3 No), 7.91 (1H, a, U - 1.3 No), 7.37 (1H, a, y - 1.3, 7.8 Ng), 7.33-7.23 (6H, t), 7.21 (1H, her, y - 7.7 Ni), 6.72 (1H, a, 9 - 7.9 No), 5.58 (4H, in Bi), 3.81 (1H, t), 3.46 (2H, 5), 2.93 (ZH, 5), 2.89 (2H .

Compound number 590 (MR: 179-180). NMR solvent: ОМ5О 130: 155.6, 150.9, 139.7, 138, 134.5, 129.8, 127.2, 125.5, 125, 123.1, 115.3, 66.3, 54.2, 31.7, 29.1 1Н: 8.57 (1Н, 25, 5), . (2H, aa, U - 3.7, 11.2 Ng), 3.39 (2H, 1, U - 11.5 H2g), 2.98 (ZH, 5), 1.87 (2H, and 4, U - 4.3, 12.2 NI), 1.71 (2H , and reg, - 12.0 Ng)

Compound number 591 (MR: 187-188). NMR solvent: ОМ5О 130: 160.1, 157.5, 150.7, 139.4, 138, 134.5, 129.7, 128.2, 124.5, 123.8, 122.2, 115.5, 56.8, 31.4, 29, 25.1, 24.8, 1H, 1.3, 1.3, 1.5, H. (IN, 1, U - 1.5 Н72), 8.19 (IN, y, У - 1.3 Но), 8.11 (1Н, а, У - 1.3 Но), 8.06 (IN. and, у - 1.5, 7.8 Н?), 7.68 (IN, ta, y) - 1.5, 7.8 No), 7.59 (IN, i, y - 7.8 No), 3.83 (1H, t), 2.94 (ZN, 5), 1.79 (AN, t), 1.58 ( ZN, t), 1.30 (2H, ad Bi, y - 13.5 H2g), 1.58 (IN, t)

Compound number 592 (MR: 148-149). NMR solvent: ОМ5О 130:158.5, 155.6, 151, 140.6, 137.5, 126.1, 126, 114, 113.1, 55.5, 55.1, 45.7, 31.6, 27.6 1Н: 8.31 (1Н, 5), 8.09 (1Н, 85), (1Н, 5), 7.77 (2Н, та, у - 68.5 Н2), 6.95 (2Н, та, у - 6.5 Н2), 5.20 (2Н, 5), 3.95 (IN, t run), 3.78 (ЗН, 5 ), 3.69 (2Н, а рт, у - 12.0 Н2), 2.92 (ЗН, 5), 2.53 (2Н, т), 1.78 (2Н, а ры, У - 12.5 Н2И), 1.70 (2Н, т)

Compound number 593 (MR: 100-103 (aes.)). IMR solvent: OMBO 130: 150.9, 140.2, 138.8, 138.4, 137.7, 134.5, 129.6, 128.9, 128.2, 127, 120.5, 118.6, 116.2, 114.8, 61.8, 55.5, 52.2 . ), 7.33 (IN, i, U - 8.0 Nl), 7.38-7.20 (5H, t), 7.11 (IN, ta, U - 8.0 No), 3.83 (IN,

Zo t B), 3.48 (2H, bi), 3.0 (ZH, 5), 2.94 (ZH, 5), 2.90 (2H, t Bi), 2.01 (2H, t Bi), 1.84 (2H, d ri, y ) - 11.0

Ng), 1.73 (2Н, а бг, У - 11.0 N?g)

Compound number 594 (MR: 138-140). NMR solvent: ОМ5О 130: 160.1, 157.6, 151, 139.4, 138, 134.4, 129.7, 128.2, 124.5, 123.9, 122.2, 115.4, 58.4, 31.3, 28.2, 24 1Н: 13.02 (1Н.352), . (IN, t y, U - 8.0 No), 7.6O (IN, y, U - 8.0 No), 4.38 (1Н, т), 2.94 (ЗН, 5), 1.88 (2Н, т), 1.69 (4Н, t), 1.54 (2Н, t)

Compound number 595 (MR: 228-229). NMR solvent: ОМ5О 130:159.1, 158.5, 151.1, 140.6, 137.5, 126.1, 126.0, 114.0, 113.1, 55.1, 54.6, 46.4, 31.7, 27.2 1Н: 14.96 (1Н, run), У, 8.10 and Bi), 3.95 (2H, ta, y - 13.0 Nz), 3.77 (ZH, 5), 313 (2H, at, 3.5, 12.5 H2g), 2.93 (ZH, 5), 1.90 (2H, t), 1.86 ( 2H, t)

Compound number 596 (MR: 178-180 (aes.)). NMR solvent: OMBO 130: Mode 1H: 8.09 (1H, a, U - 1.3 No), 7.88 (IN, 9, U - 1.3 Ng), 7.77 (2H, and, y - 9.0 H2?), 6.95 (2H , ta, y - 9.0 Н2), 5.99 (2Н, 5), 4.06 (2Н, and Bi, У - 13.5 Но), 4.02 (1Н, т), 3.77 (ЗН, 5), 2.91 (ЗН, в), 2.71 (2H,

Ir, y - 12.0 NI), 1.71 (2H, t), 1.64 (2H, y d, U - 4.0, 12.0 Ng)

Compound number 597 (MR: 162-163). NMR solvent: OM5O 130: Mode 1Н: 8.08 (1Н, а, У - 1.3 Н2g), 7.87 (IN, 9, У - 1.3 Нг), 7.76 (2Н, т и, У - 9.0 Н2), 6.95 (2Н . , 5), 2.48 (2H, t), 2.10 (2H, bi), 1.88 (2H, 5 Big), 1.75 (2H, 5 Bi). 3. Biological effectiveness of compounds according to the invention

IP tests were performed according to the protocol described below. Controls, both ip miigo and ip mimo, were the reaction mixture minus the tested compounds.

Thus, the low value in the table. 1 below for the test compounds indicates a potent inhibitor. A value of 100 indicates no measurable inhibition.

The ip mimo test was performed according to the protocol described below. VEP shows inhibition in the tissue of the central nervous system, and MP shows inhibition in the peripheral tissue, in this case, in the liver.

IP migo protocol

The pharmaceutical activity of EAAN ip mygo was determined in accordance with the following method:

Frozen brains (without cerebellum) of M/iziag rats were used, and each brain was homogenized in 15 mL of 1 mM MoCl2 solution containing 20 nM NEREZ (pH 7.0) using

RoNeg EIme|Ipet (8 strokes at 500 rpm). The homogenates were centrifuged for 20 min. at 360009 and temperature 42C (WesKtap, rotor 70Ti). The granules were resuspended in 15 ml of the same buffer solution and centrifuged under the same conditions. Then the granules were resuspended in 15 ml of the same buffer solution and incubated for 15 min. at a temperature of 372C, after which they were centrifuged for 20 min. at 360009 and a temperature of 42C. Each pellet was then resuspended in 15 mL of 3 mM MoSsSig solution containing 1 mM EDTA, 50 mM Tris (pH 7.4), and protein was determined with the Viobay Protein Azzau (Viocaid) using a standard curve of calf serum albumin (50-250 µg/ml). Aliquots of the membrane suspension were taken and stored at a temperature of -8020.

EAAN activity was determined by using AEA (labeled ZH in the ethanolamine fragment of the molecule) as a substrate and measuring the formed ZH-ethanolamine. The reaction mixture (total volume 200 μl) containing: 2 μM AEA (2 μM AEA « 5 nm ZN-AEA), 0.1 95 fat-free calf serum albumin, 5 μg protein, in 1 mM EDTA solution , containing 10 mM Tris (pH 7.6) and 10 μM or 0.1 μM compounds. Stock solutions of test compounds (10 mM) were prepared in 100 95

DMSO, and the concentration of DMSO in the assay was 0.1 95. After a period of pre-incubation for 15 min. at a temperature of 37"C, the reaction was initiated by adding a substrate solution (cold EAE - radioisotope-labeled EAE - calf serum albumin). The reaction was carried out for 10 minutes before stopping by adding 400 μl of a suspension of activated charcoal (8 g of charcoal in 32 ml of 0, 5 M NSI with continuous shaking).

After incubation for 30 min. at room temperature with shaking, the charcoal was precipitated by centrifugation in a microcentrifuge (10 min. at 13,000 rpm). 200 μl of the supernatant was added to 800 μl of Oriirnaze Ziregtikh scintillation cocktail previously placed in the wells of 24-well tablets. The number of pulses per minute was determined with the help of a scintillation counter Misgobeia TtiYih (counting within 10 min., or up to 5 - 2).

In each analysis, a blank solution (absent protein, of course, less than 200 pulses per minute) and controls (absent compound) were used. The results are given in the table. 1 as 95 controls after subtraction of blank values.

IP MIMO protocol

Treatment of animals

The animals used for the experiments were male MMKI mice (weight 27-44 g) obtained from Ipiegpatspa Iregis (Spain). Mice were kept in the amount of 5 per cage, in a controlled environment (12-hour light/dark cycle and room temperature 2212C). Food and drinking water were provided by av Ibisht, and all experiments were performed during daylight hours.

Animals were orally administered 30 mg/kg or 3 mg/kg of the compound according to the invention (8 ml/kg; the compound was suspended in a 0.5 95 solution of carboxymethylcellulose (CMC) or solubilized in water) or solvent (controls), using a curved needle for feeding the animals from stainless steel (Regiesisht, O.5.A.). In 15 min. Before killing, the animals were anesthetized with 60 mg/kg of pentobarbital administered intraperitoneally. A fragment of the liver, the left lobe of the lung, and the brain without the cerebellum were removed and placed in plastic vials containing buffer solution for membranes (3 mM Masig, 1 mM EDTA, 50 mM Tris HC, pH 7.4).

Tissues were stored at -302C until analysis.

Animals were always fasted overnight before compound administration, except for time points » 18 h, where food was taken on the morning of the day of administration and compound was administered 12 h later on the same day.

Then the animals were given only water.

All procedures with the use of animals were carried out in strict accordance with the European

Directives on the protection of vertebrate animals used for experimental and other scientific purposes (86/609CEE) and Portuguese legislation (Oesgeifo-I ey 129/92, Ropagia5 1005/92 sec 1131/97). The number of animals used was the minimum possible in accordance with current regulations and scientific expediency.

Reagents and solutions

Anandamide (ethanolamine -1-3H-| (40-60 Ki/mmol) was obtained from the American company

Cadiospetisa! 5. All other reagents were obtained from Zidt-Algisn. Oriirpaze Ziregtih was obtained from Regkip EIIiteg, and activated charcoal was obtained from bidta-Apagisa. 60 Fabric production

Tissues were thawed on ice and homogenized in 10 volumes of buffer solution for membranes (3 mM Mosi, 1 mM EDTA, 50 mM Tris HC, pH 7.4) or using a Robtseg Eime|)pet (brain -- 8 strokes at 500 rpm), or Neido!ry biah (liver -- 2 blows in position 5 for 20 s, with pauses of 30 s).

Total protein in the tissues was determined using VioKai Rgoivip Azzau (VioKai), using a standard curve of calf serum albumin (50-250 μg/ml).

Enzyme analysis

The reaction mixture (total volume 200 μl) containing: 2 μM AEA (2 μM AEA « 5 nm ZN-

AEA), 0.1 95 fatty acid-free calf serum albumin, 15 μg (brain), 5 μg (liver), or 50 μg (lung) protein, in 1 mM EDTA solution with 10 mM Tris pH 7.6. After a period of preliminary incubation for 15 min. at a temperature of 372C, the reaction was initiated by adding a substrate solution (cold AEA "radiolabeled AEA" calf serum albumin). The reaction was carried out for 10 min. (brain and lungs) or 7 min. (liver), after which it was stopped by adding 400 μl of a suspension of activated charcoal (8 g of charcoal in 32 ml of 0.5 M NH with continuous shaking). After an incubation period of 30 min. at room temperature with shaking, the charcoal was precipitated by centrifugation in a microcentrifuge (10 min. at 13,000 rpm). 200 μl of the supernatant was added to 800 μl of Oriirnaze Zyreptih scintillation cocktail previously placed in the wells of 24-well plates. The number of pulses per minute was determined using a scintillation counter

Mystovbeia Tit ikh.

A blank solution (without protein) was prepared for each analysis.

The percentage of residual enzyme activity was calculated taking into account controls after subtracting the values of the blank solution.

Table 1

GO Г11117С1111111111111111оМмю | about Mo vAp ZOYI Mi 30 VAN Z | MA Z

Name Class 10 µM 1100 nMi mg.kg, 1 | mg.kg, 1 | mg.kg, 8 | mg.kg, 8 h h h h h (1n-imidazol-1-yl)(morpholino)methanone YaPmidazoly.i | 626 | | | / Her

M-methyl-M-phenyl-THN-imidazole-i-carboxamideImidazoles.id | 177 | | / th

With morpholino(4-phenyl-1H-imidazole-1-Imidazoles 48 yl)umethanone sh "

M-methyl-M,4-diphenyl-1 H-imidazole-1- - 4 aroyuamd 0000000 mdiauli | oo |vae ma) is)

M,Z-diphenyl-1H-pyrazole-1-carboxamide |(Pyrazoles.i//// | 913 | | иЙ! her her carboxamide carboxamide 8 | M-methyl-M-phenyl-іH-pyrazole-і-carboxamide | Pyrazoles 132 M-phenyl-1H-pyrazole-1-carboxamide phenyl)-Z-phenyl-1 H- Pyrazoles 82.6 pyrazole-1-carboxamide carboxamide morpholino(Z-phenyl-IN-pyrazole-I-ylumethanone|Pyrazoles.///-/ | 897 | / / i/ her

M-methyl-4-(naphthalen-2-yl)-M-phenyl-1 H- - 14 imidazole-1-carboxamide Imidazoles 68.3 96.7 77.3

M-(biphenyl-4-yl)-3-phenyl-1 H-pyrazole-1- - 15 carboxamide Pyrazoles 103.8 16 M-(4-methoxyphenyl)-M-methyl-4-(naphthalene-2- Imidazoles 24 ,7 yl)-1H-imidazole-1-carboxamide 7 |mdaoliharbocamd 00000 6611 imidazole-1-carboxamide

M-methyl-M-phenyl-1 H-benzo|d|imidazole-1- - 18 carboxamide Imidazoles 67.5 (1H-benzoi|a)(1,2,3)Itriazole-1- 19 ylHmorpholino)methanone Benzotriazoles 01 31 46.6 41.1

C-(biphenyl-4-yl)-M-phenyl-1H-pyrazol-1- - 20 carboxamide Pyrazoles 97.3 241 morpholino(3-(pyridin-3-yl)-1H-pyrazol-1- Pyrazoles 791 il )umethanone hydrochloride p " 29 3-(biphenyl-4-yl)-M-(3-methoxyphenyl)-1H- Pyrazoles 95.8 pyrazole-1-carboxamide

Table 1

С Г111111С111111111111yumno | yuMMyuo vAppPZOII We 30) VAZ | And We Z

Name Class 10 µM 1100 nMi mg.kg, 1 | mg.kg, 1 | mg.kg, 8 | mg.kg, 8 h h h h h

C-(biphenyl-4-yl)-M-(4-methoxyphenyl)-1 H- - 23 pyrazole-1-carboxamide Pyrazoles 93 24 M-methyl-M-phenyl-3-(pyridin-3-yl)-1 N- Pyrazoles 229 pyrazole-1-carboxamide p "

3-(biphenyl-4-yl)-M-methyl-M-phenyl-1H- Pyrazoles pyrazole-1-carboxamide 25 arboyaid 000000 mdayui 6111 27 dovoli arene 00000 re | 02 imidazole-1-carboxamide 4-(4-methoxyphenyl)-M-methyl-M-phenyl-1 H- - 28 imidazole-1-carboxamide Imidazoles 0.7 851 4-(4-fluorophenyl)-M-methyl-M -phenyl-1 H- - 23 imidazole-1-carboxamide Imidazoles 52.5 10.7 17.2 4-(2-fluorophenyl)-M-methyl-M-phenyl-1 H- -

Zo imidazole-1-carboxamide Imidazoles that 12.5 4-(3-methoxyphenyl)-M-methyl-M-phenyl-1 H- -

C imidazole-1-carboxamide Imidazoles b-chloro-M-methyl-M-phenyl-1 H-

B-chloro-M-methyl-M-phenyl-1 H-

NO ten id ian EE NSS SYA NO NOYA NOYA

ZB 4-(biphenyl-4-yl)-M-methyl-M-phenyl-TH- Imidazoles 10371 imidazole-1-carboxamide

M-(4-fluorophenyl)-4-(4-methoxyphenyl)-M- - 36 methyl-1H-imidazole-1-carboxamide Imidazoles C 37 (3,4-dihydroquinolin-1(2H)-yl)(4-phenyl -t H- Imidazoles 51.7 imidazol-1-yl)umethanone 4-(4-hydroxyphenyl)-M-methyl-M-phenyl-1 H- - 38 imidazole-1-carboxamide Imidazoles 83.9 ze | (4-dihydroquinolin-T(2H)yl(4-(3- Imidazoles 16 120.6 | 10171 methoxyphenyl)-1H-imidazol-1-yl)umethanone 4-(3-hydroxyphenyl)-M-methyl-M-phenyl -1 H- - imidazole-1-carboxamide Imidazoles 01 88.8 81.5 4.5 102.8 25.6 (1H-benzoyl) (1,2,3)Itriazol-1-yl)(4-

Benzylpiperazin-1-yl)umethanone Benzotriazoles 87.6 30 (1H-benzoyl) (1,2,3)Itriazol-1-yl)(4- 42 benzylpiperidin-1-yl)umethanone Benzotriazoles 84 64 4-( 4-chlorophenyl)-M-(4-fluorophenyl)-M-methyl- - 43 1H-imidazole-1-carboxamide Imidazoles b 88 (3,4-dihydroquinolin-1(2H)-yl)(4-(4- h4 fluorophenyl)-1H-imidazol-1-yl)umethanone Imidazoles 97.8 4-(2-fluorophenyl)-M-(4-fluorophenyl)-M-methyl- - 1H-imidazole-1-carboxamide Imidazoles 83 (b -fluoro-IN-indol-1-yl)(morpholinodmethanone Pndol./-: | (71043! | !/! 47 (5-methoxy-1H-indol-1- 972 ylUumorpholino)methanone " (1H-benzoyl|a) (1,2,3)Itriazol-1-yl)(4- 48 | (benzo|h|P1,Z|dioxol-5-ylmethyl)piperazin-1- | Benzotriazoles 01 21,8 201 yl)umethanone oxalate (1H -benzoia)(1,2,3)|Itriazol-1-yl)(4-(pyridin-49 2-yl)piperazin-1-yl)methanone Benzotriazoles 01 16.9 14.9 (1H-benzoia|(1 ,2,3)triazol-1-yl)(3,4-dihydroisoquinoline-2(1H)-ilumethanone Benzotriazoles 32.6 7.8

Bi. | (4-dihydroquinolin-1(2H)-yld4(3- Imidazoles 100.8 130.4 | 132.3 hydroxyphenyl)-1 H-imidazol-1-yl)umethanone (5-hydroxy-1 H-indol-1- 52 ylUumorpholino)methanone 102.7

M-benzyl-M-methyl-1 H-

M-(4-fluorophenyl)-4-(4-hydroxyphenyl)-M- - for methyl-1H-imidazole-1-carboxamide Imidazoles 91 1H-benzo|a|1,2,3ZItriazol-1-yl(1,4 -dioxa-8- Benzotriazoles 02 22 25 42.6 37.8 azaspiro|4,5|dec-8-yl)umethanone

M-(4-phenoxyphenyl)-1 H- 56 benzo|4|11,2,3|Hygriazole-1-carboxamide Benzotriazoles 90.7

Table 1

С Г111111С111111111111yumno | yuMMyuo vAppPZOII We 30) VAZ | And We Z

Name Class 10 µM 1100 nMi mg.kg, 1 | mg.kg, 1 | mg.kg, 8 | mg.kg, 8 h h h h h

M-(4-methoxyphenyl)-1 H-97 benzo|4111,2,3|Itriazole-1-carboxamide Benzotriazoles

M-cyclohexyl-M-methyl-1 H-

M-(2,4-difluorophenyl)-1 H- 59 benzo|4111,2,3|Igriazole-1-carboxamide Benzotriazoles 100.4 in arbooid 00000000 benutivuly (6586111

M-(4-xporphenyl)-1H-benzo|a1(1,2,3)triazole- Benzotriazoles 93.7 1-carboxamide

M-(4-chlorophenyl)-M-methyl-1 H- 63 benzo|4111,2,3|Igriazole-1-carboxamide Benzotriazoles 12.6 57 49.7 3-(4-methoxyphenyl)-M-methyl-M -phenyl-1H- and ba 1,2,4-triazole-1-carboxamide 1,2,4-Triazoles 67.9 (3-(4-methoxyphenyl)-1H-1,2,4-triazole-1- and 65 ylUumorpholino)methanone 1,2,4-Triazoles 86.5

M-(4-fluorophenyl)-3-(4-methoxyphenyl)-M- -

CC methyl-1H-1,2,4-triazole-1-carboxamide 1,2,A-Triazoles 80.9 67 3-(4-chlorophenyl)-M-methyl-M-phenyl-1H-1,2, 4- 1,2,A-Triazoles v1 triazole-1-carboxamide (3-(4-chlorophenyl)-1 H-1,2,4-triazol-1-

Kk ylUumorpholino)methanone 1,2,4-Triazoles 73.5 3-(4-chlorophenyl)-M-(4-fluorophenyl)-M-methyl-1,2,A-Triazoles 80.8 1H-1,2, 4-triazole-1-carboxamide

M-(2,4-difluorophenyl)-M-methyl-1 H-70 benzo|4111,2,3|Igriazole-1-carboxamide Benzotriazoles 1,9 52 42,5 (1H-benzoia|(1,2,3 )triazol-1-yl)(4,4-7 dimethyloxazolidin-3-yl/methanone Benzotriazoles 01 2.3 0.3 2.2 1.8 2.5

Z-xpro-INiindazol-1-yl)imorpholinodmethanonindazole..0//:/ | |876Y! / morpholino(3-phenyl-1H-1,2,4-triazole-1- - 73 ilumethanone 1,2,4-Triazoles 85.8 74 M-(2,4-difluorophenyl)-M-methyl-3-phenyl -T H- 1,2,A-Triazoles 73,2 1,2,4-triazole-1-carboxamide taarboamd 00000000 benutivols | 1014271

M-methyl-M-(4-morpholinophenyl)-1 H-76 benzo|4111,2,3|Itriazole-1-carboxamide Benzotriazoles 971

M-(3,5-dimethoxyphenyl)-M-methyl-1 H- 71 benzo|4111,2,3|Igriazole-1-carboxamide Benzotriazoles 76,3 (3-(2,4-difluorophenyl)-1 H-1 . 2,4.79 | Difluorophenyl)-1H-1,2,4-triazol-1-1,2,4-Triazoles 10.3 70 45.2 yl)umethanone

M,3-bis(2,4-difluorophenyl)-M-methyl-1H-1,2,4-1,2,A-Triazoles 89.5 triazole-1-carboxamide

M-(4-(dimethylamino)phenyl)-M-methyl-1 H-81 benzo|4111,2,3|Itriazole-1-carboxamide Benzotriazoles 49,2 1,2-bipiperidin-1'-yl(1H-82 | benzo|4a|11,2,3)griazol-1-yl)umethanone Benzotriazoles 69,3 hydrochloride (1H-benzoi|a)(1,2,3)Itriazol-1-yl)(4- 83 methylpiperazin-1 -yl)umethanone hydrochloride Benzotriazole 25

M-methyl-M-(pyridin-2-yl)-1 H-

Ba benzo|4111,2,3|Itriazole-1-carboxamide Benzotriazoles 62.5 tara benutiyui | 101111 carboxamide carboxamide carboxamide yl)umethanone

Table 1

С Г111111С111111111111yumno | yuMMyuo vAppPZOII We 30) VAZ | And We Z

Name Class 10 µM 1100 nMi mg.kg, 1 | mg.kg, 1 | mg.kg, 8 | mg.kg, 8 h h h h h (1H-benzoi|a)(1,2,3)Itriazol-1-yl)(4- morpholinopiperidin-1-yl)umethanone Benzotriazoles 38.6 hydrochloride 91 (1H-benzoi| a|/1 2,3|)griazol-1 Zlua-(4- Benzotriazole (benzyloxy)phenyl)piperazine-1-ylumethanone 92 (1H-benzo|a|/1,2,3)griazol-1-yl3(4 -(pyrrolidine- Benzotriazoles 1-ylpiperidin-1-yl)umethanone hydrochloride 93 (1 H-benzo|a|y 2,Z|griazol-1 tlu4- Benzotriazoles benzylpiperazin-1-yl)umethanone hydrochloride 94 (1 H-benzo| a|y 2,ZItriazol-1 -yl)(4- Benzotriazoles phenylpiperidin-1-ylumethanone 5-(3-cyanophenyl)-M-cyclohexyl-M-methyl-1 H- 95 benzo|4111,2,3|Itriazol- 1-Carboxamide Benzotriazoles 0.7

M-cyclohexyl-5-(4-fluorophenyl)-M-methyl-1 H-

KE benzo|4111,2,3|Itriazole-1-carboxamide Benzotriazoles 143 97 5-bromo-M-cyclohexyl-M-methyl-1 H- Benzotriazoles benzo|4111,2,3|Igriazole-1-carboxamide r yl)umethanone (1H-benzo|a|P,2,3Hygriazol-1-yl4-(p- Benzotriazoles 02 99,1 71,4 tolyloxy)piperidin-1-yl)umethanone (1H-benzoi|a)(1,2,3 )Itriazol-1-yl)(4-100 phenethylpiperidin-1-yl)methanone Benzotriazoles 02 68.1 40.5 (4-phenyl-1H-imidazol-1-yl)(4- - 101 phenylpiperazin-1-yl) Umethanone Imidazoles 0.5 102 (4-benzylpiperazin-1-yl(4-phenyl-1 H- Imidazoles imidazol-1-yl)umethanone

M-cyclohexyl-M-methyl-4-phenyl-1 H- -

M-cyclohexyl-M-ethyl-1H- (1H-benzoyl) (1,2,3)Itriazol-1-yl)(4-(2-105 | (pyrrolidin-1-yl)ethyl)piperidin- 1- Benzotriazoles 64.7 il) umethanone hydrochloride

M-cyclohexyl-6-(4-fluorophenyl)-M-methyl-1 H- 106 benzo|4111,2,3|Igriazole-1-carboxamide Benzotriazoles 2,3 3-(1-(cyclohexyl(methyl)carbamoyl)- 1 H- 107 | benzo|9х4|11,2,3|Hygriazol-5-yl)benzoin Benzotriazoles 13,5 acid 5-(3-carbamoylphenyl)-M-cyclohexyl-M- 108 | methyl-1H-benzoyl|a1(1,2,3)|triazole-1- Benzotriazole 7,4 carboxamide 6-(3-carbamoylphenyl)-M-cyclohexyl-M-109 )| methyl-1H-benzoyl|a1(1,2,3)|triazol-1- Benzotriazole carboxamide (1H-benzoyl|a)(1,2,3)Itriazol-1-yl)(4-(3-110 phenylpropyl) Piperidin-1-ilumethanone Benzotriazoles b 51.7 10.2 111 (3-phenyl-TH-1,2,4-triazol-1-yl(4-1,2,A-Triazoles 15 phenylpiperazin-1-yl)umethanone 112 4-(144-benzylpiperazine-1-carbonyl)-1H- Imidazoles 72 imidazol-4-yl)benzamide 4-(4-carbamoylphenyl)-M-methyl-M-phenyl-1H- - 113 imidazol-1- carboxamide Imidazoles 90.3 841 32.3 (1H-benzoia)(1,2,3)|Itriazol-1-yl)(4-(pyridin-114 d-ylpiperidin-1-yl)methanone Benzotriazoles 01 102.9 | 109.9 115. M'methyl-M'phenethyl-!H- Benzotriazoles benzo|4111,2,3|Itriazole-1-carboxamide (1H-benzoi|a)(1,2,3)Itriazol-1-yl )(4-(3- 116 | (pyridin-3-yl)-1,2,4-oxadiazol-5- Benzotriazoles 0.5 126.2 | 115.2 yl)/piperidin-1-yl)umethanone 117 ( 1H-benzo|a|/1,2,3)griazol-1-yl3(4-(4-Benzotriazol pchlorophenoxy)piperidin-1-yl)umethanone

M-methyl-M-(3-phenylpropyl)-1 H- 118 benzo|4111,2,3|Itriazole-1-carboxamide Benzotriazoles 119 M-(3-methoxybenzyl)-M-methyl-1 H- Benzotriazoles benzo|4111 ,2,3|Igriazole-1-carboxamide p 120 (1H-benzo(a)/1,2,3)griazol-1-yl(4- Benzotriazole p phenoxypiperidin-1-yl)umethanone

Table 1

С Г111111С111111111111yumno | yuMMyuo vAppPZOII We 30) VAZ | And We Z

Name Class 10 µM 1100 nMi mg.kg, 1 | mg.kg, 1 | mg.kg, 8 | mg.kg, 8 h h h h h (1H-benzoyl|a)(1,2,3)Itriazol-1-yl)(4-(4- 121 fluorobenzyl)piperazine-1-ylumethanone Benzotriazoles 86) bi (1H- Benzoyl-(1,2,3)Itriazol-1-yl)(4-(4- 122 | methylpiperazin-1-yl/upiperidine-1- Benzotriazole 93 yl)umethanone hydrochloride

M-(Z-chlorobenzyl)-M-methyl-1 H- 123 benzo|4111,2,3|Itriazole-1-carboxamide Benzotriazoles 124 (4-benzylpiperazin-1-yl(Z-phenyl-1 N.T, 2 ,4- 1,2,A-Triazoles 15 triazol-1-yl)methanone hydrochloride (3-(4-(benzyloxy)phenyl)-1 H-1,2,4-triazol- 125 ) 1-yl)(4 -benzylpiperazin-1-yl)umethanone 1,2,4-triazole 53.5 hydrochloride

VE Ivan SNY ST NOYA NO SZZ NE (1H-benzoyl|a)(1,2,3)Itriazol-1-yl)(4- 127 cyclohexylpiperazin-1-yl)umethanone Benzotriazoles b 117.5 | 1073 128 (1H-benzoyl)(1,2,3)Itriazol-1-yl)(4- Benzotriazole (benzyloxy)piperidin-1-yl)umethanone

M-methyl-M-(5-phenylpentyl)-1 H- 129 benzo|4111,2,3|Hygriazole-1-carboxamide Benzotriazoles 295 2

M-(4-fluorobenzyl)-M-methyl-1H- 130 benzo|4111,2,3|Itriazole-1-carboxamide Benzotriazoles 131 M-methyl-M-(naphthalen-2-ylmethyl)-1 H- Benzotriazoles benzo| 4111,2,3|Itriazole-1-carboxamide p (3-(4-(4-methylpiperazin-1-iluphenyl)-1 H- 132 | 1,2,4-triazol-1-yl)(4-(p -tolyloxy)piperidine-| -ylummorpholino)methanone 1,2,4-Triazoles 90.7 (3-(2,4-difluorophenyl)-1 H-1,2,4-triazol-1- and 134 yl)(4-(p-tolyloxy) piperidin-1-yl)umethanone 1,2,4-Triazoles 34,5 (1H-benzoyl)(1,2,3)Itriazol-1-yl)(4-(3-135 phenylpropoxy)piperidine-1- yl)umethanone Benzotriazoles b 26.5 301 (1H-benzoyl|a)(1,2,3)Itriazol-1-yl)(4-(4- 136 hydroxyphenyl)piperazine-1-ylumethanone Benzotriazoles 0.2 137 (1H -benzoyl|a)(1,2,3)Itriazol-1-yl)(4-(4- Benzotriazoles 01 methoxyphenoxy)piperidin-1-ylumethanone "

M,M-dimethyl-3-(4-(4-phenylpiperazin-1- - 138 yl)phenyl)-1H-1,2,4-triazole-1-carboxamide 1,2,4-Triazoles 83.8 ( 3-(4-(4-methylpiperazine-1-iluphenyl)-1 H- and 139 1,2,4-triazol-1-ilumorpholino)methanone 1,2,4-Triazoles 80.2 7 105.7 3-( 4-(4-cyanophenoxy)phenyl)-M,M-dimethyl- and 140 1H-1,2,4-triazole-1-carboxamide 1,2,4-Triazoles 58.6 144 4-4-(1-( morpholine-4-carbonyl)-1 H-1,2,4- 1,2,A-Triazoles 159 triazol-3-ylphenoxy)benzonitrile -M-(quinuclidin-3-yl)-1 H-

A)-M-(xi and Z-yl)-1H 142 | benzo|х411Й1,2,3|griazole-1-carboxamide Benzotriazoles 101.8 hydrochloride

M-(3,3-dimethyl-1,5-dioxaspiro|5,5Iundec-9-143 yl)-M-methyl-1H-benzotriazole-1-carboxamide Benzotriazoles 25 0.4 0.7 (1H-benzoyl|a )(1,2,3)|Itriazol-1-yl)(4-(2-(4- 144 | methoxyphenoxy)ethyl)piperidine-1- Benzotriazoles 01 682 17.6 yl)umethanone 4-(4-(1 -(4-phenylpiperazine-1-carbonyl)-1 H- 145 ) 1,2,4-triazol-3-yl)uphenoxy)benzonitrile 1,2,4-Triazoles 0.3 89.9 116.5 hydrochloride 3- (4--4-carbamoylphenoxy)phenyl)-M, M- and 146 dimethyl-1H-1,2,4-triazole-1-carboxamide 1,2,4-Triazoles CD 4-(4-(1-(morpholine) -4-carbonyl)-1 H-1,2,4- and 147 triazol-3-ylphenoxy)benzamide 1,2,4-Triazoles 55.1 124.4 103 4-(4-(1-(4-phenylpiperazine) -1-carbonyl)-1 H- and 148 1,2,4-triazol-3-yl/uphenoxy)benzamide 1,2,4-Triazoles 0.3 115.7 87.6 3-(4-(4- carbamoylphenoxy)phenyl)-M-methyl- and 149 M-phenyl-1H-1,2,4-triazole-1-carboxamide 1,2,4-Triazoles 49.9

M-benzyl-4-(4-fluorophenyl)-M-methyl-1 H- - 150 imidazole-1-carboxamide Imidazoles 12 5.6 3.8

M-benzyl-3-(4-(4-carbamoylphenoxy)phenyl)- and 151 M-methyl-1H-1,2,4-triazole-1-carboxamide 1,2,4-Triazoles 0.4 116.7 65 ,8

Table 1

С Г111111С111111111111yumno | yuMMyuo vAppPZOII We 30) VAZ | And We Z

Name Class 10 µM 1100 nMi mg.kg, 1 | mg.kg, 1 | mg.kg, 8 | mg.kg, 8 h h h h h

M-(11.4g)-4-"(benzyloxy)cyclohexyl)-M- 152 | methyl-1H-benzoyl|a1(1,2,3)|triazol-1- Benzotriazoles 1,3 carboxamide (1H-benzoyl|a)|(1,2,3)|Itriazol-1-yl)(4-( (3- 153 | methoxyphenoxy)methyl)piperidin-1- Benzotriazoles yl)umethanone (1H-benzoyl|a)(1,2,3)Itriazol-1-yl)(4- 154 cyclopentylpiperazin-1-yl)umethanone Benzotriazoles 0 ,2 nn nni VAN KZ ZI NN NS NN NO EK

M-(2-(benzyloxy)ethyl)-M-methyl-1 H-156 benzo|4111,2,3|Igriazole-1-carboxamide Benzotriazoles b 672 244

M-(2-(4-methoxyphenoxy)ethyl)-M-methyl-1 H-157 benzo|4111,2,3|Itriazole-1-carboxamide Benzotriazoles 5,2 3,5 (4-benzylpiperazin-1-yl) (3-(thiophen-2-yl)-1 H- and 158 1,2,4-triazol-1-ylumethanone hydrochloride 1,2,4-Triazoles 0.3 92 85.6 159. | NN-benzoiaI1,2 ,3)griazol-1-yl(4- Benzotriazoles 4,8 hydroxypiperidine-1-ylumethanone

Z-benzyl-M-methyl-M-phenyl-1H-1,2,4- and (4,4-dimethyloxazolidin-3-yl)(4-phenyl-1H- - 161 imidazol-1-yl)umethanone Imidazoles 3,3 93,6 (6-bromo-1H-benzoyl|a1|(1,2,3|triazol-1-yl)(4,4- 162 dimethyloxazolidin-3-ylumethanone) Benzotriazoles C 3-(3-( 4,4-dimethyloxazolidine-3-carbonyl)- 163 ZH-benzoia|(1,2,3)|Itriazol-5-yl)benzamide Benzotriazoles 6,3 24 (1H-benzoi|a)(1,2,3| Griazol-1-yl)(4-(4-164) (benzyloxy)phenoxy)piperidin-1- Benzotriazole 0,3yl)umethanone (1H-benzoyl) (1,2,3)Itriazol-1-yl) (4-(4- 165 | methoxyphenoxy)methyl)piperidine-1- Benzotriazolyl)umethanone (1H-benzoyl|a)(1,2,3)Itriazol-1-yl)(4-(3- 166 methoxyphenoxy)piperidine -1-ilumethanone Benzotriazoles 1-(1,1-dioxido-1,3-thiazolidin-3-(1H-benzoyl)(1,2,3)Itriazol-1-yl)(4-(4- 168 butoxyphenoxy) )piperidine-1-ylumethanone Benzotriazoles

M-methoxy-M-methyl-1 H-stervo te janayah eetnem| 151 111 about dvanon and |Beyuyutivui| 152 Gena sedan! 151011 173 (1H-benzoia|(1,2,3)triazol-1-yl(2E,65)-2,6- Benzotriazoles 70,6 dimethylpiperidin-1-yl)umethanone "st fren ot evnyuno etem| |y| 111 (1H-benzoi|(1,2,3)triazol-1-yl)(3,5- 175 dimethylpiperidin-1-yl)umethanone Benzotriazoles 21 ethyl 1-(1H-benzoi|41(11,2,3) |triazole-1- 176 carbonyl) piperidine-4-carboxylate Benzotriazoles 0.2 177 | tyl 4-11 H-benzo|a|/ 2,3|triazole-1- Benzotriazoles carbonyl) piperazine-1-carboxylate 1-(4 -(1nH-benzoi|a|(1,2,3)|griazole-1- 178 carbonyl)piperazine-1-iluethanone Benzotriazoles 94.5 1-11 H-benzo|4h|P1,2,3|triazole-1 - 179 carbonyl)ipiperidine-4-carboxamide Benzotriazoles 43

M-methyl-M-phenyl-3-(thiophen-2-yl)-1 H-1,2,4- - 180 triazole-1-carboxamide 1,2,4-Triazoles 57.5 181 M-benzyl-M -methyl-3-(thiophen-2-yl)-1H-1,2,4-1,2,A-Triazoles triazole-1-carboxamide (3-benzyl-1H-1,2,4-triazole-1 183 )(4,4-dimethyloxazolidin-3-yl)umethanone 1,2,4-Triazoles 102,924 Tv

Table 1

С Г111111С111111111111yumno | yuMMyuo vAppPZOII We 30) VAZ | And We Z

Name Class 10 μM 1100 nMi mg.kg, 1 | mg.kg, 1 | mg.kg, 8 | mg.kg, 8 h h h h 184 (3,4-dihydroisoquinolin-2(1H)-yl)(4-phenyl-tH- Imidazoles 302 imidazol-1-yl)umethanone (3-(4-chlorophenyl)-1 H-1,2,4-triazol-1-yl)(3,4- and 185 dihydroisoquinolin-2(1H)-yl)umethanone 1,2,4-Triazoles 71,8 (4-(4-chlorophenyl)- 1H-imidazol-1-yl)(4,4- - 186 dimethyloxazolidin-3-ylumethanone Imidazoles 96.5 78.7 377 4-(4-(1-(4,4-dimethyloxazolidin-3-carbonyl)- - 187 1n-1,2,4-triazol-3-ylphenoxy)benzamide 1,2,4-Triazoles 92.8 85.6 108.6 (4,4-dimethyloxazolidin-3-yl)(3-(4- 188 | methoxyphenyl)-1H-1,2,4-triazole-1-1,2,4-Triazoles 103.3 78.7 yl)umethanone (3-(4-chlorophenyl)-1H-1,2,4-triazole -1-yl)(4,4- and 189 dimethyloxazolidin-3-ylumethanone 1,2,4-Triazoles 98.5 105.9 87.6

M-benzyl-M-methyl-3-(naphthalen-2-yl)-1 H- - 190 1,2,4-triazole-1-carboxamide 1,2,4-Triazoles 20.7

M-benzyl-M-methyl-3-(naphthalen-1-yl)-1 H- - 191 1,2,4-triazole-1-carboxamide 1,2,4-Triazoles 21 20.8 192 M-methyl- C-(naphthalene-1-yl-M-phenyl-t H-T,2,4-1,2,A-Triazoles 64,6 triazole-1-carboxamide (1H-benzoyl|a))(1,2,3 )Itriazol-1-yl3u(2E,6K)-2,6- 193 dimethylmorpholino)methanone Benzotriazoles 110.2 194 (1H-benzoia|(1,2,3)triazol-1-yl(25,6K)-2, 6- Benzotriazoles and dimethylmorpholino)methanone " (5)-M-methyl-M-(1-phenylethyl)-1 H- 195 benzo|4111,2,3|Hygriazole-1-carboxamide Benzotriazoles 15,7 z 57 (4- (biphenyl-3-yl)-1H-imidazol-1-yl)(4- and 196 phenylpiperazin-1-yl)umethanone Imidazoles 29 BB, 78.3 (4-(4-chlorophenyl)-1H-imidazole-1 -yl)(4-(3- - 197 phenylpropyl)piperidin-1-yl)umethanone Imidazoles 0.3 (4-(3,4-dichlorophenyl)-1 H-imidazol-1-yl)(1,4- - 198 dioxa-8-azaspiro|4,5|decan-8-yl)umethanone Imidazoles 33 4-(4-aminophenyl)-M-methyl-M-phenyl-1 H- - 199 imidazole-1-carboxamide Imidazoles 45.95 19.7

M-methyl-M-phenyl-4-(3-(2-(piperazin-1-200 | yl)ethoxy)phenyl)-1H-imidazole-1-carboxamide| Imidazoles 100.1 dihydrochloride (4-cyclohexylpiperazin-1-yl)(4-(3,4- - 201 difluorophenyl)-1 H-imidazol-1-ylumethanone Imidazoles 0.3

M-(2-«(benzyloxy)ethyl)-M-ethyl-1 H-202 benzo|4111,2,3|Itriazole-1-carboxamide Benzotriazoles b

M-methyl-M-phenyl-4-(4-(2-(piperazin-1-203 | yl)ethoxy)phenyl)-1H-imidazole-1-carboxamide | Imidazoles 93.5 101.8 64.3 dihydrochloride 204 (3-(4-xporphenyl)-1 H-1.2,4-triazol-1-yl)(1,4-1,2,A-Triazoles 15, 8 dioxa-8-azaspiro|(4,5|decan-8-yl)umethanone (3-(4-methoxyphenyl)-1H-1,2,4-triazol-1- and 205 yl)(4-(3- phenylpropyl)piperidin-1-yl)umethanone 1,2,4-Triazoles 0,2 (3--"naphthalen-1-yl)-1H-1,2,4-triazol-1-yl(4- and 206 phenylpiperazine -1-yl)umethanone 1,2,4-Triazoles 3,3 4-(3-(1-(1,2,3,4-tetrahydroisoquinoline-2- 207 | carbonyl)-1 H-1,2,4 -triazole-3- 1,2,4-Triazoles 31,6 yl)phenoxy)benzamide 4-(3-(1-(4-phenylpiperazine-1-carbonyl)-1 H- and 208 1,2,4-triazole) -3-yl/uphenoxy)benzamide 1,2,4-Triazoles 0.2 97.2 96.7 4-(3-(1-(4,4-dimethyloxazolidine-3-carbonyl)- - 209 1n-1, 2,4-triazol-3-ylphenoxy)benzamide 1,2,A-Triazoles 101.5 39.8 What 4-(3-(1-(morpholine-4-carbonyl)-1 H-1,2,4- and 210 triazol-3-yl)uphenoxy)benzamide 1,2,4-Triazoles 73,3 (4-(4-fluorophenyl)piperazin-1-yl)(3-(4- 211 | methoxyphenyl)-1H-1, 2,4-triazol-1- 1,2,4-Triazoles 1,9 yl)umethanone (3-(4-chlorophenyl)-1 H-1,2,4-triazol-1-yl)(4- 212 | cyclohexylpiperazin-1-ylum of ethanone 1,2,4-Triazole hydrochloride (4,4-dimethyloxazolidin-3-yl)(3-(thiophen-2-yl)-1H-1,2,4-triazol-1-yl)umethanone 1, 2,4-Triazoles 105.6 53.7 214. | (Cha-chlorophenyl)1H-1,2,4-triazol-1-1,2,A-Triazoles 23,7-iluthiazolidin-3-yl)umethanone

Table 1

GO Г1111С111111111111pMnyu | 7 yuMmo vAPPZOII We 30) VAZ | And We Z

Name Class 10 µM 1100 nMi mg.kg, 1 | mg.kg, 1 | mg.kg, 8 | mg.kg, 8 h h h h 215 (4-(3,4-difluorophenyl)-1H-imidazole-1- Imidazoles 16,7 iluthiazolidin-3-yl)umethanone (4-(3,4-dimethoxyphenyl)-1H -imidazol-1- - 216 yl)(4,4-dimethyloxazolidin-3-yl)umethanone Imidazoles 38.3 108.6 29.3 13.3

M-cyclohexyl-4-(3,4-dimethoxyphenyl)-M- - 217 methyl-1H-imidazole-1-carboxamide Imidazoles 80.5 42 (4-(3,4-dichlorophenyl)-1H-imidazole-1- - 218 iluUpyrrolidine-1-ilumethanone Imidazoles 31.6 (1H-benzoyl|d|imidazol-1-yl)(4,4- - 219 dimethyloxazolidin-3-ilumethanone Imidazoles 50.6 111.6 86.8 (2.2 -dimethyloxazolidin-3-yl)(4-phenyl-1 H- - 220 imidazol-1-yl)methanone Imidazoles 103.7 31.5 20 (28.65)-2,6-dimethylpiperidin-1-yl)(4 - - 221 phenyl-1H-imidazol-1-yl)umethanone Imidazoles 105.8 104.5 44.9

M-cyclohexyl-M-methyl-1 H- - (4-(4-chlorophenyl)-1 H-imidazol-1-yl)(4-(4- - 223 fluorophenyl)piperazin-1-yl)umethanone Imidazoles Chi

M-methyl-M-phenyl-4-(4-(2-(piperidin-1- 224 | yl)ethoxy) phenyl)-1 H-imidazole-1- Imidazoles carboxamide hydrobromide (4-(4-(benzyloxy)- 3-methoxyphenyl)-1 H- 225 | imidazol-1-yl)(4,4-dimethyloxazolidin-3- Imidazoles 79 yl)umethanone 296 (4,4-dimethyloxazolidin-3-yl)(4-(pyridin-3- Imidazoles 76.6 VA yl)-1H-imidazol-1-yl)umethanone dihydrochloride 297 (g-methyloxazolidin-3-yl)(4-phenyl-TH- Imidazoles 64.7 imidazol-1-yl)umethanone (4, 4-dimethyloxazolidin-3-yl)(4-(4-hydroxy- - 228 C-methoxyphenyl)-1 H-imidazol-1-ylumethanone Imidazoles tv 56.4 31.9 229 M-ADAMANTYL-M-ME TYL-4 -PHENYL-1H- Imidazoles 992

IMIDAZOLE-1-CARBOXAMIDE

M-methyl-4-(4--2-morpholinoethoxy)phenyl)-M- 230 | phenyl-1H-imidazole-1-carboxamide Imidazoles 96.1 hydrochloride (4-(biphenyl-3-yl)-1H-imidazol-1-yl)(4,4- - 291 dimethyloxazolidin-3-ylumethanone Imidazoles 54, 2 3.9 3.6 3-(1-(4,4-dimethyloxazolidine-3-carbonyl)- - 232 1H-imidazol-4-yl)biphenyl-3-carboxamide Imidazoles 84.7 82.8 6.5 ( 4-(4-chlorophenyl)-1H-imidazol-1-yl)u(2-ethyl-2- - 233 methyloxazolidin-3-yl)umethanone Imidazoles tA 33.5 no 2-(M-cyclopentenyl-4-phenyl -1 H-imidazol-1- 234 | safbohamido)ethyl 4-phenyl-1 H-imidazol-1- Imidazoles 78.2 carboxylate (4-(4-chlorophenyl)-1 H-imidazol-1-yl)(2, 4,4- - 235 trimethyloxazolidin-3-yl)umethanone Imidazoles 76.2 108.5 801 (4,4-dimethyloxazolidin-3-yl)(4-(3'- 236 | methoxybiphenyl-3-yl)-1 H -imidazole-1- Imidazoles 75.4 67.7 37.7 yl)umethanone

M-ADAMANTHYL-4-PHENYL-1H-IMIDAZOLE-1- - speed | she 11111 4-(3'-carbamoylbiphenyl-3-yl)-M-cyclohexyl- - 238 M-methyl-1H-imidazole-1-carboxamide Imidazoles 12 67.9 2.8 4-(biphenyl-3-yl)-M -cyclohexyl-M-methyl-1H- - 239 imidazole-1-carboxamide Imidazoles 4 16.4 4.6

M-cyclohexyl-4-(3'-methoxybiphenyl-3-yl)-M- - 240 methyl-1H-imidazole-1-carboxamide Imidazoles 224 39.5 (4-(4-chlorophenyl)-1H-imidazole-1 -yl)u(2- - ha phenyloxazolidin-3-yl)umethanone Imidazoles 176.5

M-cyclohexyl-b-hydroxy-M-methyl-1 H- 242 benzo|4111,2,3|Igriazole-1-carboxamide Benzotriazoles 3-(1-(4,4-dimethyloxazolidine-3-carbonyl)- 243 1H- benzo|a1(1,2,3|Itriazol-5-yl)benzamide Benzotriazoles 39.7 244 4-(4-chlorophenyl)-M-cyclopentyl-M-methyl-1H- Imidazoles BA imidazole-1-carboxamide 4-( 4-carbamoylbiphenyl-3-yl)-M-cyclohexyl- - 245 M-methyl-1H-imidazole-1-carboxamide Imidazoles 0.4 15.8

Table 1

GO Г1111С111111111111pMnyu | 7 yuMmo vAPPZOII We 30) VAZ | And We Z

Name Class 10 µM 1100 nMi mg.kg, 1 | mg.kg, 1 | mg.kg, 8 | mg.kg, 8 h h h h h

M-cyclohexyl-4-(3'-fluorobiphenyl-3-yl)-M- - 246 methyl-1H-imidazole-1-carboxamide Imidazoles 2,3

M-cyclohexyl-4-(3'-hydroxybiphenyl-3-yl)-M- - 247 methyl-1H-imidazole-1-carboxamide Imidazoles 0.5 191.7 85.5

M-cyclohexyl-M-methyl-4-(3'- 248 | (trifluoromethoxy)biphenyl-3-yl)-1 H-imidazole- | Imidazoles 68.9 104.2 57 1-carboxamide

M-benzyl-4-(4-chlorophenyl)-M-isopropyl-1 H- - 249 imidazole-1-carboxamide Imidazoles 95.8

M-benzyl-M-tert-butyl-4-(4-chlorophenyl)-1H- - 252 imidazole-1-carboxamide Imidazoles 83.6 3-(4-chlorophenyl)-1-(1,1-dioxido-1, 3- - 253 thiazolidin-3-yl)ucarbonyl|-1 H-1,2,4-triazole 1,2,4-Triazoles 107.7

M-cyclohexyl-M,5-dimethyl-4-phenyl-1 H- - 254 imidazole-1-carboxamide Imidazoles 109 81 98.3 89.9

M-benzyl-M-isopropyl-4-(3-methoxyphenyl)- - 255 1H-imidazole-1-carboxamide Imidazoles 96.7

M-benzyl-M-tert-butyl-4-(3-methoxyphenyl)- - 256 1H-imidazole-1-carboxamide Imidazoles 105.6 4-(3'-chlorobiphenyl-3-yl)-M-cyclohexyl-M- - 257 methyl-1H-imidazole-1-carboxamide Imidazoles 65.6 bo 122

M-cyclohexyl-4-(3'-ethoxybiphenyl-3-yl)-M- - 258 methyl-1H-imidazole-1-carboxamide Imidazoles 39.9 4-(5'-chloro-2"-fluorobiphenyl-3-yl) )-M- 259 | cyclohexyl-M-methyl-1H-imidazole-1- Imidazoles 33,7 carboxamide (4,4-dimethyloxazolidin-3-yl)(4-(4- - 260 hydroxyphenyl)-1 H-imidazole- 1-yl)umethanone Imidazoles 37.3 95.3 Vy 7.8 261 M-cyclohexyl-4-(4-hydroxyphenyl)-M-methyl- Imidazoles Bl 12 12 1H-imidazole-1-carboxamide d " " " ovo M-cyclopentyl -4-(3-hydroxyphenyl)-M-methyl-Imidazoles 75 1H-imidazole-1-carboxamide d y (4,4-dimethyloxazolidin-3-yl)(5-methyl-4- - 263 phenyl-1H-imidazole -1-yl)umethanone Imidazoles Zag ZV, 98.8

M-benzyl-4-(3-hydroxyphenyl)-M-isopropyl- - 265 1H-imidazole-1-carboxamide Imidazoles

M-cyclopentyl-M-methyl-1H-(4-(4-chlorophenyl)-1H-imidazol-1-yl(5-ethyl-267 2,.2-dimethyloxazolidin-3-yl)umethanone Imidazoly va 179 ,4 83.7 (5-chloro-4-phenyl-1 H-imidazol-1-yl(2,2- - 268 dimethyloxazolidin-3-ylumethanone) chlorophenyl)-1 H-imidazol-1- - 2659 yl)(4,4-dimethyloxazolidin-3-yl)umethanone Imidazoles 106.2 (5-ethyl-2,2-dimethyloxazolidin-3-yl)(4- - 270 phenyl-1H-imidazol-1-yl)umethanone Imidazoles Spare

M-cyclohexyl-4-(2-methoxyphenyl)-M-methyl-|,.- 271 1H-imidazole-1-carboxamide Imidazoles 55.8

M-cyclohexyl-4-(3,4-difluorophenyl)-M- - 272 methyl-1H-imidazole-1-carboxamide Imidazoles 63.6 19 t

M-cyclohexyl-4-(4-fluorophenyl)-M-methyl-TH-|, .- 273 imidazole-1-carboxamide Imidazoles 65.1 34 2.6 274 M-cyclohexyl-4-(3,4-diporphenyl) -M- Imidazoles 85 methyl-1H-imidazole-1-carboxamide 275 M-cyclohexyl-M-methyl-4-(3-nitrophenyl)-1 H- Imidazoles 43.8 12.8 2A imidazole-1-carboxamide

M-cyclohexyl-4-(4--difluoromethoxy)phenyl)-|, . 216 M-methyl-1H-imidazole-1-carboxamide Imidazoles 71.5 14 2 277 4-(4-chlorophenyl)-M-cyclohexyl-M-methyl-1H- Imidazoles 72 imidazole-1-carboxamide

M-methyl-4-phenyl-M-(tetrahydro-2H-pyran-4-2178 yl)-1H-imidazole-1-carboxamide Imidazoles 103.5 1.6 1.8

Table 1

GO Г1111С111111111111pMnyu | 7 yuMmo vAPPZOII We 30) VAZ | And We Z

Name Class 10 µM 1100 nMi mg.kg, 1 | mg.kg, 1 | mg.kg, 8 | mg.kg, 8 h h h h h

M-cyclohexyl-M,2-dimethyl-4-phenyl-1 H- - 2793 imidazole-1-carboxamide Imidazoles 87.3 91.6 941 (5-chloro-4-(4-chlorophenyl)-1 H-imidazole- 1- - 280 il)(4,4-dimethyloxazolidin-3-yl)umethanone Imidazoles 111.8

M-cyclopentyl-4-(3,4-dimethoxyphenyl)-M- - 281 methyl-1H-imidazole-1-carboxamide Imidazoles 25.5

M-(1-benzylpiperidin-4-yl)-M-methyl-4- - 282 phenyl-1H-imidazole-1-carboxamide Imidazoles 40.9 0.5 1.6 283 M-cyclohexyl-M-methyl-Z -phenyl-1 H-1,2,4- 1, 2, 4 -Triazoles 75 triazole-1-carboxamide

(4,4-Dimethyloxazolidin-3-yl)(3-phenyl-1 H- - 285 1,2,4-triazol-1-ylumethanone 1, 2, 4 "Triazoles 85.4 (4, 4-dimethyloxazolidin-3-yl)(5-methyl-3- and 286 phenyl-1 H-1,2,4-triazol-1-yl)umethanone 1, 2, 4 "Triazoles 112.8 104 93 4-( 3'-carbamoylbiphenyl-3-yl)-M-methyl-M- 287 | tricyclo I | 3,3,1,13,7 | dec-1-yl-1 H-imidazol-1- | Imidazoles 127.3 105 ,8 85,7 carboxamide - propan-2-ol (1:1) 4-IZ--(benzyloxy)phenyl|-M-methyl-M- 288 | tricyclo IZ3,3,1,13,7|dec-1 -yl-1 H-imidazole-1- | Imidazoles 114.8 carboxamide

M-methyl-4-pyridin-3-yl-M- 289 | tricycloi|3,3,1,13,7 |dec-1-yl-1 H-imidazol-1- | Imidazoles 109.8 115.2 96.1 carboxamide 4-biphenyl-3-yl-M-methyl-M- 290 | tricyclo|3,3,1,13,7|dec-1-yl-1 H-imidazol-1- | Imidazoles 115 112.4 carboxamide

M-methyl-4-(3-pyridin-4-ylphenyl)-M-tricyclo 291 113,3,1,13,7|dec-1-yl-1H-imidazol-1- Imidazoles carboxamide (4-(4- chlorophenyl)-1H-imidazol-1-yl)(2,2- - 292 dimethyl-5-phenyloxazolidin-3-yl)umethanone Imidazoles (4,4-dimethyloxazolidin-3-yl)(b-methoxy-1 H- 293 benzo|4111,2,3|griazol-1-yl)umethanone Benzotriazoles 3,5 17 294 M-cyclopentyl-4-(4-hydroxyphenyl)-M-methyl- Imidazoles 14 14 1H-imidazole-1-carboxamide d " " (5-chloro-4-phenyl-1H-imidazol-1-yl)(4,4- - 295 dimethyloxazolidin-3-ylumethanone Imidazoles 99.2 171.9 324 4-(3-hydroxyphenyl)-M-methyl- M-tricyclo 296 I13,3,1,13,7|dec-1-yl-1H-imidazole-1- Imidazoles carboxamide

M-(11,4g)-4-hydroxycyclohexyl)-M-methyl- 297 1H-benzo|41(1,2,3|Itriazole-1-carboxamide Benzotriazoles (2,2-dimethyl-5-phenyloxazolidin-3-yl )(4- - 298 phenyl-1H-imidazol-1-yl)umethanone Imidazoles tА4 59.2 299 (4-(4-chlorophenyl)-1H-imidazol-1-yl)(2,2- Imidazoles dimethyloxazolidin-3 -ilumethanone sh z00 zZ-xpor-M-cyclohexyl-M-methyl-4-phenyl-1H- Imidazoles imidazole-1-carboxamide (5-bromo-4-(4-chlorophenyl)-1H-imidazole-1- -

Zoyl)(4,4-dimethyloxazolidin-3-yl)umethanone Imidazoles (4-ethyloxazolidin-3-yl)(4-phenyl-1 H- - 302 imidazol-1-yl)umethanone Imidazoles 303 (4-(3, 4-difluorophenyl)-1H-imidazol-1-yl)(4-Imidazoles ethyloxazolidin-3-yl)umethanone sh 304 (4-ethyloxazolidin-3-yl)(4-(3-methoxyphenyl)- Imidazoles 1H-imidazol- 1-yl)umethanone d

M-methyl-4-(3-pyridin-3-ylphenyl)-M-tricyclo 305 I13,3,1,13,7|dec-1-yl-1H-imidazol-1- Imidazoles carboxamide

M-methyl-4-(3-pyrimidin-5-ylphenyl)-M- 306 | tricyclo I3,3,1,13,7|dec-1-yl-1 H-imidazol-1- | Imidazole carboxamide

M-cyclohexyl-4-(3-hydroxyphenyl)-M-methyl-|, .- 307 1H-imidazole-1-carboxamide Imidazoles 56.2 137.6 10.1 (4-(3,4-difluorophenyl)-1 N-imidazol-1-yl)(5- - 38 phenyloxazolidin-3-yl)umethanone Imidazoles 2,5

Table 1

GO Г1111С111111111111pMnyu | 7 yuMmo vAPPZOII We 30) VAZ | And We Z

Name Class 10 µM 1100 nMi mg.kg, 1 | mg.kg, 1 | mg.kg, 8 | mg.kg, 8 h h h h h (4-phenyl-1H-imidazol-1-yl(5- - 309 phenyloxazolidin-3-yl) methanone Imidazoles 310 (4-methyloxazolidin-3-yl)(4-phenyl-1 H-Imidazoles imidazol-1-yl) methanone d (4-(3,4-difluorophenyl)-1 H-imidazol-1-yl)(4- - 311 methyloxazolidin-3-yl)umethanone Imidazoles 312 M-cyclohexyl-M -ethyl-4-phenyl-1 H-imidazole- Imidazoles 1-carboxamide d

M-cyclohexyl-4-(3,4-dimethoxyphenyl)-M- - 313 ethyl-1H-imidazole-1-carboxamide Imidazoles

M-cyclohexyl-4-(3-fluoro-4-methoxyphenyl)- - 314 M-methyl-1H-imidazole-1-carboxamide Imidazoles 84.3 84.3 48

M-cyclopentyl-4-(3-fluoro-4-methoxyphenyl)- - 315 M-methyl-1H-imidazole-1-carboxamide Imidazoles (4,4-dimethyloxazolidin-3-yl)(4-(3-fluoro-4 - - 316 methoxyphenyl)-1H-imidazol-1-yl)umethanone Imidazoles 4-(4-(dimethylamino)biphenyl-3-yl|-M-methyl- 317 | M-tricyclo I3,3,1,13,7| Dec-1-yl-1H-imidazole-| 7|dec-1-yl-1H- Imidazoles imidazole-1-carboxamide

M-cyclohexyl-4-(4-fluoro-3-methoxyphenyl)- - 319 M-methyl-1H-imidazole-1-carboxamide Imidazoles 19.2 53 2 4-I3-(6-fluoropyridin-3-yl)uphenyl| -M-methyl-M- 320 | tricyclo I3,3,1,13,7|dec-1-yl-1 H-imidazol-1- | Imidazoles carboxamide 321 M-cyclopentyl-4-(4-fluoro-3-methoxyphenyl)- Imidazoles 14 12

M-methyl-1H-imidazole-1-carboxamide d " " 4-(3-hydroxybiphenyl-3-yl)-M-methyl-M- 322 | tricyclo I3,3,1,13,7|dec-1-yl-1 H-imidazol-1- | Imidazoles carboxamide 4-I3-(6-methoxypyridin-3-yl)uphenyl|-M-methyl- 323 | M-tricyclo!yl3,3,1,13,7|dec-1-yl-1 H-imidazol- | Imidazoles 1-carboxamide 4-(4-(acetylamino)biphenyl-3-yl|-M-methyl-M- 324 | tricyclo I3,3,1,13,7|dec-1-yl-1 H-imidazole-1 - | Imidazoles carboxamide 4-(3-furan-3-ylphenyl)-M-methyl-M- 325 | tricycloi|3,3,1,13,7| dec-1-yl-1 H-imidazol-1- | Imidazole carboxamide

M-cyclopentyl-4-(4-methoxyphenyl)-M-methyl-|, .- 326 1H-imidazole-1-carboxamide Imidazoles 327 M-cyclopentyl-4-(3-methoxyphenyl)-M-methyl- Imidazoles 1H-imidazole -1-carboxamide d (4,4-dimethyloxazolidin-3-yl)(4-(4- 328 methoxyphenyl)-1H-imidazol-1-yl)umethanone Imidazoles (4,4-dimethyloxazolidin-3-yl)(4 -(3- - 323 methoxyphenyl)-1H-imidazol-1-yl)umethanone Imidazoles 99.5 83.3 18.5

M-cyclohexyl-4-(3-fluoro-4-hydroxyphenyl)- - 330 M-methyl-1H-imidazole-1-carboxamide Imidazoles 29.7 22.8 that

M-cyclopentyl-4-(3-fluoro-4-hydroxyphenyl)- - 331 M-methyl-1H-imidazole-1-carboxamide Imidazoles 3,6 4 4,9 (4,4-dimethyloxazolidin-3-yl)(4 -(3-fluoro-4- - 332 hydroxyphenyl)-1H-imidazol-1-yl)umethanone Imidazoles 88.5 19.5 (4,4-dimethyloxazolidin-3-yl)(4-(4-fluoro-3 - - 333 hydroxyphenyl)-1H-imidazol-1-yl)umethanone Imidazoles 81.9 119 81.5 4-(benzofuran-2-yl)-M-cyclohexyl-M- -

For methyl-1H-imidazole-1-carboxamide Imidazoles 58.2 51

M-cyclohexyl-M-methyl-4-(pyridin-3-yl)-1 H- - 335 imidazole-1-carboxamide Imidazoles 75.4 31 1 4-I3-(b-chloropyridin-3-yl)uphenyl|- M-methyl-M- 336 | tricyclo I3,3,1,13,7|dec-1-yl-1 H-imidazol-1- | Imidazoles carboxamide (4,4-dimethyloxazolidin-3-yl)(2-methyl-4- - 337 phenyl-1H-imidazol-1-yl)umethanone Imidazoles (4-(benzofuran-2-yl)-1H-imidazol- 1-yl)(4,4- - 338 dimethyloxazolidin-3-ilumethanone Imidazoles

Table 1

GO Г1111С111111111111pMnyu | 7 yuMmo vAPPZOII We 30) VAZ | And We Z

Name Class 10 µM 1100 nMi mg.kg, 1 | mg.kg, 1 | mg.kg, 8 | mg.kg, 8 h h h h oxazolidin-3-yl(4-phenyl-1H-imidazol-1- - 339 yl)methanone Imidazoles 340 (4-(3-methoxyphenyl)-1H-imidazol-1-yl) (5-Imidazoles phenyloxazolidin-3-yl)umethanone from M-cyclohexyl-4-(4-methoxyphenyl)-M-methyl-Imidazoles 1H-imidazole-1-carboxamide from M-cyclohexyl-4-(3-methoxyphenyl) -M-methyl- Imidazoles 1H-imidazole-1-carboxamide d

M-cyclohexyl-4-(4-fluoro-3-hydroxyphenyl)- - 343 M-methyl-1H-imidazole-1-carboxamide Imidazoles 447 95.5 19.7

M-cyclopentyl-4-(4-fluoro-3-hydroxyphenyl)- -

ZA M-methyl-1H-imidazole-1-carboxamide Imidazoles 17 121 21

M-cyclohexyl-4-(4--difluoromethoxy)phenyl)-|, . 345 M-ethyl-1H-imidazole-1-carboxamide Imidazoles

M-cyclohexyl-4-(3,4-difluorophenyl)-M-ethyl- - 346 1H-imidazole-1-carboxamide Imidazoles (4,4-dimethyloxazolidin-3-yl)(4-(3- - 347 hydroxyphenyl)- 1 H-imidazol-1-yl)umethanone Imidazoles 109.6 76.6 24.5 (4,4-dimethyloxazolidin-3-yl)(4-(3-(3- 348 | hydroxy-3-methylcy-1- upui)phenyl)-1 H- Imidazoles imidazol-1-yl)umethanone

M-cyclohexyl-4-(3,4-dichlorophenyl)-M-ethyl- - 349 1H-imidazole-1-carboxamide Imidazoles

M-cyclohexyl-M-ethyl-4-(4-methoxyphenyl)- - 350 1H-imidazole-1-carboxamide Imidazoles (4,4-dimethyloxazolidin-3-yl)(4-(4-fluoro-3- -

With methoxyphenyl)-1H-imidazol-1-yl)umethanone Imidazoles 95.6 w 17 (4,4-dimethyloxazolidin-3-yl)(4-(3-(3- 352 | hydroxy-3-methylbutyl)phenyl)- 1H-imidazole-|Imidazoles 1-ilumethanone

M-methyl-4-(1-oxidopyridin-3-yl)-M- 353 | tricyclo I3,3,1,13,7|dec-1-yl-1 H-imidazol-1- | Imidazole carboxamide

M-methyl-4-(3-(1-oxidopyridin-3-yl)phenyl|- 354 | M-tricyclo I3,3,1,13,7|dec-1-yl-1H-imidazole-| Imidazoles 1- carboxamide

M-cyclohexyl-M-ethyl-4-(3-methoxyphenyl)- - 355 1H-imidazole-1-carboxamide Imidazoles (4-(3-amino-4-methoxyphenyl)-1H-imidazole-1- and 356 yl) (4,4-dimethyloxazolidin-3-yl)umethanone Imidazoles 6,5 9,4 4-(3-amino-4-hydroxyphenyl)-M-cyclohexyl- 357 | M-methyl-1H-imidazole-1-carboxamide Imidazoles 93.9 111.9 10.4 hydrochloride (4-(3-amino-4-hydroxyphenyl)-1H-imidazole-1- 358 | yl4,4-dimethyloxazolidine- 3-ilumethanone Imidazoles 117.1 81.2 hydrochloride 359 (5-chloro-1H-benzoi|41(1,2,3)griazol-1-yl)(4,4- Benzotriazoles 14 25 17 dimethyloxazolidin-3-ilumethanone " " " (4,6-difluoro-1 H-benzo|4|0P1,2,3|griazol-1-360 yl)(4,4-dimethyloxazolidin-3-yl)umethanone Benzotriazoles 1,6 zy 37 (4, 4-dimethyloxazolidin-3-yl)(6-phenyl-1 H-

Zb benzo|4111,2,3|griazol-1-yl)umethanone Benzotriazoles 1,3 6,3 1,4 3-(1-(cyclohexyl(methyl)carbamoyl)-1 H- -

Zb2 imidazol-4-yl)pyridine 1-oxide Imidazoles 18.2 1.6 1.7 4-(3-(4-cyanophenoxy)phenyl)-M-cyclohexyl-|, . 363 M-methyl-1H-imidazol-1-carboxamide Imidazoles 4-(3-(1-(4,4-dimethyloxazolidine-3-carbonyl)-|, . zba 1H-imidazol-4-yl/uphenoxy)benzonitrile Imidazoles 4 -(3-amino-4-methoxyphenyl)-M-cyclohexyl- - 365 M-methyl-1H-imidazole-1-carboxamide Imidazoles (1H-011,2,3|Itriazoloi|4,5-5|pyridine-1- yl)(4,4- - 366 dimethyloxazolidin-3-ilumethanone Benzotriazoles (ZH-11,2,3|Itriazoloi|4,5-5|pyridin-3-yl)(4,4- - 368 dimethyloxazolidin-3-ylumethanone Triazolopyridine 4,9 methane p resotiuy

Table 1

GO Г1111С111111111111pMnyu | 7 yuMmo vAPPZOII We 30) VAZ | And We Z

Name Class 10 µM 1100 nMi mg.kg, 1 | mg.kg, 1 | mg.kg, 8 | mg.kg, 8 h h h h h (4,4-dimethyloxazolidin-3-yl)(6-(2- 370 | methoxyphenyl)-1H-benzo|41(/1,2,3)|)griazol-1- | Benzotriazoles yl)umethanone (4,4-dimethyloxazolidin-3-yl)(5- 371 | (trifluoromethyl)-1 H-benzo|4|Х1,2,3|triazol- | Benzotriazoles 1-ilumethanone 372 (4,6- dimethoxy-1H-benzo|a|/1,2,3)griazol-1- Benzotriazolyl)(4,4-dimethyloxazolidin-3-yl)umethanone oztz o dimethyloxazoidinzalvuetanoi 0 eotiayut dimethyloxazolidin-3-ylumethanone

M-cyclohexyl-M-methyl-5-(trifluoromethyl)- 374 1H-benzoi|41(1,2,3|Itriazole-1-carboxamide Benzotriazoles

M-cyclohexyl-M,5,b-trimethyl-1H-benzo|c)(1,2,ZItriazole-1-carboxamide Benzotriazoles and A A VO

M-cyclohexyl-M-methyl-4-(4- 376 | sulfamoylphenyl)-1H-imidazole-1- Imidazoles 95.3 5.7 carboxamide

M-cyclohexyl-4,6-dimethoxy-M-methyl-1H-benzo(c)(1,2,ZItriazole-1-carboxamide Benzotriazolines and AA VO 378 (5,6-dimethyl-2H-benzo|a |/1,2,3)griazol-2-Benzotriazolyl)(4,4-dimethyloxazolidin-3-yl)umethanone

M-(11,4g)-4-"(benzyloxy)cyclohexyl)-M- - 379 methyl-4-phenyl-1H-imidazole-1-carboxamide Imidazoles 4-(4-(-2H-tetrazole-5-iluphenyl) )-M- 380 | cyclohexyl-M-methyl-1H-imidazole-1- Imidazoles 77.3 51.3 carboxamide (5,6-dimethyl-1H-benzo|4111,2,3Z|griazole-1-

ZV yl)(4,4-dimethyloxazolidin-3-yl)umethanone Benzotriazoles zvo (5,6-dimethoxy-1H-benzo|a|/1,2,3)griazol-1- Benzotriazolyl)(4,4-dimethyloxazolidine -3-yl)umethanone

M-(11,4g)-4-hydroxycyclohexyl)-M-methyl-4-|, . 383 phenyl-1H-imidazole-1-carboxamide Imidazoles

M-(1-hydroxy-2-methylpropan-2-yl)-4,6- 384 | Dimethoxy-1H-benzo|9111,2,3Itriazole-1- Benzotriazoles carboxamide

Z85 4-(1444,4-dimethyloxazolidin-3-carbonyl)- Imidazoles 1H-imidazol-4-yl)ibenzamid (4,4-dimethyloxazolidin-3-yl)(4-(4-(2- 386 | (piperidine- 1-yl)ethoxy)phenyl)-1H-imidazole- | Imidazoles 1-ilumethanone hydrochloride (4,4-dimethyloxazolidin-3-yl)(4-(4-(2- 387 | morpholinoethoxy)phenyl)-1H-imidazole -1- Imidazoles yl)umethanone hydrochloride (4,4-dimethyloxazolidin-3-yl)(4-(4-(2- 388 | (piperazin-1-yl) ethoxy)phenyl)-1 H-imidazole- | Imidazoles 1 -ilumethanone dihydrochloride 1-(4,4-dimethyloxazolidine-3-carbonyl)-1 H- 389 benzo|a1(11,2,3-triazole-5-carboxamide Benzotriazoles 4-(4-carbamoylphenyl)-M-cyclohexyl-M- - 390 methyl-1H-imidazole-1-carboxamide Imidazoles (4,4-dimethyloxazolidin-3-yl)(6-phenyl-ZH-Y

Св P,2,3Itriazoloi|4,5-b|pyridin-3-ylumethanone Triazolopyridine (4,4-dimethyloxazolidin-3-yl)(6-phenyl-1 H- - 392 P1,2,3)triazolo|4, 5-b|pyridin-1-ylumethanone Triazolopyridine (4,4-dimethyloxazolidin-3-yl)(4-(4- 393 | (piperidin-4-ylmethoxy)phenyl)-1H-imidazole- | Imidazoles 1-ylumethanone hydrochloride

M-cyclohexyl-M-methyl-4-(4-(2-(piperidin-1- 394. | yl)ethoxy) phenyl)-1 H-imidazole-1- Imidazole carboxamide hydrochloride

M-cyclohexyl-M-methyl-4-(4-(2- 395 | morpholinoethoxy) phenyl)-1H-imidazole-1- Imidazole carboxamide hydrochloride (4,4-dimethyloxazolidin-3-yl)(4-(4-( 2- 396 | (piperidin-4-yl)ethoxy)phenyl)-1H-imidazole- |Imidazoles of 1-ilumethanone hydrochloride

Table 1

GO Г1111С111111111111pMnyu | 7 yuMmo vAPPZOII We 30) VAZ | And We Z

Name Class 10 µM 1100 nMi mg.kg, 1 | mg.kg, 1 | mg.kg, 8 | mg.kg, 8 h h h h h

M-cyclohexyl-M-methyl-4-(4-(2-(piperazin-1- 397 | yl)ethoxy) phenyl)-1 H-imidazole-1- Imidazoles carboxamide dihydrochloride 4-(4-hydroxyphenyl)-M- methyl-M-(tetrahydro- - oze of pNomidazolarbocamd (io (4,4-dimethyloxazolidin-3-yl))(4-(3-(2- 399 | (piperidin-1-yl) ethoxy)phenyl)-1 H- imidazole-|Imidazoles 1-ilumethanone hydrochloride

M-cyclohexyl-M-methyl-4-(4-(piperidin-4- 400 | ylmethoxy) phenyl)-1H-imidazole-1- Imidazoles carboxamide hydrochloride (4,4-dimethyloxazolidin-3-yl)(4-(3 -(2- 401 | (piperazin-1-yl) ethoxy)phenyl)-1 H-imidazole- | Imidazoles 1-ilumethanenon dihydrochloride (4,4-dimethyloxazolidin-3-yl)(4-(3-(2- 402 | morpholinoethoxy) phenyl)-1H-imidazole-1-Imidazoles yl)umethanone hydrochloride he -ee 1 17111 methyl-1H-imidazole-1-carboxamide

M-cyclohexyl-M-methyl-4-(4-404 | (morpholinosulfonyl) phenyl)-1H-imidazole- | Imidazoles 1-carboxamide (4,4-dimethyloxazolidin-3-yl)(4-(3- 405 | (piperidin-4-ylmethoxy)phenyl)-1H-imidazole- | Imidazoles 1-ylumethanone hydrochloride (2)-M-cyclohexyl -4-(4-(M'- 406 | hydroxycarbamimidoyl) phenyl)-M-methyl-1 H- | Imidazoles 66.8 16.3 imidazole-1-carboxamide

M-cyclohexyl-M-methyl-4-(3-(2-(piperazin-1- 407 | yl)ethoxy) phenyl)-1 H-imidazole-1- Imidazole carboxamide dihydrochloride

M-cyclohexyl-M-methyl-4-(3-(2- 408 | morpholinoethoxy) phenyl)-1H-imidazole-1- Imidazole carboxamide hydrochloride

M-(1-benzylpiperidin-4-yl)-M-methyl-4- - doniplinimidaol arboxamiduscalate tao 1111

M-(1-benzylpiperidin-4-yl)-M-methyl-4-410 | phenyl-1H-imidazole-1-carboxamide Imidazole hydrochloride

M-(1-benzylpiperidin-4-yl)-M-methyl-4-411 | phenyl-1H-imidazole-1-carboxamide Imidazoles methanesulfonate

M-(1-benzylpiperidin-4-yl)-M-methyl-4-412 | phenyl-1H-imidazole-1-carboxamide 2- Imidazoles hydroxypropane-1,2,3-tricarboxylate

M-(1-benzylpiperidin-4-yl)-M-methyl-4-413 | phenyl-1H-imidazole-1-carboxamide (2E,3K)- Imidazoles 2,3-dihydroxysuccinate nrrneo ny 101111 phenyl-1H-imidazole-1-carboxamide phosphate 4-(4-(4-(benzyloxy)piperidine-1 - 415 |ylsulfonyl)phenyl)-M-cyclohexyl-M-methyl- | Imidazoles 109.1 95.4 1H-imidazole-1-carboxamide 6 o pyridinsil t midazolychaerokamya (Mieom (pyridin-3-yl)-1 H-imidazole-1-carboxamide 7 idazole arc 0011 imidazole-1-carboxamide

M-(1-benzylpiperidin-4-yl)-4-(3-418 | methoxyphenyl)-M-methyl-1H-imidazole-1- Imidazoles carboxamide

M-(1-benzylpiperidin-4-yl)-4-(4- 419 | methoxyphenyl)-M-methyl-1H-imidazole-1- Imidazoles 1 carboxamide 4-(4-(benzyloxy)phenyl)-M-(1 - 420 | benzylpiperidin-4-yl)-M-methyl-1H-imidazole- | Imidazoles 1-carboxamide oche (vidazoliapyridinethioud 000 lem imidazol-4-yl)pyridine 1-oxide

Table 1

GO Г1111С111111111111pMnyu | 7 yuMmo vAPPZOII We 30) VAZ | And We Z

Name Class 10 µM 1100 nMi mg.kg, 1 | mg.kg, 1 | mg.kg, 8 | mg.kg, 8 h h h h h

M-cyclohexyl-M-methyl-4-(4- 422 | (methylsulfonyl)phenyl)-1H-imidazole-1- Imidazoles 1,7 2,7 carboxamide

M-(1-benzylpiperidin-4-yl)-4-(3-423 | (hydroxycarbamoyl)phenyl)-M-methyl-1H- Imidazoles 21 imidazole-1-carboxamide

M-cyclohexyl-4-(3- 424 | (hydroxycarbamoyl)phenyl)-M-methyl-1 H- Imidazoles 1 0.5 imidazole-1-carboxamide 4-(4-(benzylamino)-3-nitrophenyl)-M- 425 | cyclohexyl-M-methyl-1H-imidazole-1- Imidazoles 111.4 | 104.6 carboxamide 4-(1-benzyl-2-oxo-2,3-dihydro-1H- 426 | benzo|d|imidazol-5-yl)-M-cyclohexyl-M- Imidazoles 115.8 methyl-1H -imidazole-1-carboxamide

M-(1-benzylpiperidin-4-yl)-4-(3,4- 427 | difluorophenyl)-M-methyl-1 H-imidazole-1- Imidazole carboxamide

M-methyl-1H-imidazole-1-carboxamide

M-(1-benzylpiperidin-4-yl)-4-(4- 429 | (difluoromethoxy)phenyl)-M-methyl-1 H- Imidazoles imidazole-1-carboxamide

M-(1-benzylpiperidin-4-yl)-4-(4-fluorophenyl)-|, . nitrogen midazol arch of houses

M-(1-(2,6-dimethoxybenzyl)piperidin-4-yl)- 431 | M-methyl-4-(pyridin-3-yl)-1H-imidazole-1- Imidazoles carboxamide

M-cyclohexyl-4-(4-(4-hydroxypiperidin-1-432 | ylsulfonyl)phenyl)-M-methyl-1 H-imidazole-1- | Imidazoles 96.1 65.5 Carboxamide

M-(1-benzylpiperidin-4-yl)-4-(3,4- 433 | dimethoxyphenyl)-M-methyl-1 H-imidazol-1- Imidazole carboxamide imidazol-1-yl)umethanone

M-cyclohexyl-4-(4--dimethylamino)-3- 435 | nitrophenyl)-M-methyl-1H-imidazole-1- Imidazoles 4,3 4,5 carboxamide 1-(4,4-dimethyloxazolidine-3-carbonyl)-1 H-

M-(benzyloxy)-1-(4,4-dimethyloxazolidine-437|Z-carbonyl)-1H-benzoi|a111,2,3|triazole-5- Benzotriazole carboxamide

M-cyclohexyl-4-(4-methoxy-3-(2H-tetrazole-438 | 5-yl)uphenyl)-M-methyl-1H-imidazole-1- Imidazoles 92.4 61 carboxamide

M-cyclohexyl-4-(4-hydroxy-3-(2H-tetrazole-439 | 5-yl)phenyl)-M-methyl-1H-imidazole-1- Imidazoles 94.4 58.6 carboxamide 1-(4, 4-dimethyloxazolidine-3-carbonyl)-M- 440 | hydroxy-1H-benzo|41(11,2,3|griazole-5- Benzotriazoles 23,2 3,3 carboxamide

M-(1-benzylpiperidin-4-yl)-4-(4-methoxy-3-441 | nitrophenyl)-M-methyl-1H-imidazole-1- Imidazoles carboxamide

M-(1-benzylpiperidin-4-yl)-4-(4-fluoro-3-442 | methoxyphenyl)-M-methyl-1H-imidazole-1- Imidazoles carboxamide

M-(1-benzylpiperidin-4-yl)-4-(3-fluoro-4- 443 | methoxyphenyl)-M-methyl-1H-imidazole-1- Imidazole carboxamide tert-butyl-4-(4-(4- (benzyloxy)phenyl)-M- 444 | methyl-1H-imidazole-1-safohamido)piperidine-| Imidazoles 1-carboxylate zav |Ketylnimidavolcarboxamide de OO -methyl-1H-imidazole-1-carboxamide

Table 1

GO Г1111С111111111111pMnyu | 7 yuMmo vAPPZOII We 30) VAZ | And We Z

Name Class 10 µM 1100 nMi mg.kg, 1 | mg.kg, 1 | mg.kg, 8 | mg.kg, 8 h h h h h

M-(1-benzylpiperidin-4-yl)-4-(3-cyano-4-446 | methoxyphenyl)-M-methyl-1H-imidazole-1- Imidazole carboxamide 4-(3-amino-4--dimethylamino) phenyl)-M- 447 | cyclohexyl-M-methyl-1H-imidazol-1- Imidazoles 11,8 6,5 carboxamide 3-(1-(4-(ethoxycarbonyl)piperazine-1- - 448 carbonyl)-1 H-imidazol-4-yl)pyridine Imidazole 1-oxide poividiocid 111111 yl)pyridine 1-oxide 4-(3-amino-4-methoxyphenyl)-M-methyl-M- - 450 (piperidin-4-yl)-1H-imidazole-1-carboxamide Imidazoles 142 65.4

M-(1-benzylpiperidin-4-yl)-4-(4- 451 | hydroxyphenyl)-M-methyl-1 H-imidazole-1- Imidazoles 11 0.3 carboxamide hydrobromid yl) pyridine 1-oxide sudo shen 11171111 imidazole -1-carboxamide

M-(1-benzylpiperidin-4-yl)-4-(3-fluoro-4-454 | hydroxyphenyl)-M-methyl-1 H-imidazole-1- Imidazoles 31 Kk) carboxamide hydrobromide 3-(1-(4 ,4-dimethyloxazolidine-3-carbonyl)- - 455 1H-imidazol-4-yl)pyridine 1-oxide Imidazoles 456 3-(1-(methyl(phenyl)carbamoyl)-1H-imidazole-4- Imidazolyl)pyridine 1-oxide

M-(1-benzylpiperidin-4-yl)-4-(4-hydroxy-3- 457 | nitrophenyl)-M-methyl-1H-imidazole-1- Imidazoles 28.1 10.6 carboxamide hydrobromide 1-carboxamide 3- (1-(1-benzylpiperidine-4-459 | yl)umethyl)carbamoyl)-1H-imidazole-4- Imidazoles 1,3 1,9 yl)upyridin 1-OoKoxide

Ethyl-1-(4,4-dimethyloxazolidine-3- 460 | carbonyl)-1 H-benzo|a|11,2,3)|triazole-b- Benzotriazole carboxylate 461 3-(1-(cyclohexylcarbamoyl)-1H- imidazole-4- Imidazoles yl) pyridine 1-oxide 1-(4,4-dimethyloxazolidine-3-carbonyl)-1 H- 462 benzo|a|/1,2,3-triazole-b-carboxamide Benzotriazoles

M-methyl-4-(pyridin-3-yl)-M-(tetrahydro-2H- - 463 pyran-4-yl)-1 H-imidazole-1-carboxamide Imidazoles 464 M-cyclohexyl-M-ethyl-4- (pyridin-Z-yl)-1H- Imidazoles imidazole-1-carboxamide

M-(1-benzylpiperidin-4-yl)-4-(3,4- 465 | dihydroxyphenyl)-M-methyl-1 H-imidazole-1- Imidazoles 3,8 31 carboxamide hydrobromide 4-(3-fluoro-4 -methoxyphenyl)-M-methyl-M- 466 | (tetrahydro-2H-pyran-4-yl)-1H-imidazole-1- Imidazoles carboxamide

M-methyl-M-(1-phenethylpiperidin-4-yl)-4- - 467 phenyl-1H-imidazole-1-carboxamide Imidazoles 4-(3-amino-4-methoxyphenyl)-M-methyl-M- 468 | (tetrahydro-2H-pyran-4-yl)-1H-imidazol-1- Imidazoles 4,7 4,3 carboxamide tert-butyl 4-(4-(4-hydroxyphenyl)-M-methyl- 469 | 1H-imidazole -1-sagrohamido)piperidine-1- Imidazoles 1,4 0,7 carboxylate 3-(1-(methyl(tetrahydro-2H-pyran-4-470|yl)ucarbamoyl)-1H-imidazol-4-yl)pyridine 1- Imidazoles oxide 7 3-1 -(cyclohexyl(ethyl)carbamoyl)-1 H- Imidazoles imidazol-4-yl)pyridine 1-oxide 472 4-(4-fluorophenyl)-M-methyl-M-(tetrahydro- 2H-Imidazoles pyran-4-yl)-1H-imidazole-1-carboxamide 4-(3,4-difluorophenyl)-M-methyl-M-(tetrahydro-|, . 473 2H-pyran-4-yl)- 1H-imidazole-1-carboxamide Imidazoles

Table 1

GO Г1111С111111111111pMnyu | 7 yuMmo vAPPZOII We 30) VAZ | And We Z

Name Class 10 µM 1100 nMi mg.kg, 1 | mg.kg, 1 | mg.kg, 8 | mg.kg, 8 h h h h h 4-(4-(difluoromethoxy)phenyl)-M-methyl-M- 474 | (tetrahydro-2H-pyran-4-yl)-1H-imidazol-1- Imidazole carboxamide 4-(4-methoxyphenyl)-M-methyl-M-(tetrahydro- - 475 onpyranyiNomidazolarbocamd (io 4-(3,4-dimethoxyphenyl )-M-methyl-M- 476 | (tetrahydro-2H-pyran-4-yl)-1 H-imidazol-1- Imidazole carboxamide pen midazolareocamide Oda pyran-4-yl)-1 H-imidazole-1-carboxamide

M-tert-butyl-1-(4,4-dimethyloxazolidine-3- 478 | carbonyl)-1 H-benzo|a|11,2,3)|triazole-b- Benzotriazole carboxamide 1-(4,4-dimethyloxazolidine -3-carbonyl)-M, M- 479 | dimethyl-1H-benzoi|a1(1,2,3Itriazole-6- Benzotriazole carboxamide zvo oko o Mrizoldicarbokovmid (Beothioeut benzo|a|/1,2,3Igriazole-1,5-dicarboxamide 1-(4,4-dimethyloxazolidine-3 -carbonyl)-M- 481 | phenyl-1 H-benzo|4h|11,2,3|griazole-b- Benzotriazole carboxamide 4-(3-carbamoyl-4-methoxyphenyl)-M- 482 | cyclohexyl-M-methyl -1H-imidazole-1- Imidazoles 83.2 16.7 carboxamide

M-methyl-M-(tetrahydro-2H-pyran-4-yl)-1H- 4-(4-fluoro-3-methoxyphenyl)-M-methyl-M- 484. | (tetrahydro-2H-pyran-4-yl)-1H-imidazole-1- Imidazoles carboxamide

M-cyclohexyl-4-(4-methoxy-3-485 | (methylsulfonamido) phenyl)-M-methyl-1H- | Imidazoles 921 15,1 imidazole-1-carboxamide 1-(4,4-dimethyloxazolidine-3-carbonyl)-M- 486 | phenyl-1 H-benzo|4|11,2,3|griazole-5- Benzotriazoles carboxamide

M-tert-butyl-1-(4,4-dimethyloxazolidine-3- 487 | carbonyl)-1H-benzo|a|11,2,3)|triazole-5- Benzotriazole carboxamide

M-methyl-M-(1-phenethylpiperidin-4-yl)-4- - zve pyridinzi nmidavolgarbokamide (myeom | | | | |z) 2

M-cyclohexyl-1-(4,4-dimethyloxazolidine-3- 489 | carbonyl)-1 H-benzo|a|11,2,3)|triazole-5- Benzotriazole carboxamide

M-cyclohexyl-1-(4,4-dimethyloxazolidine-3- 490 | carbonyl)-1 H-benzo|a|11,2,3)|triazole-b- Benzotriazoles carboxamide 91 bony o iriazole b dicarbokoamia (Benotieut benzo| 49|(11,2,3)Itriazole-1,5-dicarboxamide

M-(1-benzylpiperidin-4-yl)-M-methyl-1 H- 492 | benzo|4a|11,2,3)griazole-1-carboxamide Benzotriazoles 0.7 hydrochloride

Anne SNI NNYA PON NOYA KONYA WIN NOYA imidazole-1-carboxamide 4-(4-hydroxy-3-nitrophenyl)-M-methyl-M- 494 | (tetrahydro-2H-pyran-4-yl)-1H-imidazol-1- Imidazoles 48.9 22.3 carboxamide 4-(3-fluoro-4-hydroxyphenyl)-M-methyl-M- 495 | (tetrahydro-2H-pyran-4-yl)-1H-imidazole-1- Imidazoles 21 2,3 carboxamide

M-benzyl-1-(4,4-dimethyloxazolidin-3- 496 | carbonyl)-1 H-benzo|a|11,2,3)|triazole-5- Benzotriazole carboxamide sinya shen 1 171111 imidazol-4-yl) pyridine 1-oxide 4-(3-methoxyphenyl)-M-methyl-M-(1- 498 | propylpiperidin-4-yl)-1H-imidazole-1- Imidazoles 21.4 12.6 carboxamide

Table 1

GO Г1111С111111111111pMnyu | 7 yuMmo vAPPZOII We 30) VAZ | And We Z

Name Class 10 µM 1100 nMi mg.kg, 1 | mg.kg, 1 | mg.kg, 8 | mg.kg, 8 h h h h h 4-(3-carbamoyl-4-hydroxyphenyl)-M- 499 | cyclohexyl-M-methyl-1H-imidazole-1- Imidazoles 120.6 441 carboxamide 4-(4-fluoro-3-hydroxyphenyl)-M-methyl-M- 500 | (tetrahydro-2H-pyran-4-yl)-1H-imidazol-1- Imidazoles 75.1 21.68 carboxamide 4-(4-methoxyphenyl)-M-methyl-M-(piperidin-4-|, ovo on mdaolarvokmd el ovv| v

M-(1-ethylpiperidin-4-yl)-4-(3- 502 | methoxyphenyl)-M-methyl-1H-imidazole-1- Imidazoles 502 11.5 carboxamide

M-(1-ethylpiperidin-4-yl)-4-(3-fluoro-4-503 | methoxyphenyl)-M-methyl-1H-imidazole-1- Imidazoles 78.8 251 1-carboxamide hydrochloride (4-cyclohexylpiperazin-1-yl)(2-(4,4- dimethyloxazolidin-3-carbonyl)-2|H- 505 benzo|a|011,2,3)igriazol-5-yl)umethanone Benzotriazoles oxalate (4-(benzo|h|I1,3|dioxol-5-ylmethyl)piperazin-506 | 1-yl)/(2-(4,4-dimethyloxazolidine-3-carbonyl)-| Benzotriazoles 2H-benzo| a|(1,2,3)|griazol- (E)-M-cyclohexyl-4-(3-(M'- 507 | hydroxycarbamimidoyl)-4-methoxyphenyl)-M- | Imidazoles 101.7 34 methyl-1H -imidazole-1-carboxamide

M-((1g,4g)-4-hydroxycyclohexyl)-M-methyl-4-|, .

M-(1-ethylpiperidin-4-yl)-M-methyl-4-(3- - sov prophenium Mida cherbokamd Ole 68| and 4-(3,4-dimethoxyphenyl)-M-(1-ethylpiperidine-|, . 4-(3-Aminophenyl)-M-(1-ethylpiperidin-4-yl)- - 4-(3,4-dimethoxyphenyl)-M-methyl-M-(1 - 512 | propylpiperidin-4-yl)-1H-imidazol-1- Imidazole carboxamide 4-(3-carbamoyl-4-hydroxyphenyl)-M-methyl-M- 513 | (tetrahydro-2H-pyran-4-yl)- 1H-imidazole-1- Imidazoles 90.3 144 carboxamide 4-(3-fluoro-4-methoxyphenyl)-M-methyl-M-(1- 514 | propylpiperidin-4-yl)-1H-imidazole-1- Imidazoles carboxamide tert-butyl 4-(M-methyl-4-(pyridin-3-yl)-1 H- 515 | imidazole-1-saghbohamido)piperidine-1- Imidazole carboxylate 3-(1-((11.4g)-4 - 516 | hydroxycyclohexylmethyl)carbamoyl)-1 H- | Imidazoles imidazol-4-yl)pyridine 1-oxide (4-benzylpiperazin-1-yl(1-(4,4- dimethyloxazolidin-3-carbonyl)-1 H- 517 benzo|a|011,2,3)hygriazol-5-yl)umethanone Benzotriazole oxalate ov mal arvocamd 0001111 imidazole-1-carboxamide 3-(1-(methyl(1-propylpiper din-4- 519 | yl)ucarbamoyl)-1H-imidazol-4-yl)pyridine 1- Imidazoles 82 4,4 oxide 4-(4-methoxyphenyl)-M-methyl-M-(1- 520 | propylpiperidin-4-yl)-1H- imidazole-1- Imidazole carboxamide

M-(1-ethylpiperidin-4-yl)-4-(4-521 | methoxyphenyl)-M-methyl-1H-imidazole-1- Imidazoles carboxamide

M-methyl-4-(3Z-nitrophenyl)-M-(1- 522 | propylpiperidin-4-yl)-1H-imidazol-1- Imidazoles carboxamide

Table 1

GO Г1111С111111111111pMnyu | 7 yuMmo vAPPZOII We 30) VAZ | And We Z

Name Class 10 µM 1100 nMi mg.kg, 1 | mg.kg, 1 | mg.kg, 8 | mg.kg, 8 h h h h h

M-(1-benzylpiperidin-4-yl)-4-(4-fluoro-3-523 | hydroxyphenyl)-M-methyl-1 H-imidazole-1- Imidazole carboxamide 4-(3-aminophenyl)-M-methyl -M-(1- 524 | propylpiperidin-4-yl)-1H-imidazol-1- Imidazoles carboxamide

M-(1-ethylpiperidin-4-yl)-M-methyl-4- - sov pridikzal monkeys narbokvmd ee 1111 4-(3'-carbamoylbiphenyl-3-yl)-M-methyl-M-(1- 526 | propylpiperidine -4-yl)-1H-imidazole-1- Imidazoles carboxamide

M-cyclohexyl-M-methyl-2-oxo-5-phenyl-- thistle | dokadivolo p narbokamd 0 1111 3-(4,4-dimethyloxazolidine-3-carbonyl)-5- -

M-methyl-M-(1-propylpiperidin-4-yl)-4- - he pyridic Zina midazole narookvmd dao 11111 2-(1-(cyclohexyl(methyl)carbamoyl)-1 H- - ovo moly iridinlexide 000 dom || HER 1H-imidazole-1-carboxamide dihydrochloride 4-(4-methoxyphenyl)-M-methyl-M-(1- 532 | (methylsulfonyl)piperidin-4-yl)-1H- Imidazoles imidazole-1-carboxamide

M-methyl-M-(1--"methylsulfonyl)piperidine-4-533 | yl)-4-(pyridin-3-yl)-1 H-imidazol-1- Imidazoles 12 02 carboxamide 4-(3-fluoro-4-methoxyphenyl)-M-methyl-M- 534. | (piperidin-4-yl)-1H-imidazole-1-carboxamide | Imidazole hydrochloride

M-(1-benzylpiperidin-4-yl)-5-cyano-M-methyl-

M-(1-ethylpiperidin-4-yl)-4-(3-fluoro-4-536 | hydroxyphenyl)-M-methyl-1 H-imidazole-1- Imidazoles 74.6 18.3 carboxamide

M-(1-ethylpiperidin-4-yl)-4-(4-fluoro-3-537 | methoxyphenyl)-M-methyl-1H-imidazole-1- Imidazoles carboxamide carboxamide

M,M-dimethyl-1 H-/1,2,3|triazolo|4,5- o5ze o riridin heat 8000 O|O111 4-(3-fluoro-4-methoxyphenyl)-M-(1-(2- 540 | hydroxyethyl) piperidin-4-yl)-M-methyl-1H- | Imidazoles 89.7 33.7 imidazole-1-carboxamide

M-(1-(2-cyanoethyl)piperidin-4-yl)-4-(3-fluoro-541 | 4-methoxyphenyl)-M-methyl-1H-imidazole-1- Imidazole carboxamide

M-methyl-4-(pyridin-4-yl)-M-(tetrahydro-2H- - ovya2 rana dazolzarvoksamd Odesa 4-(1-(methyl(tetrahydro-2 H-pyran-4- 543 | yl)ucarbamoyl)- 1H-imidazol-4-yl)pyridine 1- Imidazole oxide 4-(4-methoxyphenyl)-M-methyl-M-(1-(pyridin-2- 544 | ylmethyl)piperidin-4-yl)-1 H-imidazole -1- Imidazole carboxamide 4-(4-fluoro-3-methoxyphenyl)-M-methyl-M-(1- 545 | propylpiperidin-4-yl)-1H-imidazole-1- Imidazole carboxamide 4-(4-methoxyphenyl) -M-methyl-M-(1-(2- 546 | (pyridin-Z-yl) thiazol-4-carbonyl) piperidine-4-| Imidazolyl)-1H-imidazole-1-carboxamide

M-(1-acetylpiperidin-4-yl)-4-(4- 547 | methoxyphenyl)-M-methyl-1H-imidazole-1- Imidazoles carboxamide

M-(1-acetylpiperidin-4-yl)-M-methyl-4- - 35 units pyridicaltnamidazolizarookamd deoli |O

Table 1

GO Г1111С111111111111pMnyu | 7 yuMmo vAPPZOII We 30) VAZ | And We Z

Name Class 10 µM 1100 nMi mg.kg, 1 | mg.kg, 1 | mg.kg, 8 | mg.kg, 8 h h h h 4-(4-methoxyphenyl)-M-methyl-M-(1-(3- 549 | (trifluoromethyl)phenylsulfonyl)piperidine- | Imidazoles 4-yl)-1 H-imidazole- 1-carboxamide

M-(1-benzylpiperidin-4-yl)-4-(3'- 550 | carbamoylbiphenyl-3-yl)-M-methyl-1 H- Imidazoles 94.3 5.7 imidazole-1-carboxamide

M-cyclohexyl-M-methyl-4-(4-(5-oxo-4,5- 551 | dihydro-1,2,4-oxadiazol-3-yl)uphenyl)-1 H- Imidazoles 852 3,8 imidazole -1-carboxamide 4-(3-«(hydroxycarbamoyl)phenyl)-M-methyl-M- 552 | (1-propylpiperidin-4-yl)-1H-imidazole-1- Imidazoles 902 45 carboxamide

M-cyclohexyl-4-(3-guanidinophenyl)-M- 553 | methyl-1H-imidazole-1-carboxamide Imidazoles 72.3 15.4 hydrochloride 4-(3-carbamoyl-4-hydroxyphenyl)-M-methyl-M- 554. | (1-propylpiperidin-4-yl)-1H-imidazol-1- Imidazoles 102.2 85.6 carboxamide 4-(4-hydroxyphenyl)-M-methyl-M-(piperidin-4-|, . vve | midazol narod fraction until 4-(3-amino-4--dimethylamino)phenyl)-M-(1-556 | benzylpiperidin-4-yl)-M-methyl-1H-imidazole- | Imidazoles 1-carboxamide

M-(1-(4,6-dichloro-1,3,5-triazin-2-yl)/piperidin-4-yl)-4-(4-methoxyphenyl)-M-Imidazoles methyl-1H-imidazole -1-carboxamide 2-(4-(«M-methyl-4-(pyridin-3-yl)-1 H-imidazol-1-|,. methyl-5-((4-(M-methyl-4- (pyridin-3-yl)-1 H- 559 | imidazole-1-carboxamide)piperidine-1- Imidazolyl)umethyl)/furan-2-carboxylate

M-methyl-4-(pyridin-2-yl)-M-(tetrahydro-2H-) midazole arene 1111

M-(1-ethylpiperidin-4-yl)-4-(4-fluoro-3- 561 | hydroxyphenyl)-M-methyl-1 H-imidazole-1- Imidazoles 822 78.6 carboxamide hydrobromide 4-(3-amino -4-hydroxyphenyl)-M-cyclopentyl- 562 | M-methyl-1H-imidazole-1-carboxamide Imidazole hydrochloride

M-cyclohexyl-4-(3-guanidinophenyl)-M- - ve stmlnmidezolnarecosmid 00 ee 1111

M-cyclopentyl-M-methyl-4-(2-oxo-2,3- 564 | dihydrobenzo|a|oxazol-5-yl)-1 H-imidazol-1- | Imidazoles 37,6 2,3 carboxamidyl)-M-methyl-1H-imidazole-1-carboxamide 4-(3-(hydroxycarbamoyl)phenyl)-M-(1g,4y)-4- 566 | hydroxycyclohexyl)-M-methyl-1 H-imidazole-| Imidazoles 88.5 69.8 1-carboxamide

M-(1-benzylpiperidin-4-yl)-M-methyl-4-(4- 567 | (methylsulfonyl)phenyl)-1 H-imidazole-1- Imidazoles 87.8 6.3 carboxamide 4-(4-hydroxyphenyl )-M-methyl-M-(1-(3- 568 | (trifluoromethyl) phenylsulfonyl) piperidine- | Imidazoles 4-yl)-1 H-imidazole-1-carboxamide

M-methyl-M-(1-(pyridin-2-ylmethyl)piperidin- 569 | 4-yl)-4-(pyridin-3-yl)-1H-imidazol-1- Imidazoles carboxamide 4-(4-fluoro- 3-hydroxyphenyl)-M-methyl-M-(1- 570 | propylpiperidin-4-yl)-1H-imidazol-1- Imidazoles carboxamide hydrobromide

M-(1-benzylpiperidin-4-yl)-4-(4- 571 | (hydroxycarbamoyl) phenyl)-M-methyl-1 H- Imidazoles imidazole-1-carboxamide hydrobromide

M-(1-benzylpiperidin-4-yl)-4-(3-carbamoyl- 572 | 4-hydroxyphenyl)-M-methyl-1 H-imidazol-1- Imidazole carboxamide hydrobromide

Table 1

GO Г1111С111111111111pMnyu | 7 yuMmo vAPPZOII We 30) VAZ | And We Z

Name Class 10 µM 1100 nMi mg.kg, 1 | mg.kg, 1 | mg.kg, 8 | mg.kg, 8 h h h h h

M-(1-(2-chloronicotinoyl)piperidin-4-yl)-4-(4-573 | methoxyphenyl)-M-methyl-1H-imidazole-1- Imidazoles carboxamide

M-(1-acetylpiperidin-4-yl)-4-(4- 574 | hydroxyphenyl)-M-methyl-1 H-imidazole-1- Imidazoles carboxamide

M-cyclohexyl-4-(3-guanidino-4- 575 | methoxyphenyl)-M-methyl-1H-imidazole-1- Imidazole carboxamide hydrochloride 4-(3--2H-tetrazole-5-iluphenyl)-M- 576 | cyclohexyl-M-methyl-1H-imidazole-1-Imidazole carboxamide 4-(4-aminophenyl)-M-(1-benzylpiperidine-4-)

M-(1-benzylpiperidin-4-yl)-M-methyl-4-(4- 578 | sulfamoylphenyl)-1H-imidazole-1- Imidazole carboxamide 4-(4-aminophenyl)-M-cyclohexyl-M-methyl- - here | goes erbkamd ee

M-cyclohexyl-M-methyl-4-(4- 580 | (sulfamoylamino)phenyl)-1 H-imidazole-1- Imidazole carboxamide

M-(1-benzylpiperidin-4-yl)-4-(3-guanidino-4-581 | methoxyphenyl)-M-methyl-1H-imidazol-1- Imidazoles carboxamide

M-(1-cyanopiperidin-4-yl)-4-(4- 582 | methoxyphenyl)-M-methyl-1H-imidazole-1- Imidazoles carboxamide

M-(1-"cyanomethyl)piperidin-4-yl)-4-(4- 583 | methoxyphenyl)-M-methyl-1H-imidazole-1- Imidazoles carboxamide

M-(1-(cyanomethyl)piperidin-4-yl)-M-methyl-4-|, . 4-(3-hydroxyphenyl)-M-methyl-M-(1- 585 | propylpiperidin-4-yl)-1H-imidazol-1- Imidazole carboxamide hydrobromide 4-(3,4-dihydroxyphenyl) -M-methyl-M-(1- 586 | propylpiperidin-4-yl)-1 H-imidazol-1- Imidazole carboxamide hydrobromide 4-(4-hydroxyphenyl)-M-methyl-M-(1-(pyridin- 587 | 2-ylmethyl) piperidin-4-yl)-1H-imidazole-1- Imidazoles carboxamide hydrobromide

M-(1-benzylpiperidin-4-yl)-M-methyl-4-(4- 588 | (sulfamoylamino)phenyl)-1 H-imidazole-1- Imidazole carboxamide

M-(1-benzylpiperidin-4-yl)-4-(3- 589 | guanidinophenyl)-M-methyl-1 H-imidazole-1- Imidazole carboxamide 4-(3--2H-tetrazole-5-iluphenyl)- M-methyl-M- 590 | (tetrahydro-2H-pyran-4-yl)-1H-imidazole-1- Imidazoles carboxamide

M-cyclohexyl-M-methyl-4-(3-(5-oxo-4,5- 591 | dihydro-1,2,4-oxadiazol-3-yl)uphenyl)-1 H- Imidazoles imidazole-1-carboxamide (E-M14(M-hydroxycarbamimidoyl)piperidin-4-yl)-4-(4- - 592 methoxyphenyl)-M-methyl-1H-imidazole-1- and Imidazoles carboxamide

M-(1-benzylpiperidin-4-yl)-M-methyl-4-(3-593 | (methylsulfonamido)phenyl)-1 H-imidazol-1- | Imidazole carboxamide

M-cyclopentyl-M-methyl-4-(3-(5-oxo-4,5- 594 | dihydro-1,2,4-oxadiazol-3-yl)uphenyl)-1 H- Imidazoles imidazole-1-carboxamide

M-(1--2H-tetrazol-5-yl)piperidin-4-yl)-4-(4-595 | methoxyphenyl)-M-methyl-1H-imidazol-1- Imidazoles carboxamide

Table 1 11111111 mu | 7 yuMyu rzhnroe daily limit

Name Class 10 µM 1100 nMi mg.kg, 1 | mg.kg, 1 | mg.kg, 8 | mg.kg, 8 h h h h h 4-(4-(4-methoxyphenyl)-M-methyl-1 H-imidazole-|, .

His stokhanidoipridinkaroxamid lety 1011 sebe | | | | 1 597 | methoxyphenyl)-M-methyl-1H-imidazole-1- Imidazole carboxamide 4. Biological selectivity of compounds according to the invention

EAAN inhibition was determined as described above. Inhibition of monoacylglycerol lipase (MAHL) and carboxylesterase (CE) was performed according to the protocols described below.

Controls, both ip miigo and ip mimo, were the reaction mixture minus the tested compounds.

Thus, a low value for the studied compounds in the table. 2 below indicates a potent inhibitor. A value of 100 indicates no measurable inhibition.

MAGL

The measurement of MAGL activity was based on the rate of hydrolysis (NI 2-00 (labeled glycerol) as a substrate. Briefly, cerebellar cytosol fractions (SVCsui), previously obtained from adult rats UMZTAK, were diluted to the appropriate protein concentration in the assay with Tris-HCI buffer solution (10 mM, pH 7.2) containing 1 mM EDTA, and added to the assay tubes containing the test compound. Blanks of the solution containing the assay buffer solution instead of the cytosolic samples were used as controls. Next, the substrate was added (final concentration of 2 µM Ob ), and the samples were incubated for 10 min at a temperature of 3720.

The final assay mixture contained 0.125 95, v/v fatty acid-free calf serum albumin. After the incubation phase, the reaction was stopped by adding 400 μl of a mixture of chloroform/methanol (v/v, 1:1), the contents of the tubes were vortexed twice, and they were placed on ice. The fractions were separated by centrifugation, aliquots of 200 μl of the methanol/buffer solution fraction were taken and the tritium content was analyzed by liquid scintillation spectroscopy taking into account quenching.

SE

Measurement of CE activity was based on the formation of p-nitrophenol from p-nitrophenyl acetate.

Briefly, in 9b-well plates, 8 μg/ml of rat or mouse liver microsomes (I Mtv5) were incubated with 10 μM BAAN inhibitors for 15 min, and then the substrate, p-nitrophenyl acetate, was added to a final concentration of 1 mM. The tablet was read at a wavelength of 405 nm after 10 minutes. after the addition of the substrate for the formation of p-nitrophenol using a spectrophotometer. Carboxylesterase activity in microsomal extracts without added inhibitor was taken as a control for 10095, and the residual activity of KE after incubation with inhibitors

Zo was calculated relative to the control.

Table 2 11111111 yuMiyu | 0 pjMmo | about the pump

ГАЖК ГАЖК ГАЖК | SE Moy | SE Wai MASI Wai

Name ГАЖК 100 VAZ Mi Z TSI Mtv 10) Mt 10 | Svv Vsuyu μm NM mg.kg, 8 mg.kg, 8 | µM 10 | µM 10 /|12.5 mM h. hours MIN. MIN. 8 hours

M-(4-methoxyphenyl)-M- 16 | methyl-4-(naphthalen-2-yl)- 24.7 95.4 87.5 1H-imidazole-1-carboxamide (3,4-dihydroquinolin-1(2H)- 39 | yl)/(4-(Z -methoxyphenyl)-1H- | 16 120.6 101.1 84.3 94.7 87 imidazol-1-yl)umethanone

M-(4-phenylbutyl)-1 H- 85 | benzo|411,2,3)griazol-1-01 Z1 C carboxamide 5B-bromo-M-cyclohexyl-M-methyl-1 H- 97 | benzo|a|y 2, Zygriazol-1- syn shu carboxamide

M-cyclopentyl-M-methyl-4-(2-oxo-2,3- 564 | dihydrobenzo|chCh|oxazole-5- 37.6 2.3 87.4 96.1 91.6 yl)-1H-imidazole -1- carboxamide

M-(1-benzylpiperidin-4-yl)-

M-methyl-4-(4-567 (methylsulfonyl)phenyl)- 87.8 6.3 88.6 97.8 942 1H-imidazole-1-carboxamide

Claims (21)

FORMULA OF THE INVENTION 1. Compound Formula: b M i M B5 1 he we nag where: B1 is C-alkyl; B2 is selected from H, C 1 -coalkyl, C 1 -alkyloxy, aryl, heteroaryl, partially or fully saturated heterocyclyl, C 3 -ocycloalkyl, aryl:-alkyl, heteroaryl-alkyl, heterocyclylC .-alkyl, C 3-cycloalkylC:-alkyl, Na, halogen . . B2 is C1-coalkyl, alkoxy, aryl, heteroaryl, heterocyclyl, C3-ocycloalkyl, arylC1-alkyl, heteroarylC1-alkyl, heterocyclylC1-alkyl, C3--ocycloalkylC1-alkyl, C1-alkyl, C3. cycloalkyl or represents a group containing one or more of these moieties, each of said moieties may optionally be substituted by one or more groups selected from Bc, halogen, aryl, heteroaryl, heterocyclyl, Sialkyloxy, aryloxy, heteroaryloxy, heterocyclyloxy, arylC-alkyl, heteroarylC-alkyl, heterocyclylC-alkyl, arylCi-alkoxy, heteroarylC:i-alkoxy, heterocyclylCi-alkoxy, C:-alkylamino, -((B.- vdialkylamino, Ci-oalkyl, OH, OBIs, OSOBIs, 5H, 5AI1s, 5SONIs, МН, MO», МНВИ1s, МНБЗО» МН»г, МНЗО»Атс, МАТсСОВтТа, МНе(МнуМН:, МНСОВ ts, MATevВтТа, СОВтс, SA с, SM, СООН, СООВт1с, SOMN:, SOMNON, SOMNAts, SOMNOV ts, С(MON)IMN:, SOMATeVta, 5021, ZOZN, 502MH»g, 502MATsATa, where Bis and Na are independently selected from C:-alkyl, substituted C-alkyl, aryl, heteroaryl, C3-zacycloalkyl and heterocyclyl, or Bc and B14, with the heteroatom to which they are attached, can form heterocyclyl, where, if the substituent in 2 is C1-alkyl, aryl, heteroaryl, heterocyclyl, C1-valkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, arylC1-alkyl, heteroarylC1-alkyl, heterocyclylC1-alkyl, arylC: 1-Alkoxy, heteroarylC1-1-Alkoxy, heterocyclylC1-Alkoxy, C1-alkylamino, C1-C1-dialkylamino, C1-alkyl, C3-cycloalkyl or represents a group containing one or more of these fragments, each of the indicated fragments is it's catchy may be substituted by one or more groups selected from Cl, halogen, C:i-alkyl, OH, OVtTe, OSOV'Te, 5H, ZNAte, 5SONVTe, MN», MO», MNATE, MNBO2MN:, MNBO»Ate, MATTesSonviIi, MNes(mMnuMnN», MNSOAte, MATevti, SONAtTe, C5ATe, SM, COON, SOONTe, SOMN:?, SOMNON, SOMNNAe, SOMNOA te, C(MON)MN:, SOMATents, 5O2AtTe, 5OzH, 5O»2MN:, 5O2MATenvities, wherein Be and VIII are independently selected from C1-alkyl, substituted C1-alkyl, aryl, heteroaryl, C3-acycloalkyl, and heterocyclyl, or Ni and VIII, together with the heteroatom to which they are attached, may form heterocyclyl, except that B1 and B2 are not both methyl, or B1 and B2, together with the M to which they are attached, may form a heteroaryl or heterocyclyl group, each of which may optionally be substituted by one or more oxygen atoms or one or more groups selected from aryl, heteroaryl, partially or fully saturated heterocyclyl, C3-3cycloalkyl, C1-alkyl, arylC1-alkyl, heteroaryls-alkyl, heterocycles 1C:-alkyl, C3 zcycloalkylC: -alkyl, C-alkyloxy, aryloxy, heteroaryloxy, heterocyclyloxy, Hga, halogen, OH, OVha, OoOSORha, 5H, 5Bg2a, 5СОВha, МН», МО», МНРАга, МНБЗО»МН»г . where Bha and B2Bb are independently selected from C1-6 alkyl, substituted C1-alkyl, aryl, heteroaryl, C3-cycloalkyl and heterocyclyl, or Bha and B2B, with the heteroatom to which they are attached, can form a heterocyclyl, where, if the substituent in heteroaryl or heterocyclyl, formed by NI and B2 together, is aryl, heteroaryl, heterocyclyl, C3-ccycloalkyl, C:-alkyl, arylC.-alkyl, heteroaryls:-alkyl, heterocyclylCi-alkyl, C3-acycloalkyl C-alkyl, Si-alkyl , aryloxy, heteroaryloxy, heterocyclyloxy or represents a group containing one or more of the indicated moieties, each of the indicated moieties may optionally be substituted by one or more groups selected from halogen, hydroxyl, C 1 -alkyl, aryl, heteroaryl, heterocyclyl, C 3 -cycloalkyl, C 1 -alukoxy, aryloxy, heteroaryloxy, heterocyclyloxy, C 3 -cycloalkyloxy, arylC 1 -alkyloxy, heteroarylC :-valkoxy, heterocyclylC:-4-alkyl, C3-vcycloalkylC:-4-alkoxy, B2c, OH2c, OSONo2c, 5H, 5H2c, 5СОН2C, МН, МО», МНА2с, МНБЗО2МН», МНЗО»Нес, МАгеСОо га, МНне(Мн)МН », МНоОВ2гс, МА2геВга, СОоВ2с, С5Н2О, СМ, СООН, СООВ2с, СОМН», СОМНОН, СОМНАгс, СОМНОРос, С(МОН)МН;, СОМА2сНага, 5О»Nos, BOZN, 5О»МН», ЗО2МН2сНага, where Н2с and B2a independently selected from C1-alkyl, substituted C1-alkyl, aryl, heteroaryl, C3-cycloalkyl, and heterocyclyl, or B2c and Bha, together with the heteroatom to which they are attached, may form heterocyclyl, where, if the substituent in substituent in heteroaryl or heterocyclyl, formed by NI and B2 together, is C:-alkyl, aryl, heteroaryl, heterocyclyl, C3-cycloalkyl, alkyloxy, aryloxy, heteroaryloxy, heterocyclyloxy, C3-cycloalkyloxy, and arylC-alkoxy, heteroarylC:-4-alkoxy, heterocyclylC-alkoxy, C3--cycloalkylC:--alkoxy or represents a group containing one or more of these moieties, each of said moieties may optionally be substituted by one or more groups , selected from C:-4-alkoxy, B2e, halogen, OH, OHge, OSON2e, 5H, ЗАге, 5СОНге, МН, MO», МНАге, МНЗО2МН»:, МНЗО»2Аге, МА2геСОНВай, МНОС(МН)МН», MAgenrai, МНОСОАРге, СОРге, СЗНГе, СМ, СООН, СООНге, SOMN:, SOMNON, SOMNage, SOMNONage, С(MON)МН:, SOMAgengy, 502Н2е, 5ОзН, 5О»2МНг, 502МАг2enНГой, where H2e and B2і are independently selected from Sivalkyl, substituted C-alkyl, aryl, heteroaryl, C6-cycloalkyl and heterocyclyl, or H2e and BNOI, together with the heteroatom to which they are attached, can form heterocyclyl; B5 is selected from H, S.-galkyl; and because Bb is selected from aryl and heteroaryl, wherein, if Bb is heteroaryl, said moiety may be optionally substituted with one or more oxygen atoms, and if Hb is aryl or heteroaryl, each of said moieties may be optionally substituted with one or more groups selected from halogen . . . alkyl, aryl, heteroaryl, Cz. of cycloalkyl and heterocyclyl, or Nbs and Hba, together with the heteroatom to which they are attached, may form a heterocyclyl, where, if the substituent in NE is heteroaryl or heterocyclyl, each of said moieties may optionally be substituted by one or more oxygen atoms , or if the substituent in Bb is C1-alkyl, C1-alkyl, aryl, heteroaryl, heterocyclyl, C1-valoxy, aryloxy, heteroaryloxy, heterocyclyloxy, arylC1-alkyl, heteroarylC1-alkyl, heterocyclylC1-alkyl . . MAbenby SOVbe, C5Abe, SM, СООН, SOOVbe, SOMN:, SOMNON, SOMNAbe, SOMNONVbe, С(MON)МН:, SOMAbenvby, 50»А be, 5OzH, ZO2MHn, 5O2MAbenbi, wherein Abe and Wb are independently selected from C-alkyl, substituted C-alkyl, aryl, heteroaryl, C3-cycloalkyl and heterocyclyl, or Bbe and Bb, together with the heteroatom to which they are attached, may form heterocyclyl; B8 is H; or a pharmaceutically acceptable salt or ester thereof; provided that, if NO is methyl, H2 is not 4-chlorobutyl, 4-azidobutyl, or 4-isothiocyanatobutyl, and Z0 is provided that the compound is not (4-phenyl-1H-imidazol-1-yl) (4-(quinolin-2-ylmethyl)piperazin-1-ylumethanone. 2. The compound according to claim 1, in which B! and 22 together with the M to which they are attached form a heterocyclyl group which may optionally be substituted. 3. The compound according to claim 1 or claim 2, in which B5 is H. 4. The compound according to claim 1 or claim 3, in which VI is methyl; B2 is selected from monocyclic C1-cycloalkyl or monocyclic b--lene saturated heterocyclyl containing one heteroatom of nitrogen or oxygen, where the heteroatom is in the 4-position in relation to the position of attachment of the heterocyclyl group H2 to the urea nitrogen, in which, if the heteroatom is nitrogen atom, the nitrogen atom is optionally substituted by benzyl; B5 is H; Wb is selected from phenyl or pyridyl, in which the nitrogen atom of the pyridyl group can be replaced by an oxygen atom, and where the phenyl can optionally be replaced by one or more groups selected from halogen, methoxy, OH, SOMH", MH", and phenyl; and B8 is H. 5. The compound according to claim 1 or claim 3, in which VI is methyl; B2 is selected from monocyclic C1-cycloalkyl, tetrahydropyranyl, and piperidinyl, where the heteroatom in the tetrahydropyranyl and piperidine groups is in the 4-position in relation to the attachment position of the heterocyclyl group 22 to the urea nitrogen, and in which the nitrogen atom from the piperidinyl group is replaced by benzyl; B5 is H; Bb is selected from phenyl or pyridyl, in which the nitrogen atom of the pyridyl group is replaced by an oxygen atom, and where the phenyl may optionally be substituted by one or more groups selected from halogen, methoxy, OH, SOMH", MH" and phenyl; and BB is H. 6. The compound according to claim 1 or claim 3, in which VI is methyl; B2 is a monocyclic saturated heterocyclyl containing a nitrogen heteroatom, where the nitrogen heteroatom is replaced by a SOMATSVta group. 7. The compound according to claim 1 or claim 3, in which Bb is phenyl substituted by more than one group selected from OH and C-alkyl. 8. The compound according to claim 1 or claim 3, in which Wb is phenyl substituted by МНОО»2МН». 9. The compound according to claim 1 or claim 3, in which VI is methyl; B2 is a monocyclic saturated heterocyclyl containing a nitrogen heteroatom, wherein the nitrogen heteroatom is substituted with a group selected from aryl and 502H1c. 10. The compound according to claim 1 or claim 3, in which VYab is a pyridyl substituted by a group selected from MNEAbs, MAbsNba, MNeO»MN», MNSOSOVbs and MNZO»Vbs. 11. The compound according to claim 1 or claim 3, in which Wb is pyrazinyl or pyrimidyl. 12. The compound according to any one of claims 1, C and 5, in which VI is C-alkyl. 13. The compound according to any one of claims 1, C and 5, in which VI is C3-C6cycloalkyl. 14. The compound according to claim 1 or claim 3, in which VI is methyl; B2 is a monocyclic b--lene saturated heterocyclyl containing one nitrogen heteroatom substituted by arylC-alkyl, which may be substituted or unsubstituted, where preferably the nitrogen heteroatom is substituted by phenylC-alkyl, which may be substituted or unsubstituted. 15. The compound according to claim 1, selected from the group of the following compounds: (c) ) sn o 7 id she, su" A M no ev, te V; go o A she g tomy ss sn. zh NO o / M she y i Y o o te den sche / | y h o MN not U, other ore v po; od de SHI sn o Her" ol raFf t ia la su o Uh - this IY oh su sho C r no Y c) M Ж uU- SN M SCHO; M -k A -0-M /ЙЙ 16. The compound according to claim 1, in which VI is selected from methyl and ethyl. 17. The compound of claim 16, wherein B2 is selected from aryl, heteroaryl, heterocyclyl, and C3-tocycloalkyl, each of which may be substituted or unsubstituted. 18. A pharmaceutical composition, characterized in that it contains a compound according to any of the preceding clauses, together with one or more pharmaceutically acceptable excipients. 19. Pharmaceutical composition according to claim 18, which is characterized in that it additionally contains one or more additional active pharmaceutical ingredients. 20. A compound according to any one of claims 1-17 for use in therapy. 21. The use of a compound according to any of claims 1-17 in the preparation of a medicament for the treatment or prevention of a condition, the development or symptoms of which are associated with the substrate of the enzyme GAZK, under the only condition that i) if NI represents methyl, H2 does not represent 4 -chlorobutyl, 4-azidobutyl or 4-isothiocyanatobutyl, and iii) the compound is not (4-phenyl-1H-imidazol-1-yl)(4-(quinolin-2-ylmethyl)piperazin-1-yl)methanone, where preferably the condition is a disorder associated with the endocannabinoid system, wherein the disorder is preferably selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, vomiting, alcohol disorders, drug abuse otic substances such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and cirrhosis , arthritis and osteoporosis.